FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Guy, GP Tangka, FKL Hall, IJ Miller, JW Royalty, J AF Guy, Gery P., Jr. Tangka, Florence K. L. Hall, Ingrid J. Miller, Jacqueline W. Royalty, Janet TI The reach and health impacts of the National Breast and Cervical Cancer Early Detection Program (vol 26, pg 649, 2015) SO CANCER CAUSES & CONTROL LA English DT Correction C1 [Guy, Gery P., Jr.; Tangka, Florence K. L.; Hall, Ingrid J.; Miller, Jacqueline W.; Royalty, Janet] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA 30322 USA. RP Guy, GP (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA 30322 USA. EM gguy@cdc.gov NR 2 TC 0 Z9 0 U1 1 U2 2 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0957-5243 EI 1573-7225 J9 CANCER CAUSE CONTROL JI Cancer Causes Control PD MAY PY 2015 VL 26 IS 5 SI SI BP 651 EP 651 DI 10.1007/s10552-015-0582-8 PG 1 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA CH9RP UT WOS:000354374200002 PM 25929884 ER PT J AU Howard, DH Tangka, FKL Royalty, J Dalzell, LP Miller, J O'Hara, B Joseph, K Kenney, K Guy, G Hall, IJ AF Howard, David H. Tangka, Florence K. L. Royalty, Janet Dalzell, Lucinda P. Miller, Jacqueline O'Hara, Brett Joseph, Kristy Kenney, Kristy Guy, Gery Hall, Ingrid J. TI Breast cancer screening of underserved women in the USA: results from the National Breast and Cervical Cancer Early Detection Program, 1998-2012 SO CANCER CAUSES & CONTROL LA English DT Article DE Medically uninsured; Health services accessibility; Early detection of cancer; Mammography ID SERVICES TASK-FORCE; UNITED-STATES; MAMMOGRAPHY AB To describe the number and proportion of eligible women receiving mammograms funded by the National Breast and Cervical Cancer Early Detection Program (NBCCEDP). Low-income, uninsured, and underinsured women aged 40-64 are eligible for mammography screening through the NBCCEDP. We used data from the NBCCEDP, the Current Population Survey, and Medical Expenditure Panel Survey to describe the number and proportion of women screened by the NBCCEDP and overall. In 2011 and 2012, the NBCCEDP screened 549,043 women aged 40-64, an estimated 10.6 % (90 % confidence interval [CI] 10.4-10.9 %) of the eligible population. We estimate that 30.6 % (90 % CI 26.4-34.8 %) of eligible women aged 40-64 were screened outside the NBCCEDP, and 58.8 % (90 % CI 54.6-63.0 %) were not screened. The proportion of eligible women screened by the NBCCEDP varied across states, with an estimated range of 3.2 % (90 % CI 2.9-3.5 %) to 52.8 % (90 % CI 36.1-69.6 %) and a median of 13.7 % (90 % CI 11.0-16.4 %). The estimated proportion of eligible women aged 40-64 who received mammograms through the NBCCEDP was relatively constant over time, 11.1 % (90 % CI 10.2-11.9 %) in 1998-1999 and 10.6 % (90 % CI 10.4-11.9 %) in 2011-2012 (p = 0.23), even as the number of women screened increased from 343,692 to 549,043. Although the NBCCEDP provided screening services to over a half million low-income uninsured women for mammography, it served a small percentage of those eligible. The majority of low-income, uninsured women were not screened. C1 [Howard, David H.] Emory Univ, Dept Hlth Policy & Management, Atlanta, GA 30030 USA. [Tangka, Florence K. L.; Royalty, Janet; Miller, Jacqueline; Kenney, Kristy; Guy, Gery; Hall, Ingrid J.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA USA. [Dalzell, Lucinda P.; O'Hara, Brett] US Bur Census, Social Econ & Household Stat Div, Washington, DC 20233 USA. [Joseph, Kristy] Ctr Dis Control & Prevent, Div Global Hlth Protect, Atlanta, GA USA. RP Howard, DH (reprint author), Emory Univ, Dept Hlth Policy & Management, 1518 Clifton Rd NE, Atlanta, GA 30030 USA. EM david.howard@emory.edu FU Centers for Disease Control and Prevention [12IPA1203126] FX Dr. Howard received support for this research from the Centers for Disease Control and Prevention (12IPA1203126). NR 23 TC 10 Z9 10 U1 0 U2 6 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0957-5243 EI 1573-7225 J9 CANCER CAUSE CONTROL JI Cancer Causes Control PD MAY PY 2015 VL 26 IS 5 SI SI BP 657 EP 668 DI 10.1007/s10552-015-0553-0 PG 12 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA CH9RP UT WOS:000354374200004 PM 25779379 ER PT J AU Howard, DH Tangka, FKL Royalty, J Dalzell, LP Miller, J O'Hara, B Joseph, K Kenney, K Guy, G Hall, IJ AF Howard, David H. Tangka, Florence K. L. Royalty, Janet Dalzell, Lucinda P. Miller, Jacqueline O'Hara, Brett Joseph, Kristy Kenney, Kristy Guy, Gery Hall, Ingrid J. TI Breast cancer screening of underserved women in the USA: results from the National Breast and Cervical Cancer Early Detection Program, 1998-2012 (vol 26, pg 657, 2015) SO CANCER CAUSES & CONTROL LA English DT Correction C1 [Howard, David H.] Emory Univ, Dept Hlth Policy & Management, Atlanta, GA 30030 USA. [Tangka, Florence K. L.; Royalty, Janet; Miller, Jacqueline; Kenney, Kristy; Guy, Gery; Hall, Ingrid J.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA USA. [Dalzell, Lucinda P.; O'Hara, Brett] US Bur Census, Social Econ & Household Stat Div, Washington, DC 20233 USA. [Joseph, Kristy] Ctr Dis Control & Prevent, Div Global Hlth Protect, Atlanta, GA USA. RP Howard, DH (reprint author), Emory Univ, Dept Hlth Policy & Management, 1518 Clifton Rd NE, Atlanta, GA 30030 USA. EM david.howard@emory.edu NR 2 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0957-5243 EI 1573-7225 J9 CANCER CAUSE CONTROL JI Cancer Causes Control PD MAY PY 2015 VL 26 IS 5 SI SI BP 669 EP 669 DI 10.1007/s10552-015-0591-7 PG 1 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA CH9RP UT WOS:000354374200005 PM 25929887 ER PT J AU Tangka, FKL Howard, DH Royalty, J Dalzell, LP Miller, J O'Hara, BJ Sabatino, SA Joseph, K Kenney, K Guy, GP Hall, IJ AF Tangka, Florence K. L. Howard, David H. Royalty, Janet Dalzell, Lucinda P. Miller, Jacqueline O'Hara, Brett J. Sabatino, Susan A. Joseph, Kristy Kenney, Kristy Guy, Gery P., Jr. Hall, Ingrid J. TI Cervical cancer screening of underserved women in the United States: results from the National Breast and Cervical Cancer Early Detection Program, 1997-2012 SO CANCER CAUSES & CONTROL LA English DT Article DE Cervical cancer; Papanicolaou test utilization; Screening proportions; Medically underserved; National Breast and Cervical Cancer Early Detection Program ID HEALTH; NEEDS AB The National Breast and Cervical Cancer Early Detection Program (NBCCEDP) provides breast and cervical cancer screens to low-income, uninsured, and underinsured women. We describe the number and proportion of women eligible for cervical cancer screening services and the proportion of eligible women screened over the period 1997-2012. Low-income, uninsured, and underinsured women aged 18-64 years who have not had a hysterectomy are eligible for cervical cancer screening through the NBCCEDP. We estimated the number of low-income, uninsured women using data from the US Census Bureau. We adjusted our estimates for hysterectomy status using the National Health Interview Survey and the Behavioral Risk Factor Surveillance System. We used data from the NBCCEDP to describe the number of women receiving NBCCEDP-funded screening and calculated the proportion of eligible women who received screening through the NBCCEDP at the national level (by age group, race/ethnicity) and at the state level by age group. We used the Medical Expenditure Panel Survey to estimate the proportion of NBCCEDP-eligible women who were screened outside the NBCCEDP and the proportion that are not screened. We estimate that in 2010-2012, 705,970 women aged 18-64 years, 6.5 % (705,970 of 9.8 million) of the eligible population, received NBCCEDP-funded Pap tests. We estimate that 60.2 % of eligible women aged 18-64 years were screened outside the NBCCEDP and 33.3 % were not screened. The NBCCEDP provided 623,603 screens to women aged 40-64 years, an estimated 16.5 % of the eligible population, and 83,660 screens to women aged 18-39 years, representing an estimated 1.2 % of the eligible population. The estimated proportions of eligible women screened in each state ranged from 1.5 to 32.7 % and 5 % to 73.2 % among the 18-64 and 40-64 years age groups, respectively. Changes in the proportion of eligible women screened over the study period were nonsignificant. Although the program provided cervical screening to over 700,000 women between 2010 and 2012, it served a small percent of those eligible. The proportion of women screened varied substantially across age groups, racial/ethnic groups, and states. Many low-income, uninsured women are not being screened. C1 [Tangka, Florence K. L.; Royalty, Janet; Miller, Jacqueline; Sabatino, Susan A.; Kenney, Kristy; Guy, Gery P., Jr.; Hall, Ingrid J.] Ctr Dis Control & Prevent CDC, Div Canc Prevent & Control, Atlanta, GA 30341 USA. [Howard, David H.] Emory Univ, Dept Hlth Policy & Management, Atlanta, GA 30322 USA. [Dalzell, Lucinda P.; O'Hara, Brett J.] US Bur Census, Social Econ & Household Stat Div, Washington, DC 20233 USA. [Joseph, Kristy] CDC, Div Global Hlth Protect, Ctr Global Hlth, Atlanta, GA 30329 USA. RP Tangka, FKL (reprint author), Ctr Dis Control & Prevent CDC, Div Canc Prevent & Control, 4770 Buford Highway NE,Mailstop F-76, Atlanta, GA 30341 USA. EM FTangka@cdc.gov NR 30 TC 14 Z9 14 U1 3 U2 5 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0957-5243 EI 1573-7225 J9 CANCER CAUSE CONTROL JI Cancer Causes Control PD MAY PY 2015 VL 26 IS 5 SI SI BP 671 EP 686 DI 10.1007/s10552-015-0524-5 PG 16 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA CH9RP UT WOS:000354374200006 PM 25783455 ER PT J AU Tangka, FKL Howard, DH Royalty, J Dalzell, LP Miller, J O'Hara, BJ Sabatino, SA Joseph, K Kenney, K Guy, GP Hall, IJ AF Tangka, Florence K. L. Howard, David H. Royalty, Janet Dalzell, Lucinda P. Miller, Jacqueline O'Hara, Brett J. Sabatino, Susan A. Joseph, Kristy Kenney, Kristy Guy, Gery P., Jr. Hall, Ingrid J. TI Cervical cancer screening of underserved women in the United States: results from the National Breast and Cervical Cancer Early Detection Program, 1997-2012 (vol 26, pg 671, 2015) SO CANCER CAUSES & CONTROL LA English DT Correction C1 [Tangka, Florence K. L.; Royalty, Janet; Miller, Jacqueline; Sabatino, Susan A.; Kenney, Kristy; Guy, Gery P., Jr.; Hall, Ingrid J.] Ctr Dis Control & Prevent CDC, Div Canc Prevent & Control, Atlanta, GA 30341 USA. [Howard, David H.] Emory Univ, Dept Hlth Policy & Management, Atlanta, GA 30322 USA. [Dalzell, Lucinda P.; O'Hara, Brett J.] US Bur Census, Social Econ & Household Stat Div, Washington, DC 20233 USA. [Joseph, Kristy] CDC, Div Global Hlth Protect, Ctr Global Hlth, Atlanta, GA 30329 USA. RP Tangka, FKL (reprint author), Ctr Dis Control & Prevent CDC, Div Canc Prevent & Control, 4770 Buford Highway NE,Mailstop F-76, Atlanta, GA 30341 USA. EM FTangka@cdc.gov NR 5 TC 0 Z9 0 U1 1 U2 3 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0957-5243 EI 1573-7225 J9 CANCER CAUSE CONTROL JI Cancer Causes Control PD MAY PY 2015 VL 26 IS 5 SI SI BP 687 EP 687 DI 10.1007/s10552-015-0584-6 PG 1 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA CH9RP UT WOS:000354374200007 PM 25929885 ER PT J AU Subramanian, S Tangka, FKL Ekwueme, DU Trogdon, J Crouse, W Royalty, J AF Subramanian, Sujha Tangka, Florence K. L. Ekwueme, Donatus U. Trogdon, Justin Crouse, Wesley Royalty, Janet TI Explaining variation across grantees in breast and cervical cancer screening proportions in the NBCCEDP SO CANCER CAUSES & CONTROL LA English DT Article DE Economics; Breast; Cervical ID EARLY-DETECTION PROGRAM; NATIONAL BREAST; COST-ANALYSIS AB There is substantial variation across the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) grantees in terms of the proportion of the eligible population served by the grantees each year (hereafter referred to as the screening proportion). In this paper, we assess program- and state-level factors to better understand the reason for this variation in breast and cervical cancer screening proportions across the NBCCEDP grantees. We constructed a longitudinal data set, consisting of data from NBCCEDP grantees for each of the three study years (program-years 2006-2007, 2008-2009, and 2009-2010). We performed multivariate analysis to explain the variation in breast and cervical cancer screening proportions across the grantees. The program-level factors studied were the total federal funds received, average cost of screening women by grantee, and the overall organizational structure. The state-level variables included were urban versus rural mix, access to care, and the size of the eligible population. Of the 48 grantees included in the study, those that serve larger populations, as measured by the size of the population and the percentage of women eligible for services, had lower screening proportions. Higher average cost of service delivery was also associated with lower screening proportions. In addition, grantees whose populations were more concentrated in urban areas had lower screening proportions. Overall, the average cost of screening, the overall size of the population eligible, and the concentration of population in urban areas all had a negative relationship to the proportion of eligible women screened by NBCCEDP grantees. C1 [Subramanian, Sujha; Crouse, Wesley] RTI Int, Waltham, MA 02451 USA. [Tangka, Florence K. L.; Ekwueme, Donatus U.; Royalty, Janet] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA 30341 USA. [Trogdon, Justin] Univ N Carolina, Gillings Sch Global Publ Hlth, Chapel Hill, NC 27599 USA. RP Subramanian, S (reprint author), RTI Int, 1440 Main St,Suite 310, Waltham, MA 02451 USA. EM ssubramanian@rti.org FU Centers for Disease Control and Prevention [200-2002-00575, 09] FX This work was funded in part by Centers for Disease Control and Prevention Contract Number 200-2002-00575, Task Order 09, to RTI International. NR 16 TC 2 Z9 2 U1 0 U2 1 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0957-5243 EI 1573-7225 J9 CANCER CAUSE CONTROL JI Cancer Causes Control PD MAY PY 2015 VL 26 IS 5 SI SI BP 689 EP 695 DI 10.1007/s10552-015-0569-5 PG 7 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA CH9RP UT WOS:000354374200008 PM 25840557 ER PT J AU Subramanian, S Tangka, FKL Ekwueme, DU Trogdon, J Crouse, W Royalty, J AF Subramanian, Sujha Tangka, Florence K. L. Ekwueme, Donatus U. Trogdon, Justin Crouse, Wesley Royalty, Janet TI Explaining variation across grantees in breast and cervical cancer screening proportions in the NBCCEDP (vol 26, pg 689, 2015) SO CANCER CAUSES & CONTROL LA English DT Correction C1 [Subramanian, Sujha; Crouse, Wesley] RTI Int, Waltham, MA 02451 USA. [Tangka, Florence K. L.; Ekwueme, Donatus U.; Royalty, Janet] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA 30341 USA. [Trogdon, Justin] Univ N Carolina, Gillings Sch Global Publ Hlth, Chapel Hill, NC 27599 USA. RP Subramanian, S (reprint author), RTI Int, 1440 Main St,Suite 310, Waltham, MA 02451 USA. EM ssubramanian@rti.org NR 3 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0957-5243 EI 1573-7225 J9 CANCER CAUSE CONTROL JI Cancer Causes Control PD MAY PY 2015 VL 26 IS 5 SI SI BP 697 EP 697 DI 10.1007/s10552-015-0585-5 PG 1 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA CH9RP UT WOS:000354374200009 PM 25929886 ER PT J AU Dalzell, LP Tangka, FKL Powers, DS O'Hara, BJ Holmes, W Joseph, K Royalty, J AF Dalzell, Lucinda P. Tangka, Florence K. L. Powers, David S. O'Hara, Brett J. Holmes, Walter Joseph, Kristy Royalty, Janet TI Data sources for identifying low-income, uninsured populations: application to public health-National Breast and Cervical Cancer Early Detection Program SO CANCER CAUSES & CONTROL LA English DT Article DE Annual Social and Economic Supplement to the Current Population Survey; American Community Survey; Small Area Health Insurance Estimates; National Breast and Cervical Cancer Early Detection Program; Medically underserved; Low-income and uninsured populations AB To provide information on the sources of data for estimating low-income, uninsured populations. To recommend uses of these data sources. To demonstrate the application of these data sources in the public health field, using the National Breast and Cervical Cancer Early Detection Program as an example. We describe U.S. Census Bureau data sources for identifying low-income, uninsured populations using two population surveys: the Annual Social and Economic Supplement to the Current Population Survey (CPS ASEC) and the American Community Survey (ACS), and using one model-based estimation program, the Small Area Health Insurance Estimates (SAHIE). We provide recommendations for use of these data sources, and we use CPS ASEC and SAHIE to estimate the percent of U.S. women eligible for the National Breast and Cervical Cancer Early Detection Program (NBCCEDP). CPS ASEC, ACS, and SAHIE are produced by the U.S. Census Bureau, and they are reliable sources for estimates of the low-income, uninsured populations in the USA. Key characteristics of these three data sources were presented to highlight the strengths of each to meet the needs of various programs at national and local levels. Recommendations are made on the use of the data sources. Based on these three data sources, estimates of NBCCEDP eligibility showed substantial variation over time at the national and state levels, and across states and counties. Publicly funded programs that are directed toward low-income, uninsured individuals require information on their eligible populations to make decisions about program policy and resource allocation, and to monitor and evaluate the effectiveness of the programs. The U.S. Census Bureau produces three data sources (CPS ASEC, ACS, and SAHIE) for these estimates. The percent of U.S. women eligible for NBCCEDP varies over time and across states and counties. The data sources for these estimates are changing in order to measure key dimensions of the Affordable Care Act (ACA) and can provide helpful information for assessing the legislation's impact. C1 [Dalzell, Lucinda P.; Powers, David S.; O'Hara, Brett J.; Holmes, Walter] US Bur Census, Social Econ & Housing Stat Div, Washington, DC 20233 USA. [Tangka, Florence K. L.; Royalty, Janet] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Joseph, Kristy] Ctr Dis Control & Prevent, Noncommunicable Dis Unit, Div Global Hlth Protect, Ctr Global Hlth, Atlanta, GA 30329 USA. RP Dalzell, LP (reprint author), US Bur Census, Social Econ & Housing Stat Div, 6H123,4600 Silver Hill Rd, Washington, DC 20233 USA. EM lucinda.p.dalzell@census.gov FU Centers for Disease Control and Prevention (IAA) [13FED1303129] FX The U.S. Census Bureau received support for this research from the Centers for Disease Control and Prevention (IAA # 13FED1303129). NR 30 TC 4 Z9 4 U1 3 U2 3 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0957-5243 EI 1573-7225 J9 CANCER CAUSE CONTROL JI Cancer Causes Control PD MAY PY 2015 VL 26 IS 5 SI SI BP 699 EP 709 DI 10.1007/s10552-015-0571-y PG 11 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA CH9RP UT WOS:000354374200010 PM 25916228 ER PT J AU Dalzell, LP Tangka, FKL Powers, DS O'Hara, BJ Holmes, W Joseph, K Royalty, J AF Dalzell, Lucinda P. Tangka, Florence K. L. Powers, David S. O'Hara, Brett J. Holmes, Walter Joseph, Kristy Royalty, Janet TI Data sources for identifying low-income, uninsured populations: application to public health-National Breast and Cervical Cancer Early Detection Program (vol 26, pg 699, 2015) SO CANCER CAUSES & CONTROL LA English DT Correction C1 [Dalzell, Lucinda P.; Powers, David S.; O'Hara, Brett J.; Holmes, Walter] US Bur Census, Social Econ & Housing Stat Div, Washington, DC 20233 USA. [Tangka, Florence K. L.; Royalty, Janet] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Joseph, Kristy] Ctr Dis Control & Prevent, Noncommunicable Dis Unit, Div Global Hlth Protect, Ctr Global Hlth, Atlanta, GA 30329 USA. RP Dalzell, LP (reprint author), US Bur Census, Social Econ & Housing Stat Div, 6H123,4600 Silver Hill Rd, Washington, DC 20233 USA. EM lucinda.p.dalzell@census.gov NR 3 TC 0 Z9 0 U1 0 U2 2 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0957-5243 EI 1573-7225 J9 CANCER CAUSE CONTROL JI Cancer Causes Control PD MAY PY 2015 VL 26 IS 5 SI SI BP 711 EP 711 DI 10.1007/s10552-015-0597-1 PG 1 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA CH9RP UT WOS:000354374200011 PM 25941066 ER PT J AU Benard, VB Royalty, J Saraiya, M Rockwell, T Helsel, W AF Benard, V. B. Royalty, J. Saraiya, M. Rockwell, T. Helsel, W. TI The effectiveness of targeting never or rarely screened women in a national cervical cancer screening program for underserved women SO CANCER CAUSES & CONTROL LA English DT Article DE Pap test; Mass screening; Cervix neoplasms ID UNITED-STATES; PREVENTION; GUIDELINES; MANAGEMENT; PRECURSORS; SOCIETY; BREAST; AREA AB To evaluate the effectiveness of a policy supporting early detection and prevention of cervical cancer among low-income and uninsured women by comparing women who reported never or rarely being screened (last screen > 5 years) to those who reported screening in the past a parts per thousand currency sign5 years. We analyzed data from 1,485,251 women who received their first Pap test in the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) from July 2002 through June 2012. Of these, 461,893 women (31 %) reported being never or rarely screened and 1,023,358 (69 %) reported being screened in the past 5 years. Demographic (age, race/ethnicity, residence, and region) and clinic (cytologic and histologic results) characteristics were examined for the two groups. Women who were aged a parts per thousand yen50 years, Asian and Pacific Islander, American Indian or Alaska Native, multiracial, living in non-metro areas, or living in the South or a territory were more likely to report being never or rarely screened. The percentage of abnormal Pap tests and the rate of precancer and cancer (combined) was higher in the never or rarely screened group compared with the screened group (abnormal percentage: 2.9 vs 2.6 %, p value < 0.01; rate of precancer and cancer: 6.9 vs 3.7 per 1,000 women, p value < 0.01). The priority of reaching never or rarely screened women should continue since those women who entered the NBCCEDP not adequately screened had a greater prevalence of high-grade histological lesions and invasive cervical cancers at later stages than women screened more recently. C1 [Benard, V. B.; Royalty, J.; Saraiya, M.] Ctr Dis Control & Prevent CDC, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Rockwell, T.; Helsel, W.] Informat Management Serv Inc, Rockville, MD 20852 USA. RP Benard, VB (reprint author), Ctr Dis Control & Prevent CDC, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway NE,Mailstop F-76, Atlanta, GA 30341 USA. EM vdb9@cdc.gov FU Intramural CDC HHS [CC999999] NR 26 TC 5 Z9 6 U1 2 U2 4 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0957-5243 EI 1573-7225 J9 CANCER CAUSE CONTROL JI Cancer Causes Control PD MAY PY 2015 VL 26 IS 5 SI SI BP 713 EP 719 DI 10.1007/s10552-015-0542-3 PG 7 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA CH9RP UT WOS:000354374200012 PM 25754108 ER PT J AU Benard, VB Royalty, J Saraiya, M Rockwell, T Helsel, W AF Benard, V. B. Royalty, J. Saraiya, M. Rockwell, T. Helsel, W. TI The effectiveness of targeting never or rarely screened women in a national cervical cancer screening program for underserved women (vol 26, pg 713, 2015) SO CANCER CAUSES & CONTROL LA English DT Correction C1 [Benard, V. B.; Royalty, J.; Saraiya, M.] Ctr Dis Control & Prevent CDC, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Rockwell, T.; Helsel, W.] Informat Management Serv Inc, Rockville, MD 20852 USA. RP Benard, VB (reprint author), Ctr Dis Control & Prevent CDC, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway NE,Mailstop F-76, Atlanta, GA 30341 USA. EM vdb9@cdc.gov NR 3 TC 0 Z9 0 U1 2 U2 4 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0957-5243 EI 1573-7225 J9 CANCER CAUSE CONTROL JI Cancer Causes Control PD MAY PY 2015 VL 26 IS 5 SI SI BP 721 EP 721 DI 10.1007/s10552-015-0586-4 PG 1 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA CH9RP UT WOS:000354374200013 PM 25948086 ER PT J AU White, A Miller, J Royalty, J Ryerson, AB Benard, V Helsel, W Kammerer, W AF White, Arica Miller, Jacqueline Royalty, Janet Ryerson, A. Blythe Benard, Vicki Helsel, William Kammerer, William TI Clinical outcomes of mammography in the National Breast and Cervical Cancer Early Detection Program, 2009-2012 SO CANCER CAUSES & CONTROL LA English DT Article DE Breast cancer; Mammography; Screening ID WOMEN AB The National Breast and Cervical Cancer Early Detection Program (NBCCEDP) enrolls asymptomatic women for cancer screening and symptomatic women for diagnostic services. This study describes the results of mammograms provided by the NBCCEDP, by examination indication (screening or diagnostic), and by age group. For the first NBCCEDP-funded mammogram received during 2009-2012, we calculated age-specific percentages of abnormal findings, rates of follow-up testing, and invasive and in situ breast cancer diagnoses per 1,000 mammograms. Logistic regression was used to estimate the odds for each of these outcomes by examination indication. The NBCCEDP provided 941,649 screening, 175,310 diagnostic, and 30,434 unknown indication mammograms to 1,147,393 women. The percentage with abnormal mammograms was higher for diagnostic mammograms (40.1 %) than for screening mammograms (15.5 %). Compared with women aged 40-49 years, fewer women aged 50-64 years had abnormal results for screening (13.7 vs. 19.7 %) and diagnostic mammograms (37.7 vs. 42.7 %). Follow-up rates per 1,000 mammograms were lower among women aged 50-64 compared to those aged 40-49 (screening: 143.9 vs. 207.5; diagnostic: 645.3 vs. 760.9); biopsy rates exhibited a similar pattern (screening: 24.1 vs. 32.9; diagnostic: 167.7 vs. 169.7). For screening mammograms, older women had more cancers detected than younger women (invasive: 3.6 vs. 2.2; in situ: 2.3 vs. 2.0). Similarly, for diagnostic mammograms, cancer detection was higher for older women (invasive: 67.8 vs. 36.6; in situ: 17.4 vs. 11.1). Abnormal mammograms and diagnostic follow-up procedures were less frequent in women aged 50-64 years compared to women aged 40-49 years, while breast cancer detection was higher, regardless of indication for the mammogram. Some of these differences between age groups were greater for screening mammograms than for diagnostic mammograms. Cancer detection rates were higher for diagnostic mammograms compared with screening mammograms. These findings support the NBCCEDP's priority of serving women aged 50-64 years and providing both screening and diagnostic mammograms. C1 [White, Arica; Miller, Jacqueline; Royalty, Janet; Ryerson, A. Blythe; Benard, Vicki] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Helsel, William; Kammerer, William] Informat Management Serv Inc, Calverton, MD USA. RP White, A (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway NE,Mailstop F76, Atlanta, GA 30341 USA. EM awhite5@cdc.gov FU Intramural CDC HHS [CC999999] NR 8 TC 3 Z9 3 U1 1 U2 4 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0957-5243 EI 1573-7225 J9 CANCER CAUSE CONTROL JI Cancer Causes Control PD MAY PY 2015 VL 26 IS 5 SI SI BP 723 EP 732 DI 10.1007/s10552-015-0567-7 PG 10 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA CH9RP UT WOS:000354374200014 PM 25809209 ER PT J AU Ryerson, AB Miller, J Eheman, CR AF Ryerson, A. Blythe Miller, Jacqueline Eheman, Christie R. TI Reported breast symptoms in the National Breast and Cervical Cancer Early Detection Program SO CANCER CAUSES & CONTROL LA English DT Article DE Breast cancer; Breast symptoms; Screening; Mammography ID SCREENING-PROGRAM; WOMEN; MAMMOGRAPHY; VALIDATION; SIGNS AB The frequency and types of breast symptoms reported by women in the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) have never been characterized. This study aims to establish the frequency of reported symptoms and the diagnostic outcomes associated with reported symptoms. We examined the frequency of symptoms reported prior to mammography using medical record abstraction data from women in the NBCCEDP. We also calculated adjusted odds ratios (aOR) of having an abnormal mammogram, an abnormal clinical breast examination, or a final diagnosis of breast cancer by symptoms, compared to asymptomatic women. In our sample of women, 10.3 % reported at least one symptom. Women with symptoms were younger and more likely to be non-Hispanic white. Among those reporting symptoms, breast lump (31.7 %) and pain or tenderness (49.3 %) was most common. A relatively low proportion of women with symptoms were diagnosed with in situ (0.9 %) or invasive breast cancer (4.3 %). However, a self-reported breast lump [aOR 13.7; 95 % confidence interval (CI) 7.8-24.1], inflammation or changes to the skin/nipple (aOR 27.8; 95 % CI 8.7-88.8), and other or unspecified symptoms (aOR 3.4; 95 % CI 2.1-7.5) were associated with an increased risk of invasive breast cancer. Although the prevalence of breast cancer among women reporting symptoms is relatively low, knowing which symptoms carry the highest breast cancer risk is important to assist in appropriate diagnostic workup. C1 [Ryerson, A. Blythe; Miller, Jacqueline; Eheman, Christie R.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA 30341 USA. RP Ryerson, AB (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, 4770 Buford Highway NE,F-76, Atlanta, GA 30341 USA. EM ARyerson@cdc.gov FU Intramural CDC HHS [CC999999] NR 24 TC 2 Z9 2 U1 1 U2 2 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0957-5243 EI 1573-7225 J9 CANCER CAUSE CONTROL JI Cancer Causes Control PD MAY PY 2015 VL 26 IS 5 SI SI BP 733 EP 740 DI 10.1007/s10552-015-0544-1 PG 8 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA CH9RP UT WOS:000354374200015 PM 25754109 ER PT J AU Miller, JW Royalty, J Henley, J White, A Richardson, LC AF Miller, Jacqueline W. Royalty, Janet Henley, Jane White, Arica Richardson, Lisa C. TI Breast and cervical cancers diagnosed and stage at diagnosis among women served through the National Breast and Cervical Cancer Early Detection Program SO CANCER CAUSES & CONTROL LA English DT Article DE Breast cancer; Cervical cancer; Cancer stage; Cancer screening ID SERVICES TASK-FORCE; UNITED-STATES; CARCINOMA AB To assess cancers diagnosed and the stage of cancer at the time of diagnosis among low-income, under-insured, or uninsured women who received services through the National Breast and Cervical Cancer Early Detection Program (NBCCEDP). Using the NBCCEDP database, we examined the number and percent of women diagnosed during 2009-2011 with in situ breast cancer, invasive breast cancer, and invasive cervical cancer by demographic and clinical characteristics, including age, race and ethnicity, test indication (screening or diagnostic), symptoms (for breast cancer), and screening history (for cervical cancer). We examined these characteristics by stage at diagnosis, a new variable included in the database obtained by linking with state-based central cancer registries. There were 11,569 women diagnosed with invasive breast cancer, 1,988 with in situ breast cancer, and 583 with invasive cervical cancer through the NBCCEDP. Women who reported breast symptoms or who had diagnostic mammography were more likely to be diagnosed with breast cancer, and at a later stage, than those who did not have symptoms or who had screening mammography. Women who had been rarely or never screened for cervical cancer were more likely to be diagnosed with cervical cancer, and at a later stage, than women who received regular screenings. Women served through the NBCCEDP who have not had prior screening or who have symptoms were more often diagnosed with late-stage disease. C1 [Miller, Jacqueline W.; Royalty, Janet; Henley, Jane; White, Arica; Richardson, Lisa C.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP Miller, JW (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy NE,Mailstop F-76, Atlanta, GA 30341 USA. EM JMiller5@cdc.gov FU Intramural CDC HHS [CC999999] NR 23 TC 5 Z9 5 U1 0 U2 1 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0957-5243 EI 1573-7225 J9 CANCER CAUSE CONTROL JI Cancer Causes Control PD MAY PY 2015 VL 26 IS 5 SI SI BP 741 EP 747 DI 10.1007/s10552-015-0543-2 PG 7 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA CH9RP UT WOS:000354374200016 PM 25724415 ER PT J AU Miller, JW Royalty, J Henley, J White, A Richardson, LC AF Miller, Jacqueline W. Royalty, Janet Henley, Jane White, Arica Richardson, Lisa C. TI Breast and cervical cancers diagnosed and stage at diagnosis among women served through the National Breast and Cervical Cancer Early Detection Program (vol 26, pg 741, 2015) SO CANCER CAUSES & CONTROL LA English DT Correction C1 [Miller, Jacqueline W.; Royalty, Janet; Henley, Jane; White, Arica; Richardson, Lisa C.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP Miller, JW (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy NE,Mailstop F-76, Atlanta, GA 30341 USA. EM JMiller5@cdc.gov NR 4 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0957-5243 EI 1573-7225 J9 CANCER CAUSE CONTROL JI Cancer Causes Control PD MAY PY 2015 VL 26 IS 5 SI SI BP 749 EP 749 DI 10.1007/s10552-015-0588-2 PG 1 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA CH9RP UT WOS:000354374200017 PM 25924586 ER PT J AU Wu, MX Austin, H Eheman, CR Myles, Z Miller, J Royalty, J Ryerson, AB AF Wu, Manxia Austin, Harland Eheman, Christie R. Myles, Zachary Miller, Jacqueline Royalty, Janet Ryerson, A. Blythe TI A comparative analysis of breast cancer stage between women enrolled in the National Breast and Cervical Cancer Early Detection Program and women not participating in the program SO CANCER CAUSES & CONTROL LA English DT Article DE Breast cancer; Cancer screening; Cancer stage; Tumor stage; National Breast and Cervical Cancer Early Detection Program (NPCCEDP); Social economic status (SES) ID NEW-YORK-CITY; SOCIOECONOMIC-STATUS; RACIAL-DIFFERENCES; RACE; DIAGNOSIS; MORTALITY; SURVIVAL; AGE AB To determine the proportional distribution of early- and late-stage breast cancers diagnosed in years 2004-2009 among women enrolled in the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) and to compare this distribution to that of geographically comparable non-enrolled women diagnosed with breast cancer. Using data from the National Program of Cancer Registries, we compared the demographic characteristics and cancer stage distribution of women enrollees and non-enrollees by use of conditional logistic regression using the odds ratio as a measure of association. NBCCEDP enrollees were slightly younger and more likely to identify as African-American, API and AIAN than were non-enrollees. The proportion of late-stage breast cancer (regional and distant) decreased slightly over the study period. NBCCEDP enrollees generally were diagnosed at a later stage of breast cancer than were those not enrolled in the NBCCEDP. The NBCCEDP has been effective in achieving its goal of enrolling racial and ethnic populations; however, enrollees had a poorer stage distribution of breast cancer than did non-enrollees underscoring the need to expand breast cancer control efforts among low-income, underserved populations. C1 [Wu, Manxia; Eheman, Christie R.; Myles, Zachary; Miller, Jacqueline; Royalty, Janet; Ryerson, A. Blythe] Ctr Dis Control & Prevent, Atlanta, GA 30322 USA. [Austin, Harland] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30322 USA. RP Wu, MX (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30322 USA. EM ilb8@cdc.gov FU Intramural CDC HHS [CC999999] NR 25 TC 1 Z9 1 U1 2 U2 3 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0957-5243 EI 1573-7225 J9 CANCER CAUSE CONTROL JI Cancer Causes Control PD MAY PY 2015 VL 26 IS 5 SI SI BP 751 EP 758 DI 10.1007/s10552-015-0548-x PG 8 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA CH9RP UT WOS:000354374200018 PM 25761406 ER PT J AU Watson, M Benard, V Lin, L Rockwell, T Royalty, J AF Watson, Meg Benard, Vicki Lin, Lavinia Rockwell, Tanner Royalty, Janet TI Provider management of equivocal cervical cancer screening results among underserved women, 2009-2011: follow-up of atypical squamous cells of undetermined significance SO CANCER CAUSES & CONTROL LA English DT Article DE HPV testing; ASC-US; NBCCEDP; Pap test ID EARLY-DETECTION PROGRAM; CONSENSUS GUIDELINES; RANDOMIZED-TRIAL; NATIONAL BREAST; NATIVE WOMEN; TESTS; CYTOLOGY; RISK AB Reflex human papillomavirus (HPV) testing is the preferred triage option for most women diagnosed with atypical squamous cells of undetermined significance (ASC-US). This study was conducted to describe follow-up results of women with ASC-US Pap test results in the National Breast and Cervical Cancer Early Detection Program (NBCCEDP), focusing on HPV test use. We examined the follow-up of 45,049 women in the NBCCEDP with ASC-US Pap tests during 2009-2011. Data on demographic characteristics, diagnostic procedures, and clinical outcomes were analyzed. NBCCEDP providers diagnosed 45,049 women (4.5 % of all Pap tests) with an ASC-US result. Of those, 28,271 (62.8 %) were followed with an HPV test, 3,883 (8.6 %) with a repeat Pap test, 6,592 (14.6 %) with colposcopy, and 6,303 were lost to follow-up (14.0 %). Women aged 40 and older were followed more often with an HPV test. White, black, and Asian/Pacific Islander women were followed more often with an HPV test after an ASC-US Pap compared to Hispanic and American Indian/Alaska Native (AI/AN) women. Among women with a positive HPV test on follow-up, almost 90 % continued with colposcopy as recommended. AI/AN women had the highest rates of HPV positivity (55.2 %) and of no follow-up (25.0 %). This is the first analysis describing follow-up of ASC-US Pap test results in the NBCCEDP, providing a window into current management of ASC-US results. Findings raise concerns about persistent disparities among AI/AN women. During 2009-2011, nearly two-thirds of women with an ASC-US Pap test result were followed with an HPV reflex test. C1 [Watson, Meg; Benard, Vicki; Lin, Lavinia; Royalty, Janet] Ctr Dis Control & Prevent, Epidemiol & Appl Res Branch, Div Canc Prevent & Control, Atlanta, GA 30341 USA. [Rockwell, Tanner] Informat Management Serv Inc, Calverton, MD 20705 USA. RP Watson, M (reprint author), Ctr Dis Control & Prevent, Epidemiol & Appl Res Branch, Div Canc Prevent & Control, 4770 Buford Hwy NE MS F76, Atlanta, GA 30341 USA. EM mwatson2@cdc.gov FU Centers for Disease Control and Prevention FX We would like to thank William Helsel and William Kammerer from Information Management Services, Inc. for their assistance with data analysis. This research was supported in part by an appointment (LL) to the Research Participation Program at the Centers for Disease Control and Prevention administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the US Department of Energy and CDC. NR 23 TC 6 Z9 6 U1 1 U2 3 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0957-5243 EI 1573-7225 J9 CANCER CAUSE CONTROL JI Cancer Causes Control PD MAY PY 2015 VL 26 IS 5 SI SI BP 759 EP 764 DI 10.1007/s10552-015-0549-9 PG 6 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA CH9RP UT WOS:000354374200019 PM 25794897 ER PT J AU Watson, M Benard, V Lin, L Rockwell, T Royalty, J AF Watson, Meg Benard, Vicki Lin, Lavinia Rockwell, Tanner Royalty, Janet TI Provider management of equivocal cervical cancer screening results among underserved women, 2009-2011: follow-up of atypical squamous cells of undetermined significance (vol 26, pg 759, 2015) SO CANCER CAUSES & CONTROL LA English DT Correction C1 [Watson, Meg; Benard, Vicki; Lin, Lavinia; Royalty, Janet] Ctr Dis Control & Prevent, Epidemiol & Appl Res Branch, Div Canc Prevent & Control, Atlanta, GA 30341 USA. [Rockwell, Tanner] Informat Management Serv Inc, Calverton, MD 20705 USA. RP Watson, M (reprint author), Ctr Dis Control & Prevent, Epidemiol & Appl Res Branch, Div Canc Prevent & Control, 4770 Buford Hwy NE MS F76, Atlanta, GA 30341 USA. EM mwatson2@cdc.gov NR 2 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0957-5243 EI 1573-7225 J9 CANCER CAUSE CONTROL JI Cancer Causes Control PD MAY PY 2015 VL 26 IS 5 SI SI BP 765 EP 765 DI 10.1007/s10552-015-0589-1 PG 1 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA CH9RP UT WOS:000354374200020 PM 25924587 ER PT J AU DeGroff, A Cheung, K Dawkins-Lyn, N Hall, MA Melillo, S Glover-Kudon, R AF DeGroff, Amy Cheung, Karen Dawkins-Lyn, Nicola Hall, Mary Ann Melillo, Stephanie Glover-Kudon, Rebecca TI Identifying promising practices for evaluation: the National Breast and Cervical Cancer Early Detection Program SO CANCER CAUSES & CONTROL LA English DT Article DE Cancer screening; Health promotion; Evaluation AB The Centers for Disease Control and Prevention conducted a systematic screening and assessment process to identify promising practices implemented by grantees of the National Breast and Cervical Cancer Early Detection Program and its partners that were appropriate for rigorous evaluation. The systematic screening and assessment (SSA) process was conducted from September 2010 through March 2012 and included five steps: (1) nominations of promising practices; (2) a first rating by subject matter experts; (3) field-based evaluability assessments; (4) a second rating by experts; and (5) use of results. Nominations were sought in three program areas including health education and promotion, quality assurance and quality improvement, and case management/patient navigation. A total of 98 practices were nominated of which 54 % were eligible for the first review by the experts. Fifteen practices were selected for evaluability assessment with ten forwarded for the second review by the experts. Three practices were ultimately recommended for rigorous evaluation, and one evaluation was conducted. Most nominated practices were based on evidence-based strategies rather than representing new, innovative activities. Issues were identified through the process including inconsistent implementation and lack of implementation fidelity. While the SSA was successful in identifying several programs for evaluation, the process also revealed important shortcomings in program implementation. Training and technical assistance could help address these issues and support improved programming. C1 [DeGroff, Amy; Melillo, Stephanie; Glover-Kudon, Rebecca] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA 30314 USA. [Cheung, Karen; Dawkins-Lyn, Nicola; Hall, Mary Ann] ICF Int, Publ Hlth & Survey Res, Atlanta, GA USA. RP DeGroff, A (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, 4770 Buford Hwy,MS K-57, Atlanta, GA 30314 USA. EM adegroff@cdc.gov FU Intramural CDC HHS [CC999999] NR 21 TC 2 Z9 2 U1 5 U2 12 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0957-5243 EI 1573-7225 J9 CANCER CAUSE CONTROL JI Cancer Causes Control PD MAY PY 2015 VL 26 IS 5 SI SI BP 767 EP 774 DI 10.1007/s10552-015-0538-z PG 8 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA CH9RP UT WOS:000354374200021 PM 25701247 ER PT J AU Hall, IJ Johnson-Turbes, A AF Hall, Ingrid J. Johnson-Turbes, Ashani TI Use of the Persuasive Health Message framework in the development of a community-based mammography promotion campaign SO CANCER CAUSES & CONTROL LA English DT Article DE Persuasive Health Message framework; Campaign development; PHM ID PARALLEL PROCESS MODEL; BREAST-CANCER AB We describe how the Persuasive Health Message (PHM) framework was used to guide the formative evaluation informing development of messages and materials used in a community-based multi-media campaign intended to motivate low-income African American women to obtain low- or no-cost mammograms through the CDC's National Breast and Cervical Cancer Early Detection Program. Seventy-eight African American women were recruited for eight focus groups that discussed breast cancer screening. The moderator guide was developed in accordance with the PHM framework and solicited information on perceived threat and efficacy, cues, salient beliefs and referents, and barriers to self-efficacy. We created persuasive messages to emphasize that African American women are susceptible to the threat of breast cancer, but that their personal action in obtaining regular mammograms may lead to early detection, subsequent treatment, and reduced cancer mortality. The messages addressed concerns of self-efficacy by emphasizing that uninsured women can also obtain high-quality low- or no-cost mammograms. In an attempt to combat the sentiment that breast cancer is a death sentence, the messages indicated that breast cancer can be successfully treated, especially when detected early. The PHM framework consists of three steps: (1) determine information about threat and efficacy; (2) develop an audience profile; and (3) construct a persuasive message. It offered our team easy-to-follow, flexible steps to create a persuasive and effective campaign promoting awareness and use of mammogram screening among low-income African American women. C1 [Hall, Ingrid J.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA 30341 USA. [Johnson-Turbes, Ashani] ICF Int, Atlanta, GA USA. RP Hall, IJ (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA 30341 USA. EM ihall@cdc.gov FU Intramural CDC HHS [CC999999] NR 23 TC 2 Z9 2 U1 3 U2 9 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0957-5243 EI 1573-7225 J9 CANCER CAUSE CONTROL JI Cancer Causes Control PD MAY PY 2015 VL 26 IS 5 SI SI BP 775 EP 784 DI 10.1007/s10552-015-0537-0 PG 10 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA CH9RP UT WOS:000354374200022 PM 25724414 ER PT J AU Hall, IJ Johnson-Turbes, A AF Hall, Ingrid J. Johnson-Turbes, Ashani TI Use of the Persuasive Health Message framework in the development of a community-based mammography promotion campaign (vol 26, pg 775, 2015) SO CANCER CAUSES & CONTROL LA English DT Correction C1 [Hall, Ingrid J.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA 30341 USA. [Johnson-Turbes, Ashani] ICF Int, Atlanta, GA USA. RP Hall, IJ (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA 30341 USA. EM ihall@cdc.gov NR 2 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0957-5243 EI 1573-7225 J9 CANCER CAUSE CONTROL JI Cancer Causes Control PD MAY PY 2015 VL 26 IS 5 SI SI BP 785 EP 785 DI 10.1007/s10552-015-0587-3 PG 1 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA CH9RP UT WOS:000354374200023 PM 25924585 ER PT J AU Hall, IJ Johnson-Turbes, A Berkowitz, Z Zavahir, Y AF Hall, Ingrid J. Johnson-Turbes, Ashani Berkowitz, Zahava Zavahir, Yasmine TI The African American Women and Mass Media (AAMM) campaign in Georgia: quantifying community response to a CDC pilot campaign SO CANCER CAUSES & CONTROL LA English DT Article DE African American; Breast cancer; Campaign; Evaluation; Mammography ID SOCIAL MARKETING CAMPAIGN; UNITED-STATES; CANCER; BREAST; DISPARITIES; PROJECT; INTERVENTIONS; QUITLINE; IMPACT; RADIO AB To evaluate whether a culturally appropriate campaign using "Black radio" and print media increased awareness and utilization of local mammography screening services provided by the Centers for Disease Control and Prevention's National Breast and Cervical Cancer Early Detection Program among African American women. The evaluation used a quasi-experimental design involving data collection during and after campaign implementation in two intervention sites in GA (Savannah with radio and print media and Macon with radio only) and one comparison site (Columbus, GA). We used descriptive statistics to compare mammography uptake for African American women during the initial months of the campaign (8/08-1/09) with the latter months (2/09-8/09) and a post-campaign (9/09-12/09) period in each of the study sites. Comparisons of monthly mammogram uptake between cities were performed with multinomial logistic regression. We assumed a p value < 0.05 to be significant. We observed an increase of 46 and 20 % in Savannah and Macon, respectively, from the initial period of the campaign to the later period. However, the increase did not persist in the post-campaign period. Analysis comparing monthly mammogram uptake in Savannah and Macon with Columbus showed a significant increase in uptake from the first to the second period in Savannah only (OR 1.269, 95 % CI (1.005-1.602), p = 0.0449). Dissemination of health promotion messages via a culturally appropriate, multicomponent campaign using Black radio and print media was effective in increasing mammogram uptake in Savannah among low-income, African American women. Additional research is needed to quantify the relative contribution of campaign radio, print media, and community components to sustain increased mammography uptake. C1 [Hall, Ingrid J.; Berkowitz, Zahava] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA 30341 USA. [Johnson-Turbes, Ashani] ICF Int, Atlanta, GA 30329 USA. [Zavahir, Yasmine] Hollywood, Hlth & Soc, Los Angeles, CA USA. RP Hall, IJ (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, 4770 Buford Highway, Atlanta, GA 30341 USA. EM ihall@cdc.gov FU Centers for Disease Control and Prevention, Division of Cancer Prevention and Control [200-2002-00574] FX This work was supported in part by Centers for Disease Control and Prevention, Division of Cancer Prevention and Control (Contract No. 200-2002-00574 to ICF International). NR 31 TC 3 Z9 3 U1 1 U2 3 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0957-5243 EI 1573-7225 J9 CANCER CAUSE CONTROL JI Cancer Causes Control PD MAY PY 2015 VL 26 IS 5 SI SI BP 787 EP 794 DI 10.1007/s10552-015-0540-5 PG 8 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA CH9RP UT WOS:000354374200024 PM 25732344 ER PT J AU Adams, EK Bayakly, AR Berzen, AK Blake, S Joski, P Li, C Hall, IJ Sabatino, SA AF Adams, E. Kathleen Bayakly, A. Rana Berzen, Alissa K. Blake, Sarah Joski, Peter Li, Chunyu Hall, Ingrid J. Sabatino, Susan A. TI Enhancing screening and early detection among women transitioning to Medicare from the NBCCEDP in Georgia SO CANCER CAUSES & CONTROL LA English DT Article DE Mammography; NBCCEDP; Medicare ID EARLY-DETECTION PROGRAM; BREAST-CANCER MORTALITY; NATIONAL BREAST; LOW-INCOME; MAMMOGRAPHY; IMPACT; WELCOME; RATES; CARE AB The National Breast and Cervical Cancer Early Detection Program through each state's administration serves millions of low-income and uninsured women aged 40-64. Our purpose was to assess whether cases screened through Georgia's Breast and Cervical Cancer Program (BCCP) were diagnosed at an earlier stage of disease and whether those who used the state's program regularly continued to obtain age-appropriate screens as they aged out of BCCP into Medicare between 2000 and 2005. We used BCCP screening data to identify women with more than one screen and an interval of 18 months or less between screens as "regular" users of BCCP. Using the linked BCCP and Medicare enrollment/claims data, we tested whether women with any BCCP use (n = 3,134) or "regular" users (n = 1,590) were more likely than women not using BCCP (n = 10,086) to exhibit regular screening under Medicare. We used linked BCCP and Georgia Cancer Registry data to examine breast cancer incidence and stage at diagnosis of BCCP women compared to the Georgia population. Under Medicare, almost 63 % of women with any BCCP use were re-screened versus 51 % of non-BCCP users. The probability of being screened within 18 months of Medicare enrollment was 3.5 % points higher for any BCCP user and 17.7 points higher for "regular" BCCP users, compared to nonusers. Among Black non-Hispanics, the difference for any BCCP user was 13.7 % points and for regular users, 22.4 % points. A larger percentage of BCCP users were diagnosed at in situ or localized disease stage than overall. The majority of women aging out of the GA BCCP 2000-2005 had used the program to obtain regular mammography. Regular users of GA BCCP continued to be screened within appropriate intervals once enrolled in Medicare due perhaps to educational and support components of BCCP. C1 [Adams, E. Kathleen; Blake, Sarah; Joski, Peter] Emory Univ, Rollins Sch Publ Hlth, Dept Hlth Policy & Management, Atlanta, GA 30322 USA. [Bayakly, A. Rana; Berzen, Alissa K.] Georgia Dept Publ Hlth, Program Epidemiol, Atlanta, GA 30303 USA. [Li, Chunyu; Hall, Ingrid J.; Sabatino, Susan A.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA 30341 USA. RP Adams, EK (reprint author), Emory Univ, Rollins Sch Publ Hlth, Dept Hlth Policy & Management, 1518 Clifton Rd NE Room 654, Atlanta, GA 30322 USA. EM eadam01@emory.edu FU Centers for Disease Control, Division of Cancer Prevention and Control [SIP11-043]; Georgia Cancer Registry (GCR); Medicare FX The funding for this research was provided by the Centers for Disease Control, Division of Cancer Prevention and Control under a Cooperative Agreement SIP11-043: Feasibility of Linking the Georgia Breast and Cervical Cancer Screening Program (BCCP) with the Georgia Cancer Registry (GCR) and Medicare. The findings and conclusions in this report are those of the author(s) and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 20 TC 2 Z9 2 U1 1 U2 1 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0957-5243 EI 1573-7225 J9 CANCER CAUSE CONTROL JI Cancer Causes Control PD MAY PY 2015 VL 26 IS 5 SI SI BP 795 EP 803 DI 10.1007/s10552-015-0560-1 PG 9 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA CH9RP UT WOS:000354374200025 PM 25814245 ER PT J AU White, MC Wong, FL AF White, Mary C. Wong, Faye L. TI Preventing premature deaths from breast and cervical cancer among underserved women in the United States: insights gained from a national cancer screening program SO CANCER CAUSES & CONTROL LA English DT Article DE Early detection of cancer; Healthcare disparities; Vulnerable populations; Mammography; Papanicolaou test; Medically uninsured ID MORTALITY; SERVICES; US AB This commentary highlights some of the valuable insights gained from a special collection of papers that utilized data from the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) and appear in this special issue. The data and experiences of the NBCCEDP can inform the identification of new opportunities and directions for meeting the cancer screening needs of underserved women in a complex and changing health care environment. C1 [White, Mary C.; Wong, Faye L.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP White, MC (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy NE,Mailstop F-76, Atlanta, GA 30341 USA. EM mxw5@cdc.gov RI White, Mary C./C-9242-2012 OI White, Mary C./0000-0002-9826-3962 FU Intramural CDC HHS [CC999999] NR 30 TC 2 Z9 2 U1 2 U2 6 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0957-5243 EI 1573-7225 J9 CANCER CAUSE CONTROL JI Cancer Causes Control PD MAY PY 2015 VL 26 IS 5 SI SI BP 805 EP 809 DI 10.1007/s10552-015-0541-4 PG 5 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA CH9RP UT WOS:000354374200026 PM 25783456 ER PT J AU Ford, ES AF Ford, E. S. TI Lung function, 25-hydroxyvitamin D concentrations and mortality in US adults SO EUROPEAN JOURNAL OF CLINICAL NUTRITION LA English DT Article ID OBSTRUCTIVE PULMONARY-DISEASE; NUTRITION EXAMINATION SURVEY; RESPIRATORY-TRACT INFECTION; VITAMIN-D DEFICIENCY; 3RD NATIONAL-HEALTH; YOUNG FINNISH MEN; CARDIOVASCULAR-DISEASE; UNITED-STATES; PROSPECTIVE COHORT; ALL-CAUSE AB OBJECTIVE: To explore the associations between serum concentrations of vitamin D (25(OH) D) and all-cause mortality among US adults defined by lung function (LF) status, particularly among adults with obstructive LF (OLF). METHODS: Data from 10 795 adults aged 20-79 years (685 with restrictive LF (RLF) and 1309 with OLF) who participated in the Third National Health and Nutrition Examination Survey (1988-1994), had a spirometric examination, and were followed through 2006 were included. RESULTS: During 14.2 years of follow-up, 1792 participants died. Mean adjusted concentrations of 25(OH) D were 75.0 nmol/l (s.e. 0.7) for adults with normal LF (NLF), 70.4 nmol/l (s.e. 1.8) for adults with RLF, 75.5 nmol/l (s.e. 1.5) for adults with mild obstruction and 71.0 nmol/l (s.e. 1.9) among adults with moderate or worse obstruction (P = 0.030). After adjustment for sociodemographic factors, lifestyle factors, clinical variables and prevalent chronic conditions, a concentration of <25 nmol/l compared with >= 75 nmol//l was associated with mortality only among adults with NLF (hazard ratio (HR) 1.76; 95% confidence interval (CI) 1.03, 3.00). Among participants with OLF, adjusted HRs were 0.65 (95% CI 0.29, 1.48), 1.21 (95% CI 0.89, 1.66) and 0.97 (95% CI 0.78, 1.19) among those with concentrations <25, 25- <50 and 50- <75 nmol/l, respectively. CONCLUSIONS: Baseline concentrations of 25(OH) D did not significantly predict mortality among US adults with impaired LF. C1 [Ford, E. S.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Populat Hlth, Atlanta, GA 30341 USA. RP Ford, ES (reprint author), Ctr Dis Control & Prevent, Div Populat Hlth, 4770 Buford Highway,MS F78, Atlanta, GA 30341 USA. EM eford@cdc.gov FU Intramural CDC HHS [CC999999] NR 46 TC 1 Z9 1 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0954-3007 EI 1476-5640 J9 EUR J CLIN NUTR JI Eur. J. Clin. Nutr. PD MAY PY 2015 VL 69 IS 5 BP 572 EP 578 DI 10.1038/ejcn.2014.162 PG 7 WC Nutrition & Dietetics SC Nutrition & Dietetics GA CH5SR UT WOS:000354096100007 PM 25118000 ER PT J AU Bell, JM Taylor, CA Breiding, MJ AF Bell, Jeneita M. Taylor, Christopher A. Breiding, Matthew J. TI The Public Health Approach to TBI Preface SO JOURNAL OF HEAD TRAUMA REHABILITATION LA English DT Editorial Material C1 [Bell, Jeneita M.; Taylor, Christopher A.; Breiding, Matthew J.] Ctr Dis Control & Prevent, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30329 USA. RP Bell, JM (reprint author), Ctr Dis Control & Prevent, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30329 USA. NR 1 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0885-9701 EI 1550-509X J9 J HEAD TRAUMA REHAB JI J. Head Trauma Rehabil. PD MAY-JUN PY 2015 VL 30 IS 3 BP 148 EP 149 DI 10.1097/HTR.0000000000000143 PG 2 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA CH8PJ UT WOS:000354298100127 PM 25955701 ER PT J AU Taylor, CA Greenspan, AI Xu, LK Kresnow, MJ AF Taylor, Christopher A. Greenspan, Arlene I. Xu, Likang Kresnow, Marcie-jo TI Comparability of National Estimates for Traumatic Brain Injury-Related Medical Encounters SO JOURNAL OF HEAD TRAUMA REHABILITATION LA English DT Article DE emergency department visits; epidemiology; hospitalizations; traumatic brain injury AB Objective: To describe similarities and differences in the number of civilian traumatic brain injury (TBI)-related hospitalizations and emergency department visits between national databases that capture US hospital data. Participants: TBI-related hospitalizations included in the National Hospital Discharge Survey (NHDS) and Healthcare Cost and Utilization Project Nationwide Inpatient Sample (HCUP-NIS) and emergency department visits in the National Hospital Ambulatory Medical Care Survey (NHAMCS) and HCUP Nationwide Emergency Department Sample (HCUP-NEDS) for 2006-2010. Design: Cross-sectional design. Main Measures: Nationwide counts of TBI-related medical encounters. Results: Overall, the frequency of TBI is comparable when comparing NHDS with HCUP-NIS and NHAMCS with HCUP-NEDS. However, annual counts in both NHDS and NHAMCS are consistently unstable when examined in smaller subgroups, such as by age group and injury mechanism. Injury mechanism is consistently missing from many more records in NHDS compared with HCUP-NIS. Conclusion: Given the large sample size of HCUP-NIS and HCUP-NEDS, these data can offer a valuable resource for examining TBI-related hospitalization and emergency department visits, especially by subgroup. These data hold promise for future examinations of annual TBI counts, but ongoing comparisons with national probability samples will be necessary to ensure that HCUP continues to track with estimates from these data. C1 [Taylor, Christopher A.; Greenspan, Arlene I.; Xu, Likang; Kresnow, Marcie-jo] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA. RP Taylor, CA (reprint author), Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, 4770 Buford Hwy,MS F-62, Atlanta, GA 30341 USA. EM CATaylor1@cdc.gov FU Intramural CDC HHS [CC999999] NR 17 TC 6 Z9 6 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0885-9701 EI 1550-509X J9 J HEAD TRAUMA REHAB JI J. Head Trauma Rehabil. PD MAY-JUN PY 2015 VL 30 IS 3 BP 150 EP 159 DI 10.1097/HTR.0000000000000105 PG 10 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA CH8PJ UT WOS:000354298100128 PM 25955702 ER PT J AU Cuthbert, JP Harrison-Felix, C Corrigan, JD Bell, JM Haarbauer-Krupa, JK Miller, AC AF Cuthbert, Jeffrey P. Harrison-Felix, Cynthia Corrigan, John D. Bell, Jeneita M. Haarbauer-Krupa, Juliet K. Miller, A. Cate TI Unemployment in the United States After Traumatic Brain Injury for Working-Age Individuals: Prevalence and Associated Factors 2 Years Postinjury SO JOURNAL OF HEAD TRAUMA REHABILITATION LA English DT Article DE injury outcomes; prevalence; TBI; traumatic brain injury; unemployment ID SYSTEMS NATIONAL DATABASE; EMPLOYMENT OUTCOME 2; GALVESTON ORIENTATION; RACIAL-DIFFERENCES; AMNESIA TEST; RETURN; REHABILITATION; REPRESENTATIVENESS; PREDICTORS; DISABILITY AB Objective: To estimate the prevalence of unemployment and part-time employment in the United States for working-age individuals completing rehabilitation for a primary diagnosis of traumatic brain injury (TBI) between 2001 and 2010. Design: Secondary data analysis. Setting: Acute inpatient rehabilitation facilities. Participants: Patients aged 16 to 60 years at injury who completed inpatient rehabilitation for TBI between 2001 and 2010. Main Outcome Measures: Unemployment; Part-time employment. Results: The prevalence of unemployment for persons in the selected cohort was 60.4% at 2-year postinjury. Prevalence of unemployment at 2-year postinjury was significantly associated with the majority of categories of age group, race, gender, marital status, primary inpatient rehabilitation payment source, education, preinjury vocational status, length of stay, and Disability Rating Scale. The direction of association for the majority of these variables complement previous research in this area, with only Hispanic ethnicity and the FIM Cognitive subscale demonstrating disparate findings. For those employed at 2-year postinjury, the prevalence of part-time employment was 35.0%. The model of prevalence for part-time employment at 2-year postinjury was less robust, with significant relationships with some categorical components of age group, gender, marital status, primary payment source, preinjury vocational status, and Disability Rating Scale. Conclusions: The prevalence of unemployment for patients completing inpatient rehabilitation for TBI was substantial (60.4%). The majority of factors found to associate with 2 years' unemployment were complementary of previously published research; however, these were often smaller in magnitude than previous reports. The prevalence of part-time employment was also an issue for this cohort and included 35.0% of all employed individuals. In regard to the determination of factors associated with part-time employment, additional analyses that include more fine-grained factors associated with employment, including physical and psychosocial functioning, are recommended. C1 [Cuthbert, Jeffrey P.; Harrison-Felix, Cynthia] Craig Hosp, Res Dept, Englewood, CO 80113 USA. [Corrigan, John D.] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA. [Bell, Jeneita M.; Haarbauer-Krupa, Juliet K.] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA. [Miller, A. Cate] Natl Inst Disabil & Rehabil Res, Dept Educ, Washington, DC USA. RP Cuthbert, JP (reprint author), Craig Hosp, Res Dept, 3425 S Clarkson St, Englewood, CO 80113 USA. EM JCuthbert@craighospital.org NR 48 TC 5 Z9 5 U1 0 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0885-9701 EI 1550-509X J9 J HEAD TRAUMA REHAB JI J. Head Trauma Rehabil. PD MAY-JUN PY 2015 VL 30 IS 3 BP 160 EP 174 DI 10.1097/HTR.0000000000000090 PG 15 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA CH8PJ UT WOS:000354298100129 PM 25955703 ER PT J AU Coronado, VG Haileyesus, T Cheng, TA Bell, JM Haarbauer-Krupa, J Lionbarger, MR Flores-Herrera, J McGuire, LC Gilchrist, J AF Coronado, Victor G. Haileyesus, Tadesse Cheng, Tabitha A. Bell, Jeneita M. Haarbauer-Krupa, Juliet Lionbarger, Michael R. Flores-Herrera, Javier McGuire, Lisa C. Gilchrist, Julie TI Trends in Sports- and Recreation-Related Traumatic Brain Injuries Treated in US Emergency Departments: The National Electronic Injury Surveillance System-All Injury Program (NEISS-AIP) 2001-2012 SO JOURNAL OF HEAD TRAUMA REHABILITATION LA English DT Article DE emergency department; epidemiology; recreation; sports; traumatic brain injury ID STATES HIGH-SCHOOL; UNITED-STATES; OLDER WOMEN; CONCUSSION; PREVENTION; HEAD; EPIDEMIOLOGY; LEGISLATION; SYMPTOMS; OUTCOMES AB Importance: Sports-and recreation-related traumatic brain injuries (SRR-TBIs) are a growing public health problem affecting persons of all ages in the United States. Objective: To describe the trends of SRR-TBIs treated in US emergency departments (EDs) from 2001 to 2012 and to identify which sports and recreational activities and demographic groups are at higher risk for these injuries. Design: Data on initial ED visits for an SRR-TBI from the National Electronic Injury Surveillance System-All Injury Program (NEISS-AIP) for 2001-2012 were analyzed. Setting: NEISS-AIP data are drawn from a nationally representative sample of hospital-based EDs. Participants: Cases of TBI were identified from approximately 500 000 annual initial visits for all causes and types of injuries treated in EDs captured by NEISS-AIP. Main Outcome Measure(s): Numbers and rates by age group, sex, and year were estimated. Aggregated numbers and percentages by discharge disposition were produced. Results: Approximately 3.42 million ED visits for an SRR-TBI occurred during 2001-2012. During this period, the rates of SRR-TBIs treated in US EDs significantly increased in both males and females regardless of age (all Ps < .001). For males, significant increases ranged from a low of 45.8% (ages 5-9) to a high of 139.8 % (ages 10-14), and for females, from 25.1% (ages 0-4) to 211.5% (ages 15-19) (all Ps < .001). Every year males had about twice the rates of SRR-TBIs than females. Approximately 70% of all SRR-TBIs were reported among persons aged 0 to 19 years. The largest number of SRR-TBIs among males occurred during bicycling, football, and basketball. Among females, the largest number of SRR-TBIs occurred during bicycling, playground activities, and horseback riding. Approximately 89% of males and 91% of females with an SRR-TBI were treated and released from EDs. Conclusion and Relevance: The rates of ED-treated SRR-TBIs increased during 2001-2012, affecting mainly persons aged 0 to 19 years and males in all age groups. Increases began to appear in 2004 for females and 2006 for males. Activities associated with the largest number of TBIs varied by sex and age. Reasons for the reported increases in ED visits are unknown but may be associated with increased awareness of TBI through increased media exposure and from campaigns, such as the Centers for Disease Control and Prevention's Heads Up. Prevention efforts should be targeted by sports and recreational activity, age, and sex. C1 [Coronado, Victor G.; Cheng, Tabitha A.; Bell, Jeneita M.; Haarbauer-Krupa, Juliet; Lionbarger, Michael R.; Gilchrist, Julie] Ctr Dis Control & Prevent, Div Unintent Injury Prevent, Atlanta, GA 30341 USA. [Haileyesus, Tadesse] Ctr Dis Control & Prevent, Div Anal Res Practice Integrat, Atlanta, GA 30341 USA. [Cheng, Tabitha A.] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA. [Cheng, Tabitha A.] Ctr Dis Control & Prevent, Div Sci Educ & Profess Dev, Atlanta, GA 30341 USA. [McGuire, Lisa C.] Ctr Dis Control & Prevent, Div Nutr Phys Act, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Flores-Herrera, Javier] Epidemiol Natl Ctr, Spanish Field Epidemiol Training Program, SUMMA 112, Med Emergency Serv Madrid, Madrid, Spain. RP Coronado, VG (reprint author), Ctr Dis Control & Prevent, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, 4170 Buford Hwy NE,MS F62, Atlanta, GA 30341 USA. EM vgc1@cdc.gov NR 68 TC 17 Z9 17 U1 0 U2 16 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0885-9701 EI 1550-509X J9 J HEAD TRAUMA REHAB JI J. Head Trauma Rehabil. PD MAY-JUN PY 2015 VL 30 IS 3 BP 185 EP 197 DI 10.1097/HTR.0000000000000156 PG 13 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA CH8PJ UT WOS:000354298100131 PM 25955705 ER PT J AU Parker, EM Gilchrist, J Schuster, D Lee, R Sarmiento, K AF Parker, Erin M. Gilchrist, Julie Schuster, Dan Lee, Robin Sarmiento, Kelly TI Reach and Knowledge Change Among Coaches and Other Participants of the Online Course: "Concussion in Sports: What You Need to Know" SO JOURNAL OF HEAD TRAUMA REHABILITATION LA English DT Article DE adolescent; brain concussion; coach; Heads Up; sports; TBI (traumatic brain injury); training programs ID TRAUMATIC BRAIN-INJURIES; HIGH-SCHOOL; RECREATION ACTIVITIES; UNITED-STATES; RECOVERY; CHILDREN; HEADS AB Objectives: To describe the reach of the Heads Up "Concussion in Sports: What You Need to Know," online course and to assess knowledge change. Setting: Online. Participants: Individuals who have taken the free online course since its inception in May 2010 to July 2013. Design: Descriptive, uncontrolled, before and after study design. Main Measures: Reach is measured by the number of unique participants and the number of times the course was completed by state and sport coached and the rate of participation per 100 000 population by state. Knowledge change is measured by the distribution and mean of pre- and posttest scores by sex, primary role (eg, coach, student, and parent), and sport coached. Results: Between May 2010 and July 2013, the online concussion course was completed 819 223 times, reaching 666 026 unique participants, including residents from all US states and the District of Columbia. The distribution of overall scores improved from pre- to posttests, with 21% answering all questions correctly on the pretest and 60% answering all questions correctly on the posttest. Conclusion: Online training can be effective in reaching large audiences and improving knowledge about emerging health and safety issues such as concussion awareness. C1 [Parker, Erin M.; Gilchrist, Julie; Lee, Robin; Sarmiento, Kelly] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Div Unintent Injury Prevent, Atlanta, GA 30341 USA. [Schuster, Dan] Natl Federat State High Sch Associat, Indianapolis, IN USA. RP Parker, EM (reprint author), Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Div Unintent Injury Prevent, 4770 Buford Hwy NE,MS F-62, Atlanta, GA 30341 USA. EM eparker@cdc.gov NR 19 TC 2 Z9 2 U1 2 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0885-9701 EI 1550-509X J9 J HEAD TRAUMA REHAB JI J. Head Trauma Rehabil. PD MAY-JUN PY 2015 VL 30 IS 3 BP 198 EP 206 DI 10.1097/HTR.0000000000000097 PG 9 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA CH8PJ UT WOS:000354298100132 PM 25955706 ER PT J AU Faul, M Bell, J Bergen, G AF Faul, Mark Bell, Jeneita Bergen, Gwen TI Seat Belts and Airbags in Motor Vehicle Crashes: How Protective are These Devices in Preventing or Reducing the Severity of a Traumatic Brain Injury? SO JOURNAL OF HEAD TRAUMA REHABILITATION LA English DT Meeting Abstract C1 [Faul, Mark; Bell, Jeneita; Bergen, Gwen] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 1 Z9 1 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0885-9701 EI 1550-509X J9 J HEAD TRAUMA REHAB JI J. Head Trauma Rehabil. PD MAY-JUN PY 2015 VL 30 IS 3 MA 0087 BP E96 EP E96 PG 1 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA CH8PJ UT WOS:000354298100086 ER PT J AU Haarbauer-Krupa, J Comstock, RD Lionbarger, M Hirsch, S Kavee, A Lowe, B AF Haarbauer-Krupa, Juliet Comstock, R. Dawn Lionbarger, Michael Hirsch, Shawn Kavee, Andrew Lowe, Brooks TI Medical Professional Presence and Return to Play Compliance in Concussed High School Athletes SO JOURNAL OF HEAD TRAUMA REHABILITATION LA English DT Meeting Abstract C1 [Haarbauer-Krupa, Juliet; Lionbarger, Michael] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA. [Comstock, R. Dawn] Colorado Sch Publ Hlth, Aurora, CO USA. [Hirsch, Shawn; Kavee, Andrew; Lowe, Brooks] SciMetrika LLC, Res Triangle Pk, NC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0885-9701 EI 1550-509X J9 J HEAD TRAUMA REHAB JI J. Head Trauma Rehabil. PD MAY-JUN PY 2015 VL 30 IS 3 MA 0011 BP E65 EP E66 PG 2 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA CH8PJ UT WOS:000354298100017 ER PT J AU Cook, J Xu, WP Msellem, M Vonk, M Bergstrom, B Gosling, R Al-Mafazy, AW McElroy, P Molteni, F Abass, AK Garimo, I Ramsan, M Ali, A Martensson, A Bjorkman, A AF Cook, Jackie Xu, Weiping Msellem, Mwinyi Vonk, Marlotte Bergstrom, Beatrice Gosling, Roly Al-Mafazy, Abdul-Wahid McElroy, Peter Molteni, Fabrizio Abass, Ali K. Garimo, Issa Ramsan, Mahdi Ali, Abdullah Martensson, Andreas Bjorkman, Anders TI Mass Screening and Treatment on the Basis of Results of a Plasmodium falciparum-Specific Rapid Diagnostic Test Did Not Reduce Malaria Incidence in Zanzibar SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE malaria elimination; mass screening and treatment; diagnostic tests; Zanzibar; subpatent; molecular methods; Plasmodium falciparum; Plasmodium vivax; Plasmodium malariae; Plasmodium ovale ID POLYMERASE-CHAIN-REACTION; UGANDAN CHILDREN; OVALE-WALLIKERI; FOREST MALARIA; VIVAX-MALARIA; TRANSMISSION; INFECTIONS; PCR; PARASITES; ETHIOPIA AB Background. Seasonal increases in malaria continue in hot spots in Zanzibar. Mass screening and treatment (MSAT) may help reduce the reservoir of infection; however, it is unclear whether rapid diagnostic tests (RDTs) detect a sufficient proportion of low-density infections to influence subsequent transmission. Methods. Two rounds of MSAT using Plasmodium falciparum-specific RDT were conducted in 5 hot spots (population, 12 000) in Zanzibar in 2012. In parallel, blood samples were collected on filter paper for polymerase chain reaction (PCR) analyses. Data on confirmed malarial parasite infections from health facilities in intervention and hot spot control areas were monitored as proxy for malaria transmission. Results. Approximately 64% of the population (7859) were screened at least once. P. falciparum prevalence, as measured by RDT, was 0.2% (95% confidence interval [CI], .1%-. 3%) in both rounds, compared with PCR measured prevalences (for all species) of 2.5% (95% CI, 2.1%-2.9%) and 3.8% (95% CI, 3.2%-4.4%) in rounds 1 and 2, respectively. Two fifths (40%) of infections detected by PCR included non-falciparum species. Treatment of RDT-positive individuals (4% of the PCR-detected parasite carriers) did not reduce subsequent malaria incidence, compared with control areas. Conclusions. Highly sensitive point-of-care diagnostic tools for detection of all human malaria species are needed to make MSAT an effective strategy in settings where malaria elimination programs are in the pre-elimination phase. C1 [Cook, Jackie; Xu, Weiping; Vonk, Marlotte; Bergstrom, Beatrice; Martensson, Andreas; Bjorkman, Anders] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Stockholm, Sweden. [Martensson, Andreas] Karolinska Inst, Dept Publ Hlth Sci, Global Hlth, Stockholm, Sweden. [Martensson, Andreas] Uppsala Univ, Ctr Clin Res Sormland, Uppsala, Sweden. [Msellem, Mwinyi; Al-Mafazy, Abdul-Wahid; Abass, Ali K.; Ali, Abdullah] Minist Hlth, Zanzibar Malaria Eliminat Programme, Dar Es Salaam, Tanzania. [McElroy, Peter] US Presidents Malaria Initiat, Dar Es Salaam, Tanzania. [McElroy, Peter] Ctr Dis Control & Prevent Tanzania, Dar Es Salaam, Tanzania. [Molteni, Fabrizio] Swiss Trop & Publ Hlth Inst, Dar Es Salaam, Tanzania. [Garimo, Issa; Ramsan, Mahdi] RTI Int, Dar Es Salaam, Tanzania. [Gosling, Roly] Univ Calif San Francisco, Global Hlth Grp, San Francisco, CA 94143 USA. [McElroy, Peter] Ctr Dis Control & Prevent, Malaria Branch, Atlanta, GA USA. [Molteni, Fabrizio] Univ Basel, CH-4003 Basel, Switzerland. RP Cook, J (reprint author), Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Nobels Vag 15, Stockholm, Sweden. EM jackie.cook@ki.se FU Swedish Research Council [521-2012-3255]; Bill and Melinda Gates Foundation [OPP 1013170]; President's Malaria Initiative, US Agency for International Development; Centers for Disease Control and Prevention; Revolutionary Government of Zanzibar FX This work was supported by the Swedish Research Council (grant 521-2012-3255 to the Karolinska Institutet); the Bill and Melinda Gates Foundation (grant OPP 1013170); the President's Malaria Initiative, US Agency for International Development, under an interagency agreement with the Centers for Disease Control and Prevention; and the Revolutionary Government of Zanzibar. NR 43 TC 17 Z9 17 U1 0 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD MAY 1 PY 2015 VL 211 IS 9 BP 1476 EP 1483 DI 10.1093/infdis/jiu655 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CI4LZ UT WOS:000354722000016 PM 25429102 ER PT J AU McNamara, LA Shumate, AM Johnsen, P MacNeil, JR Patel, M Bhavsar, T Cohn, AC Dinitz-Sklar, J Duffy, J Finnie, J Garon, D Hary, R Hu, F Kamiya, H Kim, HJ Kolligian, J Neglia, J Oakley, J Wagner, J Wagner, K Wang, X Yu, Y Montana, B Tan, C Izzo, R Clark, TA AF McNamara, Lucy A. Shumate, Alice M. Johnsen, Peter MacNeil, Jessica R. Patel, Manisha Bhavsar, Tina Cohn, Amanda C. Dinitz-Sklar, Jill Duffy, Jonathan Finnie, Janet Garon, Denise Hary, Robert Hu, Fang Kamiya, Hajime Kim, Hye-Joo Kolligian, John, Jr. Neglia, Janet Oakley, Judith Wagner, Jacqueline Wagner, Kathy Wang, Xin Yu, Yon Montana, Barbara Tan, Christina Izzo, Robin Clark, Thomas A. TI First Use of a Serogroup B Meningococcal Vaccine in the US in Response to a University Outbreak SO PEDIATRICS LA English DT Article ID REAL-TIME PCR; NEISSERIA-MENINGITIDIS; UNITED-STATES; COLLEGE-STUDENTS; OBSERVER-BLIND; DISEASE; IDENTIFICATION; ADOLESCENTS; PREVALENCE; DIVERSITY AB BACKGROUND: In 2013-2014, an outbreak of serogroup B meningococcal disease occurred among persons linked to a New Jersey university (University A). In the absence of a licensed serogroup B meningococcal (MenB) vaccine in the United States, the Food and Drug Administration authorized use of an investigational MenB vaccine to control the outbreak. An investigation of the outbreak and response was undertaken to determine the population at risk and assess vaccination coverage. METHODS: The epidemiologic investigation relied on compilation and review of case and population data, laboratory typing of meningococcal isolates, and unstructured interviews with university staff. Vaccination coverage data were collected during the vaccination campaign held under an expanded-access Investigational New Drug protocol. RESULTS: Between March 25, 2013, and March 10, 2014, 9 cases of serogroup B meningococcal disease occurred in persons linked to University A. Laboratory typing results were identical for all 8 isolates available. Through May 14, 2014, 89.1% coverage with the 2-dose vaccination series was achieved in the target population. From the initiation of MenB vaccination through February 1, 2015, no additional cases of serogroup B meningococcal disease occurred in University A students. However, the ninth case occurred in March 2014 in an unvaccinated close contact of University A students. CONCLUSIONS: No serogroup B meningococcal disease cases occurred in persons who received 1 or more doses of 4CMenB vaccine, suggesting 4CMenB may have protected vaccinated individuals from disease. However, the ninth case demonstrates that carriage of serogroup B Neisseria meningitidis among vaccinated persons was not eliminated. C1 [McNamara, Lucy A.; Shumate, Alice M.; Kamiya, Hajime] Ctr Dis Control & Prevent, Epidem Intelligence Serv Program, Div Sci Educ & Profess Dev, Ctr Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA. [McNamara, Lucy A.; MacNeil, Jessica R.; Patel, Manisha; Cohn, Amanda C.; Hu, Fang; Kamiya, Hajime; Wang, Xin; Clark, Thomas A.] Ctr Dis Control & Prevent, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Bhavsar, Tina; Kim, Hye-Joo; Yu, Yon] Ctr Dis Control & Prevent, Regulatory Affairs, Off Director, Atlanta, GA 30333 USA. [Duffy, Jonathan] Ctr Dis Control & Prevent, Immunizat Safety Off, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Shumate, Alice M.; Dinitz-Sklar, Jill; Garon, Denise; Montana, Barbara; Tan, Christina] New Jersey Dept Hlth, Trenton, NJ USA. [Johnsen, Peter; Finnie, Janet; Kolligian, John, Jr.; Neglia, Janet; Oakley, Judith; Wagner, Jacqueline; Wagner, Kathy; Izzo, Robin] Princeton Univ, Princeton, NJ 08544 USA. [Dinitz-Sklar, Jill] Mercer Cty Div Publ Hlth, Trenton, NJ USA. [Hary, Robert] Princeton Hlth Dept, Princeton, NJ USA. RP McNamara, LA (reprint author), Ctr Dis Control & Prevent, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd,MS C 25, Atlanta, GA 30333 USA. EM xdf4@cdc.gov OI McNamara, Lucy/0000-0001-8240-7493 FU Centers for Disease Control and Prevention [5U38HM000414-5] FX Supported in part by an appointment to the Applied Epidemiology Fellowship Program administered by the Council of State and Territorial Epidemiologists (CSTE) and funded by the Centers for Disease Control and Prevention Cooperative Agreement 5U38HM000414-5. NR 22 TC 24 Z9 24 U1 1 U2 6 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD MAY PY 2015 VL 135 IS 5 BP 798 EP 804 DI 10.1542/peds.2014-4015 PG 7 WC Pediatrics SC Pediatrics GA CH0QX UT WOS:000353728400041 PM 25917990 ER PT J AU Dunn, AC Black, CL Arnold, J Brodine, S Waalen, J Binkin, N AF Dunn, Angela C. Black, Carla L. Arnold, John Brodine, Stephanie Waalen, Jill Binkin, Nancy TI Childhood Vaccination Coverage Rates Among Military Dependents in the United States SO PEDIATRICS LA English DT Article ID HEALTH-CARE-SYSTEM; AGED 19-35 MONTHS; IMMUNIZATION STATUS; RACIAL/ETHNIC DISPARITIES; PRESCHOOL-CHILDREN; RECORD SCATTERING; INSURANCE STATUS; US CHILDREN; IMPACT; POPULATION AB BACKGROUND AND OBJECTIVES: The Military Health System provides universal coverage of all recommended childhood vaccinations. Few studies have examined the effect that being insured by the Military Health System has on childhood vaccination coverage. The purpose of this study was to compare the coverage of the universally recommended vaccines among military dependents versus other insured and uninsured children using a nationwide sample of children. METHODS: The National Immunization Survey is a multistage, random-digit dialing survey designed to measure vaccination coverage estimates of US children aged 19 to 35 months old. Data from 2007 through 2012 were combined to permit comparison of vaccination coverage among military dependent and all other children. RESULTS: Among military dependents, 28.0% of children aged 19 to 35 months were not up to date on the 4: 3: 1: 3: 3: 1 vaccination series excluding Haemophilus influenzae type b vaccine compared with 21.1% of all other children (odds ratio: 1.4; 95% confidence interval: 1.2-1.6). After controlling for sociodemographic characteristics, compared with all other US children, military dependent children were more likely to be incompletely vaccinated (odds ratio: 1.3; 95% confidence interval: 1.1-1.5). CONCLUSIONS: Lower vaccination coverage rates among US military dependent children might be due to this population being highly mobile. However, the lack of a military-wide childhood immunization registry and incomplete documentation of vaccinations could contribute to the lower vaccination coverage rates seen in this study. These results suggest the need for further investigation to evaluate vaccination coverage of children with complete ascertainment of vaccination history, and if lower immunization rates are verified, assessment of reasons for lower vaccination coverage rates among military dependent children. C1 [Dunn, Angela C.; Waalen, Jill] Univ Calif San Diego, Dept Family & Prevent Med, La Jolla, CA 92093 USA. [Dunn, Angela C.; Brodine, Stephanie; Waalen, Jill; Binkin, Nancy] San Diego State Univ, Grad Sch Publ Hlth, San Diego, CA 92182 USA. [Black, Carla L.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Arnold, John] Naval Med Ctr San Diego, Dept Pediat, San Diego, CA USA. RP Dunn, AC (reprint author), Univ Calif San Diego, Dept Family & Prevent Med, 9500 Gilman Dr,0811, La Jolla, CA 92093 USA. EM acdunn@cdc.gov NR 40 TC 0 Z9 0 U1 1 U2 2 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD MAY PY 2015 VL 135 IS 5 BP E1148 EP E1156 DI 10.1542/peds.2014-2101 PG 9 WC Pediatrics SC Pediatrics GA CH0QX UT WOS:000353728400005 PM 25869378 ER PT J AU Jo, H Schieve, LA Sharma, AJ Hinkle, SN Li, RW Lind, JN AF Jo, Heejoo Schieve, Laura A. Sharma, Andrea J. Hinkle, Stefanie N. Li, Ruowei Lind, Jennifer N. TI Maternal Prepregnancy Body Mass Index and Child Psychosocial Development at 6 Years of Age SO PEDIATRICS LA English DT Article ID DIFFICULTIES QUESTIONNAIRE; INTELLECTUAL DISABILITY; PSYCHOMETRIC PROPERTIES; COGNITIVE-DEVELOPMENT; WEIGHT-GAIN; PREGNANCY; OBESITY; ASSOCIATIONS; TRENDS; RISK AB BACKGROUND: Both obesity and developmental disabilities have increased in recent decades. Limited studies suggest associations between maternal prepregnancy obesity and child neurodevelopment. METHODS: The Infant Feeding Practices Study II, a US nationally distributed longitudinal study of maternal health and infant health and feeding practices, was conducted from 2005 to 2007. In 2012, mothers were recontacted for information on their children's health and development. We examined associations between maternal prepregnancy BMI and child psychosocial development in 1311 mother-child pairs included in this follow-up study. Children's development was assessed by maternal report of child psychosocial difficulties from the Strengths and Difficulties Questionnaire, past developmental diagnoses, and receipt of special needs services. RESULTS: Adjusting for sociodemographic factors, children of obese class II/III mothers (BMI > 35.0) had increased odds of emotional symptoms (adjusted odds ratio [aOR] 2.24; 95% confidence interval [CI], 1.27-3.98), peer problems (aOR 2.07; 95% CI, 1.26-3.40), total psychosocial difficulties (aOR 2.17; 95% CI, 1.24-3.77), attention-deficit/hyperactivity disorder diagnosis (aOR 4.55; 95% CI, 1.80-11.46), autism or developmental delay diagnosis (aOR 3.13; 95% CI, 1.10-8.94), receipt of speech language therapy (aOR 1.93; 95% CI, 1.18-3.15), receipt of psychological services (aOR 2.27; 95% CI, 1.09-4.73), and receipt of any special needs service (aOR 1.99; 95% CI, 1.33-2.97) compared with children of normal weight mothers (BMI 18.5-24.9). Adjustment for potential causal pathway factors including pregnancy weight gain, gestational diabetes, breastfeeding duration, postpartum depression, and child's birth weight did not substantially affect most estimates. CONCLUSIONS: Children whose mothers were severely obese before pregnancy had increased risk for adverse developmental outcomes. C1 [Jo, Heejoo; Schieve, Laura A.] Ctr Dis Control & Prevent, Div Birth Defects & Dev Disabil, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Li, Ruowei; Lind, Jennifer N.] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA 30333 USA. [Lind, Jennifer N.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Off Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA. [Jo, Heejoo] Oak Ridge Inst Sci & Educ, Oak Ridge, TN USA. [Sharma, Andrea J.] Ctr Dis Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Reprod Hlth, Atlanta, GA 30333 USA. [Sharma, Andrea J.; Lind, Jennifer N.] US Publ Hlth Serv Commissioned Corps, Atlanta, GA USA. [Hinkle, Stefanie N.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Div Intramural Populat Hlth Res, NIH, Bethesda, MD USA. RP Jo, H (reprint author), Ctr Dis Control & Prevent, Div Birth Defects & Dev Disabil, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd,MS-E86, Atlanta, GA 30333 USA. EM heejoojo@usc.edu RI Hinkle, Stefanie/F-8253-2013; OI Hinkle, Stefanie/0000-0003-4312-708X; Sharma, Andrea/0000-0003-0385-0011 FU intramural research program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health; National Institutes of Health (NIH) FX Supported in part by the intramural research program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health. Funded by the National Institutes of Health (NIH). NR 42 TC 12 Z9 12 U1 3 U2 21 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD MAY PY 2015 VL 135 IS 5 BP E1198 EP E1209 DI 10.1542/peds.2014-3058 PG 12 WC Pediatrics SC Pediatrics GA CH0QX UT WOS:000353728400011 PM 25917989 ER PT J AU Schillie, S Walker, T Veselsky, S Crowley, S Dusek, C Lazaroff, J Morris, SA Onye, K Ko, S Fenlon, N Nelson, NP Murphy, TV AF Schillie, Sarah Walker, Tanja Veselsky, Steven Crowley, Susan Dusek, Cristina Lazaroff, Julie Morris, Sandra A. Onye, Kenneth Ko, Stephen Fenlon, Nancy Nelson, Noele P. Murphy, Trudy V. TI Outcomes of Infants Born to Women Infected With Hepatitis B SO PEDIATRICS LA English DT Article ID PERINATAL TRANSMISSION; E-ANTIGEN; SURFACE-ANTIGEN; IMMUNE GLOBULIN; CARRIER STATE; FOLLOW-UP; VIRUS; PREGNANCY; EFFICACY; MOTHERS AB BACKGROUND AND OBJECTIVES: Perinatal exposure is an important mode of hepatitis B virus (HBV) transmission, resulting in chronic disease in similar to 90% of infected infants. Immunoprophylaxis recommended for infants born to hepatitis B surface antigen-positive mothers reduces up to 95% of perinatal HBV infections. We sought to identify factors associated with perinatal HBV transmission. METHODS: We analyzed prospectively collected data from 5 of 64 US-funded Perinatal Hepatitis B Prevention Programs during 2007-2013. We examined effects of maternal demographic and laboratory results, infant gestational age and birth weight, and immunoprophylactic management on perinatal HBV infection. RESULTS: Data from 17 951 mother-infant pairs were analyzed. Among 9252 (51.5%) infants for whom hepatitis B surface antigen testing results were available, 100 (1.1%) acquired perinatal HBV infection. Both hepatitis B (HepB) vaccine and hepatitis B immune globulin were administered within 12 hours of birth for 10 760 (94.9%) of 11 335 infants with information. Perinatal HBV infection was associated with younger maternal age (P = .01), Asian/Pacific Islander race (P < .01), maternal hepatitis B e-antigen positivity (P < .01), maternal antibody to hepatitis B e-antigen negativity (P < .01), maternal viral load >= 2000 IU/mL (P = .04), and infant receipt of <3 HepB vaccine doses (P = .01). Four infants born to 429 mothers with viral load testing were infected; all 4 were born to mothers with viral loads in the ninth or tenth decile. CONCLUSIONS: Perinatal HBV infection occurred among 1% of infants, most of whom received recommended immunoprophylaxis. Infants at greatest risk of infection were those born to women who were younger, hepatitis B e-antigen positive, or who had a high viral load or those infants who received <3 HepB vaccine doses. C1 [Schillie, Sarah; Veselsky, Steven; Ko, Stephen; Nelson, Noele P.; Murphy, Trudy V.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA 30333 USA. [Walker, Tanja] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. [Fenlon, Nancy] Ctr Dis Control & Prevent, Div Immunizat Serv, Atlanta, GA 30333 USA. [Crowley, Susan] Minnesota Dept Hlth, St Paul, MN USA. [Dusek, Cristina] Florida Dept Hlth, Tallahassee, FL USA. [Lazaroff, Julie] New York City Dept Hlth & Mental Hyg, New York, NY USA. [Morris, Sandra A.] Texas Dept State Hlth Serv, Austin, TX USA. [Onye, Kenneth] Michigan Dept Community Hlth, Lansing, MI USA. RP Schillie, S (reprint author), Ctr Dis Control & Prevent, Div Viral Hepatitis, MS G-37,1600 Clifton Rd, Atlanta, GA 30333 USA. EM sschillie@cdc.gov NR 30 TC 8 Z9 8 U1 0 U2 3 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD MAY PY 2015 VL 135 IS 5 BP E1141 EP E1147 DI 10.1542/peds.2014-3213 PG 7 WC Pediatrics SC Pediatrics GA CH0QX UT WOS:000353728400004 PM 25896839 ER PT J AU Lowell, JL Antolin, MF Andersen, GL Hu, P Stokowski, RP Gage, KL AF Lowell, Jennifer L. Antolin, Michael F. Andersen, Gary L. Hu, Ping Stokowski, Renee P. Gage, Kenneth L. TI Single-Nucleotide Polymorphisms Reveal Spatial Diversity Among Clones of Yersinia pestis During Plague Outbreaks in Colorado and the Western United States SO VECTOR-BORNE AND ZOONOTIC DISEASES LA English DT Article DE Colorado; Spatial diversity; Yersinia pestis; Plague-Single-nucleotide polymorphisms; Western United States ID TAILED PRAIRIE DOGS; COMPLETE GENOME SEQUENCE; CYNOMYS-LUDOVICIANUS; EVOLUTION; CLIMATE; POPULATIONS; ABUNDANCE; PERSISTENCE; THRESHOLDS; EPIZOOTICS AB Background: In western North America, plague epizootics caused by Yersinia pestis appear to sweep across landscapes, primarily infecting and killing rodents, especially ground squirrels and prairie dogs. During these epizootics, the risk of Y. pestis transmission to humans is highest. While empirical models that include climatic conditions and densities of rodent hosts and fleas can predict when epizootics are triggered, bacterial transmission patterns across landscapes, and the scale at which Y. pestis is maintained in nature during inter-epizootic periods, are poorly defined. Elucidating the spatial extent of Y. pestis clones during epizootics can determine whether bacteria are propagated across landscapes or arise independently from local inter-epizootic maintenance reservoirs. Material and Methods: We used DNA microarray technology to identify single-nucleotide polymorphisms (SNPs) in 34 Y. pestis isolates collected in the western United States from 1980 to 2006, 21 of which were collected during plague epizootics in Colorado. Phylogenetic comparisons were used to elucidate the hypothesized spread of Y. pestis between the mountainous Front Range and the eastern plains of northern Colorado during epizootics. Isolates collected from across the western United States were included for regional comparisons. Results: By identifying SNPs that mark individual clones, our results strongly suggest that Y. pestis is maintained locally and that widespread epizootic activity is caused by multiple clones arising independently at small geographic scales. This is in contrast to propagation of individual clones being transported widely across landscapes. Regionally, our data are consistent with the notion that Y. pestis diversifies at relatively local scales following long-range translocation events. We recommend that surveillance and prediction by public health and wildlife management professionals focus more on models of local or regional weather patterns and ecological factors that may increase risk of widespread epizootics, rather than predicting or attempting to explain epizootics on the basis of movement of host species that may transport plague. C1 [Lowell, Jennifer L.] Carroll Coll, Dept Hlth Sci, Helena, MT 59625 USA. [Lowell, Jennifer L.; Antolin, Michael F.] Colorado State Univ, Dept Biol, Ft Collins, CO 80523 USA. [Andersen, Gary L.; Hu, Ping] Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Div Earth Sci, Berkeley, CA 94720 USA. [Stokowski, Renee P.] Ariosa Diagnost, San Jose, CA USA. [Lowell, Jennifer L.; Gage, Kenneth L.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO USA. RP Lowell, JL (reprint author), Carroll Coll, Dept Hlth Sci, 1601 N Benton Ave, Helena, MT 59625 USA. EM jlowell@carroll.edu RI Hu, Ping/G-2384-2015; Andersen, Gary/G-2792-2015 OI Andersen, Gary/0000-0002-1618-9827 FU ISTC Biotechnology Engagement Program [K- 584 p]; National Science Foundation-Ecology of Infectious Diseases (NSF-EID) [0327052] FX We thank John Montenieri and Scott Bearden from the Centers for Disease Control and Prevention, Division of Vector Borne Diseases, respectively, for geographic information systems and laboratory support. We also thank Dan Tripp and the field crews from the Antolin Laboratory at Colorado State University, Fort Collins, CO. This work was supported by the ISTC Biotechnology Engagement Program (award K- 584 p) and National Science Foundation-Ecology of Infectious Diseases (NSF-EID) (grant no. 0327052). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 63 TC 4 Z9 4 U1 4 U2 22 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1530-3667 EI 1557-7759 J9 VECTOR-BORNE ZOONOT JI Vector-Borne Zoonotic Dis. PD MAY 1 PY 2015 VL 15 IS 5 BP 291 EP 302 DI 10.1089/vbz.2014.1714 PG 12 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA CI3XV UT WOS:000354681600002 PM 25988438 ER PT J AU Yendell, SJ Fischer, M Staples, JE AF Yendell, Stephanie J. Fischer, Marc Staples, J. Erin TI Colorado Tick Fever in the United States, 2002-2012 SO VECTOR-BORNE AND ZOONOTIC DISEASES LA English DT Article DE Tick-borne diseases; Colorado tick fever virus; Public health surveillance; Coltivirus ID MOUNTAIN WOOD TICK; VIRUS; INFECTION AB Background: Colorado tick fever (CTF) is an acute systemic febrile illness caused by the CTF virus (CTFV). The last national summary of CTF cases in the United States included cases reported through 2001. This study summarizes national surveillance data for CTF from 2002 through 2012 and examines trends in the epidemiology and testing of identified CTF cases. Methods: Because CTF is not nationally notifiable, we identified CTF cases through solicited reports from state health departments and diagnostic laboratory records. For all cases, we collected data on age, sex, county of residence, travel history, symptom onset date, laboratory testing, and clinical outcome. Poisson regression was used to examine trends over time in case counts, and simple linear regression and logistic regression were used to examine trends in case characteristics. Results: From 2002 through 2012, 75 CTF cases were identified with a median of five cases per year (range 3-14). Forty-seven (63%) cases occurred in males and 49 (65%) occurred in people aged >= 40 years. The majority (80%) of cases had onset of illness during May through July. Cases occurred in residents of 14 states but the infections were acquired in six western states. Wyoming had the highest annual incidence of CTF among residents (3.4 cases per million population), followed by Montana (1.5 per million), and Utah (0.5 per million). Over the 11 years, there was an increase in the proportion of cases diagnosed by RT-PCR testing and in the proportion of cases among travelers to another state. Conclusions: CTF cases continue to occur annually among residents and visitors to the western United States. Public health prevention messages about decreasing tick exposure should be targeted to residents and travelers who will spend time outdoors in an endemic region during the spring and summer months. C1 [Yendell, Stephanie J.; Fischer, Marc; Staples, J. Erin] Ctr Dis Control & Prevent, Arboviral Dis Branch, Ft Collins, CO 80521 USA. [Yendell, Stephanie J.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. RP Staples, JE (reprint author), Ctr Dis Control & Prevent, Arboviral Dis Branch, 3156 Rampart Rd, Ft Collins, CO 80521 USA. EM estaples@cdc.gov NR 18 TC 1 Z9 1 U1 3 U2 5 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1530-3667 EI 1557-7759 J9 VECTOR-BORNE ZOONOT JI Vector-Borne Zoonotic Dis. PD MAY 1 PY 2015 VL 15 IS 5 BP 311 EP 316 DI 10.1089/vbz.2014.1755 PG 6 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA CI3XV UT WOS:000354681600004 PM 25988440 ER PT J AU Kebaabetswe, PM Stirratt, MJ McLellan-Lemal, E Henderson, FL Gray, SC Rose, CE Williams, T Paxton, LA AF Kebaabetswe, Poloko M. Stirratt, Michael J. McLellan-Lemal, Eleanor Henderson, Faith L. Gray, Simone C. Rose, Charles E. Williams, Tiffany Paxton, Lynn A. TI Factors Associated with Adherence and Concordance Between Measurement Strategies in an HIV Daily Oral Tenofovir/Emtricitibine as Pre-exposure Prophylaxis (Prep) Clinical Trial, Botswana, 2007-2010 SO AIDS AND BEHAVIOR LA English DT Article DE Oral pre-exposure prophylaxis (PrEP); Adherence; HIV prevention ID ANTIRETROVIRAL MEDICATIONS; BEHAVIOR-CHANGE; DOUBLE-BLIND; PREVENTION; INFECTION; WOMEN; TENOFOVIR; CHEMOPROPHYLAXIS; ACCEPTABILITY; CHALLENGES AB This study examined study product adherence and its determinants in the Botswana oral pre-exposure prophylaxis efficacy trial. Among the 1,219 participants, the mean adherence by pill count and 3-day self-report was 94 % for each. In multivariable models, pill count adherence was significantly associated with adverse events (nausea, dizziness, vomiting) (RR 0.98 95 % CI 0.98-1.00; p = 0.03) and side effect concerns (RR 0.98 95 % CI 0.96-0.99; p = 0.01). Self-reported adherence was significantly associated with having an HIV-positive partner (RR 1.02 95 % CI 1.00-1.04; p = 0.02) and Francistown residence (RR 0.98 95 % CI 0.96, 0.99; p = 0.0001). Detectable drug concentrations showed modest associations with self-report and pill count adherence, and drug levels were higher among those self-reporting 100 % adherence than those reporting < 100 %. Most common adherence barriers involved refill delays and other logistic challenges; cellphone alarm reminder use was the most common facilitator. C1 [Kebaabetswe, Poloko M.] CDC Botswana, HIV Prevent Res Unit, Gaborone, Botswana. [Kebaabetswe, Poloko M.] Univ Botswana, Sch Med, Gaborone, Botswana. [Stirratt, Michael J.] NIMH, Div AIDS Res, Bethesda, MD 20892 USA. [McLellan-Lemal, Eleanor; Henderson, Faith L.; Gray, Simone C.; Rose, Charles E.; Williams, Tiffany; Paxton, Lynn A.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Off Infect Dis, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Williams, Tiffany] ICF Int, Atlanta, GA USA. RP McLellan-Lemal, E (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Off Infect Dis, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, 1600 Clifton Rd,MS E-45, Atlanta, GA 30333 USA. EM poloko.kebaabetswe@mopipi.ub.bw; stirrattm@mail.nih.gov; emclellanlemal@cdc.gov; fhenderson@cdc.gov; simonegray@cdc.gov; crose@cdc.gov; twilliams13@cdc.gov; paxtonl@tz.cdc.gov FU Centers for Disease Control and Prevention National, Office of Infectious Diseases, Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Division of HIV/AIDS Prevention FX Funding for this study was provided by the Centers for Disease Control and Prevention National, Office of Infectious Diseases, Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Division of HIV/AIDS Prevention. TDF2 Clinical-Trials.gov number: NCT00448669. We are indebted to all TDF2 participants and the entire HIV Prevention Research Team, and appreciate the leadership of Drs. Michael Thigpen and Dawn Smith. NR 42 TC 2 Z9 2 U1 1 U2 2 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 EI 1573-3254 J9 AIDS BEHAV JI AIDS Behav. PD MAY PY 2015 VL 19 IS 5 BP 758 EP 769 DI 10.1007/s10461-014-0891-z PG 12 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA CH2WU UT WOS:000353886500003 PM 25186785 ER PT J AU Diallo, K Zheng, DP Rottinghaus, EK Bassey, O Yang, CF AF Diallo, Karidia Zheng, Du-Ping Rottinghaus, Erin K. Bassey, Orji Yang, Chunfu TI Viral Genetic Diversity and Polymorphisms in a Cohort of HIV-1-Infected Patients Eligible for Initiation of Antiretroviral Therapy in Abuja, Nigeria SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; DRUG-RESISTANCE MUTATIONS; HIV TYPE-1 SUBTYPE; NON-B-SUBTYPE; TREATMENT-NAIVE PATIENTS; NORTH-CENTRAL NIGERIA; REVERSE-TRANSCRIPTASE; PROTEASE INHIBITORS; PREGNANT-WOMEN; NONNUCLEOSIDE INHIBITORS AB Studying the genetic diversity and natural polymorphisms of HIV-1 would benefit our understanding of HIV drug resistance (HIVDR) development and predict treatment outcomes. In this study, we have characterized the HIV-1 genetic diversity and natural polymorphisms at the 5 ' region of the pol gene encompassing the protease (PR) and reverse transcriptase (RT) from 271 plasma specimens collected in 2008 from HIV-1-infected patients who were eligible for initiating antiretroviral therapy in Abuja (Nigeria). The analysis indicated that the predominant subtype was subtype G (31.0%), followed by CRF02-AG (19.2 %), CRF43-02G (18.5%), and A/CRF36-cpx (11.4%); the remaining (19.9%) were other subtypes and circulating (CRF) and unique (URF) recombinant forms. Recombinant viruses (68.6%) were the major viral strains in the region. Eighty-four subtype G sequences were further mainly classified into two major and two minor clusters; sequences in the two major clusters were closely related to the HIV-1 strains in two of the three major subtype G clusters detected worldwide. Those in the two minor clusters appear to be new subtype G strains circulating only in Abuja. The pretreatment DR prevalence was <3%; however, numerous natural polymorphisms were present. Eleven polymorphic mutations (G16E, K20I, L23P, E35D, M36I, N37D/S/T, R57K, L63P, and V82I) were detected in the PR that were subtype or CRF specific while only three mutations (D123N, I135T, and I135V) were identified in the RT. Overall, this study indicates an evolving HIV-1 epidemic in Abuja with recombinant viruses becoming the dominant strains and the emergence of new subtype G strains; pretreatment HIVDR was low and the occurrence of natural polymorphism in the PR region was subtype or CRF dependent. C1 [Diallo, Karidia; Zheng, Du-Ping; Rottinghaus, Erin K.; Yang, Chunfu] Ctr Dis Control & Prevent, Int Lab Branch, Div Global HIV AIDS, CGH, Atlanta, GA 30333 USA. [Bassey, Orji] Ctr Dis Control & Prevent, Abuja, Nigeria. RP Yang, CF (reprint author), Ctr Dis Control & Prevent, Int Lab Branch, Div Global HIV AIDS, CGH, Mail Stop A-11,1600 Clifton Rd,NE, Atlanta, GA 30333 USA. EM cxy0@cdc.gov FU President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention FX This research was supported by the President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention. NR 73 TC 2 Z9 2 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD MAY 1 PY 2015 VL 31 IS 5 BP 564 EP 575 DI 10.1089/aid.2014.0168 PG 12 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA CH0FN UT WOS:000353695000017 PM 25582324 ER PT J AU Maalouf, J Cogswell, ME Yuan, K Martin, C Gunn, JP Pehrsson, P Merritt, R Bowman, B AF Maalouf, Joyce Cogswell, Mary E. Yuan, Keming Martin, Carrie Gunn, Janelle P. Pehrsson, Pamela Merritt, Robert Bowman, Barbara TI Top sources of dietary sodium from birth to age 24 mo, United States, 2003-2010 SO AMERICAN JOURNAL OF CLINICAL NUTRITION LA English DT Article DE children; infants; nutrition; sodium; birth; foods; toddler ID BLOOD-PRESSURE TRENDS; NON-HISPANIC INFANTS; FEEDING INFANTS; US INFANTS; CHILDREN; CHILDHOOD; TODDLERS; METAANALYSIS; ADOLESCENTS; CONSUMPTION AB Background: Sodium intake is high in US children. Data are limited on the dietary sources of sodium, especially from birth to age 24 mo. Objective: We identified top sources of dietary sodium in US children from birth to age 24 mo. Design: Data from the NHANES 2003-2010 were used to examine food sources of sodium (population proportions and mean intakes) in 778 participants aged 0-5.9 mo, 914 participants aged 6-11.9 mo, and 1219 participants aged 12-23.9 mo by sociodemographic characteristics. Results: Overall, mean dietary sodium intake was low in 0-5.9-mo-old children, and the top contributors were formula (71.7%), human milk (22.9%), and commercial baby foods (2.2%). In infants aged 6-11.9 mo, the top 5 contributors were formula (26.7%), commercial baby foods (8.8%), soups (6.1%), pasta mixed dishes (4.0%), and human milk (3.9%). In children aged 12-23.9 mo, the top contributors were milk (12.2%), soups (5.4%), cheese (5.2%), pasta mixed dishes (5.1%), and frankfurters and sausages (4.6%). Despite significant variation in top food categories across racial/ethnic groups, commercial baby foods were a top food contributor in children aged 6-11.9 mo, and frankfurters and sausages were a top food contributor in children aged 12-23.9 mo. The top 5 food categories that contributed to sodium intake also differed by sex. Most of the sodium consumed (83-90%) came from store foods (e.g., from the supermarket). In children aged 12-23.9 mo, 9% of sodium consumed came from restaurant foods, and 4% of sodium came from childcare center foods. Conclusions: The vast majority of sodium consumed comes from foods other than infant formula or human milk after the age of 6 mo. Although the majority of sodium intake was from store foods, after age 12 mo, restaurant foods contribute significantly to intake. Reducing the sodium content in these settings would reduce sodium intake in the youngest consumers. C1 [Maalouf, Joyce; Cogswell, Mary E.; Yuan, Keming; Gunn, Janelle P.; Merritt, Robert; Bowman, Barbara] CDC, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Maalouf, Joyce] IHRC Inc, Atlanta, GA USA. [Martin, Carrie; Pehrsson, Pamela] ARS, USDA, Beltsville, MD USA. RP Maalouf, J (reprint author), 4770 Buford Highway Northeast,Mailstop F72, Atlanta, GA 30341 USA. EM vjh6@cdc.gov FU CDC FX Supported by the CDC. NR 40 TC 4 Z9 6 U1 1 U2 6 PU AMER SOC NUTRITION-ASN PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0002-9165 EI 1938-3207 J9 AM J CLIN NUTR JI Am. J. Clin. Nutr. PD MAY PY 2015 VL 101 IS 5 BP 1021 EP 1028 DI 10.3945/ajcn.114.099770 PG 8 WC Nutrition & Dietetics SC Nutrition & Dietetics GA CH5KS UT WOS:000354075100017 PM 25762806 ER PT J AU Davis, SM Wiegand, RE Mulama, F Kareko, EI Harris, R Ochola, E Samuels, AM Rawago, F Mwinzi, PM Fox, LM Odiere, MR Won, KY AF Davis, Stephanie M. Wiegand, Ryan E. Mulama, Fridah Kareko, Edmund Ireri Harris, Robert Ochola, Elizabeth Samuels, Aaron M. Rawago, Fredrick Mwinzi, Pauline M. Fox, LeAnne M. Odiere, Maurice R. Won, Kimberly Y. TI Morbidity Associated with Schistosomiasis Before and After Treatment in Young Children in Rusinga Island, Western Kenya SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID PRESCHOOL-AGED CHILDREN; INTESTINAL SCHISTOSOMIASIS; MANSONI INFECTION; AFRICAN INFANTS; PRE-SCHOOL; PRAZIQUANTEL; HAEMATOBIUM; LIVER; EFFICACY; SAFETY AB Schistosoma mansoni infection is a major cause of organomegaly and ultimately liver fibrosis in adults. Morbidity in pre-school-aged children is less defined, and they are currently not included in mass drug administration (MDA) programs for schistosomiasis control. We report results of a study of the association of schistosomiasis with organomegaly in a convenience sample of 201 children under 7 years old in Rusinga, Kenya on two cross-sectional visits, before and after praziquantel treatment. Data included stool examination and serology for schistosomiasis, the Niamey ultrasound protocol to stage hepatosplenic morbidity including organomegaly, and potential confounders including malaria. Unadjusted and adjusted Poisson regressions were performed. The baseline prevalence of schistosomiasis by antibody and/or stool was 80.3%. Schistomiasis was associated with hepatomegaly (adjusted prevalence ratio [aPR] = 1.4; 95% confidence interval [CI]: 1.0-2.1) and splenomegaly (aPR = 2.1; 95% CI: 1.2-3.7). The association with hepatomegaly persisted posttreatment. (aPR = 1.4; 95% Cl: 1.1-1.6). Schistosomiasis was associated with morbidity in this cohort. Efforts to include young children in mass treatment campaigns should intensify. C1 [Davis, Stephanie M.; Samuels, Aaron M.; Fox, LeAnne M.; Won, Kimberly Y.] US Ctr Dis Control & Prevent, Parasit Dis Branch, Div Parasit Dis & Malaria, Atlanta, GA 30333 USA. US Ctr Dis Control & Prevent, Data Management Act, Div Parasit Dis & Malaria, Atlanta, GA 30333 USA. Kenya Govt Med Res Ctr, Neglected Trop Dis Unit, Kisumu, Kenya. [Mulama, Fridah; Ochola, Elizabeth; Rawago, Fredrick; Mwinzi, Pauline M.; Odiere, Maurice R.] Kenya Govt Med Res Ctr, Ctr Global Hlth Res, Kisumu, Kenya. [Harris, Robert] Dartmouth Coll, Geisel Sch Med, Dept Radiol, Hanover, NH USA. [Kareko, Edmund Ireri] Kenya Govt Med Res Ctr, Nairobi, Kenya. RP Davis, SM (reprint author), US Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS E-04, Atlanta, GA 30333 USA. EM vic6@cdc.gov; fwk2@cdc.gov; fridamulama@yahoo.com; ikareko@kemri.org; Robert.D.Harris@hitchcock.org; eakinyi@kemricdc.org; iyp2@cdc.gov; fredrickrawago@yahoo.com; pmwinzi@kemricdc.org; lff4@cdc.gov; modiere@kemricdc.org; kfw@cdc.gov FU Bill and Melinda Gates Foundation FX We gratefully acknowledge the Bill and Melinda Gates Foundation for providing the funding for this study, and the contributions of the KEMRI-CDC clinical field staff, and the participants, without whom this work would not have been possible. Special thanks to Patrick Lammie and W. Evan Secor for valuable input in study design and manuscript development. This paper is published with the permission of the Director of the Kenya Medical Research Institute. NR 49 TC 0 Z9 0 U1 2 U2 5 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD MAY PY 2015 VL 92 IS 5 BP 952 EP 958 DI 10.4269/ajtmh.14-0346 PG 7 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA CH5KQ UT WOS:000354074900015 PM 25758651 ER PT J AU Waterman, SH Margolis, HS Sejvar, JJ AF Waterman, Stephen H. Margolis, Harold S. Sejvar, James J. TI Surveillance for Dengue and Dengue-Associated Neurologic Syndromes in the United States SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID HEMORRHAGIC-FEVER; VIRUS-INFECTION; IMMUNOGLOBULIN-M; MEXICO BORDER; TEXAS; ENCEPHALOPATHY; TRANSMISSION; ASSAY AB Autochthonous dengue virus transmission has occurred in the continental United States with increased frequency during the last decade; the principal vector, Aedes aegypti, has expanded its geographic distribution in the southern United States. Dengue, a potentially fatal arboviral disease, is underreported, and US clinicians encountering patients with acute febrile illness consistent with dengue are likely to not be fully familiar with dengue diagnosis and management. Recently, investigators suggested that an outbreak of dengue likely occurred in Houston during 2003 based on retrospective laboratory testing of hospitalized cases with encephalitis and aseptic meningitis. Although certain aspects of the Houston testing results and argument for local transmission are doubtful, the report highlights the importance of prospective surveillance for dengue in Aedes-infested areas of the United States, the need for clinical training on dengue and its severe manifestations, and the need for laboratory testing in domestic patients presenting with febrile neurologic illness in these regions to include dengue. C1 [Waterman, Stephen H.] US Ctr Dis Control & Prevent, US Mexico Unit, Div Global Migrat & Quarantine, San Diego, CA 92110 USA. [Margolis, Harold S.] US Ctr Dis Control & Prevent, Dengue Branch, Div Vector Borne Dis, San Juan, PR USA. [Sejvar, James J.] US Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Atlanta, GA USA. RP Waterman, SH (reprint author), US Ctr Dis Control & Prevent, US Mexico Unit, Div Global Migrat & Quarantine, 3851 Rosecrans St, San Diego, CA 92110 USA. EM shw2@cdc.gov; hsm1@cdc.gov; zea3@cdc.gov NR 23 TC 0 Z9 0 U1 1 U2 3 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD MAY PY 2015 VL 92 IS 5 BP 996 EP 998 DI 10.4269/ajtmh.14-0016 PG 3 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA CH5KQ UT WOS:000354074900023 PM 25371183 ER PT J AU Hahn, MB Monaghan, AJ Hayden, MH Eisen, RJ Delorey, MJ Lindsey, NP Nasci, RS Fischer, M AF Hahn, Micah B. Monaghan, Andrew J. Hayden, Mary H. Eisen, Rebecca J. Delorey, Mark J. Lindsey, Nicole P. Nasci, Roger S. Fischer, Marc TI Meteorological Conditions Associated with Increased Incidence of West Nile Virus Disease in the United States, 2004-2012 SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID NEW-YORK-CITY; LAND-COVER; TRANSMISSION; CULICIDAE; INFECTION; DIPTERA; RISK; CLIMATE; AMPLIFICATION; ENCEPHALITIS AB West Nile virus (WNV) is a leading cause of mosquito-borne disease in the United States. Annual seasonal outbreaks vary in size and location. Predicting where and when higher than normal WNV transmission will occur can help direct limited public health resources. We developed models for the contiguous United States to identify meteorological anomalies associated with above average incidence of WNV neuroinvasive disease from 2004 to 2012. We used county-level WNV data reported to ArboNET and meteorological data from the North American Land Data Assimilation System. As a result of geographic differences in WNV transmission, we divided the United States into East and West, and 10 climate regions. Above average annual temperature was associated with increased likelihood of higher than normal WNV disease incidence, nationally and in most regions. Lower than average annual total precipitation was associated with higher disease incidence in the eastern United States, but the opposite was true in most western regions. Although multiple factors influence WNV transmission, these findings show that anomalies in temperature and precipitation are associated with above average WNV disease incidence. Readily accessible meteorological data may be used to develop predictive models to forecast geographic areas with elevated WNV disease risk before the coming season. C1 [Hahn, Micah B.; Monaghan, Andrew J.; Hayden, Mary H.] Natl Ctr Atmospher Res, Boulder, CO 80307 USA. [Hahn, Micah B.; Eisen, Rebecca J.; Delorey, Mark J.; Lindsey, Nicole P.; Nasci, Roger S.; Fischer, Marc] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO 80521 USA. RP Fischer, M (reprint author), Ctr Dis Control & Prevent, Arboviral Dis Branch, 3156 Rampart Rd, Ft Collins, CO 80521 USA. EM mhahn@ucar.edu; monaghan@ucar.edu; mhayden@ucar.edu; rjeisen@cdc.gov; mdelorey@cdc.gov; nplindsey@cdc.gov; rnasci@cdc.gov; mfischer@cdc.gov OI Monaghan, Andrew/0000-0002-8170-2359 FU Climate and Health Program of the National Center for Environmental Health, U.S. Centers for Disease Control and Prevention; National Science Foundation FX This work was funded by the Climate and Health Program of the National Center for Environmental Health, U.S. Centers for Disease Control and Prevention. The National Center for Atmospheric Research is sponsored by the National Science Foundation. NR 64 TC 11 Z9 11 U1 2 U2 15 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD MAY PY 2015 VL 92 IS 5 BP 1013 EP 1022 DI 10.4269/ajtmh.14-0737 PG 10 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA CH5KQ UT WOS:000354074900026 PM 25802435 ER PT J AU Liebman, K Swamidoss, I Vizcaino, L Lenhart, A Dowell, F Wirtz, R AF Liebman, Kelly Swamidoss, Isabel Vizcaino, Lucrecia Lenhart, Audrey Dowell, Floyd Wirtz, Robert TI The Influence of Diet on the Use of Near-Infrared Spectroscopy to Determine the Age of Female Aedes aegypti Mosquitoes SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID INSECTICIDE RESISTANCE; CUTICULAR HYDROCARBONS; FIELD VALIDATION; DENGUE VECTOR; CULICIDAE; DIPTERA; POPULATIONS; MECHANISMS; TEMPERATURE; VIRUS AB Interventions targeting adult mosquitoes are used to combat transmission of vector-borne diseases, including dengue. Without available vaccines, targeting the primary vector, Aedes aegypti, is essential to prevent transmission. Older mosquitoes (>= 7 days) are of greatest epidemiological significance due to the 7-day extrinsic incubation period of the virus. Age-grading of female mosquitoes is necessary to identify post-intervention changes in mosquito population age structure. We developed models using near-infrared spectroscopy (NIRS) to age-grade adult female Ae. aegypti. To determine if diet affects the ability of NIRS models to predict age, two identical larval groups were fed either fish food or infant cereal. Adult females were separated and fed sugar water +/- blood, resulting in four experimental groups. Females were killed 1, 4, 7, 10, 13, or 16 days postemergence. The head/thorax of each mosquito was scanned using a near-infrared spectrometer. Scans from each group were analyzed, and multiple models were developed using partial least squares regression. The best model included all experimental groups, and positively predicted the age group (< or >= 7 days) of 90.2% mosquitoes. These results suggest both larval and adult diets can affect the ability of NIRS models to accurately assign age categories to female Ae. aegypti. C1 Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. USDA, Manhattan, KS USA. [Liebman, Kelly; Swamidoss, Isabel; Vizcaino, Lucrecia; Lenhart, Audrey; Wirtz, Robert] Ctr Dis Control & Prevent, CGH DPDM EB, Atlanta, GA 30329 USA. [Dowell, Floyd] USDA, Ctr Grain & Anim Hlth Res, Manhattan, KS USA. RP Liebman, K (reprint author), Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Entomol Branch, 1600 Clifton Rd NE,MS-G49, Atlanta, GA 30329 USA. EM wuq4@cdc.gov; gtz8@cdc.gov; vtb6@cdc.gov; ajl8@cdc.gov; floyd.dowell@ars.usda.gov; bew5@cdc.gov NR 28 TC 1 Z9 1 U1 1 U2 6 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD MAY PY 2015 VL 92 IS 5 BP 1070 EP 1075 DI 10.4269/ajtmh.14.0790 PG 6 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA CH5KQ UT WOS:000354074900034 PM 25802436 ER PT J AU Millman, AJ Havers, F Iuliano, AD Davis, CT Sar, B Sovann, L Chin, S Corwin, AL Vongphrachanh, P Douangngeun, B Lindblade, KA Chittaganpitch, M Kaewthong, V Kile, JC Nguyen, HT Pham, DV Donis, RO Widdowson, MA AF Millman, Alexander J. Havers, Fiona Iuliano, A. Danielle Davis, C. Todd Sar, Borann Sovann, Ly Chin, Savuth Corwin, Andrew L. Vongphrachanh, Phengta Douangngeun, Bounlom Lindblade, Kim A. Chittaganpitch, Malinee Kaewthong, Viriya Kile, James C. Nguyen, Hien T. Pham, Dong V. Donis, Ruben O. Widdowson, Marc-Alain TI Detecting Spread of Avian Influenza A(H7N9) Virus Beyond China SO EMERGING INFECTIOUS DISEASES LA English DT Article ID A H7N9 VIRUS; LIVE POULTRY MARKETS; HUMAN INFECTIONS; H5N1 VIRUSES; WILD BIRDS; HPAI H5N1; VIETNAM; TRANSMISSION; EMERGENCE; THAILAND AB During February 2013 March 2015, a total of 602 human cases of low pathogenic avian influenza A(H7N9) were reported; no autochthonous cases were reported outside mainland China. In contrast, since highly pathogenic avian influenza A(H5N1) reemerged during 2003 in China, 784 human cases in 16 countries and poultry outbreaks in 53 countries have been reported. Whether the absence of reported A(H7N9) outside mainland China represents lack of spread or lack of detection remains unclear. We compared epidemiologic and virologic features of A(H5N1) and A(H7N9) and used human and animal influenza surveillance data collected during April 2013 May 2014 from 4 Southeast Asia countries to assess the likelihood that A(H7N9) would have gone undetected during 2014. Surveillance in Vietnam and Cambodia detected human A(H5N1) cases; no A(H7N9) cases were detected in humans or poultry in Southeast Asia. Although we cannot rule out the possible spread of A(H7N9), substantial spread causing severe disease in humans is unlikely. C1 [Millman, Alexander J.; Havers, Fiona; Iuliano, A. Danielle; Davis, C. Todd; Donis, Ruben O.; Widdowson, Marc-Alain] Ctr Dis Control & Prevent, CDC, Atlanta, GA 30329 USA. [Sar, Borann] CDC, Phnom Penh, Cambodia. [Sovann, Ly] Minist Hlth, Phnom Penh, Cambodia. [Chin, Savuth] Natl Inst Publ Hlth, Phnom Penh, Cambodia. [Corwin, Andrew L.] CDC, Viangchan, Laos. [Vongphrachanh, Phengta] Natl Ctr Lab Epidemiol, Viangchan, Laos. [Douangngeun, Bounlom] Minist Agr & Forestry, Viangchan, Laos. [Lindblade, Kim A.] Thailand Minist Publ Hlth CDC Collaborat, Nonthaburi, Thailand. [Chittaganpitch, Malinee] Natl Inst Hlth, Nonthaburi, Thailand. [Kaewthong, Viriya] Minist Agr & Cooperat, Bangkok, Thailand. [Kile, James C.] CDC, Hanoi, Vietnam. [Nguyen, Hien T.] Minist Hlth, Hanoi, Vietnam. [Pham, Dong V.] Minist Agr & Rural Dev, Hanoi, Vietnam. RP Millman, AJ (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop A32, Atlanta, GA 30329 USA. EM amillman@cdc.gov FU Centers for Disease Control and Prevention FX This work was funded by the Centers for Disease Control and Prevention. Data collection was funded by national governments and international organizations. NR 37 TC 3 Z9 3 U1 0 U2 16 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD MAY PY 2015 VL 21 IS 5 BP 741 EP 749 DI 10.3201/eid2105.141756 PG 9 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CG9BW UT WOS:000353610400001 PM 25897654 ER PT J AU Maheshwari, A Fischer, M Gambetti, P Parker, A Ram, A Soto, C Concha-Marambio, L Cohen, Y Belay, ED Maddox, RA Mead, S Goodman, C Kass, JS Schonberger, LB Hussein, HM AF Maheshwari, Atul Fischer, Michael Gambetti, Pierluigi Parker, Alicia Ram, Aarthi Soto, Claudio Concha-Marambio, Luis Cohen, Yvonne Belay, Ermias D. Maddox, Ryan A. Mead, Simon Goodman, Clay Kass, Joseph S. Schonberger, Lawrence B. Hussein, Haitham M. TI Recent US Case of Variant Creutzfeldt-Jakob Disease-Global Implications SO EMERGING INFECTIOUS DISEASES LA English DT Article ID HUMAN PRION DISEASE; DIAGNOSTIC-CRITERIA; PULVINAR SIGN; UNITED-KINGDOM; VCJD; CLASSIFICATION; VALIDATION; CJD; UK AB Variant Creutzfeldt-Jakob disease (vCJD) is a rare, fatal prion disease resulting from transmission to humans of the infectious agent of bovine spongiform encephalopathy. We describe the clinical presentation of a recent case of vCJD in the United States and provide an update on diagnostic testing. The location of this patient's exposure is less clear than those in the 3 previously reported US cases, but strong evidence indicates that exposure to contaminated beef occurred outside the United States more than a decade before illness onset. This case exemplifies the persistent risk for vCJD acquired in unsuspected geographic locations and highlights the need for continued global surveillance and awareness to prevent further dissemination of vCJD. C1 [Maheshwari, Atul; Parker, Alicia; Ram, Aarthi; Goodman, Clay; Kass, Joseph S.] Baylor Coll Med, Houston, TX 77030 USA. [Maheshwari, Atul; Parker, Alicia; Ram, Aarthi; Kass, Joseph S.] Harris Hlth Syst, Houston, TX USA. [Fischer, Michael] Texas Dept State Hlth Serv, Austin, TX USA. [Gambetti, Pierluigi; Cohen, Yvonne] Case Western Reserve Univ, Sch Med, Cleveland, OH USA. [Soto, Claudio; Concha-Marambio, Luis] Univ Texas Houston, Med Sch Houston, Houston, TX USA. [Concha-Marambio, Luis] Univ Los Andes, Santiago, Chile. [Belay, Ermias D.; Maddox, Ryan A.; Schonberger, Lawrence B.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Mead, Simon] UCL, Inst Neurol, London, England. [Hussein, Haitham M.] HealthPartners Clin & Serv, St Paul, MN USA. RP Maheshwari, A (reprint author), Baylor Coll Med, 1 Baylor Plaza, Houston, TX 77030 USA. EM atul.maheshwari@bcm.edu OI Concha-Marambio, Luis/0000-0002-9454-8389 FU Medical Research Council [MC_U123160651] NR 37 TC 10 Z9 10 U1 0 U2 14 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD MAY PY 2015 VL 21 IS 5 BP 750 EP 759 DI 10.3201/eid2105.142017 PG 10 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CG9BW UT WOS:000353610400002 PM 25897712 ER PT J AU Kosoy, OI Lambert, AJ Hawkinson, DJ Pastula, DM Goldsmith, CS Hunt, DC Staples, JE AF Kosoy, Olga I. Lambert, Amy J. Hawkinson, Dana J. Pastula, Daniel M. Goldsmith, Cynthia S. Hunt, D. Charles Staples, J. Erin TI Novel Thogotovirus Associated with Febrile Illness and Death, United States, 2014 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID MOLECULAR CHARACTERIZATION; DHORI VIRUS; FEVER; DISEASE AB A previously healthy man from eastern Kansas, USA, sought medical care in late spring because of a history of tick bite, fever, and fatigue. The patient had thrombocytopenia and leukopenia and was given doxycycline for a presumed tickborne illness. His condition did not improve. Multiorgan failure developed, and he died 11 days after illness onset from cardiopulmonary arrest. Molecular and serologic testing results for known tickborne pathogens were negative. However, testing of a specimen for antibodies against Heartland virus by using plaque reduction neutralization indicated the presence of another virus. Next-generation sequencing and phylogenetic analysis identified the virus as a novel member of the genus Thogotovirus. C1 [Kosoy, Olga I.; Lambert, Amy J.; Pastula, Daniel M.; Staples, J. Erin] Ctr Dis Control & Prevent, Ft Collins, CO 80521 USA. [Hawkinson, Dana J.] Univ Kansas, Med Ctr, Kansas City, KS 66103 USA. [Goldsmith, Cynthia S.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Hunt, D. Charles] Kansas Dept Hlth & Environm, Topeka, KS USA. RP Staples, JE (reprint author), Ctr Dis Control & Prevent, Arboviral Dis Branch, Div Vector Borne Dis, 3156 Rampart Rd,Mailstop P02, Ft Collins, CO 80521 USA. EM estaples@cdc.gov NR 20 TC 16 Z9 17 U1 0 U2 8 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD MAY PY 2015 VL 21 IS 5 BP 760 EP 764 DI 10.3201/eid2105.150150 PG 5 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CG9BW UT WOS:000353610400003 PM 25899080 ER PT J AU Hassan, HK Bolcen, S Kubofcik, J Nutman, TB Eberhard, ML Middleton, K Wekesa, JW Ruedas, G Nelson, KJ Dubielzig, R De Lombaert, M Silverman, B Schorling, JJ Adler, PH Unnasch, TR Beeler, ES AF Hassan, Hassan K. Bolcen, Shanna Kubofcik, Joseph Nutman, Thomas B. Eberhard, Mark L. Middleton, Kelly Wekesa, Joseph Wakoli Ruedas, Gimena Nelson, Kimberly J. Dubielzig, Richard De Lombaert, Melissa Silverman, Bruce Schorling, Jamie J. Adler, Peter H. Unnasch, Thomas R. Beeler, Emily S. TI Isolation of Onchocerca lupi in Dogs and Black Flies, California, USA SO EMERGING INFECTIOUS DISEASES LA English DT Article ID CANINE OCULAR ONCHOCERCOSIS; OF-THE-LITERATURE; UNITED-STATES; ABERRANT INFECTION; DIPTERA; SIMULIIDAE; PARASITE; GREECE; HOST; IDENTIFICATION AB In southern California, ocular infections caused by Onchocerca lupi were diagnosed in 3 dogs (1 in 2006, 2 in 2012). The infectious agent was confirmed through morphologic analysis of fixed parasites in tissues and by PCR and sequencing of amplicons derived from 2 mitochondrially encoded genes and 1 nuclear-encoded gene. A nested PCR based on the sequence of the cytochrome oxidase subunit 1 gene of the parasite was developed and used to screen Simullum black flies collected from southern California for O. lupi DNA. Six (2.8%; 95% Cl 0.6%-5.0%) of 213 black flies contained O. lupi DNA. Partial mitochondril 16S rRNA gene sequences from the infected flies matched sequences derived from black fly larvae cytotaxonomically identified as Simulium tribulatum. These data implicate S. tribulatum flies as a putative vector for O. lupi in southern California. C1 [Hassan, Hassan K.] Univ S Florida, Dept Global Hlth, Tampa, FL USA. [Bolcen, Shanna; Unnasch, Thomas R.] Univ S Florida, Tampa, FL USA. [Kubofcik, Joseph; Nutman, Thomas B.] NIAID, Bethesda, MD 20892 USA. [Eberhard, Mark L.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Middleton, Kelly; Wekesa, Joseph Wakoli; Ruedas, Gimena; Nelson, Kimberly J.] San Gabriel Valley Mosquito & Vector Control Dist, West Covina, CA USA. [Dubielzig, Richard; De Lombaert, Melissa] Univ Wisconsin, Madison, WI USA. [Silverman, Bruce] Complete Anim Eye Care, Sherman Oaks, CA USA. [Schorling, Jamie J.] Eye Clin Anim, San Diego, CA USA. [Adler, Peter H.] Clemson Univ, Clemson, SC USA. [Beeler, Emily S.] Los Angeles Cty Dept Publ Hlth, Los Angeles, CA USA. RP Unnasch, TR (reprint author), Global Hlth Infect Dis Res Program, 3720 Spectrum Blvd,Ste 304, Tampa, FL 33612 USA. EM tunnasch@health.usf.edu FU Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health FX This study was funded in part by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.K. and T.B.N.). NR 40 TC 5 Z9 5 U1 2 U2 9 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD MAY PY 2015 VL 21 IS 5 BP 789 EP 796 DI 10.3201/eid2105.142011 PG 8 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CG9BW UT WOS:000353610400007 PM 25897954 ER PT J AU Baldeviano, GC Okoth, SA Arrospide, N Gonzalez, RV Sanchez, JF Macedo, S Conde, S Tapia, LL Salas, C Gamboa, D Herrera, Y Edgel, KA Udhayakumar, V Lescano, AG AF Christian Baldeviano, G. Okoth, Sheila Akinyi Arrospide, Nancy Gonzalez, Rommell V. Sanchez, Juan F. Macedo, Silvia Conde, Silvia Lorena Tapia, L. Salas, Carola Gamboa, Dionicia Herrera, Yeni Edgel, Kimberly A. Udhayakumar, Venkatachalam Lescano, Andres G. TI Molecular Epidemiology of Plasmodium falciparum Malaria Outbreak, Tumbes, Peru, 2010-2012 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID AMAZON REGION; SULFADOXINE-PYRIMETHAMINE; DRUG-RESISTANCE; MICROSATELLITE MARKERS; CHLOROQUINE; POPULATION; FIXATION; EFFICACY; AMERICA; ALLELES AB During 2010-2012, an outbreak of 210 cases of malaria occurred in Tumbes, in the northern coast of Peru, where no Plasmodium falciparum malaria case had been reported since 2006. To identify the source of the parasite causing this outbreak, we conducted a molecular epidemiology investigation. Microsatellite typing showed an identical genotype in all 54 available isolates. This genotype was also identical to that of parasites isolated in 2010 in the Loreto region of the Peruvian Amazon and closely related to clonet B, a parasite lineage previously reported in the Amazon during 1998-2000. These findings are consistent with travel history of index case-patients. DNA sequencing revealed mutations in the Pfdhfr, Pfdhps, Pfcrt, and Pfmdr1 loci, which are strongly associated with resistance to chloroquine and sulfadoxine/pyrimethamine, and deletion of the Pfhrp2 gene. These results highlight the need for timely molecular epidemiology investigations to trace the parasite source during malaria reintroduction events. C1 [Christian Baldeviano, G.; Sanchez, Juan F.; Macedo, Silvia; Lorena Tapia, L.; Salas, Carola; Edgel, Kimberly A.; Lescano, Andres G.] US Naval Med Res Unit 6, Callao 2, Peru. [Okoth, Sheila Akinyi; Udhayakumar, Venkatachalam] Ctr Dis Control & Prevent, Atlanta, GA USA. [Arrospide, Nancy] Inst Nacl Salud Peru, Lima, Peru. [Gonzalez, Rommell V.; Conde, Silvia] Direcc Reg Salud Tumbes, Tumbes, Peru. [Gamboa, Dionicia] Univ Peruana Cayetano Heredia, Lima, Peru. [Herrera, Yeni] Minist Hlth Peru, Lima, Peru. RP Baldeviano, GC (reprint author), US Naval Med Res Unit 6, Ave Venezuela,Cuadra 36 S-N, Callao 2, Peru. EM gbaldevi@gmail.com RI Lescano, Andres/B-8479-2008; OI Lescano, Andres/0000-0001-9779-633X; ARROSPIDE, NANCY/0000-0001-5031-5850 FU US Department of Defense Armed Forces Health Surveillance Center, Global Emerging Infectious Systems Division, through the Malaria Pillar Sustainment grant; Amazon Malaria Initiative - US Agency for International Development; American Society of Microbiology/CDC Postdoctoral Fellowship Program; Fogarty International Center of the US National Institutes of Health [NIH/FIC 2D43 TW007393] FX This work was funded by the US Department of Defense Armed Forces Health Surveillance Center, Global Emerging Infectious Systems Division, through the Malaria Pillar Sustainment grant awarded to A.G.L. In addition, this investigation was partly supported by the Amazon Malaria Initiative, which is financially supported by the US Agency for International Development. S.A. was supported by the American Society of Microbiology/CDC Postdoctoral Fellowship Program. The participation of A.G.L. in this investigation was sponsored by training grant NIH/FIC 2D43 TW007393 awarded to NAMRU-6 by the Fogarty International Center of the US National Institutes of Health. NR 27 TC 4 Z9 4 U1 0 U2 9 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD MAY PY 2015 VL 21 IS 5 BP 797 EP 803 DI 10.3201/eid2105.141427 PG 7 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CG9BW UT WOS:000353610400008 PM 25897626 ER PT J AU Lambert, AJ Fryxell, RT Freyman, K Ulloa, A Velez, JO Paulsen, D Lanciotti, RS Moncayo, A AF Lambert, Amy J. Fryxell, Rebecca Trout Freyman, Kimberly Ulloa, Armando Velez, Jason O. Paulsen, Dave Lanciotti, Robert S. Moncayo, Abelardo TI Comparative Sequence Analyses of La Crosse Virus Strain Isolated from Patient with Fatal Encephalitis, Tennessee, USA SO EMERGING INFECTIOUS DISEASES LA English DT Article ID RNA; BUNYAVIRIDAE; INFECTIONS; PROTEINS AB We characterized a La Crosse virus (LACV) isolate from the brain of a child who died of encephalitis-associated complications in eastern Tennessee, USA, during summer 2012. We compared the isolate with LACV sequences from mosquitoes collected near the child's home just after his postmortem diagnosis. In addition, we conducted phylogenetic analyses of these and other sequences derived from LACV strains representing varied temporal, geographic, and ecologic origins. Consistent with historical findings, results of these analyses indicate that a limited range of LACV lineage I genotypes is associated with severe clinical outcomes. C1 [Lambert, Amy J.; Velez, Jason O.; Lanciotti, Robert S.] Ctr Dis Control & Prevent, Ft Collins, CO 80521 USA. [Fryxell, Rebecca Trout; Paulsen, Dave] Univ Tennessee, Knoxville, TN USA. [Freyman, Kimberly; Ulloa, Armando; Moncayo, Abelardo] Tennessee Dept Hlth, Nashville, TN USA. RP Lambert, AJ (reprint author), Ctr Dis Control & Prevent, Div Vector Borne Infect Dis, Natl Ctr Zoonot Vector Borne & Enter Dis, 3150 Rampart Rd, Ft Collins, CO 80521 USA. EM ahk7@cdc.gov FU University of Tennessee Institute of Agriculture (Hatch project) [TENN00433] FX Funding was provided in part by the University of Tennessee Institute of Agriculture (Hatch project TENN00433). NR 14 TC 3 Z9 3 U1 0 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD MAY PY 2015 VL 21 IS 5 BP 833 EP 836 DI 10.3201/eid2105.141992 PG 4 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CG9BW UT WOS:000353610400012 PM 25898269 ER PT J AU Otranto, D Giannelli, A Latrofa, MS Dantas-Torres, F Trumble, NS Chavkin, M Kennard, G Eberhard, ML Bowman, DD AF Otranto, Domenico Giannelli, Alessio Latrofa, Maria S. Dantas-Torres, Filipe Trumble, Nicole Scotty Chavkin, Matt Kennard, Gavin Eberhard, Mark L. Bowman, Dwight D. TI Canine Infections with Onchocerca lupi Nematodes, United States, 2011-2014 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID OF-THE-LITERATURE; 2 DOGS; HELMINTHS; SPIRURIDA; DISEASE AB Infections with Onchocerca lupi nematodes are diagnosed sporadically in the United States. We report 8 cases of canine onchocercosis in Minnesota, New Mexico, Colorado, and Florida. Identification of 1 cytochrome c oxidase subunit 1 gene haplotype identical to 1 of 5 from Europe suggests recent introduction of this nematode into the United States. C1 [Otranto, Domenico; Giannelli, Alessio; Latrofa, Maria S.; Dantas-Torres, Filipe] Univ Bari, I-70010 Valenzano, Italy. [Dantas-Torres, Filipe] Aggeu Magalhaes Res Inst, Recife, PE, Brazil. [Trumble, Nicole Scotty] BluePearl Vet Partners, Eden Prairie, MN USA. [Chavkin, Matt] Vet Specialty & Emergency Hosp, Englewood, CO USA. [Kennard, Gavin] Eye Care Anim, Albuquerque, NM USA. [Eberhard, Mark L.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Bowman, Dwight D.] Cornell Univ, Ithaca, NY USA. RP Otranto, D (reprint author), Univ Bari, Str Prov Casamassima Km 3, I-70010 Valenzano, Italy. EM domenico.otranto@uniba.it RI Dantas-Torres, Filipe/G-1617-2012; OI Latrofa, Maria Stefania/0000-0001-9061-437X; Otranto, Domenico/0000-0002-7518-476X; Giannelli, Alessio/0000-0001-5855-2906 NR 15 TC 2 Z9 2 U1 2 U2 11 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD MAY PY 2015 VL 21 IS 5 BP 868 EP 871 DI 10.3201/eid2105.141812 PG 4 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CG9BW UT WOS:000353610400020 PM 25897859 ER PT J AU Petrosian-Husa, CCH Breedlove, B AF Petrosian-Husa, Carmen C. H. Breedlove, Byron TI The Mosquito - a Cog in the Ideal Nature Machine SO EMERGING INFECTIOUS DISEASES LA English DT Editorial Material C1 [Breedlove, Byron] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Petrosian-Husa, CCH (reprint author), Prinz Eugen Str 80-18, A-1040 Vienna, Austria. EM cchph2000@yahoo.com OI Breedlove, Byron/0000-0002-1026-1963 NR 3 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD MAY PY 2015 VL 21 IS 5 BP 919 EP 920 DI 10.3201/eid2105.AC2105 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CG9BW UT WOS:000353610400043 ER PT J AU Holtfreter, B Albandar, JM Dietrich, T Dye, BA Eaton, KA Eke, PI Papapanou, PN Kocher, T AF Holtfreter, Birte Albandar, Jasim M. Dietrich, Thomas Dye, Bruce A. Eaton, Kenneth A. Eke, Paul I. Papapanou, Panos N. Kocher, Thomas TI Standards for reporting chronic periodontitis prevalence and severity in epidemiologic studies Proposed standards from the Joint EU/USA Periodontal Epidemiology Working Group SO JOURNAL OF CLINICAL PERIODONTOLOGY LA English DT Article DE chronic periodontitis; epidemiologic study; prevalence; report; standards; surveillance ID PARTIAL RECORDING PROTOCOLS; AGGRESSIVE PERIODONTITIS; CASE DEFINITIONS; UNITED-STATES; DISEASE; POPULATION; SURVEILLANCE; ADULTS; PROBES AB Periodontal diseases are common and their prevalence varies in different populations. However, prevalence estimates are influenced by the methodology used, including measurement techniques, case definitions, and periodontal examination protocols, as well as differences in oral health status. As a consequence, comparisons between populations are severely hampered and inferences regarding the global variation in prevalence can hardly be drawn. To overcome these limitations, the authors suggest standardized principles for the reporting of the prevalence and severity of periodontal diseases in future epidemiological studies. These principles include the comprehensive reporting of the study design, the recording protocol, and specific subject-related and oral data. Further, a range of periodontal data should be reported in the total population and within specific age groups. Periodontal data include the prevalence and extent of clinical attachment loss (CAL) and probing depth (PD) on site and tooth level according to specific thresholds, mean CAL/PD, the CDC/AAP case definition, and bleeding on probing. Consistent implementation of these standards in future studies will ensure improved reporting quality, permit meaningful comparisons of the prevalence of periodontal diseases across populations, and provide better insights into the determinants of such variation. C1 [Holtfreter, Birte; Kocher, Thomas] Ernst Moritz Arndt Univ Greifswald, Univ Med Greifswald, Dept Restorat Dent Periodontol & Endodontol, Unit Periodontol, Greifswald, Germany. [Albandar, Jasim M.] Temple Univ, Sch Dent, Dept Periodontol & Oral Implantol, Philadelphia, PA USA. [Dietrich, Thomas] Univ Birmingham, Sch Dent, Dept Oral Surg, Coll Med & Dent Sci, Birmingham, W Midlands, England. [Dye, Bruce A.] Ctr Dis Control & Prevent CDC, Div Hlth & Nutr Examinat Surveys, Natl Ctr Hlth Stat, Hyattsville, MD USA. [Eaton, Kenneth A.] UCL, Eastman Dent Inst, London, England. [Eaton, Kenneth A.] Kings Coll London, Inst Dent, London WC2R 2LS, England. [Eaton, Kenneth A.] Univ Kent, Ctr Profess Practice, Canterbury, Kent, England. [Eke, Paul I.] Ctr Dis Control & Prevent, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Papapanou, Panos N.] Columbia Univ, Sect Oral & Diagnost Sci, Div Periodont, Coll Dent Med, New York, NY USA. RP Holtfreter, B (reprint author), Univ Med Greifswald, Dept Restorat Dent Periodontol & Endodontol, Unit Periodontol, Rotgerberstr 8, D-17475 Greifswald, Germany. EM birte.holtfreter@uni-greifswald.de OI Albandar, Jasim M./0000-0001-7801-3811; Dietrich, Thomas/0000-0002-2557-7645 NR 34 TC 14 Z9 14 U1 0 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0303-6979 EI 1600-051X J9 J CLIN PERIODONTOL JI J. Clin. Periodontol. PD MAY PY 2015 VL 42 IS 5 BP 407 EP 412 DI 10.1111/jcpe.12392 PG 6 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA CI1HU UT WOS:000354495400001 PM 25808877 ER PT J AU Zhang, P Shrestha, S AF Zhang, Ping Shrestha, Sundar TI Estimating the costs of diabetes by episodes of care: Promises and challenges SO JOURNAL OF DIABETES AND ITS COMPLICATIONS LA English DT Editorial Material ID PAYMENT C1 [Zhang, Ping; Shrestha, Sundar] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA 30341 USA. RP Zhang, P (reprint author), Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA 30341 USA. EM Pzhang@cdc.gov FU Intramural CDC HHS [CC999999] NR 13 TC 1 Z9 1 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1056-8727 EI 1873-460X J9 J DIABETES COMPLICAT JI J. Diabetes Complications PD MAY-JUN PY 2015 VL 29 IS 4 BP 463 EP 464 DI 10.1016/j.jdiacomp.2015.03.003 PG 2 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CH6PE UT WOS:000354157700001 PM 25777556 ER PT J AU Schwartz, MD Trecki, J Edison, LA Steck, AR Arnold, JK Gerona, RR AF Schwartz, Michael D. Trecki, Jordan Edison, Laura A. Steck, Alaina R. Arnold, Justin K. Gerona, Roy R. TI A COMMON SOURCE OUTBREAK OF SEVERE DELIRIUM ASSOCIATED WITH EXPOSURE TO THE NOVEL SYNTHETIC CANNABINOID ADB-PINACA SO JOURNAL OF EMERGENCY MEDICINE LA English DT Article DE synthetic cannabinoid; delirium; ADB-PI-NACA; cluster; outbreak; spice; K2; DEA scheduling ID RECEPTOR AGONIST AM-2201; CASE SERIES; IDENTIFICATION; METABOLISM; MARIJUANA; JWH-018; K2 AB Background: Since 2009, synthetic cannabinoid (SC) use has emerged as a growing public health threat in the United States (US). Several outbreaks of unexpected, severe toxicity linked to SC use have been reported since 2012. Reports of varied and significant morbidity after SC use are expected to increase because newer compounds enter the marketplace more frequently as manufacturers attempt to circumvent regulatory efforts. Case Report: We report a cluster of 7 patients who experienced a spectrum of anxiety, delirium, psychosis, and aggressive behaviors after smoking the same SC-containing product at a party. An 8th patient with the same exposure source presented with delayed onset seizures. Biologic samples were analyzed for novel, newly identified SCs belonging to the FUBINACA family of compounds. A previously unknown SC, N-(1-amino-3, 3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (ADB-PINACA) was identified in biologic samples from 7 of the individuals. ADB-PINACA was identified in the SC-containing product ("Crazy Clown") seized by law enforcement and identified as the product smoked by the 8 patients in the reported cluster. Why Should an Emergency Physician Be Aware of This?: The information compiled using this cluster of cases, and a similar reported outbreak of altered mental status in Colorado, implicating the same SC (ADB-PINACA) and brands of SC-containing products, aided the US Drug Enforcement Administration in its temporary scheduling of ADB-PINACA and three other SCs. In this outbreak, close cooperation between public health and law enforcement allowed for a rapid intervention, which halted the outbreak by interrupting the common source and accelerated regulatory efforts to prevent further morbidity and mortality. Published by Elsevier Inc. C1 [Schwartz, Michael D.] Ctr Dis Control, Natl Ctr Environm Hlth, Off Environm Hlth Emergencies, Atlanta, GA 30333 USA. [Trecki, Jordan] Drug Enforcement Adm, Off Divers Control, Drug & Chem Evaluat Sect, Springfield, VA USA. [Edison, Laura A.] Ctr Dis Control & Prevent, Epidemiol Program Off, Atlanta, GA USA. [Steck, Alaina R.; Arnold, Justin K.] Georgia Poison Ctr, Atlanta, GA USA. [Gerona, Roy R.] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA. RP Schwartz, MD (reprint author), Ctr Dis Control, Natl Ctr Environm Hlth, Off Environm Hlth Emergencies, 1600 Clifton Rd,MS F-09, Atlanta, GA 30333 USA. NR 25 TC 14 Z9 14 U1 0 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0736-4679 EI 1090-1280 J9 J EMERG MED JI J. Emerg. Med. PD MAY PY 2015 VL 48 IS 5 BP 573 EP 580 DI 10.1016/j.jemermed.2014.12.038 PG 8 WC Emergency Medicine SC Emergency Medicine GA CH4VB UT WOS:000354030200012 PM 25726258 ER PT J AU McCree, DH Koenig, LJ Basile, KC Fowler, D Green, Y AF McCree, Donna Hubbard Koenig, Linda J. Basile, Kathleen C. Fowler, Dawnovise Green, Yvonne TI Addressing the Intersection of HIV and Intimate Partner Violence Among Women with or at Risk for HIV in the United States SO JOURNAL OF WOMENS HEALTH LA English DT Article ID POSITIVE WOMEN; US STATES/TERRITORIES; RACIAL DISPARITIES; TRANSMISSION RISK; HIV/AIDS; COLOR; CARE; SUPPRESSION; DIRECTIONS; ADHERENCE AB In 2012, the White House established a working group in recognition of the need to understand and address the intersection of human immunodeficiency virus (HIV) infection and violence against women and girls. This report describes the Centers for Disease Control and Prevention (CDC)'s efforts for addressing intimate partner violence and HIV among women and provides suggestions for future prevention efforts. CDC's current efforts are focused on understanding these often co-occurring public health problems, identifying effective interventions, and ensuring that states and communities have the capacity and resources to implement prevention approaches based on the best available evidence. Additional research is needed on effective strategies for integrating violence prevention and HIV programming into health services targeting adolescent girls and women who experience intimate partner violence or are at risk for HIV. C1 [McCree, Donna Hubbard; Koenig, Linda J.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30329 USA. [Basile, Kathleen C.; Fowler, Dawnovise] Ctr Dis Control & Prevent, Div Violence Prevent, Atlanta, GA 30329 USA. [Green, Yvonne] Ctr Dis Control & Prevent, Off Minor Hlth & Hlth Equ, Atlanta, GA 30329 USA. RP McCree, DH (reprint author), Ctr Dis Control & Prevent, Hlth Equ, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, 1600 Clifton Rd Northeast,MS D-21, Atlanta, GA 30329 USA. EM zyr1@cdc.gov NR 49 TC 3 Z9 3 U1 2 U2 7 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 EI 1931-843X J9 J WOMENS HEALTH JI J. Womens Health PD MAY 1 PY 2015 VL 24 IS 5 BP 331 EP 335 DI 10.1089/jwh.2015.5301 PG 5 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA CI0ZF UT WOS:000354468500002 PM 25973798 ER PT J AU Henninger, ML Irving, SA Thompson, M Avalos, LA Ball, SW Shifflett, P Naleway, AL AF Henninger, Michelle L. Irving, Stephanie A. Thompson, Mark Avalos, Lyndsay Ammon Ball, Sarah W. Shifflett, Pat Naleway, Allison L. CA Pregnancy Influenza Project PIP TI Factors Associated with Seasonal Influenza Vaccination in Pregnant Women SO JOURNAL OF WOMENS HEALTH LA English DT Article ID 2009 H1N1 INFLUENZA; HEALTH BELIEF MODEL; UNITED-STATES; A H1N1; COVERAGE; PREDICTORS; CALIFORNIA; BEHAVIOR; CARE AB Background: This observational study followed a cohort of pregnant women during the 2010-2011 influenza season to determine factors associated with vaccination. Methods: Participants were 1105 pregnant women who completed a survey assessing health beliefs related to vaccination upon enrollment and were then followed to determine vaccination status by the end of the 2010-2011 influenza season. We conducted univariate and multivariate analyses to explore factors associated with vaccination status and a factor analysis of survey items to identify health beliefs associated with vaccination. Results: Sixty-three percent (n=701) of the participants were vaccinated. In the univariate analyses, multiple factors were associated with vaccination status, including maternal age, race, marital status, educational level, and gravidity. Factor analysis identified two health belief factors associated with vaccination: participant's positive views (factor 1) and negative views (factor 2) of influenza vaccination. In a multivariate logistic regression model, factor 1 was associated with increased likelihood of vaccination (adjusted odds ratio [aOR]=2.18; 95% confidence interval [CI]=1.72-2.78), whereas factor 2 was associated with decreased likelihood of vaccination (aOR=0.36; 95% CI=0.28-0.46). After controlling for the two health belief factors in multivariate analyses, demographic factors significant in univariate analyses were no longer significant. Women who received a provider recommendation were about three times more likely to be vaccinated (aOR=3.14; 95% CI=1.99-4.96). Conclusion: Pregnant women's health beliefs about vaccination appear to be more important than demographic and maternal factors previously associated with vaccination status. Provider recommendation remains one of the most critical factors influencing vaccination during pregnancy. C1 [Henninger, Michelle L.; Irving, Stephanie A.; Naleway, Allison L.] Kaiser Permanente Northwest, Ctr Hlth Res, Portland, OR 97227 USA. [Thompson, Mark] Ctr Dis Control & Prevent, Atlanta, GA USA. [Avalos, Lyndsay Ammon] Kaiser Permanente No Calif, Oakland, CA USA. [Ball, Sarah W.; Shifflett, Pat] ABT Associates Inc, Cambridge, MA 02138 USA. RP Henninger, ML (reprint author), Kaiser Permanente Northwest, Ctr Hlth Res, 3800 North Interstate Ave, Portland, OR 97227 USA. EM Michelle.L.Henninger@kpchr.org OI Irving, Stephanie/0000-0001-7437-6797 FU Centers for Disease Control and Prevention [200-2010-F-33132]; UCSF-Kaiser/DOR Building Interdisciplinary Research Careers in Women's Health Program (NICHD/NIH, Guglielmo, PI) [K12HD052163] FX This study was supported by the Centers for Disease Control and Prevention (Contract 200-2010-F-33132 to Abt Associates Inc). Participation on this study by Lyndsay Ammon Avalos was funded by UCSF-Kaiser/DOR Building Interdisciplinary Research Careers in Women's Health Program (K12HD052163, NICHD/NIH, Guglielmo, PI). The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention, Abt Associates Inc, Kaiser Permanente Center for Health Research, or Kaiser Permanente Northern California Division of Research. NR 38 TC 7 Z9 7 U1 1 U2 5 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 EI 1931-843X J9 J WOMENS HEALTH JI J. Womens Health PD MAY 1 PY 2015 VL 24 IS 5 BP 394 EP 402 DI 10.1089/jwh.2014.5105 PG 9 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA CI0ZF UT WOS:000354468500011 PM 25874550 ER PT J AU Herrero, R Gonzalez, P Markowitz, LE AF Herrero, Rolando Gonzalez, Paula Markowitz, Lauri E. TI Present status of human papillomavirus vaccine development and implementation SO LANCET ONCOLOGY LA English DT Article ID HPV-16/18 AS04-ADJUVANTED VACCINE; RANDOMIZED CLINICAL-TRIAL; 18 RECOMBINANT VACCINE; HPV BIVALENT VACCINE; BLIND PATRICIA TRIAL; OF-STUDY ANALYSIS; YOUNG-WOMEN; GENITAL WARTS; COSTA-RICA; INTRAEPITHELIAL NEOPLASIA AB Oncogenic human papillomavirus (HPV) infection is the cause of nearly all cervical cancers and a proportion of other anogenital and oropharyngeal cancers. A bivalent vaccine containing HPV 16 and 18 and a quadrivalent vaccine containing HPV 6, 11, 16, and 18 antigens are in use in vaccination programmes around the world. In clinical trials, three vaccine doses provided 90-100% protection against cervical infection and pre-cancer related to HPV 16 and 18 in women aged 15-26 years who were not infected at vaccination. Partial cross-protection against other HPV types has been reported but its duration is unknown. The vaccines were also efficacious at the prevention of HPV 16 and 18 infections at other anatomical sites in both sexes. Immunobridging studies allowed licensing of the vaccines for use starting at age 9 years for both sexes. Two-dose schedules elicit high antibody concentrations, leading to the recommendation of two-dose schedules for girls aged 9-14 years. Pre-licensure and post-licensure studies have provided data supporting vaccine safety. In 2014, a nonavalent vaccine containing HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 antigens was licensed by the US Food and Drug Administration. HPV vaccination was first introduced in high-income countries owing to vaccine cost, logistic challenges, and competing health priorities. Since 2011, vaccine prices have lowered, allowing the introduction of the vaccine in some middle-income countries. Funding of the vaccine by the GAVI Alliance in 2012 led to demonstration projects in some low-income countries. By 2014, more than 57 countries had included the HPV vaccine in their national health programmes. Data from several countries have shown the effect of vaccination on HPV infection and associated disease, and provided evidence of herd immunity. Expansion of programmes to countries with the highest burden of disease is beginning, but further efforts are needed to realise the potential of HPV vaccines. C1 [Herrero, Rolando; Gonzalez, Paula] Int Agcy Res Canc, Sect Early Detect & Prevent, Prevent & Implementat Grp, F-69372 Lyon, France. [Gonzalez, Paula] Proyecto Epidemiol Guanacaste, Liberia, Guanacaste, Costa Rica. [Markowitz, Lauri E.] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. RP Herrero, R (reprint author), Int Agcy Res Canc, Sect Early Detect & Prevent, Prevent & Implementat Grp, 150 Cours Albert Thomas, F-69372 Lyon, France. EM herreror@iarc.fr NR 99 TC 35 Z9 43 U1 10 U2 22 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1470-2045 EI 1474-5488 J9 LANCET ONCOL JI Lancet Oncol. PD MAY PY 2015 VL 16 IS 5 BP E206 EP E216 PG 11 WC Oncology SC Oncology GA CH3DW UT WOS:000353908200022 PM 25943065 ER PT J AU Byrne, DC Themann, CL Stephenson, MR AF Byrne, David C. Themann, Christa L. Stephenson, Mark R. TI Comment on "Concerns with amplitude variation in calibrated audiometer systems in clinical simulations" SO NOISE & HEALTH LA English DT Editorial Material C1 [Byrne, David C.; Themann, Christa L.; Stephenson, Mark R.] NIOSH, Dept Hlth & Human Serv, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. RP Byrne, DC (reprint author), NIOSH, Dept Hlth & Human Serv, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. EM DByrne@cdc.gov NR 1 TC 1 Z9 1 U1 0 U2 0 PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD PI MUMBAI PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA SN 1463-1741 EI 1998-4030 J9 NOISE HEALTH JI Noise Health PD MAY-JUN PY 2015 VL 17 IS 76 BP 172 EP 172 DI 10.4103/1463-1741.155851 PG 1 WC Audiology & Speech-Language Pathology; Public, Environmental & Occupational Health SC Audiology & Speech-Language Pathology; Public, Environmental & Occupational Health GA CH3VM UT WOS:000353958700007 PM 25913557 ER PT J AU Hawkins, NA Berkowitz, Z Rodriguez, JL Miller, JW Sabatino, SA Pollack, LA AF Hawkins, Nikki A. Berkowitz, Zahava Rodriguez, Juan L. Miller, Jacqueline W. Sabatino, Susan A. Pollack, Lori A. TI Examining Adherence With Recommendations for Follow-Up in the Prevention Among Colorectal Cancer Survivors Study SO ONCOLOGY NURSING FORUM LA English DT Article DE cancer survivorship; adherence; cancer surveillance; colorectal cancer; long-term care; public health ID TREATMENT SUMMARIES; CURATIVE RESECTION; PRACTICE GUIDELINE; SURVEILLANCE; UPDATE; CARE; INTERVENTION; FACILITATORS; INSTRUCTIONS; METAANALYSIS AB Purpose/Objectives: To explore the impact of health professionals' recommendations for medical follow-up among colorectal cancer (CRC) survivors. Design: Cross-sectional survey. Setting: Mailed surveys and telephone interviews with CRC survivors in California. Sample: 593 adults diagnosed with a primary CRC six to seven years before the time of the study. Methods: Participants were identified through California Cancer Registry records and invited to take part in a survey delivered via mail or through telephone interview. Main Research Variables: The survey assessed cancer history, current preventive health practices, health status, demographics, and other cancer-related experiences. Findings: More than 70% of CRC survivors received recommendations for routine checkups, surveillance colonoscopy, or other cancer screenings after completing CRC treatment, and 18%-22% received no such recommendations. Recommendations were sometimes given in writing. Receiving a recommendation for a specific type of follow-up was associated with greater adherence to corresponding guidelines for routine checkups, colonoscopy, mammography, and Papanicolaou testing. Receiving written (versus unwritten) recommendations led to greater adherence only for colonoscopy. Conclusions: Most CRC survivors reported receiving recommendations for long-term medical follow-up and largely adhered to guidelines for follow-up. Receiving a health professional's recommendation for follow-up was consistently associated with patient adherence, and limited evidence showed that recommendations in written form led to greater adherence than unwritten recommendations. Implications for Nursing: Given the increasingly important role of the oncology nurse in survivorship care, nurses can be instrumental in ensuring appropriate surveillance and follow-up care among CRC survivors. Conveying recommendations in written form, as is done in survivorship care plans, may be particularly effective. C1 [Hawkins, Nikki A.; Berkowitz, Zahava; Rodriguez, Juan L.; Miller, Jacqueline W.; Sabatino, Susan A.; Pollack, Lori A.] Ctr Dis Control & Prevent CDC, Atlanta, GA 30333 USA. RP Hawkins, NA (reprint author), Ctr Dis Control & Prevent CDC, Atlanta, GA 30333 USA. EM nhawkins@cdc.gov FU ICF International [200-2002-00574] FX Nikki A. Hawkins, PhD, is a behavioral scientist; Zahava Berkowitz, MS, is a statistician; Juan L. Rodriguez, MPH, is an epidemiologist; and Jacqueline W. Miller, MD, Susan A. Sabatino, MD, MPH, and Lori A. Pollack, MD, MPH, are medical officers, all at the Centers for Disease Control and Prevention (CDC) in Atlanta, GA. This article was written in the course of employment by the United States Government and it is not subject to copyright in the United States. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC. Data collection was undertaken through a CDC contract with ICF International (200-2002-00574). Hawkins can be reached at nhawkins@cdc.gov, with copy to editor at ONFEditor@ons.org. (Submitted September 2014. Accepted for publication December 17, 2014.) NR 33 TC 2 Z9 2 U1 0 U2 5 PU ONCOLOGY NURSING SOC PI PITTSBURGH PA 125 ENTERPRISE DR, PITTSBURGH, PA 15275 USA SN 0190-535X EI 1538-0688 J9 ONCOL NURS FORUM JI Oncol. Nurs. Forum PD MAY PY 2015 VL 42 IS 3 BP 233 EP 240 DI 10.1188/15.ONF.233-240 PG 8 WC Oncology; Nursing SC Oncology; Nursing GA CH7QZ UT WOS:000354233000006 PM 25901375 ER PT J AU Mason, J Wheeler, W Brown, MJ AF Mason, Jacquelyn Wheeler, William Brown, Mary Jean TI The Economic Burden of Exposure to Secondhand Smoke for Child and Adult Never Smokers Residing in US Public Housing SO PUBLIC HEALTH REPORTS LA English DT Article ID ENVIRONMENTAL TOBACCO-SMOKE; LOW-BIRTH-WEIGHT; UNITED-STATES; CARDIOVASCULAR-DISEASE; PARENTAL SMOKING; HEALTH; ASTHMA; COST; IMPACT; CANCER AB Objective. The World Health Organization (WHO) reports that nonsmokers experience disease and death due to secondhand smoke (SHS) exposure in the home. We estimated the total excess burden and costs to society due to SHS exposure in U.S. public housing. Methods. We quantified the public health burden for outcomes causally related to SHS exposure for nationally representative never-smoking residents in U.S. public housing using (1) WHO-recommended health outcomes and methodology, (2) publicly available and other large databases, and (3) published estimates of morbidity and mortality rates. We used published estimates of direct medical and nonmedical care costs and the value of productivity losses to estimate SHS-related societal costs for disease and death. We estimated the public health and economic burden for two serum cotinine limits of detection (LODs): 0.05 nanograms per milliliter (ng/mL) and 0.015 ng/mL. Results. In 2011, an estimated 37,791 never-smoking child and adult U.S. public housing residents experienced illness and death due to SHS exposure at home based on an LOD=0.05 ng/mL (50,967 residents at LOD=0.015 ng/mL). Costs incurred by society for these illnesses and deaths totaled $183 million (LOD=0.05 ng/mL) and $267 million (LOD=0.015 ng/mL) annually. Of the total costs, direct costs (medical and nonmedical) accounted for $128 million and $176 million for LOD=0.05 ng/mL and LOD=0.015 ng/mL, respectively. Medical care accounted for the majority of direct costs-$110 million at LOD=0.05 ng/mL and $153 million at LOD=0.015 ng/mL. Adverse respiratory health outcomes accounted for approximately one-half (56% at LOD=0.05 ng/mL and 52% at LOD=0.015 ng/mL) of total societal costs. Conclusion. Implementing smoke-free policies in all U.S. public housing could save lives and decrease SHS-related morbidity and mortality in never-smoking residents, resulting in annual societal savings of $183 million at LOD=0.05 ng/mL and $267 million at LOD=0.015 ng/mL. C1 [Mason, Jacquelyn; Wheeler, William; Brown, Mary Jean] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Emergency & Environm Hlth Serv, Atlanta, GA 30341 USA. RP Mason, J (reprint author), Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Emergency & Environm Hlth Serv, 4770 Buford Hwy NE,MS F-58, Atlanta, GA 30341 USA. EM zao4@cdc.gov NR 66 TC 6 Z9 6 U1 0 U2 9 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1900 M ST NW, STE 710, WASHINGTON, DC 20036 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD MAY-JUN PY 2015 VL 130 IS 3 BP 230 EP 244 PG 15 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CH5JJ UT WOS:000354071600010 PM 25931627 ER PT J AU Karch, DL Hall, HI Tang, T Hu, XH Mermin, J AF Karch, Debra L. Hall, H. Irene Tang, Tian Hu, Xiaohong Mermin, Jonathan TI Comparative Mortality Among People Diagnosed with HIV Infection or AIDS in the US, 2001-2010 SO PUBLIC HEALTH REPORTS LA English DT Article ID UNITED-STATES; CARE; ADULTS; ADOLESCENTS; RETENTION; HIV/AIDS; COHORT; RATIOS AB Objective. The comparative mortality figure (CMF) is the expected number of deaths in the standard population compared with those observed. We assessed state-based CMFs for people with HIV infection to allow standardized assessment of mortality in all states. Methods. We used National HIV Surveillance System data to compute CMFs for people diagnosed with HIV and AIDS from 2001 to 2010 who met the CDC HIV case definition; were alive on December 31, 2009; and died during 2010. Results. In 33 U.S. states with name-based HIV reporting since 2001, the 2010 CMF for people with an HIV diagnosis was 2.8 compared with 4.5 for those with an AIDS diagnosis. CMFs for males were higher than for females (3.4 vs. 3.1) and black people had higher CMFs than white people for HIV (3.2 vs. 2.2) and AIDS (4.7 vs. 4.3). CMFs by state ranged from 0.9 to 4.2 for HIV and 1.9 to 9.7 for AIDS. In 50 states and the District of Columbia with AIDS reporting, CMFs for males and females were similar (4.5 and 4.6, respectively), CMFs for black people remained higher than for white people (5.0 and 3.9, respectively), and the range for states remained broad (1.2-9.4). Conclusion. State mortality figures varied based on population composition and disease stage at diagnosis, possibly indicating a need for state-specific testing, linkage to care, and viral suppression strategies to reduce mortality. C1 [Karch, Debra L.; Hall, H. Irene; Hu, Xiaohong; Mermin, Jonathan] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30329 USA. [Tang, Tian] ICF Int Inc, Atlanta, GA USA. RP Karch, DL (reprint author), Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div HIV Prevent, HIV Incidence & Case Surveillance Branch, 1600 Clifton Rd NE,MS E-47, Atlanta, GA 30329 USA. EM dkarch@cdc.gov NR 38 TC 1 Z9 1 U1 0 U2 1 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1900 M ST NW, STE 710, WASHINGTON, DC 20036 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD MAY-JUN PY 2015 VL 130 IS 3 BP 253 EP 260 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CH5JJ UT WOS:000354071600012 PM 25931629 ER PT J AU Waters, TR Dick, RB AF Waters, Thomas R. Dick, Robert B. TI Evidence of Health Risks Associated with Prolonged Standing at Work and Intervention Effectiveness SO REHABILITATION NURSING LA English DT Editorial Material DE Prolonged standing; low back pain; leg pain; cardiovascular problems; subjective measures; biomechanical; physiological measures; interventions (floor mats; shoe inserts; sit-stand chairs; workstations); guidelines ID LOW-BACK-PAIN; CHRONIC VENOUS DISORDERS; LOW-BIRTH-WEIGHT; COMPRESSION STOCKINGS; PRETERM DELIVERY; MUSCULOSKELETAL COMPLAINTS; BIOMECHANICAL RESPONSES; FLOORING CONDITIONS; PHYSICAL EXERTION; OXIDATIVE STRESS AB PurposeProlonged standing at work has been shown to be associated with a number of potentially serious health outcomes, such as lower back and leg pain, cardiovascular problems, fatigue, discomfort, and pregnancy-related health outcomes. Recent studies have been conducted examining the relationship between these health outcomes and the amount of time spent standing while on the job. The purpose of this article was to provide a review of the health risks and interventions for workers and employers that are involved in occupations requiring prolonged standing. A brief review of recommendations by governmental and professional organizations for hours of prolonged standing is also included. FindingsBased on our review of the literature, there seems to be ample evidence showing that prolonged standing at work leads to adverse health outcomes. Review of the literature also supports the conclusion that certain interventions are effective in reducing the hazards associated with prolonged standing. Suggested interventions include the use of floor mats, sit-stand workstations/chairs, shoes, shoe inserts and hosiery or stockings. Studies could be improved by using more precise definitions of prolonged standing (e.g., duration, movement restrictions, and type of work), better measurement of the health outcomes, and more rigorous study protocols. Conclusion and Clinical RelevanceUse of interventions and following suggested guidelines on hours of standing from governmental and professional organizations should reduce the health risks from prolonged standing. C1 [Waters, Thomas R.; Dick, Robert B.] NIOSH, Cincinnati, OH 45226 USA. RP Dick, RB (reprint author), NIOSH, 4676 Columbia Pkwy,MS C24, Cincinnati, OH 45226 USA. EM rbd1@cdc.gov FU Intramural CDC HHS [CC999999] NR 71 TC 6 Z9 7 U1 3 U2 16 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0278-4807 EI 2048-7940 J9 REHABIL NURS JI Rehabil. Nurs. PD MAY-JUN PY 2015 VL 40 IS 3 BP 148 EP 165 DI 10.1002/rnj.166 PG 18 WC Nursing; Rehabilitation SC Nursing; Rehabilitation GA CH8FJ UT WOS:000354271500004 PM 25041875 ER PT J AU Walsh, CE Soucie, JM Miller, CH AF Walsh, Christopher E. Soucie, J. Michael Miller, Connie H. CA US Hemophilia Treatment Ctr Networ TI Impact of inhibitors on hemophilia A mortality in the United States SO AMERICAN JOURNAL OF HEMATOLOGY LA English DT Article ID LIFE EXPECTANCY; FACTOR-VIII; DISORDERS; DEATH; SURVEILLANCE; PROPHYLAXIS; KINGDOM; FINLAND; HIV AB The previously published mortality studies are limited in hemophilia populations but suggest that there is no increased risk of mortality in factor VIII inhibitor patients. This retrospective study analyzed surveillance data collected on 7,386 males with severe hemophilia A over a 13-year period to assess the association between a current inhibitor and death. During the study period, 432 participants died, among whom 48 were patients with an inhibitor. Clinical characteristics most strongly associated with death were increased number of reported bleeds, signs of liver disease, infection with either HIV or HCV, and the presence of inhibitor. Patients who underwent successful tolerization were not considered inhibitor patients in our analysis. In a multivariable analysis, the odds of death were 70% higher among patients with a current inhibitor compared to those without an inhibitor (P<0.01). Deaths among patients with inhibitors were much more likely to be attributed to bleeding complications than those among patients without an inhibitor (42 vs. 12%, P<0.0001). We conclude that males with severe hemophilia A and a current inhibitor are at increased risk of death.Am. J. Hematol. 90:400-405, 2015. (c) 2015 Wiley Periodicals, Inc. C1 [Walsh, Christopher E.] Mt Sinai Sch Med, New York, NY USA. [Soucie, J. Michael; Miller, Connie H.] Ctr Dis Control & Prevent, Div Blood Disorders, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. RP Walsh, CE (reprint author), Mt Sinai Sch Med, One Gustave Levy Pl,Box 1079, Nyc, NY 10029 USA. EM christopher-e.walsh@mountsinai.org RI Kerlin, Bryce/E-3369-2011; OI Kerlin, Bryce/0000-0002-1756-8271; Miller, Connie H/0000-0002-3989-7973 NR 18 TC 10 Z9 10 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0361-8609 EI 1096-8652 J9 AM J HEMATOL JI Am. J. Hematol. PD MAY PY 2015 VL 90 IS 5 BP 400 EP 405 DI 10.1002/ajh.23957 PG 6 WC Hematology SC Hematology GA CG6FS UT WOS:000353393300017 PM 25616111 ER PT J AU Quinn, MM Henneberger, PK AF Quinn, Margaret M. Henneberger, Paul K. CA Natl Inst Occupational Safety & Hl Natl Occupational Res Agenda NORA TI Cleaning and disinfecting environmental surfaces in health care: Toward an integrated framework for infection and occupational illness prevention SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Article DE Disinfection; Infection prevention; Occupational exposure; Asthma; Green cleaning ID WORK-RELATED ASTHMA; VANCOMYCIN-RESISTANT ENTEROCOCCUS; CLOSTRIDIUM-DIFFICILE INFECTION; IN-HOSPITAL WORKERS; RISK-FACTORS; STAPHYLOCOCCUS-AUREUS; PROFESSIONAL CLEANERS; RESPIRATORY SYMPTOMS; NONDOMESTIC CLEANERS; NOSOCOMIAL PATHOGENS AB Background: The Cleaning and Disinfecting in Healthcare Working Group of the National Institute for Occupational Safety and Health, National Occupational Research Agenda, is a collaboration of infection prevention and occupational health researchers and practitioners with the objective of providing a more integrated approach to effective environmental surface cleaning and disinfection (C&D) while protecting the respiratory health of health care personnel. Methods: The Working Group, comprised of >40 members from 4 countries, reviewed current knowledge and identified knowledge gaps and future needs for research and practice. Results: An integrated framework was developed to guide more comprehensive efforts to minimize harmful C&D exposures without reducing the effectiveness of infection prevention. Gaps in basic knowledge and practice that are barriers to an integrated approach were grouped in 2 broad areas related to the need for improved understanding of the (1) effectiveness of environmental surface C&D to reduce the incidence of infectious diseases and colonization in health care workers and patients and (2) adverse health impacts of C&D on health care workers and patients. Specific needs identified within each area relate to basic knowledge, improved selection and use of products and practices, effective hazard communication and training, and safer alternatives. Conclusion: A more integrated approach can support multidisciplinary teams with the capacity to maximize effective and safe C&D in health care. Copyright (C) 2015 by the Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier Inc. C1 [Quinn, Margaret M.] Univ Massachusetts Lowell, Dept Work Environm, Lowell, MA 01854 USA. [Henneberger, Paul K.] NIOSH, Div Resp Dis Studies, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. RP Quinn, MM (reprint author), Univ Massachusetts Lowell, Dept Work Environm, 1 Univ Ave, Lowell, MA 01854 USA. EM Margaret_Quinn@uml.edu RI LeMoual, Nicole/R-8976-2016 OI LeMoual, Nicole/0000-0002-2723-5569 FU National Institute for Occupational Safety and Health FX The National Institute for Occupational Safety and Health provided support for Working Group telephone conference calls. NR 117 TC 13 Z9 15 U1 2 U2 15 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 EI 1527-3296 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD MAY 1 PY 2015 VL 43 IS 5 BP 424 EP 434 DI 10.1016/j.ajic.2015.01.029 PG 11 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA CH2XZ UT WOS:000353890100004 PM 25792102 ER PT J AU Takashita, E Meijer, A Lackenby, A Gubareva, L Rebelo-de-Andrade, H Besselaar, T Fry, A Gregory, V Leang, SK Huang, WJ Lo, J Pereyaslov, D Siqueira, MM Wang, DY Mak, GC Zhang, WQ Daniels, RS Hurt, AC Tashiro, M AF Takashita, Emi Meijer, Adam Lackenby, Angie Gubareva, Larisa Rebelo-de-Andrade, Helena Besselaar, Terry Fry, Alicia Gregory, Vicky Leang, Sook-Kwan Huang, Weijuan Lo, Janice Pereyaslov, Dmitriy Siqueira, Marilda M. Wang, Dayan Mak, Gannon C. Zhang, Wenqing Daniels, Rod S. Hurt, Aeron C. Tashiro, Masato TI Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013-2014 SO ANTIVIRAL RESEARCH LA English DT Article DE Influenza virus; Antiviral resistance; Neuraminidase inhibitors; Oseltamivir; Global analysis; Reduced susceptibility ID H275Y OSELTAMIVIR-RESISTANT; UNITED-STATES; COMMUNITY CLUSTER; A(H1N1) VIRUS; H1N1; MUTATIONS; SEASON; JAPAN AB Four World Health Organization (WHO) Collaborating Centres for Reference and Research on Influenza and one WHO Collaborating Centre for the Surveillance, Epidemiology and Control of Influenza (WHO CCs) tested 10,641 viruses collected by WHO-recognized National Influenza Centres between May 2013 and May 2014 to determine 50% inhibitory concentration (IC50) data for neuraminidase inhibitors (NAIs) oseltamivir, zanamivir, peramivir and laninamivir. In addition, neuraminidase (NA) sequence data, available from the WHO CCs and from sequence databases (n = 3206), were screened for amino acid substitutions associated with reduced NAI susceptibility. Ninety-five per cent of the viruses tested by the WHO CCs were from three WHO regions: Western Pacific, the Americas and Europe. Approximately 2% (n = 172) showed highly reduced inhibition (HRI) against at least one of the four NAIs, commonly oseltamivir, while 0.3% (n = 32) showed reduced inhibition (RI). Those showing HRI were A(H1N1)pdm09 with NA H275Y (n = 169), A(H3N2) with NA E119V (n = 1), B/Victoria-lineage with NA E117G (n = 1) and B/Yamagata-lineage with NA H273Y (n = 1); amino acid position numbering is A subtype and B type specific. Although approximately 98% of circulating viruses tested during the 2013-2014 period were sensitive to all four NAIs, a large community cluster of A(H1N1)pdm09 viruses with the NA H275Y substitution from patients with no previous exposure to antivirals was detected in Hokkaido, Japan. Significant numbers of A(H1N1)pdm09 NA H275Y viruses were also detected in China and the United States: phylogenetic analyses showed that the Chinese viruses were similar to those from Japan, while the United States viruses clustered separately from those of the Hokkaido outbreak, indicative of multiple resistance-emergence events. Consequently, global surveillance of influenza antiviral susceptibility should be continued from a public health perspective. (C) 2015 The Authors. Published by Elsevier B.V. C1 [Takashita, Emi; Tashiro, Masato] Natl Inst Infect Dis, World Hlth Org Collaborating Ctr Reference & Res, Tokyo 2080011, Japan. [Meijer, Adam] Natl Inst Publ Hlth & Environm, NL-3720 BA Bilthoven, Netherlands. [Lackenby, Angie] Publ Hlth England Colindale, London NW9 5EQ, England. [Gubareva, Larisa; Fry, Alicia] Ctr Dis Control & Prevent, World Hlth Org Collaborating Ctr Surveillance Epi, Atlanta, GA USA. [Rebelo-de-Andrade, Helena] Inst Nacl Saude, P-1649016 Lisbon, Portugal. [Rebelo-de-Andrade, Helena] Univ Lisbon, Fac Farm, P-1649003 Lisbon, Portugal. [Besselaar, Terry; Zhang, Wenqing] WHO, Global Influenza Programme, CH-1211 Geneva 27, Switzerland. [Gregory, Vicky; Daniels, Rod S.] Natl Inst Med Res, MRC, World Hlth Org Collaborating Ctr Reference & Res, London NW7 1AA, England. [Leang, Sook-Kwan; Hurt, Aeron C.] Peter Doherty Inst Infect & Immun, VIDRL, World Hlth Org Collaborating Ctr Reference & Res, Melbourne, Vic 3000, Australia. [Huang, Weijuan; Wang, Dayan] Chinese Ctr Dis Control & Prevent, Natl Inst Viral Dis Control & Prevent, Chinese Natl Influenza Ctr, World Hlth Org Collaborating Ctr Reference & Res, Beijing 102206, Peoples R China. [Lo, Janice; Mak, Gannon C.] Publ Hlth Lab Ctr, Kowloon, Hong Kong, Peoples R China. [Pereyaslov, Dmitriy] WHO, Reg Off Europe, Div Communicable Dis Hlth Secur & Environm, DK-2100 Copenhagen O, Denmark. [Siqueira, Marilda M.] Fiocruz MS, Resp Viruses Lab IOC, BR-4365 Rio De Janeiro, Brazil. [Hurt, Aeron C.] Univ Melbourne, Melbourne Sch Populat & Global Hlth, Melbourne, Vic 3010, Australia. RP Tashiro, M (reprint author), Natl Inst Infect Dis, Influenza Virus Res Ctr, Gakuen 4-7-1, Tokyo 2080011, Japan. EM emitaka@nih.go.jp; adam.meijer@rivm.nl; Angie.Lackenby@phe.gov.uk; LGubareva@CDC.gov; h.rebelo.andrade@insa.min-saude.pt; besselaart@who.int; agf1@cdc.gov; vgregor@nimr.mrc.ac.uk; leah.leang@influenzacentre.org; huangweijuan@cnic.org.cn; janicelo@dh.gov.hk; PDM@euro.who.int; mmsiq@ioc.fiocruz.br; dayanwang@cnic.org.cn; so_phls10@dh.gov.hk; zhangw@who.int; rdaniel@nimr.mrc.ac.uk; Aeron.Hurt@influenzacentre.org; mtashiro2@gmail.com RI Rebelo-de-Andrade, Helena/E-1871-2014; iMed.ULisboa, iMed.ULisboa/C-6292-2014; iMed.ULisboa, HPI /B-4239-2014; OI Rebelo-de-Andrade, Helena/0000-0002-0138-0944; iMed.ULisboa, HPI /0000-0001-5934-0198; Takashita, Emi/0000-0002-9064-4699; Hurt, Aeron/0000-0003-1826-4314 FU Ministry of Health, Labour, and Welfare, Japan; JSPS KAKENHI Grant [26460816]; British Medical Research Council [U117512723]; Australian Government Department of Health FX We thank all laboratories, mostly NICs of the WHO GISRS (http://www.who.int/influenza/gisrs_laboratory/national_influenza_cen-tr esflist/en/), which contributed to this global analysis by submitting influenza virus positive samples (clinical specimens or virus isolates) to WHO CCs for detailed characterisation. We gratefully acknowledge the authors, originating and submitting laboratories of the sequences submitted to the GISAID database (Supplementary Table 3), and the sequences retrieved from the NCBI-IVR, that were included in this global analysis. The Tokyo WHO CC is supported by Grants-in-Aid for Emerging and Re-emerging Infectious Diseases from the Ministry of Health, Labour, and Welfare, Japan and by JSPS KAKENHI Grant number 26460816. The London WHO CC is funded by the British Medical Research Council through programme U117512723. The Melbourne WHO CC is supported by the Australian Government Department of Health. NR 32 TC 39 Z9 43 U1 1 U2 17 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0166-3542 EI 1872-9096 J9 ANTIVIR RES JI Antiviral Res. PD MAY PY 2015 VL 117 BP 27 EP 38 DI 10.1016/j.antiviral.2015.02.003 PG 12 WC Pharmacology & Pharmacy; Virology SC Pharmacology & Pharmacy; Virology GA CH0TH UT WOS:000353734800004 PM 25721488 ER PT J AU Sauter, SL Wells, SI Zhang, X Hoskins, EE Davies, SM Myers, KC Mueller, R Panicker, G Unger, ER Sivaprasad, U Brown, DR Mehta, PA Kovacic, MB AF Sauter, Sharon L. Wells, Susanne I. Zhang, Xue Hoskins, Elizabeth E. Davies, Stella M. Myers, Kasiani C. Mueller, Robin Panicker, Gitika Unger, Elizabeth R. Sivaprasad, Umasundari Brown, Darron R. Mehta, Parinda A. Kovacic, Melinda Butsch TI Oral Human Papillomavirus Is Common in Individuals with Fanconi Anemia SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION LA English DT Article ID SQUAMOUS-CELL CARCINOMAS; DNA-DAMAGE RESPONSE; SEXUAL-BEHAVIORS; INFECTION; PATHWAY; PREVALENCE; CHILDREN; REGISTRY; REPAIR; HEAD AB Background: Fanconi anemia is a rare genetic disorder resulting in a loss of function of the Fanconi anemia-related DNA repair pathway. Individuals with Fanconi anemia are predisposed to some cancers, including oropharyngeal and gynecologic cancers, with known associations with human papillomavirus (HPV) in the general population. As individuals with Fanconi anemia respond poorly to chemotherapy and radiation, prevention of cancer is critical. Methods: To determine whether individuals with Fanconi anemia are particularly susceptible to oral HPV infection, we analyzed survey-based risk factor data and tested DNA isolated from oral rinses from 126 individuals with Fanconi anemia and 162 unaffected first-degree family members for 37 HPV types. Results: Fourteen individuals (11.1%) with Fanconi anemia tested positive, significantly more (P = 0.003) than family members (2.5%). While HPV prevalence was even higher for sexually active individuals with Fanconi anemia (17.7% vs. 2.4% in family; P = 0.003), HPV positivity also tended to be higher in the sexually inactive (8.7% in Fanconi anemia vs. 2.9% in siblings). Indeed, having Fanconi anemia increased HPV positivity 4.9-fold (95% CI, 1.6-15.4) considering age and sexual experience, but did not differ by other potential risk factors. Conclusion: Our studies suggest that oral HPV is more common in individuals with Fanconi anemia. It will be essential to continue to explore associations between risk factors and immune dysfunction on HPV incidence and persistence over time. Impact: HPV vaccination should be emphasized in those with Fanconi anemia as a first step to prevent oropharyngeal cancers, although additional studies are needed to determine whether the level of protection it offers in this population is adequate. (C) 2015 AACR. C1 [Sauter, Sharon L.; Wells, Susanne I.; Zhang, Xue; Hoskins, Elizabeth E.; Davies, Stella M.; Myers, Kasiani C.; Mueller, Robin; Sivaprasad, Umasundari; Mehta, Parinda A.; Kovacic, Melinda Butsch] Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Cincinnati, OH 45229 USA. [Panicker, Gitika; Unger, Elizabeth R.] Ctr Dis Control & Prevent, Chron Viral Dis Branch, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Brown, Darron R.] Indiana Univ Sch Med, Div Infect Dis, Indianapolis, IN 46202 USA. RP Kovacic, MB (reprint author), Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Dept Pediat, 3333 Burnet Ave,ML 7037, Cincinnati, OH 45229 USA. EM melinda.butsch.kovacic@cchmc.org FU Fanconi Anemia Research Fund; CCHMC; NIH [R01 HL108102]; Center for Clinical and Translational Science and Training grant [UL1-RR026314-01 NCRR/NIH] FX This study was funded through the Fanconi Anemia Research Fund (Principal Investigator, S.I. Wells), a CCHMC-sponsored Translational Research Initiative Grant (Principal Investigator, S.I. Wells), and by an NIH R01 HL108102 (Principal Investigator, M. Butsch Kovacic). REDCap was hosted at CCHMC and supported by the Center for Clinical and Translational Science and Training grant UL1-RR026314-01 NCRR/NIH. NR 32 TC 4 Z9 4 U1 0 U2 1 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1055-9965 EI 1538-7755 J9 CANCER EPIDEM BIOMAR JI Cancer Epidemiol. Biomarkers Prev. PD MAY PY 2015 VL 24 IS 5 BP 864 EP 872 DI 10.1158/1055-9965.EPI-15-0097-T PG 9 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA CH0IK UT WOS:000353702800012 PM 25809863 ER PT J AU Knight, J Cassell, CH Meyer, RE Strauss, RP AF Knight, Jessica Cassell, Cynthia H. Meyer, Robert E. Strauss, Ronald P. TI Academic Outcomes of Children With Isolated Orofacial Clefts Compared With Children Without a Major Birth Defect SO CLEFT PALATE-CRANIOFACIAL JOURNAL LA English DT Article DE academic outcomes; cleft lip; cleft palate; orofacial clefts ID QUALITY-OF-LIFE; LIP AND/OR PALATE; MENTAL-RETARDATION; DISABILITY; ADOLESCENTS; COMMUNICATION; ACHIEVEMENT; LANGUAGE; INFANTS; HEARING AB Objective: To compare academic outcomes between children with orofacial cleft (OFC) and children without major birth defects. Design and Setting: In 2007-2008, we mailed questionnaires to a random sample of mothers of school-aged children with OFC and mothers of children without major birth defects (comparison group). The questionnaire included Likert-scale, closed-ended, and open-ended questions from validated instruments. We conducted bivariate and multivariable analyses on parent-reported educational outcomes and bivariate analyses on parent-reported presence of related medical conditions between children with isolated OFC and unaffected children. Patients/Participants: A random sample of 504 parents of children with OFCs born 1996-2002 (age 5-12 years) were identified by the North Carolina Birth Defects Monitoring Program. A random sample of 504 parents of children without birth defects born 1996-2002 was selected from North Carolina birth certificates. Of the 289 (28.7%) respondents, we analyzed 112 children with isolated OFC and 138 unaffected children. Main Outcome Measures: Letter grades, school days missed, and grade retention. Results: Parents of children with isolated OFC reported more developmental disabilities and hearing and speech problems among their children than comparison parents. Children with isolated OFC were more likely to receive lower grades and miss more school days than unaffected children. Because of the low response rate, results should be interpreted cautiously. Conclusion: Children with isolated OFC may have poorer academic outcomes during elementary school than their unaffected peers. Future studies are needed to confirm these results and determine whether these differences persist in later grades. C1 [Knight, Jessica] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30322 USA. [Knight, Jessica; Cassell, Cynthia H.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Meyer, Robert E.] North Carolina Dept Hlth & Human Serv, North Carolina Birth Defects Monitoring Program, North Carolina State Ctr Hlth Stat, North Carolina Div Publ Hlth, Raleigh, NC USA. [Strauss, Ronald P.] Univ N Carolina, Chapel Hill, NC USA. [Strauss, Ronald P.] Univ N Carolina, Dent Ecol, Sch Dent, Craniofacial Ctr, Chapel Hill, NC USA. RP Knight, J (reprint author), Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, 1518 Clifton Rd NE,Mailstop 1518-002-3BB, Atlanta, GA 30322 USA. EM jhknigh@emory.edu FU National Center on Birth Defects and Developmental Disabilities at the Centers for Disease Control and Prevention [U50/CCU422096] FX This work was supported by the National Center on Birth Defects and Developmental Disabilities at the Centers for Disease Control and Prevention (grant number U50/CCU422096). NR 40 TC 6 Z9 6 U1 3 U2 8 PU ALLIANCE COMMUNICATIONS GROUP DIVISION ALLEN PRESS PI LAWRENCE PA 810 EAST 10TH STREET, LAWRENCE, KS 66044 USA SN 1545-1569 EI 1055-6656 J9 CLEFT PALATE-CRAN J JI Cleft Palate-Craniofac. J. PD MAY PY 2015 VL 52 IS 3 BP 259 EP 268 DI 10.1597/13-293 PG 10 WC Dentistry, Oral Surgery & Medicine; Surgery SC Dentistry, Oral Surgery & Medicine; Surgery GA CH2YG UT WOS:000353890900005 PM 24878348 ER PT J AU Hicks, LA Bartoces, MG Roberts, RM Suda, KJ Hunkler, RJ Taylor, TH Schrag, SJ AF Hicks, Lauri A. Bartoces, Monina G. Roberts, Rebecca M. Suda, Katie J. Hunkler, Robert J. Taylor, Thomas H., Jr. Schrag, Stephanie J. TI US Outpatient Antibiotic Prescribing Variation According to Geography, Patient Population, and Provider Specialty in 2011 SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE anti-bacterial agents; antibiotic; inappropriate prescribing ID INFECTIOUS-DISEASES-SOCIETY; RESPIRATORY-TRACT INFECTIONS; COMMUNITY-ACQUIRED PNEUMONIA; CLINICAL-PRACTICE GUIDELINES; AMBULATORY CARE PHYSICIANS; UNITED-STATES; VISIT RATES; CHILDREN; AMERICA; MANAGEMENT AB Background. Appropriate antibiotic prescribing is an essential strategy to reduce the spread of antibiotic resistance. US prescribing practices have not been thoroughly characterized. We analyzed outpatient antibiotic prescribing data to identify where appropriate antibiotic prescribing interventions could have the most impact. Methods. Oral antibiotic prescriptions dispensed during 2011 were extracted from the IMS Health Xponent database. The number of prescriptions and census denominators were used to calculate prescribing rates. Prescription totals were calculated for each provider specialty. Regression modeling was used to examine the association between socioeconomic and population health factors and prescribing rates. Results. Healthcare providers prescribed 262.5 million courses of antibiotics in 2011(842 prescriptions per 1000 persons). Penicillins and macrolides were the most common antibiotic categories prescribed. The most commonly prescribed individual antibiotic agent was azithromycin. Family practitioners prescribed the most antibiotic courses (24%). The prescribing rate was higher in the South census region (931 prescriptions per 1000 persons) than in the West (647 prescriptions per 1000 persons; P<.001); this pattern was observed among all age groups, including children <= 2 and persons >= 65 years of age. Counties with a high proportion of obese persons, infants and children <= 2 years of age, prescribers per capita, and females were more likely to be high prescribing by multivariable analysis (adjusted odds ratio, >1.0). Conclusions. Efforts to characterize antibiotic prescribing practices should focus on the South census region and family practitioners. Further understanding of the factors leading to high prescribing among key target populations will inform appropriate prescribing interventions. C1 [Hicks, Lauri A.; Bartoces, Monina G.; Roberts, Rebecca M.; Taylor, Thomas H., Jr.; Schrag, Stephanie J.] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. [Suda, Katie J.] Univ Illinois, Dept Vet Affairs, Chicago, IL USA. [Hunkler, Robert J.] IMS Hlth, Plymouth Meeting, Plymouth Meeting, PA USA. RP Hicks, LA (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,MS C-25, Atlanta, GA 30329 USA. EM lhicks@cdc.gov NR 40 TC 41 Z9 41 U1 5 U2 14 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD MAY 1 PY 2015 VL 60 IS 9 BP 1308 EP 1316 DI 10.1093/cid/civ076 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CH0NS UT WOS:000353718400004 PM 25747410 ER PT J AU von Mollendorf, C von Gottberg, A Tempia, S Meiring, S de Gouveia, L Quan, V Lengana, S Avenant, T du Plessis, N Eley, B Finlayson, H Reubenson, G Moshe, M O'Brien, KL Klugman, KP Whitney, CG Cohen, C AF von Mollendorf, Claire von Gottberg, Anne Tempia, Stefano Meiring, Susan de Gouveia, Linda Quan, Vanessa Lengana, Sarona Avenant, Theunis du Plessis, Nicolette Eley, Brian Finlayson, Heather Reubenson, Gary Moshe, Mamokgethi O'Brien, Katherine L. Klugman, Keith P. Whitney, Cynthia G. Cohen, Cheryl CA Grp Enteric Resp & Meningeal Dis S TI Increased Risk for and Mortality From Invasive Pneumococcal Disease in HIV-Exposed but Uninfected Infants Aged < 1 Year in South Africa, 2009-2013 SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE Streptococcus pneumoniae; HIV exposure; children; South Africa; pneumococcal conjugate vaccine ID IMMUNODEFICIENCY-VIRUS-INFECTION; STREPTOCOCCUS-PNEUMONIAE; CONJUGATE VACCINE; CHILD-MORTALITY; ANTIRETROVIRAL THERAPY; ANTIBODY-RESPONSES; MOTHERS; 1ST; POPULATION; MORBIDITY AB Background. High antenatal human immunodeficiency virus (HIV) seroprevalence rates (similar to 30%) with low perinatal HIV transmission rates (2.5%), due to HIV prevention of mother-to-child transmission program improvements in South Africa, has resulted in increasing numbers of HIV-exposed but uninfected (HEU) children. We aimed to describe the epidemiology of invasive pneumococcal disease (IPD) in HEU infants. Methods. We conducted a cross-sectional study of infants aged <1 year with IPD enrolled in a national, laboratory-based surveillance program for incidence estimations. Incidence was reported for 2 time points, 2009 and 2013. At enhanced sites we collected additional data including HIV status and in-hospital outcome. Results. We identified 2099 IPD cases in infants from 2009 to 2013 from all sites. In infants from enhanced sites (n = 1015), 92% had known HIV exposure status and 86% had known outcomes. IPD incidence was highest in HIV-infected infants, ranging from 272 to 654 per 100 000 population between time points (2013 and 2009), followed by HEU (33-88 per 100 000) and HIV-unexposed and uninfected (HUU) infants (18-28 per 100 000). The case-fatality rate in HEU infants (29% [74/253]) was intermediate between HUU (25% [94/377]) and HIV-infected infants (34% [81/242]). When restricted to infants <6 months of age, HEU infants (37% [59/175]) were at significantly higher risk of dying than HUU infants (32% [51/228]; adjusted relative risk ratio, 1.76 [95% confidence interval, 1.09-2.85]). Discussion. HEU infants are at increased risk of IPD and mortality from IPD compared with HUU children, especially as young infants. HEU infants, whose numbers will likely continue to increase, should be prioritized for interventions such as pneumococcal vaccination along with HIV-infected infants and children. C1 [von Mollendorf, Claire; von Gottberg, Anne; Tempia, Stefano; de Gouveia, Linda; Lengana, Sarona; Cohen, Cheryl] Natl Inst Communicable Dis, Ctr Resp Dis & Meningitis, Div Natl Hlth Lab Serv, ZA-2193 Gauteng, South Africa. [von Mollendorf, Claire; Cohen, Cheryl] Univ Witwatersrand, Fac Hlth Sci, Sch Publ Hlth, Johannesburg, South Africa. [von Gottberg, Anne] Univ Witwatersrand, Sch Pathol, Resp & Meningeal Pathogens Res Unit, Med Res Council, Johannesburg, South Africa. [Tempia, Stefano] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. [Tempia, Stefano] Ctr Dis Control & Prevent, Influenza Div, Pretoria, South Africa. [Meiring, Susan; Quan, Vanessa] Natl Inst Communicable Dis, Div Natl Hlth Lab Serv, Div Publ Hlth Surveillance & Response, Johannesburg, South Africa. [Avenant, Theunis; du Plessis, Nicolette] Univ Pretoria, Steve Biko Pretoria Acad Hosp, Pediat Infect Dis Unit, Gauteng, South Africa. [Avenant, Theunis; du Plessis, Nicolette] Univ Pretoria, Kalafong Hosp, Gauteng, South Africa. [Eley, Brian] Univ Cape Town, Dept Paediat & Child Hlth, Red Cross War Mem Childrens Hosp, ZA-7925 Cape Town, Western Cape, South Africa. [Finlayson, Heather] Univ Stellenbosch, Tygerberg Hosp, Cape Town, Western Cape, South Africa. [Finlayson, Heather] Univ Stellenbosch, Dept Paediat & Child Hlth, Cape Town, Western Cape, South Africa. [Reubenson, Gary] Univ Witwatersrand, Rahima Moosa Mother & Child Hosp, Fac Hlth Sci, Dept Paediat & Child Hlth, Johannesburg, South Africa. [Moshe, Mamokgethi] Medunsa Univ, Dr George Mukhari Hosp, Dept Paediat & Child Hlth, Tshwane, Gauteng Provinc, South Africa. [O'Brien, Katherine L.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Int Vaccine Access Ctr, Baltimore, MD USA. [Klugman, Keith P.] Emory Univ, Rollins Sch Publ Hlth, Hubert Dept Global Hlth, Atlanta, GA 30322 USA. [Klugman, Keith P.] Emory Univ, Sch Med, Div Infect Dis, Atlanta, GA 30322 USA. [Whitney, Cynthia G.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP von Mollendorf, C (reprint author), Natl Inst Communicable Dis, Ctr Resp Dis & Meningitis, NHLS, 1 Modderfontein Rd, ZA-2193 Gauteng, South Africa. EM clairevm@nicd.ac.za FU NICD/NHLS; President's Emergency Plan for AIDS Relief through the CDC [5U2GPS001328]; GAVI Accelerated Vaccine Initiative-Special Studies Team FX This work was supported by NICD/NHLS; the President's Emergency Plan for AIDS Relief through the CDC (grant number 5U2GPS001328); and the GAVI Accelerated Vaccine Initiative-Special Studies Team. NR 39 TC 22 Z9 22 U1 2 U2 9 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD MAY 1 PY 2015 VL 60 IS 9 BP 1346 EP 1356 DI 10.1093/cid/civ059 PG 11 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CH0NS UT WOS:000353718400010 PM 25645212 ER PT J AU Biggerstaff, M Reed, C Swerdlow, DL Gambhir, M Graitcer, S Finelli, L Borse, RH Rasmussen, SA Meltzer, MI Bridges, CB AF Biggerstaff, Matthew Reed, Carrie Swerdlow, David L. Gambhir, Manoj Graitcer, Samuel Finelli, Lyn Borse, Rebekah H. Rasmussen, Sonja A. Meltzer, Martin I. Bridges, Carolyn B. TI Estimating the Potential Effects of a Vaccine Program Against an Emerging Influenza Pandemic-United States SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE influenza; influenza A(H7N9); influenza vaccine; mathematical modeling; pandemic ID A H7N9 VIRUS; HUMAN INFECTION; TRIAL; H1N1; IMMUNOGENICITY; EPIDEMIOLOGY; ADULTS AB Background. Human illness from influenza A(H7N9) was identified in March 2013, and candidate vaccine viruses were soon developed. To understand factors that may impact influenza vaccination programs, we developed a model to evaluate hospitalizations and deaths averted considering various scenarios. Methods. We utilized a model incorporating epidemic curves with clinical attack rates of 20% or 30% in a single wave of illness, case hospitalization ratios of 0.5% or 4.2%, and case fatality ratios of 0.08% or 0.53%. We considered scenarios that achieved 80% vaccination coverage, various starts of vaccination programs (16 or 8 weeks before, the same week of, or 8 or 16 weeks after start of pandemic), an administration rate of 10 or 30 million doses per week (the latter rate is an untested assumption), and 2 levels of vaccine effectiveness (2 doses of vaccine required; either 62% or 80% effective for persons aged <60 years, and either 43% or 60% effective for persons aged >= 60 years). Results. The start date of vaccination campaigns most influenced impact; 141 000-2 200 000 hospitalizations and 11 000-281 000 deaths were averted when campaigns started before a pandemic, and <100-1 300 000 hospitalizations and 0-165 000 deaths were averted for programs beginning the same time as or after the introduction of the pandemic virus. The rate of vaccine administration and vaccine effectiveness did not influence campaign impact as much as timing of the start of campaign. Conclusions. Our findings suggest that efforts to improve the timeliness of vaccine production will provide the greatest impacts for future pandemic vaccination programs. C1 [Biggerstaff, Matthew; Reed, Carrie; Finelli, Lyn] Ctr Dis Control & Prevent CDC, Epidemiol & Prevent Branch, Influenza Div, NCIRD, Atlanta, GA USA. [Swerdlow, David L.; Gambhir, Manoj] Ctr Dis Control & Prevent CDC, Modeling Unit, NCIRD, Atlanta, GA USA. [Swerdlow, David L.] Ctr Dis Control & Prevent CDC, Off Director, NCIRD, Atlanta, GA USA. [Gambhir, Manoj] Monash Univ, Epidemiol Modelling Unit, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia. [Graitcer, Samuel; Bridges, Carolyn B.] NCIRD, Immunizat Serv Div, Atlanta, GA USA. [Borse, Rebekah H.; Meltzer, Martin I.] Natl Ctr Emerging & Zoonot Infect Dis, Sci & Program Serv Branch, Div Preparedness & Emerging Infect, Atlanta, GA USA. [Rasmussen, Sonja A.] CDC, Influenza Coordinat Unit, Off Infect Dis, Atlanta, GA 30333 USA. RP Biggerstaff, M (reprint author), Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd NE,MS A-32, Atlanta, GA 30333 USA. EM mbiggerstaff@cdc.gov FU CDC FX This article appears as part of the supplement titled "CDC Modeling Efforts in Response to a Potential Public Health Emergency: Influenza A(H7N9) as an Example," sponsored by the CDC. NR 29 TC 5 Z9 5 U1 0 U2 4 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD MAY 1 PY 2015 VL 60 SU 1 BP S20 EP S29 DI 10.1093/cid/ciu1175 PG 10 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CH0ND UT WOS:000353716200004 PM 25878298 ER PT J AU Carias, C Rainisch, G Shankar, M Adhikari, BB Swerdlow, DL Bower, WA Pillai, SK Meltzer, MI Koonin, LM AF Carias, Cristina Rainisch, Gabriel Shankar, Manjunath Adhikari, Bishwa B. Swerdlow, David L. Bower, William A. Pillai, Satish K. Meltzer, Martin I. Koonin, Lisa M. TI Potential Demand for Respirators and Surgical Masks During a Hypothetical Influenza Pandemic in the United States SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE influenza pandemic; respiratory protective devices ID PROTECTIVE EQUIPMENT; H1N1 INFLUENZA; VIRUS AB Background. To inform planning for an influenza pandemic, we estimated US demand for N95 filtering facepiece respirators (respirators) by healthcare and emergency services personnel and need for surgical masks by pandemic patients seeking care. Methods. We used a spreadsheet-based model to estimate demand for 3 scenarios of respirator use: base case (usage approximately follows epidemic curve), intermediate demand (usage rises to epidemic peak and then remains constant), and maximum demand (all healthcare workers use respirators from pandemic onset). We assumed that in the base case scenario, up to 16 respirators would be required per day per intensive care unit patient and 8 per day per general ward patient. Outpatient healthcare workers and emergency services personnel would require 4 respirators per day. Patients would require 1.2 surgical masks per day. Results and Conclusions. Assuming that 20% to 30% of the population would become ill, 1.7 to 3.5 billion respirators would be needed in the base case scenario, 2.6 to 4.3 billion in the intermediate demand scenario, and up to 7.3 billion in the maximum demand scenario (for all scenarios, between 0.1 and 0.4 billion surgical masks would be required for patients). For pandemics with a lower attack rate and fewer cases (eg, 2009-like pandemic), the number of respirators needed would be higher because the pandemic would have longer duration. Providing these numbers of respirators and surgical masks represents a logistic challenge for US public health agencies. Public health officials must urgently consider alternative use strategies for respirators and surgical masks during a pandemic that may vary from current practices. C1 [Carias, Cristina; Swerdlow, David L.] NCIRD, Atlanta, GA USA. [Carias, Cristina] IHRC Inc, Atlanta, GA USA. [Rainisch, Gabriel; Shankar, Manjunath; Adhikari, Bishwa B.; Pillai, Satish K.; Meltzer, Martin I.] Natl Ctr Emerging & Zoonot Infect Dis, Div Preparedness & Emerging Infect, Atlanta, GA USA. [Swerdlow, David L.] NCIRD, Modeling Unit, Atlanta, GA USA. [Swerdlow, David L.] NCIRD, Off Director, Atlanta, GA USA. [Bower, William A.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Atlanta, GA 30333 USA. [Koonin, Lisa M.] Ctr Dis Control & Prevent, Influenza Coordinat Unit, Off Infect Dis, Atlanta, GA 30333 USA. RP Carias, C (reprint author), Ctr Dis Control & Prevent, Off Sci & Integrated Programs, 1600 Clifton Rd NE,MS A-27, Atlanta, GA 30333 USA. EM vnn9@cdc.gov FU CDC FX This article appears as part of the supplement titled "CDC Modeling Efforts in Response to a Potential Public Health Emergency: Influenza A(H7N9) as an Example," sponsored by the CDC. NR 28 TC 3 Z9 3 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD MAY 1 PY 2015 VL 60 SU 1 BP S42 EP S51 DI 10.1093/cid/civ141 PG 10 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CH0ND UT WOS:000353716200006 PM 25878300 ER PT J AU Fung, ICH Gambhir, M Glasser, JW Gao, HJ Washington, ML Uzicanin, A Meltzer, MI AF Fung, Isaac Chun-Hai Gambhir, Manoj Glasser, John W. Gao, Hongjiang Washington, Michael L. Uzicanin, Amra Meltzer, Martin I. TI Modeling the Effect of School Closures in a Pandemic Scenario: Exploring Two Different Contact Matrices SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE influenza; mathematical model; social distancing ID INFLUENZA AB Background. School closures may delay the epidemic peak of the next influenza pandemic, but whether school closure can delay the peak until pandemic vaccine is ready to be deployed is uncertain. Methods. To study the effect of school closures on the timing of epidemic peaks, we built a deterministic susceptible-infected-recoveredmodel of influenza transmission. We stratified the U.S. population into 4 age groups (0-4, 5-19, 20-64, and >= 65 years), and used contact matrices to model the average number of potentially disease transmitting, nonphysical contacts. Results. For every week of school closure at day 5 of introduction and a 30% clinical attack rate scenario, epidemic peak would be delayed by approximately 5 days. For a 15% clinical attack rate scenario, 1 week closure would delay the peak by 9 days. Closing schools for less than 84 days (12 weeks) would not, however, reduce the estimated total number of cases. Conclusions. Unless vaccine is available early, school closure alone may not be able to delay the peak until vaccine is ready to be deployed. Conversely, if vaccination begins quickly, school closure may be helpful in providing the time to vaccinate school-aged children before the pandemic peaks. C1 [Fung, Isaac Chun-Hai] Georgia So Univ, Jiann Ping Hsu Coll Publ Hlth, Dept Epidemiol, Statesboro, GA 30460 USA. [Fung, Isaac Chun-Hai; Gambhir, Manoj; Glasser, John W.; Gao, Hongjiang; Washington, Michael L.; Uzicanin, Amra; Meltzer, Martin I.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Gambhir, Manoj] IHRC Inc, Atlanta, GA USA. [Gambhir, Manoj] Monash Univ, Epidemiol Modelling Unit, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia. [Washington, Michael L.; Meltzer, Martin I.] Natl Ctr Emerging & Zoonot Infect Dis, Div Preparedness & Emerging Infect, Atlanta, GA USA. RP Fung, ICH (reprint author), Georgia So Univ, Jiann Ping Hsu Coll Publ Hlth, Statesboro, GA 30460 USA. EM cfung@georgiasouthern.edu OI Fung, Isaac Chun-Hai/0000-0001-5496-2529 FU CDC FX This article appears as part of the supplement titled "CDC Modeling Efforts in Response to a Potential Public Health Emergency: Influenza A(H7N9) as an Example," sponsored by the CDC. NR 9 TC 2 Z9 2 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD MAY 1 PY 2015 VL 60 SU 1 BP S58 EP S63 DI 10.1093/cid/civ086 PG 6 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CH0ND UT WOS:000353716200008 PM 25878302 ER PT J AU Gambhir, M Bozio, C O'Hagan, JJ Uzicanin, A Johnson, LE Biggerstaff, M Swerdlow, DL AF Gambhir, Manoj Bozio, Catherine O'Hagan, Justin J. Uzicanin, Amra Johnson, Lucinda E. Biggerstaff, Matthew Swerdlow, David L. TI Infectious Disease Modeling Methods as Tools for Informing Response to Novel Influenza Viruses of Unknown Pandemic Potential SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID A H1N1 VIRUS; REAL-TIME; MATHEMATICAL-MODELS; REPRODUCTIVE NUMBER; SCHOOL CLOSURE; UNITED-STATES; EPIDEMIC; OUTBREAK; TRANSMISSION; EVOLUTION AB The rising importance of infectious disease modeling makes this an appropriate time for a guide for public health practitioners tasked with preparing for, and responding to, an influenza pandemic. We list several questions that public health practitioners commonly ask about pandemic influenza and match these with analytical methods, giving details on when during a pandemic the methods can be used, how long it might take to implement them, and what data are required. Although software to perform these tasks is available, care needs to be taken to understand: (1) the type of data needed, (2) the implementation of the methods, and (3) the interpretation of results in terms of model uncertainty and sensitivity. Public health leaders can use this article to evaluate the modeling literature, determine which methods can provide appropriate evidence for decision-making, and to help them request modeling work from in-house teams or academic groups. C1 [Gambhir, Manoj] Monash Univ, Dept Epidemiol & Prevent Med, Epidemiol Modelling Unit, Melbourne, Vic 3004, Australia. [Gambhir, Manoj; O'Hagan, Justin J.] Ctr Dis Control & Prevent CDC, Modeling Unit, NCIRD, Atlanta, GA USA. [Gambhir, Manoj; O'Hagan, Justin J.] IHRC Inc, Atlanta, GA USA. [Bozio, Catherine] Emory Univ, Laney Grad Sch, Grad Program Epidemiol & Mol Mankind, Atlanta, GA 30322 USA. [Uzicanin, Amra] Natl Ctr Emerging & Zoonot Infect Dis, Div Global Migrat & Quarantine, Atlanta, GA USA. [Johnson, Lucinda E.; Biggerstaff, Matthew] CDC, Influenza Div, NCIRD, Atlanta, GA USA. [Swerdlow, David L.] CDC, Modeling Unit, NCIRD, Atlanta, GA USA. [Swerdlow, David L.] CDC, Off Director, NCIRD, Atlanta, GA USA. RP Gambhir, M (reprint author), Monash Univ, Melbourne, Vic 3004, Australia. EM manoj.gambhir@monash.edu FU CDC FX This article appears as part of the supplement titled "CDC Modeling Efforts in Response to a Potential Public Health Emergency: Influenza A(H7N9) as an Example," sponsored by the CDC. NR 47 TC 0 Z9 0 U1 0 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD MAY 1 PY 2015 VL 60 SU 1 BP S11 EP S19 DI 10.1093/cid/civ083 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CH0ND UT WOS:000353716200003 PM 25878297 ER PT J AU Meltzer, MI Gambhir, M Atkins, CY Swerdlow, DL AF Meltzer, Martin I. Gambhir, Manoj Atkins, Charisma Y. Swerdlow, David L. TI Standardizing Scenarios to Assess the Need to Respond to an Influenza Pandemic SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE standardized scenarios; influenza; pandemic; interventions C1 [Meltzer, Martin I.; Atkins, Charisma Y.] Ctr Dis Control & Prevent CDC, Div Preparedness & Emerging Infect, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Gambhir, Manoj] Monash Univ, Dept Epidemiol & Prevent Med, Epidemiol Modelling Unit, Melbourne, Vic 3004, Australia. [Gambhir, Manoj; Swerdlow, David L.] CDC, Modeling Unit, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Gambhir, Manoj; Swerdlow, David L.] CDC, Off Director, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Gambhir, Manoj] IHRC Inc, Atlanta, GA USA. RP Meltzer, MI (reprint author), Ctr Dis Control & Prevent, Div Preparedness & Emerging Infect, Natl Ctr Emerging & Zoonot Infect Dis, Mailstop C-18,1600 Clifton Rd, Atlanta, GA 30333 USA. EM qzm4@cdc.gov FU US National Institutes of Health, National Institute of General Medical Sciences [1U01GM110721-01] FX M. I. M., C. Y. A., and D. L. S. conducted this research as part of their usual duties as employees of the CDC. M. G. was funded through a grant from the US National Institutes of Health, National Institute of General Medical Sciences (grant number 1U01GM110721-01). NR 13 TC 6 Z9 6 U1 1 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD MAY 1 PY 2015 VL 60 SU 1 BP S1 EP S8 DI 10.1093/cid/civ088 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CH0ND UT WOS:000353716200001 PM 25878296 ER PT J AU Meltzer, MI Patel, A Ajao, A Nystrom, SV Koonin, LM AF Meltzer, Martin I. Patel, Anita Ajao, Adebola Nystrom, Scott V. Koonin, Lisa M. TI Estimates of the Demand for Mechanical Ventilation in the United States During an Influenza Pandemic SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE ventilation; demand; influenza pandemic; ventilator ID CRITICALLY-ILL PATIENTS; H1N1 INFLUENZA; RISK-FACTORS; INFECTION; TRANSMISSION; A(H1N1); VIRUS; ICU AB An outbreak in China in April 2013 of human illnesses due to avian influenza A(H7N9) virus provided reason for US public health officials to revisit existing national pandemic response plans. We built a spreadsheet model to examine the potential demand for invasive mechanical ventilation (excluding "rescue therapy" ventilation). We considered scenarios of either 20% or 30% gross influenza clinical attack rate (CAR), with a "low severity" scenario with case fatality rates (CFR) of 0.05%-0.1%, or a "high severity" scenario (CFR: 0.25%-0.5%). We used rates-of-influenza-related illness to calculate the numbers of potential clinical cases, hospitalizations, admissions to intensive care units, and need for mechanical ventilation. We assumed 10 days ventilator use per ventilated patient, 13% of total ventilator demand will occur at peak, and a 33.7% weighted average mortality risk while on a ventilator. At peak, for a 20% CAR, low severity scenario, an additional 7000 to 11 000 ventilators will be needed, averting a pandemic total of 35 000 to 55 000 deaths. A 30% CAR, high severity scenario, will need approximately 35 000 to 60 500 additional ventilators, averting a pandemic total 178 000 to 308 000 deaths. Estimates of deaths averted may not be realized because successful ventilation also depends on sufficient numbers of suitably trained staff, needed supplies (eg, drugs, reliable oxygen sources, suction apparatus, circuits, and monitoring equipment) and timely ability to match access to ventilators with critically ill cases. There is a clear challenge to plan and prepare to meet demands for mechanical ventilators for a future severe pandemic. C1 [Meltzer, Martin I.] Natl Ctr Emerging & Zoonot Infect Dis, Div Preparedness & Emerging Infect, Atlanta, GA USA. [Patel, Anita] Ctr Dis Control & Prevent, Div Strateg Natl Stockpile, Off Publ Hlth Preparedness & Response, Atlanta, GA USA. [Ajao, Adebola] GAP Solut Inc, Washington, DC USA. [Nystrom, Scott V.] US Dept HHS, Div Med Countermeasure Strategy & Requirements, Off Assistant Secretary Preparedness & Response, Washington, DC 20201 USA. [Koonin, Lisa M.] Ctr Dis Control & Prevent, Influenza Coordinat Unit, Off Infect Dis, Atlanta, GA USA. RP Meltzer, MI (reprint author), Ctr Dis Control & Prevent CDC, MS C-18,1600 Clifton Rd, Atlanta, GA 30333 USA. EM qzm4@cdc.gov FU CDC FX This article appears as part of the supplement titled "CDC Modeling Efforts in Response to a Potential Public Health Emergency: Influenza A(H7N9) as an Example," sponsored by the CDC. NR 21 TC 5 Z9 5 U1 2 U2 4 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD MAY 1 PY 2015 VL 60 SU 1 BP S52 EP S57 DI 10.1093/cid/civ089 PG 6 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CH0ND UT WOS:000353716200007 PM 25878301 ER PT J AU O'Hagan, JJ Wong, KK Campbell, AP Patel, A Swerdlow, DL Fry, AM Koonin, LM Meltzer, MI AF O'Hagan, Justin J. Wong, Karen K. Campbell, Angela P. Patel, Anita Swerdlow, David L. Fry, Alicia M. Koonin, Lisa M. Meltzer, Martin I. TI Estimating the United States Demand for Influenza Antivirals and the Effect on Severe Influenza Disease During a Potential Pandemic SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE influenza; antivirals; neuraminidase inhibitors; hospitalization; death ID RANDOMIZED CONTROLLED-TRIAL; NEURAMINIDASE INHIBITOR ZANAMIVIR; B VIRUS-INFECTIONS; MITIGATION STRATEGIES; INHALED ZANAMIVIR; HEALTH-CARE; EFFICACY; OSELTAMIVIR; SAFETY; METAANALYSIS AB Following the detection of a novel influenza strain A(H7N9), we modeled the use of antiviral treatment in the United States to mitigate severe disease across a range of hypothetical pandemic scenarios. Our outcomes were total demand for antiviral (neuraminidase inhibitor) treatment and the number of hospitalizations and deaths averted. The model included estimates of attack rate, healthcare-seeking behavior, prescription rates, adherence, disease severity, and the potential effect of antivirals on the risks of hospitalization and death. Based on these inputs, the total antiviral regimens estimated to be available in the United States (as of April 2013) were sufficient to meet treatment needs for the scenarios considered. However, distribution logistics were not examined and should be addressed in future work. Treatment was estimated to avert many severe outcomes (5200-248 000 deaths; 4800-504 000 hospitalizations); however, large numbers remained (25 000-425 000 deaths; 580 0003 700 000 hospitalizations), suggesting that the impact of combinations of interventions should be examined. C1 [O'Hagan, Justin J.; Swerdlow, David L.] Ctr Dis Control & Prevent CDC, NCIRD, Atlanta, GA USA. [O'Hagan, Justin J.] IHRC Inc, Atlanta, GA USA. [Wong, Karen K.] NCIRD, Epidem Intelligence Serv Assigned Influenza Div, Atlanta, GA USA. [Campbell, Angela P.; Fry, Alicia M.] NCIRD, Epidemiol & Prevent Branch, Influenza Div, Atlanta, GA USA. [Patel, Anita] NCIRD, Div Strateg Natl Stockpile, Atlanta, GA USA. [Swerdlow, David L.] NCIRD, Modeling Unit, Atlanta, GA USA. [Swerdlow, David L.] NCIRD, Off Director, Atlanta, GA USA. [Koonin, Lisa M.] CDC, Influenza Coordinat Unit, Off Infect Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Meltzer, Martin I.] CDC, Div Preparedness & Emerging Infect, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. RP O'Hagan, JJ (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop A-27, Atlanta, GA 30333 USA. EM johagan@cdc.gov FU CDC FX This article appears as part of the supplement titled "CDC Modeling Efforts in Response to a Potential Public Health Emergency: Influenza A(H7N9) as an Example," sponsored by the CDC. NR 60 TC 3 Z9 3 U1 0 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD MAY 1 PY 2015 VL 60 SU 1 BP S30 EP S41 DI 10.1093/cid/civ084 PG 12 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CH0ND UT WOS:000353716200005 PM 25878299 ER PT J AU Rasmussen, SA Redd, SC AF Rasmussen, Sonja A. Redd, Stephen C. TI Using Results From Infectious Disease Modeling to Improve the Response to a Potential H7N9 Influenza Pandemic SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE H7N9; modeling; pandemic influenza; infectious disease ID VIRUS AB As the Centers for Disease Control and Prevention (CDC) and other government agencies prepared for a possible H7N9 pandemic, many questions arose about the virus's expected burden and the effectiveness of key interventions. Public health decision makers need information to compare interventions so that efforts can be focused on interventions most likely to have the greatest impact on morbidity and mortality. To guide decision making, CDC's pandemic response leadership turned to experts in modeling for assistance. H7N9 modeling results provided a quantitative estimate of the impact of different interventions and emphasized the importance of key assumptions. In addition, these H7N9 modeling efforts highlighted the need for modelers to work closely with investigators collecting data so that model assumptions can be adjusted as new information becomes available and with decision makers to ensure that the results of modeling impact policy decisions. C1 [Rasmussen, Sonja A.; Redd, Stephen C.] Ctr Dis Control & Prevent, Influenza Coordinat Unit, Off Infect Dis, Atlanta, GA USA. RP Rasmussen, SA (reprint author), CDC, Influenza Coordinat Unit, 1600 Clifton Rd,MS A-28, Atlanta, GA 30333 USA. EM skr9@cdc.gov FU CDC FX This article appears as part of the supplement titled "CDC Modeling Efforts in Response to a Potential Public Health Emergency: Influenza A(H7N9) as an Example," sponsored by the CDC. NR 5 TC 0 Z9 0 U1 0 U2 4 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD MAY 1 PY 2015 VL 60 SU 1 BP S9 EP S10 DI 10.1093/cid/civ090 PG 2 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CH0ND UT WOS:000353716200002 PM 25878303 ER PT J AU Cavallo, SJ Daly, ER Seiferth, J Nadeau, AM Mahoney, J Finnigan, J Wikoff, P Kiebler, CA Simmons, L AF Cavallo, Steffany J. Daly, Elizabeth R. Seiferth, John Nadeau, Alisha M. Mahoney, Jennifer Finnigan, Jayne Wikoff, Peter Kiebler, Craig A. Simmons, Latoya TI Human Outbreak of Salmonella Typhimurium Associated with Exposure to Locally Made Chicken Jerky Pet Treats, New Hampshire, 2013 SO FOODBORNE PATHOGENS AND DISEASE LA English DT Article ID UNITED-STATES; DRY DOG; FOOD; CANADA; INFECTION AB Pet treats and pet food can be contaminated with Salmonella and other pathogens, though they are infrequently implicated as the source of human outbreaks. In 2013, the New Hampshire Department of Health and Human Services investigated a cluster of Salmonella Typhimurium infections associated with contaminated locally made pet treats. Case-patients were interviewed with standardized questionnaires to assess food, animal, and social histories. Laboratory and environmental investigations were conducted, including testing of clinical specimens, implicated product, and environmental swabs. Between June and October 2013, a total of 43 ill persons were identified. Sixteen patients (37%) were hospitalized. Among 43 case-patients interviewed, the proportion exposed to dogs (95%) and pet treats (69%) in the 7 days prior to illness was statistically higher than among participants in a U.S. population-based telephone survey (61%, p<0.0001 and 16%, p<0.0001, respectively). On further interview, 38 (88%) reported exposure to Brand X Chicken Jerky, the maker of Brand X chicken jerky, or the facility in which it was made. Product testing isolated the outbreak strain from four of four Brand X Chicken Jerky samples, including an unopened package purchased at retail, opened packages collected from patient households, and unpackaged jerky obtained from the jerky maker. A site visit revealed inadequate processing of the chicken jerky, bare-hand contact with the finished product prior to packaging, and use of vacuum-sealed packaging, which may have enabled facultative anaerobic bacteria to proliferate. Seven (78%) of nine environmental swabs taken during the site visit also yielded the outbreak strain. Brand X Chicken Jerky was voluntarily recalled on September 9, 2013. Consumers should be made aware of the potential for locally made products to be exempt from regulation and for animals and animal food to carry pathogens that cause human illness, and be educated to perform hand hygiene after handling pet food or treats. C1 [Cavallo, Steffany J.; Daly, Elizabeth R.; Seiferth, John; Nadeau, Alisha M.; Mahoney, Jennifer; Finnigan, Jayne; Wikoff, Peter] New Hampshire Dept Hlth & Human Serv, Div Publ Hlth Serv, Concord, NH 03301 USA. [Kiebler, Craig A.; Simmons, Latoya] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Cavallo, SJ (reprint author), New Hampshire Dept Hlth & Human Serv, Div Publ Hlth Serv, Infect Dis Surveillance Sect, Bur Infect Dis Control, 29 Hazen Dr, Concord, NH 03301 USA. EM steffany.cavallo@dhhs.state.nh.us FU Centers for Disease Control and Prevention; Epidemiology and Laboratory Capacity Cooperative Agreement [3U50CI000874-02S3]; Food and Drug Administration, Food Emergency Response Network Microbiological Cooperative Agreement [U18FD0038220] FX We wish to thank the following persons for their contributions to study design, data collection, and specimen collection and testing: Shannon Casey, Christine Villeneuve, and Betty Wendt (City of Nashua, NH Health Department); Christine Adamski and Mary Lee Greaves, (New Hampshire Department of Health and Human Services); Elizabeth A. Talbot, MD (Dartmouth College, Hanover NH); and the PulseNet Team and MLVA Laboratory at the U.S. Centers for Disease Control and Prevention. This work was supported, in part, by the Centers for Disease Control and Prevention, Epidemiology and Laboratory Capacity Cooperative Agreement (grant number 3U50CI000874-02S3) and the Food and Drug Administration, Food Emergency Response Network Microbiological Cooperative Agreement (grant number U18FD0038220). The findings and conclusions in this report are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention. NR 23 TC 2 Z9 2 U1 1 U2 15 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1535-3141 EI 1556-7125 J9 FOODBORNE PATHOG DIS JI Foodborne Pathog. Dis. PD MAY 1 PY 2015 VL 12 IS 5 BP 441 EP 446 DI 10.1089/fpd.2014.1889 PG 6 WC Food Science & Technology SC Food Science & Technology GA CH1JO UT WOS:000353777800009 PM 25793722 ER PT J AU Ogedengbe, ME Qvarnstrom, Y da Silva, AJ Arrowood, MJ Barta, JR AF Ogedengbe, Mosun E. Qvarnstrom, Yvonne da Silva, Alexandre J. Arrowood, Michael J. Barta, John R. TI A linear mitochondrial genome of Cyclospora cayetanensis (Eimeriidae, Eucoccidiorida, Coccidiasina, Apicomplexa) suggests the ancestral start position within mitochondrial genomes of eimeriid coccidia SO INTERNATIONAL JOURNAL FOR PARASITOLOGY LA English DT Article DE Mitochondrial genome; Eimeriidae; Cyclospora cayetanensis; Apicomplexa; Linear genome; Genomics ID MOLECULAR CHARACTERIZATION; DNA; PARASITES; SEQUENCES; BABESIA AB The near complete mitochondria] genome for Cyclospora cayetanensis is 6184 bp in length with three protein-coding genes (Cox1, Cox3, CytB) and numerous lsrDNA and ssrDNA fragments. Gene arrangements were conserved with other coccidia in the Eimeriidae, but the C. cayetanensis mitochondrial genome is not circular-mapping. Terminal transferase tailing and nested PCR completed the 5'-terminus of the genome starting with a 21 bp A/T-only region that forms a potential stem-loop. Regions homologous to the C. cayetanensis mitochondrial genome 5'-terminus are found in all eimeriid mitochondrial genomes available and suggest this may be the ancestral start of eimeriid mitochondrial genomes. (C) 2015 Australian Society for Parasitology Inc. Published by Elsevier Ltd. All rights reserved. C1 [Ogedengbe, Mosun E.; Barta, John R.] Univ Guelph, Dept Pathobiol, Guelph, ON N1G 2W1, Canada. [Qvarnstrom, Yvonne; da Silva, Alexandre J.; Arrowood, Michael J.] US Ctr Dis Control & Prevent, Atlanta, GA USA. [da Silva, Alexandre J.] US FDA, Laurel, MD USA. RP Barta, JR (reprint author), Univ Guelph, Dept Pathobiol, 50 Stone Rd East, Guelph, ON N1G 2W1, Canada. EM jbarta@uoguelph.ca OI Barta, John/0000-0001-6896-2271 FU Ontario Veterinary College, Canada; Natural Sciences and Engineering Research Council of Canada (NSERC) [DG 400566]; Centers for Disease Control (CDC) Initiative for Advanced Molecular Detection and Response to Infectious Disease Outbreak, USA FX This work was supported by scholarship support to M.E.O. from the Ontario Veterinary College, Canada and a Discovery Grant (DG 400566) from the Natural Sciences and Engineering Research Council of Canada (NSERC) to J.R.B. This work was supported by the Centers for Disease Control (CDC) Initiative for Advanced Molecular Detection and Response to Infectious Disease Outbreak, USA. The authors acknowledge Julia Whale for her technical support. NR 25 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0020-7519 EI 1879-0135 J9 INT J PARASITOL JI Int. J. Parasit. PD MAY PY 2015 VL 45 IS 6 BP 361 EP 365 DI 10.1016/j.ijpara.2015.02.006 PG 5 WC Parasitology SC Parasitology GA CH0WP UT WOS:000353743400002 PM 25812835 ER PT J AU Munn, MS Duchin, JS Kay, M Pecha, M Thibault, CS Narita, M AF Munn, M. S. Duchin, J. S. Kay, M. Pecha, M. Thibault, C. S. Narita, M. TI Analysis of risk factors for tuberculous infection following exposure at a homeless shelter SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE LA English DT Article DE tuberculosis control; epidemiology; contact investigation; homeless shelter; retrospective cohort study ID CONTACT INVESTIGATIONS; TRANSMISSION; OUTBREAK AB SETTING: A homeless shelter for men aged 50 years in Seattle, Washington, USA. OBJECTIVES: We examined risk factors for tuberculous infection following exposure to an active pulmonary tuberculosis (TB) case residing in a homeless shelter setting. METHODS: A contact investigation identified shelter clients exposed to the index case; these contacts were then assessed for tuberculous infection. Risk factors, including proximity and duration of exposure to the index case, were evaluated for association with infection. A retrospective cohort study was conducted and a multivariate logistic regression model determined the magnitude of the association between tuberculous infection and significant risk factors. RESULTS: Of the 64 contacts evaluated, 25 (39%) had latent tuberculous infection and one had active TB. The multivariate logistic regression model found that duration of exposure and birthplace were significantly associated with odds of infection. CONCLUSIONS: Birthplace and duration of exposure were significant risk factors for tuberculous infection, underscoring the importance of this information when prioritizing contact investigations after TB exposure in congregate settings. We recommend that public health agencies work with homeless shelters to ensure that clients' attendance records contain the necessary information to facilitate contact tracing during public health TB investigations. C1 [Munn, M. S.] Ctr Dis Control & Prevent, CSTE, Appl Epidemiol Fellowship Program, Atlanta, GA USA. [Munn, M. S.; Duchin, J. S.; Kay, M.] Publ Hlth Seattle & King Cty, Communicable Dis Epidemiol & Immunizat Sect, Seattle, WA 98104 USA. [Duchin, J. S.; Narita, M.] Univ Washington, Seattle, WA 98195 USA. [Pecha, M.; Narita, M.] Publ Hlth Seattle & King Cty, TB Control Program, Seattle, WA 98104 USA. [Thibault, C. S.] Publ Hlth Seattle & King Cty, HIV STD Program, Seattle, WA 98104 USA. RP Munn, MS (reprint author), Publ Hlth Seattle & King Cty, Communicable Dis Epidemiol & Immunizat Sect, Suite 900,401 5th Ave, Seattle, WA 98104 USA. EM meaghan.munn@kingcounty.gov FU Centers for Disease Control and Prevention (CDC, Atlanta, GA, USA) [5U38HM000414-5] FX This research was supported in part by an appointment to the Applied Epidemiology Fellowship Program administered by the Council of State and Territorial Epidemiologists (CSTE, Atlanta, GA) and funded by the Centers for Disease Control and Prevention (CDC, Atlanta, GA, USA) Cooperative Agreement Number 5U38HM000414-5. NR 20 TC 0 Z9 0 U1 2 U2 4 PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D) PI PARIS PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE SN 1027-3719 EI 1815-7920 J9 INT J TUBERC LUNG D JI Int. J. Tuberc. Lung Dis. PD MAY PY 2015 VL 19 IS 5 BP 570 EP 575 DI 10.5588/ijtld.14.0648 PG 6 WC Infectious Diseases; Respiratory System SC Infectious Diseases; Respiratory System GA CG9WG UT WOS:000353670200014 PM 25868026 ER PT J AU Marjuki, H Mishin, VP Chesnokov, AP De La Cruz, JA Davis, CT Villanuev, JM Fry, AM Gubareva, LV AF Marjuki, Henju Mishin, Vasiliy P. Chesnokov, Anton P. De La Cruz, Juan A. Davis, Charles T. Villanuev, Julie M. Fry, Alicia M. Gubareva, Larisa V. TI Neuraminidase Mutations Conferring Resistance to Oseltamivir in Influenza A(H7N9) Viruses SO JOURNAL OF VIROLOGY LA English DT Article ID A H7N9 VIRUS; INHIBITOR OSELTAMIVIR; H1N1 VIRUS; INFECTION; SUSCEPTIBILITY; PATIENT; FERRETS; TAIWAN; MODEL; DRUG AB Human infections by avian influenza A(H7N9) virus entail substantial morbidity and mortality. Treatment of infected patients with the neuraminidase (NA) inhibitor oseltamivir was associated with emergence of viruses carrying NA substitutions. In the NA inhibition (NI) assay, R292K conferred highly reduced inhibition by oseltamivir, while E119V and I222K each caused reduced inhibition. To facilitate establishment of laboratory correlates of clinically relevant resistance, experiments were conducted in ferrets infected with virus carrying wild-type or variant NA genes recovered from the A/Taiwan/1/2013 isolate. Oseltamivir treatment (5 or 25 mg/kg of body weight/dose) was given 4 h postinfection, followed by twice-daily treatment for 5 days. Treatment of ferrets infected with wild-type virus resulted in a modest dose-dependent reduction (0.7 to 1.5 log(10) 50% tissue culture infectious dose [TCID50]) in nasal wash viral titers and inflammation response. Conversely, treatment failed to significantly inhibit the replication of R292K or E119V virus. A small reduction of viral titers was detected on day 5 in ferrets infected with the I222K virus. The propensity for oseltamivir resistance emergence was assessed in oseltamivir-treated animals infected with wild-type virus; emergence of R292K virus was detected in 3 of 6 ferrets within 5 to 7 days postinfection. Collectively, we demonstrate that R292K, E119V, and I222K reduced the inhibitory activity of oseltamivir, not only in the NI assay, but also in infected ferrets, judged particularly by viral loads in nasal washes, and may signal the need for alternative therapeutics. Thus, these clinical outcomes measured in the ferret model may correlate with clinically relevant oseltamivir resistance in humans. IMPORTANCE This report provides more evidence for using the ferret model to assess the susceptibility of influenza A(H7N9) viruses to oseltamivir, the most prescribed anti-influenza virus drug. The information gained can be used to assist in the establishment of laboratory correlates of human disease and drug therapy. The rapid emergence of viruses with R292K in treated ferrets correlates well with the multiple reports on this NA variant in treated human patients. Our findings highlight the importance of the discovery and characterization of new antiviral drugs with different mechanisms of action and the use of combination treatment strategies against emerging viruses with pandemic potential, such as avian H7N9 virus, particularly against those carrying drug resistance markers. C1 [Marjuki, Henju; Mishin, Vasiliy P.; Chesnokov, Anton P.; De La Cruz, Juan A.; Davis, Charles T.; Villanuev, Julie M.; Fry, Alicia M.; Gubareva, Larisa V.] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Chesnokov, Anton P.; De La Cruz, Juan A.] Battelle Mem Inst, Atlanta, GA USA. RP Gubareva, LV (reprint author), Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM lgubareva@cdc.gov FU U.S. CDC Influenza Division; Biomedical Advanced Research and Development Authority (BARDA); U.S. CDC FX Funding was made available through the U.S. CDC Influenza Division with partial funding by the interagency agreement between the Biomedical Advanced Research and Development Authority (BARDA) and the U.S. CDC. NR 39 TC 12 Z9 12 U1 2 U2 21 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X EI 1098-5514 J9 J VIROL JI J. Virol. PD MAY PY 2015 VL 89 IS 10 BP 5419 EP 5426 DI 10.1128/JVI.03513-14 PG 8 WC Virology SC Virology GA CG5KB UT WOS:000353329300022 PM 25740997 ER PT J AU Cegielski, P Vernon, A AF Cegielski, Peter Vernon, Andrew TI Tuberculosis and vitamin D: what's the rest of the story? SO LANCET INFECTIOUS DISEASES LA English DT Editorial Material ID T-CELL-ACTIVATION; TRIAL; SUPPLEMENTATION; CHILDREN C1 [Cegielski, Peter; Vernon, Andrew] US Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div TB Eliminat, Atlanta, GA 30329 USA. RP Cegielski, P (reprint author), US Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div TB Eliminat, Atlanta, GA 30329 USA. EM anv3@cdc.gov FU Intramural CDC HHS [CC999999] NR 14 TC 1 Z9 1 U1 0 U2 2 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1473-3099 EI 1474-4457 J9 LANCET INFECT DIS JI Lancet Infect. Dis. PD MAY PY 2015 VL 15 IS 5 BP 489 EP 490 DI 10.1016/S1473-3099(15)70163-5 PG 2 WC Infectious Diseases SC Infectious Diseases GA CG9WK UT WOS:000353670600003 PM 25863560 ER PT J AU Drolet, M Benard, E Boily, MC Ali, H Baandrup, L Bauer, H Beddows, S Brisson, J Brotherton, JML Cummings, T Donovan, B Fairley, CK Flagg, EW Johnson, AM Kahn, JA Kavanagh, K Kjaer, SK Kliewer, EV Lemieux-Mellouki, P Markowitz, L Mboup, A Mesher, D Niccolai, L Oliphant, J Pollock, KG Soldan, K Sonnenberg, P Tabrizi, SN Tanton, C Brisson, M AF Drolet, Melanie Benard, Elodie Boily, Marie-Claude Ali, Hammad Baandrup, Louise Bauer, Heidi Beddows, Simon Brisson, Jacques Brotherton, Julia M. L. Cummings, Teresa Donovan, Basil Fairley, Christopher K. Flagg, Elaine W. Johnson, Anne M. Kahn, Jessica A. Kavanagh, Kimberley Kjaer, Susanne K. Kliewer, Erich V. Lemieux-Mellouki, Philippe Markowitz, Lauri Mboup, Aminata Mesher, David Niccolai, Linda Oliphant, Jeannie Pollock, Kevin G. Soldan, Kate Sonnenberg, Pam Tabrizi, Sepehr N. Tanton, Clare Brisson, Marc TI Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis SO LANCET INFECTIOUS DISEASES LA English DT Article ID HPV-16/18 AS04-ADJUVANTED VACCINE; CROSS-PROTECTIVE EFFICACY; MIDDLE-INCOME COUNTRIES; GRADE CERVICAL LESIONS; LIFE-STYLES NATSAL; GENITAL WARTS; YOUNG-WOMEN; HPV TYPES; ANOGENITAL WARTS; COST-EFFECTIVENESS AB Background Human papillomavirus (HPV) vaccination programmes were first implemented in several countries worldwide in 2007. We did a systematic review and meta-analysis to assess the population-level consequences and herd effects after female HPV vaccination programmes, to verify whether or not the high efficacy reported in randomised controlled clinical trials are materialising in real-world situations. Methods We searched the Medline and Embase databases (between Jan 1, 2007 and Feb 28, 2014) and conference abstracts for time-trend studies that analysed changes, between the pre-vaccination and post-vaccination periods, in the incidence or prevalence of at least one HPV-related endpoint: HPV infection, anogenital warts, and high-grade cervical lesions. We used random-effects models to derive pooled relative risk (RR) estimates. We stratified all analyses by age and sex. We did subgroup analyses by comparing studies according to vaccine type, vaccination coverage, and years since implementation of the vaccination programme. We assessed heterogeneity across studies using I-2 and chi(2) statistics and we did trends analysis to examine the dose response association between HPV vaccination coverage and each study effect measure. Findings We identified 20 eligible studies, which were all undertaken in nine high-income countries and represent more than 140 million person-years of follow-up. In countries with female vaccination coverage of at least 50%, HPV type 16 and 18 infections decreased significantly between the pre-vaccination and post-vaccination periods by 68% (RR 0.32, 95% CI 0.19-0.52) and anogenital warts decreased significantly by 61% (0.39, 0.22-0.71) in girls 13-19 years of age. Significant reductions were also recorded in HPV types 31, 33, and 45 in this age group of girls (RR 0.72, 95% CI 0.54-0.96), which suggests cross-protection. Additionally, significant reductions in anogenital warts were also reported in boys younger than 20 years of age (0.66 [95% CI 0.47-0.91]) and in women 20-39 years of age (0.68 [95% CI 0.51-0.89]), which suggests herd effects. In countries with female vaccination coverage lower than 50%, significant reductions in HPV types 16 and 18 infection (RR 0.50, 95% CI 0.34-0.741) and in anogenital warts (0.86 [95% CI 0.79-0.94]) occurred in girls younger than 20 years of age, with no indication of cross-protection or herd effects. Interpretation Our results are promising for the long-term population-level effects of HPV vaccination programmes. However, continued monitoring is essential to identify any signals of potential waning efficacy or type-replacement. C1 [Drolet, Melanie; Benard, Elodie; Boily, Marie-Claude; Brisson, Jacques; Lemieux-Mellouki, Philippe; Mboup, Aminata; Brisson, Marc] CHU Quebec, Ctr Rech, Quebec City, PQ, Canada. [Drolet, Melanie; Benard, Elodie; Boily, Marie-Claude; Brisson, Jacques; Lemieux-Mellouki, Philippe; Brisson, Marc] Univ Laval, Dept Med Sociale & Prevent, Quebec City, PQ, Canada. [Boily, Marie-Claude; Brisson, Marc] Univ London Imperial Coll Sci Technol & Med, Dept Infect Dis Epidemiol, London, England. [Ali, Hammad; Donovan, Basil] Univ New S Wales, Kirby Inst, Sydney, NSW, Australia. [Baandrup, Louise; Kjaer, Susanne K.] Danish Canc Soc Res Ctr, Unit Virus Lifestyle & Genes, Copenhagen, Denmark. [Bauer, Heidi] Calif Dept Publ Hlth, STD Control Branch, Richmond, CA USA. [Beddows, Simon] Publ Hlth England, Virus Reference Dept, London, England. [Mesher, David; Soldan, Kate] Publ Hlth England, HIV & STI Dept, Ctr Infect Dis Surveillance & Control, London, England. [Brotherton, Julia M. L.] Victorian Cytol Serv, Natl HPV Vaccinat Program Register, Melbourne, Vic, Australia. [Brotherton, Julia M. L.] Univ Melbourne, Melbourne Sch Populat & Global Hlth, Melbourne, Vic, Australia. [Tabrizi, Sepehr N.] Univ Melbourne, Dept Obstet & Gynecol, Melbourne, Vic, Australia. [Cummings, Teresa] Indiana Univ Sch Med, Dept Pediat, Indianapolis, IN 46202 USA. [Fairley, Christopher K.] Melbourne Sexual Hlth Ctr, Melbourne, Vic, Australia. [Fairley, Christopher K.] Monash Univ, Alfred Hosp, Cent Clin Sch, Melbourne, Vic 3181, Australia. [Flagg, Elaine W.; Markowitz, Lauri] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. [Johnson, Anne M.; Sonnenberg, Pam; Tanton, Clare] UCL, Res Dept Infect & Populat Hlth, London, England. [Kahn, Jessica A.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA. [Kahn, Jessica A.] Univ Cincinnati, Coll Med, Cincinnati, OH USA. [Kavanagh, Kimberley] Univ Strathclyde, Dept Math & Stat, Glasgow, Lanark, Scotland. [Kjaer, Susanne K.] Univ Copenhagen, Rigshosp, Dept Gynecol, DK-2100 Copenhagen, Denmark. [Kliewer, Erich V.] Univ Manitoba, Community Hlth Sci, Winnipeg, MB, Canada. [Kliewer, Erich V.] British Columbia Canc Agcy, Canc Control Res, Vancouver, BC V5Z 4E6, Canada. [Kliewer, Erich V.] CancerCare Manitoba, Epidemiol & Canc Registry, Winnipeg, MB, Canada. [Niccolai, Linda] Yale Univ, Yale Sch Publ Hlth, Dept Epidemiol Microbial Dis, New Haven, CT 06520 USA. [Oliphant, Jeannie] Auckland Sexual Hlth Serv, Auckland, New Zealand. [Pollock, Kevin G.] Hlth Protect Scotland, Glasgow, Lanark, Scotland. [Tabrizi, Sepehr N.] Royal Womens Hosp, Dept Microbiol & Infect Dis, Reg WHO HPV Reference Lab, Parkville, Vic, Australia. [Tabrizi, Sepehr N.] Murdoch Childrens Res Inst, Parkville, Vic, Australia. RP Drolet, M (reprint author), CHU Quebec, Ctr Rech, Quebec City, PQ, Canada. OI Mesher, David/0000-0001-9163-6757; Kjaer, Susanne/0000-0002-8347-1398; Sonnenberg, Pam/0000-0002-1067-1583; Christopher, Fairley/0000-0001-9081-1664 FU Canadian Institutes of Health Research FX The Canadian Institutes of Health Research. NR 75 TC 98 Z9 102 U1 4 U2 25 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1473-3099 EI 1474-4457 J9 LANCET INFECT DIS JI Lancet Infect. Dis. PD MAY PY 2015 VL 15 IS 5 BP 565 EP 580 DI 10.1016/S1473-3099(14)71073-4 PG 16 WC Infectious Diseases SC Infectious Diseases GA CG9WK UT WOS:000353670600043 PM 25744474 ER PT J AU Runfola, JK House, J Miller, L Colton, L Hite, D Hawley, A Mead, P Schriefer, M Petersen, J Casaceli, C Erlandson, KM Foster, C Pabilonia, KL Mason, G Douglas, JM AF Runfola, Janine K. House, Jennifer Miller, Lisa Colton, Leah Hite, Donna Hawley, Alex Mead, Paul Schriefer, Martin Petersen, Jeannine Casaceli, Colleen Erlandson, Kristine M. Foster, Clayton Pabilonia, Kristy L. Mason, Gary Douglas, John M., Jr. TI Untitled SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Editorial Material ID PRIMARY PNEUMONIC PLAGUE; YERSINIA-PESTIS; TRANSMISSION; OREGON; RISK C1 [Runfola, Janine K.; Hite, Donna; Hawley, Alex; Douglas, John M., Jr.] Tricty Hlth Dept, Greenwood Village, CO 80111 USA. [House, Jennifer; Miller, Lisa; Colton, Leah] Colorado Dept Publ Hlth & Environm, Denver, CO USA. [Mead, Paul; Schriefer, Martin; Petersen, Jeannine] CDC, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Casaceli, Colleen] Platte Valley Med Ctr, Brighton, CO USA. [Erlandson, Kristine M.; Foster, Clayton] Univ Colorado, Boulder, CO 80309 USA. [Pabilonia, Kristy L.; Mason, Gary] Colorado State Univ, Vet Diagnost Labs, Ft Collins, CO 80523 USA. RP Runfola, JK (reprint author), Tricty Hlth Dept, Greenwood Village, CO 80111 USA. EM jrunfola@tchd.org NR 10 TC 8 Z9 8 U1 0 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAY 1 PY 2015 VL 64 IS 16 BP 429 EP 434 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CH3GV UT WOS:000353918400001 PM 25928467 ER PT J AU Hsu, CH Fadand, J Winters, T Gunn, J Caron, D Evans, J Osadebe, L Bethune, L McCollum, AM Patel, N Wilkins, K Davidson, W Petersen, B Barry, MA AF Hsu, Christopher H. Fadand, Julien Winters, Thomas Gunn, Julia Caron, Donna Evans, Jennifer Osadebe, Lynda Bethune, Leon McCollum, Andrea M. Patel, Nishi Wilkins, Kimberly Davidson, Whitni Petersen, Brett Barry, M. Anita TI Laboratory-Acquired Vaccinia Virus Infection in a Recently Immunized Person - Massachusetts, 2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID SMALLPOX VACCINE; MONKEYPOX; OUTBREAK C1 [Hsu, Christopher H.; Osadebe, Lynda] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Hsu, Christopher H.; Osadebe, Lynda; McCollum, Andrea M.; Patel, Nishi; Wilkins, Kimberly; Davidson, Whitni; Petersen, Brett] CDC, Div High Consequence Pathogens & Pathol, Atlanta, GA 30333 USA. [Fadand, Julien; Gunn, Julia; Caron, Donna; Evans, Jennifer; Bethune, Leon; Barry, M. Anita] Boston Publ Hlth Commiss, Boston, MA USA. [Winters, Thomas] Occupat Environm Hlth Network, Marlborough, MA USA. RP Hsu, CH (reprint author), CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. EM CHsu@cdc.gov NR 10 TC 1 Z9 1 U1 0 U2 4 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAY 1 PY 2015 VL 64 IS 16 BP 435 EP 438 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CH3GV UT WOS:000353918400002 PM 25928468 ER PT J AU Heisey-Grove, D Wall, HK Helwig, A Wright, JS AF Heisey-Grove, Dawn Wall, Hilary K. Helwig, Amy Wright, Janet S. TI Using Electronic Clinical Quality Measure Reporting for Public Health Surveillance SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Heisey-Grove, Dawn] CDC, Off Planning Evaluat & Anal, Off Natl Coordinator Hlth Informat Technol, Atlanta, GA 30333 USA. [Wall, Hilary K.; Wright, Janet S.] CDC, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Helwig, Amy] Agcy Healthcare Res & Qual, Rockville, MD USA. RP Heisey-Grove, D (reprint author), CDC, Off Planning Evaluat & Anal, Off Natl Coordinator Hlth Informat Technol, Atlanta, GA 30333 USA. EM Dawn.Heisey-Grove@hhs.gov NR 6 TC 2 Z9 2 U1 0 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAY 1 PY 2015 VL 64 IS 16 BP 439 EP 442 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CH3GV UT WOS:000353918400003 PM 25928469 ER PT J AU Conrad, C Bradley, HM Broz, D Buddhal, S Chapman, EL Galang, RR Hillman, D Hon, J Hoover, KW Patel, MR Perez, A Peters, PJ Pontones, P Roseberry, JC Sandoval, M Shields, J Walthall, J Waterhouse, D Weidle, PJ Wu, H Duwve, JM AF Conrad, Caitlin Bradley, Heather M. Broz, Dita Buddhal, Swamy Chapman, Erika L. Galang, Romeo R. Hillman, Daniel Hon, John Hoover, Karen W. Patel, Monita R. Perez, Andrea Peters, Philip J. Pontones, Pam Roseberry, Jeremy C. Sandoval, Michelle Shields, Jessica Walthall, Jennifer Waterhouse, Dorothy Weidle, Paul J. Wu, Hsiu Duwve, Joan M. TI Community Outbreak of HIV Infection Linked to Injection Drug Use of Oxymorphone - Indiana, 2015 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Conrad, Caitlin; Buddhal, Swamy; Chapman, Erika L.; Hillman, Daniel; Hon, John; Perez, Andrea; Pontones, Pam; Roseberry, Jeremy C.; Walthall, Jennifer; Duwve, Joan M.] CDC, Indiana State Dept Hlth, Atlanta, GA 30333 USA. [Bradley, Heather M.; Broz, Dita; Galang, Romeo R.; Hoover, Karen W.; Patel, Monita R.; Peters, Philip J.; Sandoval, Michelle; Weidle, Paul J.; Wu, Hsiu] CDC, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Galang, Romeo R.; Patel, Monita R.; Sandoval, Michelle; Wu, Hsiu] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Shields, Jessica; Waterhouse, Dorothy] Clark Cty Hlth Dept, Jeffersonville, IN USA. [Duwve, Joan M.] Indiana Univ, Richard M Fairbanks Sch Publ Hlth, Indianapolis, IN 46204 USA. RP Duwve, JM (reprint author), CDC, Indiana State Dept Hlth, Atlanta, GA 30333 USA. EM jduwve@iu.edu NR 4 TC 62 Z9 62 U1 1 U2 6 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAY 1 PY 2015 VL 64 IS 16 BP 443 EP 444 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CH3GV UT WOS:000353918400004 PM 25928470 ER PT J AU Schauer, GL Malarcher, AM Babb, SD AF Schauer, Gillian L. Malarcher, Ann M. Babb, Stephen D. TI Gradual Reduction of Cigarette Consumption as a Cessation Strategy: Prevalence, Correlates, and Relationship With Quitting SO NICOTINE & TOBACCO RESEARCH LA English DT Article ID SMOKING-CESSATION; SMOKERS AB Introduction: Gradually reducing cigarette consumption is an approach used to quit smoking, but has not been widely studied at a population level. The purpose of this study was to assess the prevalence and demographic characteristics of U.S. adult smokers who tried to reduce to quit, and the relationship between reducing and successful quitting. Methods: Data came from 12,571 adults in the 2010-2011 Tobacco Use Supplement to the Current Population Survey who tried to quit smoking in the past year. Frequencies and percentages were used to assess prevalence of reducing to quit; bivariate and multiple logistic regression models were used to assess correlates of reducing to quit and successful past year cessation. Analyses were conducted in SAS-callable SUDAAN. Results: Among adults who tried to quit smoking in the past year, 43.0% (n = 5,444) tried reducing to quit. Compared to those who tried to quit without reducing consumption, those reducing to quit had a significantly higher prevalence of using counseling or medication (40.2% vs. 25.0%). In adjusted multivariable models, females (vs. males), Blacks (vs. Whites), current some day smokers (vs. every day smokers), and those who used counseling or medication had greater odds of trying to reduce to quit. Reducing to quit was negatively associated with successful past-year quitting (AOR = 0.59, 95% CI = 0.48, 0.72). Conclusion: Reducing to quit is a common cessation strategy and, in these analyses, was associated with lower cessation success rates. More research on reducing to quit in a real-world setting is needed before widely recommending it as a cessation strategy. C1 [Schauer, Gillian L.] US Ctr Dis Control & Prevent, Carter Consulting Inc, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Schauer, Gillian L.] Emory Univ, Dept Behav Sci & Hlth Educ, Atlanta, GA 30322 USA. [Malarcher, Ann M.; Babb, Stephen D.] US Ctr Dis Control & Prevent, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. RP Schauer, GL (reprint author), Ctr Dis Control & Prevent, Off Smoking & Hlth, 4770 Buford Highway,NE Mailstop K-79, Atlanta, GA 30341 USA. EM gschauer@cdc.gov NR 19 TC 2 Z9 2 U1 1 U2 2 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1462-2203 EI 1469-994X J9 NICOTINE TOB RES JI Nicotine Tob. Res. PD MAY PY 2015 VL 17 IS 5 BP 530 EP 538 DI 10.1093/ntr/ntu172 PG 9 WC Substance Abuse; Public, Environmental & Occupational Health SC Substance Abuse; Public, Environmental & Occupational Health GA CH3CL UT WOS:000353904000005 PM 25180077 ER PT J AU Syamlal, G Mazurek, JM Hendricks, SA Jamal, A AF Syamlal, Girija Mazurek, Jacek M. Hendricks, Scott A. Jamal, Ahmed TI Cigarette Smoking Trends Among US Working Adult by Industry and Occupation: Findings From the 2004-2012 National Health Interview Survey SO NICOTINE & TOBACCO RESEARCH LA English DT Article ID SMOKELESS TOBACCO USE; UNITED-STATES; WORKPLACE POLICIES; INTERVENTION; DISPARITIES; PREVALENCE; WORKERS AB Objective: To examine trends in age-adjusted cigarette smoking prevalence among working adults by industry and occupation during 2004-2012, and to project those prevalences and compare them to the 2020 Healthy People objective (TU-1) to reduce cigarette smoking prevalence to <= 12%. Methods: We analyzed the 2004-2012 National Health Interview Survey (NHIS) data. Respondents were aged >= 18 years working in the week prior to the interview. Temporal changes in cigarette smoking prevalence were assessed using logistic regression. We used the regression model to extrapolate to the period 2013-2020. Results: Overall, an estimated 19.0% of working adults smoked cigarettes: 22.4% in 2004 to 18.1% in 2012. The largest declines were among workers in the education services (6.5%) industry and in the life, physical, and social science (9.7%) occupations. The smallest declines were among workers in the real estate and rental and leasing (0.9%) industry and the legal (0.4%) occupations. The 2020 projected smoking prevalences in 15 of 21 industry groups and 13 of the 23 occupation groups were greater than the 2020 Healthy People goal. Conclusions: During 2004-2012, smoking prevalence declined in the majority of industry and occupation groups. The decline rate varied by industry and occupation groups. Projections suggest that certain groups may not reach the 2020 Healthy People goal. Consequently, smoking cessation, prevention, and intervention efforts may need to be revised and strengthened, particularly in specific occupational groups. C1 [Syamlal, Girija; Mazurek, Jacek M.] NIOSH, Div Resp Dis Studies, CDC, Morgantown, WV 26505 USA. [Hendricks, Scott A.] NIOSH, Div Safety Res, CDC, Morgantown, WV 26505 USA. [Jamal, Ahmed] Ctr Dis Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Off Smoking & Hlth, CDC, Atlanta, GA 30333 USA. RP Syamlal, G (reprint author), NIOSH, Div Resp Dis Studies, CDC, 1095 Willowdale Rd,Mail Stop HG 900-2, Morgantown, WV 26505 USA. EM gsyamlal@cdc.gov FU National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention FX Study was supported by the National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention. NR 40 TC 2 Z9 2 U1 2 U2 4 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1462-2203 EI 1469-994X J9 NICOTINE TOB RES JI Nicotine Tob. Res. PD MAY PY 2015 VL 17 IS 5 BP 599 EP 606 DI 10.1093/ntr/ntu185 PG 8 WC Substance Abuse; Public, Environmental & Occupational Health SC Substance Abuse; Public, Environmental & Occupational Health GA CH3CL UT WOS:000353904000012 PM 25239956 ER PT J AU Schauer, GL Malarcherd, AM Babb, SD AF Schauer, Gillian L. Malarcherd, Ann M. Babb, Stephen D. TI Prevalence and Correlates of Switching to Another Tobacco Product to Quit Smoking Cigarettes SO NICOTINE & TOBACCO RESEARCH LA English DT Article ID SMOKELESS TOBACCO; CONTROLLED-TRIAL; POPULATION HARM; CESSATION; SNUS AB Introduction: Using nationally representative data, we assessed the prevalence and correlates of cigarette smokers who tried switching to smokeless tobacco (SLT) or to other combusted tobacco (OCT) products to quit. Methods: Data came from 12,400 current or former adult smokers who made a quit attempt in the past year and responded to the 2010-2011 Tobacco Use Supplement to the Current Population Survey. Demographics and smoking characteristics were computed among those switching to SLT, switching to OCT, or trying to quit without using either strategy. Bivariate and multinomial logistic regression models identified correlates of using each strategy. Results: Overall, 3.1% of smokers tried switching to SLT to quit, 2.2% tried switching to OCT, and 0.6% tried both strategies. Compared to those not using either switching strategy to try to quit, males were more likely than females to try switching to SLT or OCT; Blacks were less likely than Whites to try switching to SLT, but more likely to try switching to OCT; younger age groups were more likely to try switching to SLT or OCT; current someday smokers were more likely to have try switching to SLT (vs. everyday smokers), while recent former smokers were more likely to have tried switching to OCT. Both switching groups were more likely to have used cessation medication versus those not using switching strategies. Conclusion: Data suggest that switching to other tobacco products is a prevalent cessation approach; messages are needed to help clinicians encourage smokers who try to quit by switching to use evidence-based cessation approaches. C1 [Schauer, Gillian L.] Ctr Dis Control & Prevent, Carter Consulting Inc, Off Smoking & Hlth, Atlanta, GA 30341 USA. [Schauer, Gillian L.] Emory Univ, Dept Behav Sci & Hlth Educ, Atlanta, GA 30322 USA. [Malarcherd, Ann M.; Babb, Stephen D.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Off Smoking & Hlth, Atlanta, GA 30341 USA. RP Schauer, GL (reprint author), Ctr Dis Control & Prevent, Carter Consulting Inc, Off Smoking & Hlth, 4770 Buford Highway,NE,MS F-79, Atlanta, GA 30341 USA. EM vyc9@cdc.gov NR 21 TC 1 Z9 1 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1462-2203 EI 1469-994X J9 NICOTINE TOB RES JI Nicotine Tob. Res. PD MAY PY 2015 VL 17 IS 5 BP 622 EP 627 DI 10.1093/ntr/ntu181 PG 6 WC Substance Abuse; Public, Environmental & Occupational Health SC Substance Abuse; Public, Environmental & Occupational Health GA CH3CL UT WOS:000353904000016 PM 25239959 ER PT J AU Ford, ES Cunningham, TJ Mannino, DM AF Ford, Earl S. Cunningham, Timothy J. Mannino, David M. TI Inflammatory markers and mortality among US adults with obstructive lung function SO RESPIROLOGY LA English DT Article DE chronic obstructive pulmonary disease; C-reactive protein; fibrinogen; leukocytes; mortality ID C-REACTIVE PROTEIN; PULMONARY-DISEASE; RHEUMATOID-ARTHRITIS; HEART-DISEASE; COPD; METAANALYSIS; RISK; COHORT; SALMETEROL/FLUTICASONE; EXACERBATIONS AB Background and objectiveChronic obstructive pulmonary disease is characterized by an inflammatory state of uncertain significance. The objective of this study was to examine the association between elevated inflammatory marker count (white blood cell count, C-reactive protein and fibrinogen) on all-cause mortality in a national sample of US adults with obstructive lung function (OLF). MethodsData for 1144 adults aged 40-79 years in the National Health and Nutrition Examination Survey III Linked Mortality Study were analysed. Participants entered the study from 1988 to 1994, and mortality surveillance was conducted through 2006. White blood cell count and fibrinogen were dichotomized at their medians, and C-reactive protein was divided into >3 and 3g/L. The number of elevated inflammatory markers was summed to create a score of 0-3. ResultsThe age-adjusted distribution of the number of elevated inflammatory markers differed significantly among participants with normal lung function, mild OLF, and moderate or worse OLF. Of the three dichotomized markers, only fibrinogen was significantly associated with mortality among adults with any OLF (maximally adjusted hazard ratio 1.49; 95% confidence interval (CI): 1.17-1.91). The maximally adjusted hazard ratios for having 1, 2 or 3 elevated markers were 1.17 (95% CI: 0.71-1.94), 1.44 (95% CI: 0.89-2.32) and 2.08 (95% CI: 1.29-3.37), respectively (P=0.003). ConclusionsAn index of elevated inflammatory markers predicted all-cause mortality among adults with OLF. Among adults with OLF in the United States, the associations among C-reactive protein, fibrinogen and leukocyte count and mortality were examined. The hazard ratios for having 1, 2 or 3 elevated markers were 1.17 (95% CI: 0.71-1.94), 1.44 (95% CI: 0.89-2.32) and 2.08 (95% CI: 1.29-3.37), respectively. C1 [Ford, Earl S.; Cunningham, Timothy J.] Ctr Dis Control & Prevent, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Mannino, David M.] Univ Kentucky, Coll Publ Hlth, Dept Prevent Med & Environm Hlth, Lexington, KY USA. RP Ford, ES (reprint author), Ctr Dis Control & Prevent, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway,MS F78, Atlanta, GA 30341 USA. EM eford@cdc.gov OI Mannino, David/0000-0003-3646-7828 FU Intramural CDC HHS [CC999999] NR 37 TC 3 Z9 3 U1 1 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1323-7799 EI 1440-1843 J9 RESPIROLOGY JI Respirology PD MAY PY 2015 VL 20 IS 4 BP 587 EP 593 DI 10.1111/resp.12499 PG 7 WC Respiratory System SC Respiratory System GA CH2XW UT WOS:000353889700011 PM 25739826 ER PT J AU Ford, ES Cunningham, TJ Croft, JB AF Ford, Earl S. Cunningham, Timothy J. Croft, Janet B. TI Trends in Self-Reported Sleep Duration among US Adults from 1985 to 2012 SO SLEEP LA English DT Article DE health surveys; sleep; trends ID METAANALYSIS; MORTALITY; PREVALENCE; WOMEN; RISK AB Study Objective: The trend in sleep duration in the United States population remains uncertain. Our objective was to examine changes in sleep duration from 1985 to 2012 among US adults. Design: Trend analysis. Setting: Civilian noninstitutional population of the United States. Participants: 324,242 US adults aged >= 18 y of the National Health Interview Survey (1985, 1990, and 2004-2012). Measurements and Results: Sleep duration was defined on the basis of the question "On average, how many hours of sleep do you get in a 24-h period?" The age-adjusted mean sleep duration was 7.40 h (standard error [SE] 0.01) in 1985, 7.29 h (SE 0.01) in 1990, 7.18 h (SE 0.01) in 2004, and 7.18 h (SE 0.01) in 2012 (P 2012 versus 1985 < 0.001; P trend 2004-2012 = 0.982). The age-adjusted percentage of adults sleeping <= 6 h was 22.3% (SE 0.3) in 1985, 24.4% (SE 0.3) in 1990, 28.6% (SE 0.3) in 2004, and 29.2% (SE 0.3) in 2012 (P 2012 versus 1985 < 0.001; P trend 2004-2012 = 0.050). In 2012, approximately 70.1 million US adults reported sleeping <= 6 h. Conclusions: Since 1985, age-adjusted mean sleep duration has decreased slightly and the percentage of adults sleeping <= 6 h increased by 31%. Since 2004, however, mean sleep duration and the percentage of adults sleeping <= 6 h have changed little. C1 [Ford, Earl S.; Cunningham, Timothy J.; Croft, Janet B.] Ctr Dis Control & Prevent, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP Ford, ES (reprint author), Ctr Dis Control & Prevent, 4770 Buford Highway,MS F78, Atlanta, GA 30341 USA. EM eford@cdc.gov NR 25 TC 16 Z9 16 U1 2 U2 4 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 EI 1550-9109 J9 SLEEP JI Sleep PD MAY 1 PY 2015 VL 38 IS 5 BP 829 EP + DI 10.5665/sleep.4684 PG 5 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA CH2TD UT WOS:000353876600020 PM 25669182 ER PT J AU Wang, GJ Joo, H Tong, X George, MG AF Wang, Guijing Joo, Heesoo Tong, Xin George, Mary G. TI Hospital Costs Associated With Atrial Fibrillation for Patients With Ischemic Stroke Aged 18-64 Years in the United States SO STROKE LA English DT Article DE atrial fibrillation; hospital costs; stroke ID INTERNATIONAL CLASSIFICATION; HEART-ASSOCIATION; CARE COSTS; PREVENTION; DABIGATRAN; WARFARIN; DISEASE; PERSPECTIVE; POPULATION; EXPENDITURES AB Background and Purpose-Hospital costs associated with atrial fibrillation (AFib) among patients with stroke have not been well-studied, especially among people aged <65 years. We estimated the AFib-associated hospital costs in US patients aged 18 to 64 years. Methods-We identified hospital admissions with a primary diagnosis of ischemic stroke from the 2010 to 2012 MarketScan Commercial Claims and Encounters inpatient data sets, excluding those with capitated health insurance plans, aged <18 or >64 years, missing geographic region, hospital costs below the 1st or above 99th percentile, and having carotid intervention (n=40 082). We searched the data for AFib and analyzed the costs for nonrepeat and repeat stroke admissions separately. We estimated the AFib-associated costs using multivariate regression models controlling for age, sex, geographic region, and Charlson comorbidity index. Results-Of the 33 500 nonrepeat stroke admissions, 2407 (7.2%) had AFib. Admissions with AFib cost $4991 more than those without AFib ($23 770 versus $18 779). For the 6582 repeat stroke admissions, 397 (6.0%) had AFib. The costs were $3260 more for those with AFib than those without ($24 119 versus $20 929). After controlling for potential confounders, AFib-associated costs for nonrepeat stroke admissions were $4905, representing 20.6% of the total costs for the admissions. Both the hospital costs and the AFib-associated costs were associated with age, but not with sex. AFib-associated costs for repeat stroke admissions were not significantly higher than for non-AFib patients, except for those aged 55 to 64 years ($3537). Conclusions-AFib increased the hospital cost of ischemic stroke substantially. Further investigation on AFib-associated costs for repeat stroke admissions is needed. C1 [Wang, Guijing; Tong, Xin; George, Mary G.] CDC, Div Heart Dis & Stroke Prevent, Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. [Joo, Heesoo] IHRC Inc, Atlanta, GA USA. RP Wang, GJ (reprint author), CDC, Div Heart Dis & Stroke, Prevent Ctr Dis Control & Prevent, 4770 Buford Hwy,MS F-75, Atlanta, GA 30341 USA. EM Gbw9@cdc.gov OI Joo, Heesoo/0000-0002-1342-6428 FU Intramural CDC HHS [CC999999] NR 46 TC 5 Z9 5 U1 0 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0039-2499 EI 1524-4628 J9 STROKE JI Stroke PD MAY PY 2015 VL 46 IS 5 BP 1314 EP 1320 DI 10.1161/STROKEAHA.114.008563 PG 7 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA CG8LR UT WOS:000353559800043 PM 25851767 ER PT J AU van Ravesteyn, NT van Lier, L Schechter, CB Ekwueme, DU Royalty, J Miller, JW Near, AM Cronin, KA Heijnsdijk, EAM Mandelblatt, JS de Koning, HJ AF van Ravesteyn, Nicolien T. van Lier, Lisanne Schechter, Clyde B. Ekwueme, Donatus U. Royalty, Janet Miller, Jacqueline W. Near, Aimee M. Cronin, Kathleen A. Heijnsdijk, Eveline A. M. Mandelblatt, Jeanne S. de Koning, Harry J. TI Transition From Film to Digital Mammography Impact for Breast Cancer Screening Through the National Breast and Cervical Cancer Early Detection Program SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID COST-EFFECTIVENESS; RANDOMIZED-TRIALS; UNITED-STATES; INSURANCE STATUS; RACE; PERFORMANCE; BENEFITS; WOMEN; RATES; CONSEQUENCES AB Introduction: The National Breast and Cervical Cancer Early Detection Program (NBCCEDP) provides mammograms and diagnostic services for low-income, uninsured women aged 40-64 years. Mammography facilities within the NBCCEDP gradually shifted from plain-film to digital mammography. The purpose of this study is to assess the impact of replacing film with digital mammography on health effects (deaths averted, life-years gained [LYG]); costs (for screening and diagnostics); and number of women reached. Methods: NBCCEDP 2010 data and data representative of the program's target population were used in two established microsimulation models. Models simulated observed screening behavior including different screening intervals (annual, biennial, irregular) and starting ages (40, 50 years) for white, black, and Hispanic women. Model runs were performed in 2012. Results: The models predicted 8.0-8.3 LYG per 1,000 film screens for black women, 5.9-7.5 for white women, and 4.0-4.5 for Hispanic women. For all race/ethnicity groups, digital mammography had more LYG than film mammography (2%-4%), but had higher costs (34%-35%). Assuming a fixed budget, 25%-26% fewer women could be served, resulting in 22%-24% fewer LYG if all mammograms were converted to digital. The loss in LYG could be reversed to an 8%-13% increase by only including biennial screening. Conclusions: Digital could result in slightly more LYG than film mammography. However, with a fixed budget, fewer women may be served with fewer LYG. Changes in the program, such as only including biennial screening, will increase LYG/screen and could offset the potential decrease in LYG when shifting to digital mammography. (C) 2015 American Journal of Preventive Medicine. All rights reserved. C1 [van Ravesteyn, Nicolien T.; van Lier, Lisanne; Heijnsdijk, Eveline A. M.; de Koning, Harry J.] Univ Med Ctr, Erasmus MC, Dept Publ Hlth, Rotterdam, Netherlands. [van Lier, Lisanne] Vrije Univ Amsterdam, Dept Gen Practice & Elderly Care Med, Med Ctr, Amsterdam, Netherlands. [Schechter, Clyde B.] Albert Einstein Coll Med, Dept Family & Social Med, Bronx, NY USA. [Schechter, Clyde B.] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY USA. [Ekwueme, Donatus U.; Royalty, Janet; Miller, Jacqueline W.] CDC, Atlanta, GA 30333 USA. [Near, Aimee M.; Mandelblatt, Jeanne S.] Georgetown Univ, Lombardi Comprehens Canc Ctr, Dept Oncol, Washington, DC USA. [Cronin, Kathleen A.] NCI, Stat Res & Applicat Branch, Div Canc Control & Populat Sci, NIH, Bethesda, MD 20892 USA. RP van Ravesteyn, NT (reprint author), Erasmus MC, Dept Publ Hlth, POB 2040, NL-3000 CA Rotterdam, Netherlands. EM n.vanravesteyn@erasmusmc.nl FU National Cancer Institute (NCI)-funded Breast Cancer Surveillance Consortium [HHSN261201100031C]; Interagency Agreement from CDC to the NCI [U01CA115337-10S1]; NCI [U01CA152958, U01CA088283, KO5CA96940]; Department of Defense [BC043120] FX We thank the National Comprehensive Cancer Network investigators for use of data on treatment dissemination. We thank the Breast Cancer Surveillance Consortium (BCSC) investigators for the data they have provided for this study. BCSC data collection was supported by the National Cancer Institute (NCI)-funded Breast Cancer Surveillance Consortium (Grant No. HHSN261201100031C). A list of the BCSC investigators and procedures for requesting BCSC data for research purposes are provided at: breastscreening.cancer.gov/. Drs. Mandelblatt and de Koning contributed equally to this work as senior authors. This study was supported by an Interagency Agreement from CDC to the NCI and funded under Grant No. U01CA115337-10S1.; This study was also supported in part by the NCI (Grant Nos. U01CA152958, U01CA088283; grant No. KO5CA96940 [JM]) and the Department of Defense (Grant No. BC043120 [JM]). Model results are the sole responsibility of the authors. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of CDC. NR 33 TC 0 Z9 0 U1 0 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD MAY PY 2015 VL 48 IS 5 BP 535 EP 542 DI 10.1016/j.amepre.2014.11.010 PG 8 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA CG1XO UT WOS:000353069300008 PM 25891052 ER PT J AU Pan, LP McGuire, LC Blanck, HM May-Murriel, AL Grummer-Strawn, LM AF Pan, Liping McGuire, Lisa C. Blanck, Heidi M. May-Murriel, Ashleigh L. Grummer-Strawn, Laurence M. TI Racial/Ethnic Differences in Obesity Trends Among Young Low-Income Children SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID PRESCHOOL-AGED CHILDREN; UNITED-STATES; CHILDHOOD OBESITY; AMERICAN-INDIANS; PREVALENCE; POPULATIONS; ENVIRONMENT; REGRESSION; HEALTH; RISK AB Introduction: Racial/ethnic differences in recent obesity trends have not been reported among young low-income children. The purpose of this study is to examine trends in obesity prevalence from 1998 through 2011 by race/ethnicity among low-income children aged 2-4 years. Methods: The study was based on measured weight and height records of 29,040,851 participants of federally funded health and nutrition programs from 30 states and the District of Columbia, which provided data each year from 1998 through 2011. More than 80% of data were collected through the Special Supplemental Nutrition Program for Women, Infants, and Children, and about 50% of eligible children were included. In 2014, joinpoint regression was used to identify the inflection years when significant changes in obesity trends occurred and piecewise logistic regression was used to examine annual changes in obesity prevalence before and after the inflection years controlling for age, sex, and race/ethnicity. Results: The overall obesity prevalence increased from 13.05% in 1998 to 15.21% in 2003, and decreased slightly to 14.74% in 2011. The increasing trends among non-Hispanic white, non-Hispanic black, and Hispanic children began decreasing in 2003. Asian/Pacific Islander was the only racial/ethnic group with a continual decreasing trend in obesity prevalence from 1998 (14.34%) through 2011 (11.66%). Among American Indian/Alaska Native children, obesity prevalence consistently increased from 16.32% in 1998 to 21.11% in 2011, although the annual increases slowed since 2001. Conclusions: The study findings indicate modest recent declines in obesity prevalence for most racial/ethnic groups of low-income children aged 2-4 years. However, obesity prevalence remains high. Published by Elsevier Inc. C1 [Pan, Liping; McGuire, Lisa C.; Blanck, Heidi M.; May-Murriel, Ashleigh L.; Grummer-Strawn, Laurence M.] CDC, Div Nutr Phys Act & Obes, Atlanta, GA 30341 USA. RP Pan, LP (reprint author), CDC, Div Nutr Phys Act & Obes, 4770 Buford Highway,Mail Stop F-77, Atlanta, GA 30341 USA. EM lpan@cdc.gov FU Intramural CDC HHS [CC999999] NR 20 TC 6 Z9 6 U1 0 U2 14 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD MAY PY 2015 VL 48 IS 5 BP 570 EP 574 DI 10.1016/j.amepre.2014.11.009 PG 5 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA CG1XO UT WOS:000353069300012 PM 25891056 ER PT J AU Hahn, RA Knopf, JA Wilson, SJ Truman, BI Milstein, B Johnson, RL Fielding, JE Muntaner, CJM Jones, CP Fullilove, MT Moss, RD Ueffing, E Hunt, PC AF Hahn, Robert A. Knopf, John A. Wilson, Sandra Jo Truman, Benedict I. Milstein, Bobby Johnson, Robert L. Fielding, Jonathan E. Muntaner, Carles J. M. Jones, Camara Phyllis Fullilove, Mindy T. Moss, Regina Davis Ueffing, Erin Hunt, Pete C. CA Community Preventive Serv Task For TI Programs to Increase High School Completion A Community Guide Systematic Health Equity Review SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID PREVENTIVE-SERVICES; POVERTY; DROPOUT; IMPACT AB Context: High school completion (HSC) is an established predictor of long-term morbidity and mortality. U.S. rates of HSC are substantially lower among students from low-income families and most racial/ethnic minority populations than students from high-income families and the non-Hispanic white population. This systematic review assesses the effectiveness of programs to increase HSC and the potential of these programs to improve lifelong health among at-risk students. Evidence acquisition: A search located a meta-analysis (search period 1985-2010/2011) on the effects of programs to increase HSC or General Educational Development (GED) diploma receipt; the meta-analysis was concordant with Community Guide definitions and methodologic standards. Programs were assessed separately for the general student population (152 studies) and students who were parents or pregnant (15 studies). A search for studies published between 2010 and August 2012 located ten more recent studies, which were assessed for consistency with the meta-analysis. Analyses were conducted in 2013. Evidence synthesis: The review focused on themeta-analysis. Program effectiveness was measured as the increased rate of HSC (or GED receipt) by the intervention group compared with controls. All assessed program types were effective in increasing HSC in the general student population: vocational training, alternative schooling, social-emotional skills training, college-oriented programming, mentoring and counseling, supplemental academic services, school and class restructuring, multiservice packages, attendance monitoring and contingencies, community service, and case management. For students who had children or were pregnant, attendance monitoring and multiservice packages were effective. Ten studies published after the search period for the meta-analysis were consistent with its findings. Conclusions: There is strong evidence that a variety of HSC programs can improve high school or GED completion rates. Because many programs are targeted to high-risk students and communities, they are likely to advance health equity. Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Hahn, Robert A.; Knopf, John A.] CDC, Community Guide Branch, Atlanta, GA 30333 USA. [Jones, Camara Phyllis] CDC, Analyt Tools & Methods Branch, Atlanta, GA 30333 USA. CDC, Div Epidemiol Anal, Atlanta, GA 30333 USA. [Truman, Benedict I.] CDC, Lib Serv, Off Associate Sci Natl Ctr, HIV AIDS,Viral Hepatitis,STD,TB Prevent, Atlanta, GA 30333 USA. [Hunt, Pete C.] CDC, Div Adolescent & Sch Hlth, Atlanta, GA 30333 USA. [Wilson, Sandra Jo] Vanderbilt Univ, Peabody Res Inst, Nashville, TN 37235 USA. [Milstein, Bobby] Hygeia Dynam, Cambridge, MA USA. [Johnson, Robert L.] Univ Med & Dent New Jersey, New Jersey Med Sch, Newark, NJ 07103 USA. [Fielding, Jonathan E.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Los Angeles, CA USA. [Fullilove, Mindy T.] Columbia Univ, Dept Publ Hlth & Psychiat, New York, NY USA. [Moss, Regina Davis] Amer Assoc Publ Hlth, Washington, DC USA. RP Hahn, RA (reprint author), CDC, Community Guide Branch, MS-E69,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM rhahn@cdc.gov FU Oak Ridge Institute for Scientific Education (ORISE) FX The work of John Knopf was supported with funds from the Oak Ridge Institute for Scientific Education (ORISE). NR 50 TC 7 Z9 7 U1 6 U2 27 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD MAY PY 2015 VL 48 IS 5 BP 599 EP 608 DI 10.1016/j.amepre.2014.12.005 PG 10 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA CG1XO UT WOS:000353069300016 PM 25818117 ER PT J AU Hahn, RA AF Hahn, Robert A. TI High School Completion Programs Recommended to Improve Health Equity Community Preventive Services Task Force SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Editorial Material C1 CDC, Community Guide Branch, Atlanta, GA 30333 USA. RP Hahn, RA (reprint author), CDC, Community Guide Branch, MS-E69,1600 Clifton Rd,NE, Atlanta, GA 30333 USA. EM rhahn@cdc.gov NR 4 TC 2 Z9 2 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD MAY PY 2015 VL 48 IS 5 BP 609 EP 612 DI 10.1016/j.amepre.2015.01.001 PG 4 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA CG1XO UT WOS:000353069300017 ER PT J AU Eyler, AA Blanck, HM Gittelsohn, J Karpyn, A McKenzie, TL Partington, S Slater, SJ Winters, M AF Eyler, Amy A. Blanck, Heidi M. Gittelsohn, Joel Karpyn, Allison McKenzie, Thomas L. Partington, Susan Slater, Sandy J. Winters, Meghan TI Physical Activity and Food Environment Assessments Implications for Practice SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID WALKABILITY SCALE; PUBLIC PARKS; NEIGHBORHOOD; RELIABILITY; BRAZIL; AUDIT; NEMS AB There is growing interest in the use of physical activity and nutrition environmental measures by both researchers and practitioners. Built environment assessment methods and tools range from simple to complex and encompass perceived, observed, and geographic data collection. Even though challenges in tool selection and use may exist for non-researchers, there are opportunities to incorporate these measures into practice. The aims of this paper are to (1) describe examples of built environment assessment methods and tools in the practice context; (2) present case studies that outline successful approaches for the use of built environment assessment tools and data among practitioners; and (3) make recommendations for both research and practice. As part of the Built Environment Assessment Training Think Tank meeting in July 2013, experts who work with community partners gathered to provide input on conceptualizing recommendations for collecting and analyzing built environment data in practice and research. The methods were summarized in terms of perceived environment measures, observational measures, and geographic measures for physical activity and food environment assessment. Challenges are outlined and case study examples of successful use of assessments in practice are described. Built environment assessment tools and measures are important outside the research setting. There is a need for improved collaboration between research and practice in forming partnerships for developing tools, collecting and analyzing data, and using the results to work toward positive environmental changes. (C) 2015 American Journal of Preventive Medicine. All rights reserved. C1 [Eyler, Amy A.] Washington Univ, Prevent Res Ctr, St Louis, MO 63130 USA. [Blanck, Heidi M.] CDC, Div Nutr Phys Act & Obes, Atlanta, GA 30333 USA. [Gittelsohn, Joel] Johns Hopkins Univ, Sch Publ Hlth, Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Karpyn, Allison] Univ Delaware Newark, Ctr Res Educ & Social Policy, Delaware, OH USA. [McKenzie, Thomas L.] San Diego State Univ, Exercise & Nutr Sci, San Diego, CA 92182 USA. [Partington, Susan] W Virginia Univ, Human Nutr & Food Sci, Morgantown, WV 26506 USA. [Slater, Sandy J.] Univ Illinois, Sch Publ Hlth, Chicago, IL USA. [Winters, Meghan] Simon Fraser Univ, Hlth Sci, Burnaby, BC V5A 1S6, Canada. RP Eyler, AA (reprint author), Washington Univ, Prevent Res Ctr, 621 Skinker Blvd St, St Louis, MO 63130 USA. EM aeyler@wustl.edu FU Agriculture and Food Research Initiative of the U.S. Department of Agriculture National Institute of Food and Agriculture [2010-85215-20659] FX This work was supported in part by Grant No. 2010-85215-20659 from the Agriculture and Food Research Initiative of the U.S. Department of Agriculture National Institute of Food and Agriculture. The authors acknowledge case study work contributed by Drs. Alyson Goodman, David Wong, and Gayathri Kumar, Mr. Kurt Rausch, and the Navajo Division of Health. NR 37 TC 3 Z9 3 U1 2 U2 10 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD MAY PY 2015 VL 48 IS 5 BP 639 EP 645 DI 10.1016/j.amepre.2014.10.008 PG 7 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA CG1XO UT WOS:000353069300022 PM 25891064 ER PT J AU Apostolou, A Bartholomew, ML Greeley, R Guilfoyle, SM Gordon, M Genese, C Davis, JP Montana, B Borlaug, G AF Apostolou, Andria Bartholomew, Michael L. Greeley, Rebecca Guilfoyle, Sheila M. Gordon, Marcia Genese, Carol Davis, Jeffrey P. Montana, Barbara Borlaug, Gwen TI Transmission of Hepatitis C Virus Associated With Surgical Procedures-New Jersey 2010 and Wisconsin 2011 SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Reprint ID GENOTYPES C1 [Apostolou, Andria; Bartholomew, Michael L.] CDC, Epidem Intelligence Serv, Piscataway, NJ 08854 USA. [Apostolou, Andria; Greeley, Rebecca; Genese, Carol; Montana, Barbara] New Jersey Dept Hlth, Piscataway, NJ USA. [Bartholomew, Michael L.; Guilfoyle, Sheila M.; Davis, Jeffrey P.; Borlaug, Gwen] Wisconsin Div Publ Hlth, Piscataway, NJ USA. [Greeley, Rebecca] Rutgers Sch Publ Hlth, Piscataway, NJ USA. [Gordon, Marcia] Christ Hosp, Jersey City, NJ USA. RP Apostolou, A (reprint author), CDC, Epidem Intelligence Serv, Piscataway, NJ 08854 USA. EM andria.apostolou@ihs.gov NR 9 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD MAY PY 2015 VL 15 IS 5 BP 1436 EP 1440 DI 10.1111/ajt.13333 PG 5 WC Surgery; Transplantation SC Surgery; Transplantation GA CG5ML UT WOS:000353335900037 ER PT J AU Vaughan, AS Kramer, MR Waller, LA Schieb, LJ Greer, S Casper, M AF Vaughan, Adam S. Kramer, Michael R. Waller, Lance A. Schieb, Linda J. Greer, Sophia Casper, Michele TI Comparing methods of measuring geographic patterns in temporal trends: an application to county-level heart disease mortality in the United States, 1973 to 2010 SO ANNALS OF EPIDEMIOLOGY LA English DT Article DE Heart disease mortality; Spatiotemporal trends; Geographic patterns; Bayesian methods; Joinpoint regression; Generalized linear mixed models; Spatial analysis ID SPACE-TIME VARIATION; JOINPOINT REGRESSION; CANCER-MORTALITY; BREAST-CANCER; DISPARITIES; RISK; DIFFERENTIALS; DECLINE; REGION; ONSET AB Purpose: To demonstrate the implications of choosing analytical methods for quantifying spatiotemporal trends, we compare the assumptions, implementation, and outcomes of popular methods using county-level heart disease mortality in the United States between 1973 and 2010. Methods: We applied four regression-based approaches (joinpoint regression, both aspatial and spatial generalized linear mixed models, and Bayesian space-time model) and compared resulting inferences for geographic patterns of local estimates of annual percent change and associated uncertainty. Results: The average local percent change in heart disease mortality from each method was -4.5%, with the Bayesian model having the smallest range of values. The associated uncertainty in percent change differed markedly across the methods, with the Bayesian space-time model producing the narrowest range of variance (0.0-0.8). The geographic pattern of percent change was consistent across methods with smaller declines in the South Central United States and larger declines in the Northeast and Midwest. However, the geographic patterns of uncertainty differed markedly between methods. Conclusions: The similarity of results, including geographic patterns, for magnitude of percent change across these methods validates the underlying spatial pattern of declines in heart disease mortality. However, marked differences in degree of uncertainty indicate that Bayesian modeling offers substantially more precise estimates. (C) 2015 Elsevier Inc. All rights reserved. C1 [Vaughan, Adam S.; Kramer, Michael R.] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30322 USA. [Vaughan, Adam S.; Kramer, Michael R.; Schieb, Linda J.; Greer, Sophia; Casper, Michele] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Atlanta, GA USA. [Waller, Lance A.] Emory Univ, Rollins Sch Publ Hlth, Dept Biostat & Bioinformat, Atlanta, GA 30322 USA. RP Vaughan, AS (reprint author), Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, 1518 Clifton Rd NE, Atlanta, GA 30322 USA. EM asvaugh@emory.edu OI Vaughan, Adam/0000-0002-2445-1725 FU Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health [K01HD074726] FX This research was supported in part by appointments for M.R.K. and A.S.V. to the Research Participation Program at the CDC administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the U.S. Department of Energy and CDC. M.R.K. was also supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health under award number K01HD074726. NR 36 TC 3 Z9 3 U1 1 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1047-2797 EI 1873-2585 J9 ANN EPIDEMIOL JI Ann. Epidemiol. PD MAY PY 2015 VL 25 IS 5 BP 329 EP 335 DI 10.1016/j.annepidem.2015.02.007 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CG5XI UT WOS:000353368800004 PM 25776848 ER PT J AU Aldrich, MC Hidalgo, B Widome, R Briss, P Brownson, RC Teutsch, SM AF Aldrich, Melinda C. Hidalgo, Bertha Widome, Rachel Briss, Peter Brownson, Ross C. Teutsch, Steven M. TI The role of epidemiology in evidence-based policy making: a case study of tobacco use in youth SO ANNALS OF EPIDEMIOLOGY LA English DT Article DE Tobacco; Smoking; Adolescents; Public health policy ID PUBLIC-HEALTH; CIGARETTE-SMOKING; ADOLESCENTS; INDUSTRY AB Purpose: Sound public health policy is based on relevant and timely information. A brief review of the history of youth tobacco control illustrates the central role of epidemiology to inform policy choices and evaluate their consequences. Methods: A narrative review was conducted. Results: Epidemiologic studies have shown that most smokers begin as adolescents or young adults and individuals who reach their mid-20s as nonsmokers are unlikely to ever become smokers. This key recognition made it clear that long-term tobacco control must prevent initiation of smoking among youth. Over time, tobacco use prevention interventions have evolved, increasing in reach and effectiveness as they moved from initially focusing on the individual to an approach that targets both populations and communities. Effective interventions for preventing youth smoking include raising tobacco prices, clean indoor air laws, and intensive mass media campaigns. Conclusions: Great strides have been made in youth tobacco control but 18% of high-school students continue to smoke. It is up to epidemiologists, fellow scientists, practitioners, and advocates to assure that strategies that are known to work are fully implemented and to continue to find more successful solutions that can further lower the incidence of youth smoking initiation and can address new tobacco products and changing contexts. (C) 2015 Elsevier Inc. All rights reserved. C1 [Aldrich, Melinda C.] Vanderbilt Univ, Med Ctr, Dept Thorac Surg, Nashville, TN USA. [Aldrich, Melinda C.] Vanderbilt Univ, Med Ctr, Div Epidemiol, Nashville, TN USA. [Hidalgo, Bertha] Univ Alabama Birmingham, Dept Biostat, Sect Stat Genet, Birmingham, AL USA. [Widome, Rachel] Univ Minnesota, Sch Publ Hlth, Div Epidemiol & Community Hlth, Minneapolis, MN USA. [Briss, Peter] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Brownson, Ross C.] Washington Univ, Brown Sch, Prevent Res Ctr St Louis, St Louis, MO USA. [Brownson, Ross C.] Washington Univ, Sch Med St Louis, Div Publ Hlth Sci, St Louis, MO USA. [Brownson, Ross C.] Washington Univ, Sch Med St Louis, Alvin J Siteman Canc Ctr, St Louis, MO USA. [Teutsch, Steven M.] Los Angeles Cty Dept Publ Hlth, Los Angeles, CA 90012 USA. RP Teutsch, SM (reprint author), Los Angeles Cty Dept Publ Hlth, 313 N Figueroa,Rm 708, Los Angeles, CA 90012 USA. EM steutsch@ph.lacounty.gov FU NHLBI, UAB Statistical Genetics Postdoctoral Training Program [5T32HL072757]; NIH/NCI [5K07CA172294] FX The authors thank Terry Pechacek for his thoughtful comments and feedback. Dr. Bertha Hidalgo was funded by the NHLBI, UAB Statistical Genetics Postdoctoral Training Program, grant 5T32HL072757. Dr. Melinda Aldrich was supported by a NIH/NCI 5K07CA172294 grant. NR 46 TC 1 Z9 1 U1 1 U2 9 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1047-2797 EI 1873-2585 J9 ANN EPIDEMIOL JI Ann. Epidemiol. PD MAY PY 2015 VL 25 IS 5 BP 360 EP 365 DI 10.1016/j.annepidem.2014.03.005 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CG5XI UT WOS:000353368800008 PM 24875267 ER PT J AU Moorman, AC Xing, J Ko, S Rupp, LB Xu, FJ Gordon, SC Lu, M Spradling, PR Teshale, EH Boscarino, JA Vijayadeva, V Schmidt, MA Holmberg, SD AF Moorman, Anne C. Xing, Jian Ko, Stephen Rupp, Loralee B. Xu, Fujie Gordon, Stuart C. Lu, Mei Spradling, Philip R. Teshale, Eyasu H. Boscarino, Joseph A. Vijayadeva, Vinutha Schmidt, Mark A. Holmberg, Scott D. CA CHeCS Investigators TI Late Diagnosis of Hepatitis C Virus Infection in the Chronic Hepatitis Cohort Study (CHeCS): Missed Opportunities for Intervention SO HEPATOLOGY LA English DT Article ID UNITED-STATES; FIBROSIS; FIBROTEST; MORTALITY; DISEASE; INDEX; FIB-4; CARE AB To determine the stage of liver disease at initial diagnosis of hepatitis C virus (HCV) infection, we analyzed data from the Chronic Hepatitis Cohort Study (CHeCS), a large U.S. observational study. We examined the temporal relationships of initial HCV infection diagnosis with cirrhosisdefined by liver biopsy or mean FIB-4 score >5.88and time to onset of cirrhotic decompensation in electronic medical records. We determined time in the health system prior to HCV diagnosis and rates of hospitalization and death following HCV diagnosis. Of 14,717 patients with chronic HCV seen during 2006-2011, 6,166 (42%) had a definable time of initial HCV diagnosis. Of these, 1,056 (17%) patients met our definition for late diagnosis with either cirrhosis concurrent with initial HCV diagnosis (n=550), a first diagnosis of hepatic decompensation before or within 12 months after initial HCV diagnosis (n=506), or both (n=314). Patients with late diagnosis had an average of 6 years in the health system before their HCV diagnosis. In a comparison with patients without late diagnosis, hospitalization (59% versus 35%) and death (33% versus 9%) were more frequent among patients with late diagnosis. Among all who died, mean (median) time from initial HCV diagnosis to death was 4.8 (4.2) years. Conclusion: Many CHeCS patients had advanced liver disease concurrent with their initial HCV diagnosis despite many years of engagement with the healthcare system, and these patients had high rates of hospitalization and mortality. (Hepatology 2015;61:1479-1484) C1 [Moorman, Anne C.; Xing, Jian; Ko, Stephen; Xu, Fujie; Spradling, Philip R.; Teshale, Eyasu H.; Holmberg, Scott D.] CDC, Div Viral Hepatitis, Atlanta, GA 30333 USA. [Rupp, Loralee B.; Gordon, Stuart C.; Lu, Mei] Henry Ford Hlth Syst, Detroit, MI USA. [Boscarino, Joseph A.] Geisinger Hlth Syst, Danville, PA USA. [Vijayadeva, Vinutha] Kaiser Permanente Hawaii, Honolulu, HI USA. [Schmidt, Mark A.] Kaiser Permanente Northwest, Portland, OR USA. RP Moorman, AC (reprint author), Div Viral Hepatitis, CDC Mailstop G-37, Atlanta, GA 30329 USA. EM Amoorman@cdc.gov FU CDC Foundation; AbbVie; Janssen Pharmaceuticals, Inc.; Vertex Pharmaceuticals; Genentech, a member of the Roche Group; Bristol-Myers Squibb FX CHeCS was funded by the CDC Foundation, which currently receives grants from AbbVie, Janssen Pharmaceuticals, Inc., and Vertex Pharmaceuticals. Past funders include Genentech, a member of the Roche Group. Partial past funders include Bristol-Myers Squibb. Granting corporations do not have access to CHeCS data and do not contribute to data analysis or writing of the article. NR 14 TC 10 Z9 10 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD MAY PY 2015 VL 61 IS 5 BP 1479 EP 1484 DI 10.1002/hep.27365 PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CG4DR UT WOS:000353233500008 PM 25131217 ER PT J AU SteelFisher, GK Blendon, RJ Kang, M Ward, JRM Kahn, EB Maddox, KEW Lubell, KM Tucker, M Ben-Porath, EN AF SteelFisher, Gillian K. Blendon, Robert J. Kang, Minah Ward, Johanna R. M. Kahn, Emily B. Maddox, Kathryn E. W. Lubell, Keri M. Tucker, Myra Ben-Porath, Eran N. TI Adoption of preventive behaviors in response to the 2009 H1N1 influenza pandemic: a multiethnic perspective SO Influenza and Other Respiratory Viruses LA English DT Article DE H1N1 subtype; health behavior; influenza A virus; pandemic; public opinion; race ID RISK COMMUNICATION; TELEPHONE SURVEY; NATIVE CHILDREN; PUBLIC-HEALTH; UNITED-STATES; VACCINATION; DISPARITIES; POPULATIONS; EPIDEMIC; NONRESPONSE AB BackgroundAs public health leaders prepare for possible future influenza pandemics, the rapid spread of 2009 H1N1 influenza highlights the need to focus on measures the public can adopt to help slow disease transmission. Such measures may relate to hygiene (e.g., hand washing), social distancing (e.g., avoiding places where many people gather), and pharmaceutical interventions (e.g., vaccination). Given the disproportionate impact of public health emergencies on minority communities in the United States, it is important to understand whether there are differences in acceptance across racial/ethnic groups that could lead to targeted and more effective policies and communications. ObjectivesThis study explores racial/ethnic differences in the adoption of preventive behaviors during the 2009 H1N1 influenza pandemic. Patients/MethodsData are from a national telephone poll conducted March 17 to April 11, 2010, among a representative sample of 1123 white, 330 African American, 317 Hispanic, 268 Asian, and 262 American Indian/Alaska Native adults in the USA. ResultsPeople in at least one racial/ethnic minority group were more likely than whites to adopt several behaviors related to hygiene, social distancing, and healthcare access, including increased hand washing and talking with a healthcare provider (P-values <005). Exceptions included avoiding others with influenza-like illnesses and receiving 2009 H1N1 and seasonal influenza vaccinations. After we controlled the data for socioeconomic status, demographic factors, healthcare access, and illness- and vaccine-related attitudes, nearly all racial/ethnic differences in behaviors persisted. ConclusionsMinority groups appear to be receptive to several preventive behaviors, but barriers to vaccination are more pervasive. C1 [SteelFisher, Gillian K.; Blendon, Robert J.; Kang, Minah; Ward, Johanna R. M.] Harvard Univ, TH Chan Sch Publ Hlth, Boston, MA 02115 USA. [Blendon, Robert J.] Harvard Univ, John F Kennedy Sch Govt, Cambridge, MA 02138 USA. [Kang, Minah] Ewha Womans Univ, Seoul, South Korea. [Kahn, Emily B.; Lubell, Keri M.; Tucker, Myra] Ctr Dis Control & Prevent, Atlanta, GA USA. [Maddox, Kathryn E. W.] Chenega Govt Consulting LLC, Chesapeake, VA USA. [Ben-Porath, Eran N.] SSRS Media, Media, PA USA. RP SteelFisher, GK (reprint author), Harvard Univ, TH Chan Sch Publ Hlth, Dept Hlth Policy & Management, 677 Huntington Ave,4 Floor, Boston, MA 02115 USA. EM gsteel@hsph.harvard.edu FU Centers for Disease Control and Prevention (CDC); National Public Health Information Coalition (NPHIC) FX The poll was funded under a cooperative agreement with the Centers for Disease Control and Prevention (CDC) and the National Public Health Information Coalition (NPHIC). NR 37 TC 3 Z9 3 U1 0 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1750-2640 EI 1750-2659 J9 INFLUENZA OTHER RESP JI Influenza Other Respir. Viruses PD MAY PY 2015 VL 9 IS 3 BP 131 EP 142 DI 10.1111/irv.12306 PG 12 WC Infectious Diseases; Virology SC Infectious Diseases; Virology GA CG6JU UT WOS:000353407400005 PM 25688806 ER PT J AU McAnerney, JM Walaza, S Cohen, AL Tempia, S Buys, A Venter, M Blumberg, L Duque, J Cohen, C AF McAnerney, Johanna M. Walaza, Sibongile Cohen, Adam L. Tempia, Stefano Buys, Amelia Venter, Marietjie Blumberg, Lucille Duque, Jazmin Cohen, Cheryl TI Effectiveness and knowledge, attitudes and practices of seasonal influenza vaccine in primary healthcare settings in South Africa, 2010-2013 SO Influenza and Other Respiratory Viruses LA English DT Article DE attitudes; Influenza-like illness; knowledge; practices; vaccine ID SURVEILLANCE AB ObjectivesInfluenza vaccine effectiveness (VE) and coverage data for sub-Saharan Africa are scarce. Using a test-negative case-control design, we estimated influenza VE annually among individuals with influenza-like illness presenting to an outpatient sentinel surveillance programme in South Africa from 2010 to 2013. A knowledge, attitudes and practices (KAP) influenza vaccine survey of programme clinicians was conducted in 2013. SampleIn total, 9420 patients were enrolled in surveillance of whom 5344 (56.7%) were included in the VE analysis: 2678 (50.1%) were classified as controls (influenza test-negative) and 2666 (49.9%) as cases (influenza test-positive). ResultsMean annual influenza vaccine coverage among controls was 4.5% for the four years. Annual VE estimates adjusted for age, underlying medical conditions and seasonality for 2010-2013 were 54.2% (95% confidence interval (CI): 2.4-78.6%), 57.1% (95% CI: 15.5-78.2%), 38.4% (95% CI: -71.7-78.1%) and 87.2% (95% CI: 67.2-95.0%), respectively. The KAP survey showed that >90% of clinicians were familiar with the indications for and the benefits of influenza vaccination. ConclusionsOur study showed that the vaccine was significantly protective in 2010, 2011 and 2013, but not in 2012 when the circulating A(H3N2) strain showed genetic drift. Vaccine coverage was low despite good clinician knowledge of vaccination indications. Further studies are needed to investigate the reason for the low uptake of influenza vaccine. C1 [McAnerney, Johanna M.; Walaza, Sibongile; Tempia, Stefano; Buys, Amelia; Venter, Marietjie; Blumberg, Lucille; Cohen, Cheryl] Natl Hlth Lab Serv, Natl Inst Communicable Dis, Johannesburg, South Africa. [Cohen, Adam L.; Tempia, Stefano; Duque, Jazmin] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Cohen, Adam L.; Tempia, Stefano] US Ctr Dis Control & Prevent, Pretoria, South Africa. [Duque, Jazmin] Battelle Atlanta, Atlanta, GA USA. RP McAnerney, JM (reprint author), Natl Inst Communicable Dis, Private Bag X4, ZA-2131 Johannesburg, South Africa. EM jomca@nicd.ac.za RI Venter, Marietjie/P-9604-2016; OI Venter, Marietjie/0000-0003-2696-824X; Duque, Jazmin/0000-0003-3484-276X NR 26 TC 7 Z9 7 U1 1 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1750-2640 EI 1750-2659 J9 INFLUENZA OTHER RESP JI Influenza Other Respir. Viruses PD MAY PY 2015 VL 9 IS 3 BP 143 EP 150 DI 10.1111/irv.12305 PG 8 WC Infectious Diseases; Virology SC Infectious Diseases; Virology GA CG6JU UT WOS:000353407400006 PM 25677874 ER PT J AU Thompson, MG Ferber, JR Odouli, R David, D Shifflett, P Meece, JK Naleway, AL Bozeman, S Spencer, SM Fry, AM Li, DK AF Thompson, Mark G. Ferber, Jeannette R. Odouli, Roxana David, Donna Shifflett, Pat Meece, Jennifer K. Naleway, Allison L. Bozeman, Sam Spencer, Sarah M. Fry, Alicia M. Li, De-Kun TI Results of a pilot study using self-collected mid-turbinate nasal swabs for detection of influenza virus infection among pregnant women SO Influenza and Other Respiratory Viruses LA English DT Article DE Acute respiratory illness; influenza; nasal swab; pregnancy; self-collection ID REVERSE TRANSCRIPTION-PCR; TIME RT-PCR; RESPIRATORY VIRUSES; SURVEILLANCE; ILLNESS; QUANTIFICATION; VACCINE; SEASONS; TOOL AB BackgroundWe evaluated the feasibility of asking pregnant women to self-collect and ship respiratory specimens. MethodsIn a preliminary laboratory study, we compared the RT-PCR cycle threshold (CT) values of influenza A and B viruses incubated at 4 storage temperatures (from 4 to 35 degrees C) for 6 time periods (8, 24, 48, 72, and 168hours and 30days), resulting in 24 conditions that were compared to an aliquot tested after standard freezing (-20 degrees C) (baseline condition). In a subsequent pilot study, during January-February, 2014, we delivered respiratory specimen collection kits to 53 pregnant women with a medically attended acute respiratory illness using three delivery methods. ResultsCT values were stableafter storage at temperatures <27 degrees C for up to 72hours for influenza A viruses and 48hours for influenza B viruses. Of 53 women who received kits during the pilot, 89% collected and shipped nasal swabs as requested. However, 30% (14/47) of the women took over 2days to collect and ship their specimen. The human control gene, ribonuclease P (RNase P), was detected in 100% of nasal swab specimens. However, the mean CT values for RNase P (265, 95% confidence interval [CI]=260-271) and for the 8 influenza A virus positives in our pilot (322, 95% CI=289-355) were significantly higher than the CTs observed in our 2010-2012 study using staff-collected nasal pharyngeal swabs (P-values<001). DiscussionSelf-collection of respiratory specimens is a promising research method, but further research is needed to quantify the sensitivity and specificity of the approach. C1 [Thompson, Mark G.; Spencer, Sarah M.; Fry, Alicia M.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30333 USA. [Ferber, Jeannette R.; Odouli, Roxana; Li, De-Kun] Kaiser Fdn Res Inst, Div Res, Oakland, CA USA. [David, Donna; Meece, Jennifer K.] Marshfield Clin Res Fdn, Marshfield, WI USA. [Shifflett, Pat; Bozeman, Sam] Abt Associates Inc, Cambridge, MA USA. [Naleway, Allison L.] Kaiser Permanente Northwest, Ctr Hlth Res, Portland, OR USA. RP Thompson, MG (reprint author), Ctr Dis Control & Prevent, Influenza Div, 1600 Clifton Rd NE,MS A-32, Atlanta, GA 30333 USA. EM isq8@cdc.gov FU Centers for Disease Control and Prevention [200-2010-F-33132] FX We thank Marc-Alain Widdowson, David Shay, and Jerome Tokars for their feedback on early versions of this manuscript. Supported by the Centers for Disease Control and Prevention (contract 200-2010-F-33132 to Abt Associates Inc.). The findings and conclusions in this report are those of the authors and do not necessarily represent the views of CDC, Abt Associates, Inc., Center for Health Research, or Kaiser Foundation Research Institute. NR 25 TC 2 Z9 2 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1750-2640 EI 1750-2659 J9 INFLUENZA OTHER RESP JI Influenza Other Respir. Viruses PD MAY PY 2015 VL 9 IS 3 BP 155 EP 160 DI 10.1111/irv.12309 PG 6 WC Infectious Diseases; Virology SC Infectious Diseases; Virology GA CG6JU UT WOS:000353407400008 PM 25711978 ER PT J AU Robledo, CA Peck, JD Stoner, J Calafat, AM Carabin, H Cowan, L Goodman, JR AF Robledo, Candace A. Peck, Jennifer D. Stoner, Julie Calafat, Antonia M. Carabin, Helene Cowan, Linda Goodman, Jean R. TI Urinary phthalate metabolite concentrations and blood glucose levels during pregnancy SO INTERNATIONAL JOURNAL OF HYGIENE AND ENVIRONMENTAL HEALTH LA English DT Article DE Phthalate; Pregnancy; Blood glucose ID TEMPORAL VARIABILITY; INSULIN-RESISTANCE; UNITED-STATES; EXPOSURE; WOMEN; HORMONES; SAMPLES; SERUM; DEHP AB Purpose: To examine associations between phthalate metabolite urinary concentrations during early pregnancy and blood glucose levels obtained at the time of screening for gestational diabetes mellitus (GDM). Methods: Upon initiation of prenatal care, women with a mean gestational age of 12.8 weeks were recruited for a study of environmental chemical exposures (n = 110) and provided a spot urinary specimen. Blood glucose concentrations (mg/dl) were obtained from the electronic medical record for those patients who did not experience a pregnancy loss and did not transfer care to another facility prior to glucose screening (n = 72). Urinary concentrations of nine phthalate metabolites and creatinine were measured at the US Centers for Disease Control and Prevention. Associations between tertiles of phthalate metabolites concentrations and blood glucose levels were estimated using linear regression. Results: Compared to pregnant women in the lowest concentration tertile, women with the highest urinary concentrations (>= 3rd tertile) of mono-iso-butyl phthalate (tertile: >= 15.3 mu g/l, beta = -18.3, 95% CI: -35.4, -1.2) and monobenzyl phthalate (tertile: >= 30.3 mu g/l, beta = -17.3, 95% CI: -34.1, -0.4) had lower blood glucose levels at the time of GDM screening after adjustment for urinary creatinine and demographic covariates. Conclusion: Because maternal glucose levels increase during pregnancy to provide adequate nutrition for fetal growth and development, these findings may have implications for fetal health. However, given the limitations of our study, findings should be interpreted cautiously. (C) 2015 Elsevier GmbH. All rights reserved. C1 [Robledo, Candace A.; Peck, Jennifer D.; Stoner, Julie; Carabin, Helene; Cowan, Linda] Univ Oklahoma, Coll Publ Hlth, Hlth Sci Ctr, Dept Biostat & Epidemiol, Oklahoma City, OK 73104 USA. [Calafat, Antonia M.] Ctr Dis Control & Prevent CDC, Natl Ctr Environm Hlth, Div Sci Lab, Atlanta, GA 30341 USA. [Goodman, Jean R.] Loyola Univ Hlth Syst, Stritch Sch Med, Dept Obstet & Gynecol, Maternal Fetal Med, Maywood, IL 60153 USA. RP Robledo, CA (reprint author), 3500 Camp Bowie Blvd, Ft Worth, TX 76107 USA. EM candace.robledo@unthsc.edu; jennifer-peck@ouhsc.edu; julie-stoner@ouhsc.edu; acalafat@cdc.gov; helene-carabin@ouhsc.edu; linda-cowan@ouhsc.edu; jrgoodman@lumc.edu RI Carabin, Helene/B-7600-2016 FU Oklahoma Center for the Advancement of Science and Technology [HR06-170]; National Institute for Occupational Safety and Health through the Southwest Center for Occupational and Environmental Health [5 T42 OH008421-03] FX Grant funds were provided by Grant No. HR06-170 from the Oklahoma Center for the Advancement of Science and Technology and Grant No. 5 T42 OH008421-03 from the National Institute for Occupational Safety and Health through the Southwest Center for Occupational and Environmental Health to the Southwest Center for Occupational and Environmental Health (SWCOEH), a NIOSH Education and Research Center. We acknowledge Manori Silva, Ella Samandar, Jim Preau and Tao Jia for measuring the concentrations of phthalate metabolites. NR 30 TC 0 Z9 0 U1 3 U2 13 PU ELSEVIER GMBH, URBAN & FISCHER VERLAG PI JENA PA OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY SN 1438-4639 EI 1618-131X J9 INT J HYG ENVIR HEAL JI Int. J. Hyg. Environ. Health. PD MAY PY 2015 VL 218 IS 3 BP 324 EP 330 DI 10.1016/j.ijheh.2015.01.005 PG 7 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA CG2IF UT WOS:000353097400005 PM 25726127 ER PT J AU Stokley, S AF Stokley, Shannon TI Interventions to Improve Adolescent Vaccination Coverage SO JOURNAL OF ADOLESCENT HEALTH LA English DT Editorial Material ID IMMUNIZATION PRACTICES ACIP; ADVISORY-COMMITTEE; RECOMMENDATIONS; VACCINES C1 Ctr Dis Control & Prevent, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Stokley, S (reprint author), Ctr Dis Control & Prevent, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. FU Society for Adolescent Health and Medicine through Merck Co., Inc. FX Disclaimer: Publication of this article was supported by the Society for Adolescent Health and Medicine through a grant from Merck & Co., Inc. The opinions or views expressed in this supplement are those of the authors and do not represent the position of the funder. NR 15 TC 1 Z9 1 U1 2 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X EI 1879-1972 J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD MAY PY 2015 VL 56 IS 5 SU S BP S3 EP S4 DI 10.1016/j.jadohealth.2015.02.004 PG 2 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA CG1QZ UT WOS:000353049800002 PM 25863552 ER PT J AU Wiggins, LD Reynolds, A Rice, CE Moody, EJ Bernal, P Blaskey, L Rosenberg, SA Lee, LC Levy, SE AF Wiggins, Lisa D. Reynolds, Ann Rice, Catherine E. Moody, Eric J. Bernal, Pilar Blaskey, Lisa Rosenberg, Steven A. Lee, Li-Ching Levy, Susan E. TI Using Standardized Diagnostic Instruments to Classify Children with Autism in the Study to Explore Early Development SO JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS LA English DT Article DE ADI-R; ADOS; Autism; Classification; Phenotypes; Study methods ID SOCIAL COMMUNICATION QUESTIONNAIRE; SPECTRUM DISORDERS; OBSERVATION SCHEDULE; ADI-R; PRESCHOOL-CHILDREN; INTERVIEW; VALIDITY; ADOS; AGE AB The Study to Explore Early Development (SEED) is a multi-site case-control study designed to explore the relationship between autism spectrum disorder (ASD) phenotypes and etiologies. The goals of this paper are to (1) describe the SEED algorithm that uses the Autism Diagnostic Interview-Revised (ADI-R) and Autism Diagnostic Observation Schedule (ADOS) to classify children with ASD, (2) examine psychometric properties of different ASD classification methods, including the SEED method that incorporates rules for resolving ADI-R and ADOS discordance, and (3) determine whether restricted interests and repetitive behaviors were noted for children who had instrument discordance resolved using ADI-R social and communication scores. Results support the utility of SEED criteria when well-defined groups of children are an important clinical or research outcome. C1 [Wiggins, Lisa D.; Rice, Catherine E.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Reynolds, Ann; Moody, Eric J.; Rosenberg, Steven A.] Univ Colorado, Sch Med, Aurora, CO USA. [Bernal, Pilar] Kaiser Permanente No Calif, San Jose Med Ctr, Autism Spectrum Disorders Ctr, San Jose, CA USA. [Blaskey, Lisa; Levy, Susan E.] Univ Penn, Childrens Hosp Philadelphia, Perelman Sch Med, Ctr Autism Res, Philadelphia, PA 19104 USA. [Lee, Li-Ching] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. RP Wiggins, LD (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd MS E-86, Atlanta, GA 30333 USA. EM lwiggins@cdc.gov RI Rice, Catherine/D-6305-2016; OI Reynolds, Ann/0000-0002-0836-746X FU Centers for Disease Control and Prevention, Colorado Department of Public Health [U10DD000180]; Kaiser Foundation Research Institute (CA) [U10DD000181]; University of Pennsylvania [U10DD000182]; Johns Hopkins University [U10DD000183]; University of North Carolina at Chapel Hill [U10DD000184]; Michigan State University [U10DD000498] FX We would like to thank Lisa Croen, Julie Daniels, Ellen Giarelli, Rebecca Landa, Cordelia Robinson, Diana Schendel, Amy Sims, and Patrick Thompson for their contributions to the development of the SEED final classification algorithm and/or comments on previous versions of this paper. We would also like to thank Aimee Alexander, Rebecca Cantrell, and Laura Schieve for their assistance with data cleaning and the SEED principal investigators, co-principal investigators, project coordinators, project staff, and children and families who participated in this research. This publication was supported by six cooperative agreements from the Centers for Disease Control and Prevention: Cooperative Agreement Number U10DD000180, Colorado Department of Public Health; Cooperative Agreement Number U10DD000181, Kaiser Foundation Research Institute (CA); Cooperative Agreement Number U10DD000182, University of Pennsylvania; Cooperative Agreement Number U10DD000183, Johns Hopkins University; Cooperative Agreement Number U10DD000184, University of North Carolina at Chapel Hill; and Cooperative Agreement Number U10DD000498, Michigan State University. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 30 TC 4 Z9 4 U1 7 U2 18 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0162-3257 EI 1573-3432 J9 J AUTISM DEV DISORD JI J. Autism Dev. Disord. PD MAY PY 2015 VL 45 IS 5 BP 1271 EP 1280 DI 10.1007/s10803-014-2287-3 PG 10 WC Psychology, Developmental SC Psychology GA CG6JS UT WOS:000353407200013 PM 25348175 ER PT J AU Zhang, YG Pohl, J Brooks, WA Erdman, DD AF Zhang, Yange Pohl, Jan Brooks, W. Abdullah Erdman, Dean D. TI Serologic Cross-Reactions between Nucleocapsid Proteins of Human Respiratory Syncytial Virus and Human Metapneumovirus SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID MONOCLONAL-ANTIBODIES; UNITED-STATES; N-PROTEIN; IMMUNOLOGICAL CHARACTERIZATION; AVIAN PNEUMOVIRUSES; SEQUENCE-ANALYSIS; YOUNG-CHILDREN; TRACT DISEASE; F-PROTEIN; INFECTIONS AB Human respiratory syncytial virus (hRSV) and human metapneumovirus (hMPV) share virologic and epidemiologic features and cause clinically similar respiratory illness predominantly in young children. In a previous study of acute febrile respiratory illness in Bangladesh, we tested paired serum specimens from 852 children presenting fever and cough for diagnostic increases in titers of antibody to hRSV and hMPV by enzyme immunoassay (EIA). Unexpectedly, of 93 serum pairs that showed a >= 4-fold increase in titers of antibody to hRSV, 24 (25.8%) showed a concurrent increase in titers of antibody to hMPV; of 91 pairs showing an increase to hMPV, 13 (14.3%) showed a concurrent increase to hRSV. We speculated that common antigens shared by these viruses explain this finding. Since the nucleocapsid (N) proteins of these viruses show the greatest sequence homology, we tested hyperimmune antisera prepared for each virus against baculovirus-expressed recombinant N (recN) proteins for potential cross-reactivity. The antisera were reciprocally reactive with both proteins. To localize common antigenic regions, we first expressed the carboxy domain of the hMPV N protein that was the most highly conserved region within the hRSV N protein. Although reciprocally reactive with antisera by Western blotting, this truncated protein did not react with hMPV IgG-positive human sera by EIA. Using 5 synthetic peptides that spanned the amino-terminal portion of the hMPV N protein, we identified a single peptide that was cross-reactive with human sera positive for either virus. Antiserum prepared for this peptide was reactive with recN proteins of both viruses, indicating that a common immunoreactive site exists in this region. C1 [Zhang, Yange; Erdman, Dean D.] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA 30333 USA. [Pohl, Jan] Ctr Dis Control & Prevent, Div Sci Resources, Atlanta, GA USA. [Brooks, W. Abdullah] ICDDR B, Dhaka, Bangladesh. [Zhang, Yange] Battelle Mem Inst, Atlanta, GA USA. RP Erdman, DD (reprint author), Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA 30333 USA. EM dde1@cdc.gov NR 53 TC 1 Z9 2 U1 1 U2 3 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 EI 1098-660X J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD MAY PY 2015 VL 53 IS 5 BP 1609 EP 1615 DI 10.1128/JCM.03649-14 PG 7 WC Microbiology SC Microbiology GA CG1MK UT WOS:000353036500020 PM 25740767 ER PT J AU Guo, YQ Cebelinski, E Matusevich, C Alderisio, KA Lebbad, M McEvoy, J Roellig, DM Yang, CF Feng, Y Xiao, LH AF Guo, Yaqiong Cebelinski, Elizabeth Matusevich, Christine Alderisio, Kerri A. Lebbad, Marianne McEvoy, John Roellig, Dawn M. Yang, Chunfu Feng, Yaoyu Xiao, Lihua TI Subtyping Novel Zoonotic Pathogen Cryptosporidium Chipmunk Genotype I SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID NEW-YORK; GLYCOPROTEIN; COEVOLUTION; MELEAGRIDIS; INFECTION; PROTEASE; CLONING; HUMANS; SPP. AB Cryptosporidium chipmunk genotype I is an emerging zoonotic pathogen in humans. The lack of subtyping tools makes it impossible to determine the role of zoonotic transmission in epidemiology. To identify potential subtyping markers, we sequenced the genome of a human chipmunk genotype I isolate. Altogether, 9,509,783 bp of assembled sequences in 853 contigs were obtained, with an N50 of 117,886 bp and >200-fold coverage. Based on the whole-genome sequence data, two genetic markers encoding the 60-kDa glycoprotein (gp60) and a mucin protein (ortholog of cgd1_470) were selected for the development of a subtyping tool. The tool was used for characterizing chipmunk genotype I in 25 human specimens from four U.S. states and Sweden, one specimen each from an eastern gray squirrel, a chipmunk, and a deer mouse, and 4 water samples from New York. At the gp60 locus, although different subtypes were seen among the animals, water, and humans, the 15 subtypes identified differed mostly in the numbers of trinucleotide repeats (TCA, TCG, or TCT) in the serine repeat region, with only two single nucleotide polymorphisms in the nonrepeat region. Some geographic differences were found in the subtype distribution of chipmunk genotype I from humans. In contrast, only two subtypes were found at the mucin locus, which differed from each other in the numbers of a 30-bp minisatellite repeat. Thus, Cryptosporidium chipmunk genotype I isolates from humans and wildlife are genetically similar, and zoonotic transmission might play a potential role in human infections. C1 [Guo, Yaqiong; Feng, Yaoyu] E China Univ Sci & Technol, Sch Resources & Environm Engn, State Key Lab Bioreactor Engn, Shanghai 200237, Peoples R China. [Guo, Yaqiong; Roellig, Dawn M.; Xiao, Lihua] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Cebelinski, Elizabeth] Minnesota Dept Hlth, Publ Hlth Lab, St Paul, MN USA. [Matusevich, Christine] Vermont Dept Hlth Lab, Burlington, VT USA. [Alderisio, Kerri A.] New York City Dept Environm Protect, Valhalla, NY USA. [Lebbad, Marianne] Publ Hlth Agcy Sweden, Solna, Sweden. [McEvoy, John] N Dakota State Univ, Dept Vet & Microbiol Sci, Fargo, ND 58105 USA. [Yang, Chunfu] Ctr Dis Control & Prevent, Div Global HIV AIDS, Ctr Global Hlth, Atlanta, GA USA. RP Feng, Y (reprint author), E China Univ Sci & Technol, Sch Resources & Environm Engn, State Key Lab Bioreactor Engn, Shanghai 200237, Peoples R China. EM yyfeng@ecust.edu.cn; lxiao@cdc.gov RI Yaqiong, Guo/N-4927-2015; Xiao, Lihua/B-1704-2013; Feng, Yaoyu/B-3076-2014 OI Xiao, Lihua/0000-0001-8532-2727; FU National Natural Science Foundation of China [31229005, 31110103901, 31425025]; Water Special Project [2014ZX07104006]; National Special Fund for State Key Laboratory of Bioreactor Engineering [2060204]; U.S. Centers for Disease Control and Prevention FX This work was supported by the National Natural Science Foundation of China (31229005, 31110103901, and 31425025), the Water Special Project (2014ZX07104006), the National Special Fund for State Key Laboratory of Bioreactor Engineering (no. 2060204), and the U.S. Centers for Disease Control and Prevention. NR 21 TC 7 Z9 9 U1 1 U2 5 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 EI 1098-660X J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD MAY PY 2015 VL 53 IS 5 BP 1648 EP 1654 DI 10.1128/JCM.03436-14 PG 7 WC Microbiology SC Microbiology GA CG1MK UT WOS:000353036500025 PM 25762767 ER PT J AU Zhang, SK Yin, YL Jones, MB Zhang, ZZ Kaiser, BLD Dinsmore, BA Fitzgerald, C Fields, PI Deng, XY AF Zhang, Shaokang Yin, Yanlong Jones, Marcus B. Zhang, Zhenzhen Kaiser, Brooke L. Deatherage Dinsmore, Blake A. Fitzgerald, Collette Fields, Patricia I. Deng, Xiangyu TI Salmonella Serotype Determination Utilizing High-Throughput Genome Sequencing Data SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID ANTIGEN GENE-CLUSTER; O-ANTIGENS; ANTIMICROBIAL RESISTANCE; ESCHERICHIA-COLI; EPIDEMIOLOGY; SURVEILLANCE; OUTBREAK; TYPHIMURIUM; SEROVAR AB Serotyping forms the basis of national and international surveillance networks for Salmonella, one of the most prevalent food-borne pathogens worldwide (1-3). Public health microbiology is currently being transformed by whole-genome sequencing (WGS), which opens the door to serotype determination using WGS data. SeqSero (www.denglab.info/SeqSero) is a novel Web-based tool for determining Salmonella serotypes using high-throughput genome sequencing data. SeqSero is based on curated databases of Salmonella serotype determinants (rfb gene cluster, fliC and fljB alleles) and is predicted to determine serotype rapidly and accurately for nearly the full spectrum of Salmonella serotypes (more than 2,300 serotypes), from both raw sequencing reads and genome assemblies. The performance of SeqSero was evaluated by testing (i) raw reads from genomes of 308 Salmonella isolates of known serotype; (ii) raw reads from genomes of 3,306 Salmonella isolates sequenced and made publicly available by GenomeTrakr, a U.S. national monitoring network operated by the Food and Drug Administration; and (iii) 354 other publicly available draft or complete Salmonella genomes. We also demonstrated Salmonella serotype determination from raw sequencing reads of fecal metagenomes from mice orally infected with this pathogen. SeqSero can help to maintain the well-established utility of Salmonella serotyping when integrated into a platform of WGS-based pathogen subtyping and characterization. C1 [Zhang, Shaokang; Deng, Xiangyu] Univ Georgia, Dept Food Sci & Technol, Ctr Food Safety, Griffin, GA 30223 USA. [Yin, Yanlong] IIT, Dept Comp Sci, Chicago, IL 60616 USA. [Jones, Marcus B.] J Craig Venter Inst, Dept Infect Dis, Rockville, MD USA. [Zhang, Zhenzhen] Univ Michigan, Sch Publ Hlth, Dept Biostat, Ann Arbor, MI 48109 USA. [Kaiser, Brooke L. Deatherage] Pacific NW Natl Lab, Div Biol Sci, Richard, WA USA. [Dinsmore, Blake A.; Fitzgerald, Collette; Fields, Patricia I.] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA USA. RP Deng, XY (reprint author), Univ Georgia, Dept Food Sci & Technol, Ctr Food Safety, Griffin, GA 30223 USA. EM xdeng@uga.edu FU Board of Advisors, Center for Food Safety, University of Georgia; University of Georgia FX This work was supported in part by contributions from the Board of Advisors, Center for Food Safety, University of Georgia, and by University of Georgia startup funds to X.D. NR 35 TC 24 Z9 25 U1 2 U2 24 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 EI 1098-660X J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD MAY PY 2015 VL 53 IS 5 BP 1685 EP 1692 DI 10.1128/JCM.00323-15 PG 8 WC Microbiology SC Microbiology GA CG1MK UT WOS:000353036500030 PM 25762776 ER PT J AU Stromdahl, EY Nadolny, RM Gibbons, JA Auckland, LD Vince, MA Elkins, CE Murphy, MP Hickling, GJ Eshoo, MW Carolan, HE Crowder, CD Pilgard, MA Hamer, SA AF Stromdahl, Ellen Y. Nadolny, Robyn M. Gibbons, Jennifer A. Auckland, Lisa D. Vince, Mary A. Elkins, Chad E. Murphy, Michael P. Hickling, Graham J. Eshoo, Mark W. Carolan, Heather E. Crowder, Chris D. Pilgard, Mark A. Hamer, Sarah A. TI Borrelia burgdorferi Not Confirmed in Human-Biting Amblyomma americanum Ticks from the Southeastern United States SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID LYME-DISEASE SPIROCHETE; IXODES-SCAPULARIS; DERMACENTOR-VARIABILIS; ERYTHEMA MIGRANS; IXODIDAE; ACARI; INFECTION; TRANSMISSION; PREVALENCE; STRAIN AB The predominant human-biting tick throughout the southeastern United States is Amblyomma americanum. Its ability to transmit pathogens causing Lyme disease-like illnesses is a subject of ongoing controversy. Results of previous testing by the Department of Defense Human Tick Test Kit Program and other laboratories indicated that it is highly unlikely that A. americanum transmits any pathogen that causes Lyme disease. In contrast, a recent publication by Clark and colleagues (K. L. Clark, B. Leydet, and S. Hartman, Int. J. Med. Sci. 10: 915-931, 2013) reported detection of Lyme group Borrelia in A. americanum using a nested-flagellin-gene PCR. We evaluated this assay by using it and other assays to test 1,097 A. americanum ticks collected from humans. Using the Clark assay, in most samples we observed nonspecific amplification and nonrepeatability of results on subsequent testing of samples. Lack of reaction specificity and repeatability is consistent with mispriming, likely due to high primer concentrations and low annealing temperatures in this protocol. In six suspect-positive samples, Borrelia lonestari was identified by sequencing of an independent gene region; this is not a Lyme group spirochete and is not considered zoonotic. B. burgdorferi was weakly amplified from one pool using some assays, but not others, and attempts to sequence the amplicon of this pool failed, as did attempts to amplify and sequence B. burgdorferi from the five individual samples comprising this pool. Therefore, B. burgdorferi was not confirmed in any sample. Our results do not support the hypothesis that A. americanum ticks are a vector for Lyme group Borrelia infections. C1 [Stromdahl, Ellen Y.; Nadolny, Robyn M.; Vince, Mary A.; Elkins, Chad E.; Murphy, Michael P.] US Army Publ Hlth Command, Aberdeen Proving Ground, MD 21010 USA. [Nadolny, Robyn M.] Old Dominion Univ, Dept Biol Sci, Norfolk, VA 23529 USA. [Gibbons, Jennifer A.] US Army Edgewood Chem & Biol Ctr, Aberdeen Proving Ground, MD USA. [Gibbons, Jennifer A.] Sci & Technol Corp, Hampton, VA USA. [Auckland, Lisa D.; Hamer, Sarah A.] Texas A&M Univ, Dept Vet Integrat Biosci, College Stn, TX USA. [Hickling, Graham J.] Univ Tennessee, Inst Agr, Ctr Wildlife Hlth, Knoxville, TN 37901 USA. [Eshoo, Mark W.; Carolan, Heather E.; Crowder, Chris D.] Ibis Biosci, Carlsbad, CA USA. [Pilgard, Mark A.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO USA. RP Stromdahl, EY (reprint author), US Army Publ Hlth Command, Aberdeen Proving Ground, MD 21010 USA. EM Ellen.y.stromdahl.civ@mail.mil NR 38 TC 6 Z9 6 U1 1 U2 7 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 EI 1098-660X J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD MAY PY 2015 VL 53 IS 5 BP 1697 EP 1704 DI 10.1128/JCM.03454-14 PG 8 WC Microbiology SC Microbiology GA CG1MK UT WOS:000353036500032 PM 25788545 ER PT J AU McAlister, AJ Driscoll, J Metchock, B AF McAlister, Allison J. Driscoll, Jeffrey Metchock, Beverly TI DNA Sequencing for Confirmation of Rifampin Resistance Detected by Cepheid Xpert MTB/RIF Assay SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID MYCOBACTERIUM-TUBERCULOSIS; DRUG-RESISTANCE; DIAGNOSIS; STRAINS AB DNA sequencing of rpoB and culture-based drug susceptibility results were evaluated for samples referred for confirmation of rifampin resistance detected by the Cepheid Xpert MTB/RIF assay. Silent mutations and mutations associated with low-level resistance were found in the study population. These data support CDC recommendations to confirm Xpert rifampin resistance results. C1 [McAlister, Allison J.; Driscoll, Jeffrey; Metchock, Beverly] Ctr Dis Control & Prevent, Div TB Eliminat, US Dept Hlth & Human Serv, Atlanta, GA 30333 USA. RP McAlister, AJ (reprint author), Ctr Dis Control & Prevent, Div TB Eliminat, US Dept Hlth & Human Serv, Atlanta, GA 30333 USA. EM ihk5@cdc.gov NR 10 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 EI 1098-660X J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD MAY PY 2015 VL 53 IS 5 BP 1752 EP 1753 DI 10.1128/JCM.03433-14 PG 2 WC Microbiology SC Microbiology GA CG1MK UT WOS:000353036500046 PM 25740782 ER PT J AU Schneeberger, CL O'Driscoll, M Humphrey, C Henry, K Deal, N Seiber, K Hill, VR Zarate-Bermudez, M AF Schneeberger, Chandra L. O'Driscoll, Michael Humphrey, Charles Henry, Keaton Deal, Nancy Seiber, Kathy Hill, Vincent R. Zarate-Bermudez, Max TI Fate and Transport of Enteric Microbes From Septic Systems in a Coastal Watershed SO JOURNAL OF ENVIRONMENTAL HEALTH LA English DT Article ID 16S RIBOSOMAL-RNA; FECAL POLLUTION; GROUNDWATER CONTAMINATION; CLOSTRIDIUM-PERFRINGENS; GENETIC-MARKERS; DRINKING-WATER; NORTH-CAROLINA; WASTE; PCR; COLI AB Onsite wastewater treatment systems (OWTS) are commonly used in coastal areas to treat household wastewater. These systems represent potential sources of fecal pollution of groundwater and nearby surface water. OWTS are expected to reduce microbial concentrations in wastewater; however, system and environmental factors can affect treatment efficiency and impacts on ground and surface water. In the study of OWTS described in this article, the authors sampled septic tanks and groundwater at two households in coastal North Carolina between October 2009 and October 2011. Samples were tested for the fecal indicator microbes E. coli, enterococci, and Clostridium perfringens. Microbial source tracking was also performed in year two. Results showed that enteric microbe concentrations in groundwater significantly decreased with distance from the OWTS. Human markers of fecal contamination were also detected in the OWT'S and downgradient groundwater, indicating that OWTS can impact the microbial quality of shallow groundwater. C1 [Schneeberger, Chandra L.] IHRC Inc, Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30342 USA. [O'Driscoll, Michael] E Carolina Univ, Coastal Water Resources Ctr, Inst Coastal Sci & Policy, Dept Geol Sci, Greenville, NC 27858 USA. [Humphrey, Charles] E Carolina Univ, Environm Hlth Sci Program, Greenville, NC 27858 USA. [Henry, Keaton] E Carolina Univ, Dept Geol Sci, Greenville, NC 27858 USA. [Deal, Nancy] North Carolina Dept Hlth & Human Serv, Robbins, NC USA. [Seiber, Kathy] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Assoc Publ Hlth Labs, Emerging Infect Dis Fellowship, Atlanta, GA USA. [Hill, Vincent R.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Zarate-Bermudez, Max] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. RP Schneeberger, CL (reprint author), IHRC Inc, Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30342 USA. FU National Environmental Health Association FX We acknowledge the contributions of Dr. David Lindbo from North Carolina State University during the planning and site evaluation phases of the study Funding for this study was provided in part through a project grant from the National Environmental Health Association. The findings and conclusions in this report are those of the authors and do not necessarily represent those of CDC. Use of trade names and commercial sources is for identification only and does not imply endorsement by CDC or the U.S. Department of Health and Human Services. NR 37 TC 4 Z9 4 U1 3 U2 16 PU NATL ENVIRON HEALTH ASSOC PI DENVER PA 720 S COLORADO BLVD SUITE 970, SOUTH TOWER, DENVER, CO 80246 USA SN 0022-0892 J9 J ENVIRON HEALTH JI J. Environ. Health PD MAY PY 2015 VL 77 IS 9 BP 22 EP 30 PG 9 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA CG4JF UT WOS:000353250700004 PM 25985535 ER PT J AU Hlavsa, MC Kunz, JM Beach, MJ AF Hlavsa, Michele C. Kunz, Jasen M. Beach, Michael J. TI DIRECT FROM CDC ENVIRONMENTAL HEALTH SERVICES BRANCH It's All About the Return on Investment: The Model Aquatic Health Code SO JOURNAL OF ENVIRONMENTAL HEALTH LA English DT Editorial Material ID UNITED-STATES C1 [Hlavsa, Michele C.] CDC, Hlth Swimming Program, NCEZID, Atlanta, GA 30333 USA. [Kunz, Jasen M.] CDC, CMAHC, Atlanta, GA 30333 USA. [Beach, Michael J.] CDC, Hlth Water, NCEZID, Atlanta, GA 30333 USA. RP Hlavsa, MC (reprint author), Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, 1600 Clifton Rd,MS C-09, Atlanta, GA 30333 USA. EM acz3@cdc.gov NR 2 TC 0 Z9 0 U1 0 U2 2 PU NATL ENVIRON HEALTH ASSOC PI DENVER PA 720 S COLORADO BLVD SUITE 970, SOUTH TOWER, DENVER, CO 80246 USA SN 0022-0892 J9 J ENVIRON HEALTH JI J. Environ. Health PD MAY PY 2015 VL 77 IS 9 BP 34 EP 35 PG 2 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA CG4JF UT WOS:000353250700006 PM 25985536 ER PT J AU Namulanda, G AF Namulanda, Gonza TI DIRECT FROM CDC ENVIRONMENTAL PUBLIC HEALTH TRACKING NETWORK Biomonitoring and Environmental Public Health Tracking SO JOURNAL OF ENVIRONMENTAL HEALTH LA English DT Editorial Material ID ISSUES RP Namulanda, G (reprint author), Ctr Dis Control & Prevent, Environm Hlth Tracking Branch, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, 4770 Buford Hwy,MS F-57, Atlanta, GA 30341 USA. EM fos0@cdc.gov NR 5 TC 0 Z9 0 U1 0 U2 2 PU NATL ENVIRON HEALTH ASSOC PI DENVER PA 720 S COLORADO BLVD SUITE 970, SOUTH TOWER, DENVER, CO 80246 USA SN 0022-0892 J9 J ENVIRON HEALTH JI J. Environ. Health PD MAY PY 2015 VL 77 IS 9 BP 36 EP 38 PG 3 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA CG4JF UT WOS:000353250700007 PM 25985537 ER PT J AU Christensen, KLY Lorber, M Ye, XY Calafat, AM AF Christensen, Krista L. Y. Lorber, Matthew Ye, Xiaoyun Calafat, Antonia M. TI Reconstruction of bisphenol A intake using a simple pharmacokinetic model SO Journal of Exposure Science and Environmental Epidemiology LA English DT Article DE biomonitoring; BPA; exposure; metabolism; pharmacokinetic ID TANDEM MASS-SPECTROMETRY; HUMAN EXPOSURE; URINARY CONCENTRATIONS; DI(2-ETHYLHEXYL) PHTHALATE; SAMPLES; VARIABILITY; ROUTE; NONYLPHENOL; HUMANS; PAPER AB Bisphenol A (BPA) is used in the manufacture of a range of consumer products, and human biomonitoring studies suggest that exposure to BPA is nearly ubiquitous. We constructed and calibrated a simple pharmacokinetic model to predict urinary concentrations of BPA based on a known initial dose. This descriptive (rather than physiologically based) model has three compartments: "stomach/liver,'' "blood,'' and "bladder.'' We calibrated and validated the model parameters using blood and urine measurements from nine volunteers who consumed 5mg of d(16)-BPA. We then applied the model to a second group of eight persons, who supplied full volumes of urine over 7 consecutive days and a diary identifying times and types of food and beverage consumed, to "reconstruct'' the time and mass of BPA intakes. These reconstructed daily intakes ranged on average from 60 to 100 ng/kg-day, within the range of, but slightly higher than, those surmised from other studies. About two-thirds of intakes occurred within an hour of reported food or drink consumption, supporting the hypothesis that diet is the main pathway of exposure to BPA. However, one-third of all reconstructed intakes took place outside this time window, suggesting that other sources of BPA exposure may also be relevant. C1 [Christensen, Krista L. Y.; Lorber, Matthew] US EPA, Off Res & Dev, Natl Ctr Environm Assessment, Washington, DC 20460 USA. [Ye, Xiaoyun; Calafat, Antonia M.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. RP Christensen, KLY (reprint author), US EPA, Off Res & Dev, Natl Ctr Environm Assessment, 1200 Penn Ave NW,Mailcode 8623P, Washington, DC 20460 USA. EM Christensen.Krista@epa.gov NR 42 TC 4 Z9 4 U1 1 U2 9 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1559-0631 EI 1559-064X J9 J EXPO SCI ENV EPID JI J. Expo. Sci. Environ. Epidemiol. PD MAY-JUN PY 2015 VL 25 IS 3 BP 240 EP 248 DI 10.1038/jes.2013.81 PG 9 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA CG6JF UT WOS:000353405500002 PM 24252884 ER PT J AU Curwin, BD Deddens, JA McKernan, LT AF Curwin, Brian D. Deddens, Jim A. McKernan, Lauralynn T. TI Flavoring exposure in food manufacturing SO Journal of Exposure Science and Environmental Epidemiology LA English DT Article DE Exposure; flavorings; diacetyl; 2,3-pentanedione; food manufacturing ID BRONCHIOLITIS OBLITERANS SYNDROME; POPCORN PRODUCTION PLANT; DIACETYL SUBSTITUTES; WORKERS; IDENTIFICATION; DISEASE AB Flavorings are substances that alter or enhance the taste of food. Workers in the food-manufacturing industry, where flavorings are added to many products, may be exposed to any number of flavoring compounds. Although thousands of flavoring substances are in use, little is known about most of these in terms of worker health effects, and few have occupational exposure guidelines. Exposure assessment surveys were conducted at nine food production facilities and one flavor manufacturer where a total of 105 area and 74 personal samples were collected for 13 flavoring compounds including five ketones, five aldehydes, and three acids. The majority of the samples were below the limit of detection (LOD) for most compounds. Diacetyl had eight area and four personal samples above the LOD, whereas 2,3-pentanedione had three area samples above the LOD. The detectable values ranged from 25-3124 ppb and 15-172 ppb for diacetyl and 2,3-pentanedione respectively. These values exceed the proposed National Institute for Occupational Safety and Health (NIOSH) recommended exposure limit for these compounds. The aldehydes had the most detectable samples, with each of them having >50% of the samples above the LOD. Acetaldehyde had all but two samples above the LOD, however, these samples were below the OSHA PEL. It appears that in the food-manufacturing facilities surveyed here, exposure to the ketones occurs infrequently, however levels above the proposed NIOSH REL were found. Conversely, aldehyde exposure appears to be ubiquitous. C1 [Curwin, Brian D.; Deddens, Jim A.] NIOSH, Div Surveillance Hazard Evaluat & Field Studies, Cincinnati, OH 45226 USA. [McKernan, Lauralynn T.] NIOSH, Educ & Informat Div, Cincinnati, OH 45226 USA. RP Curwin, BD (reprint author), NIOSH, Div Surveillance Hazard Evaluat & Field Studies, 4676 Columbia Pkwy,Mailstop R-14, Cincinnati, OH 45226 USA. EM bcurwin@cdc.gov FU Intramural CDC HHS [CC999999]; NIEHS NIH HHS [Y1-ES-9018-02] NR 27 TC 1 Z9 1 U1 3 U2 8 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1559-0631 EI 1559-064X J9 J EXPO SCI ENV EPID JI J. Expo. Sci. Environ. Epidemiol. PD MAY-JUN PY 2015 VL 25 IS 3 BP 324 EP 333 DI 10.1038/jes.2014.52 PG 10 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA CG6JF UT WOS:000353405500013 PM 25052692 ER PT J AU Todd, SR Dahlgren, FS Traeger, MS Beltran-Aguilar, ED Marianos, DW Hamilton, C McQuiston, JH Regan, JJ AF Todd, Suzanne R. Dahlgren, F. Scott Traeger, Marc S. Beltran-Aguilar, Eugenio D. Marianos, Donald W. Hamilton, Charlene McQuiston, Jennifer H. Regan, Joanna J. TI No Visible Dental Staining in Children Treated with Doxycycline for Suspected Rocky Mountain Spotted Fever SO JOURNAL OF PEDIATRICS LA English DT Article ID PERMANENT TEETH; TETRACYCLINES AB Objective To evaluate whether cosmetically relevant dental effects occurred among children who had received doxycycline for treatment of suspected Rocky Mountain spotted fever (RMSF). Study design Children who lived on an American Indian reservation with high incidence of RMSF were classified as exposed or unexposed to doxycycline, based on medical and pharmacy record abstraction. Licensed, trained dentists examined each child's teeth and evaluated visible staining patterns and enamel hypoplasia. Objective tooth color was evaluated with a spectrophotometer. Results Fifty-eight children who received an average of 1.8 courses of doxycycline before 8 years of age and who now had exposed permanent teeth erupted were compared with 213 children who had never received doxycycline. No tetracycline-like staining was observed in any of the exposed children's teeth (0/58, 95% CI 0%-5%), and no significant difference in tooth shade (P = .20) or hypoplasia (P = 1.0) was found between the 2 groups. Conclusions This study failed to demonstrate dental staining, enamel hypoplasia, or tooth color differences among children who received short-term courses of doxycycline at <8 years of age. Healthcare provider confidence in use of doxycycline for suspected RMSF in children may be improved by modifying the drug's label. C1 [Todd, Suzanne R.; Dahlgren, F. Scott; Marianos, Donald W.; McQuiston, Jennifer H.; Regan, Joanna J.] Ctr Dis Control & Prevent, Div Vectorborne Dis, Rickettsial Zoonoses Branch, Atlanta, GA 30333 USA. [Traeger, Marc S.] Indian Hlth Serv, Whiteriver, AZ USA. [Beltran-Aguilar, Eugenio D.] Ctr Dis Control & Prevent, Div Oral Hlth, Atlanta, GA 30333 USA. [Hamilton, Charlene] White Mt Apache Tribe, Whiteriver, AZ USA. RP McQuiston, JH (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,MS D-25, Atlanta, GA 30333 USA. EM fzh7@cdc.gov OI Regan, Joanna/0000-0002-9179-6694 FU Centers for Disease Control and Prevention FX Supported by internal program funds from the Centers for Disease Control and Prevention. The opinions expressed in this paper are those of the authors, and do not necessarily represent the opinions of the Centers for Disease Control and Prevention or the Indian Health Service. NR 22 TC 12 Z9 13 U1 0 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-3476 EI 1097-6833 J9 J PEDIATR-US JI J. Pediatr. PD MAY PY 2015 VL 166 IS 5 BP 1246 EP 1251 DI 10.1016/j.jpeds.2015.02.015 PG 6 WC Pediatrics SC Pediatrics GA CG6DW UT WOS:000353387100031 PM 25794784 ER PT J AU Eke, PI Dye, BA Wei, L Slade, GD Thornton-Evans, GO Borgnakke, WS Taylor, GW Page, RC Beck, JD Genco, RJ AF Eke, Paul I. Dye, Bruce A. Wei, Liang Slade, Gary D. Thornton-Evans, Gina O. Borgnakke, Wenche S. Taylor, George W. Page, Roy C. Beck, James D. Genco, Robert J. TI Update on Prevalence of Periodontitis in Adults in the United States: NHANES 2009 to 2012 SO JOURNAL OF PERIODONTOLOGY LA English DT Article DE Dental health surveys; epidemiology; periodontal diseases; periodontitis; population surveillance; United States ID DISEASE SURVEILLANCE PROJECT; EXAMINATION PROTOCOLS; CASE DEFINITIONS; POPULATION; EXTENT; OLDER; HALF AB Background: This report describes prevalence, severity, and extent of periodontitis in the US adult population using combined data from the 2009 to 2010 and 2011 to 2012 cycles of the National Health and Nutrition Examination Survey (NHANES). Methods: Estimates were derived for dentate adults, aged >= 30 years, from the US civilian non-institutionalized population. Periodontitis was defined by combinations of clinical attachment loss (AL) and periodontal probing depth (PD) from six sites per tooth on all teeth, except third molars, using standard surveillance case definitions. For the first time in NHANES history, sufficient numbers of non-Hispanic Asians were sampled in 2011 to 2012 to provide reliable estimates of their periodontitis prevalence. Results: In 2009 to 2012, 46% of US adults, representing 64.7 million people, had periodontitis, with 8.9% having severe periodontitis. Overall, 3.8% of all periodontal sites (10.6% of all teeth) had PD >= 4 mm, and 19.3% of sites (37.4% teeth) had AL >= 3 mm. Periodontitis prevalence was positively associated with increasing age and was higher among males. Periodontitis prevalence was highest in Hispanics (63.5%) and non-Hispanic blacks (59.1%), followed by non-Hispanic Asian Americans (50.0%), and lowest in non-Hispanic whites (40.8%). Prevalence varied two-fold between the lowest and highest levels of socioeconomic status, whether defined by poverty or education. Conclusions: This study confirms a high prevalence of periodontitis in US adults aged >= 30 years, with almost fifty-percent affected. The prevalence was greater in non-Hispanic Asians than non-Hispanic whites, although lower than other minorities. The distribution provides valuable information for population-based action to prevent or manage periodontitis in US adults. C1 [Eke, Paul I.] CDC, Ctr Dis Control & Prevent, Div Populat Hlth, Atlanta, GA 30341 USA. [Dye, Bruce A.] CDC, Div Hlth & Nutr Examinat Surveys, Hyattsville, MD USA. [Wei, Liang] DB Consulting Grp, Atlanta, GA USA. [Slade, Gary D.; Beck, James D.] Univ N Carolina, Sch Dent, Dept Dent Ecol, Chapel Hill, NC 27599 USA. [Thornton-Evans, Gina O.] CDC, Div Oral Hlth, Atlanta, GA 30341 USA. [Borgnakke, Wenche S.] Univ Michigan, Sch Dent, Dept Periodont & Oral Med, Ann Arbor, MI 48109 USA. [Taylor, George W.] Univ Calif San Francisco, Sch Dent, Dept Prevent & Restorat Dent Sci, San Francisco, CA 94143 USA. [Page, Roy C.] Univ Washington, Sch Dent, Dept Periodont, Seattle, WA 98195 USA. [Genco, Robert J.] SUNY Buffalo, Sch Dent Med, Dept Oral Biol, Buffalo, NY 14260 USA. RP Eke, PI (reprint author), CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Populat Hlth, Atlanta, GA 30341 USA. EM peke@cdc.gov FU Intramural CDC HHS [CC999999]; NIDDK NIH HHS [P30 DK020572] NR 23 TC 88 Z9 89 U1 8 U2 32 PU AMER ACAD PERIODONTOLOGY PI CHICAGO PA 737 NORTH MICHIGAN AVENUE, SUITE 800, CHICAGO, IL 60611-2690 USA SN 0022-3492 EI 1943-3670 J9 J PERIODONTOL JI J. Periodont. PD MAY PY 2015 VL 86 IS 5 BP 611 EP 622 DI 10.1902/jop.2015.140520 PG 12 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA CG6LE UT WOS:000353411400005 PM 25688694 ER PT J AU Becasen, JS Ford, J Hogben, M AF Becasen, Jeffrey S. Ford, Jessie Hogben, Matthew TI Sexual Health Interventions: A Meta-Analysis SO JOURNAL OF SEX RESEARCH LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; HIV-PREVENTION INTERVENTION; RISK REDUCTION INTERVENTION; BEHAVIOR-CHANGE; WOMEN; PROGRAM; EDUCATION; OUTCOMES; MEN; PREGNANCY AB In the second of two companion papers, we conducted a meta-analysis of sexual health interventions in three domains. The interventions chosen for the meta-analysis were a subset of studies presented in a narrative review (the first of the two companion papers); these in turn were selected on the basis of fit to principles derived from the World Health Organization (WHO) and other definitions of sexual health. Studies (n=20) were drawn from Medline and PsycINFO databases (English language, adult populations, 1996-2011) and fell into three domains: knowledge, attitudes, and sexual behaviors. We estimated intervention effects via Hedges' g, using the random-effects approach. Initial estimates revealed a large effect for knowledge, g=1.32 (95% CI=0.51-2.14), and smaller effects for attitude change, g=0.17 (0.11-0.24) and behavior, g=0.21 (0.13-0.29). After removing outliers to produce more precise estimates, the final effect sizes for knowledge, attitudes, and sexual behavior were, respectively, 0.25 (0.03-0.48), 0.18 (0.12-0.24), and 0.18 (0.11-0.24). Interventions yielded positive effects across populations and in all the domains studied. C1 [Becasen, Jeffrey S.; Hogben, Matthew] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Ford, Jessie] NYU, New York, NY 10003 USA. RP Becasen, JS (reprint author), Ctr Dis Control & Prevent, Mail Stop E-44, Atlanta, GA 30333 USA. EM jbecasen@cdc.gov NR 36 TC 2 Z9 2 U1 1 U2 5 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0022-4499 EI 1559-8519 J9 J SEX RES JI J. Sex Res. PD MAY-JUN PY 2015 VL 52 IS 4 SI SI BP 433 EP 443 DI 10.1080/00224499.2014.947399 PG 11 WC Psychology, Clinical; Social Sciences, Interdisciplinary SC Psychology; Social Sciences - Other Topics GA CG8PA UT WOS:000353569400006 PM 25211119 ER PT J AU Hogben, M Ford, J Becasen, JS Brown, KF AF Hogben, Matthew Ford, Jessie Becasen, Jeffrey S. Brown, Kathryn F. TI A Systematic Review of Sexual Health Interventions for Adults: Narrative Evidence SO JOURNAL OF SEX RESEARCH LA English DT Article ID HIV-PREVENTION INTERVENTION; RANDOMIZED CONTROLLED-TRIAL; RISK REDUCTION INTERVENTION; BEHAVIORAL INTERVENTION; CONDOM USE; TRANSMITTED INFECTIONS; CLINICAL-TRIAL; UNITED-STATES; PREGNANCY PREVENTION; YOUNG-PEOPLE AB Recent work has explored the intersection between sexual health (as construed by the World Health Organization and others) and public health domains of action in the United States of America. This article reports the narrative results of a systematic review of sexual health intervention effects on public health-relevant outcomes. To qualify, interventions had to be based on the principles (1) that sexual health is intrinsic to individuals and their overall health and (2) that relationships reflecting sexual health must be positive for all parties concerned. Outcomes were classed in domains: knowledge, attitudes, communication, health care use, sexual behavior, and adverse events. We summarized data from 58 studies (English language, adult populations, 1996-2011) by population (adults, parents, sexual minorities, vulnerable populations) across domains. Interventions were predominantly individual and small-group designs that addressed sexual behaviors (72%) and attitudes/norms (55%). They yielded positive effects in that 98% reported a positive finding in at least one domain; 50% also reported null effects. The most consistently positive effects on behaviors and adverse events were found for sexual minorities, vulnerable populations, and parental communication. Whether via direct action or through partnerships, incorporating principles from existing sexual health definitions in public health efforts may help improve sexual health. C1 [Hogben, Matthew; Becasen, Jeffrey S.] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA 30333 USA. [Ford, Jessie] NYU, Dept Sociol, New York, NY 10003 USA. [Brown, Kathryn F.] Ctr Dis Control & Prevent, Div Global HIV AIDS, Atlanta, GA 30333 USA. RP Hogben, M (reprint author), Ctr Dis Control & Prevent, Mail Stop E-44, Atlanta, GA 30333 USA. EM mhogben@cdc.gov FU Intramural CDC HHS [CC999999] NR 103 TC 2 Z9 2 U1 4 U2 8 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0022-4499 EI 1559-8519 J9 J SEX RES JI J. Sex Res. PD MAY-JUN PY 2015 VL 52 IS 4 SI SI BP 444 EP 469 DI 10.1080/00224499.2014.973100 PG 26 WC Psychology, Clinical; Social Sciences, Interdisciplinary SC Psychology; Social Sciences - Other Topics GA CG8PA UT WOS:000353569400007 PM 25406027 ER PT J AU Kaur, J Lamb, MM Ogden, CL AF Kaur, Jasbir Lamb, Molly M. Ogden, Cynthia L. TI The Association between Food Insecurity and Obesity in Children-The National Health and Nutrition Examination Survey SO Journal of the Academy of Nutrition and Dietetics LA English DT Article DE Food insecurity; Obesity; Child-level; Personal National Health and Nutrition Examination Survey (NHANES) ID CHILDHOOD OBESITY; OVERWEIGHT STATUS; RISK-FACTORS; US CHILDREN; HUNGER; INCOME; SECURITY; FAMILIES; INSUFFICIENCY; ADOLESCENTS AB Background Food insecurity can put children at greater risk of obesity because of altered food choices and nonuniform consumption patterns. Objective We examined the association between obesity and both child-level food insecurity and personal food insecurity in US children. Design Data from 9,701 participants in the National Health and Nutrition Examination Survey, 2001-2010, aged 2 to 11 years were analyzed. Child-level food insecurity was assessed with the US Department of Agriculture's Food Security Survey Module based on eight child-specific questions. Personal food insecurity was assessed with five additional questions. Obesity was defined, using physical measurements, as body mass index (calculated as kg/m(2)) greater than or equal to the age-and sex-specific 95th percentile of the Centers for Disease Control and Prevention growth charts. Logistic regressions adjusted for sex, race/ethnic group, poverty level, and survey year were conducted to describe associations between obesity and food insecurity. Results Obesity was significantly associated with personal food insecurity for children aged 6 to 11 years (odds ratio = 1.81; 95% CI 1.33 to 2.48), but not in children aged 2 to 5 years (odds ratio = 0.88; 95% CI 0.51 to 1.51). Child-level food insecurity was not associated with obesity among 2-to 5-year-olds or 6-to 11-year-olds. Conclusions Personal food insecurity is associated with an increased risk of obesity only in children aged 6 to 11 years. Personal food-insecurity measures may give different results than aggregate food-insecurity measures in children. C1 [Kaur, Jasbir; Lamb, Molly M.; Ogden, Cynthia L.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. [Lamb, Molly M.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Lamb, Molly M.] Univ Colorado, Colorado Sch Publ Hlth, Aurora, CO 80045 USA. RP Lamb, MM (reprint author), Univ Colorado, Colorado Sch Publ Hlth, 13001 E 17th Pl,B119, Aurora, CO 80045 USA. EM Molly.Lamb@ucdenver.edu NR 41 TC 5 Z9 6 U1 3 U2 46 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 2212-2672 EI 2212-2680 J9 J ACAD NUTR DIET JI J. Acad. Nutr. Diet. PD MAY PY 2015 VL 115 IS 5 BP 751 EP 758 DI 10.1016/j.jand.2015.01.003 PG 8 WC Nutrition & Dietetics SC Nutrition & Dietetics GA CG5QO UT WOS:000353348600010 PM 25737437 ER PT J AU Liu, SJ Sharapov, U Klevens, M AF Liu, Stephen J. Sharapov, Umid Klevens, Monina TI Patient Awareness of Need for Hepatitis A Vaccination (Prophylaxis) Before International Travel SO JOURNAL OF TRAVEL MEDICINE LA English DT Article ID UNITED-STATES; VIRAL-HEPATITIS; EPIDEMIOLOGY; PREVENTION; RISK; HEALTH AB IntroductionAlthough hepatitis A virus (HAV) infection is preventable through vaccination, cases associated with international travel continue to occur. The purpose of this study was to examine the frequency of international travel and countries visited among persons infected with HAV and assess reasons why travelers had not received hepatitis A vaccine before traveling. MethodsUsing data from sentinel surveillance for HAV infection in seven US counties during 1996 to 2006, we examined the role of international travel in hepatitis A incidence and the reasons for patients not being vaccinated. ResultsOf 2,002 hepatitis A patients for whom travel history was available, 300 (15%) reported traveling outside of the United States. Compared to non-travelers, travelers were more likely to be female [odds ratio (OR)=1.74 (95% confidence interval [95% CI], 1.35, 2.24)], aged 0 to 17years [OR=3.30 (1.83, 5.94)], Hispanic [OR=3.69 (2.81, 4.86)], Asian [OR=2.00 (1.06, 3.77)], and were less likely to be black non-Hispanic [OR=0.30 (0.11, 0.82)]. The majority, 189 (61.6%), had traveled to Mexico. The most common reason for not getting pre-travel vaccination was Didn't know I could [or should] get shots [100/154 (65%)]. ConclusionLow awareness of HAV vaccination was the predominant reason for not being protected before travel. Different modes of traveler education could improve prevention of hepatitis A. To highlight the risk of infection before traveling to endemic countries including Mexico, travel and consulate websites could list reminders of vaccine recommendations. C1 [Liu, Stephen J.; Sharapov, Umid; Klevens, Monina] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div Viral Hepatitis, Epidemiol & Surveillance Branch, Atlanta, GA USA. RP Liu, SJ (reprint author), Epidemiol & Surveillance Branch, Div Viral Hepatitis, 1600 Clifton Rd NE,Mail Stop G-37, Atlanta, GA 30333 USA. EM STL45@pitt.edu FU Research Participation Program at the CDC; US Department of Energy; CDC FX This work was supported in part by the Research Participation Program at the CDC, administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the US Department of Energy and CDC. The CDC funded the primary author's salary. NR 18 TC 1 Z9 1 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1195-1982 EI 1708-8305 J9 J TRAVEL MED JI J. Travel Med. PD MAY-JUN PY 2015 VL 22 IS 3 BP 174 EP 178 DI 10.1111/jtm.12186 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA CG6CJ UT WOS:000353382800006 PM 25619557 ER PT J AU Tinker, SC Broussard, CS Frey, MT Gilboa, SM AF Tinker, Sarah C. Broussard, Cheryl S. Frey, Meghan T. Gilboa, Suzanne M. TI Prevalence of Prescription Medication Use Among Non-pregnant Women of Childbearing Age and Pregnant Women in the United States: NHANES, 1999-2006 SO MATERNAL AND CHILD HEALTH JOURNAL LA English DT Article DE Medication; Pregnancy; Women; Prescription; NHANES ID MATERNAL THYROID-DISEASE; OPIOID PAIN RELIEVERS; BIRTH-DEFECTS; DRUG-USE; HEALTH; POPULATION; OUTCOMES; TERATOGENICITY; PREVENTION; PATTERNS AB Many prescription medications have limited information regarding safety for use during pregnancy. In order to inform research on safer medication use during pregnancy, we examined prescription medication use among women in the United States. We analyzed data from the 1999-2006 National Health and Nutrition Examination Survey (NHANES) to estimate the prevalence of prescription medication use in the past 30 days among pregnant women and non-pregnant women of childbearing age (15-44 years) and to ascertain the most commonly reported prescription medications by women in these groups. We assessed how the most commonly reported medications differed among groups defined by selected demographic characteristics, including age, race/ethnicity, and markers of socioeconomic status. Prescription medication use in the past 30 days was reported by 22 % of pregnant women and 47 % of non-pregnant women of childbearing age. The most commonly reported prescription medications by NHANES participants differed somewhat by pregnancy status; allergy and anti-infective medications were more common among pregnant women, while oral contraceptives were more common among non-pregnant women. Use of prescription medication for asthma and thyroid disorders was reported by both groups. Although prescription medication use in the previous 30 days was less common among pregnant women than non-pregnant women, its use was reported among almost 1 in 4 pregnant women. Many of the most common medications reported were for the treatment of chronic medical conditions. Given the potential impact of medications on the developing fetus, our data underscore the importance of understanding the safety of these medications during pregnancy. C1 [Tinker, Sarah C.; Broussard, Cheryl S.; Frey, Meghan T.; Gilboa, Suzanne M.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Frey, Meghan T.] Oak Ridge Inst Sci & Educ, Oak Ridge, TN USA. RP Tinker, SC (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Mail Stop E-86,1600 Clifton Rd, Atlanta, GA 30333 USA. EM zzu9@cdc.gov FU Centers for Disease Control and Prevention FX This work was supported in part by an appointment to the Research Participation Program at the Centers for Disease Control and Prevention administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the U.S. Department of Energy and the Centers for Disease Control and Prevention. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 52 TC 6 Z9 6 U1 3 U2 9 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1092-7875 EI 1573-6628 J9 MATERN CHILD HLTH J JI Matern. Child Health J. PD MAY PY 2015 VL 19 IS 5 BP 1097 EP 1106 DI 10.1007/s10995-014-1611-z PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CG0SM UT WOS:000352978500018 PM 25287251 ER PT J AU Streby, A Mull, BJ Levy, K Hill, VR AF Streby, Ashleigh Mull, Bonnie J. Levy, Karen Hill, Vincent R. TI Comparison of real-time PCR methods for the detection of Naegleria fowleri in surface water and sediment SO PARASITOLOGY RESEARCH LA English DT Article DE Naegleria fowleri; Real-time PCR; Environmental detection; Method comparison ID PRIMARY AMEBIC MENINGOENCEPHALITIS; MELTING-CURVE ANALYSIS; FREE-LIVING AMEBAS; NESTED PCR; BALAMUTHIA-MANDRILLARIS; QUANTITATIVE DETECTION; ACANTHAMOEBA SPP.; TAP WATER; SAMPLES; ASSAY AB Naegleria fowleri is a thermophilic free-living ameba found in freshwater environments worldwide. It is the cause of a rare but potentially fatal disease in humans known as primary amebic meningoencephalitis. Established N. fowleri detection methods rely on conventional culture techniques and morphological examination followed by molecular testing. Multiple alternative real-time PCR assays have been published for rapid detection of Naegleria spp. and N. fowleri. Foursuch assays were evaluated for the detection of N. fowleri from surface water and sediment. The assays were compared for thermodynamic stability, analytical sensitivity and specificity, detection limits, humic acid inhibition effects, and performance with seeded environmental matrices. Twenty-one ameba isolates were included in the DNA panel used for analytical sensitivity and specificity analyses. N. fowleri genotypes I and III were used for method performance testing. Two of the real-time PCR assays were determined to yield similar performance data for specificity and sensitivity for detecting N. fowleri in environmental matrices. C1 [Streby, Ashleigh; Levy, Karen] Emory Univ, Rollins Sch Publ Hlth, Dept Environm Hlth, Atlanta, GA 30322 USA. [Mull, Bonnie J.] Florida Dept Hlth, Bur Epidemiol, Food & Waterborne Dis Program, Tallahassee, FL 32399 USA. [Hill, Vincent R.] Ctr Dis Control & Prevent, Waterborne Dis Prevent Branch, Atlanta, GA 30329 USA. RP Hill, VR (reprint author), Ctr Dis Control & Prevent, Waterborne Dis Prevent Branch, 1600 Clifton Rd NE, Atlanta, GA 30329 USA. EM vhill@cdc.gov FU Intramural CDC HHS [CC999999] NR 26 TC 2 Z9 2 U1 3 U2 17 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0932-0113 EI 1432-1955 J9 PARASITOL RES JI Parasitol. Res. PD MAY PY 2015 VL 114 IS 5 BP 1739 EP 1746 DI 10.1007/s00436-015-4359-5 PG 8 WC Parasitology SC Parasitology GA CF7GB UT WOS:000352723200011 PM 25855343 ER PT J AU Li, N Ye, JB Arrowood, MJ Ma, JB Wang, L Xu, HL Feng, YY Xiao, LH AF Li, Na Ye, Jianbin Arrowood, Michael J. Ma, Jingbo Wang, Lin Xu, Hailing Feng, Yaoyu Xiao, Lihua TI Identification and morphologic and molecular characterization of Cyclospora macacae n. sp from rhesus monkeys in China SO PARASITOLOGY RESEARCH LA English DT Article DE Cyclospora; Cyclospora macacae; Rhesus monkeys; SSU rRNA gene ID PATHOGENIC ENTEROCYTOZOON-BIENEUSI; UNITED-STATES; CAYETANENSIS; ANIMALS; SURVEILLANCE; INFECTION; PAPIONIS; PRIMATES; PARASITE; BABOONS AB Cyclospora spp. in nonhuman primates are most closely related to Cyclospora cayetanensis, an emerging human pathogen causing outbreaks of cyclosporiasis in North America. Studies thus far indicate the possible existence of host specificity in Cyclospora spp. In this study, 411 fecal specimens from free-range rhesus monkeys (Macaca mulatta) were collected and examined for Cyclospora by sequence analysis of the small subunit rRNA gene. A novel Cyclospora species was identified in 28 (6.8 %) specimens and named Cyclospora macacae based on morphologic and molecular characterizations. The oocyst of C. macacae is spherical and measures 8.49 +/- 0.55 x 8.49 +/- 0.49 mu m in diameter. Phylogenetic analysis grouped this species together with the other four Cyclospora species infecting primates, including C. cayetanensis in humans, forming a monophyletic group closely related to avian Eimeria species. In addition, C. cayetanensis was detected in one specimen, although whether rhesus monkeys can serve as a natural reservoir host of C. cayetanensis needs further investigation. C1 [Li, Na; Ye, Jianbin; Ma, Jingbo; Wang, Lin; Xu, Hailing; Feng, Yaoyu] E China Univ Sci & Technol, Sch Resources & Environm Engn, State Key Lab Bioreactor Engn, Shanghai 200237, Peoples R China. [Arrowood, Michael J.; Xiao, Lihua] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div Foodborne Waterborne & Environm Dis, Atlanta, GA USA. RP Feng, YY (reprint author), E China Univ Sci & Technol, Sch Resources & Environm Engn, State Key Lab Bioreactor Engn, Shanghai 200237, Peoples R China. EM yyfeng@ecust.edu.cn RI Feng, Yaoyu/B-3076-2014; Xiao, Lihua/B-1704-2013 OI Xiao, Lihua/0000-0001-8532-2727 FU National Natural Science Foundation of China [31425025, 31302078]; China Postdoctoral Science Foundation [2014 M560310]; Open Funding Project of the State Key Laboratory of Veterinary Etiological Biology, Lanzhou, China [SKLVEB2014KFKT008]; Fundamental Research Funds for the Central Universities, China FX This work was supported in part by the National Natural Science Foundation of China (31425025 and 31302078), China Postdoctoral Science Foundation (2014 M560310), Open Funding Project of the State Key Laboratory of Veterinary Etiological Biology, Lanzhou, China (SKLVEB2014KFKT008), and Fundamental Research Funds for the Central Universities, China. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. NR 28 TC 0 Z9 0 U1 1 U2 6 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0932-0113 EI 1432-1955 J9 PARASITOL RES JI Parasitol. Res. PD MAY PY 2015 VL 114 IS 5 BP 1811 EP 1816 DI 10.1007/s00436-015-4367-5 PG 6 WC Parasitology SC Parasitology GA CF7GB UT WOS:000352723200018 PM 25673080 ER PT J AU Caicedo, Y Paez, A Kuzmin, I Niezgoda, M Orciari, LA Yager, PA Recuenco, S Franka, R Velasco-Villa, A Willoughby, RE AF Caicedo, Yolanda Paez, Andres Kuzmin, Ivan Niezgoda, Michael Orciari, Lillian A. Yager, Pamela A. Recuenco, Sergio Franka, Richard Velasco-Villa, Andres Willoughby, Rodney E., Jr. TI Virology, Immunology and Pathology of Human Rabies During Treatment SO PEDIATRIC INFECTIOUS DISEASE JOURNAL LA English DT Article DE rabies; therapy; pathology; immunology; recovery of function; cerebral edema ID CENTRAL-NERVOUS-SYSTEM; SUBARACHNOID HEMORRHAGE; THERAPEUTIC COMA; VIRUS; CLEARANCE; ANTIBODY; DIAGNOSIS; BRAIN; MANAGEMENT; RECOVERY AB Background: Rabies is an acute fatal encephalitis caused by all members of the Lyssavirus genus. The first human rabies survivor without benefit of prior vaccination was reported from Milwaukee in 2005. We report a second unvaccinated patient who showed early recovery from rabies and then died accidentally during convalescence, providing an unparalleled opportunity to examine the histopathology as well as immune and virological correlates of early recovery from human rabies. Methods: Case report, rapid fluorescent focus inhibition test, enzyme-linked immunosorbent assay, indirect and direct fluorescent antibody assays, reverse-transcriptase polymerase chain reaction, phylogenetic reconstruction, isolation in tissue culture, pathology and immunohistochemistry. Results: The 9 year old died 76 days after presenting with rabies of vampire bat phylogeny transmitted by cat bite. Antibody response in serum and cerebrospinal fluid was robust and associated with severe cerebral edema. No rabies virus was cultured at autopsy. Rabies virus antigen was atypical in size and distribution. Rabies virus genome was present in neocortex but absent in brainstem. Conclusions: Clinical recovery was associated with detection of neutralizing antibody and clearance of infectious rabies virus in the central nervous system by 76 days but not clearance of detectable viral subcomponents such as nucleoprotein antigen or RNA in brain. C1 [Caicedo, Yolanda] Hosp Univ Valle, Cali, Colombia. [Paez, Andres] INS, Virol Lab, Bogota, Colombia. [Kuzmin, Ivan; Niezgoda, Michael; Orciari, Lillian A.; Yager, Pamela A.; Recuenco, Sergio; Franka, Richard; Velasco-Villa, Andres] Ctr Dis Control & Prevent, Rabies Program, Atlanta, GA USA. Ctr Dis Control & Prevent, Infect Dis Pathol Branch, Atlanta, GA USA. [Willoughby, Rodney E., Jr.] Med Coll Wisconsin, Milwaukee, WI 53201 USA. RP Willoughby, RE (reprint author), Med Coll Wisconsin, Dept Pediat Infect Dis, C450 POB 1997, Milwaukee, WI 53201 USA. EM rewillou@mcw.edu OI Recuenco-Cabrera, Sergio/0000-0002-8446-7411; PAEZ MARTINEZ, ANDRES/0000-0001-7316-3706 FU Zach Jones Foundation; NIH [1RO1AI093369] FX Supported, in part, by the Zach Jones Foundation and by the NIH 1RO1AI093369 (R.E.W.). The authors have no other funding or conflicts of interest to disclose. NR 45 TC 4 Z9 4 U1 5 U2 26 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0891-3668 EI 1532-0987 J9 PEDIATR INFECT DIS J JI Pediatr. Infect. Dis. J. PD MAY PY 2015 VL 34 IS 5 BP 520 EP 528 DI 10.1097/INF.0000000000000624 PG 9 WC Immunology; Infectious Diseases; Pediatrics SC Immunology; Infectious Diseases; Pediatrics GA CG5PH UT WOS:000353344500018 PM 25405805 ER PT J AU Pathela, P Klingler, EJ Guerry, SL Bernstein, KT Kerani, RP Llata, L Mark, HD Tabidze, I Rietmeijer, CA AF Pathela, Preeti Klingler, Ellen J. Guerry, Sarah L. Bernstein, Kyle T. Kerani, Roxanne P. Llata, Lisa Mark, Hayley D. Tabidze, Irina Rietmeijer, Cornelis A. CA SSuN Working Grp TI Sexually Transmitted Infection Clinics as Safety Net Providers: Exploring the Role of Categorical Sexually Transmitted Infection Clinics in an Era of Health Care Reform SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID PARTNER NOTIFICATION; CHLAMYDIA; MEN; SEX; RESOURCES AB Background: For many individuals, the implementation of the US Affordable Care Act will involve a transition from public to private health care venues for sexually transmitted infection (STI) care and prevention. To anticipate challenges primary care providers may face and to inform the future role of publicly funded STI clinics, it is useful to consider their current functions. Methods: Data collected by 40 STI clinics that are a part of the Sexually Transmitted Disease Surveillance Network were used to describe patient demographic and behavioral characteristics, STI diagnoses, and laboratory testing data in 2010 and 2011. Results: A total of 608,536 clinic visits were made by 363,607 unique patients. Most patients (61.9%) were male; 21.9% of men reported sex with men (MSM). Roughly half of patients were 20 to 29 years old (47.1%) and non-Hispanic black (56.2%). There were 212,765 STI diagnoses (mostly nonreportable) that required clinical examinations. A high volume of chlamydia, gonorrhea, and HIV testing was performed (> 350,000 tests); the prevalence was 11.5% for chlamydia, 5.8% for gonorrhea, 0.9% for HIV, and varied greatly by sex and MSM status. Among MSM with chlamydia or gonorrhea, 40.1% (1811/4448) of chlamydial and 46.2% (3370/7300) of gonococcal infections were detected at extragenital sites. Conclusions: Sexually Transmitted Disease Surveillance Network clinics served populations with high STI rates. Given experience with diagnoses of both nonreportable and reportable STIs and extragenital chlamydia and gonorrhea testing, STI clinics comprise a critical specialty network in STI diagnosis, treatment, and prevention. C1 [Pathela, Preeti; Klingler, Ellen J.] New York City Dept Hlth & Mental Hyg, Queens, NY 11101 USA. [Guerry, Sarah L.] Los Angeles Cty Dept Publ Hlth, Los Angeles, CA USA. [Bernstein, Kyle T.] San Francisco Dept Publ Hlth, San Francisco, CA USA. [Kerani, Roxanne P.] Publ Hlth Seattle & King Cty, Seattle, WA USA. [Kerani, Roxanne P.] Univ Washington, Ctr AIDS & STD Res, Seattle, WA 98195 USA. [Llata, Lisa] Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. [Mark, Hayley D.] Baltimore City Dept Hlth, Baltimore, MD USA. [Tabidze, Irina] Chicago Dept Publ Hlth, Chicago, IL USA. [Rietmeijer, Cornelis A.] Denver Publ Hlth Dept, Denver, CO USA. RP Pathela, P (reprint author), New York City Dept Hlth & Mental Hyg, 42-09 28th St, Queens, NY 11101 USA. EM ppathela@health.nyc.gov NR 26 TC 9 Z9 9 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD MAY PY 2015 VL 42 IS 5 BP 286 EP 293 DI 10.1097/OLQ.0000000000000255 PG 8 WC Infectious Diseases SC Infectious Diseases GA CG1QY UT WOS:000353049700011 PM 25868143 ER PT J AU Tong, VT Dietz, PM Rolle, IV Kennedy, SM Thomas, W England, LJ AF Tong, Van T. Dietz, Patricia M. Rolle, Italia V. Kennedy, Sara M. Thomas, William England, Lucinda J. TI Clinical interventions to reduce secondhand smoke exposure among pregnant women: a systematic review SO TOBACCO CONTROL LA English DT Review ID ENVIRONMENTAL TOBACCO-SMOKE; RANDOMIZED CONTROLLED-TRIAL; FREE HOMES; BEHAVIORAL INTERVENTION; PASSIVE SMOKING; HEALTH BELIEF; BIRTH-WEIGHT; OUTCOMES; METAANALYSIS; CESSATION AB Objective To conduct a systematic review of clinical interventions to reduce secondhand smoke (SHS) exposure among non-smoking pregnant women. Data sources We searched 16 databases for publications from 1990 to January 2013, with no language restrictions. Study selection Papers were included if they met the following criteria: (1) the study population included non-smoking pregnant women exposed to SHS, (2) the clinical interventions were intended to reduce SHS exposure at home, (3) the study included a control group and (4) outcomes included either reduced SHS exposure of non-smoking pregnant women at home or quit rates among smoking partners during the pregnancy of the woman. Data extraction Two coders independently reviewed each abstract or full text to identify eligible papers. Two abstractors independently coded papers based on US Preventive Services Task Force criteria for study quality (good, fair, poor), and studies without biochemically-verified outcome measures were considered poor quality. Data synthesis From 4670 papers, we identified five studies that met our inclusion criteria: four focused on reducing SHS exposure among non-smoking pregnant women, and one focused on providing cessation support for smoking partners of pregnant women. All were randomised controlled trials, and all reported positive findings. Three studies were judged poor quality because outcome measures were not biochemically-verified, and two were considered fair quality. Conclusions Clinical interventions delivered in prenatal care settings appear to reduce SHS exposure, but study weaknesses limit our ability to draw firm conclusions. More rigorous studies, using biochemical validation, are needed to identify strategies for reducing SHS exposure in pregnant women. C1 [Tong, Van T.; Dietz, Patricia M.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Rolle, Italia V.; England, Lucinda J.] Ctr Dis Control & Prevent, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Kennedy, Sara M.] Res Triangle Inst, Int, Atlanta, GA USA. [Thomas, William] Ctr Dis Control & Prevent, Div Epidemiol Anal & Lib Serv, Ctr Surveillance Epidemiol & Lab Serv, Atlanta, GA 30341 USA. RP Tong, VT (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy NE,MS F74, Atlanta, GA 30341 USA. EM vtong@cdc.gov FU Centers for Disease Control and Prevention, Department of Health and Human Services FX Financial support for this analysis was provided by the Centers for Disease Control and Prevention, Department of Health and Human Services. NR 60 TC 6 Z9 6 U1 2 U2 4 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0964-4563 EI 1468-3318 J9 TOB CONTROL JI Tob. Control PD MAY PY 2015 VL 24 IS 3 BP 217 EP 223 DI 10.1136/tobaccocontrol-2013-051200 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CG5NA UT WOS:000353337500008 PM 24789602 ER PT J AU Dement, JM Kuempel, ED Zumwalde, RD Ristich, AM Fernback, JE Smith, RJ AF Dement, John M. Kuempel, Eileen D. Zumwalde, Ralph D. Ristich, Anna M. Fernback, Joseph E. Smith, Randall J. TI Airborne Fiber Size Characterization in Exposure Estimation: Evaluation of a Modified Transmission Electron Microcopy Protocol for Asbestos and Potential Use for Carbon Nanotubes and Nanofibers SO AMERICAN JOURNAL OF INDUSTRIAL MEDICINE LA English DT Article DE asbestos; carbon nanotubes; carbon nanofibers; transmission electron microscopy (TEM); exposure estimation ID LUNG-CANCER MORTALITY; CHRYSOTILE ASBESTOS; HISTORICAL EXPOSURES; TEXTILE WORKERS; NORTH-CAROLINA; PHASE-CONTRAST; INHALATION; MESOTHELIOMA; DIMENSIONS; MICROSCOPY AB BackgroundAirborne fiber size has been shown to be an important factor relative to adverse lung effects of asbestos and suggested in animal studies of carbon nanotubes and nanofibers (CNT/CNF). Materials and MethodsThe International Standards Organization (ISO) transmission electron microscopy (TEM) method for asbestos was modified to increase the statistical precision of fiber size determinations, improve efficiency, and reduce analysis costs. Comparisons of the fiber size distributions and exposure indices by laboratory and counting method were performed. ResultsNo significant differences in size distributions by the ISO and modified ISO methods were observed. Small but statistically-significant inter-lab differences in the proportion of fibers in some size bins were found, but these differences had little impact on the summary exposure indices. The modified ISO method produced slightly more precise estimates of the long fiber fraction (>15m). ConclusionsThe modified ISO method may be useful for estimating size-specific structure exposures, including CNT/CNF, for risk assessment research. Am. J. Ind. Med. 58:494-508, 2015. (c) 2015 Wiley Periodicals, Inc. C1 [Dement, John M.] Duke Univ, Med Ctr, Div Occupat & Environm Med, Dept Community & Family Med, Durham, NC 27705 USA. [Kuempel, Eileen D.; Zumwalde, Ralph D.; Smith, Randall J.] NIOSH, Educ & Informat Div, Cincinnati, OH 45226 USA. [Ristich, Anna M.] DataChem Labs, Cincinnati, OH USA. [Fernback, Joseph E.] NIOSH, Div Appl Res & Technol, Cincinnati, OH 45226 USA. RP Dement, JM (reprint author), Duke Univ, Med Ctr, Div Occupat & Environm Med, Dept Community & Family Med, 2200 W Main St,Suite 400, Durham, NC 27705 USA. EM john.dement@duke.edu FU National Institute for Occupational Safety and Health FX This work was supported by the National Institute for Occupational Safety and Health. We would like to thank the following individuals who were instrumental in the set-up and generation of the data analyzed in this study: Kenneth M. Wallingford, NIOSH, for providing access to and information about the historical data files and samples used in this study; James Bena, formerly at NIOSH, for performing data management and stratified random sampling of the filters for the TEM analysis; and Bernadette and Anthony Kolk, EMS Laboratories, for their excellent execution of both the NIOSH and ISO protocols. NR 42 TC 2 Z9 2 U1 4 U2 14 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0271-3586 EI 1097-0274 J9 AM J IND MED JI Am. J. Ind. Med. PD MAY PY 2015 VL 58 IS 5 BP 494 EP 508 DI 10.1002/ajim.22422 PG 15 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CF5UB UT WOS:000352621500003 PM 25675894 ER PT J AU Fan, ZJ Harris-Adamson, C Gerr, F Eisen, EA Hegmann, KT Silverstein, B Evanoff, B Dale, AM Thiese, MS Garg, A Kapellusch, J Burt, S Merlino, L Rempel, D AF Fan, Z. Joyce Harris-Adamson, Carisa Gerr, Fred Eisen, Ellen A. Hegmann, Kurt T. Silverstein, Barbara Evanoff, Bradley Dale, Ann Marie Thiese, Matthew S. Garg, Arun Kapellusch, Jay Burt, Susan Merlino, Linda Rempel, David TI Associations Between Workplace Factors and Carpal Tunnel Syndrome: A Multi-Site Cross Sectional Study SO AMERICAN JOURNAL OF INDUSTRIAL MEDICINE LA English DT Article DE musculoskeletal disorders; physical work-load; workers; individual-level assessment; confounders ID HAND-ACTIVITY LEVEL; INDIVIDUAL RISK-FACTORS; THRESHOLD LIMIT VALUE; GENERAL-POPULATION; UPPER EXTREMITY; OCCUPATIONAL FACTORS; INDUSTRIAL-WORKERS; NERVE-CONDUCTION; PREVALENCE; DISORDERS AB BackgroundFew large epidemiologic studies have used rigorous case criteria, individual-level exposure measurements, and appropriate control for confounders to examine associations between workplace psychosocial and biomechanical factors and carpal tunnel syndrome (CTS). MethodsPooling data from five independent research studies, we assessed associations between prevalent CTS and personal, work psychosocial, and biomechanical factors while adjusting for confounders using multivariable logistic regression. ResultsPrevalent CTS was associated with personal factors of older age, obesity, female sex, medical conditions, previous distal upper extremity disorders, workplace measures of peak forceful hand activity, a composite measure of force and repetition (ACGIH Threshold Limit Value for Hand Activity Level), and hand vibration. ConclusionsIn this cross-sectional analysis of production and service workers, CTS prevalence was associated with workplace and biomechanical factors. The findings were similar to those from a prospective analysis of the same cohort with differences that may be due to recall bias and other factors. Am. J. Ind. Med. 58:509-518, 2015. (c) 2015 Wiley Periodicals, Inc. C1 [Fan, Z. Joyce] Washington Traff Safety Commiss, Olympia, WA USA. [Harris-Adamson, Carisa; Eisen, Ellen A.] Univ Calif Berkeley, Dept Environm Hlth Sci, Berkeley, CA 94720 USA. [Harris-Adamson, Carisa] Samuel Merritt Univ, Dept Phys Therapy, Oakland, CA USA. [Gerr, Fred; Merlino, Linda] Univ Iowa, Coll Publ Hlth, Dept Occupat & Environm Hlth, Iowa City, IA USA. [Hegmann, Kurt T.; Thiese, Matthew S.] Univ Utah, RMCOEH, Salt Lake City, UT USA. [Silverstein, Barbara] Washington State Dept Labor & Ind, Safety & Hlth Assessment & Res Prevent SHARP Prog, Olympia, WA 98504 USA. [Evanoff, Bradley; Dale, Ann Marie] Washington Univ, Sch Med, Div Gen Med Sci, St Louis, MO USA. [Garg, Arun; Kapellusch, Jay] Univ Wisconsin, Ctr Ergon, Milwaukee, WI 53201 USA. [Burt, Susan] NIOSH, Cincinnati, OH 45226 USA. [Rempel, David] Univ Calif San Francisco, Div Occupat & Environm Med, Richmond, CA 94804 USA. RP Rempel, D (reprint author), Univ Calif San Francisco, Div Occupat & Environm Med, 1301 S 46th St,Bldg 163, Richmond, CA 94804 USA. EM David.Rempel@ucsf.edu OI Evanoff, Bradley A./0000-0003-0085-333X FU National Institute for Occupational Safety and Health (NIOSH/CDC) [R01-OH009712] FX This study was funded, in part, by a grant from the National Institute for Occupational Safety and Health (NIOSH/CDC) R01-OH009712. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of NIOSH. NR 65 TC 5 Z9 5 U1 3 U2 17 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0271-3586 EI 1097-0274 J9 AM J IND MED JI Am. J. Ind. Med. PD MAY PY 2015 VL 58 IS 5 BP 509 EP 518 DI 10.1002/ajim.22443 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CF5UB UT WOS:000352621500004 PM 25778111 ER PT J AU Ng, TFF Wellehan, JFX Coleman, JK Kondov, NO Deng, XT Waltzek, TB Reuter, G Knowles, NJ Delwart, E AF Ng, Terry Fei Fan Wellehan, James F. X. Coleman, James K. Kondov, Nikola O. Deng, Xutao Waltzek, Thomas B. Reuter, Gabor Knowles, Nick J. Delwart, Eric TI A tortoise-infecting picornavirus expands the host range of the family Picornaviridae SO ARCHIVES OF VIROLOGY LA English DT Article ID RECOMBINATION; REVEALS; VIRUSES; ISOLATE AB While picornaviruses can cause diseases in many mammals, little is known of their host range for replication in non-mammalian vertebrates. Here, a picornavirus in liver and kidney tissues from diseased Sulawesi tortoises (Indotestudo forsteni) was genetically characterized. Tortoise rafivirus A (ToRaV-A, KJ415177) represents a potential new genus in the family Picornaviridae, for which we propose the name "Rafivirus". Our finding confirms the susceptibility of reptiles to picornaviruses. C1 [Ng, Terry Fei Fan; Kondov, Nikola O.; Deng, Xutao; Delwart, Eric] Blood Syst Res Inst, San Francisco, CA USA. [Ng, Terry Fei Fan; Deng, Xutao; Delwart, Eric] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA. [Wellehan, James F. X.; Coleman, James K.; Waltzek, Thomas B.] Univ Florida, Coll Vet Med, Gainesville, FL USA. [Reuter, Gabor] ANTSZ Reg Inst State Publ Hlth Serv, Reg Lab Virol, Pecs, Hungary. [Knowles, Nick J.] Pirbright Inst, Woking, Surrey, England. RP Ng, TFF (reprint author), Ctr Dis Control & Prevent, NCIRD, Atlanta, GA 30333 USA. EM terryfeifan@gmail.com RI Reuter, Gabor/I-7412-2013; Institute, Pirbright/K-4476-2014; OI Reuter, Gabor/0000-0002-5857-4934; Delwart, Eric/0000-0002-6296-4484; Ng, Terry Fei Fan/0000-0002-4815-8697 FU NHLBI [R01 HL105770]; Blood Systems Research Institute; Hungarian Scientific Research Fund [OTKA K83013, OTKA K111615] FX This work was supported by NHLBI grant R01 HL105770 to E.L.D and the Blood Systems Research Institute and grants from the Hungarian Scientific Research Fund (OTKA K83013 and OTKA K111615). NR 25 TC 4 Z9 4 U1 0 U2 16 PU SPRINGER WIEN PI WIEN PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA SN 0304-8608 EI 1432-8798 J9 ARCH VIROL JI Arch. Virol. PD MAY PY 2015 VL 160 IS 5 BP 1319 EP 1323 DI 10.1007/s00705-015-2366-6 PG 5 WC Virology SC Virology GA CF8FB UT WOS:000352790400021 PM 25721297 ER PT J AU Spradling, PR Kamili, S Xing, J Drobeniuc, J Hu, DJ AF Spradling, Philip R. Kamili, Saleem Xing, Jian Drobeniuc, Jan Hu, Dale J. TI Response to Challenge Dose Among Young Adults Vaccinated for Hepatitis B as Infants: Importance of Detectable Residual Antibody to Hepatitis B Surface Antigen SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID PROTECTION AB OBJECTIVE. To determine whether a difference in antibody to hepatitis B surface antigen (anti-HBs) response to a hepatitis B vaccine challenge dose existed among persons with a baseline anti-HBs level of 0 mIU/mL (group 1) and those with "non-zero" levels of 0.1-4.9 (group 2) and 5.0-9.9 (group 3) mIU/mL, according to the VITROS ECi anti-HBs assay. DESIGN. Subanalysis of randomized clinical trial. Response was defined as a postchallenge anti-HBs level of at least 10 mIU/mL and 4-fold rise in anti-HBs level 2 weeks after a single challenge dose of 10 vs 20 mu g Engerix-B. Baseline was defined as the anti-HBs level immediately before administration of the challenge dose. SETTING. Pediatric integrated healthcare system near Houston, Texas. PARTICIPANTS. Three hundred nineteen US-born 16-19-year-olds who completed the hepatitis B vaccine series during the first year of life. RESULTS. One hundred seventy-eight persons had zero (group 1) and 141 (114 group 2 and 27 group 3) had non-zero anti-HBs levels at baseline. Response to the challenge dose was significantly higher among those with non-zero vs zero anti-HBs levels, irrespective of challenge dosage; only 1 person with a non-zero anti-HBs level failed to respond to the challenge dose (group 3, 27/27 [100%] vs group 2, 113/114 [99%] vs group 1, 145/178 [82%]; P<.0001). CONCLUSIONS. Among participants with residual anti-HBs levels less than 10 mIU/mL 16-19 years after primary hepatitis B vaccination during infancy, non-zero anti-HBs levels, with rare exception, indicated persistence of immune memory to HBsAg. C1 [Spradling, Philip R.; Kamili, Saleem; Xing, Jian; Drobeniuc, Jan] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA 30333 USA. [Hu, Dale J.] Baylor Coll Med, Houston, TX 77030 USA. RP Spradling, PR (reprint author), Ctr Dis Control & Prevent, Div Viral Hepatitis, Mailstop G37,1600 Clifton Rd,NE, Atlanta, GA 30333 USA. EM pspradling@cdc.gov FU US Centers for Disease Control and Prevention FX US Centers for Disease Control and Prevention. NR 11 TC 3 Z9 4 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0899-823X EI 1559-6834 J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD MAY PY 2015 VL 36 IS 5 BP 529 EP 533 DI 10.1017/ice.2015.6 PG 5 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA CG1MP UT WOS:000353037100004 PM 25643863 ER PT J AU Kenyon, CR Kirungi, W Kaharuza, F Buyze, J Bunnell, R AF Kenyon, Chris Richard Kirungi, Wilford Kaharuza, Frank Buyze, Jozefien Bunnell, Rebecca TI Who Knows Their Partner's HIV Status? Results From a Nationally Representative Survey in Uganda SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE serodiscordance; couple testing; condom; sexual behavior; surveillance ID DISCORDANT COUPLES; SEXUAL-BEHAVIOR; PREVENTION INTERVENTIONS; ANTIRETROVIRAL THERAPY; POSITIVE PREVENTION; INFECTED ADULTS; RURAL UGANDA; AFRICA; RISK; SEROCONVERSION AB Objective: We examine the extent to which Ugandans accurately know their HIV status and that of their partners. Methods: The 2011 Uganda AIDS Indicator Survey (UAIS) was a nationally representative study of 15-59 year olds that tested 21,366 individuals for HIV. We compared self-reported HIV status with UAIS-determined HIV status for respondents. We were able to link 3285 couples in the survey, and in this group, we compared the reported HIV status of partners with that determined by UAIS. Multiple logistic regression analysis was used to identify factors associated with inaccurate knowledge of HIV status. Results: An estimated 55.8% of adult Ugandans reported having had an HIV test. Of 1495 HIV-infected Ugandans, 59.1% were unaware of their HIV infection. Among 3285 linked couples in this analysis, 273 couples (8.3%) had at least 1 infected partner, with 96 couples (2.9%) having both members infected and the remaining 177 couples (5.4%) being HIV discordant. This meant that 369 persons in the linked couple group had an HIV-infected partner. One hundred ten (29.8%) of this group knew that their partner was HIV infected. In multiple logistic regression analysis, accurately knowing that ones partner was HIV infected was strongly associated with couple HIV testing [adjusted odds ratio (AOR): 4.3, 95% confidence interval (CI): 2.2 to 8.4] and reporting oneself to be HIV positive versus reporting HIV negative (AOR: 7.3, 95% CI: 3.8 to 14.3) or HIV status unknown (AOR: 30.6, 95% CI: 3.8 to 263.4). Conclusions: Respondents may be reporting the HIV status of their partners based on their own HIV status. Campaigns to inform people about the prevalence of serodiscordance in conjunction with further promotion of couple counseling may help increase the proportion of Ugandans who know their own HIV status and that of their partners. C1 [Kenyon, Chris Richard] Inst Trop Med, Sexually Transmitted Infect, HIV STI Unit, B-2000 Antwerp, Belgium. [Kenyon, Chris Richard] Univ Cape Town, Div Infect Dis & HIV Med, Dept Med, ZA-7700 Cape Town, South Africa. [Kirungi, Wilford] Uganda Minist Hlth, AIDS Control Programme, Kampala, Uganda. [Kaharuza, Frank] Makerere Univ, Sch Publ Hlth, Kampala, Uganda. [Buyze, Jozefien] Inst Trop Med, Dept Clin Sci, B-2000 Antwerp, Belgium. [Bunnell, Rebecca] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. RP Kenyon, CR (reprint author), Univ Cape Town, Div Infect Dis & HIV Med, Anzio Rd, ZA-7700 Cape Town, South Africa. EM ckenyon@itg.be NR 20 TC 3 Z9 3 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD MAY 1 PY 2015 VL 69 IS 1 BP 92 EP 97 PG 6 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CG1LE UT WOS:000353033300020 PM 25622056 ER PT J AU Auld, AF Kamiru, H Azih, C Baughman, AL Nuwagaba-Biribonwoha, H Ehrenkranz, P Agolory, S Sahabo, R Ellerbrock, TV Okello, V Bicego, G AF Auld, Andrew F. Kamiru, Harrison Azih, Charles Baughman, Andrew L. Nuwagaba-Biribonwoha, Harriet Ehrenkranz, Peter Agolory, Simon Sahabo, Ruben Ellerbrock, Tedd V. Okello, Velephi Bicego, George TI Evaluation of Swaziland's Hub-and-Spoke Model for Decentralizing Access to Antiretroviral Therapy Services SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE antiretroviral therapy; down-referral; outcomes; Swaziland; decentralization ID SOUTH-AFRICA; FOLLOW-UP; SCALE-UP; SOCIOECONOMIC-STATUS; MULTIPLE IMPUTATION; INFECTED PATIENTS; HIV-1 INFECTION; MISSING VALUES; OUTCOMES; PROGRAMS AB Background: In 2007, Swaziland initiated a hub-and-spoke model for decentralizing antiretroviral therapy (ART) access. Decentralization was facilitated through (1) down-referral of stable ART patients from overburdened central facilities (hubs) to primary health care clinics (spokes) and (2) ART initiation at spokes (spoke initiation). Methods: We conducted a nationally representative retrospective cohort study among adult ART enrollees during 2004-2010 to assess the effect of down-referral and spoke-initiation on rates of loss to follow-up (LTFU), death, and attrition (death or LTFU). Sixteen of 31 hubs were randomly selected using probability-proportional-to-size sampling. Seven selected facilities had initiated the hub-and-spoke model by study start. At these facilities, 1149 of 24,782 hub-initiated and maintained and 878 of 7722 down-referred or spoke-initiated patient records were randomly selected and analyzed. At the 9 hub-only facilities, 483 of 6638 records were randomly selected and analyzed. Multivariable proportional hazards regression was used to assess effect of down-referral (a time-varying covariate) and spoke-initiation on outcomes. Results: At ART initiation, median age was 35, 65% were female, and median CD4 count was 147 cells per microliter. Controlling for known confounders, down-referral was strongly protective against LTFU [ adjusted hazard ratio (AHR) 0.38; 95% confidence interval (CI): 0.29 to 0.50] and attrition (AHR = 0.50; 95% CI: 0.34 to 0.76) but not mortality. Compared with hub-initiated and maintained patients, spoke-initiated patients had lower LTFU (AHR 0.59; 95% CI: 0.45 to 0.77) and attrition rates (AHR 0.60; 95% CI: 0.47 to 0.77), but not mortality. Conclusions: Down-referral and spoke-initiation within a hub-and-spoke ART decentralization model were protective against LTFU and overall attrition and could facilitate future ART program expansion. C1 [Auld, Andrew F.; Baughman, Andrew L.; Agolory, Simon; Ellerbrock, Tedd V.] Ctr Dis Control & Prevent, Div Global HIV AIDS, Ctr Global Hlth, Atlanta, GA USA. [Kamiru, Harrison; Nuwagaba-Biribonwoha, Harriet; Sahabo, Ruben] Columbia Univ, Mailman Sch Publ Hlth, ICAP, New York, NY USA. [Azih, Charles; Okello, Velephi] Govt Kingdom Swaziland, Minist Hlth, Mbabane, Swaziland. [Ehrenkranz, Peter; Bicego, George] Ctr Dis Control & Prevent, Div Global HIV AIDS, Ctr Global Hlth, Mbabane, Swaziland. RP Auld, AF (reprint author), US Ctr Dis Control & Prevent CDC, 1600 Clifton Rd,Mailstop E04, Atlanta, GA 30333 USA. EM aauld@cdc.gov FU President's Emergency Plan for AIDS Relief (PEPFAR) through US Centers for Disease Control and Prevention FX Supported by the President's Emergency Plan for AIDS Relief (PEPFAR) through the US Centers for Disease Control and Prevention. NR 54 TC 4 Z9 4 U1 2 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD MAY 1 PY 2015 VL 69 IS 1 BP E1 EP E12 PG 12 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CG1LE UT WOS:000353033300001 PM 25942465 ER PT J AU Reed, JB Grund, J Liu, Y Mwandi, Z Howard, AA McNairy, ML Chesang, K Cherutich, P Bock, N AF Reed, Jason Bailey Grund, Jonathan Liu, Yang Mwandi, Zebedee Howard, Andrea A. McNairy, Margaret L. Chesang, Kipruto Cherutich, Peter Bock, Naomi TI Evaluation of Loss-to-Follow-up and Postoperative Adverse Events in a Voluntary Medical Male Circumcision Program in Nyanza Province, Kenya SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE male circumcision; follow-up; adverse events ID HIV PREVENTION; MEN; UGANDA; SAFETY; TRIAL; RAKAI AB Background: More than 4.7 million voluntary medical male circumcisions (VMMCs) had been provided by HIV prevention programs in sub-Saharan Africa through 2013. All VMMC clients are recommended to return to the clinic for postoperative follow-up, although adherence is variable. The clinical status of clients who do not return is largely unknown. Methods: VMMC clients from Nyanza Province, Kenya, aged older than or equal to 13 years, were recruited immediately after surgery from April to October 2012 from high-volume sites. Medical record reviews at 13-14 days after surgery indicated which clients had been adherent with recommended follow-up (ADFU) and which were lost-to-follow-up (LTFU). Clients in the LTFU group received clinical evaluations at home approximately 2 weeks postsurgery. Adverse events (AEs) and AE rates were compared between the ADFU and LTFU groups. Results: Of 4504 males approached in 50 VMMC sites, 1699 (37.7%) were eligible and enrolled and 1600 of 1699 (94.2%) contributed to follow-up and AE data. Medical record review indicated 897 of 1600 (56.1%) were LTFU, and 762 (84.9%) of these received home-based clinical evaluations. The rate of moderate or severe AE diagnosis was 6.8% in the LTFU group vs. 3.3% in the ADFU group (relative risk = 2.1, 95% confidence interval: 1.3 to 3.4). Conclusions: The moderate or severe AE diagnosis rate was approximately 2 times higher in the LTFU group. National programs should consider instituting surveillance systems to detect AEs that might otherwise go unnoticed. Providers should emphasize the importance of follow-up and actively contact LTFU clients to ensure care is provided throughout the entire postoperative course for all. C1 [Reed, Jason Bailey; Grund, Jonathan; Liu, Yang; Bock, Naomi] US Ctr Dis Control & Prevent, Div Global HIV AIDS, Ctr Global Hlth, Atlanta, GA USA. [Mwandi, Zebedee; Chesang, Kipruto] US Ctr Dis Control & Prevent, Div Global HIV AIDS, Ctr Global Hlth, Nairobi, Kenya. [Howard, Andrea A.; McNairy, Margaret L.] Columbia Univ, ICAP, New York, NY USA. [Cherutich, Peter] Minist Hlth, Natl AIDS & Sexually Transmitted Infect Control P, Nairobi, Kenya. RP Reed, JB (reprint author), US Dept State, S GAC, SA-22 Room 10300,2201 C St NW, Washington, DC 20522 USA. EM reedjb@state.gov FU US President's Emergency Plan for AIDS Relief (PEPFAR) through a cooperative agreement from the US Centers for Disease Control and Prevention (CDC), Division of Global HIV/AIDS (DGHA) FX Supported by the US President's Emergency Plan for AIDS Relief (PEPFAR) through a cooperative agreement from the US Centers for Disease Control and Prevention (CDC), Division of Global HIV/AIDS (DGHA). NR 16 TC 2 Z9 2 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD MAY 1 PY 2015 VL 69 IS 1 BP E13 EP E23 PG 11 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CG1LE UT WOS:000353033300002 PM 25942466 ER PT J AU Pabst, LJ Williams, W AF Pabst, Laura J. Williams, Warren TI Immunization Information Systems SO JOURNAL OF PUBLIC HEALTH MANAGEMENT AND PRACTICE LA English DT Editorial Material C1 [Pabst, Laura J.; Williams, Warren] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30329 USA. RP Pabst, LJ (reprint author), Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd NE,MS A-19, Atlanta, GA 30329 USA. EM lnw9@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1078-4659 EI 1550-5022 J9 J PUBLIC HEALTH MAN JI J. Public Health Manag. Pract. PD MAY-JUN PY 2015 VL 21 IS 3 BP 225 EP 226 DI 10.1097/PHH.0000000000000202 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CF1KL UT WOS:000352303900005 PM 25806848 ER PT J AU Groom, H Hopkins, DP Pabst, LJ Morgan, JM Patel, M Calonge, N Coyle, R Dombkowski, K Groom, AV Kurilo, MB Rasulnia, B Shefer, A Town, C Wortley, PM Zucker, J AF Groom, Holly Hopkins, David P. Pabst, Laura J. Morgan, Jennifer Murphy Patel, Mona Calonge, Ned Coyle, Rebecca Dombkowski, Kevin Groom, Amy V. Kurilo, Mary Beth Rasulnia, Bobby Shefer, Abigail Town, Cecile Wortley, Pascale M. Zucker, Jane CA Community Preventive Serv Task TI Immunization Information Systems to Increase Vaccination Rates: A Community Guide Systematic Review SO JOURNAL OF PUBLIC HEALTH MANAGEMENT AND PRACTICE LA English DT Review DE immunization registry; immunization information systems; systematic review; vaccination ID PNEUMOCOCCAL CONJUGATE VACCINE; PEDIATRIC EMERGENCY-DEPARTMENT; PENTAVALENT ROTAVIRUS VACCINE; REGISTRY-BASED RECALL; HIGH-RISK CONDITIONS; 6 MONTHS-18 YEARS; AGED 6-59 MONTHS; WELL-CHILD CARE; NEW-YORK-CITY; UNITED-STATES AB Context: Immunizations are the most effective way to reduce incidence of vaccine-preventable diseases. Immunization information systems (IISs) are confidential, population-based, computerized databases that record all vaccination doses administered by participating providers to people residing within a given geopolitical area. They facilitate consolidation of vaccination histories for use by health care providers in determining appropriate client vaccinations. Immunization information systems also provide aggregate data on immunizations for use in monitoring coverage and program operations and to guide public health action. Evidence Acquisition: Methods for conducting systematic reviews for the Guide to Community Preventive Services were used to assess the effectiveness of IISs. Reviewed evidence examined changes in vaccination rates in client populations or described expanded IIS capabilities related to improving vaccinations. The literature search identified 108 published articles and 132 conference abstracts describing or evaluating the use of IISs in different assessment categories. Evidence Synthesis: Studies described or evaluated IIS capabilities to (1) create or support effective interventions to increase vaccination rates, such as client reminder and recall, provider assessment and feedback, and provider reminders; (2) determine client vaccination status to inform decisions by clinicians, health care systems, and schools; (3) guide public health responses to outbreaks of vaccine-preventable disease; (4) inform assessments of vaccination coverage, missed vaccination opportunities, invalid dose administration, and disparities; and (5) facilitate vaccine management and accountability. Conclusions: Findings from 240 articles and abstracts demonstrate IIS capabilities and actions in increasing vaccination rates with the goal of reducing vaccine-preventable disease. C1 [Hopkins, David P.; Morgan, Jennifer Murphy; Patel, Mona] Ctr Dis Control & Prevent, Community Guide Branch, Div Epidemiol Anal & Lib Serv, Atlanta, GA USA. [Groom, Holly; Pabst, Laura J.; Shefer, Abigail; Town, Cecile; Zucker, Jane] Ctr Dis Control & Prevent, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Rasulnia, Bobby] Ctr Dis Control & Prevent, Off State Tribal Local & Terr Support, Atlanta, GA USA. [Wortley, Pascale M.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [Calonge, Ned] Colorado Trust, Denver, CO USA. [Coyle, Rebecca] Amer Immunizat Registry Assoc, Washington, DC USA. [Dombkowski, Kevin] Univ Michigan, Child Hlth Evaluat & Res CHEAR Unit, Ann Arbor, MI 48109 USA. [Kurilo, Mary Beth] Oregon Immunizat Program, Portland, OR USA. RP Groom, H (reprint author), Kaiser Permanente Northwest, Ctr Hlth Res, 3800 N Interstate Ave, Portland, OR 97227 USA. EM Holly.c.groom@kpchr.org OI Groom, Holly/0000-0003-2866-9788 NR 250 TC 17 Z9 17 U1 2 U2 16 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1078-4659 EI 1550-5022 J9 J PUBLIC HEALTH MAN JI J. Public Health Manag. Pract. PD MAY-JUN PY 2015 VL 21 IS 3 BP 227 EP 248 DI 10.1097/PHH.0000000000000069 PG 22 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CF1KL UT WOS:000352303900006 PM 24912082 ER PT J AU Hopkins, DP AF Hopkins, David P. CA Community Preventive Serv Task TI Recommendation for Use of Immunization Information Systems to Increase Vaccination Rates SO JOURNAL OF PUBLIC HEALTH MANAGEMENT AND PRACTICE LA English DT Article DE immunization information systems; immunization registries; vaccination coverage AB Based on findings of a systematic review, the Community Preventive Services Task Force recommends immunization information systems on the basis of strong evidence of effectiveness in increasing vaccination rates. Evidence is considered strong, based on the findings from 108 published articles and 132 conference abstracts showing that immunization information systems are effective in increasing vaccination rates and reducing vaccine-preventable disease through their capabilities to (1) create or support effective interventions such as client reminder and recall systems, provider assessment and feedback, and provider reminders; (2) generate and evaluate public health responses to outbreaks of vaccine-preventable disease; (3) facilitate vaccine management and accountability; (4) determine client vaccination status for decisions made by clinicians, health departments, and schools; and (5) aid surveillance and investigations on vaccination rates, missed vaccination opportunities, invalid dose administration, and disparities in vaccination coverage. C1 Ctr Dis Control & Prevent, Community Guide Branch, Div Epidemiol Anal & Lib Serv, Atlanta, GA 30329 USA. RP Hopkins, DP (reprint author), Ctr Dis Control & Prevent, Community Guide Branch, Div Epidemiol Anal & Lib Serv, 1600 Clifton Rd,MS E-69, Atlanta, GA 30329 USA. EM dhh4@cdc.gov NR 5 TC 5 Z9 5 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1078-4659 EI 1550-5022 J9 J PUBLIC HEALTH MAN JI J. Public Health Manag. Pract. PD MAY-JUN PY 2015 VL 21 IS 3 BP 249 EP 252 DI 10.1097/PHH.0000000000000092 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CF1KL UT WOS:000352303900007 ER PT J AU Patel, M Pabst, L Chattopadhyay, S Hopkins, D Groom, H Myerburg, S Morgan, JM AF Patel, Mona Pabst, Laura Chattopadhyay, Sajal Hopkins, David Groom, Holly Myerburg, Stuart Morgan, Jennifer Murphy CA Community Preventive Serv Task TI Economic Review of Immunization Information Systems to Increase Vaccination Rates: A Community Guide Systematic Review SO JOURNAL OF PUBLIC HEALTH MANAGEMENT AND PRACTICE LA English DT Review DE benefit; Community Guide; Community Preventive Services Task Force; cost; cost-effectiveness; economics; immunization; immunization information system; systematic review ID UNITED-STATES; REGISTRIES; COSTS; CHILDREN; INTERVENTIONS; SAVINGS AB Context: A recent systematic review found that use of an immunization information system (IIS) is an effective intervention to increase vaccination rates. The purpose of this review was to evaluate costs and benefits associated with implementing, operating, and participating with an IIS. The speed of technology change has had an effect on costs and benefits of IIS and is considered in this review. Evidence Acquisition: An economic evaluation for IIS was conducted using methods developed for Community Guide systematic reviews. The literature search covered the period from January 1994 to March 2012 and identified 12 published articles and 2 government reports. Evidence Synthesis: Most studies involving cost data evaluated (1) system costs of building an IIS and (2) cost of exchanging immunization data; most economic benefits focused on administrative efficiency. Conclusions: A major challenge to evaluating a technology-based intervention is the evolution that comes with technology improvements and advancements. Although the cost and benefit data may be less applicable today due to changes in system technology, data exchange methods, availability of vendor support, system functionalities, and scope of IIS, it is likely that more up-to-date estimates and comprehensive estimates of benefits would support the findings of cost savings in this review. More research is needed to update and address limitations in the available evidence and to enable assessment of economic costs and benefits of present-day IIS. C1 [Patel, Mona; Chattopadhyay, Sajal; Hopkins, David; Morgan, Jennifer Murphy] Ctr Dis Control & Prevent, Community Guide Branch, Div Epidemiol Anal & Lib Serv, Atlanta, GA 30329 USA. [Pabst, Laura; Myerburg, Stuart] Ctr Dis Control & Prevent, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30329 USA. [Groom, Holly] Kaiser Permanente, Ctr Hlth Res, Portland, OR USA. RP Patel, M (reprint author), Ctr Dis Control & Prevent, Community Guide Branch, Div Epidemiol Anal & Lib Serv, 1600 Clifton Rd,MS E-69, Atlanta, GA 30329 USA. EM iwi2@cdc.gov OI Groom, Holly/0000-0003-2866-9788 NR 29 TC 2 Z9 2 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1078-4659 EI 1550-5022 J9 J PUBLIC HEALTH MAN JI J. Public Health Manag. Pract. PD MAY-JUN PY 2015 VL 21 IS 3 BP 253 EP 262 DI 10.1097/PHH.0000000000000100 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CF1KL UT WOS:000352303900008 PM 24912081 ER PT J AU Martin, DW Lowery, NE Brand, B Gold, R Horlick, G AF Martin, Daniel W. Lowery, N. Elaine Brand, Bill Gold, Rebecca Horlick, Gail TI Immunization Information Systems: A Decade of Progress in Law and Policy SO JOURNAL OF PUBLIC HEALTH MANAGEMENT AND PRACTICE LA English DT Article DE electronic data interchange; health information exchange; immunization information system; informatics ID CHILDHOOD IMMUNIZATION; REGISTRIES; RECORD AB This article reports on a study of laws, regulations, and policies governing Immunization Information Systems (IIS, also known as "immunization registries") in states and selected urban areas of the United States. The study included a search of relevant statutes, administrative codes and published attorney general opinions/findings, an online questionnaire completed by immunization program managers and/or their staff, and follow-up telephone interviews. The legal/regulatory framework for IIS has changed considerably since 2000, largely in ways that improve IIS' ability to perform their public health functions while continuing to maintain strict confidentiality and privacy controls. Nevertheless, the exchange of immunization data and other health information between care providers and public health and between entities in different jurisdictions remains difficult due in part to ongoing regulatory diversity. To continue to be leaders in health information exchange and facilitate immunization of children and adults, IIS will need to address the challenges presented by the interplay of federal and state legislation, regulations, and policies and continue to move toward standardized data collection and sharing necessary for interoperable systems. C1 [Martin, Daniel W.] Ctr Dis Control & Prevent, Immunizat Informat Syst Support Branch, Immunizat Serv Div, NCIRD, Atlanta, GA 30333 USA. [Lowery, N. Elaine; Brand, Bill] Publ Hlth Informat Inst, Decatur, GA USA. [Gold, Rebecca] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Horlick, Gail] Ctr Dis Control & Prevent, Off Associate Director Sci, Atlanta, GA 30333 USA. RP Martin, DW (reprint author), Ctr Dis Control & Prevent, Immunizat Informat Syst Support Branch, Immunizat Serv Div, NCIRD, 1600 Clifton Rd,Mailstop A-19, Atlanta, GA 30333 USA. EM dwm5@cdc.gov FU Centers for Disease Control and Prevention [HM08-080502CONT12] FX Data gathering and analysis were conducted by the Public Health Informatics Institute, Decatur, Georgia, under cooperative agreement no. HM08-080502CONT12 from the Centers for Disease Control and Prevention. NR 20 TC 17 Z9 17 U1 1 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1078-4659 EI 1550-5022 J9 J PUBLIC HEALTH MAN JI J. Public Health Manag. Pract. PD MAY-JUN PY 2015 VL 21 IS 3 BP 296 EP 303 DI 10.1097/PHH.0000000000000040 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CF1KL UT WOS:000352303900014 PM 24402434 ER PT J AU Kim, H Lindley, MC Dube, D Kalayil, EJ Paiva, KA Raymond, P AF Kim, Hanna Lindley, Megan C. Dube, Donna Kalayil, Elizabeth J. Paiva, Kristi A. Raymond, Patricia TI Evaluation of the Impact of the 2012 Rhode Island Health Care Worker Influenza Vaccination Regulations: Implementation Process and Vaccination Coverage SO JOURNAL OF PUBLIC HEALTH MANAGEMENT AND PRACTICE LA English DT Article DE evaluation; health care worker (HCW); regulations; influenza vaccination ID RANDOMIZED CONTROLLED-TRIAL; LONG-TERM-CARE; UNITED-STATES; INSTITUTIONAL REQUIREMENTS; HOME STAFF; PERSONNEL; MORTALITY; HOSPITALS; IMMUNIZATION; CALIFORNIA AB Context: In October 2012, the Rhode Island Department of Health (HEALTH) amended its health care worker (HCW) vaccination regulations to require all HCWs to receive annual influenza vaccination or wear a surgical mask during direct patient contact when influenza is widespread. Unvaccinated HCWs failing to wear a mask are subject to a fine and disciplinary action. Objective: To describe the implementation of the 2012 Rhode Island HCW influenza vaccination regulations and examine their impact on vaccination coverage. Design: Two data sources were used: (1) a survey of all health care facilities subject to the HCW regulations and (2) HCW influenza vaccination coverage data reported to HEALTH by health care facilities. Descriptive statistics and paired t tests were performed using SAS Release 9.2. Setting and participants: For the 2012-2013 influenza season, 271 inpatient and outpatient health care facilities in Rhode Island were subject to the HCW regulations. Main Outcome Measure: Increase in HCW influenza vaccination coverage. Results: Of the 271 facilities, 117 facilities completed the survey (43.2%) and 160 facilities reported vaccination data to HEALTH (59.0%). Between the 2011-2012 and 2012-2013 influenza seasons, the proportion of facilities having a masking policy, as required by the revised regulations, increased from 9.4% to 94.0% (P < .001). However, the proportion of facilities implementing Advisory Committee on Immunization Practices-recommended strategies to promote HCW influenza vaccination did not increase. The majority of facilities perceived benefits to collecting HCW influenza vaccination data, including strengthening infection prevention efforts (83.2%) and improving patient and coworker safety (75.2%). Concurrent with the new regulations, influenza vaccination coverage among employee HCWs in Rhode Island increased from 69.7% in the 2011-2012 influenza season to 87.2% in the 2012-2013 season. Conclusion: Rhode Island's experience demonstrates that statewide HCW influenza vaccination requirements incorporating mask wearing and moderate penalties for noncompliance can be effective in improving influenza vaccination coverage among HCWs. C1 [Kim, Hanna; Paiva, Kristi A.; Raymond, Patricia] Rhode Isl Dept Hlth, Div Commun Family Hlth & Equ, Providence, RI 02908 USA. [Kim, Hanna] Brown Univ, Sch Publ Hlth, Dept Epidemiol, Providence, RI 02912 USA. [Lindley, Megan C.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Kalayil, Elizabeth J.] Carter Consulting Inc, Atlanta, GA USA. RP Kim, H (reprint author), Rhode Isl Dept Hlth, Div Commun Family Hlth & Equ, 3 Capitol Hill, Providence, RI 02908 USA. EM hanna.kim@health.ri.gov FU Intramural CDC HHS [CC999999] NR 35 TC 0 Z9 0 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1078-4659 EI 1550-5022 J9 J PUBLIC HEALTH MAN JI J. Public Health Manag. Pract. PD MAY-JUN PY 2015 VL 21 IS 3 BP E1 EP E9 DI 10.1097/PHH.0000000000000128 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CF1KL UT WOS:000352303900001 PM 25105280 ER PT J AU Vora, NM Clippard, JR Stobierski, MG Signs, K Blanton, JD AF Vora, Neil M. Clippard, Jessie R. Stobierski, Mary Grace Signs, Kimberly Blanton, Jesse D. TI Animal Bite and Rabies Postexposure Prophylaxis Reporting-United States, 2013 SO JOURNAL OF PUBLIC HEALTH MANAGEMENT AND PRACTICE LA English DT Article DE bites; rabies; rabies vaccine ID EPIDEMIOLOGY; SURVEILLANCE AB Context: Rabies virus causes a fatal encephalitis and is typically acquired through the bite of an infected mammal. Rabies is preventable through administration of rabies postexposure prophylaxis (PEP), but this must be balanced with the need to avoid unnecessary PEP use. Though not nationally notifiable, some state health departments (SHDs) have made animal bites and use of PEP reportable within their jurisdictions. Objective: We evaluated whether animal bites and PEP were reportable to SHDs as of 2013 for every state in the United States. Design: The list of reportable conditions for each SHD as of 2013 was reviewed on the Internet for every state in the United States to determine whether animal bites or PEP were reportable. We then contacted an SHD representative (typically the State Public Health Veterinarian) to confirm data generated through Internet searches. Health departments in states where PEP was reportable were asked to complete a follow-up survey. Results: Animal bites and PEP both were reportable in 9 states (18%). Another 9 states (18%) mandated animal bite reporting but not PEP reporting, while 12 states (24%) mandated PEP reporting but not animal bite reporting. These events were not reportable in 20 states (40%). The benefits reported by personnel from SHDs with PEP reporting systems varied greatly. Conclusions: Additional investigations focusing on the value of information returned by PEP reporting and identifying best practices for implementation and management are needed. The lack of standardization between current animal bite and PEP reporting systems limits completeness of reporting and comparability of outcomes. National recommendations to standardize case definitions and other data elements might help jurisdictions developing new animal bite or PEP reporting systems. C1 [Vora, Neil M.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Vora, Neil M.; Blanton, Jesse D.] Ctr Dis Control & Prevent, Poxvirus & Rabies Branch, Atlanta, GA 30333 USA. [Clippard, Jessie R.; Stobierski, Mary Grace; Signs, Kimberly] Michigan Dept Community Hlth, Lansing, MI USA. RP Vora, NM (reprint author), Ctr Dis Control & Prevent, Epidem Intelligence Serv, 1600 Clifton Rd NE,Mailstop D68, Atlanta, GA 30333 USA. EM nvora@cdc.gov NR 13 TC 0 Z9 0 U1 0 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1078-4659 EI 1550-5022 J9 J PUBLIC HEALTH MAN JI J. Public Health Manag. Pract. PD MAY-JUN PY 2015 VL 21 IS 3 BP E24 EP E27 DI 10.1097/PHH.0000000000000125 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CF1KL UT WOS:000352303900004 PM 25084537 ER PT J AU Blanchet, S Bouchez, O Chapman, CA Etter, PD Goldberg, TL Johnson, EA Jones, JH Loot, G Omeja, PA Rey, O Ruiz-Lopez, MJ Switzer, WM Ting, N AF Blanchet, Simon Bouchez, Olivier Chapman, Colin A. Etter, Paul D. Goldberg, Tony L. Johnson, Eric A. Jones, James H. Loot, Geraldine Omeja, Patrick A. Rey, Olivier Ruiz-Lopez, Maria Jose Switzer, William M. Ting, Nelson CA Genomic Resources Dev Consortium TI Genomic Resources Notes Accepted 1 December 2014-31 January 2015 SO MOLECULAR ECOLOGY RESOURCES LA English DT Editorial Material AB This article documents the public availability of (i) transcriptome sequence data and assembly for the rostrum dace (Leuciscus burdigalensis) naturally infected by a copepod ectoparasite (Tracheliastes polycolpus) and (ii) SNPs identified and validated from RAD sequencing for the Ugandan red colobus (Procolobus rufomitratus tephrosceles) using RAD sequencing. C1 [Blanchet, Simon] Mol Ecol Resources Editorial Off, Vancouver, BC V6T 1Z4, Canada. [Blanchet, Simon; Loot, Geraldine; Rey, Olivier] CNRS, Stn Ecol Experimentale, USR 2936, F-09200 Moulis, France. [Blanchet, Simon; Loot, Geraldine] Univ Toulouse, UPS, UMR15174, EDB, F-31062 Toulouse 9, France. [Bouchez, Olivier] INRA, GeT PlaGe, Genotoul, F-31326 Castanet Tolosan, France. [Bouchez, Olivier] INRA, UMR1388 Genet, Physiol & Syst Elevage, F-31326 Castanet Tolosan, France. [Chapman, Colin A.] McGill Univ, Dept Anthropol, Montreal, PQ H3A 2T7, Canada. [Chapman, Colin A.] McGill Univ, McGill Sch Environm, Montreal, PQ H3A 2T7, Canada. [Chapman, Colin A.] Wildlife Conservat Soc, Bronx, NY 10460 USA. [Etter, Paul D.; Johnson, Eric A.] Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA. [Goldberg, Tony L.] Univ Wisconsin, Sch Vet Med, Madison, WI 53706 USA. [Jones, James H.] Stanford Univ, Dept Anthropol, Stanford, CA 94305 USA. [Omeja, Patrick A.] Makerere Univ, Biol Field Stn, Ft Portal, Uganda. [Ruiz-Lopez, Maria Jose; Ting, Nelson] Univ Oregon, Inst Ecol & Evolut, Eugene, OR 97403 USA. [Switzer, William M.] Ctr Dis Control & Prevent, Branch Lab, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30329 USA. [Ting, Nelson] Univ Oregon, Dept Anthropol, Eugene, OR 97403 USA. RP Blanchet, S (reprint author), Mol Ecol Resources Editorial Off, 6270 Univ Blvd, Vancouver, BC V6T 1Z4, Canada. EM editorial.office@molecol.com RI Blanchet, Simon/D-4850-2013; OI Blanchet, Simon/0000-0002-3843-589X; Jones, James/0000-0003-1680-6757 NR 0 TC 1 Z9 1 U1 0 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1755-098X EI 1755-0998 J9 MOL ECOL RESOUR JI Mol. Ecol. Resour. PD MAY PY 2015 VL 15 IS 3 BP 684 EP 684 DI 10.1111/1755-0998.12388 PG 1 WC Biochemistry & Molecular Biology; Ecology; Evolutionary Biology SC Biochemistry & Molecular Biology; Environmental Sciences & Ecology; Evolutionary Biology GA CF6FY UT WOS:000352653700020 ER PT J AU Gallagher, LG Park, RM Checkoway, H AF Gallagher, Lisa G. Park, Robert M. Checkoway, Harvey TI Extended follow-up of lung cancer and non-malignant respiratory disease mortality among California diatomaceous earth workers SO OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article ID GERMAN URANIUM MINERS; SILICA EXPOSURE; CRYSTALLINE SILICA; INDUSTRY WORKERS; RISK-ASSESSMENT; COHORT; DUST; EPIDEMIOLOGY AB Objectives Millions of workers worldwide are employed in occupations involving potentiality hazardous exposure to crystalline silica. The diatomaceous earth industry can have particularly high exposures, but there is a lower likelihood of simultaneously occurring confounding exposures. We extended follow-up for diatomaceous earth industry workers previously studied for mortality. Methods The cohort included 2342 white men who were employed for at least 1 year at a diatomaceous earth plant in Lompoc, California beginning in 1942. Workers' vital status was updated using the National Death Index through 2011, an extension of 19 years from earlier studies. Detailed work history and quantitative air monitoring measurements estimated exposure intensity. Cox proportional hazards modelling estimated HRs and 95% CIs. SMRs were calculated. Results Elevated mortality was observed by quartile of cumulative crystalline silica exposure for lung cancer (HR=2.03, 95% CI 1.07 to 3.85, highest quartile, unlagged) and non-malignant respiratory disease (NMRD) (HR=3.59, 95% CI 1.94 to 6.67, highest quartile, unlagged), although trends were not statistically significant. Associations were attenuated when adjusted for smoking and asbestos exposure. Mortality from NMRD was significantly increased over the entire followup compared to the general population (SMR=1.37, 95% CI 1.17 to 1.60). An increase for lung cancer was confined to the earlier follow-up (SMR=1.29, 95% CI 1.01 to 1.61). Conclusions The risk of lung cancer and NMRD mortality remained elevated, although generally nonsignificant, and exposure-response trends with cumulative crystalline silica persisted on extended followup of this cohort. The findings support a generally consistently observed aetiological relation between crystalline silica and lung cancer. C1 [Gallagher, Lisa G.] Univ Washington, Dept Environm & Occupat Hlth Sci, Seattle, WA 98195 USA. [Park, Robert M.] NIOSH, US Dept HHS, Publ Hlth Serv, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. [Checkoway, Harvey] Univ Calif San Diego, Dept Family & Prevent Med, San Diego, CA 92103 USA. RP Gallagher, LG (reprint author), Univ Washington, Dept Environm & Occupat Hlth Sci, Box 357234, Seattle, WA 98195 USA. EM lgallag@u.washington.edu FU National Institute for Occupational Safety and Health [R01 OH03126] FX Initial study supported by grant R01 OH03126 from the National Institute for Occupational Safety and Health. Mortality update supported by interagency agreement between NIOSH Division of Surveillance, Hazard Evaluations and Field Studies and the National Death Index. NR 27 TC 4 Z9 4 U1 0 U2 5 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1351-0711 EI 1470-7926 J9 OCCUP ENVIRON MED JI Occup. Environ. Med. PD MAY PY 2015 VL 72 IS 5 BP 360 EP 365 DI 10.1136/oemed-2014-102412 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CG0UV UT WOS:000352987900008 PM 25759179 ER PT J AU Liu, F Veguilla, V Gross, F Levin, M Xu, XY Tumpey, T Katz, J Lu, XH AF Liu, Feng Veguilla, Vic Gross, Felicia Levin, Min Xu, Xiyan Tumpey, Terrence Katz, Jacqueline Lu, Xiuhua TI Age-related prevalence of serum hemagglutination-inhibition antibodies cross-reactive to 2012 and 2013 newly emerging swine-origin influenza A(H3N2) variant viruses SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-of-Immunologists (IMMUNOLOGY) CY MAY 08-12, 2015 CL New Orleans, LA SP Amer Assoc Immunologists C1 [Liu, Feng; Veguilla, Vic; Gross, Felicia; Levin, Min; Xu, Xiyan; Tumpey, Terrence; Katz, Jacqueline; Lu, Xiuhua] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD MAY 1 PY 2015 VL 194 SU 1 MA VIR5P.1134 PG 1 WC Immunology SC Immunology GA DQ7RG UT WOS:000379404504024 ER PT J AU Reber, A Music, N York, I AF Reber, Adrian Music, Nedzad York, Ian TI Extensive cell-mediated cross-reactivity between diverse influenza strains in the ferret model SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-of-Immunologists (IMMUNOLOGY) CY MAY 08-12, 2015 CL New Orleans, LA SP Amer Assoc Immunologists C1 [Reber, Adrian; Music, Nedzad; York, Ian] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD MAY 1 PY 2015 VL 194 SU 1 MA VIR5P.1143 PG 1 WC Immunology SC Immunology GA DQ7RG UT WOS:000379404504007 ER PT J AU Simons, B Spradling, P Zanis, C Choromanski, T Case, S Bruce, M Bruden, D Murphy, T Knall, C McMahon, B AF Simons, Brenna Spradling, Philip Zanis, Carolyn Choromanski, Tammy Case, Samantha Bruce, Michael Bruden, Dana Murphy, Trudy Knall, Cindy McMahon, Brian TI Preliminary assessment of hepatitis B-specific cellular immunity amongst a longitudinal vaccine cohort demonstrates evidence of natural exposure SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-of-Immunologists (IMMUNOLOGY) CY MAY 08-12, 2015 CL New Orleans, LA SP Amer Assoc Immunologists C1 [Simons, Brenna; Choromanski, Tammy; McMahon, Brian] Alaska Native Tribal Hlth Consortium, Liver Dis & Hepatitis Program, Anchorage, AK USA. [Simons, Brenna; Knall, Cindy] Univ Alaska Anchorage, WWAMI Sch Med Educ, Anchorage, AK USA. [Spradling, Philip; Murphy, Trudy] Ctr Dis Control & Prevent, Div Viral Hepatitis, NCHHSTP, Atlanta, GA USA. [Zanis, Carolyn; Case, Samantha; Bruce, Michael; Bruden, Dana; McMahon, Brian] Ctr Dis Control & Prevent, Arctic Invest Program, NCEZID, Anchorage, AK USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD MAY 1 PY 2015 VL 194 SU 1 PG 2 WC Immunology SC Immunology GA DQ7RG UT WOS:000379404500208 ER PT J AU Stevens, M McKeithen, D Martinez, O Igietseme, J Eko, F Black, C He, Q Ananaba, G AF Stevens, Mumbi McKeithen, D. Martinez, O. Igietseme, J. Eko, Francis Black, C. He, Q. Ananaba, G. TI Vibrio cholerae ghosts elicit the production of soluble immunostimulatory factors and prevent development of Chlamydia infection SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-of-Immunologists (IMMUNOLOGY) CY MAY 08-12, 2015 CL New Orleans, LA SP Amer Assoc Immunologists C1 [Stevens, Mumbi; McKeithen, D.; Martinez, O.; Ananaba, G.] Clark Atlanta Univ, Biol Sci, Atlanta, GA 30314 USA. [McKeithen, D.; Eko, Francis; He, Q.] Morehouse Sch Med, Microbiol Biochem & Immunol, Atlanta, GA 30310 USA. [Igietseme, J.; Black, C.] Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD MAY 1 PY 2015 VL 194 SU 1 MA INM3P.408 PG 1 WC Immunology SC Immunology GA DQ7RG UT WOS:000379404503213 ER PT J AU Swaims, A Haaland, R Evans-Strickfaden, T Haadad, L Sheth, A Lupo, L Cordes, S Aguirre, A Lupoli, K Chen, CY Ofotokun, I Kohlmeier, J Hart, C AF Swaims, Alison Haaland, Richard Evans-Strickfaden, Tammy Haadad, Lisa Sheth, Anadi Lupo, L. Cordes, Sarah Aguirre, Alfredo Lupoli, Kathryn Chen, Cheng-Yen Ofotokun, Igho Kohlmeier, Jacob Hart, Clyde TI Recirculating HIV-target T lymphocytes at the mucosal surface of the female genital tract are associated with progesterone increases during the menstrual cycle SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-of-Immunologists (IMMUNOLOGY) CY MAY 08-12, 2015 CL New Orleans, LA SP Amer Assoc Immunologists C1 [Swaims, Alison; Haaland, Richard; Evans-Strickfaden, Tammy; Lupo, L.; Lupoli, Kathryn; Chen, Cheng-Yen; Hart, Clyde] Ctr Dis Control & Prevent, Atlanta, GA USA. [Haadad, Lisa; Sheth, Anadi; Cordes, Sarah; Aguirre, Alfredo; Ofotokun, Igho; Kohlmeier, Jacob] Emory Univ, Sch Med, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD MAY 1 PY 2015 VL 194 SU 1 MA MUC2P.938 PG 1 WC Immunology SC Immunology GA DQ7RG UT WOS:000379404504045 ER PT J AU Tripp, R van der Sanden, SMG Wu, W Dybdahl-Sissoko, N Weldon, W Brooks, P O'donnell, J Jones, L Brown, C Tompkins, S Oberste, M Karpilow, J AF Tripp, Ralph van der Sanden, S. M. G. Wu, W. Dybdahl-Sissoko, N. Weldon, William Brooks, P. O'donnell, J. Jones, L. Brown, C. Tompkins, Stephen Oberste, M. Karpilow, J. TI Engineering enhanced vaccine cell lines to eradicate vaccine preventable diseases: the polio endgame SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-of-Immunologists (IMMUNOLOGY) CY MAY 08-12, 2015 CL New Orleans, LA SP Amer Assoc Immunologists C1 [Tripp, Ralph; Wu, W.; Brooks, P.; O'donnell, J.; Jones, L.; Tompkins, Stephen] Univ Georgia, Coll Vet Med, Athens, GA USA. [van der Sanden, S. M. G.; Wu, W.; Dybdahl-Sissoko, N.; Brown, C.; Oberste, M.] Ctr Dis Control, Atlanta, GA USA. [Karpilow, J.] Proventus Bio, Athens, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD MAY 1 PY 2015 VL 194 SU 1 MA VAC9P.1107 PG 1 WC Immunology SC Immunology GA DQ7RG UT WOS:000379404503200 ER PT J AU Dye, BA Hsu, KLC Afful, J AF Dye, Bruce A. Hsu, Kuei-Ling C. Afful, Joseph TI Prevalence and Measurement of Dental Caries in Young Children SO PEDIATRIC DENTISTRY LA English DT Article DE EARLY CHILDHOOD CARIES; NURSING BOTTLE CARIES; TOOTH DECAY; NHANES; EPIDEMIOLOGY ID EARLY-CHILDHOOD CARIES; ORAL-HEALTH COMPONENT; RANDOMIZED CONTROLLED-TRIAL; EXAMINATION SURVEY NHANES; PRESCHOOL-CHILDREN; RISK-FACTORS; NATIONAL-HEALTH; UNITED-STATES; BEHAVIORAL DETERMINANTS; SOCIOECONOMIC-STATUS AB Purpose: Dental caries in preschool children was historically considered to have a unique and more intense pattern of decoy and was known by a variety of terms. In 1999, the term early childhood caries (ECC), along with a classification system, was proposed to facilitate epidemiologic research of dental caries in young children. The purpose of this study was to assess the impact of those early childhood caries recommendations on the prevalence and measurement of caries in preschool children. Methods: A systematic search of the MEDLINE database was performed. Key search words included: ECC, dental decay, dental caries, carious dentin, baby bottle tooth decay, nursing caries, maxillary anterior caries, and labial caries. English language studies and studies on more than 100 children younger than six years old were eligible for selection. National Health and Nutrition Examination Survey data collected from 1988 to 1994, 1999 to 2004, and 2011 to 2072 were used to assess ECC prevalence using different operational definitions. Results: There were 87 articles selected for this review. The term ECC was used in 55 percent of the selected articles as the primary outcome measure. The majority of studies used a cross-section study design, but diagnostic criteria varied greatly. Caries experience in young children may be shifting away from majority of untreated surfaces to a majority of restored surfaces. Little difference was observed by dental surface type in the distribution of decayed and filled surfaces in primary teeth. Conclusions: Although the term early childhood caries is widely used, varied use of diagnostic criteria and operational definitions continue to limit comparability across studies. Emerging changes in the proportion of decayed and filled surfaces in the United States also raises questions regarding the ECC case definition limiting our ability to understand the epidemiology of dental caries in preschool children. C1 [Dye, Bruce A.] Natl Inst Dent & Craniofacial Res, NIH, Bethesda, MD USA. [Hsu, Kuei-Ling C.] Univ Maryland, Sch Dent, Div Pediat Dent, Baltimore, MD 21201 USA. [Afful, Joseph] Ctr Dis Control & Prevent, Harris Corp, Natl Ctr Hlth Stat, Hyattsville, MD USA. RP Dye, BA (reprint author), Natl Inst Dent & Craniofacial Res, NIH, Bethesda, MD USA. EM bruce.dye@nih.gov NR 108 TC 11 Z9 11 U1 4 U2 8 PU AMER ACAD PEDIATRIC DENTISTRY PI CHICAGO PA 211 E CHICAGO AVENUE SUITE 1036, CHICAGO, IL 60611-2616 USA SN 0164-1263 EI 1942-5473 J9 PEDIATR DENT JI Pediatr. Dent. PD MAY-JUN PY 2015 VL 37 IS 3 BP 200 EP 216 PG 17 WC Dentistry, Oral Surgery & Medicine; Pediatrics SC Dentistry, Oral Surgery & Medicine; Pediatrics GA DL6DO UT WOS:000375729600002 PM 26063550 ER PT J AU Bennett, SD Littrell, KW Hill, TA Mahovic, M Behravesh, CB AF Bennett, S. D. Littrell, K. W. Hill, T. A. Mahovic, M. Behravesh, C. Barton TI Multistate foodborne disease outbreaks associated with raw tomatoes, United States, 1990-2010: a recurring public health problem SO EPIDEMIOLOGY AND INFECTION LA English DT Article DE Food safety; foodborne infections; outbreaks; produce; Salmonella; tomatoes ID SALMONELLA-ENTERICA; FRESH PRODUCE; SURVIVAL; PLANTS; MONTEVIDEO; COLONIZATION; TEMPERATURE; RESTAURANTS; SURFACES; CONTACT AB We examined multistate outbreaks attributed to raw tomatoes in the United States from 1990 to 2010. We summarized the demographic and epidemiological characteristics of 15 outbreaks resulting in 1959 illnesses, 384 hospitalizations, and three deaths. Most (80%) outbreaks were reported during 2000-2010; 73% occurred May-September. Outbreaks commonly affected adult (median age 34 years) women (median 58% of outbreak cases). All outbreaks were caused by Salmonella [serotypes Newport (n = 6 outbreaks), Braenderup (n = 2), Baildon, Enteritidis, Javiana, Montevideo, Thompson, Typhimurium (n = 1 each); multiple serotypes (n = 1)]. Red, round (69% of outbreaks), Roma (23%), and grape (8%) tomatoes were implicated. Most (93%) outbreaks were associated with tomatoes served predominantly in restaurants. However, traceback investigations suggested that contamination occurred on farms, at packinghouses, or at fresh-cut processing facilities. Government agencies, academia, trade associations, and the fresh tomato industry should consider further efforts to identify interventions to reduce contamination of tomatoes during production and processing. C1 [Bennett, S. D.; Behravesh, C. Barton] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30333 USA. [Littrell, K. W.] Univ Minnesota, Sch Publ Hlth, St Paul, MN 55108 USA. [Hill, T. A.] Food & Drug Adm, Coordinated Outbreak Response & Evaluat Network, College Pk, MD USA. [Mahovic, M.] Food & Drug Adm, Ctr Food Safety & Appl Nutr, Produce Safety Staff, College Pk, MD USA. RP Bennett, SD (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS C 09, Atlanta, GA 30333 USA. EM iyk3@cdc.gov FU Centers for Disease Control and Prevention FX This work was supported by the Centers for Disease Control and Prevention. The findings of this study are based in part on contributions by state, local, tribal and territorial health departments. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. NR 35 TC 13 Z9 13 U1 2 U2 17 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0950-2688 EI 1469-4409 J9 EPIDEMIOL INFECT JI Epidemiol. Infect. PD MAY PY 2015 VL 143 IS 7 BP 1352 EP 1359 DI 10.1017/S0950268814002167 PG 8 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA CF6ZW UT WOS:000352706700002 PM 25167220 ER PT J AU Haber, M An, Q Foppa, IM Shay, DK Ferdinands, JM Orenstein, WA AF Haber, M. An, Q. Foppa, I. M. Shay, D. K. Ferdinands, J. M. Orenstein, W. A. TI A probability model for evaluating the bias and precision of influenza vaccine effectiveness estimates from case-control studies SO EPIDEMIOLOGY AND INFECTION LA English DT Article DE Influenza vaccines; mathematical modelling; statistics ID TEST-NEGATIVE DESIGN AB As influenza vaccination is now widely recommended, randomized clinical trials are no longer ethical in many populations. Therefore, observational studies on patients seeking medical care for acute respiratory illnesses (ARIs) are a popular option for estimating influenza vaccine effectiveness (VE). We developed a probability model for evaluating and comparing bias and precision of estimates of VE against symptomatic influenza from two commonly used case-control study designs: the test-negative design and the traditional case-control design. We show that when vaccination does not affect the probability of developing non-influenza ARI then VE estimates from test-negative design studies are unbiased even if vaccinees and non-vaccinees have different probabilities of seeking medical care against ARI, as long as the ratio of these probabilities is the same for illnesses resulting from influenza and non-influenza infections. Our numerical results suggest that in general, estimates from the test-negative design have smaller bias compared to estimates from the traditional case-control design as long as the probability of non-influenza ARI is similar among vaccinated and unvaccinated individuals. We did not find consistent differences between the standard errors of the estimates from the two study designs. C1 [Haber, M.; An, Q.] Emory Univ, Rollins Sch Publ Hlth, Dept Biostat & Bioinformat, Atlanta, GA 30322 USA. [Foppa, I. M.; Shay, D. K.; Ferdinands, J. M.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. [Orenstein, W. A.] Emory Univ, Sch Med, Dept Med, Atlanta, GA 30322 USA. RP Haber, M (reprint author), Emory Univ, Rollins Sch Publ Hlth, Dept Biostat & Bioinformat, Atlanta, GA 30322 USA. EM mhaber@emory.edu OI Shay, David/0000-0001-9619-4820 FU National Institute of Allergies and Infectious Diseases of the National Institutes of Health (NIH) [R01AI110474]; Centers for Disease Controls and Prevention (CDC); IPA [1110376-05] FX We thank three anonymous reviewers for their helpful comments. Dr Haber's research was supported by the National Institute of Allergies and Infectious Diseases of the National Institutes of Health (NIH) under Award R01AI110474, and by IPA 1110376-05 with the Centers for Disease Controls and Prevention (CDC). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or the CDC. NR 11 TC 3 Z9 3 U1 0 U2 3 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0950-2688 EI 1469-4409 J9 EPIDEMIOL INFECT JI Epidemiol. Infect. PD MAY PY 2015 VL 143 IS 7 BP 1417 EP 1426 DI 10.1017/S0950268814002179 PG 10 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA CF6ZW UT WOS:000352706700009 PM 25147970 ER PT J AU Mixson-Hayden, T Dawson, GJ Teshale, E Le, T Cheng, K Drobeniuc, J Ward, J Kamili, S AF Mixson-Hayden, Tonya Dawson, George J. Teshale, Eyasu Le, Thao Cheng, Kevin Drobeniuc, Jan Ward, John Kamili, Saleem TI Performance of ARCHITECT HCV core antigen test with specimens from US plasma donors and injecting drug users SO JOURNAL OF CLINICAL VIROLOGY LA English DT Article DE HCV core antigen; HCV RNA; HCV screening ID HEPATITIS-C VIRUS; ENZYME-IMMUNOASSAY; CLINICAL-USEFULNESS; INTERFERON-ALPHA; HUMAN SERUM; ASSAY; QUANTIFICATION; INFECTION; RNA; THERAPY AB Background: Hepatitis C virus (HCV) core antigen is a serological marker of current HCV infection. Objectives: The aim of this study was mainly to evaluate the performance characteristics of the ARCITECT HCV core antigen assay with specimens from US plasma donors and injecting drug users. Study design: A total of 551 serum and plasma samples with known anti-HCV and HCV RNA status were tested for HCV core antigen using the Abbott ARCHITECT HCV core antigen test. Results: HCV core antigen was detectable in 100% of US plasma donor samples collected during the pre-seroconversion phase of infection (anti-HCV negative/HCV RNA positive). Overall sensitivity of the HCV core antigen assay was 88.9-94.3% in samples collected after seroconversion. The correlation between HCV core antigen and HCV RNA titers was 0.959. Conclusions: HCV core antigen testing may be reliably used to identify current HCV infection. Published by Elsevier B.V. C1 [Mixson-Hayden, Tonya; Teshale, Eyasu; Le, Thao; Drobeniuc, Jan; Ward, John; Kamili, Saleem] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA 30333 USA. [Dawson, George J.; Cheng, Kevin] Abbott Labs, Abbott Pk, IL 60064 USA. RP Kamili, S (reprint author), Ctr Dis Control & Prevent, Div Viral Hepatitis, 1600 Clifton Rd,MS A33, Atlanta, GA 30333 USA. EM skamili@cdc.gov FU Centers for Disease Control and Prevention FX This work was supported by the Centers for Disease Control and Prevention. Reagents for HCV core antigen testing were supplied by Abbott Diagnostics. NR 39 TC 2 Z9 2 U1 0 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1386-6532 EI 1873-5967 J9 J CLIN VIROL JI J. Clin. Virol. PD MAY PY 2015 VL 66 BP 15 EP 18 DI 10.1016/j.jcv.2015.02.015 PG 4 WC Virology SC Virology GA CF6YE UT WOS:000352702000004 PM 25866329 ER PT J AU Moran-Gilad, J Mendelson, E Burns, CC Bassal, R Gdalevich, M Sofer, D Oberste, MS Shulman, LM Kaliner, E Hindiye, M Mor, O Shahar, L Iber, J Yishay, R Manor, J Lev, B Gamzu, R Grotto, I AF Moran-Gilad, Jacob Mendelson, Ella Burns, Cara C. Bassal, Ravit Gdalevich, Michael Sofer, Danit Oberste, M. Steven Shulman, Lester M. Kaliner, Ehud Hindiye, Musa Mor, Orna Shahar, Liora Iber, Jane Yishay, Ruth Manor, Joseph Lev, Boaz Gamzu, Ronni Grotto, Itamar TI Field study of fecal excretion as a decision support tool in response to silent reintroduction of wild-type poliovirus 1 into Israel SO JOURNAL OF CLINICAL VIROLOGY LA English DT Article DE Poliovirus; Stool; Surveillance; Excretion; Survey; Wild type ID SURVEILLANCE AB Background: Israel has used an inactivated polio vaccine (IPV)-only schedule since 2005 (95% coverage). Silent reintroduction of wild type poliovirus 1 (WPV1) into Israel in early 2013 was detected in Southern Israel via routine environmental surveillance without clinical cases. Objectives: To estimate the rate of WPV1 excretion by age and residence and inform decision-making regarding supplemental immunization with OPV. Study design: A convenience sample of Bedouin and Jewish residential areas in the epicenter of the incident, focusing on under 8 year-olds who not previously given OPV. Fecal samples were directly tested for WPV1 RNA using a novel qRT-PCR assay. Positive samples were confirmed by gold standard cell culture and subject to genotyping. Results: Overall, 2196 non-duplicate fecal samples were collected and analyzed. WPV1 was detected in 61 samples (2.8%), 55 of which (90.2%) were from Bedouins. WPV1 excretion rates were 5.4% among Bedouins and 0.6% among Jewish individuals. Respective age-specific rates among Bedouin and Jewish children were 4.9% and 0.2% for 0-2 years and 7.2% and 1.7% for 2-8 years. Molecular testing had 89.5% sensitivity (higher than culture) and 100% specificity. Conclusion: The rapid performance of a field study to evaluate WPV1 excretion unequivocally demonstrated substantial WPV1 infection rates among children under 8 years in Southern Israel, thus informing the decision to vaccinate this age group with bOPV and risk communication to both healthcare personnel and the public. Rapid development and implementation of molecular screening can thus underpin risk assessment and management in complex epidemiological situations. (C) 2015 Elsevier B.V. All rights reserved. C1 [Moran-Gilad, Jacob; Kaliner, Ehud; Grotto, Itamar] Minist Hlth, Publ Hlth Serv, Jerusalem, Israel. [Moran-Gilad, Jacob; Grotto, Itamar] Ben Gurion Univ Negev, Fac Hlth Sci, Beer Sheva, Israel. [Mendelson, Ella; Sofer, Danit; Shulman, Lester M.; Hindiye, Musa; Mor, Orna; Manor, Joseph] Minist Hlth, Cent Virol Lab, Tel Hashomer, Israel. [Mendelson, Ella; Shulman, Lester M.; Gamzu, Ronni] Tel Aviv Univ, Sch Publ Hlth, IL-69978 Tel Aviv, Israel. [Burns, Cara C.; Oberste, M. Steven; Iber, Jane] Ctr Dis Control & Prevent, Viruses Branch, Atlanta, GA USA. [Bassal, Ravit] Minist Hlth, Israel Ctr Dis Control, Tel Hashomer, Israel. [Gdalevich, Michael; Shahar, Liora] Minist Hlth, Southern Dist Hlth Off, Beer Sheva, Israel. [Yishay, Ruth] Minist Hlth, Publ Hlth Serv, Dept Labs, Jerusalem, Israel. [Lev, Boaz; Gamzu, Ronni] Minist Hlth, Jerusalem, Israel. RP Moran-Gilad, J (reprint author), Minist Hlth, Publ Hlth Serv, 39 Yermiyahu St, Jerusalem, Israel. EM giladko@post.bgu.ac.il NR 12 TC 4 Z9 4 U1 1 U2 5 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1386-6532 EI 1873-5967 J9 J CLIN VIROL JI J. Clin. Virol. PD MAY PY 2015 VL 66 BP 51 EP 55 DI 10.1016/j.jcv.2015.03.005 PG 5 WC Virology SC Virology GA CF6YE UT WOS:000352702000012 PM 25866337 ER PT J AU Koontz, D Baecher, K Amin, M Nikolova, S Gallagher, M Dollard, S AF Koontz, D. Baecher, K. Amin, M. Nikolova, S. Gallagher, M. Dollard, S. TI Evaluation of DNA extraction methods for the detection of Cytomegalovirus in dried blood spots SO JOURNAL OF CLINICAL VIROLOGY LA English DT Article DE qPCR; Dried blood spots; Newborn screening ID POLYMERASE-CHAIN-REACTION; CONGENITAL CMV INFECTION; HEARING-LOSS; FILTER-PAPER; REACTION ASSAYS; NEWBORNS; CYTORNEGALOVIRUS; ASSOCIATION; PREVALENCE; DIAGNOSIS AB Background: Dried blood spots (DBS) are collected universally from newborns and may be valuable for the diagnosis of congenital Cytomegalovirus (CMV) infection. The reported analytical sensitivity for DBS testing compared to urine or saliva varies greatly across CMV studies. The purpose of this study was to directly compare the performance of various DNA extraction methods for identification of CMV in DBS including those used most often in CMV studies. Study design: Whatman (R) Grade 903 filter paper cards were spotted with blood samples from 25 organ transplant recipients who had confirmed CMV viremia. Six DNA extraction methods were compared for relative yield of viral and cellular DNA: 2 manual solution-based methods (Gentra Puregene, thermal shock), 2 manual silica column-based methods (QIAamp DNA Mini, QIAamp DNA Investigator), and 2 automated methods (M48 MagAttract Mini, QIAcube Investigator). DBS extractions were performed in triplicate followed by real-time quantitative PCR (qPCR). Results: For extraction of both viral and cellular DNA, two methods (QIAamp DNA Investigator and thermal shock) consistently gave the highest yields, and two methods (M48 MagAttract Mini and QIAamp DNA Mini) consistently gave the lowest yields. There was an average 3-fold difference in DNA yield between the highest and lowest yield methods. Conclusion: The choice of DNA extraction method is a major factor in the ability to detect low levels of CMV in DBS and can largely account for the wide range of DBS sensitivities reported in studies to date. Published by Elsevier B.V. C1 [Koontz, D.; Baecher, K.; Nikolova, S.; Gallagher, M.] Ctr Dis Control & Prevent, Newborn Screening & Mol Biol Branch, Atlanta, GA 30341 USA. [Amin, M.; Dollard, S.] Ctr Dis Control & Prevent, Measles Mumps Rubella & Herpesvirus Lab Branch, Atlanta, GA 30329 USA. RP Koontz, D (reprint author), Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, 4770 Buford Highway,MS F-24, Chamblee, GA 30341 USA. EM duk5@cdc.gov FU Centers for Disease Control and Prevention FX This work was supported by intramural funding from the Centers for Disease Control and Prevention. NR 23 TC 5 Z9 6 U1 3 U2 16 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1386-6532 EI 1873-5967 J9 J CLIN VIROL JI J. Clin. Virol. PD MAY PY 2015 VL 66 BP 95 EP 99 DI 10.1016/j.jcv.2015.03.015 PG 5 WC Virology SC Virology GA CF6YE UT WOS:000352702000021 PM 25866346 ER PT J AU Kumar, G Onufrak, S Zytnick, D Kingsley, B Park, S AF Kumar, Gayathri Onufrak, Stephen Zytnick, Deena Kingsley, Beverly Park, Sohyun TI Self-reported advertising exposure to sugar-sweetened beverages among US youth SO PUBLIC HEALTH NUTRITION LA English DT Article DE Food marketing; Advertising; Adolescents; Sugar-sweetened beverages; Self-reported ID TELEVISION FOOD ADVERTISEMENTS; HIGH-SCHOOL-STUDENTS; UNITED-STATES; PHYSICAL-ACTIVITY; CONSUMPTION; ADOLESCENTS; CHILDREN; ADULTS; TRENDS AB Objective: According to the Federal Trade Commission, in 2009, the top food category with teen-directed marketing expenditures was sugar-sweetened beverages (SSB). The present study reports on exposure to SSB advertisements using self-report data from adolescents. Design: Cross-sectional study design using descriptive statistics to assess self-reported frequency of exposure to SSB advertisements and multivariable logistic regression to examine associations between frequency of SSB advertising exposure and sociodemographic variables. Setting: Online survey conducted at home. Subjects: US adolescents aged 12-17 years (n 847). Results: Among the surveyed adolescents, 42 % to 54 % reported seeing/hearing SSB advertisements >= 1 time/d. Those aged 14-15 years were more likely to report seeing/hearing soda, sports drink and energy drink advertisements >= 1 time/d than 16- to 17-year-olds. Males were more likely to report seeing/hearing sports drink advertising >= 1 time/d than females. Non-Hispanic black adolescents were more likely to report seeing/hearing fruit drink and sports drink advertisements >= 1 time/d than non-Hispanic white adolescents. Adolescents whose parents had high-school education or less were more likely to report seeing/hearing soda, fruit drink and energy drink advertisements >= 1 time/d than adolescents whose parents were college graduates. Conclusions: Almost half of the adolescents sampled reported daily SSB advertising exposure, with higher exposure among African Americans and adolescents with less educated parents. These data can help inform potential actions that decision makers might take, such as education of adolescents and their caregivers on the potential impact of beverage advertising, especially among groups at higher risk for obesity. C1 [Kumar, Gayathri; Onufrak, Stephen; Zytnick, Deena; Kingsley, Beverly; Park, Sohyun] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP Kumar, G (reprint author), Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, 4771 Buford Highway, Atlanta, GA 30341 USA. EM wiz3@cdc.gov RI Dey, Kamalesh/E-6568-2017 NR 22 TC 3 Z9 3 U1 4 U2 37 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND SN 1368-9800 EI 1475-2727 J9 PUBLIC HEALTH NUTR JI Public Health Nutr. PD MAY PY 2015 VL 18 IS 7 BP 1173 EP 1179 DI 10.1017/S1368980014001785 PG 7 WC Public, Environmental & Occupational Health; Nutrition & Dietetics SC Public, Environmental & Occupational Health; Nutrition & Dietetics GA CF0NB UT WOS:000352239800005 PM 25166512 ER PT J AU Cavanaugh, J Viney, K Kienene, T Harley, D Kelly, PM Sleigh, A O'Connor, J Mase, S AF Cavanaugh, J. Viney, K. Kienene, T. Harley, D. Kelly, P. M. Sleigh, A. O'Connor, J. Mase, S. TI Effect of diabetes on tuberculosis presentation and outcomes in Kiribati SO TROPICAL MEDICINE & INTERNATIONAL HEALTH LA English DT Article DE Tuberculosis; diabetes mellitus; Pacific; case-control study; treatment outcomes ID PULMONARY TUBERCULOSIS; ACTIVE TUBERCULOSIS; GLOBAL TRENDS; MELLITUS; PREVALENCE; IMPACT AB ObjectivesTo determine the association between diabetes and the clinical features and treatment outcomes of TB in Kiribati. MethodsWe enrolled consecutive patients with TB who presented from August 2010 to February 2012 and compared clinical features and TB treatment outcomes for patients with and without diabetes, as measured by haemoglobin A1c assay. Poor outcome was defined as death, default or treatment failure, and good outcome as treatment success or cure. ResultsTwo hundred and seventy-five eligible persons with TB disease were enrolled; 101 (37%) had diabetes. TB patients with diabetes were more likely to have acid-fast bacilli (AFB) seen on sputum smear microscopy (RR: 1.3; 95% CI: 1.03-1.62). The risk of poor outcome did not differ between patients with or without diabetes (RR: 1.1; 95% CI: 0.5-2.7). ConclusionTB patients with diabetes are more likely than those without to have sputum with AFB on microscopy. This could increase transmission in the community. Early detection of TB by screening patients with diabetes, and the converse, could be important public health interventions where diabetes and TB are prevalent. C1 [Cavanaugh, J.; Mase, S.] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA USA. [Viney, K.] Secretariat Pacific Community, Publ Hlth Div, Noumea, New Caledonia. [Kienene, T.] Minist Hlth & Med Serv, Natl TB Program, Tarawa, Kiribati. [Viney, K.; Harley, D.; Sleigh, A.] Australian Natl Univ, Natl Ctr Epidemiol & Populat Hlth, Canberra, ACT, Australia. [Kelly, P. M.] ACT Govt Hlth Directorate, Populat Hlth Div, Canberra, ACT, Australia. [Kelly, P. M.] Australian Natl Univ, Sch Med, Canberra, ACT, Australia. RP Cavanaugh, J (reprint author), US Ctr Dis Control & Prevent, 1600 Clifton Rd MS E 10, Atlanta, GA 30333 USA. EM hgi7@cdc.gov RI Harley, David/C-1326-2010; Harley, David/B-4910-2017; OI Harley, David/0000-0001-6691-5420; Sleigh, Adrian/0000-0001-8443-7864; Viney, Kerri/0000-0002-0453-4339 FU Global Fund to Fight AIDS, TB and Malaria; Australian Agency for International Development FX We gratefully acknowledge the patients with TB who willingly participated in the study; the study personnel who interviewed the patients with TB; Dr Teatao Tiira (Kiribati Ministry of Health and Medical Services) and Dr Viliami Puloka (Healthy Pacific Lifestyle Team, Secretariat of the Pacific Community), who supported the implementation of the project; and the Global Fund to Fight AIDS, TB and Malaria and the Australian Agency for International Development for providing financial support for the study. We especially acknowledge the contribution of Dr Kenneth Tabutoa, who made this study possible. No authors report any conflict of interest. NR 31 TC 2 Z9 2 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1360-2276 EI 1365-3156 J9 TROP MED INT HEALTH JI Trop. Med. Int. Health PD MAY PY 2015 VL 20 IS 5 BP 643 EP 649 DI 10.1111/tmi.12468 PG 7 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA CF4QG UT WOS:000352534600009 PM 25630576 ER PT J AU Viney, K Cavanaugh, J Kienene, T Harley, D Kelly, PM Sleigh, A O'Connor, J Mase, S AF Viney, K. Cavanaugh, J. Kienene, T. Harley, D. Kelly, P. M. Sleigh, A. O'Connor, J. Mase, S. TI Tuberculosis and diabetes mellitus in the Republic of Kiribati: a case-control study SO TROPICAL MEDICINE & INTERNATIONAL HEALTH LA English DT Article DE Tuberculosis; diabetes mellitus; Pacific; case-control study ID ACTIVE TUBERCULOSIS; PREVALENCE; EPIDEMICS; CHINA; RISK; A1C AB ObjectivesTo better inform local management of TB-diabetes collaborative activities, we aimed to determine the prevalence of diabetes among persons with and without TB and to determine the association between TB and diabetes in Kiribati, a Pacific Island nation. MethodsWe compared consecutively enrolled TB cases to a group of randomly selected community controls without evidence of TB. Diabetes was diagnosed by HbA1c, and clinical and demographic data were collected. A tuberculin skin test was administered to controls. The chi-square test was used to assess significance in differences between cases and controls. We also calculated an odds ratio, with 95% confidence intervals, for the odds of diabetes among cases relative to controls. Unweighted multivariate logistic regression was performed to adjust for the effects of age and sex. ResultsA total of 275 TB cases and 499 controls were enrolled. The diabetes prevalence in cases (101, 37%) was significantly greater than in controls (94, 19%) (adjusted odds ratio: 2.8; 95% CI 2.0-4.1). Fifty-five percent (108) of all diabetic diagnoses were new; this proportion was higher among controls (64.8%) than cases (46.5%). Five patients with TB were screened to detect one patient with diabetes. ConclusionsThere is a strong association between TB and diabetes in Kiribati and bidirectional screening should be conducted in this setting. C1 [Viney, K.] Secretariat Pacific Community, Publ Hlth Div, Noumea, New Caledonia. [Viney, K.; Harley, D.; Sleigh, A.] Australian Natl Univ, Natl Ctr Epidemiol & Populat Hlth, Canberra, ACT, Australia. [Cavanaugh, J.; Mase, S.] US Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA USA. [Kienene, T.] Minist Hlth & Med Serv, Natl TB Programme, Tarawa, Kiribati. [Kelly, P. M.] ACT Hlth Directorate, Populat Hlth Div, Canberra, ACT, Australia. [Kelly, P. M.] Australian Natl Univ, Sch Med, Canberra, ACT, Australia. RP Viney, K (reprint author), Australian Natl Univ, Natl Ctr Epidemiol & Populat Hlth, Res Sch Populat Hlth, Bldg 62,Cnr Mills & Eggleston Rd, Canberra, ACT 0200, Australia. EM kerri.viney@hotmail.com RI Harley, David/C-1326-2010; Harley, David/B-4910-2017; OI Harley, David/0000-0001-6691-5420; Sleigh, Adrian/0000-0001-8443-7864; Viney, Kerri/0000-0002-0453-4339 FU Global Fund to Fight AIDS, TB and Malaria; Australian Aid Programme, Department of Foreign Affairs and Trade FX We gratefully acknowledge the patients with TB and people from the community who willingly participated in the study, the study interviewers who interviewed the patients with TB and community members, Dr Teatao Tiira and Dr Kenneth Tabutoa (Kiribati Ministry of Health and Medical Services; Dr Tabutoa is recently deceased), and Dr Viliami Puloka (Healthy Pacific Lifestyle Team, Secretariat of the Pacific Community) who supported the implementation of the project, and the Global Fund to Fight AIDS, TB and Malaria and the Australian Aid Programme, Department of Foreign Affairs and Trade for the financial support provided the study through a dedicated operational research grant. We would like to dedicate this study to Dr Kenneth Tabutoa (now deceased and former Deputy Director of Public Health, Kiribati Ministry of Health and Medical Services) for his tireless work to manage and control TB in Kiribati. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 47 TC 1 Z9 1 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1360-2276 EI 1365-3156 J9 TROP MED INT HEALTH JI Trop. Med. Int. Health PD MAY PY 2015 VL 20 IS 5 BP 650 EP 657 DI 10.1111/tmi.12462 PG 8 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA CF4QG UT WOS:000352534600010 ER PT J AU Fereidouni, S Kwasnitschka, L Buschmann, AB Muller, T Freuling, C Schatz, J Pikula, J Bandouchova, H Hoffmann, R Ohlendorf, B Kerth, G Tong, S Donis, R Beer, M Harder, T AF Fereidouni, S. Kwasnitschka, L. Buschmann, A. Balkema Mueller, T. Freuling, C. Schatz, J. Pikula, J. Bandouchova, H. Hoffmann, R. Ohlendorf, B. Kerth, G. Tong, S. Donis, R. Beer, M. Harder, T. TI No Virological Evidence for an Influenza A - like Virus in European Bats SO ZOONOSES AND PUBLIC HEALTH LA English DT Article DE Influenza; infectious disease; surveillance; bats AB New members of the influenza A virus genus have been detected recently in bats from South America. By molecular investigations, using a generic real-time RT-PCR (RT-qPCR) that detects all previously known influenza A virus subtypes (H1-H16) and a newly developed RT-qPCR specific for the South American bat influenza-like virus of subtype H17, a total of 1571 samples obtained from 1369 individual bats of 26 species from Central Europe were examined. No evidence for the occurrence of such influenza viruses was found. Further attempts towards a more comprehensive evaluation of the role of bats in the ecology and epidemiology of influenza viruses should be based on more intense monitoring efforts. However, given the protected status of bats, not only in Europe, such activities need to be embedded into existing pathogen-monitoring programs. C1 [Fereidouni, S.; Kwasnitschka, L.; Buschmann, A. Balkema; Mueller, T.; Freuling, C.; Schatz, J.; Beer, M.; Harder, T.] Friedrich Loeffler Inst, Riems, Germany. [Pikula, J.; Bandouchova, H.] Univ Vet & Pharmaceut Sci, Brno, Czech Republic. [Hoffmann, R.] Romanian Bat Protect Assoc, Satu Mare, Romania. [Ohlendorf, B.] Bat Protect Off, Saxony Anhalt, Germany. [Kerth, G.] Ernst Moritz Arndt Univ Greifswald, Museum & Inst Zool, Greifswald, Germany. [Tong, S.; Donis, R.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Fereidouni, S (reprint author), Friedrich Loeffler Inst, Riems, Germany. EM sasan.fereidouni@wesca.net; timm.harder@fli.bund.de FU Intramural CDC HHS [CC999999] NR 5 TC 5 Z9 5 U1 1 U2 11 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1863-1959 EI 1863-2378 J9 ZOONOSES PUBLIC HLTH JI Zoonoses Public Health PD MAY PY 2015 VL 62 IS 3 BP 187 EP 189 DI 10.1111/zph.12131 PG 3 WC Public, Environmental & Occupational Health; Infectious Diseases; Veterinary Sciences SC Public, Environmental & Occupational Health; Infectious Diseases; Veterinary Sciences GA CF5TO UT WOS:000352620200004 PM 24837569 ER PT J AU Lankau, EW Cox, SW Ferguson, SC Blanton, JD Tack, DM Petersen, BW Rupprecht, CE AF Lankau, E. W. Cox, S. W. Ferguson, S. C. Blanton, J. D. Tack, D. M. Petersen, B. W. Rupprecht, C. E. TI Community Survey of Rabies Knowledge and Exposure to Bats in Homes - Sumter County, South Carolina, USA SO ZOONOSES AND PUBLIC HEALTH LA English DT Article DE Bats; prevention; rabies; survey; zoonotic disease ID UNITED-STATES AB Subsequent to a human rabies death in Sumter County, South Carolina, we assessed the frequency of exposures to bats in homes and citizens' rabies knowledge. A self-administered survey was mailed to 6033 randomly selected Sumter County addresses. The survey inquired about household exposures to bats and respondents' rabies knowledge. Surveys were returned by mail for descriptive analysis. Of 597 respondents, 3.5% (21/597) reported having bats living in (2.8% or 17/597) or entering their homes (2.5% or 15/597) during 2010-2012. Respondents generally understood that mammals transmit rabies virus through bites, but were less aware of the severity of rabies illness and modern post-exposure vaccine administration. Respondents were unsure about how to exclude bats from homes and ranked highly both healthcare and non-healthcare entities as preferred resources for obtaining assistance with bat-related concerns. We found potential for human exposures to bats in Sumter County households and gaps in citizen knowledge of rabies and bat exclusion. Public health officials should engage non-healthcare partners in assistance disseminating rabies educational materials and for providing appropriate referral for persons potentially exposed to bats. C1 [Lankau, E. W.; Tack, D. M.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Lankau, E. W.] Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Atlanta, GA USA. [Cox, S. W.; Ferguson, S. C.] South Carolina Dept Hlth & Environm Control, Columbia, SC USA. [Blanton, J. D.; Tack, D. M.; Petersen, B. W.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Atlanta, GA USA. [Rupprecht, C. E.] Global Alliance Rabies Control, Manhattan, KS USA. [Rupprecht, C. E.] Ross Univ, Sch Vet Med, Basseterre St Kitts, W Ind Assoc St. RP Lankau, EW (reprint author), LandCow Consulting, POB 7403, Athens, GA 30604 USA. EM landcow.ecohealth@gmail.com RI Lankau, Emily/C-8057-2011 OI Lankau, Emily/0000-0002-7094-7780 NR 12 TC 1 Z9 1 U1 0 U2 19 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1863-1959 EI 1863-2378 J9 ZOONOSES PUBLIC HLTH JI Zoonoses Public Health PD MAY PY 2015 VL 62 IS 3 BP 190 EP 198 DI 10.1111/zph.12135 PG 9 WC Public, Environmental & Occupational Health; Infectious Diseases; Veterinary Sciences SC Public, Environmental & Occupational Health; Infectious Diseases; Veterinary Sciences GA CF5TO UT WOS:000352620200005 PM 24815566 ER PT J AU Dato, VM Campagnolo, ER Shah, DU Bellush, MJ Rupprecht, CE AF Dato, V. M. Campagnolo, E. R. Shah, D. U. Bellush, M. J. Rupprecht, C. E. TI Recurrent Temporary Paralysis Reported After Human Rabies Post-Exposure Prophylaxis SO ZOONOSES AND PUBLIC HEALTH LA English DT Article DE Post-exposure prophylaxis; bat; rabies; bat-variant rabies; rabies exposure; recurrent temporary paralysis; rabies immunization; human rabies immunoglobulin; human diploid cell vaccine; purified chick embryo cell vaccine ID VACCINE; VIRUS AB Adverse events can occur after rabies post-exposure prophylaxis (PEP), and linkage to causality is often difficult to determine. We report a case of recurrent temporary paralysis that began immediately after the initiation of rabies PEP in a man exposed to a bat. The recurrent temporary paralysis first occurred in the patient after his initial dose and then again after day 3 of his rabies PEP. The PEP was terminated prior to a serologic response. The patient continued to experience numerous discrete episodes of temporary paralysis for over two years. C1 [Dato, V. M.; Campagnolo, E. R.] Penn Dept Hlth, Bur Epidemiol, Harrisburg, PA 17108 USA. [Campagnolo, E. R.] Ctr Dis Control & Prevent, Off Publ Hlth Preparedness & Response, Off Sci & Publ Hlth Practice, Atlanta, GA USA. [Shah, D. U.] Jewish Hosp, Kentuckyone Hlth, Louisville, KY USA. [Bellush, M. J.] Excela Hlth Westmoreland Hosp, Greensburg, PA USA. [Rupprecht, C. E.] Global Alliance Rabies Control, Manhattan, KS USA. [Rupprecht, C. E.] Ross Univ, Sch Vet Med, Basseterre St Kitts, W Ind Assoc St. RP Campagnolo, ER (reprint author), Penn Dept Hlth, Northwest Dist Off, 19 McQuiston Dr, Jackson Ctr, PA 16133 USA. EM ejc5@cdc.gov NR 24 TC 0 Z9 0 U1 1 U2 11 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1863-1959 EI 1863-2378 J9 ZOONOSES PUBLIC HLTH JI Zoonoses Public Health PD MAY PY 2015 VL 62 IS 3 BP 222 EP 227 DI 10.1111/zph.12143 PG 6 WC Public, Environmental & Occupational Health; Infectious Diseases; Veterinary Sciences SC Public, Environmental & Occupational Health; Infectious Diseases; Veterinary Sciences GA CF5TO UT WOS:000352620200008 PM 24995792 ER PT J AU Kerlin, BA Smoyer, WE Tsai, J Boulet, SL AF Kerlin, Bryce A. Smoyer, William E. Tsai, James Boulet, Sheree L. TI Healthcare burden of venous thromboembolism in childhood chronic renal diseases SO PEDIATRIC NEPHROLOGY LA English DT Article DE Thrombosis; Embolism; Chronic Kidney Disease; Vascular Disease; Infection; Surgery; Hemodialysis ID NEPHROTIC SYNDROME; UNITED-STATES; CANADIAN REGISTRY; KIDNEY-DISEASE; RISK-FACTORS; CHILDREN; THROMBOSIS; TRANSPLANTATION; COMPLICATIONS; EPIDEMIOLOGY AB Chronic renal diseases (CRD) are associated with approximately 5 % of pediatric venous thromboembolism (VTE) cases, but the epidemiology of VTE in CRD is ill-defined. Children (< 18 years) with CRD were identified from MarketScanA (R) Research databases. The VTE status of subjects with CRD who qualified for this study was ascertained during the 6 months following the initial diagnosis of CRD. Demographics, healthcare utilization, mortality, and co-morbid conditions were assessed. A total of 22,877 children with predefined CRD ICD-9-CM codes were identified between April 1, 2003 and June 30, 2012, among whom 0.55 % had VTE. Our analysis revealed that in-hospital mortality was more likely in children with VTE than in those without VTE (11.9 vs. 0.9 %, respectively; p < 0.0001). The usage of healthcare facilities, based on the number of inpatient admissions, length of stay, outpatient visits, and pharmaceutical claims, was also significantly higher in patients with VTE than in those without (p < 0.0001). Total mean healthcare expenditures for the 6-month follow-up period were 13-fold greater in the VTE group than in the group without VTE ($338,338 +/- $544,045 vs. $25,171 +/- $90,792; p < 0.0001). In a multivariate model, infection, hemodialysis, and trauma/surgery significantly increased the likelihood of VTE. Venous thromboembolism is rare in children with CRD, but it is associated with higher mortality and healthcare utilization when present. Among the children with CRD enrolled in our study, the likelihood of VTE was increased among those with co-morbid, non-renal chronic conditions. C1 [Kerlin, Bryce A.; Smoyer, William E.] Ohio State Univ, Coll Med, Dept Pediat, Columbus, OH 43210 USA. [Kerlin, Bryce A.; Smoyer, William E.] Res Inst Nationwide Childrens, Ctr Clin & Translat Res, Columbus, OH 43205 USA. [Tsai, James] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Boulet, Sheree L.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. RP Kerlin, BA (reprint author), Res Inst Nationwide Childrens, Ctr Clin & Translat Res, 700 Childrens Dr,W325, Columbus, OH 43205 USA. EM Bryce.Kerlin@NationwideChildrens.org RI Kerlin, Bryce/E-3369-2011 OI Kerlin, Bryce/0000-0002-1756-8271 FU Research Institute at Nationwide Children's [239409]; National Institute of Diabetes and Digestive and Kidney Diseases [U54DK083912-05S1]; National Center for Research Resources [UL1RR025755] FX This project was supported by grants 239409 from The Research Institute at Nationwide Children's and U54DK083912-05S1 from the National Institute of Diabetes and Digestive and Kidney Diseases (both in support of BAK) and Award Number UL1RR025755 from the National Center for Research Resources. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIDDK, NCRR, or the National Institutes of Health. NR 33 TC 3 Z9 3 U1 1 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0931-041X EI 1432-198X J9 PEDIATR NEPHROL JI Pediatr. Nephrol. PD MAY PY 2015 VL 30 IS 5 BP 829 EP 837 DI 10.1007/s00467-014-3008-z PG 9 WC Pediatrics; Urology & Nephrology SC Pediatrics; Urology & Nephrology GA CE3DY UT WOS:000351706700018 PM 25487668 ER PT J AU Bullard, KM Ali, MK Imperatore, G Geiss, LS Saydah, SH Albu, JB Cowie, CC Sohler, N Albright, A Gregg, EW AF Bullard, Kai McKeever Ali, Mohammed K. Imperatore, Giuseppina Geiss, Linda S. Saydah, Sharon H. Albu, Jeanine B. Cowie, Catherine C. Sohler, Nancy Albright, Ann Gregg, Edward W. TI Receipt of Glucose Testing and Performance of Two US Diabetes Screening Guidelines, 2007-2012 SO PLOS ONE LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; COST-EFFECTIVENESS; PREVENTION PROGRAM; NATIONAL-HEALTH; SECULAR CHANGES; UNITED-STATES; LIFE-STYLE; FOLLOW-UP; PREVALENCE; ADULTS AB Background Screening guidelines are used to help identify prediabetes and diabetes before implementing evidence-based prevention and treatment interventions. We examined screening practices benchmarking against two US guidelines, and the capacity of each guideline to identify dysglycemia. Methods Using 2007-2012 National Health and Nutrition Examination Surveys, we analyzed nationally-representative, cross-sectional data from 5,813 fasting non-pregnant adults aged >= 20 years without self-reported diabetes. We examined proportions of adults eligible for diagnostic glucose testing and those who self-reported receiving testing in the past three years, as recommended by the American Diabetes Association (ADA) and the US Preventive Services Task Force (USPSTF-2008) guidelines. For each screening guideline, we also assessed sensitivity, specificity, and positive (PPV) and negative predictive values in identifying dysglycemia (defined as fasting plasma glucose >= 100 mg/dl or hemoglobin A1c >= 5.7%). Results In 2007-2012, 73.0% and 23.7% of US adults without diagnosed diabetes met ADA and USPSTF-2008 criteria for screening, respectively; and 91.5% had at least one major risk factor for diabetes. Of those ADA- or USPSTF-eligible adults, about 51% reported being tested within the past three years. Eligible individuals not tested were more likely to be lower educated, poorer, uninsured, or have no usual place of care compared to tested eligible adults. Among adults with >= 1 major risk factor, 45.7% reported being tested, and dysglycemia yields (i.e., PPV) ranged from 45.8% (high-risk ethnicity) to 72.6% (self-reported prediabetes). ADA criteria and having any risk factor were more sensitive than the USPSTF-2008 guideline (88.8-97.7% vs. 31.0%) but less specific (13.5-39.7% vs. 82.1%) in recommending glucose testing, resulting in lower PPVs (47.7-54.4% vs. 58.4%). Conclusion Diverging recommendations and variable performance of different guidelines may be impeding national diabetes prevention and treatment efforts. Efforts to align screening recommendations may result in earlier identification of adults at high risk for prediabetes and diabetes. C1 [Bullard, Kai McKeever; Ali, Mohammed K.; Imperatore, Giuseppina; Geiss, Linda S.; Saydah, Sharon H.; Albright, Ann; Gregg, Edward W.] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA 30333 USA. [Albu, Jeanine B.] Columbia Univ, St Lukes Roosevelt Hosp Ctr, Dept Med, New York, NY USA. [Cowie, Catherine C.] NIH, NIDDK, Bethesda, MD 20892 USA. [Sohler, Nancy] CUNY City Coll, Sophie Davis Sch Biomed Educ, New York, NY 10031 USA. RP Bullard, KM (reprint author), Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA 30333 USA. EM kbullard@cdc.gov FU NIDDK NIH HHS [P30 DK020541, P60 DK020541] NR 34 TC 4 Z9 4 U1 0 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD APR 30 PY 2015 VL 10 IS 4 AR e0125249 DI 10.1371/journal.pone.0125249 PG 14 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CH0MA UT WOS:000353713100073 PM 25928306 ER PT J AU Van Handel, MM Branson, BM AF Van Handel, Michelle M. Branson, Bernard M. TI Monitoring HIV Testing in the United States: Consequences of Methodology Changes to National Surveys SO PLOS ONE LA English DT Article ID HEALTH; CARE AB Objective In 2011, the National Health Interview Survey (NHIS), an in-person household interview, revised the human immunodeficiency virus (HIV) section of the survey and the Behavioral Risk Factor Surveillance System (BRFSS), a telephone-based survey, added cellphone numbers to its sampling frame. We sought to determine how these changes might affect assessment of HIV testing trends. Methods We used linear regression with pairwise contrasts with 2003-2013 data from NHIS and BRFSS to compare percentages of persons aged 18-64 years who reported HIV testing in landline versus cellphone-only households before and after 2011, when NHIS revised its in-person questionnaire and BRFSS added cellphone numbers to its telephone-based sample. Results In NHIS, the percentage of persons in cellphone-only households increased 13-fold from 2003 to 2013. The percentage ever tested for HIV was 6%-10% higher among persons in cellphone-only than landline households. The percentage ever tested for HIV increased significantly from 40.2% in 2003 to 45.0% in 2010, but was significantly lower in 2011 (40.6%) and 2012 (39.7%). In BRFSS, the percentage ever tested decreased significantly from 45.9% in 2003 to 40.2% in 2010, but increased to 42.9% in 2011 and 43.5% in 2013. Conclusions HIV testing estimates were lower after NHIS questionnaire changes but higher after BRFSS methodology changes. Data before and after 2011 are not comparable, complicating assessment of trends. C1 [Van Handel, Michelle M.; Branson, Bernard M.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. RP Van Handel, MM (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. EM ioq4@cdc.gov NR 22 TC 2 Z9 2 U1 1 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD APR 30 PY 2015 VL 10 IS 4 AR e0125637 DI 10.1371/journal.pone.0125637 PG 12 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CH0MA UT WOS:000353713100109 PM 25927983 ER PT J AU Qi, M Zhou, H Wang, HY Wang, RJ Xiao, LH Arrowood, MJ Li, JQ Zhang, LX AF Qi, Meng Zhou, Huan Wang, Haiyan Wang, Rongjun Xiao, Lihua Arrowood, Michael J. Li, Junqiang Zhang, Longxian TI Molecular identification of Cryptosporidium spp. and Giardia duodenalis in grazing horses from Xinjiang, China SO VETERINARY PARASITOLOGY LA English DT Article DE Assemblage; Genotype; Cryptosporidium; Giardia duodenalis; Horses; PCR ID NEW-YORK; PARVUM; INFECTION; DIARRHEA; FOALS AB A total of 262 fecal specimens collected from grazing horses at five locations in Xinjiang, China were examined by PCR for Cryptosporidium spp. and Giardia duodenalis. The Cryptosporidium and G. duodenalis infection rates were 2.7% and 1.5%, respectively. Seven Cryptosporidium-positive specimens were found in foals (16.3%), and four G. duodenalispositive specimens were found in mares (2.5%). Sequence analyses of 18S rRNA and gp60 genes revealed that seven animals were positive for the subtype VIaA15G4 of Cryptosporidium horse genotype. G. duodenalis assemblages A and B were identified by molecular characterization of the 16S rRNA and tpi genes. This is the first report of Clyptosporidium horse genotype and G. duodenalis in grazing horses from China. (C) 2015 Elsevier B.V. All rights reserved. C1 [Qi, Meng; Zhou, Huan; Wang, Rongjun; Li, Junqiang; Zhang, Longxian] Henan Agr Univ, Coll Anim Sci & Vet Med, Zhengzhou 450002, Peoples R China. [Qi, Meng; Zhou, Huan; Wang, Rongjun; Li, Junqiang; Zhang, Longxian] Int Joint Res Lab Zoonot Dis Henan, Zhengzhou 450002, Peoples R China. [Wang, Haiyan] Henan Vocat Coll Agr, Dept Anim Sci, Zhongmu 451450, Henan, Peoples R China. [Xiao, Lihua; Arrowood, Michael J.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30333 USA. RP Zhang, LX (reprint author), Henan Agr Univ, Coll Anim Sci & Vet Med, Zhengzhou 450002, Peoples R China. EM zhanglx8999@henau.edu.cn RI Xiao, Lihua/B-1704-2013; OI Xiao, Lihua/0000-0001-8532-2727; zhang, longxian/0000-0002-5706-131X FU State Key Program of National Natural Science Foundation of China [31330079]; Specialized Research Fund for the Doctoral Program of Higher Education [20124105120003]; National Natural Science Foundation of China [U1204328, 31302079] FX This study was supported in part by the State Key Program of National Natural Science Foundation of China (No. 31330079), Specialized Research Fund for the Doctoral Program of Higher Education (No. 20124105120003), and the National Natural Science Foundation of China (Nos. U1204328, 31302079). NR 14 TC 7 Z9 7 U1 1 U2 5 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0304-4017 EI 1873-2550 J9 VET PARASITOL JI Vet. Parasitol. PD APR 30 PY 2015 VL 209 IS 3-4 BP 169 EP 172 DI 10.1016/j.vetpar.2015.02.030 PG 4 WC Parasitology; Veterinary Sciences SC Parasitology; Veterinary Sciences GA CG8YY UT WOS:000353602800004 PM 25794943 ER PT J AU Tang, L Lyles, RH King, CC Celentano, DD Lo, YT AF Tang, Li Lyles, Robert H. King, Caroline C. Celentano, David D. Lo, Yungtai TI Binary regression with differentially misclassified response and exposure variables SO STATISTICS IN MEDICINE LA English DT Article DE likelihood; logistic regressions; misclassification; odds ratio ID LOGISTIC-REGRESSION; PREDICTIVE-VALUE; RELATIVE RISK; ODDS RATIOS; SENSITIVITY-ANALYSIS; MEASUREMENT-ERROR; BIAS; LIKELIHOOD AB Misclassification is a long-standing statistical problem in epidemiology. In many real studies, either an exposure or a response variable or both may be misclassified. As such, potential threats to the validity of the analytic results (e.g., estimates of odds ratios) that stem from misclassification are widely discussed in the literature. Much of the discussion has been restricted to the nondifferential case, in which misclassification rates for a particular variable are assumed not to depend on other variables. However, complex differential misclassification patterns are common in practice, as we illustrate here using bacterial vaginosis and Trichomoniasis data from the HIV Epidemiology Research Study (HERS). Therefore, clear illustrations of valid and accessible methods that deal with complex misclassification are still in high demand. We formulate a maximum likelihood (ML) framework that allows flexible modeling of misclassification in both the response and a key binary exposure variable, while adjusting for other covariates via logistic regression. The approach emphasizes the use of internal validation data in order to evaluate the underlying misclassification mechanisms. Data-driven simulations show that the proposed ML analysis outperforms less flexible approaches that fail to appropriately account for complex misclassification patterns. The value and validity of the method are further demonstrated through a comprehensive analysis of the HERS example data. Copyright (c) 2015John Wiley & Sons, Ltd. C1 [Tang, Li] St Jude Childrens Res Hosp, Dept Biostat, Memphis, TN 38105 USA. [Lyles, Robert H.] Emory Univ, Rollins Sch Publ Hlth, Dept Biostat & Bioinformat, Atlanta, GA 30322 USA. [King, Caroline C.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA. [Celentano, David D.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Lo, Yungtai] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA. RP Tang, L (reprint author), St Jude Childrens Res Hosp, Dept Biostat, 332 N Lauderdale St, Memphis, TN 38105 USA. EM li.tang@stjude.org FU National Institute of Nursing Research [1RC4NR012527-01]; National Institute of Environmental Health Sciences [5R01ES012458-07]; National Center for Advancing Translational Sciences [UL1TR000454]; Centers for Disease Control and Prevention [U64/CCU106795, U64/CCU206798, U64/CCU306802, U64/CCU506831] FX This research was supported in part by grants from the National Institute of Nursing Research (1RC4NR012527-01), the National Institute of Environmental Health Sciences (5R01ES012458-07), and the National Center for Advancing Translational Sciences (UL1TR000454). The HERS was supported by the Centers for Disease Control and Prevention: U64/CCU106795, U64/CCU206798, U64/CCU306802, and U64/CCU506831. The findings and conclusions in this report are solely those of the authors and do not necessarily represent the official position of the National Institutes of Health or the Centers for Disease Control and Prevention. NR 36 TC 1 Z9 1 U1 4 U2 15 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0277-6715 EI 1097-0258 J9 STAT MED JI Stat. Med. PD APR 30 PY 2015 VL 34 IS 9 BP 1605 EP 1620 DI 10.1002/sim.6440 PG 16 WC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Medicine, Research & Experimental; Statistics & Probability SC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Research & Experimental Medicine; Mathematics GA CF4MV UT WOS:000352524100012 PM 25652841 ER PT J AU Braun, KVN Christensen, D Doernberg, N Schieve, L Rice, C Wiggins, L Schendel, D Yeargin-Allsopp, M AF Braun, Kim Van Naarden Christensen, Deborah Doernberg, Nancy Schieve, Laura Rice, Catherine Wiggins, Lisa Schendel, Diana Yeargin-Allsopp, Marshalyn TI Trends in the Prevalence of Autism Spectrum Disorder, Cerebral Palsy, Hearing Loss, Intellectual Disability, and Vision Impairment, Metropolitan Atlanta, 1991-2010 SO PLOS ONE LA English DT Article ID DEVELOPMENTAL-DISABILITIES; CHILDREN; SURVEILLANCE; INFANTS AB This study examined the prevalence and characteristics of autism spectrum disorder (ASD), cerebral palsy (CP), hearing loss (HL), intellectual disability (ID), and vision impairment (VI) over a 15-20 year time period, with specific focus on concurrent changes in ASD and ID prevalence. We used data from a population-based developmental disabilities surveillance program for 8-year-olds in metropolitan Atlanta. From 1991-2010, prevalence estimates of ID and HL were stable with slight increases in VI prevalence. CP prevalence was constant from 1993-2010. The average annual increase in ASD prevalence was 9.3% per year from 1996-2010, with a 269% increase from 4.2 per 1,000 in 1996 to 15.5 per 1,000 in 2010. From 2000-2010, the prevalence of ID without ASD was stable; during the same time, the prevalence of ASD with and without co-occurring ID increased by an average of 6.6% and 9.6% per year, respectively. ASD prevalence increases were found among both males and females, and among nearly all racial/ethnic subgroups and levels of intellectual ability. Average annual prevalence estimates from 1991-2010 underscore the significant community resources needed to provide early intervention and ongoing supports for children with ID (13.0 per 1,000), CP, (3.5 per 1,000), HL (1.4 per 1,000) and VI (1.3 in 1,000), with a growing urgency for children with ASD. C1 [Braun, Kim Van Naarden; Christensen, Deborah; Doernberg, Nancy; Schieve, Laura; Rice, Catherine; Wiggins, Lisa; Schendel, Diana; Yeargin-Allsopp, Marshalyn] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Dev Disabil Branch, Atlanta, GA 30333 USA. RP Braun, KVN (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Dev Disabil Branch, Atlanta, GA 30333 USA. EM kbn5@cdc.gov RI Rice, Catherine/D-6305-2016 NR 43 TC 12 Z9 12 U1 3 U2 14 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD APR 29 PY 2015 VL 10 IS 4 AR e0124120 DI 10.1371/journal.pone.0124120 PG 21 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CH0LO UT WOS:000353711600071 ER PT J AU Wingate, LT Coleman, MS Posey, DL Zhou, WG Olson, CK Maskery, B Cetron, MS Painter, JA AF Wingate, La'Marcus T. Coleman, Margaret S. Posey, Drew L. Zhou, Weigong Olson, Christine K. Maskery, Brian Cetron, Martin S. Painter, John A. TI Cost-Effectiveness of Screening and Treating Foreign-Born Students for Tuberculosis before Entering the United States SO PLOS ONE LA English DT Article ID US-BOUND IMMIGRANTS; PULMONARY TUBERCULOSIS; FOLLOW-UP; INFECTION; PREVALENCE; COUNTRIES; REFUGEES; SYSTEM; CHINA AB Introduction The Centers for Disease Control and Prevention is considering implementation of overseas medical screening of student-visa applicants to reduce the numbers of active tuberculosis cases entering the United States. Objective To evaluate the costs, cases averted, and cost-effectiveness of screening for, and treating, tuberculosis in United States-bound students from countries with varying tuberculosis prevalence. Methods Costs and benefits were evaluated from two perspectives, combined and United States only. The combined perspective totaled overseas and United States costs and benefits from a societal perspective. The United States only perspective was a domestic measure of costs and benefits. A decision tree was developed to determine the cost-effectiveness of tuberculosis screening and treatment from the combined perspective. Results From the United States only perspective, overseas screening programs of Chinese and Indian students would prevent the importation of 157 tuberculosis cases annually, and result in $2.7 million in savings. From the combined perspective, screening programs for Chinese students would cost more than $2.8 million annually and screening programs for Indian students nearly $440,000 annually. From the combined perspective, the incremental cost for each tuberculosis case averted by screening Chinese and Indian students was $22,187 and $15,063, respectively. Implementing screening programs for German students would prevent no cases in most years, and would result in increased costs both overseas and in the United States. The domestic costs would occur because public health departments would need to follow up on students identified overseas as having an elevated risk of tuberculosis. Conclusions Tuberculosis screening and treatment programs for students seeking long term visas to attend United States schools would reduce the number of tuberculosis cases imported. Implementing screening in high-incidence countries could save the United States millions of dollars annually; however there would be increased costs incurred overseas for students and their families. C1 [Wingate, La'Marcus T.; Coleman, Margaret S.; Posey, Drew L.; Zhou, Weigong; Olson, Christine K.; Maskery, Brian; Cetron, Martin S.; Painter, John A.] Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Atlanta, GA 30333 USA. RP Wingate, LT (reprint author), Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Atlanta, GA 30333 USA. EM latewing@gmail.com NR 73 TC 4 Z9 4 U1 0 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD APR 29 PY 2015 VL 10 IS 4 AR e0124116 DI 10.1371/journal.pone.0124116 PG 19 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CH0LO UT WOS:000353711600069 PM 25924009 ER PT J AU Xeuatvongsa, A Mirza, S Winter, C Feldon, K Vongphrachanh, P Phonekeo, D Denny, J Khanthamaly, V Kounnavong, B Lylianou, D Phousavath, S Norasingh, S Boutta, N Olsen, S Bresee, J Moen, A Corwin, A AF Xeuatvongsa, Anonh Mirza, Sara Winter, Christian Feldon, Keith Vongphrachanh, Phengta Phonekeo, Darouny Denny, Justin Khanthamaly, Viengphone Kounnavong, Bounheuang Lylianou, Doualy Phousavath, Sisouphane Norasingh, Sisouveth Boutta, Nao Olsen, Sonja Bresee, Joseph Moen, Ann Corwin, Andrew TI The Lao Experience in Deploying Influenza A (H1N1)pdm09 Vaccine: Lessons Made Relevant in Preparing for Present Day Pandemic Threats SO PLOS ONE LA English DT Article AB The Lao PDR, as did most countries of the Mekong Region, embarked on a pandemic vaccine initiative to counter the threat posed by influenza A(H1N1)pdm09. Overall, estimated vaccine coverage of the Lao population was 14%, with uptake in targeted health care workers and pregnant women 99% and 41%, respectively. Adverse Events Following Immunization accounted for only 6% of survey driven, reported vaccination experiences, with no severe consequences or deaths. Public acceptability of the vaccine campaign was high (98%). Challenges to vaccine deployment included: 1) no previous experience in fielding a seasonal influenza vaccine, 2) safety and efficacy concerns, and 3) late arrival of vaccine 10 months into the pandemic. The Lao success in surmounting these hurdles was in large measure attributed to the oversight assigned the National Immunization Program, and national sensitivities in responding to the avian influenza A(H5N1) crisis in the years leading up to the pandemic. The Lao "lessons learned" from pandemic vaccine deployment are made even more relevant four years on, given the many avian influenza strains circulating in the region, all with pandemic potential. C1 [Xeuatvongsa, Anonh; Norasingh, Sisouveth] Minist Hlth, Natl Immunizat Program, Viangchan, Laos. [Mirza, Sara; Olsen, Sonja; Bresee, Joseph; Moen, Ann] US Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. [Winter, Christian; Denny, Justin] World Hlth Org Western Pacific Reg, Emerging Dis Surveillance & Response Unit, Country Off, Viangchan, Laos. [Feldon, Keith] WHO, Country Off, Expanded Program Immunizat, Viangchan, Laos. [Vongphrachanh, Phengta; Phonekeo, Darouny] Minist Hlth, Natl Ctr Lab & Epidemiol, Viangchan, Laos. [Khanthamaly, Viengphone; Kounnavong, Bounheuang] US Ctr Dis Control & Prevent, Country Off, Viangchan, Laos. [Lylianou, Doualy; Phousavath, Sisouphane] Minist Hlth, Field Epidemiol Training Program, Natl Ctr Lab & Epidemiol, Viangchan, Laos. [Boutta, Nao] Minist Hlth, Cabinet, Viangchan, Laos. RP Corwin, A (reprint author), US Ctr Dis Control & Prevent, Country Off, Viangchan, Laos. EM Corwinal2e@yahoo.com FU World Health Organization [001] NR 12 TC 0 Z9 0 U1 0 U2 1 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD APR 29 PY 2015 VL 10 IS 4 AR e0121717 DI 10.1371/journal.pone.0121717 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CH0LO UT WOS:000353711600007 PM 25923779 ER PT J AU Kossyvakis, A Tao, Y Lu, XY Pogka, V Tsiodras, S Emmanouil, M Mentis, AF Tong, SX Erdman, DD Antoniadis, A AF Kossyvakis, Athanasios Tao, Ying Lu, Xiaoyan Pogka, Vasiliki Tsiodras, Sotirios Emmanouil, Mary Mentis, Andreas F. Tong, Suxiang Erdman, Dean D. Antoniadis, Antonios TI Laboratory Investigation and Phylogenetic Analysis of an Imported Middle East Respiratory Syndrome Coronavirus Case in Greece SO PLOS ONE LA English DT Article ID RECEPTOR-BINDING DOMAIN; PROTEIN AB Rapid and reliable laboratory diagnosis of persons suspected of Middle East respiratory syndrome coronavirus (MERS-CoV) infection is important for timely implementation of infection control practices and disease management. In addition, monitoring molecular changes in the virus can help elucidate chains of transmission and identify mutations that might influence virus transmission efficiency. This was illustrated by a recent laboratory investigation we conducted on an imported MERS-CoV case in Greece. Two oropharyngeal swab specimens were collected on the 1st and 2nd day of patient hospitalization and tested using two real-time RT-PCR (rRT-PCR) assays targeting the UpE and Orf-1a regions of the MERS-CoV genome and RT-PCR and partial sequencing of RNA-dependent RNA polymerase and nucleocapsid genes. Serum specimens were also collected and serological test were performed. Results from the first swab sample were inconclusive while the second swab was strongly positive for MERS-CoV RNA by rRT-PCR and confirmed positive by RTPCR and partial gene sequencing. Positive serologic test results further confirmed MERSCoV infection. Full-length nucleocapsid and spike gene coding sequences were later obtained from the positive swab sample. Phylogenetic analysis revealed that the virus was closely related to recent human-derived MERS-CoV strains obtained in Jeddah and Makkah, Saudi Arabia, in April 2014 and dromedary camels in Saudi Arabia and Qatar. These findings were consistent with the patient's history. We also identified a unique amino acid substitution in the spike receptor binding domain that may have implications for receptor binding efficiency. Our initial inconclusive rRT-PCR results highlight the importance of collecting multiple specimens from suspect MERS-CoV cases and particularly specimens from the lower respiratory tract. C1 [Kossyvakis, Athanasios; Pogka, Vasiliki; Emmanouil, Mary; Mentis, Andreas F.; Antoniadis, Antonios] Hellenic Pasteur Inst, Natl Influenza Reference Lab Southern Greece, Athens, Greece. [Tao, Ying; Lu, Xiaoyan; Tong, Suxiang; Erdman, Dean D.] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA USA. [Tsiodras, Sotirios] Hellen Ctr Dis Control & Prevent, Dept Epidemiol Surveillance & Intervent, Athens, Greece. RP Mentis, AF (reprint author), Hellenic Pasteur Inst, Natl Influenza Reference Lab Southern Greece, Athens, Greece. EM mentis@pasteur.gr NR 16 TC 3 Z9 4 U1 0 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD APR 28 PY 2015 VL 10 IS 4 AR e0125809 DI 10.1371/journal.pone.0125809 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CG9SE UT WOS:000353659400089 PM 25919137 ER PT J AU Rutanga, C Lowrance, DW Oeltmann, JE Mutembayire, G Willis, M Uwizeye, CB Hinda, R Bassirou, C Gutreuter, S Gasana, M AF Rutanga, Claude Lowrance, David W. Oeltmann, John E. Mutembayire, Grace Willis, Matt Uwizeye, Claude Bernard Hinda, Ruton Bassirou, Chitou Gutreuter, Steve Gasana, Michel TI Latent Tuberculosis Infection and Associated Factors among Health Care Workers in Kigali, Rwanda SO PLOS ONE LA English DT Article ID MULTIDRUG-RESISTANT TUBERCULOSIS; MYCOBACTERIUM-TUBERCULOSIS; RISK-FACTORS; 2 HOSPITALS; HIV; PREVALENCE; OUTBREAK; SETTINGS; DISEASE; CHINA AB Introduction Data are limited regarding tuberculosis (TB) and latent TB infection prevalence in Rwandan health facilities. Methods We conducted a cross-sectional survey among healthcare workers (HCWs) in Kigali during 2010. We purposively selected the public referral hospital, both district hospitals, and randomly selected 7 of 17 health centers. School workers (SWs) from the nearest willing public schools served as a local reference group. We tested for latent TB infection (LTBI) using tuberculin skin testing (TST) and asked about past TB disease. We assessed risk of LTBI and past history of TB disease associated with hospital employment. Among HCWs, we assessed risk associated with facility type (district hospital, referral hospital, health center), work setting (inpatient, outpatient), and occupation. Results Age, gender, and HIV status was similar between the enrolled 1,131 HCWs and 381 SWs. LTBI was more prevalent among HCWs (62%) than SWs (39%). Adjusted odds of a positive TST result were 2.71 (95% CI 2.01-3.67) times greater among HCWs than SWs. Among HCWs, there was no detectable difference between prevalence of LTBI according to facility type, work setting, or occupation. Conclusion HCWs are at greater risk of LTBI, regardless of facility type, work setting, or occupation. The current status of TB infection control practices should be evaluated in the entire workforce in all Rwandan healthcare facilities. C1 [Rutanga, Claude; Mutembayire, Grace; Gasana, Michel] Rwanda Biomed Ctr, Div TB & Other Resp Communicable Dis, Kigali, Rwanda. [Lowrance, David W.; Uwizeye, Claude Bernard; Bassirou, Chitou] Ctr Dis Control & Prevent, Div Global HIV AIDS, Kigali, Rwanda. [Oeltmann, John E.; Willis, Matt] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA USA. [Hinda, Ruton] Rwanda Biomed Ctr, Sexually Transmitted Infect, Div HIV AIDS, Kigali, Rwanda. [Hinda, Ruton] Rwanda Biomed Ctr, Other Blood Borne Dis, Kigali, Rwanda. [Gutreuter, Steve] Ctr Dis Control & Prevent, Div Global HIV AIDS, Atlanta, GA USA. RP Rutanga, C (reprint author), Rwanda Biomed Ctr, Div TB & Other Resp Communicable Dis, Kigali, Rwanda. EM rutanga75@yahoo.fr FU US Centres for Disease Control and Prevention [5U2GPS000643-03] FX Implementaion of this study was supported with funding from the US Centres for Disease Control and Prevention under the cooperative agreement between the Department of Health and Human Services/National Centre for HIV, Viral hepatitis, STDs and TB prevention, and the Rwanda Treatment/Research on AIDS Centre, on the grant number: 5U2GPS000643-03. The Centres for Disease Control and Prevention played a role in the study design, data analysis which was performed anonymously, decision to publish and preparation of the manuscript. NR 34 TC 2 Z9 2 U1 1 U2 5 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD APR 28 PY 2015 VL 10 IS 4 AR e0124485 DI 10.1371/journal.pone.0124485 PG 14 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CG9SE UT WOS:000353659400052 PM 25919759 ER PT J AU Boulet, SL Mehta, A Kissin, DM AF Boulet, Sheree L. Mehta, Akanksha Kissin, Dmitry M. TI Intracytoplasmic Sperm Injection and Reproductive Outcomes Reply SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Letter C1 [Boulet, Sheree L.; Mehta, Akanksha; Kissin, Dmitry M.] US Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30341 USA. RP Boulet, SL (reprint author), US Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy, Atlanta, GA 30341 USA. EM sbu1@cdc.gov NR 5 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD APR 28 PY 2015 VL 313 IS 16 BP 1672 EP 1673 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA CG8WD UT WOS:000353595200021 PM 25919534 ER PT J AU Sicuri, E Fernandes, S Macete, E Gonzalez, R Mombo-Ngoma, G Massougbodgi, A Abdulla, S Kuwawenaruwa, A Katana, A Desai, M Cot, M Ramharter, M Kremsner, P Slustker, L Aponte, J Hanson, K Menendez, C AF Sicuri, Elisa Fernandes, Silke Macete, Eusebio Gonzalez, Raquel Mombo-Ngoma, Ghyslain Massougbodgi, Achille Abdulla, Salim Kuwawenaruwa, August Katana, Abraham Desai, Meghna Cot, Michel Ramharter, Michael Kremsner, Peter Slustker, Laurence Aponte, John Hanson, Kara Menendez, Clara TI Economic Evaluation of an Alternative Drug to Sulfadoxine-Pyrimethamine as Intermittent Preventive Treatment of Malaria in Pregnancy SO PLOS ONE LA English DT Article ID SUB-SAHARAN AFRICA; EFFECTIVENESS ACCEPTABILITY CURVES; COST-EFFECTIVENESS ANALYSIS; PLASMODIUM-FALCIPARUM; CONTROLLED-TRIAL; HIV-INFECTION; WEST-AFRICA; IMPACT; MORTALITY; WOMEN AB Background Intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) is recommended in HIV-negative women to avert malaria, while this relies on cotrimoxazole prophylaxis (CTXp) in HIV-positive women. Alternative antimalarials are required in areas where parasite resistance to antifolate drugs is high. The cost-effectiveness of IPTp with alternative drugs is needed to inform policy. Methods The cost-effectiveness of 2-dose IPTp-mefloquine (MQ) was compared with IPTp-SP in HIV-negative women (Benin, Gabon, Mozambique and Tanzania). In HIV-positive women the cost-effectiveness of 3-dose IPTp-MQ added to CTXp was compared with CTXp alone (Kenya, Mozambique and Tanzania). The outcomes used were maternal clinical malaria, anaemia at delivery and non-obstetric hospital admissions. The poor tolerability to MQ was included as the value of women's loss of working days. Incremental cost-effectiveness ratios (ICERs) were calculated and threshold analysis undertaken. Results For HIV-negative women, the ICER for IPTp-MQ versus IPTp-SP was 136.30 US$ (2012 US$) (95%,CI 131.41; 141.18) per disability-adjusted life-year (DALY) averted, or 237.78 US$ (95%CI 230.99; 244.57), depending on whether estimates from Gabon were included or not. For HIV-positive women, the ICER per DALY averted for IPTp-MQ added to CTXp, versus CTXp alone was 6.96 US$ (95%CI 4.22; 9.70). In HIV-negative women, moderate shifts of variables such as malaria incidence, drug cost, and IPTp efficacy increased the ICERs above the cost-effectiveness threshold. In HIV-positive women the intervention remained cost-effective for a substantial (up to 21 times) increase in cost per tablet. Conclusions Addition of IPTp with an effective antimalarial to CTXp was very cost-effective in HIV-positive women. IPTp with an efficacious antimalarial was more cost-effective than IPTp-SP in HIV-negative women. However, the poor tolerability of MQ does not favour its use as IPTp. Regardless of HIV status, prevention of malaria in pregnancy with a highly efficacious, well tolerated antimalarial would be cost-effective despite its high price. C1 [Sicuri, Elisa; Gonzalez, Raquel; Aponte, John; Menendez, Clara] Univ Barcelona, Hosp Clin Barcelona, Barcelona Ctr Int Hlth Res CRESIB, ISGlobal, Barcelona, Spain. [Fernandes, Silke; Hanson, Kara] London Sch Hyg & Trop Med, London WC1, England. [Macete, Eusebio; Gonzalez, Raquel; Aponte, John; Menendez, Clara] Manhica Hlth Res Ctr CISM, Manhica, Mozambique. [Mombo-Ngoma, Ghyslain; Ramharter, Michael; Kremsner, Peter] Albert Schweitzer Hosp, Ctr Rech Med Lambarene CERMEL, Lambarene, Gabon. [Mombo-Ngoma, Ghyslain; Ramharter, Michael; Kremsner, Peter] Univ Tubingen, Inst Trop Med, Tubingen, Germany. [Massougbodgi, Achille] Univ Abomey Calavi, Fac Sci Sante, Cotonou, Benin. [Abdulla, Salim; Kuwawenaruwa, August] Ifakara Hlth Inst, Dar Es Salaam, Tanzania. [Katana, Abraham] Kenya Med Res Inst KEMRI, Ctr Global Hlth Res, Kisumu, Kenya. [Desai, Meghna; Slustker, Laurence] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA USA. [Desai, Meghna; Slustker, Laurence] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Ctr Global Hlth, Kisumu, Kenya. [Cot, Michel] Inst Rech Dev, Paris, France. [Cot, Michel] Univ Paris 05, Paris, France. [Ramharter, Michael] Med Univ Vienna, Dept Med 1, Div Infect Dis & Trop Med, Vienna, Austria. RP Sicuri, E (reprint author), Univ Barcelona, Hosp Clin Barcelona, Barcelona Ctr Int Hlth Res CRESIB, ISGlobal, Barcelona, Spain. EM elisa.sicuri@cresib.cat RI Sicuri, Elisa/L-8012-2014; Ramharter, Michael/C-5273-2013 OI Sicuri, Elisa/0000-0002-2499-2732; Ramharter, Michael/0000-0002-9259-1885 FU MiP Consortium - Bill & Melinda Gates Foundation FX This study was supported by MiP Consortium, which is funded through a grant from the Bill & Melinda Gates Foundation to the Liverpool School of Tropical Medicine. NR 69 TC 2 Z9 2 U1 2 U2 10 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD APR 27 PY 2015 VL 10 IS 4 AR e0125072 DI 10.1371/journal.pone.0125072 PG 23 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CG9SB UT WOS:000353659100094 PM 25915616 ER PT J AU Simhadri, VR Dimitrova, M Mariano, JL Zenarruzabeitia, O Zhong, WM Ozawa, T Muraguchi, A Kishi, H Eichelberger, MC Borrego, F AF Simhadri, Venkateswara R. Dimitrova, Milena Mariano, John L. Zenarruzabeitia, Olatz Zhong, Weimin Ozawa, Tatsuhiko Muraguchi, Atsushi Kishi, Hiroyuki Eichelberger, Maryna C. Borrego, Francisco TI A Human Anti-M2 Antibody Mediates Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Cytokine Secretion by Resting and Cytokine-Preactivated Natural Killer (NK) Cells SO PLOS ONE LA English DT Article ID INFLUENZA-A VIRUS; HUMAN MONOCLONAL-ANTIBODY; MATRIX PROTEIN-2; M2 PROTEIN; EXTRACELLULAR DOMAIN; SEASONAL INFLUENZA; ADAPTIVE IMMUNITY; UNIVERSAL VACCINE; INFECTION; PROTECTION AB The highly conserved matrix protein 2 (M2) is a good candidate for the development of a broadly protective influenza vaccine that induces long-lasting immunity. In animal models, natural killer (NK) cells have been proposed to play an important role in the protection provided by M2-based vaccines through a mechanism of antibody-dependent cell-mediated cytotoxicity (ADCC). We investigated the ability of the human anti-M2 Ab1-10 monoclonal antibody (mAb) to activate human NK cells. They mediated ADCC against M2-expressing cells in the presence of Ab1-10 mAb. Furthermore, NK cell pro-inflammatory cytokine and chemokine secretion is also enhanced when Ab1-10 mAb is present. We also generated cytokine-preactivated NK cells and showed that they still displayed increased effector functions in the presence of Ab1-10 mAb. Thus, our study has demonstrated that human resting and cytokine-preactivated NK cells may have a very important role in the protection provided by anti-M2 Abs. C1 [Simhadri, Venkateswara R.; Dimitrova, Milena; Mariano, John L.; Borrego, Francisco] US FDA, Div Biotechnol Review & Res 1, Off Biotechnol Prod Review & Res, Ctr Drug Evaluat & Res, Silver Spring, MD 20903 USA. [Zenarruzabeitia, Olatz] BioCruces Hlth Res Inst, Immunopathol Grp, Baracaldo, Basque Country, Spain. [Zenarruzabeitia, Olatz] Basque Ctr Transfus & Human Tissues, Cell Therapy & Stem Cell Grp, Galdakao, Basque Country, Spain. [Zhong, Weimin] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Ozawa, Tatsuhiko; Muraguchi, Atsushi; Kishi, Hiroyuki] Toyama Univ, Grad Sch Med & Pharmaceut Sci, Dept Immunol, Toyama, Japan. [Eichelberger, Maryna C.] Food & Drug Adm, Div Viral Prod, Ctr Biol Evaluat & Res, Silver Spring, MD USA. [Borrego, Francisco] Basque Fdn Sci, Ikerbasque, Bilbao, Basque Country, Spain. RP Simhadri, VR (reprint author), US FDA, Div Biotechnol Review & Res 1, Off Biotechnol Prod Review & Res, Ctr Drug Evaluat & Res, Silver Spring, MD 20903 USA. EM venkateswara.simhadri@fda.hhs.gov; francisco.borregorabasco@osakidetza.net FU Medical Counter Measure Initiatives (MCMi), U.S. Food and Drug Administration (FDA) FX This work was funded by the Medical Counter Measure Initiatives (MCMi), U.S. Food and Drug Administration (FDA). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 49 TC 4 Z9 4 U1 0 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD APR 27 PY 2015 VL 10 IS 4 AR e0124677 DI 10.1371/journal.pone.0124677 PG 13 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CG9SB UT WOS:000353659100060 PM 25915748 ER PT J AU Liu, YV Massare, MJ Pearce, MB Sun, XJ Belser, JA Maines, TR Creager, HM Glenn, GM Pushko, P Smith, GE Tumpey, TM AF Liu, Ye V. Massare, Michael J. Pearce, Melissa B. Sun, Xiangjie Belser, Jessica A. Maines, Taronna R. Creager, Hannah M. Glenn, Gregory M. Pushko, Peter Smith, Gale E. Tumpey, Terrence M. TI Recombinant virus-like particles elicit protective immunity against avian influenza A(H7N9) virus infection in ferrets SO VACCINE LA English DT Article DE Influenza; Virus; Vaccine; Avian influenza; Ferret ID A H7N9 VIRUS; INTRANASAL VACCINATION; CONFERS PROTECTION; MICE; RESPONSES; HEMAGGLUTININ; CHALLENGE; VACCINES; ANTIBODIES; CANDIDATE AB In March 2013, diagnosis of the first reported case of human infection with a novel avian-origin influenza A(H7N9) virus occurred in eastern China. Most human cases have resulted in severe respiratory illness and, in some instances, death. Currently there are no licensed vaccines against H7N9 virus, which continues to cause sporadic human infections. Recombinant virus-like particles (VLPs) have been previously shown to be safe and effective vaccines for influenza. In this study, we evaluated the immunogenicity and protective efficacy of a H7N9 VLP vaccine in the ferret challenge model. Purified recombinant H7N9 VLPs morphologically resembled influenza virions and elicited high-titer serum hemagglutination inhibition (HI) and neutralizing antibodies specific for A/Anhui/1/2013 (H7N9) virus. H7N9 VLP-immunized ferrets subsequently challenged with homologous virus displayed reductions in fever, weight loss, and virus shedding compared to these parameters in unimmunized control ferrets. H7N9 VLP was also effective in protecting against lung and tracheal infection. The addition of either ISCOMATRIX or Matrix-MI adjuvant improved immunogenicity and protection of the VLP vaccine against H7N9 virus. These results provide support for the development of a safe and effective human VLP vaccine with potent adjuvants against avian influenza H7N9 virus with pandemic potential. Published by Elsevier Ltd. C1 [Liu, Ye V.; Massare, Michael J.; Glenn, Gregory M.; Smith, Gale E.] Novavax Inc, Gaithersburg, MD 20878 USA. [Pushko, Peter] Medigen Inc, Frederick, MD USA. [Pearce, Melissa B.; Sun, Xiangjie; Belser, Jessica A.; Maines, Taronna R.; Creager, Hannah M.; Tumpey, Terrence M.] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Creager, Hannah M.] Emory Univ, Microbiol & Mol Genet Grad Program, Atlanta, GA 30322 USA. RP Tumpey, TM (reprint author), Influenza Div, MS G-16,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM tft9@cdc.gov NR 43 TC 14 Z9 14 U1 0 U2 8 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD APR 27 PY 2015 VL 33 IS 18 BP 2152 EP 2158 DI 10.1016/j.vaccine.2015.03.009 PG 7 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA CH0XQ UT WOS:000353746100007 PM 25772674 ER PT J AU Messacar, K Schreiner, TL Maloney, JA Wallace, A Ludke, J Oberste, MS Nix, WA Robinson, CC Glode, MP Abzug, MJ Dominguez, SR AF Messacar, Kevin Schreiner, Teri L. Maloney, John A. Wallace, Adam Ludke, Jan Oberste, M. Stephen Nix, W. Allan Robinson, Christine C. Glode, Mary P. Abzug, Mark J. Dominguez, Samuel R. TI A cluster of acute flaccid paralysis and cranial nerve dysfunction temporally associated with an outbreak of enterovirus D68 in children in Colorado, USA SO LANCET LA English DT Article ID POLIOMYELITIS-LIKE ILLNESS; RESPIRATORY ILLNESS; UNITED-STATES; PCR; INFECTION; SPECIMENS; MYELITIS; DISEASE; VIRUS AB Background Clusters of acute flaccid paralysis or cranial nerve dysfunction in children are uncommon. We aimed to assess a cluster of children with acute flaccid paralysis and cranial nerve dysfunction geographically and temporally associated with an outbreak of enterovirus-D68 respiratory disease. Methods We defined a case of neurological disease as any child admitted to Children's Hospital Colorado (Aurora, CO, USA) with acute flaccid paralysis with spinal-cord lesions involving mainly grey matter on imaging, or acute cranial nerve dysfunction with brainstem lesions on imaging, who had onset of neurological symptoms between Aug 1, 2014, and Oct 31, 2014. We used Poisson regression to assess whether the numbers of cases during the outbreak period were significantly greater than baseline case numbers from a historical control period (July 31, 2010, to July 31, 2014). Findings 12 children met the case definition (median age 11.5 years [IQR 6.75-15]). All had a prodromal febrile illness preceding neurological symptoms by a median of 7 days (IQR 5.75-8). Neurological deficits included flaccid limb weakness (n=10; asymmetric n=7), bulbar weakness (n=6), and cranial nerve VI (n=3) and VII (n=2) dysfunction. Ten (83%) children had confluent, longitudinally extensive spinal-cord lesions of the central grey matter, with predominant anterior horn-cell involvement, and nine (75%) children had brainstem lesions. Ten (91%) of 11 children had cerebrospinal fluid pleocytosis. Nasopharyngeal specimens from eight (73%) of 11 children were positive for rhinovirus or enterovirus. Viruses from five (45%) of 11 children were typed as enterovirus D68. Enterovirus PCR of cerebrospinal fluid, blood, and rectal swabs, and tests for other causes, were negative. Improvement of cranial nerve dysfunction has been noted in three (30%) of ten children. All ten children with limb weakness have residual deficits. Interpretation We report the first geographically and temporally defined cluster of acute flaccid paralysis and cranial nerve dysfunction in children associated with an outbreak of enterovirus-D68 respiratory illness. Our findings suggest the possibility of an association between enterovirus D68 and neurological disease in children. If enterovirus-D68 infections continue to happen in an endemic or epidemic pattern, development of effective antiviral or immunomodulatory therapies and vaccines should become scientific priorities. C1 [Messacar, Kevin; Glode, Mary P.; Abzug, Mark J.; Dominguez, Samuel R.] Childrens Hosp Colorado, Dept Pediat Infect Dis, Aurora, CO 80045 USA. [Messacar, Kevin] Childrens Hosp Colorado, Hosp Med, Aurora, CO 80045 USA. [Schreiner, Teri L.; Wallace, Adam; Ludke, Jan] Childrens Hosp Colorado, Dept Child Neurol, Aurora, CO 80045 USA. [Maloney, John A.] Childrens Hosp Colorado, Dept Radiol, Aurora, CO 80045 USA. [Robinson, Christine C.] Childrens Hosp Colorado, Dept Pathol & Lab Med, Aurora, CO 80045 USA. Univ Colorado, Sch Med, Aurora, CO 80045 USA. [Oberste, M. Stephen; Nix, W. Allan] Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Dominguez, SR (reprint author), Childrens Hosp Colorado, Dept Pediat Infect Dis, Aurora, CO 80045 USA. EM samuel.dominguez@childrenscolorado.org FU National Center for Advancing Translational Sciences, National Institutes of Health FX National Center for Advancing Translational Sciences, National Institutes of Health. NR 31 TC 62 Z9 63 U1 1 U2 10 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0140-6736 EI 1474-547X J9 LANCET JI Lancet PD APR 25 PY 2015 VL 385 IS 9978 BP 1662 EP 1671 DI 10.1016/S0140-6736(14)62457-0 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA CG6NG UT WOS:000353418000039 PM 25638662 ER PT J AU Cali, I Miller, C Kitamoto, T Parisi, J Geschwind, M Gambetti, P Schonberger, L AF Cali, Ignazio Miller, Cathleen Kitamoto, Tetsuyuky Parisi, Joseph Geschwind, Michael Gambetti, Pierluigi Schonberger, Lawrence TI Distinct pathological phenotypes of Creutzfeldt-Jakob disease in recipients of prion-contaminated growth hormone SO PRION LA English DT Meeting Abstract C1 [Cali, Ignazio; Gambetti, Pierluigi] Case Western Reserve Univ, Sch Med, Dept Pathol, NPDPSC, Cleveland, OH 44106 USA. [Cali, Ignazio] Univ Naples 2, Dept Clin & Expt Med, Naples, Italy. [Miller, Cathleen] Kaiser Permanente Vancouver Med Ctr, Vancouver, WA USA. [Kitamoto, Tetsuyuky] Tohoku Univ, Grad Sch Med, Sendai, Miyagi 980, Japan. [Parisi, Joseph] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA. [Parisi, Joseph] Mayo Clin, Dept Neurol, Rochester, MN USA. [Geschwind, Michael] Univ Calif San Francisco, Dept Neurol, Memory & Aging Ctr, San Francisco, CA USA. [Schonberger, Lawrence] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1933-6896 EI 1933-690X J9 PRION JI Prion PD APR 24 PY 2015 VL 9 SU 1 MA P.69 BP S47 EP S48 PG 2 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA CI0RG UT WOS:000354444900087 ER PT J AU Maddox, R Person, M Minino, A Blevins, J Schonberger, L Belay, E AF Maddox, Ryan Person, Marissa Minino, Arialdi Blevins, Janis Schonberger, Lawrence Belay, Ermias TI Improving Creutzfeldt-Jakob disease incidence estimates by incorporating results of neuropathological analyses, United States, 2003-2011 SO PRION LA English DT Meeting Abstract C1 [Maddox, Ryan; Person, Marissa; Schonberger, Lawrence; Belay, Ermias] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Minino, Arialdi] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. [Blevins, Janis] Case Western Reserve Univ, Natl Prion Dis Pathol Surveillance Ctr, Cleveland, OH 44106 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1933-6896 EI 1933-690X J9 PRION JI Prion PD APR 24 PY 2015 VL 9 SU 1 MA P.85 BP S55 EP S56 PG 2 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA CI0RG UT WOS:000354444900103 ER PT J AU Hakim, AJ Aho, J Semde, G Diarrassouba, M Ehoussou, K Vuylsteke, B Murrill, CS Thiam, M Wingate, T AF Hakim, Avi J. Aho, Josephine Semde, Gisele Diarrassouba, Mamadou Ehoussou, Konan Vuylsteke, Bea Murrill, Christopher S. Thiam, Marguerite Wingate, Therese CA SHARM Study Grp TI The Epidemiology of HIV and Prevention Needs of Men Who Have Sex with Men in Abidjan, Cote d'Ivoire SO PLOS ONE LA English DT Article ID PREVALENCE; INFECTION; RISKS AB To determine HIV prevalence and associated risk factors among men who have sex with men (MSM) in Abidjan, C (o) over cap te d'Ivoire. We conducted a cross-sectional RDS survey of MSM in Abidjan from October 2011 to February 2012. Eligibility criteria included age >= 18 years and having had oral or anal sex with another man in the last 12 months. Weighted data analysis was conducted with RDSAT and SAS. We enrolled 603 participants, of whom 601 (99.7%) completed the questionnaire and 581 (96.7%) consented to HIV testing. HIV population prevalence was estimated as 18.0% (95% CI: 13.0-23.1); 86.4%(95% CI: 75.1-94.9) of HIV-positive MSM were unaware of their serostatus. In multivariable analysis, adjusting for age, education, and income, HIV infection was associated with unprotected sex at last sex with a woman, more than two male anal sex partners in last 12 months, inconsistent condom use during anal sex with a man, self-perceived risk of HIV, history of forced sex, history of physical abuse due to MSM status, and not receiving last HIV test result prior to study. HIV prevalence among MSM in Abidjan is more than four times as high as that of general population men. MSM engage in high-risk sexual behavior and most HIV-positive MSM are unaware of their serostatus. Greater access to HIV prevention, care, and treatment services targeted to MSM is necessary. C1 [Hakim, Avi J.; Murrill, Christopher S.] US Ctr Dis Control & Prevent, Div Global HIV AIDS, Atlanta, GA 30333 USA. [Aho, Josephine; Vuylsteke, Bea] Inst Trop Med, B-2000 Antwerp, Belgium. [Semde, Gisele] FHI 360, Abidjan, Cote Ivoire. [Diarrassouba, Mamadou; Ehoussou, Konan; Wingate, Therese] US Ctr Dis Control & Prevent, Div Global HIV AIDS, Abidjan, Cote Ivoire. [Thiam, Marguerite] Minist Hlth & Fight HIV, Abidjan, Cote Ivoire. RP Hakim, AJ (reprint author), US Ctr Dis Control & Prevent, Div Global HIV AIDS, Atlanta, GA 30333 USA. EM hxv8@cdc.gov FU U.S. President's Emergency Plan for AIDS Relief through U.S. Centers for Disease Control and Prevention (CDC) [FHI360]; Canadian Institutes for Health Research FX The survey was funded by the U.S. President's Emergency Plan for AIDS Relief through the U.S. Centers for Disease Control and Prevention (CDC), which provided funding to FHI360. JA is a recipient of a postdoctoral fellowship by the Canadian Institutes for Health Research. CDC employees were involved in the study design, analysis, decision to publish, and preparation of the manuscript. NR 27 TC 4 Z9 4 U1 0 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD APR 24 PY 2015 VL 10 IS 4 AR e0125218 DI 10.1371/journal.pone.0125218 PG 13 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CG6AH UT WOS:000353376800135 PM 25909484 ER PT J AU Martin, M Vanichseni, S Suntharasamai, P Sangkum, U Mock, PA Leethochawalit, M Chiamwongpaet, S Curlin, ME Na-pompet, S Warapronmongkholkul, A Kittimunkong, S Gvetadze, RJ McNicholl, JM Paxton, LA Choopanya, K AF Martin, Michael Vanichseni, Suphak Suntharasamai, Pravan Sangkum, Udomsak Mock, Philip A. Leethochawalit, Manoj Chiamwongpaet, Sithisat Curlin, Marcel E. Na-pompet, Supawadee Warapronmongkholkul, Anchalee Kittimunkong, Somyot Gvetadze, Roman J. McNicholl, Janet M. Paxton, Lynn A. Choopanya, Kachit CA Bangkok Tenofovir Study Grp TI The impact of adherence to preexposure prophylaxis on the risk of HIV infection among people who inject drugs SO AIDS LA English DT Article DE adherence; HIV; people who inject drugs; preexposure prophylaxis; tenofovir ID HUMAN-IMMUNODEFICIENCY-VIRUS; ANTIRETROVIRAL PROPHYLAXIS; PHASE-3 TRIAL; DOUBLE-BLIND; PREVENTION; TENOFOVIR; WOMEN; EMTRICITABINE; TRANSMISSION; COMBINATION AB Objective:To describe participant adherence to daily oral tenofovir in an HIV preexposure prophylaxis (PrEP) trial, examine factors associated with adherence, and assess the impact of adherence on the risk of HIV infection.Design:The Bangkok Tenofovir Study was a randomized, double-blind, placebo-controlled trial conducted among people who inject drugs, 2005-2012.Methods:Participants chose daily visits or monthly visits. Study nurses observed participants swallow study drug and both initialed a diary. We assessed adherence using the diary. We examined adherence by age group and sex and used logistic regression to evaluate demographics and risk behaviors as predictors of adherence and Cox regression to assess the impact of adherence on the risk of HIV infection.Results:A total of 2413 people enrolled and contributed 9665 person-years of follow-up (mean 4.0 years, maximum 6.9 years). The risk of HIV infection decreased as adherence improved, from 48.9% overall to 83.5% for those with at least 97.5% adherence. In multivariable analysis, men were less adherent than women (P=0.006) and participants 20-29 years old (P<0.001) and 30-39 years old (P=0.01) were less adherent than older participants. Other factors associated with poor adherence included incarceration (P=0.02) and injecting methamphetamine (P=0.04).Conclusion:In this HIV PrEP trial among people who inject drugs, improved adherence to daily tenofovir was associated with a lower risk of HIV infection. This is consistent with trials among MSM and HIV-discordant heterosexual couples and suggests that HIV PrEP can provide a high level of protection from HIV infection. C1 [Martin, Michael; Mock, Philip A.; Curlin, Marcel E.; Na-pompet, Supawadee; Warapronmongkholkul, Anchalee] Thailand MOPH US CDC Collaborat, Nonthaburi, Thailand. [Martin, Michael; Mock, Philip A.; Curlin, Marcel E.; Gvetadze, Roman J.; McNicholl, Janet M.; Paxton, Lynn A.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Vanichseni, Suphak; Suntharasamai, Pravan; Sangkum, Udomsak; Choopanya, Kachit] Bangkok Tenofovir Study Grp, Bangkok, Thailand. [Leethochawalit, Manoj; Chiamwongpaet, Sithisat] Bangkok Metropolitan Adm, Bangkok, Thailand. [Kittimunkong, Somyot] Thailand Minist Publ Hlth, Nonthaburi, Thailand. RP Martin, M (reprint author), Minist Publ Hlth, HIV Clin Res, Thailand MOPH US CDC Collaborat, DDC 7 Bldg,4th Floor,Soi 4, Nonthaburi 11000, Thailand. EM Znd9@cdc.gov FU U.S. Centers for Disease Control and Prevention; Bangkok Metropolitan Administration FX Source of funding: The study was supported by the U.S. Centers for Disease Control and Prevention and the Bangkok Metropolitan Administration. Study drug was donated by Gilead Sciences. NR 33 TC 11 Z9 12 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0269-9370 EI 1473-5571 J9 AIDS JI Aids PD APR 24 PY 2015 VL 29 IS 7 BP 819 EP 824 DI 10.1097/QAD.0000000000000613 PG 6 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA CG7FV UT WOS:000353469000008 PM 25985403 ER PT J AU Chang, TS Wiener, J Dollard, SC Amin, MM Ellington, S Chasela, C Kayira, D Tegha, G Kamwendo, D Jamieson, DJ van der Horst, C Kourtis, AP AF Chang, Tiffany S. Wiener, Jeffrey Dollard, Sheila C. Amin, Minal M. Ellington, Sascha Chasela, Charles Kayira, Dumbani Tegha, Gerald Kamwendo, Deborah Jamieson, Denise J. van der Horst, Charlie Kourtis, Athena P. CA BAN Study Team TI Effect of cytomegalovirus infection on breastfeeding transmission of HIV and on the health of infants born to HIV-infected mothers SO AIDS LA English DT Article DE breastfeeding; cytomegalovirus; HIV; infant; mother-to-child transmission ID IMMUNODEFICIENCY-VIRUS TYPE-1; ACTIVE ANTIRETROVIRAL THERAPY; CHILDREN; PROGRESSION; DISEASE; MILK; MORTALITY; AFRICA; CMV AB Background:Cytomegalovirus (CMV) infection can be acquired in utero or postnatally through horizontal transmission and breastfeeding. The effect of postnatal CMV infection on postnatal HIV transmission is unknown.Methods:The Breastfeeding, Antiretrovirals and Nutrition study, conducted in Malawi, randomized 2369 mothers and their infants to three antiretroviral prophylaxis arms - mother (triple regimen), infant (nevirapine), or neither - for 28 weeks of breastfeeding, followed by weaning. Stored plasma and peripheral blood mononuclear cell specimens were available for 492 infants at 24 weeks and were tested with CMV PCR. Available samples from infants who were CMV PCR-positive at 24 weeks were also tested at birth (N=242), and from infants PCR-negative at 24 weeks were tested at 48 weeks (N=96). Cox proportional-hazards models were used to determine if CMV infection was associated with infant morbidity, mortality, or postnatal HIV acquisition.Results:At 24 weeks of age, CMV DNA was detected in 345/492 infants (70.1%); the estimated congenital CMV infection rate was 2.3%, and the estimated rate of CMV infection at 48 weeks was 78.5%. CMV infection at 24 weeks was associated with subsequent HIV acquisition through breastfeeding or infant death between 24 and 48 weeks of age (hazard ratio 4.27, P=0.05).Conclusion:Most breastfed infants of HIV-infected mothers in this resource-limited setting are infected with CMV by 24 weeks of age. Early CMV infection may be a risk factor for subsequent infant HIV infection through breastfeeding, pointing to the need for comprehensive approaches in order to achieve elimination of breastfeeding transmission of HIV. C1 [Chang, Tiffany S.] Emory Univ, Sch Med, Atlanta, GA 30341 USA. [Wiener, Jeffrey; Dollard, Sheila C.; Amin, Minal M.; Ellington, Sascha; Jamieson, Denise J.; Kourtis, Athena P.] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Chasela, Charles; Kayira, Dumbani; Tegha, Gerald; Kamwendo, Deborah] UNC Project, Lilongwe, Malawi. [van der Horst, Charlie] Univ N Carolina, Chapel Hill, NC USA. RP Kourtis, AP (reprint author), Emory Univ, Sch Med, Div Reprod Hlth, NCCDPHP,Ctr Dis Control & Prevent,Pediat, 4770 Buford Highway NE, Atlanta, GA 30341 USA. EM apk3@cdc.gov OI Flax, Valerie/0000-0003-0200-3355 FU Prevention Research Centers Special Interest Project of the Centers for Disease Control and Prevention [SIP 13-01 U48-CCU409660-09, SIP 26-04 U48-DP000059-01, SIP 22-09 U48-DP001944-01]; National Institute of Allergy and Infectious Diseases; University of North Carolina Center for AIDS Research [P30-AI50410]; NIH Fogarty AIDS International Training and Research Program (DHHS/NIH/FIC) [2-D43 Tw01039-06, R24 Tw00798]; Bill and Melinda Gates Foundation [OPP53107]; Elizabeth Glaser Pediatric AIDS Foundation; United Nations Children's Fund; World Food Program; Malawi Ministry of Health and Population; Johnson Johnson; U.S. Agency for International Development FX Funding: The Breastfeeding, Antiretrovirals, and Nutrition Study was supported by grants from the Prevention Research Centers Special Interest Project of the Centers for Disease Control and Prevention (SIP 13-01 U48-CCU409660-09, SIP 26-04 U48-DP000059-01, and SIP 22-09 U48-DP001944-01); the National Institute of Allergy and Infectious Diseases, the University of North Carolina Center for AIDS Research (P30-AI50410); the NIH Fogarty AIDS International Training and Research Program (DHHS/NIH/FIC 2-D43 Tw01039-06 and R24 Tw00798; the American Recovery and Reinvestment Act); and the Bill and Melinda Gates Foundation (Grant # OPP53107). The antiretrovirals used in the BAN study were donated by Abbott Laboratories, GlaxoSmithKline, Boehringer Ingelheim, Roche Pharmaceuticals, and Bristol-Myers Squibb. The Call to Action PMTCT program was supported by the Elizabeth Glaser Pediatric AIDS Foundation, the United Nations Children's Fund, the World Food Program, the Malawi Ministry of Health and Population, Johnson & Johnson, and the U.S. Agency for International Development. NR 23 TC 9 Z9 9 U1 1 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0269-9370 EI 1473-5571 J9 AIDS JI Aids PD APR 24 PY 2015 VL 29 IS 7 BP 831 EP 836 DI 10.1097/QAD.0000000000000617 PG 6 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA CG7FV UT WOS:000353469000010 PM 25985405 ER PT J AU Gomaa, AE Tapp, LC Luckhaupt, SE Vanoli, K Sarmiento, RF Raudabaugh, WM Nowlin, S Sprigg, SM AF Gomaa, Ahmed E. Tapp, Loren C. Luckhaupt, Sara E. Vanoli, Kelly Sarmiento, Raymond Francis Raudabaugh, William M. Nowlin, Susan Sprigg, Susan M. TI Occupational Traumatic Injuries Among Workers in Health Care Facilities - United States, 2012-2014 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Gomaa, Ahmed E.; Tapp, Loren C.; Luckhaupt, Sara E.; Vanoli, Kelly; Sarmiento, Raymond Francis; Raudabaugh, William M.; Nowlin, Susan; Sprigg, Susan M.] NIOSH, Div Surveillance Hazard Evaluat & Field Studies, Washington, DC 20201 USA. [Sarmiento, Raymond Francis] CDC, Publ Hlth Informat Fellowship Program, Div Sci Educ & Profess Dev, Ctr Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA. RP Gomaa, AE (reprint author), NIOSH, Div Surveillance Hazard Evaluat & Field Studies, Washington, DC 20201 USA. EM agomaa@cdc.gov NR 8 TC 4 Z9 4 U1 2 U2 10 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD APR 24 PY 2015 VL 64 IS 15 BP 405 EP 410 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CG6NJ UT WOS:000353418400001 PM 25905893 ER PT J AU Casey, M Stanton, ML Cummings, KJ Pechter, E Fitzsimmons, K LeBouf, RF Schuler, CR Kreiss, K AF Casey, Megan Stanton, Marcia L. Cummings, Kristin J. Pechter, Elise Fitzsimmons, Kathleen LeBouf, Ryan F. Schuler, Christine R. Kreiss, Kathleen TI Work-Related Asthma Cluster at a Syntactic Foam Manufacturing Facility - Massachusetts 2008-2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Editorial Material ID MANAGEMENT; STATEMENT; ANHYDRIDE C1 [Casey, Megan] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Casey, Megan; Stanton, Marcia L.; Cummings, Kristin J.; LeBouf, Ryan F.; Kreiss, Kathleen] NIOSH, Div Resp Dis Studies, CDC, Washington, DC 20201 USA. [Pechter, Elise; Fitzsimmons, Kathleen] Massachusetts Dept Publ Hlth, Occupat Hlth Surveillance Program, Boston, MA 02111 USA. [Schuler, Christine R.] NIOSH, Div Safety Res, CDC, Washington, DC 20201 USA. RP Casey, M (reprint author), CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. EM mcasey@cdc.gov NR 10 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD APR 24 PY 2015 VL 64 IS 15 BP 411 EP 414 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CG6NJ UT WOS:000353418400003 PM 25905894 ER PT J AU Porter, KA Diop, OM Burns, CC Tangermann, RH Wassilak, SGF AF Porter, Kimberly A. Diop, Ousmane M. Burns, Cara C. Tangermann, Rudolph H. Wassilak, Steven G. F. TI Tracking Progress Toward Polio Eradication - Worldwide, 2013-2014 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Editorial Material ID SURVEILLANCE; SYSTEMS C1 [Porter, Kimberly A.; Wassilak, Steven G. F.] CDC, Global Immunizat Div, Atlanta, GA 30333 USA. [Diop, Ousmane M.; Tangermann, Rudolph H.] WHO, Polio Eradicat Dept, CH-1211 Geneva, Switzerland. [Burns, Cara C.] CDC, Div Viral Dis, Atlanta, GA 30333 USA. RP Porter, KA (reprint author), CDC, Global Immunizat Div, Atlanta, GA 30333 USA. EM kaporter@cdc.gov NR 8 TC 15 Z9 15 U1 0 U2 3 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD APR 24 PY 2015 VL 64 IS 15 BP 415 EP 420 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CG6NJ UT WOS:000353418400004 PM 25905895 ER PT J AU Cordero, AM Crider, KS Rogers, LM Cannon, MJ Berry, RJ AF Cordero, Amy M. Crider, Krista S. Rogers, Lisa M. Cannon, Michael J. Berry, R. J. TI Optimal Serum and Red Blood Cell Folate Concentrations in Women of Reproductive Age for Prevention of Neural Tube Defects: World Health Organization Guidelines SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Editorial Material ID FOLIC-ACID C1 [Cordero, Amy M.; Crider, Krista S.; Cannon, Michael J.; Berry, R. J.] CDC, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Rogers, Lisa M.] WHO, Dept Nutr Hlth & Dev, Geneva, Switzerland. RP Cordero, AM (reprint author), CDC, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. EM ACordero@cdc.gov OI Berry, Robert/0000-0002-7162-5046 NR 10 TC 8 Z9 9 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD APR 24 PY 2015 VL 64 IS 15 BP 421 EP 423 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CG6NJ UT WOS:000353418400005 PM 25905896 ER PT J AU Talbot, HK Coleman, LA Zhu, YW Spencer, S Thompson, M Cheng, PY Sundaram, ME Belongia, EA Griffin, MR AF Talbot, H. Keipp Coleman, Laura A. Zhu, Yuwei Spencer, Sarah Thompson, Mark Cheng, Po-Yung Sundaram, Maria E. Belongia, Edward A. Griffin, Marie R. TI Factors associated with maintenance of antibody responses to influenza vaccine in older, community-dwelling adults SO BMC INFECTIOUS DISEASES LA English DT Article DE Influenza; Older adults; Immunogenicity; Vaccine ID IMMUNE-RESPONSE; IMMUNOGENICITY; ADJUVANT AB Background: Little is known about factors associated with maintenance of hemagglutinin inhibition (HAI) antibodies after influenza vaccination in older adults. Methods: Adults >= 50 years of age were vaccinated prior to the 2009-10 influenza season. Serum was drawn pre-vaccination (S1), 21-28 days post-vaccination (S2), and after the influenza season (S3) for HAI assays. Seroconversion was defined as >= 4-fold increase S1 to S2 (or if S1 < 10, by an S2 >= 40) and seroprotection was defined as S2 >= 40. Maintenance of antibody response was measured in participants with an S2 = 40, and defined as an S3 >= 40. Results: We enrolled 510 participants during Fall 2009 at Vanderbilt University Medical Center and Marshfield Clinic Research Foundation. Participants' mean age was 64 years with 62% female and 96% white. Seroconversion and seroprotection rates were lowest for influenza A H1N1 (12% and 26%, respectively), highest for influenza A H3N2 (45% and 82%), and intermediate for influenza B (28% and 72%). Of the participants with an S2 >= 40, 36% (46/126), 71% (289/407), and 74% (263/354) maintained an S3 >= 40 for H1N1, H3N2, and B influenza vaccine strains, respectively. S1 HAI titer was strongly associated with both post-vaccination seroprotection and maintaining seroprotection at S3 for all three influenza antigens. Age, sex, body mass index, self-reported stress, and vaccination site were not consistently associated with vaccine response or maintenance of response. Conclusions: Pre-vaccination antibody titer was the only study variable consistently and positively associated with both serologic response to vaccination and maintenance of response. Antibody responses were lowest for the H1N1 vaccine strain. C1 [Talbot, H. Keipp; Zhu, Yuwei; Griffin, Marie R.] Vanderbilt Univ, Med Ctr, Nashville, TN 37232 USA. [Coleman, Laura A.] Abbott Nutr, Columbus, OH 43219 USA. [Spencer, Sarah; Thompson, Mark; Cheng, Po-Yung] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Sundaram, Maria E.] Univ Minnesota, Minneapolis, MN 55455 USA. [Belongia, Edward A.] Marshfield Clin Res Fdn, Marshfield, WI 54449 USA. RP Talbot, HK (reprint author), Vanderbilt Univ, Med Ctr, A2200 MCN 1161 21st Ave, Nashville, TN 37232 USA. EM Keipp.talbot@vanderbilt.edu FU Atlantic Philanthropies (USA) Inc; Infectious Diseases Society of America; John A. Hartford Foundation, Inc.; Association of Specialty Professors; CDC [1 U18 IP000184-01, 5 U18 IP000183-02]; CTSA award from the National Center for Advancing Translational Sciences [UL1TR000445]; [K23 AI074863-01A1] FX This research was supported by: K23 AI074863-01A1 (PI, Talbot HK), CDC 1 U18 IP000184-01 (PI, Griffin MR), CDC 5 U18 IP000183-02 (PI, Belongia EA), CTSA award No. UL1TR000445 from the National Center for Advancing Translational Sciences and the Atlantic Philanthropies (USA) Inc, the Infectious Diseases Society of America, the John A. Hartford Foundation, Inc., and the Association of Specialty Professors. NR 18 TC 2 Z9 2 U1 1 U2 2 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2334 J9 BMC INFECT DIS JI BMC Infect. Dis. PD APR 23 PY 2015 VL 15 AR 195 DI 10.1186/s12879-015-0926-8 PG 6 WC Infectious Diseases SC Infectious Diseases GA CH1BZ UT WOS:000353757400001 PM 25903659 ER PT J AU Iqbal, S Li, RX Gargiullo, P Vellozzi, C AF Iqbal, Shahed Li, Rongxia Gargiullo, Paul Vellozzi, Claudia TI Relationship between Guillain-Barre syndrome, influenza-related hospitalizations, and influenza vaccine coverage SO VACCINE LA English DT Article DE Cuillain-Barre syndrome; Influenza; Influenza vaccine; Vaccine safety; Vaccines; Epidemiology ID PRACTICE RESEARCH DATABASE; UNITED-STATES; SEASONAL INFLUENZA; A H1N1; POPULATION; RISK; CAMPYLOBACTER; ASSOCIATION; INFECTION; VIRUS AB Some studies reported an increased risk of Guillain-Barre syndrome (GBS) within six weeks of influenza vaccination. It has also been suggested that this finding could have been confounded by influenza illnesses. We explored the complex relationship between influenza illness, influenza vaccination, and GBS, from an ecologic perspective using nationally representative data. We also studied seasonal patterns for GBS hospitalizations. Monthly hospitalization data (2000-2009) for GBS, and pneumonia and influenza (P&I) in the Nation-wide Inpatient Sample were included. Seasonal influenza vaccination coverage for 2004-2005 through the 2008-2009 influenza seasons (August-May) was estimated from the National Health Interview Survey data. GBS seasonality was determined using Poisson regression. GBS and P&I temporal clusters were identified using scan statistics. The association between P&I and CBS hospitalizations in the same month (concurrent) or in the following month (lagged) were determined using negative binomial regression. Vaccine coverage increased over the years (from 19.7% during 2004-2005 to 35.5% during 2008-2009 season) but GBS hospitalization did not follow a similar pattern. Overall, a significant correlation between monthly P&I and GBS hospitalizations was observed (Spearman's correlation coefficient=0.7016, p < 0.0001). A significant (p = 0.001) cluster of P&I hospitalizations during December 2004-March 2005 overlapped a significant (p = 0.001) cluster of GBS hospitalizations during January 2005-February 2005. After accounting for effects of monthly vaccine coverage and age, P&I hospitalization was significantly associated (p < 0.0001) with GBS hospitalization in the concurrent month but not with GBS hospitalization in the following month. Monthly vaccine coverage was not associated with GBS hospitalization in adjusted models (both concurrent and lagged). CBS hospitalizations demonstrated a seasonal pattern with winter months having higher rates compared to the month of June. P&I hospitalization rates were significantly correlated with hospitalization rates for GBS. Vaccine coverage did not significantly affect the rates of GBS hospitalization at the population level. Published by Elsevier Ltd. C1 [Iqbal, Shahed; Li, Rongxia; Vellozzi, Claudia] Ctr Dis Control & Prevent, Immunizat Safety Off, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Gargiullo, Paul] Ctr Dis Control & Prevent, Epidemiol & Prevent Branch, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Iqbal, S (reprint author), Ctr Dis Control & Prevent, Immunizat Safety Off, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. EM SIqbal@cdc.gov NR 42 TC 1 Z9 1 U1 4 U2 9 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD APR 21 PY 2015 VL 33 IS 17 BP 2045 EP 2049 DI 10.1016/j.vaccine.2015.02.064 PG 5 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA CG2BE UT WOS:000353079100008 PM 25749247 ER PT J AU Zuo, SY Cairns, L Hutin, Y Liang, XF Tong, YB Zhu, Q Zhang, DY Lee, LA Strebel, P Quick, LD AF Zuo, Shuyan Cairns, Lisa Hutin, Yvan Liang, Xiaofeng Tong, Yibing Zhu, Qing Zhang, Dayong Lee, Lisa A. Strebel, Peter Quick, Linda TI Accelerating measles elimination and strengthening routine immunization services in Guizhou Province, China, 2003-2009 SO VACCINE LA English DT Article DE China; Epidemiology; Child; Immunization programs; Immunization schedule; Measles; Measles: epidemiology; Measles: prevention and control; Measles: elimination; School entry requirement; Surveillance ID SCHOOL AB Background: To develop a successful model for accelerating measles elimination in poor areas of China, we initiated a seven-year project in Guizhou, one of the poorest provinces, with reported highest measles incidence of 360 per million population in 2002. Methods: Project strategies consisted of strengthening routine immunization services, enforcement of school entry immunization requirements at kindergarten and school, conducting supplemental measles immunization activities (SIAs), and enhancing measles surveillance. We measured coverage of measles containing vaccines (MCV) by administrative reporting and population-based sample surveys, systematic random sampling surveys, and convenience sampling surveys for routine immunization services, school entry immunization, and SIAs respectively. We measured impact using surveillance based measles incidence. Results: Routine immunization coverage of the 1st dose of MCV (MCV1) increased from 82% to 93%, while 2nd dose of MCV (MCV2) coverage increased from 78% to 91%. Enforcement of school entry immunization requirements led to an increase in MCV2 coverage from 36% on primary school entry in 2004 to 93% in 2009. Province-wide SIAs achieved coverage greater than 90%. The reported annual incidence of measles dropped from 200 to 300 per million in 2003 to 6 per million in 2009, and sustained at 0.9-2.2 per million in 2010-2013. Conclusions: This project found that a package of strategies including periodic SIAs, strengthened routine immunization, and enforcing school entry immunization requirements, was an effective approach toward achieving and sustaining measles elimination in less-developed area of China. (C) 2015 Published by Elsevier Ltd. C1 [Zuo, Shuyan; Cairns, Lisa; Hutin, Yvan; Lee, Lisa A.] Off WHO Representat, Beijing, Peoples R China. [Liang, Xiaofeng] Chinese Ctr Dis Control & Prevent, Beijing, Peoples R China. [Tong, Yibing] Guizhou Prov Hlth Bur, Guiyang, Peoples R China. [Zhu, Qing; Zhang, Dayong] Guizhou Prov Ctr Dis Control & Prevent, Guiyang, Peoples R China. [Strebel, Peter] WHO, CH-1211 Geneva, Switzerland. [Quick, Linda] US Ctr Dis Control & Prevent, Atlanta, GA USA. RP Zuo, SY (reprint author), 401,Dongwai Diplomat Off Bldg 23, Beijing 100600, Peoples R China. EM zuosh@wpro.who.int FU United Nations Children's Fund; Japan International Cooperation Agency; United States Centers for Disease Control and Prevention [WP/2003/CHN/IVD/1.1/001] FX This work was supported by United Nations Children's Fund, Japan International Cooperation Agency and the United States Centers for Disease Control and Prevention (grant WP/2003/CHN/IVD/1.1/001). NR 17 TC 2 Z9 2 U1 0 U2 4 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD APR 21 PY 2015 VL 33 IS 17 BP 2050 EP 2055 DI 10.1016/j.vaccine.2015.02.078 PG 6 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA CG2BE UT WOS:000353079100009 PM 25769207 ER PT J AU Carias, C Walters, MS Wefula, E Date, KA Swerdlow, DL Vijayaraghayan, M Mintz, E AF Carias, Cristina Walters, Maroya Spalding Wefula, Edward Date, Kashmira A. Swerdlow, David L. Vijayaraghayan, Maya Mintz, Eric TI Economic evaluation of typhoid vaccination in a prolonged typhoid outbreak setting: The case of Kasese district in Uganda SO VACCINE LA English DT Article DE Typhoid; Typhoid vaccination; Uganda; Cost-effectiveness ID VI POLYSACCHARIDE VACCINE; COST-EFFECTIVENESS; FEVER OUTBREAK; COUNTRIES; IMPACT; CAMPAIGN; BURDEN; TRIAL AB Background: Vaccination has been increasingly promoted to help control epidemic and endemic typhoid fever in high-incidence areas. Despite growing recognition that typhoid incidence in some areas of sub-Saharan Africa is similar to high-incidence areas of Asia, no large-scale typhoid vaccination campaigns have been conducted there. We performed an economic evaluation of a hypothetical one-time, fixed-post typhoid vaccination campaign in Kasese, a rural district in Uganda where a large, multi-year outbreak of typhoid fever has been reported. Methods: We used medical cost and epidemiological data retrieved on-site and campaign costs from previous fixed-post vaccination campaigns in Kasese to account for costs from a public sector health care delivery perspective. We calculated program costs and averted disability-adjusted life years (DALYs) and medical costs as a result of vaccination, to calculate the cost of the intervention per DALY and case averted. Results: Over the 3 years of projected vaccine efficacy, a one-time vaccination campaign was estimated to avert 1768 (90%CI: 684-4431) typhoid fever cases per year and a total of 3868 (90%CI: 1353-9807) DALYs over the duration of the immunity conferred by the vaccine. The cost of the intervention per DALY averted was US$ 484 (90%CI: 18-1292) and per case averted US$ 341 (90%CI: 13-883). Conclusion: We estimated the vaccination campaign in this setting to be highly cost-effective, according to WHO's cost-effective guidelines. Results may be applicable to other African settings with similar high disease incidence estimates. (C) 2015 Elsevier Ltd. All rights reserved. C1 [Carias, Cristina; Swerdlow, David L.] Ctr Dis Control & Prevent, Off Sci & Integrated Programs, Atlanta, GA 30333 USA. [Carias, Cristina] IHRC Inc, Atlanta, GA USA. [Walters, Maroya Spalding] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Sci Educ & Profess Dev Program Off, Atlanta, GA 30333 USA. [Walters, Maroya Spalding; Mintz, Eric] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30333 USA. [Wefula, Edward] Kilembe Mines Hosp, Kasese, Uganda. [Date, Kashmira A.; Vijayaraghayan, Maya] Ctr Dis Control & Prevent, Global Immunizat Div, Atlanta, GA 30333 USA. RP Carias, C (reprint author), Ctr Dis Control & Prevent, Off Sci & Integrated Programs, 1600 Clifton Rd NE,MS A-27, Atlanta, GA 30333 USA. EM vnn9@cdc.gov NR 29 TC 1 Z9 1 U1 0 U2 3 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD APR 21 PY 2015 VL 33 IS 17 BP 2079 EP 2085 DI 10.1016/j.vaccine.2015.02.027 PG 7 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA CG2BE UT WOS:000353079100013 PM 25712333 ER PT J AU Liu, S Sun, W Chu, J Huang, XF Wu, ZX Yan, MX Zhang, Q Zhao, P Igietseme, JU Black, CM He, C Li, YQ AF Liu, Shanshan Sun, Wei Chu, Jun Huang, Xiufen Wu, Zongxue Yan, Minxin Zhang, Qiang Zhao, Peng Igietseme, Joseph U. Black, Carolyn M. He, Cheng Li, Yongqing TI Construction of Recombinant HVT Expressing PmpD, and Immunological Evaluation against Chlamydia psittaci and Marek's Disease Virus SO PLOS ONE LA English DT Article ID OUTER-MEMBRANE PROTEIN; CHLAMYDOPHILA-PSITTACI; DNA VACCINATION; TURKEYS; INFECTIONS; PROTECTION; CHICKENS; HERPESVIRUS; CHALLENGE; ADJUVANT AB Chlamydia psittaci (C. psittaci) is an obligate intracellular zoonotic pathogen that can be transmitted to humans from birds. No efficacious commercial vaccine is available for clearing chlamydial infection due to lack of potential vaccine candidates and effective delivery vehicles. Herpesvirus of turkeys (HVT) is an efficacious commercially available vaccine against Marek's Disease virus (MDV). In this study, a recombinant HVT-delivered vaccine against C. psittaci and Marek's disease was developed and examined. The 5'-terminus of pmpD gene (pmpD-N) encoding the N-terminal fragment of polymorphic membrane protein D of C. psittaci was inserted into a nonessential region of HVT genome using reverse genetics based on an infectious bacterial artificial chromosome (BAC) clone of HVT. The recombinant virus (rHVT-pmpD-N) was recovered from primary chicken embryo fibroblast (CEF) cells by transfection of modified HVT BAC DNA containing the pmpD-N gene. The rHVT-pmpD-N construct was confirmed to express PmpD-N by immunoblot and immunofluorescence. The rHVT-pmpD-N was stable during 20 passages in vitro. The growth kinetics of rHVT-pmpD-N was comparable to that of parental HVT in vitro and in vivo. One-day-old SPF chickens inoculated subcutaneously with rHVT-pmpD-N displayed increased PmpD-specific antibody levels and a vigorous PmpD-specific lymphocyte proliferation response using HVT vector or CEF cells as control. Furthermore, the percentage of CD4+ cells was significantly elevated in rHVT-pmpD-N-immunized birds as compared to the parental HVT. All chickens vaccinated with rHVT-pmpD-N or parental HVT were protected completely against challenge with a very virulent strain of Marek's Disease virus (MDV) RB-1B. Post challenge with C. psittaci CB7 strain, a significant decrease in respiratory distress, lesions and Chlamydia load was found in the rHVT-pmpD-N-vaccinated group compared to the parental HVT. In conclusion, our study suggests that the rHVT-pmpD-N live vaccine may be viable as a candidate dual vaccine that provides protection against both very virulent MDV and C. psittaci. C1 [Liu, Shanshan; Chu, Jun; Wu, Zongxue; Zhang, Qiang; Zhao, Peng; He, Cheng] China Agr Univ, Coll Vet Med, Key Lab Anim Epidemiol & Zoonosis, Minist Agr, Beijing 100193, Peoples R China. [Liu, Shanshan; Sun, Wei; Huang, Xiufen; Yan, Minxin; Li, Yongqing] Beijing Acad Agr & Forestry Sci, Inst Anim Husb & Vet Med, Beijing 100097, Peoples R China. [Igietseme, Joseph U.; Black, Carolyn M.] CDC, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. RP He, C (reprint author), China Agr Univ, Coll Vet Med, Key Lab Anim Epidemiol & Zoonosis, Minist Agr, Beijing 100193, Peoples R China. EM hecheng@cau.edu.cn; liyngqng@yahoo.com FU Beijing Municipal Science and Technology Project [Z121100001212001]; National Natural Science Foundation of China [31172305, 31372420]; Ministry of Science and Technology (MoST) [2012BAD31B05]; Beijing Natural Science Foundation [6122018] FX This work was supported by Beijing Municipal Science and Technology Project (Grant No. Z121100001212001), the National Natural Science Foundation of China (Grant No. 31172305 and 31372420) Ministry of Science and Technology (MoST) (Grant No. 2012BAD31B05) and Beijing Natural Science Foundation (Grant No. 6122018). All of the funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 39 TC 3 Z9 5 U1 1 U2 9 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD APR 20 PY 2015 VL 10 IS 4 AR UNSP e0124992 DI 10.1371/journal.pone.0124992 PG 16 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CG3XA UT WOS:000353211700131 PM 25893439 ER PT J AU Guo, YQ Tang, K Rowe, LA Li, N Roellig, DM Knipe, K Frace, M Yang, CF Feng, YY Xiao, LH AF Guo, Yaqiong Tang, Kevin Rowe, Lori A. Li, Na Roellig, Dawn M. Knipe, Kristine Frace, Michael Yang, Chunfu Feng, Yaoyu Xiao, Lihua TI Comparative genomic analysis reveals occurrence of genetic recombination in virulent Cryptosporidium hominis subtypes and telomeric gene duplications in Cryptosporidium parvum SO BMC GENOMICS LA English DT Article DE Cryptosporidium; Genomics; Whole genome sequencing; Genetic recombination; Virulence ID CYSTEINE PROTEASE INHIBITOR; UNITED-STATES; SURVEILLANCE; INFECTION; SEQUENCE; OUTBREAK; POPULATION; CHILDREN; APICOMPLEXA; DIVERSITY AB Background: Cryptosporidium hominis is a dominant species for human cryptosporidiosis. Within the species, IbA10G2 is the most virulent subtype responsible for all C. hominis-associated outbreaks in Europe and Australia, and is a dominant outbreak subtype in the United States. In recent yearsIaA28R4 is becoming a major new subtype in the United States. In this study, we sequenced the genomes of two field specimens from each of the two subtypes and conducted a comparative genomic analysis of the obtained sequences with those from the only fully sequenced Cryptosporidium parvum genome. Results: Altogether, 8.59-9.05 Mb of Cryptosporidium sequences in 45-767 assembled contigs were obtained from the four specimens, representing 94.36-99.47% coverage of the expected genome. These genomes had complete synteny in gene organization and 96.86-97.0% and 99.72-99.83% nucleotide sequence similarities to the published genomes of C. parvum and C. hominis, respectively. Several major insertions and deletions were seen between C. hominis and C. parvum genomes, involving mostly members of multicopy gene families near telomeres. The four C. hominis genomes were highly similar to each other and divergent from the reference IaA25R3 genome in some highly polymorphic regions. Major sequence differences among the four specimens sequenced in this study were in the 5' and 3' ends of chromosome 6 and the gp60 region, largely the result of genetic recombination. Conclusions: The sequence similarity among specimens of the two dominant outbreak subtypes and genetic recombination in chromosome 6, especially around the putative virulence determinant gp60 region, suggest that genetic recombination plays a potential role in the emergence of hyper-transmissible C. hominis subtypes. The high sequence conservation between C. parvum and C. hominis genomes and significant differences in copy numbers of MEDLE family secreted proteins and insulinase-like proteases indicate that telomeric gene duplications could potentially contribute to host expansion in C. parvum. C1 [Guo, Yaqiong; Li, Na; Feng, Yaoyu] E China Univ Sci & Technol, Sch Resources & Environm Engn, State Key Lab Bioreactor Engn, Shanghai 200237, Peoples R China. [Guo, Yaqiong; Roellig, Dawn M.; Xiao, Lihua] Ctr Dis Control & Prevent, Divis Foodborne Waterborne & Environm Dis, Atlanta, GA 30333 USA. [Tang, Kevin; Rowe, Lori A.; Knipe, Kristine; Frace, Michael] Ctr Dis Control & Prevent, Div Sci Resources, Atlanta, GA 30333 USA. [Yang, Chunfu] Ctr Dis Control & Prevent, Div Global HIV AIDS, Atlanta, GA 30333 USA. RP Feng, YY (reprint author), E China Univ Sci & Technol, Sch Resources & Environm Engn, State Key Lab Bioreactor Engn, Shanghai 200237, Peoples R China. EM yyfeng@ecust.edu.cn; lxiao@cdc.gov RI Yaqiong, Guo/N-4927-2015; Xiao, Lihua/B-1704-2013; Feng, Yaoyu/B-3076-2014 OI Xiao, Lihua/0000-0001-8532-2727; FU National Natural Science Foundation of China [31229005, 31425025, 31110103901]; National Special Fund for State Key Laboratory of Bioreactor Engineering, China [2060204]; Centers for Disease Control and Prevention, USA FX We thank Scott Sammons of the Centers for Disease Control and Prevention for technical assistance. This work was supported by the National Natural Science Foundation of China (31229005, 31425025 and 31110103901), National Special Fund for State Key Laboratory of Bioreactor Engineering, China (No. 2060204), and Centers for Disease Control and Prevention, USA. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. NR 57 TC 7 Z9 7 U1 2 U2 8 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2164 J9 BMC GENOMICS JI BMC Genomics PD APR 18 PY 2015 VL 16 AR 320 DI 10.1186/s12864-015-1517-1 PG 18 WC Biotechnology & Applied Microbiology; Genetics & Heredity SC Biotechnology & Applied Microbiology; Genetics & Heredity GA CG6EZ UT WOS:000353390700001 PM 25903370 ER PT J AU Sanchez, D Sodha, SV Kurtis, HJ Ghisays, G Wannemuehler, KA Danovaro-Holliday, MC Ropero-Alvarez, AM AF Sanchez, Daniel Sodha, Samir V. Kurtis, Hannah J. Ghisays, Gladys Wannemuehler, Kathleen A. Danovaro-Holliday, M. Carolina Ropero-Alvarez, Alba Maria TI Vaccination Week in the Americas, 2011: an opportunity to assess the routine vaccination program in the Bolivarian Republic of Venezuela SO BMC PUBLIC HEALTH LA English DT Article DE Vaccination Week in the Americas; Expanded Program on Immunization; Cluster survey; Venezuela ID COMMUNICATION; IMMUNIZATION; SERVICES; COVERAGE; CHILDREN AB Background: Vaccination Week in the Americas (VWA) is an annual initiative in countries and territories of the Americas every April to highlight the work of national expanded programs on immunization (EPI) and increase access to vaccination services for high-risk population groups. In 2011, as part of VWA, Venezuela targeted children aged less than 6 years in 25 priority border municipalities using social mobilization to increase institution-based vaccination. Implementation of social communication activities was decentralized to the local level. We conducted a survey in one border municipality of Venezuela to evaluate the outcome of VWA 2011 and provide a snapshot of the overall performance of the routine EPI at that level. Methods: We conducted a coverage survey, using stratified cluster sampling, in the Venezuelan municipality of Bolivar (bordering Colombia) in August 2011. We collected information for children aged < 6 years through caregiver interviews and transcription of vaccination card data. We estimated each child's eligibility to receive a specific vaccine dose during VWA 2011 and whether or not they were actually vaccinated during VWA activities. We also estimated baseline vaccination coverage, timeliness and 95% confidence intervals (CI), and used chi-square tests to compare coverage across age cohorts, taking into account the sampling design. Results: We surveyed 839 children from 698 households; 93% of children had a vaccination card. Among households surveyed, 216 (31%) caregivers reported having heard about a vaccination activity during April or May 2011. Of the 528 children eligible to receive a vaccine during VWA, 24% received at least one dose, while 13% received all doses due. Overall, baseline coverage with routine vaccines, as measured by the survey, was > 85%, with a few exceptions. Conclusion: Low levels of VWA awareness among caregivers probably contributed to the limited vaccination of eligible children during the VWA activities in Bolivar in 2011. However, vaccine coverage for most EPI vaccines was high. Additionally, high vaccination card availability and high participation in VWA among those caregivers aware of it in 2011 suggest public trust in the EPI program in the municipality. Health authorities have used survey findings to inform changes to the routine EPI and better VWA implementation in subsequent years. C1 [Sanchez, Daniel] MPPS, Programa Nacl Inmunizac Venezuela, Caracas, Venezuela. [Sodha, Samir V.; Wannemuehler, Kathleen A.] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. [Kurtis, Hannah J.; Danovaro-Holliday, M. Carolina; Ropero-Alvarez, Alba Maria] Pan Amer Hlth Org, Comprehens Family Immunizat Unit, Washington, DC 20037 USA. [Ghisays, Gladys] Pan Amer Hlth Org, Country Off, Caracas, Venezuela. RP Kurtis, HJ (reprint author), Pan Amer Hlth Org, Comprehens Family Immunizat Unit, 525 23rd St NW, Washington, DC 20037 USA. EM kurtisha@paho.org NR 15 TC 0 Z9 0 U1 0 U2 2 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2458 J9 BMC PUBLIC HEALTH JI BMC Public Health PD APR 17 PY 2015 VL 15 AR 395 DI 10.1186/s12889-015-1723-4 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CG6AZ UT WOS:000353378700001 PM 25909437 ER PT J AU Clemmon, NS Gastanaduy, PA Fichelkorn, AP Redd, SB Wallace, GS AF Clemmon, Nakia S. Gastanaduy, Paul A. Fichelkorn, Amy Parker Redd, Susan B. Wallace, Gregory S. TI Measles - United States, January 4-April 2, 2015 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Clemmon, Nakia S.; Gastanaduy, Paul A.; Fichelkorn, Amy Parker; Redd, Susan B.; Wallace, Gregory S.] CDC, Natl Ctr Immunizat & Rep Dis, Div Vital Dis, Atlanta, GA 30333 USA. RP Clemmon, NS (reprint author), CDC, Natl Ctr Immunizat & Rep Dis, Div Vital Dis, Atlanta, GA 30333 USA. NR 10 TC 57 Z9 57 U1 1 U2 8 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD APR 17 PY 2015 VL 64 IS 14 BP 373 EP 376 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CG5WS UT WOS:000353367200001 PM 25879894 ER PT J AU Arrozola, RA Singh, T Corey, CC Husten, CC Neff, LJ Apelberg, BJ Bunnell, RJ Choiniere, CJ King, BA Cox, S McAfee, T Carahallo, RS AF Arrozola, Rene A. Singh, Tushar Corey, Catherine C. Husten, Corinne C. Neff, Linda J. Apelberg, Benjamin J. Bunnell, Rebecca J. Choiniere, Conrad J. King, Brian A. Cox, Shanna McAfee, Tim Carahallo, Ralph S. TI Tobacco Use Among Middle and High School Students - United States, 2011-2014 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Arrozola, Rene A.; Singh, Tushar; Neff, Linda J.; Bunnell, Rebecca J.; King, Brian A.; Cox, Shanna; McAfee, Tim; Carahallo, Ralph S.] CDC, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Singh, Tushar] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Corey, Catherine C.; Husten, Corinne C.; Apelberg, Benjamin J.; Choiniere, Conrad J.] US FDA, Ctr Tobacco Prod, Rockville, MD 20857 USA. RP Arrozola, RA (reprint author), CDC, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM rarra/ola@cdc.gov NR 9 TC 97 Z9 97 U1 0 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD APR 17 PY 2015 VL 64 IS 14 BP 381 EP 385 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CG5WS UT WOS:000353367200003 ER PT J AU Victory, KR Coronado, F Ifono, SO Soropogui, T Dahl, BA AF Victory, Kerton R. Coronado, Fatima Ifono, Saa O. Soropogui, Therese Dahl, Benjamin A. TI Ebola Transmission Linked to a Single Traditional Funeral Ceremony - Kissidougou, Guinea, December, 2014-January 2015 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID LIBERIA C1 [Victory, Kerton R.] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Victory, Kerton R.] CDC, Div Surveillance Hazard Evaluat & Field Studies, Natl Inst Occupat Safety & Hlth, Atlanta, GA 30333 USA. [Coronado, Fatima] CDC, Off Publ Hlth Sci Serv, Ctr Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA. [Ifono, Saa O.] WHO, Kissidougou, Guinea. [Soropogui, Therese] Guinea Minist Hlth, Kissidougou, Guinea. [Dahl, Benjamin A.] CDC, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA 30333 USA. RP Victory, KR (reprint author), CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. NR 6 TC 13 Z9 13 U1 0 U2 17 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD APR 17 PY 2015 VL 64 IS 14 BP 386 EP 388 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CG5WS UT WOS:000353367200004 PM 25879897 ER PT J AU O'Neil, ME Henley, SJ Singh, SD Wilson, RJ Ortiz-Ortiz, KJ Rios, NP Cintron, CRT Luna, GT Zegarra, DFZ Ryerson, AB AF O'Neil, Mary Elizabeth Henley, S. Jane Singh, Simple D. Wilson, Reda J. Ortiz-Ortiz, Karen J. Rios, Naydi Perez Cintron, Carlos R. Torres Luna, Guillermo Tortolero Zegarra, Diego F. Zavala Ryerson, A. Blythe TI Invasive Cancer Incidence - Puerto Rico, 2007-2011 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID UNITED-STATES C1 [O'Neil, Mary Elizabeth; Henley, S. Jane; Singh, Simple D.; Wilson, Reda J.; Ryerson, A. Blythe] CDC, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Ortiz-Ortiz, Karen J.; Rios, Naydi Perez; Cintron, Carlos R. Torres; Luna, Guillermo Tortolero; Zegarra, Diego F. Zavala] Puerto Rico Cent Canc Registry, Columbia, RC, Brazil. RP O'Neil, ME (reprint author), CDC, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. NR 10 TC 1 Z9 1 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD APR 17 PY 2015 VL 64 IS 14 BP 389 EP 393 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CG5WS UT WOS:000353367200005 PM 25879898 ER PT J AU Scott, MK Geissler, A Poissani, T DeBess, E Melius, B Bekmann, R Salchi, E Cieslak, PR AF Scott, Magdalena Kendall Geissler, Aimee Poissani, Tasha DeBess, Emilio Melius, Beth Bekmann, Raye Salchi, Ellen Cieslak, Paul R. TI Campylobacteriosis Outbreak Associated with Consuming Undercooked Chicken Liver Pate - Ohio and Oregon, December 2013-January 2014 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Scott, Magdalena Kendall] CDC, Oregon Publ Hlth Div, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. CDC, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. Washington State Dept Hlth, Washington, DC USA. Ohio Dept Hlth, Springfield, OH USA. RP Scott, MK (reprint author), CDC, Oregon Publ Hlth Div, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. NR 6 TC 0 Z9 1 U1 1 U2 3 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD APR 17 PY 2015 VL 64 IS 14 BP 399 EP 399 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CG5WS UT WOS:000353367200007 PM 25879900 ER PT J AU Crank, MC Gordon, IJ Yamshchikov, GV Sitar, S Hu, ZH Enama, ME Holman, LA Bailer, RT Pearce, MB Koup, RA Mascola, JR Nebel, GJ Tumpey, TM Schwartz, RM Graham, BS Ledgerwood, JE AF Crank, Michelle C. Gordon, Ingelise J. Yamshchikov, Galina V. Sitar, Sandra Hu, Zonghui Enama, Mary E. Holman, LaSonji A. Bailer, Robert T. Pearce, Melissa B. Koup, Richard A. Mascola, John R. Nebel, Gary J. Tumpey, Terrence M. Schwartz, Richard M. Graham, Barney S. Ledgerwood, Julie E. CA VRC 308 Study Team TI Phase 1 Study of Pandemic H1 DNA Vaccine in Healthy Adults SO PLOS ONE LA English DT Article ID I CLINICAL-TRIAL; SEASONAL INFLUENZA VACCINE; NEUTRALIZING ANTIBODY; PROTECTIVE IMMUNITY; CANDIDATE VACCINE; HEPATITIS-B; VIRUS; IMMUNOGENICITY; RESPONSES; HUMANS AB Background A novel, swine-origin influenza A (H1N1) virus was detected worldwide in April 2009, and the World Health Organization (WHO) declared a global pandemic that June. DNA vaccine priming improves responses to inactivated influenza vaccines. We describe the rapid production and clinical evaluation of a DNA vaccine encoding the hemagglutinin protein of the 2009 pandemic A/California/04/2009(H1N1) influenza virus, accomplished nearly two months faster than production of A/California/07/2009(H1N1) licensed monovalent inactivated vaccine (MIV). Methods 20 subjects received three H1 DNA vaccinations (4 mg intramuscularly with Biojector) at 4-week intervals. Eighteen subjects received an optional boost when the licensed H1N1 MIV became available. The interval between the third H1 DNA injection and MIV boost was 3-17 weeks. Vaccine safety was assessed by clinical observation, laboratory parameters, and 7-day solicited reactogenicity. Antibody responses were assessed by ELISA, HAI and neutralization assays, and T cell responses by ELISpot and flow cytometry. Results Vaccinations were safe and well-tolerated. As evaluated by HAI, 6/20 developed positive responses at 4 weeks after third DNA injection and 13/18 at 4 weeks after MIV boost. Similar results were detected in neutralization assays. T cell responses were detected after DNA and MIV. The antibody responses were significantly amplified by the MIV boost, however, the boost did not increased T cell responses induced by DNA vaccine. Conclusions H1 DNA vaccine was produced quickly, was well-tolerated, and had modest immunogenicity as a single agent. Other HA DNA prime-MIV boost regimens utilizing one DNA prime vaccination and longer boost intervals have shown significant immunogenicity. Rapid and large-scale production of HA DNA vaccines has the potential to contribute to an efficient response against future influenza pandemics. C1 [Crank, Michelle C.; Gordon, Ingelise J.; Yamshchikov, Galina V.; Sitar, Sandra; Enama, Mary E.; Holman, LaSonji A.; Bailer, Robert T.; Koup, Richard A.; Mascola, John R.; Nebel, Gary J.; Schwartz, Richard M.; Graham, Barney S.; Ledgerwood, Julie E.] NIAID, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA. [Hu, Zonghui] NIAID, Biostat Res Branch, Div Clin Res, NIH, Bethesda, MD 20892 USA. [Pearce, Melissa B.; Tumpey, Terrence M.] US Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Ledgerwood, JE (reprint author), NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA. EM Ledgerwood@mail.nih.gov FU National Institutes of Health Intramural Research Program FX This research was supported by the National Institutes of Health Intramural Research Program. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 36 TC 3 Z9 3 U1 1 U2 1 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD APR 17 PY 2015 VL 10 IS 4 AR e0123969 DI 10.1371/journal.pone.0123969 PG 12 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CG1EX UT WOS:000353017000096 PM 25884189 ER PT J AU Rayamajhi, A Nightingale, S Bhatta, NK Singh, R Ledger, E Bista, KP Lewthwaite, P Mahaseth, C Turtle, L Robinson, JS Galbraith, SE Wnek, M Johnson, BW Faragher, B Griffiths, MJ Solomon, T AF Rayamajhi, Ajit Nightingale, Sam Bhatta, Nisha Keshary Singh, Rupa Ledger, Elizabeth Bista, Krishna Prasad Lewthwaite, Penny Mahaseth, Chandeshwar Turtle, Lance Robinson, Jaimie Sue Galbraith, Sareen Elizabeth Wnek, Malgorzata Johnson, Barbara Wilmot Faragher, Brian Griffiths, Michael John Solomon, Tom TI A Preliminary Randomized Double Blind Placebo-Controlled Trial of Intravenous Immunoglobulin for Japanese Encephalitis in Nepal SO PLOS ONE LA English DT Article ID NILE-VIRUS-INFECTION; CENTRAL-NERVOUS-SYSTEM; TUMOR-NECROSIS-FACTOR; MONOCLONAL-ANTIBODIES; CYTOKINE PRODUCTION; NEUTRALIZING ANTIBODY; WEST; MICE; INTERLEUKIN-6; EXPRESSION AB Background Japanese encephalitis (JE) virus (JEV) is a mosquito-borne flavivirus found across Asia that is closely related to West Nile virus. There is no known antiviral treatment for any flavivirus. Results from in vitro studies and animal models suggest intravenous immunoglobulin (IVIG) containing virus-specific neutralizing antibody may be effective in improving outcome in viral encephalitis. IVIG's anti-inflammatory properties may also be beneficial. Methodology/Principal Findings We performed a pilot feasibility randomized double-blind placebo-controlled trial of IVIG containing anti-JEV neutralizing antibody (ImmunoRel, 400mg/kg/day for 5 days) in children with suspected JE at two sites in Nepal; we also examined the effect on serum neutralizing antibody titre and cytokine profiles. 22 children were recruited, 13 of whom had confirmed JE; 11 received IVIG and 11 placebo, with no protocol violations. One child (IVIG group) died during treatment and two (placebo) subsequently following hospital discharge. Overall, there was no difference in outcome between treatment groups at discharge or follow up. Passive transfer of anti-JEV antibody was seen in JEV negative children. JEV positive children treated with IVIG had JEV-specific neutralizing antibody titres approximately 16 times higher than those treated with placebo (p=0.2), which was more than could be explained by passive transfer alone. IL-4 and IL-6 were higher in the IVIG group. Conclusions/Significance A trial of IVIG for JE in Nepal is feasible. IVIG may augment the development of neutralizing antibodies in JEV positive patients. IVIG appears an appealing option for JE treatment that warrants further study. C1 [Rayamajhi, Ajit; Nightingale, Sam; Ledger, Elizabeth; Lewthwaite, Penny; Turtle, Lance; Wnek, Malgorzata; Griffiths, Michael John; Solomon, Tom] Univ Liverpool, Inst Infect & Global Hlth, Liverpool L69 3BX, Merseyside, England. [Rayamajhi, Ajit; Mahaseth, Chandeshwar] Natl Acad Med Sci, Kathmandu, Nepal. [Rayamajhi, Ajit; Bista, Krishna Prasad; Mahaseth, Chandeshwar] Kanti Childrens Hosp, Kathmandu, Nepal. [Bhatta, Nisha Keshary; Singh, Rupa] BP Koirala Inst Hlth Sci, Dharan, Nepal. [Robinson, Jaimie Sue; Johnson, Barbara Wilmot] Ctr Dis Control & Prevent, Arbovirus Dis Branch, Diagnost & Reference Lab, Div Vector Borne Dis, Ft Collins, CO USA. [Galbraith, Sareen Elizabeth] Leeds Metropolitan Univ, Inst Hlth & Wellbeing, Leeds LS1 3HE, W Yorkshire, England. [Faragher, Brian] Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England. [Griffiths, Michael John] Alder Hey Childrens Natl Hlth Serv Fdn Trust, Liverpool, Merseyside, England. [Solomon, Tom] Walton Ctr Natl Hlth Serv Fdn Trust, Liverpool, Merseyside, England. [Solomon, Tom] Natl Consortium Zoonosis Res, Liverpool, Merseyside, England. [Solomon, Tom] Natl Inst Hlth Res, Hlth Protect Res Unit Emerging & Zoonot Infect, Liverpool, Merseyside, England. RP Rayamajhi, A (reprint author), Univ Liverpool, Inst Infect & Global Hlth, Liverpool L69 3BX, Merseyside, England. EM ajitrnp@yahoo.com OI Solomon, Tom/0000-0001-7266-6547; Turtle, Lance/0000-0002-0778-1693; Galbraith, Sareen/0000-0002-1009-6179 FU Liverpool Brain Infections Group; Program for Appropriate Technology in Health (PATH) FX This study was funded by the Liverpool Brain Infections Group. Sam Nightingale is a UK Medical Research Council (MRC) clinical fellow. Lance Turtle is a Wellcome Trust MB PhD postdoctoral research training fellow. Professor Tom Solomon is an MRC senior clinical fellow. Penny Lewthwaite was supported by a grant from the Program for Appropriate Technology in Health (PATH). The funders of this study had no role in study design, data collection, data analysis, data interpretation, decision to publish or preparation of the manuscript. NR 79 TC 3 Z9 3 U1 0 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD APR 17 PY 2015 VL 10 IS 4 AR e0122608 DI 10.1371/journal.pone.0122608 PG 21 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CG1EX UT WOS:000353017000035 PM 25886645 ER PT J AU Tsai, J Grant, AM Beckman, MG Grosse, SD Yusuf, HR Richardson, LC AF Tsai, James Grant, Althea M. Beckman, Michele G. Grosse, Scott D. Yusuf, Hussain R. Richardson, Lisa C. TI Determinants of Venous Thromboembolism among Hospitalizations of US Adults: A Multilevel Analysis SO PLOS ONE LA English DT Article ID DEEP-VEIN THROMBOSIS; QUALITY-OF-CARE; PULMONARY-EMBOLISM; MEDICAL PATIENTS; RISK-FACTORS; ADMINISTRATIVE DATA; AMERICAN-COLLEGE; HEALTH; THROMBOPROPHYLAXIS; PROPHYLAXIS AB Background Venous thromboembolism (VTE) is a significant clinical and public health concern. We evaluated a variety of multilevel factors-demographics, clinical and insurance status, preexisting comorbid conditions, and hospital characteristics-for VTE diagnosis among hospitalizations of US adults. Methods We generated adjusted odds ratios with 95% confidence intervals (CIs) and determined sources of outcome variation by conducting multilevel logistic regression analysis of data from the 2011 Nationwide Inpatient Sample that included 6,710,066 hospitalizations of US adults nested within 1,039 hospitals. Results Among hospitalizations of adults, age, sex, race or ethnicity, total days of hospital stay, status of health insurance, and operating room procedure were important determinants of VTE diagnosis; each of the following preexisting comorbid conditions-acquired immune deficiency syndrome, anemia, arthritis, congestive heart failure, coagulopathy, hypertension, lymphoma, metastatic cancer, other neurological disorders, obesity, paralysis, pulmonary circulation disorders, renal failure, solid tumor without metastasis, and weight loss-was associated independently with 1.04 (95% CI: 1.02-1.06) to 2.91 (95% CI: 2.81-3.00) times increased likelihood of VTE diagnosis than among hospitalizations of adults without any of these corresponding conditions. The presence of 2 or more of such conditions was associated a 180%-450% increased likelihood of a VTE diagnosis. Hospitalizations of adults who were treated in urban hospitals were associated with a 14%-15% increased likelihood of having a VTE diagnosis than those treated in rural hospitals. Approximately 7.4% of the total variation in VTE diagnosis occurred between hospitals. Conclusion The presence of certain comorbidities and hospital contextual factors is associated with significantly elevated likelihood of VTE diagnosis among hospitalizations of adults. The findings of this study underscore the importance of clinical risk assessment and adherence to evidence-based clinical practice guidelines in preventing VTE, as well as the need to evaluate potential contextual factors that might modify the risk of VTE among hospitalized patients. C1 [Tsai, James; Grant, Althea M.; Beckman, Michele G.; Grosse, Scott D.; Yusuf, Hussain R.; Richardson, Lisa C.] Ctr Dis Control & Prevent, Div Blood Disorders, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. RP Tsai, J (reprint author), Ctr Dis Control & Prevent, Div Blood Disorders, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. EM jxt9@cdc.gov NR 49 TC 5 Z9 5 U1 0 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD APR 16 PY 2015 VL 10 IS 4 AR UNSP e0123842 DI 10.1371/journal.pone.0123842 PG 15 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CG1ES UT WOS:000353016500064 PM 25879844 ER PT J AU Bateganya, MH Dong, MX Oguntomilade, J Suraratdecha, C AF Bateganya, Moses H. Dong, Maxia Oguntomilade, John Suraratdecha, Chutima TI The Impact of Social Services Interventions in Developing Countries: A Review of the Evidence of Impact on Clinical Outcomes in People Living With HIV SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE economic strengthening; social services; mortality; morbidity; retention; quality of life; developing countries ID MICROFINANCE; HEALTH AB Background:Social service interventions have been implemented in many countries to help people living with HIV (PLHIV) and household members cope with economic burden as a result of reduced earning or increased spending on health care. However, the evidence for specific interventionseconomic strengthening and legal serviceson key health outcomes has not been appraised.Methods:We searched electronic databases from January 1995 to May 2014 and reviewed relevant literature from resource-limited settings on the impact of social service interventions on mortality, morbidity, retention in HIV care, quality of life, and ongoing HIV transmission and their cost-effectiveness.Results:Of 1685 citations, 8 articles reported the health impact of economic strengthening interventions among PLHIV in resource-limited settings. None reported on legal services. Six of the 8 studies were conducted in sub-Saharan Africa: 1 reported on all 5 outcomes and 2 reported on 4 and 2 outcomes, respectively. The remaining 5 reported on 1 outcome each. Seven studies reported on quality of life. Although all studies reported some association between economic strengthening interventions and HIV care outcomes, the quality of evidence was rated fair or poor because studies were of low research rigor (observational or qualitative), had small sample size, or had other limitations. The expected impact of economic strengthening interventions was rated as high for quality of life but uncertain for all the other outcomes.Conclusions:Implementation of economic strengthening interventions is expected to have a high impact on the quality of life for PLHIV but uncertain impact on mortality, morbidity, retention in care, and HIV transmission. More rigorous research is needed to explore the impact of more targeted intervention components on health outcomes. C1 [Bateganya, Moses H.; Dong, Maxia] Ctr Dis Control & Prevent CDC, Div Global AIDS, Atlanta, GA USA. [Oguntomilade, John] US Dept HHS, Bur Hlth Workforce, Off Global Hlth Affairs S Dept Hlth & Human Serv, Rockville, MD USA. [Suraratdecha, Chutima] US Agcy Int Dev, Hlth Econ & Financing Off HIV AIDS, Bur Global Hlth, Washington, DC 20523 USA. RP Bateganya, MH (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS E-04, Atlanta, GA 30333 USA. EM mbateganya@cdc.gov FU US President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention (CDC); Health Resources and Services Administration (HRSA); United States Agency for International Development (USAID) FX Supported by the US President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention (CDC), the Health Resources and Services Administration (HRSA), and the United States Agency for International Development (USAID). NR 19 TC 4 Z9 4 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD APR 15 PY 2015 VL 68 SU 3 BP S357 EP S367 DI 10.1097/QAI.0000000000000498 PG 11 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CH6CN UT WOS:000354123500012 PM 25768875 ER PT J AU Bateganya, MH Amanyeiwe, U Roxo, U Dong, MX AF Bateganya, Moses H. Amanyeiwe, Ugo Roxo, Uchechi Dong, Maxia TI Impact of Support Groups for People Living With HIV on Clinical Outcomes: A Systematic Review of the Literature SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE support groups; clinical outcomes; resource-limited settings; PLHIV ID ANTIRETROVIRAL THERAPY; SOUTH-AFRICA; DISCLOSURE; PROGRAM; DEPRESSION; ACCESS; WOMEN AB Background:Support groups for people living with HIV are integrated into HIV care and treatment programs as a modality for increasing patient literacy and as an intervention to address the psychosocial needs of patients. However, the impact of support groups on key health outcomes has not been fully determined.Methods:We searched electronic databases from January 1995 through May 2014 and reviewed relevant literature on the impact of support groups on mortality, morbidity, retention in HIV care, quality of life (QOL), and ongoing HIV transmission, as well as their cost-effectiveness.Results:Of 1809 citations identified, 20 met the inclusion criteria. One reported on mortality, 7 on morbidity, 5 on retention in care, 7 on QOL, and 7 on ongoing HIV transmission. Eighteen (90%) of the articles reported largely positive results on the impact of support group interventions on key outcomes. Support groups were associated with reduced mortality and morbidity, increased retention in care, and improved QOL. Because of study limitations, the overall quality of evidence was rated as fair for mortality, morbidity, retention in care, and QOL, and poor for HIV transmission.Conclusions:Implementing support groups as an intervention is expected to have a high impact on morbidity and retention in care and a moderate impact on mortality and QOL of people living with HIV. Support groups improve disclosure with potential prevention benefits but the impact on ongoing transmission is uncertain. It is unclear whether this intervention is cost-effective given the paucity of studies in this area. C1 [Bateganya, Moses H.; Dong, Maxia] Ctr Dis Control & Prevent CDC, Div Global AIDS, Atlanta, GA 30333 USA. [Amanyeiwe, Ugo] US Agcy Int Dev, Tech Leadership & Res Div, Off HIV & AIDS, Global Hlth Bur, Washington, DC 20523 USA. [Roxo, Uchechi] US Agcy Int Dev, Strateg Planning Evaluat & Res Div, Off HIV & AIDS, Global Hlth Bur, Washington, DC 20523 USA. RP Bateganya, MH (reprint author), Ctr Dis Control & Prevent CDC, 1600 Clifton Rd NE,MS E-04, Atlanta, GA 30333 USA. EM mbateganya@cdc.gov FU US President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention (CDC); United States Agency for International Development (USAID) FX Supported by the US President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention (CDC) and the United States Agency for International Development (USAID). NR 38 TC 15 Z9 15 U1 1 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD APR 15 PY 2015 VL 68 SU 3 BP S368 EP S374 DI 10.1097/QAI.0000000000000519 PG 7 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CH6CN UT WOS:000354123500013 PM 25768876 ER PT J AU Briggs, MA Emerson, C Modi, S Taylor, NK Date, A AF Briggs, Melissa A. Emerson, Courtney Modi, Surbhi Taylor, Nicholas Kenji Date, Anand TI Use of Isoniazid Preventive Therapy for Tuberculosis Prophylaxis Among People Living With HIV/AIDS: A Review of the Literature SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE tuberculosis; isoniazid preventive therapy; prophylaxis; PLHIV ID HIV-INFECTED ADULTS; RIO-DE-JANEIRO; ACTIVE ANTIRETROVIRAL THERAPY; HUMAN-IMMUNODEFICIENCY-VIRUS; RANDOMIZED CONTROLLED-TRIAL; PLACEBO-CONTROLLED TRIAL; SOUTH-AFRICA; RECURRENT TUBERCULOSIS; LATENT TUBERCULOSIS; DOUBLE-BLIND AB Background:Tuberculosis (TB) is the leading preventable cause of death in persons living with HIV (PLHIV), accounting for over a quarter of all HIV-associated deaths in 2012. Isoniazid preventive therapy (IPT) has the potential to decrease TB-related cases and deaths in PLHIV; however, implementation of this has been slow in many high HIV- and TB-burden settings.Methodology:We performed an assessment of the evidence for the use of IPT in adults living with HIV based on a review of the literature published from 1995 to 2013. Eligible articles included data on mortality, morbidity, or retention in care related to the provision of IPT to adults with HIV in low- or middle-income countries. Cost-effectiveness information was also abstracted.Results:We identified 41 articles involving over 45,000 PLHIV. While there was little evidence to demonstrate that IPT reduced mortality in PLHIV, there was substantial evidence that IPT reduced TB incidence. While these findings were consistent irrespective of CD4 or antiretroviral therapy status, studies frequently demonstrated a greater benefit among patients with a positive TB skin test (TST). Duration of effectiveness and benefits of prolonged therapy varied across settings.Conclusions:This analysis supports World Health Organization recommendations for the provision of IPT to PLHIV to reduce TB-associated morbidity and serves to highlight the need to strengthen IPT implementation. While there appears to be a greater benefit of IPT among PLHIV who are TST positive, IPT should be provided to all PLHIV without presumptive TB when TST is not available. C1 [Briggs, Melissa A.; Emerson, Courtney; Date, Anand] Ctr Dis Control & Prevent, HIV Care & Treatment Branch, Div Global HIV AIDS, Atlanta, GA 30333 USA. [Modi, Surbhi; Taylor, Nicholas Kenji] Ctr Dis Control & Prevent, Maternal & Child Hlth Branch, Div Global HIV AIDS, Atlanta, GA 30333 USA. RP Briggs, MA (reprint author), Ctr Dis Control & Prevent, Div Global HIV AIDS, 1600 Clifton Rd,MS E-04, Atlanta, GA 30333 USA. EM vka5@cdc.gov FU US President's Emergency Plan for AIDS Relief (PEPFAR) through the US Department of State Office of the US Global AIDS Coordinator and Health Diplomacy; US Centers for Disease Control and Prevention FX Supported by the US President's Emergency Plan for AIDS Relief (PEPFAR) through the US Department of State Office of the US Global AIDS Coordinator and Health Diplomacy and the US Centers for Disease Control and Prevention. NR 55 TC 10 Z9 11 U1 1 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD APR 15 PY 2015 VL 68 SU 3 BP S297 EP S305 DI 10.1097/QAI.0000000000000497 PG 9 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CH6CN UT WOS:000354123500006 PM 25768869 ER PT J AU Date, A Modi, S AF Date, Anand Modi, Surbhi TI TB Screening Among People Living With HIV/AIDS in Resource-Limited Settings SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE tuberculosis; HIV; Xpert MTB; RIF ID HIV-ASSOCIATED TUBERCULOSIS; ANTIRETROVIRAL THERAPY; EARLY MORTALITY; INFECTION; AFRICA; CARE; DIAGNOSIS; ACCURACY AB Tuberculosis (TB) continues to be the leading cause of morbidity and mortality among people living with HIV (PLHIV), making improved prevention and treatment of HIV-associated TB critical to ensuring long-term survival of PLHIV. TB screening among PLHIV is central to implementation of the World Health Organization's 3 I's interventions for reducing the impact of the TB and HIV syndemics. Effective TB screening will result in the identification of PLHIV with presumptive TB disease (ie, those with a positive symptom screen who require appropriate evaluation, including the use of diagnostic tools such as the Xpert MTB/RIF assay) and those eligible for isoniazid preventive therapy (ie, those who have a negative clinical symptom screen or who have a positive screen but are found not to have TB disease). Identification of PLHIV with presumptive TB also facilitates implementation of basic administrative measures for TB infection control, including fast tracking of coughing patients and separation from noncoughing PLHIV to reduce TB transmission. By contributing to the early diagnosis of TB disease among PLHIV, TB screening is also critical to facilitate early initiation of antiretroviral treatment among PLHIV diagnosed with TB disease who might not otherwise be eligible for antiretroviral treatment based on CD4 count or clinical staging. TB screening thus serves as a gateway for multiple TB/HIV interventions and is an integral part of routine clinical services for PLHIV at each clinic visit. C1 [Date, Anand] US Ctr Dis Control & Prevent, HIV Care & Treatment Branch, Div Global HIV AIDS, Ctr Global Hlth, Atlanta, GA USA. [Modi, Surbhi] US Ctr Dis Control & Prevent, Maternal & Child Hlth Branch, Div Global HIV AIDS, Ctr Global Hlth, Atlanta, GA USA. RP Date, A (reprint author), Ctr Dis Control & Prevent, Div Global HIV AIDS, Ctr Global Hlth, Atlanta, GA 30333 USA. EM adate@cdc.gov FU US President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention FX Supported by the US President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention. NR 39 TC 4 Z9 4 U1 0 U2 10 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD APR 15 PY 2015 VL 68 SU 3 BP S270 EP S273 DI 10.1097/QAI.0000000000000485 PG 4 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CH6CN UT WOS:000354123500003 PM 25768866 ER PT J AU Forhan, SE Godfrey, CC Watts, DH Langley, CL AF Forhan, Sara E. Godfrey, Catherine C. Watts, D. Heather Langley, Carol L. TI A Systematic Review of the Effects of Visual Inspection With Acetic Acid, Cryotherapy, and Loop Electrosurgical Excision Procedures for Cervical Dysplasia in HIV-Infected Women in Low- and Middle-Income Countries SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE cervical cancer prevention; cervical dysplasia; HPV; HIV; LMIC ID SCREEN-AND-TREAT; CANCER PREVENTION; POSITIVE WOMEN; WESTERN KENYA; MORTALITY; CYTOLOGY; LESIONS; ZAMBIA AB Background:Cervical cancer, almost all of which is caused by human papillomavirus, accounts for 12% of female cancers worldwide and is more common among HIV-infected women. Nine of 10 deaths from cervical cancer occur in low- and middle-income countries (LMICs). Simple screening methods and outpatient treatment of precursor lesions save lives but the benefit of these interventions among HIV-infected women is uncertain.Objective:We reviewed evidence of the effects of screening with visual inspection with acetic acid (VIA), and outpatient treatment for cervical precancer among HIV-infected women in LMIC.Methods:A systematic review of articles published from January 1995 through July 2013 was conducted using key terms for VIA cervical screening, cervical precancer treatment with cryotherapy or loop electrosurgical excision procedure, HIV-infected women, low-resource settings, and outcomes, including morbidity and mortality.Results:Of 2159 articles screened, 14 met inclusion criteria; all considered only morbidity outcomes. No articles dealt with the long-term impact of screening/treatment on cervical cancer incidence or mortality among HIV-infected women. Articles reported on performance of VIA, prevalence of cervical dysplasia, and complications and rates of recurrent dysplasia after treatment.Conclusions:Dysplasia prevalence and recurrence were higher among HIV-infected compared with HIV-uninfected women but morbidity from treatment was similar. Few data exist on long-term outcomes of VIA, cryotherapy, or loop electrosurgical excision procedure interventions among HIV-infected women in LMIC; longer-term outcomes research is needed to assess the effects of VIA or other screening modalities and outpatient treatment on prevention of cervical cancer among HIV-infected women. C1 [Forhan, Sara E.] Ctr Dis Control & Prevent CDC, Div Global HIV AIDS, Atlanta, GA 30333 USA. [Godfrey, Catherine C.] NIAID, Div Aids, NIH, US Natl Inst Hlth NIH, Bethesda, MD 20892 USA. [Watts, D. Heather; Langley, Carol L.] US Dept State, Off US Global AIDS Coordinator & Hlth Diplomacy O, Washington, DC 20520 USA. RP Forhan, SE (reprint author), Ctr Dis Control & Prevent CDC, Div Global HIV AIDS, 1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM sforhan@cdc.gov FU US President's Emergency Plan for AIDS Relief (PEPFAR) FX Supported by the US President's Emergency Plan for AIDS Relief (PEPFAR). NR 26 TC 4 Z9 4 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD APR 15 PY 2015 VL 68 SU 3 BP S350 EP S356 DI 10.1097/QAI.0000000000000488 PG 7 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CH6CN UT WOS:000354123500011 PM 25768874 ER PT J AU Hassani, AS Marston, BJ AF Hassani, Ahmed Saadani Marston, Barbara J. TI Impact of Cotrimoxazole and Insecticide-Treated Nets for Malaria Prevention on Key Outcomes Among HIV-Infected Adults in Low- and Middle-Income Countries: A Systematic Review SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE cotrimoxazole; insecticide-treated nets; malaria prevention; HIV; resource-limited settings ID ANTIRETROVIRAL THERAPY; HIV-1-INFECTED ADULTS; PLASMODIUM-FALCIPARUM; PREGNANT-WOMEN; TRIMETHOPRIM-SULFAMETHOXAZOLE; CONTROLLED-TRIAL; WATER FILTERS; PROPHYLAXIS; DISEASE; UGANDA AB Background:HIV-infected adults are at increased risk of severe malaria and death. Malaria prevention in people living with HIV (PLHIV) consists of several interventions, including cotrimoxazole (CTX) prophylaxis and insecticide-treated nets (ITNs). We conducted a systematic review of the available evidence.Methods:MEDLINE, EmBase, Global Health, CINAHL, SOCA, and African Index Medicus were used to identify articles relevant to the CTX prophylaxis and ITNs interventions from 1995 to July 2014. For each individual study, we assessed the quality of evidence and the impact of the 2 interventions on the outcomes of mortality, morbidity, retention in care, quality of life, and/or prevention of ongoing HIV transmission. For each outcome, we summarized the quality of the overall body of evidence, the expected impact, and costing and cost-effectiveness (CE).Findings:The overall quality of evidence regarding malaria-related morbidity was rated as good for CTX prophylaxis and fair for ITN use; the expected impact of these interventions on morbidity was rated high and uncertain, respectively. Three studies that addressed the costing and CE of ITN provision for malaria prevention in PLHIV consisted of 2 full level 1 and 1 partial level 2 economic evaluations.Conclusions:CTX prophylaxis is effective in reducing malaria-related morbidity among PLHIV. Limited evidence is available with respect to the impact and the CE of ITN use and/or provision in this population. C1 [Hassani, Ahmed Saadani] Ctr Dis Control & Prevent, HIV Care & Treatment Branch, Div Global HIV AIDS, Atlanta, GA USA. [Marston, Barbara J.] Ctr Dis Control & Prevent, Emergency Response & Recovery Branch, Div Global Hlth Protect, Atlanta, GA USA. RP Hassani, AS (reprint author), Ctr Dis Control & Prevent CDC, Div Global HIV AIDS, 1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM wio5@cdc.gov FU US President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention FX Supported by the US President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention. NR 49 TC 1 Z9 1 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD APR 15 PY 2015 VL 68 SU 3 BP S306 EP S317 DI 10.1097/QAI.0000000000000522 PG 12 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CH6CN UT WOS:000354123500007 ER PT J AU Hassani, AS Marston, BJ Kaplan, JE AF Hassani, Ahmed Saadani Marston, Barbara J. Kaplan, Jonathan E. TI Assessment of the Impact of Cotrimoxazole Prophylaxis on Key Outcomes Among HIV-Infected Adults in Low- and Middle-Income Countries: A Systematic Review SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE cotrimoxazole; trimethoprim-sulfamethoxazole; HIV; resource-limited settings ID PLACEBO-CONTROLLED TRIAL; INTERMITTENT PREVENTIVE TREATMENT; RANDOMIZED CONTROLLED-TRIAL; SUB-SAHARAN AFRICA; ANTIRETROVIRAL THERAPY; COTE-DIVOIRE; COST-EFFECTIVENESS; HIV-1-INFECTED ADULTS; PREGNANT-WOMEN; TRIMETHOPRIM-SULFAMETHOXAZOLE AB Background:Cotrimoxazole (CTX) prophylaxis is among the key interventions provided to HIV-infected individuals in resource-limited settings. We conducted a systematic review of the available evidence.Methods:MEDLINE, Embase, Global Health, CINAHL, SOCA, and African Index Medicus (AIM) were used to identify articles relevant to the CTX prophylaxis intervention from 1995 to 2014. Included articles addressed impact of CTX prophylaxis on the outcomes of mortality, morbidity, retention in care, quality of life, and/or prevention of ongoing HIV transmission. We rated the quality of evidence in individual articles and assessed the overall quality of the body of evidence, the expected impact, and the cost effectiveness (CE) for each outcome.Results:Of the initial 1418 identified articles, 42 met all inclusion criteria. These included 9 randomized controlled trials, 26 observational studies, 2 systematic reviews with meta-analysis, 1 other systematic review, and 4 CE studies. The overall quality of evidence was rated as good and the expected impact high for both mortality and morbidity. The overall quality of evidence from the 4 studies addressing retention in care was rated as poor, and the expected impact on retention was rated as uncertain. The 4 assessed CE studies showed that provision of CTX prophylaxis is cost effective and sometimes cost saving. No studies addressed impact on quality of life or HIV transmission.Conclusions:CTX prophylaxis is a cost-effective intervention with expected high impact on morbidity and mortality reduction in HIV-infected adults in resource-limited settings. Benefits are seen in both pre-antiretroviral therapy and antiretroviral therapy populations. C1 [Hassani, Ahmed Saadani; Kaplan, Jonathan E.] Ctr Dis Control & Prevent, HIV Care & Treatment Branch, Div Global HIV AIDS, Atlanta, GA 30333 USA. [Marston, Barbara J.] Ctr Dis Control & Prevent, Emergency Response & Recovery Branch, Div Global Hlth Protect, Atlanta, GA 30333 USA. RP Hassani, AS (reprint author), Ctr Dis Control & Prevent, HIV Care & Treatment Branch, Div Global HIV AIDS, 1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM wio5@cdc.gov FU US President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention FX Supported by the US President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention. NR 56 TC 4 Z9 4 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD APR 15 PY 2015 VL 68 SU 3 BP S257 EP S269 DI 10.1097/QAI.0000000000000486 PG 13 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CH6CN UT WOS:000354123500002 ER PT J AU Kaplan, JE Hamm, TE Forhan, S Hassani, AS Bang, G Weyant, E Tchuenche, M Langley, C Lapidos-Salaiz, I Bateganya, MH AF Kaplan, Jonathan E. Hamm, Tiffany E. Forhan, Sara Hassani, Ahmed Saadani Bang, Gail Weyant, Emily Tchuenche, Michel Langley, Carol Lapidos-Salaiz, Ilana Bateganya, Moses H. TI The Impact of HIV Care and Support Interventions on Key Outcomes in Low- and Middle-Income Countries: A Literature Review-Introduction SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article C1 [Kaplan, Jonathan E.; Forhan, Sara; Hassani, Ahmed Saadani; Tchuenche, Michel; Bateganya, Moses H.] Ctr Dis Control & Prevent, Div Global HIV AIDS, Ctr Global Hlth, Atlanta, GA 30333 USA. [Hamm, Tiffany E.] Walter Reed Army Inst Res, US Mil HIV Res Program, Silver Spring, MD USA. [Hamm, Tiffany E.] Henry M Jackson Fdn Adv Mil Med, Bethesda, MD USA. [Bang, Gail; Weyant, Emily] CDC, Div Epidemiol Anal & Lib Serv, Ctr Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA. [Langley, Carol] US Dept State, Off US Global AIDS Coordinator & Hlth Diplomacy, Washington, DC 20520 USA. [Lapidos-Salaiz, Ilana] US Agcy Int Dev, Washington, DC 20523 USA. RP Kaplan, JE (reprint author), Ctr Dis Control & Prevent, Div Global HIV AIDS, Mailstop E-04,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM jxk2@cdc.gov FU US President's Emergency Plan for AIDS Relief (PEPFAR) through the US Department of State, Office of the US Global AIDS Coordinator and Health Diplomacy; US Centers for Disease Control and Prevention; US Agency for International Development; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. [W81XWH-07-2-0067]; US Department of Defense [W81XWH-07-2-0067] FX Supported by the US President's Emergency Plan for AIDS Relief (PEPFAR) through the US Department of State, Office of the US Global AIDS Coordinator and Health Diplomacy, the US Centers for Disease Control and Prevention, and the US Agency for International Development, and also supported through a cooperative agreement (W81XWH-07-2-0067) between The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. and the US Department of Defense. NR 7 TC 13 Z9 13 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD APR 15 PY 2015 VL 68 SU 3 BP S253 EP S256 DI 10.1097/QAI.0000000000000495 PG 4 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CH6CN UT WOS:000354123500001 PM 25768864 ER PT J AU Kaplan, JE Vallabhaneni, S Smith, RM Chideya-Chihota, S Chehab, J Park, B AF Kaplan, Jonathan E. Vallabhaneni, Snigdha Smith, Rachel M. Chideya-Chihota, Sekai Chehab, Joel Park, Benjamin TI Cryptococcal Antigen Screening and Early Antifungal Treatment to Prevent Cryptococcal Meningitis: A Review of the Literature SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE cryptococcal antigen; screening; cryptococcal meningitis ID HIV-INFECTED PATIENTS; OPPORTUNISTIC INFECTIONS; SOUTH-AFRICA; PHNOM-PENH; MORTALITY; DISEASE; DETERMINANTS; PREVALENCE; DIAGNOSIS; CAMBODIA AB Background:Screening individuals with AIDS for serum cryptococcal antigen (CrAg), followed by treatment of CrAg positives with antifungals, may prevent cryptococcal meningitis. This review examined data on CrAg screening and treatment in resource-limited settings.Methods:We searched articles published during 2007-2014 on the effectiveness and cost-effectiveness of CrAg screening and treatment on the outcomes of mortality, morbidity, retention in care, quality of life, and/or prevention of ongoing HIV transmission. We rated overall quality of individual articles, summarized the body of evidence, the expected impact, and cost-effectiveness for each outcome.Results:We identified 2613 articles. Eight met all inclusion criteria. Five studies addressed mortality and/or morbidity outcomes; all were observational and had small sample sizes; 3 lacked a comparison group. Ratings of study quality ranged from medium to weak, and the quality of the overall body of evidence for mortality and morbidity outcomes was rated as fair. The intervention's expected impact on mortality and morbidity was rated as moderate. The 4 cost-effectiveness studies included in the analysis showed that CrAg screening and treatment interventions are highly cost-effective. No studies addressed retention in care, quality of life, or HIV transmission.Conclusions:Although limited, the body of evidence regarding CrAg screening and treatment suggests that the intervention may have an impact on preventing cryptococcal meningitis and death in persons with AIDS. Additional research is needed to quantify the intervention's effectiveness and identify optimal treatment dosing and implementation best practices. C1 [Kaplan, Jonathan E.] Ctr Dis Control & Prevent, HIV Care & Treatment Branch, Div Global HIV AIDS, Atlanta, GA USA. [Vallabhaneni, Snigdha; Smith, Rachel M.; Chideya-Chihota, Sekai; Chehab, Joel; Park, Benjamin] Ctr Dis Control & Prevent, Mycot Dis Branch, Div Foodborne Waterborne & Environm Dis, Atlanta, GA USA. RP Kaplan, JE (reprint author), Ctr Dis Control & Prevent CDC, Div Global HIV AIDS, Mailstop E-04,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM jxk2@cdc.gov FU US President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention FX Supported by the US President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention. NR 29 TC 9 Z9 9 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD APR 15 PY 2015 VL 68 SU 3 BP S331 EP S339 DI 10.1097/QAI.0000000000000484 PG 9 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CH6CN UT WOS:000354123500009 PM 25768872 ER PT J AU Langley, CL Lapidos-Salaiz, I Hamm, TE Bateganya, MH Firth, J Wilson, M Martin, J Dierberg, K AF Langley, Carol L. Lapidos-Salaiz, Ilana Hamm, Tiffany E. Bateganya, Moses H. Firth, Jacqueline Wilson, Melinda Martin, Julia Dierberg, Kerry TI Prioritizing HIV Care and Support Interventions-Moving From Evidence to Policy SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE HIV; care; support; policy; LMIC C1 [Langley, Carol L.; Martin, Julia; Dierberg, Kerry] US Dept State, Off US Global AIDS Coordinator & Hlth Diplomacy S, Washington, DC 20522 USA. [Lapidos-Salaiz, Ilana; Firth, Jacqueline; Wilson, Melinda] US Agcy Int Dev, Off HIV AIDS, Washington, DC 20523 USA. [Hamm, Tiffany E.] Walter Reed Army Inst Res, US Mil HIV Res Program, Silver Spring, MD USA. [Hamm, Tiffany E.] Henry M Jackson Fdn Adv Mil Med, Bethesda, MD USA. [Bateganya, Moses H.] Ctr Dis Control & Prevent CDC, Div Global HIV AIDS, Ctr Global Hlth, Atlanta, GA USA. RP Langley, CL (reprint author), US Dept State, Off US Global AIDS Coordinator & Hlth Diplomacy S, SA-22,Room 10300, Washington, DC 20522 USA. EM langleycl@state.gov FU US President's Emergency Plan for AIDS Relief (PEPFAR) through the United States Department of State, Office of the US Global AIDS Coordinator and Health Diplomacy; US Centers for Disease Control; US Agency for International Development; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. [W81XWH-07-2-0067]; US Department of Defense [W81XWH-07-2-0067] FX Supported by the US President's Emergency Plan for AIDS Relief (PEPFAR) through the United States Department of State, Office of the US Global AIDS Coordinator and Health Diplomacy, the US Centers for Disease Control, and the US Agency for International Development as well as supported through a cooperative agreement (W81XWH-07-2-0067) between The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. and the US Department of Defense. NR 5 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD APR 15 PY 2015 VL 68 SU 3 BP S375 EP S378 DI 10.1097/QAI.0000000000000545 PG 4 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CH6CN UT WOS:000354123500014 PM 25768877 ER PT J AU Medley, A Bachanas, P Grillo, M Hasen, N Amanyeiwe, U AF Medley, Amy Bachanas, Pamela Grillo, Michael Hasen, Nina Amanyeiwe, Ugochukwu TI Integrating Prevention Interventions for People Living With HIV Into Care and Treatment Programs: A Systematic Review of the Evidence SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Review DE HIV; AIDS; resource-limited settings; HIV prevention; people living with HIV; positive health; dignity; and prevention ID RANDOMIZED CONTROLLED-TRIAL; HERPES-SIMPLEX-VIRUS; FAMILY-PLANNING-SERVICES; PLACEBO-CONTROLLED TRIAL; ANTIRETROVIRAL THERAPY ADHERENCE; HORMONAL CONTRACEPTIVE METHODS; SOUTH-AFRICA; DISCORDANT COUPLES; COST-EFFECTIVENESS; EPIDEMIOLOGIC EVIDENCE AB Introduction:This review assesses the impact of prevention interventions for people living with HIV on HIV-related mortality, morbidity, retention in care, quality of life, and prevention of ongoing HIV transmission in resource-limited settings (RLSs).Methods:We conducted a systematic review of studies reporting the results of prevention interventions for people living with HIV in RLS published between January 2000 and August 2014. Standardized methods of searching and data abstraction were used.Results:Ninety-two studies met the eligibility criteria: 24 articles related to adherence counseling and support, 13 on risk reduction education and condom provision, 19 on partner HIV testing and counseling, 14 on provision of family planning services, and 22 on assessment and treatment of other sexually transmitted infections. Findings indicate good evidence that adherence counseling and sexually transmitted infection treatment can have a high impact on morbidity, whereas risk reduction education, partner HIV testing and counseling, and family planning counseling can prevent transmission of HIV. More limited evidence was found to support the impact of these interventions on retention in care and quality of life. Most studies did not report cost information, making it difficult to draw conclusions about the cost-effectiveness of these interventions.Conclusions:This evidence suggests that these prevention interventions, if brought to sufficient scale and coverage, can help support and optimize the impact of core treatment and prevention interventions in RLS. Further operational research with more rigorous study designs, and ideally with biomarkers and costing information, is needed to determine the best model for providing these interventions in RLS. C1 [Medley, Amy; Bachanas, Pamela] US Ctr Dis Control & Prevent, Div Global HIV AIDS, Atlanta, GA USA. [Grillo, Michael] US Dept Def, Naval Hlth Res Ctr, HIV AIDS Prevent Program, San Diego, CA USA. [Hasen, Nina] US Dept State, Off US Global AIDS Coordinator & Hlth Diplomacy, Washington, DC 20520 USA. [Amanyeiwe, Ugochukwu] US Agcy Int Dev, Off HIV AIDS, Washington, DC 20523 USA. RP Medley, A (reprint author), 1600 Clifton Rd,MS E04, Atlanta, GA 30333 USA. EM amedley@cdc.gov FU US President's Emergency Plan for AIDS Relief (PEPFAR) through the US Department of State Office of the US Global AIDS Coordinator and Health Diplomacy; US Centers for Disease Control and Prevention; US Department of Defense; US Agency for International Development FX Supported by the US President's Emergency Plan for AIDS Relief (PEPFAR) through the US Department of State Office of the US Global AIDS Coordinator and Health Diplomacy, the US Centers for Disease Control and Prevention, the US Department of Defense, and the US Agency for International Development. NR 109 TC 4 Z9 4 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD APR 15 PY 2015 VL 68 SU 3 BP S286 EP S296 DI 10.1097/QAI.0000000000000520 PG 11 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CH6CN UT WOS:000354123500005 PM 25768868 ER PT J AU Stabinski, L O'Connor, S Barnhart, M Kahn, RJ Hamm, TE AF Stabinski, Lara O'Connor, Siobhan Barnhart, Matthew Kahn, Rebecca J. Hamm, Tiffany E. TI Prevalence of HIV and Hepatitis B Virus Co-Infection in Sub-Saharan Africa and the Potential Impact and Program Feasibility of Hepatitis B Surface Antigen Screening in Resource-Limited Settings SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE hepatitis B virus; resource-limited setting; hepatitis B surface antigen; rapid strip assay; HIV; HBV co-infection ID HUMAN-IMMUNODEFICIENCY-VIRUS; RECEIVING ANTIRETROVIRAL THERAPY; CAMILLE MEDICAL-CENTER; C VIRAL COINFECTIONS; DAR-ES-SALAAM; INFECTED PATIENTS; SOUTH-AFRICA; PREGNANT-WOMEN; BURKINA-FASO; POSITIVE PATIENTS AB Background:Screening people living with HIV for hepatitis B virus (HBV) co-infection is recommended in resource-rich settings to optimize HIV antiretroviral therapy (ART) and mitigate HBV-related liver disease. This review examines the need, feasibility, and impact of screening for HBV in resource-limited settings (RLS).Methods:We searched 6 databases to identify peer-reviewed publications between 2007 and 2013 addressing (1) HIV/HBV co-infection frequency in sub-Saharan Africa (SSA); (2) performance of hepatitis B surface antigen (HBsAg) rapid strip assays (RSAs) in RLS; (3) impact of HBV co-infection on morbidity, mortality, or liver disease progression; and/or (4) impact of HBV-suppressive antiretroviral medications as part of ART on at least one of 5 outcomes (mortality, morbidity, HIV transmission, retention in HIV care, or quality of life). We rated the quality of individual articles and summarized the body of evidence and expected impact of each intervention per outcome addressed.Results:Of 3940 identified studies, 85 were included in the review: 55 addressed HIV/HBV co-infection frequency; 6 described HBsAg RSA performance; and 24 addressed the impact of HIV/HBV co-infection and ART. HIV/HBV frequency in sub-Saharan Africa varied from 0% to >28.4%. RSA performance in RLS showed good, although variable, sensitivity and specificity. Quality of studies ranged from strong to weak. Overall quality of evidence for the impact of HIV/HBV co-infection and ART on morbidity and mortality was fair and good to fair, respectively.Conclusions:Combined, the body of evidence reviewed suggests that HBsAg screening among people living with HIV could have substantial impact on preventing morbidity and mortality among HIV/HBV co-infected individuals in RLS. C1 [Stabinski, Lara; Kahn, Rebecca J.] US Dept State, Off US Global AIDS Coordinator & Hlth Diplomacy, Washington, DC 20006 USA. [O'Connor, Siobhan] US Ctr Dis Control & Prevent, Div Viral Hepatitis, Natl Ctr HIV AIDS STD & TB Prevent, Atlanta, GA USA. [Barnhart, Matthew] US Agcy Int Dev, Off HIV & AIDS, Bur Global Hlth, Washington, DC 20523 USA. [Hamm, Tiffany E.] Walter Reed Army Inst Res, US Mil HIV Res Program, Silver Spring, MD USA. [Hamm, Tiffany E.] Henry M Jackson Fdn Adv Mil Med Inc, Bethesda, MD USA. RP Stabinski, L (reprint author), US Dept State, Off US Global AIDS Coordinator & Hlth Diplomacy, 1800 G St NW,SA-22, Washington, DC 20006 USA. EM stabinskill@state.gov FU US President's Emergency Plan for AIDS Relief (PEPFAR) through the United States Department of State, Office of the US Global AIDS Coordinator and Health Diplomacy; US Agency for International Development; US Centers for Disease Control and Prevention; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. [W81XWH-07-2-0067]; US Department of Defense [W81XWH-07-2-0067] FX Supported by the US President's Emergency Plan for AIDS Relief (PEPFAR) through the United States Department of State, Office of the US Global AIDS Coordinator and Health Diplomacy, the US Agency for International Development, the US Centers for Disease Control and Prevention, as well as supported through a cooperative agreement (W81XWH-07-2-0067) between the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. and the US Department of Defense. NR 98 TC 5 Z9 5 U1 0 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD APR 15 PY 2015 VL 68 SU 3 BP S274 EP S285 DI 10.1097/QAI.0000000000000496 PG 12 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CH6CN UT WOS:000354123500004 PM 25768867 ER PT J AU Yates, T Lantagne, D Mintz, E Quick, R AF Yates, Travis Lantagne, Daniele Mintz, Eric Quick, Robert TI The Impact of Water, Sanitation, and Hygiene Interventions on the Health and Well-Being of People Living With HIV: A Systematic Review SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE WASH; water; sanitation; hygiene; PLHIV ID HUMAN-IMMUNODEFICIENCY-VIRUS; COST-EFFECTIVENESS; DEVELOPING-COUNTRIES; DRINKING-WATER; RISK-FACTORS; INTESTINAL PARASITES; HIV/AIDS PATIENTS; CHILD-MORTALITY; DIARRHEA; PREVENTION AB Background:Access to improved water supply and sanitation is poor in low-income and middle-income countries. Persons living with HIV/AIDS (PLHIV) experience more severe diarrhea, hospitalizations, and deaths from diarrhea because of waterborne pathogens than immunocompetent populations, even when on antiretroviral therapy (ART).Methods:We examined the existing literature on the impact of water, sanitation, and hygiene (WASH) interventions on PLHIV for these outcomes: (1) mortality, (2) morbidity, (3) retention in HIV care, (4) quality of life, and (5) prevention of ongoing HIV transmission. Cost-effectiveness was also assessed. Relevant abstracts and articles were gathered, reviewed, and prioritized by thematic outcomes of interest. Articles meeting inclusion criteria were summarized in a grid for comparison.Results:We reviewed 3355 citations, evaluated 132 abstracts, and read 33 articles. The majority of the 16 included articles focused on morbidity, with less emphasis on mortality. Contaminated water, lack of sanitation, and poor hygienic practices in homes of PLHIV increase the risk of diarrhea, which can result in increased viral load, decreased CD4 counts, and reduced absorption of nutrients and antiretroviral medication. We found WASH programming, particularly water supply, household water treatment, and hygiene interventions, reduced morbidity. Data were inconclusive on mortality. Research gaps remain in retention in care, quality of life, and prevention of ongoing HIV transmission. Compared with the standard threshold of 3 times GDP per capita, WASH interventions were cost-effective, particularly when incorporated into complementary programs.Conclusions:Although research is required to address behavioral aspects, evidence supports that WASH programming is beneficial for PLHIV. C1 [Yates, Travis; Lantagne, Daniele] Tufts Univ, Dept Civil & Environm Engn, Medford, MA 02155 USA. [Mintz, Eric; Quick, Robert] Ctr Dis Control & Prevent, Waterborne Dis Prevent Branch, Div Foodborne Waterborne & Environm Dis, Atlanta, GA USA. RP Yates, T (reprint author), Tufts Univ, 200 Coll Ave, Medford, MA 02155 USA. EM travis.yates@tufts.edu FU US President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention; National Science Foundation [0966093] FX Supported by the US President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention, and supported partially by the National Science Foundation 0966093. NR 57 TC 1 Z9 1 U1 1 U2 11 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD APR 15 PY 2015 VL 68 SU 3 BP S318 EP S330 DI 10.1097/QAI.0000000000000487 PG 13 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CH6CN UT WOS:000354123500008 PM 25768871 ER PT J AU Howards, PP Johnson, CY Honein, MA Flanders, WD AF Howards, Penelope P. Johnson, Candice Y. Honein, Margaret A. Flanders, W. Dana CA Natl Birth Defects Prevention Stud TI Adjusting for Bias Due to Incomplete Case Ascertainment in Case-Control Studies of Birth Defects SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Article DE bias correction; birth defects; case-control studies; selection bias; spina bifida ID NEURAL-TUBE DEFECTS; CONGENITAL DIAPHRAGMATIC-HERNIA; PRENATAL-DIAGNOSIS; SELECTION BIAS; MATERNAL OBESITY; UNITED-STATES; ELECTIVE TERMINATION; RISK; PREGNANCY; SURVEILLANCE AB Case-control studies of birth defects might be subject to selection bias when there is incomplete ascertainment of cases among pregnancies that are terminated after a prenatal diagnosis of the defect. We propose a simple method to estimate inverse probability of selection weights (IPSWs) for cases ascertained from both pregnancies that end in termination and those that do not end in termination using data directly available from the National Birth Defects Prevention Study and other published information. The IPSWs can then be used to adjust for selection bias analytically. We can also allow for uncertainty in the selection probabilities through probabilistic bias analysis. We provide an illustrative example using data from National Birth Defects Prevention Study (1997-2009) to examine the association between prepregnancy obesity (body mass index, measured as weight in kilograms divided by height in meters squared, of >= 30 vs. < 30) and spina bifida. The unadjusted odds ratio for the association between prepregnancy obesity and spina bifida was 1.48 (95% confidence interval: 1.26, 1.73), and the simple selection bias-adjusted odds ratio was 1.26 (95% confidence interval: 1.04, 1.53). The probabilistic bias analysis resulted in a median adjusted odds ratio of 1.22 (95% simulation interval: 0.97, 1.47). The proposed method provides a quantitative estimate of the IPSWs and the bias introduced by incomplete ascertainment of cases among terminated pregnancies conditional on a set of assumptions. C1 [Howards, Penelope P.; Johnson, Candice Y.; Flanders, W. Dana] Emory Univ, Dept Epidemiol, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Johnson, Candice Y.; Honein, Margaret A.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Johnson, Candice Y.] NIOSH, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. [Johnson, Candice Y.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. RP Howards, PP (reprint author), Emory Univ, Dept Epidemiol, 1518 Clifton Rd NE,CNR 3029, Atlanta, GA 30322 USA. EM penelope.howards@emory.edu FU Centers for Disease Control and Prevention [PA 96043, PA 02081, FOA DD09-001] FX This work was supported in part by cooperative agreements under PA 96043, PA 02081, and FOA DD09-001 from the Centers for Disease Control and Prevention to the Centers for Birth Defects Research and Prevention participating in the National Birth Defects Prevention Study. NR 37 TC 3 Z9 3 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 EI 1476-6256 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD APR 15 PY 2015 VL 181 IS 8 BP 595 EP 607 DI 10.1093/aje/kwu323 PG 13 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CH1XG UT WOS:000353815700007 PM 25792608 ER PT J AU Smith, BD Yartel, AK Krauskopf, K Massoud, OI Brown, KA Fallon, MB Rein, DB AF Smith, Bryce D. Yartel, Anthony K. Krauskopf, Katherine Massoud, Omar I. Brown, Kimberly A. Fallon, Michael B. Rein, David B. TI Hepatitis C Virus Antibody Positivity and Predictors Among Previously Undiagnosed Adult Primary Care Outpatients: Cross-Sectional Analysis of a Multisite Retrospective Cohort Study SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE hepatitis C virus (HCV); anti-HCV prevalence; predictors of HCV positivity; outpatient primary care; HCV testing ID UNITED-STATES; BIRTH-COHORT; DRUG-USERS; INFECTION; PREVALENCE; MORTALITY; RISK; ASSOCIATION; DISCLOSURE; BARRIERS AB Background. Hepatitis C virus (HCV) testing guidance issued by the Centers for Disease Control and Prevention in 1998 recommends HCV antibody (anti-HCV) testing for persons with specified risk factors. The purpose of this study was to determine the prevalence and predictors of anti-HCV positivity among primary care outpatients and estimate the proportion of unidentified anti-HCV-positive (anti-HCV+) persons using risk-based testing. Methods. We analyzed electronic medical record data from a 4-site retrospective study. Patients were aged >= 18 years, utilized >= 1 outpatient primary care service(s) between 2005 and 2010, and had no documented evidence of prior HCV diagnosis. Among persons tested for anti-HCV, we fit a multilevel logistic regression model to identify patient-level independent predictors of anti-HCV positivity. We estimated the proportion of unidentified anti-HCV+ persons by using multiple imputation to assign anti-HCV results to untested patients. Results. We observed 209 076 patients for a median of 5 months (interquartile range, 1-23 months). Among 17 464 (8.4%) patients who were tested for anti-HCV, 6.4% (n = 1115) were positive. We identified history of injection drug use (adjusted odds ratio [95% confidence interval], 6.3 [5.2-7.6]), 1945-1965 birth cohort (4.4 [3.8-5.1]), and elevated alanine aminotransferase levels (4.8 [4.2-5.6]) as independently associated with anti-HCV positivity. We estimated that 81.5% (n = 4890/6005) of anti-HCV+ patients were unidentified using risk-based testing. Conclusions. In these outpatient primary care settings, risk-based testing may have missed 4 of 5 newly enrolled patients who are anti-HCV+. Without knowing their status, unidentified anti-HCV+ persons cannot receive further clinical evaluation or antiviral treatment, and are unlikely to benefit from secondary prevention recommendations to limit disease progression and mortality. C1 [Smith, Bryce D.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA 30333 USA. [Yartel, Anthony K.] Ctr Dis Control & Prevent Fdn, Atlanta, GA USA. [Krauskopf, Katherine] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Massoud, Omar I.] Univ Alabama Birmingham, Birmingham, AL USA. [Brown, Kimberly A.] Henry Ford Hosp, Detroit, MI 48202 USA. [Fallon, Michael B.] Univ Texas Houston, Houston, TX USA. [Rein, David B.] Univ Chicago, NORC, Chicago, IL 60637 USA. RP Smith, BD (reprint author), Ctr Dis Control & Prevent, Div Viral Hepatitis, 1600 Clifton Rd,MS G-37, Atlanta, GA 30333 USA. EM Bsmith6@cdc.gov FU CDC FX This study was supported by the CDC. NR 39 TC 6 Z9 6 U1 1 U2 5 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD APR 15 PY 2015 VL 60 IS 8 BP 1145 EP 1152 DI 10.1093/cid/civ002 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CH0MX UT WOS:000353715600003 PM 25595745 ER PT J AU Hamilton, KW Gerber, JS Moehring, R Anderson, DJ Calderwood, MS Han, JH Mehta, JM Pollack, LA Zaoutis, T Srinivasan, A Camins, BC Schwartz, DN Lautenbach, E AF Hamilton, Keith W. Gerber, Jeffrey S. Moehring, Rebekah Anderson, Deverick J. Calderwood, Michael S. Han, Jennifer H. Mehta, Jimish M. Pollack, Lori A. Zaoutis, Theoklis Srinivasan, Arjun Camins, Bernard C. Schwartz, David N. Lautenbach, Ebbing CA Ctr Dis Control Prevention Epictr TI Point-of-Prescription Interventions to Improve Antimicrobial Stewardship SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE antimicrobial stewardship; point of prescription; frontline; antimicrobial prescribing ID INFECTIOUS-DISEASES SOCIETY; HEALTH-CARE EPIDEMIOLOGY; ANTIBIOTIC USE; INSTITUTIONAL PROGRAM; MANAGEMENT PROGRAM; AMERICA GUIDELINES; HOSPITALS; IMPLEMENTATION; SUPPORT; IMPACT AB Antimicrobial stewardship is pivotal to improving patient outcomes, reducing adverse events, decreasing healthcare costs, and preventing further emergence of antimicrobial resistance. In an era in which antimicrobial resistance is increasing, judicious antimicrobial use is the responsibility of every healthcare provider. Antimicrobial stewardship programs (ASPs) have made headway in improving antimicrobial prescribing using such "top-down" methods as formulary restriction and prospective audit with feedback; however, engagement of prescribers has not been fully explored. Strategies that include frontline prescribers and other unit-based healthcare providers have the potential to expand stewardship, both to augment existing centralized ASPs and to provide alternative approaches to perform stewardship at healthcare facilities with limited resources. This review discusses interventions focusing on antimicrobial prescribing at the point of prescription as well as a pilot project to engage unit-based healthcare providers in antimicrobial stewardship. C1 [Hamilton, Keith W.; Han, Jennifer H.; Lautenbach, Ebbing] Hosp Univ Penn, Div Infect Dis, Philadelphia, PA 19104 USA. [Gerber, Jeffrey S.; Zaoutis, Theoklis] Childrens Hosp Philadelphia, Div Infect Dis, Philadelphia, PA USA. [Moehring, Rebekah; Anderson, Deverick J.] Duke Univ, Med Ctr, Div Infect Dis, Durham, NC USA. [Moehring, Rebekah; Anderson, Deverick J.] Duke Antimicrobial Stewardship Outreach Network, Durham, NC USA. [Calderwood, Michael S.] Brigham & Womens Hosp, Div Infect Dis, Boston, MA 02115 USA. [Mehta, Jimish M.] GlaxoSmithKline, North Amer Med Affairs, Philadelphia, PA USA. [Pollack, Lori A.; Srinivasan, Arjun] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA USA. [Camins, Bernard C.] Washington Univ, Sch Med, Div Infect Dis, St Louis, MO 63110 USA. [Schwartz, David N.] John H Stroger Jr Hosp Cook Cty, Div Infect Dis, Chicago, IL USA. RP Hamilton, KW (reprint author), Hosp Univ Penn, Div Infect Dis, 1 Convent Ave,Ste 101, Philadelphia, PA 19104 USA. EM keith.hamilton@uphs.upenn.edu FU CDC (Cooperative Agreement FOA) [CK11 001] FX This work was supported by the CDC (Cooperative Agreement FOA#CK11 001 Epicenters for the Prevention of Healthcare Associated Infections). NR 30 TC 4 Z9 4 U1 2 U2 5 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD APR 15 PY 2015 VL 60 IS 8 BP 1252 EP 1258 DI 10.1093/cid/civ018 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CH0MX UT WOS:000353715600019 PM 25595748 ER PT J AU Baker, BJ Holtom, PD AF Baker, Brian J. Holtom, Paul D. TI Additional Benefits of GeneXpert MTB/RIF Assay for the Evaluation of Pulmonary Tuberculosis Among Inpatients SO CLINICAL INFECTIOUS DISEASES LA English DT Letter ID MYCOBACTERIUM-TUBERCULOSIS; UNITED-STATES; TRANSMISSION C1 [Baker, Brian J.] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA 30329 USA. [Holtom, Paul D.] Univ So Calif, Med Ctr, Div Infect Dis, Los Angeles Cty Univ Southern Calif, Los Angeles, CA 90089 USA. RP Baker, BJ (reprint author), Ctr Dis Control & Prevent, Div TB Eliminat, 1600 Clifton Rd,MS E-10, Atlanta, GA 30329 USA. EM bjbaker@cdc.gov NR 8 TC 3 Z9 3 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD APR 15 PY 2015 VL 60 IS 8 BP 1287 EP U214 DI 10.1093/cid/civ006 PG 2 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CH0MX UT WOS:000353715600029 PM 25586683 ER PT J AU Cope, JR Ratard, RC Hill, VR Sokol, T Causey, JJ Yoder, JS Mirani, G Mull, B Mukerjee, KA Narayanan, J Doucet, M Qvarnstrom, Y Poole, CN Akingbola, OA Ritter, JM Xiong, ZG da Silva, AJ Roellig, D van Dyke, RB Stern, H Xiao, LH Beach, MJ AF Cope, Jennifer R. Ratard, Raoult C. Hill, Vincent R. Sokol, Theresa Causey, Jonathan Jake Yoder, Jonathan S. Mirani, Gayatri Mull, Bonnie Mukerjee, Kimberly A. Narayanan, Jothikumar Doucet, Meggie Qvarnstrom, Yvonne Poole, Charla N. Akingbola, Olugbenga A. Ritter, Jana M. Xiong, Zhenggang da Silva, Alexandre J. Roellig, Dawn van Dyke, Russell B. Stern, Harlan Xiao, Lihua Beach, Michael J. TI The First Association of a Primary Amebic Meningoencephalitis Death With Culturable Naegleria fowleri in Tap Water From a US Treated Public Drinking Water System SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE Naegleria fowleri; primary amebic meningoencephalitis; free-living ameba ID BALAMUTHIA-MANDRILLARIS; ACANTHAMOEBA SPP.; PCR AB Background. Naegleria fowleri is a climate-sensitive, thermophilic ameba found in warm, freshwater lakes and rivers. Primary amebic meningoencephalitis (PAM), which is almost universally fatal, occurs when N. fowleri-containing water enters the nose, typically during swimming, and migrates to the brain via the olfactory nerve. In August 2013, a 4-year-old boy died of meningoencephalitis of unknown etiology in a Louisiana hospital. Methods. Clinical and environmental testing and a case investigation were initiated to determine the cause of death and to identify potential exposures. Results. Based on testing of cerebrospinal fluid and brain specimens, the child was diagnosed with PAM. His only reported water exposure was tap water; in particular, tap water that was used to supply water to a lawn water slide on which the child had played extensively prior to becoming ill. Water samples were collected from both the home and the water distribution system that supplied the home and tested; N. fowleri was identified in water samples from both the home and the water distribution system. Conclusions. This case is the first reported PAM death associated with culturable N. fowleri in tap water from a US treated drinking water system. This case occurred in the context of an expanding geographic range for PAM beyond southern states, with recent case reports from Minnesota, Kansas, and Indiana. This case also highlights the role of adequate disinfection throughout drinking water distribution systems and the importance of maintaining vigilance when operating drinking water systems using source waters with elevated temperatures. C1 [Cope, Jennifer R.; Hill, Vincent R.; Yoder, Jonathan S.; Mull, Bonnie; Narayanan, Jothikumar; Qvarnstrom, Yvonne; Ritter, Jana M.; da Silva, Alexandre J.; Roellig, Dawn; Xiao, Lihua; Beach, Michael J.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Ratard, Raoult C.; Sokol, Theresa; Causey, Jonathan Jake] Louisiana Dept Hlth & Hosp, New Orleans, LA USA. [Ratard, Raoult C.; Sokol, Theresa; Causey, Jonathan Jake] Louisiana Dept Hlth & Hosp, Baton Rouge, LA 70821 USA. [Mirani, Gayatri; Mukerjee, Kimberly A.; Doucet, Meggie; Poole, Charla N.; Akingbola, Olugbenga A.; Xiong, Zhenggang; van Dyke, Russell B.; Stern, Harlan] Tulane Univ, Hlth Sci Ctr, New Orleans, LA 70118 USA. RP Cope, JR (reprint author), 1600 Clifton Rd NE,MS C-09, Atlanta, GA 30333 USA. EM bjt9@cdc.gov RI Xiao, Lihua/B-1704-2013 OI Xiao, Lihua/0000-0001-8532-2727 FU Intramural CDC HHS [CC999999] NR 18 TC 15 Z9 15 U1 3 U2 37 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD APR 15 PY 2015 VL 60 IS 8 BP E36 EP E42 DI 10.1093/cid/civ017 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CH0MX UT WOS:000353715600002 PM 25595746 ER PT J AU Grosset, J Vernon, A AF Grosset, Jacques Vernon, Andrew TI A Reader's Guide to the Bactericidal Activity of Pyrazinamide and Clofazimine Alone and in Combinations with Pretomanid and Bedaquiline SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Editorial Material ID MULTIDRUG-RESISTANT TUBERCULOSIS; PULMONARY TUBERCULOSIS; DIARYLQUINOLINE TMC207; MOXIFLOXACIN; REGIMEN; TRIAL; DRUGS C1 [Grosset, Jacques] Johns Hopkins Univ, Sch Med, Ctr TB Res, Baltimore, MD 21218 USA. [Vernon, Andrew] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Grosset, J (reprint author), Johns Hopkins Univ, Sch Med, Ctr TB Res, Baltimore, MD 21218 USA. NR 17 TC 2 Z9 2 U1 0 U2 1 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD APR 15 PY 2015 VL 191 IS 8 BP 871 EP 873 PG 3 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA CG2EB UT WOS:000353086600006 PM 25876201 ER PT J AU Gordon, PH Mehal, JM Holman, RC Bartholomew, ML Cheek, JE Rowland, AS AF Gordon, Paul H. Mehal, Jason M. Holman, Robert C. Bartholomew, Michael L. Cheek, James E. Rowland, Andrew S. TI Incidence and Prevalence of Parkinson's Disease Among Navajo People Living in the Navajo Nation SO MOVEMENT DISORDERS LA English DT Article DE Parkinson's disease; incidence; prevalence; neurodegeneration; American Indian; Navajo; epidemiology ID AMERICAN-INDIANS; RACIAL-DIFFERENCES; ALASKA NATIVES; DIAGNOSIS; RISK; AGE AB Parkinson's disease (PD) is largely unstudied among American Indians. Unique populations might harbor clues to elusive causes. We describe the incidence and prevalence of PD among Navajo people residing in the Navajo Nation, home to the largest American Indian tribe in the United States. We analyzed 2001-2011 inpatient and outpatient visit data for Navajo people obtained from the Indian Health Service, which provides health care to American Indian people living on the Navajo Reservation. Cases were defined by at least two inpatient or outpatient visits with the diagnosis of PD. Crude and age-adjusted incidence and prevalence rates were calculated overall as well as by age, sex, region of residence, and time period. Five hundred twenty-four Navajo people with median age-at-onset of 74.0 years were diagnosed with PD during the study period, yielding an average annual crude incidence rate of 22.5/100,000. Age-specific incidence was 232.0 for patients 65 years of age or older and 302.0 for 80 years of age or older. Age-adjusted incidence was 35.9 overall (238.1 for 65 years), was higher in men than in women (47.5 vs. 27.7; P<0.001), varied by region (P=0.03), and was similar between time periods (2002-2004 vs. 2009-2011). The age-adjusted point prevalence rate was 261.0. The rate of PD among Navajo People appears to be as high as or higher than rates reported in many other populations. Rates increased to the highest age group, consistent with population-based studies. Further investigation is warranted to examine risk factors for PD in this remote population. (c) 2015 International Parkinson and Movement Disorder Society C1 [Gordon, Paul H.] Northern Navajo Med Ctr, Indian Hlth Serv, US Dept Hlth & Human Serv, Shiprock, NM 87420 USA. [Mehal, Jason M.; Holman, Robert C.] Ctr Dis Control & Prevent CDC, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Bartholomew, Michael L.] Off Publ Hlth Support, Div Epidemiol & Dis Prevent, Rockville, MD USA. [Cheek, James E.; Rowland, Andrew S.] Univ New Mexico, Hlth Sci Ctr, Dept Family & Community Med, Publ Hlth Program, Albuquerque, NM 87131 USA. RP Gordon, PH (reprint author), Northern Navajo Med Ctr, Med Staff Off, Hwy 491 North, Shiprock, NM 87420 USA. EM paul.gordon@ihs.gov NR 39 TC 3 Z9 3 U1 1 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-3185 EI 1531-8257 J9 MOVEMENT DISORD JI Mov. Disord. PD APR 15 PY 2015 VL 30 IS 5 BP 714 EP 720 DI 10.1002/mds.26147 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA CF8FE UT WOS:000352790700016 PM 25649219 ER PT J AU Shvedova, AA Kisin, ER Yanamala, N Tkach, AV Gutkin, DW Star, A Shurin, GV Kagan, VE Shurin, MR AF Shvedova, Anna A. Kisin, Elena R. Yanamala, Naveena Tkach, Alexey V. Gutkin, Dmitriy W. Star, Alexander Shurin, Galina V. Kagan, Valerian E. Shurin, Michael R. TI MDSC and TGF beta Are Required for Facilitation of Tumor Growth in the Lungs of Mice Exposed to Carbon Nanotubes SO CANCER RESEARCH LA English DT Article ID ENVIRONMENTAL RISK-FACTORS; SUPPRESSOR-CELLS; MYELOID CELLS; PULMONARY TOXICITY; OXIDATIVE STRESS; EPITHELIAL-CELLS; CANCER; INFLAMMATION; ASBESTOS; IMMUNOSUPPRESSION AB During the last decades, changes have been observed in the frequency of different histologic subtypes of lung cancer, one of the most common causes of morbidity and mortality, with a declining proportion of squamous cell carcinomas and an increasing proportion of adenocarcinomas, particularly in developed countries. This suggests the emergence of new etiologic factors and mechanisms, including those defining the lung microenvironment, promoting tumor growth. Assuming that the lung is the main portal of entry for broadly used nanomaterials and their established proinflammatory propensities, we hypothesized that nanomaterials may contribute to changes facilitating tumor growth. Here, we report that an acute exposure to single-walled carbon nanotubes (SWCNT) induces recruitment and accumulation of lung-associated myeloid-derived suppressor cells (MDSC) and MDSC-derived production of TGF beta, resulting in upregulated tumor burden in the lung. The production of TGF beta by MDSC requires their interaction with both SWCNT and tumor cells. We conclude that pulmonary exposure to SWCNT favors the formation of a niche that supports ingrowth of lung carcinoma in vivo via activation of TGF beta production by SWCNT-attracted and -presensitized MDSC. (C) 2015 AACR. C1 [Shvedova, Anna A.; Kisin, Elena R.; Yanamala, Naveena; Tkach, Alexey V.] CDC, HELD, NIOSH, Morgantown, WV 26505 USA. [Shvedova, Anna A.] W Virginia Univ, Dept Pharmacol & Physiol, Morgantown, WV 26506 USA. [Gutkin, Dmitriy W.; Shurin, Galina V.; Shurin, Michael R.] Univ Pittsburgh, Dept Pathol, Med Ctr, Pittsburgh, PA USA. [Star, Alexander] Univ Pittsburgh, Dept Chem, Pittsburgh, PA 15260 USA. [Kagan, Valerian E.] Univ Pittsburgh, Dept Environm & Occupat Hlth, Pittsburgh, PA USA. [Kagan, Valerian E.] Univ Pittsburgh, Ctr Free Rad & Antioxidant Hlth, Pittsburgh, PA USA. [Shurin, Michael R.] Univ Pittsburgh, Med Ctr, Dept Immunol, Pittsburgh, PA USA. RP Shvedova, AA (reprint author), CDC, NIOSH, 1095 Willowdale Rd, Morgantown, WV 26505 USA. EM ats1@cdc.gov FU NIOSH [OH008282]; NTRC [927ZJHF, 939011K]; NIEHS [R01ES019304]; NIH RO1 [CA154369]; NANOSOLUTIONS FP7 [309329] FX This work was supported in part by NIOSH OH008282, NTRC 927ZJHF and 939011K, NIEHS R01ES019304, NIH RO1 CA154369, and NANOSOLUTIONS FP7 309329. NR 55 TC 11 Z9 11 U1 2 U2 12 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2015 VL 75 IS 8 BP 1615 EP 1623 DI 10.1158/0008-5472.CAN-14-2376 PG 9 WC Oncology SC Oncology GA CF9PH UT WOS:000352896900008 PM 25744719 ER PT J AU Norton, EB Bauer, DL Weldon, WC Oberste, MS Lawson, LB Clements, JD AF Norton, Elizabeth B. Bauer, David L. Weldon, William C. Oberste, M. Steven Lawson, Louise B. Clements, John D. TI The novel adjuvant dmLT promotes dose sparing, mucosal immunity and longevity of antibody responses to the inactivated polio vaccine in a murine model SO VACCINE LA English DT Article DE dmLT; Polio; Vaccination; Adjuvant; Mucosal immunity ID ENTEROTOXIGENIC ESCHERICHIA-COLI; INTRADERMAL DELIVERY; ACTIVATION ANTIGEN; IMMUNIZATION; TOXIN; IMMUNOGENICITY; POLYSACCHARIDE; SUBPOPULATIONS; EXPRESSION; PROTECTION AB One option for achieving global polio eradication is to replace the oral poliovirus vaccine (OPV), which has the risk of reversion to wild-type virulence, with the inactivated poliovirus vaccine (IPV) vaccine. Adjuvants and alternate routes of immunization are promising options that may reduce antigen dose in IPV vaccinations, potentially allowing dose sparing and cost savings. Use of adjuvants and alternate routes of immunization could also help promote mucosal immunity, potentially mimicking the protection against intestinal virus shedding seen with OPV. In the current study, we examined the impact of combining the novel adjuvant dmLT with trivalent IPV for dose sparing, induction of mucosal immunity and increasing longevity of anti-poliovirus (PV) responses in a mouse model following either intradermal (ID) or intramuscular (IM) delivery. We found that non-adjuvanted ID delivery was not superior to IM delivery for fractional dose sparing, but was associated with development of mucosal immunity. Vaccination with IPV + dmLT promoted serum anti-PV neutralizing antibodies with fractional IPV doses by either IM or ID delivery, achieving at least five-fold dose sparing above non-adjuvanted fractional doses. These responses were most noticeable with the PV1 component of the trivalent vaccine. dmLT also promoted germinal center formation and longevity of serum anti-PV neutralizing titers. Lastly, dmLT enhanced mucosal immunity, as defined by fecal and intestinal anti-PV IgA secretion, when included in IPV immunization by ID or IM delivery. These studies demonstrate that dmLT is an effective adjuvant for either IM or ID delivery of IPV. Inclusion of dmLT in IPV immunizations allows antigen dose sparing and enhances mucosal immunity and longevity of anti-PV responses. (C) 2015 The Authors. Published by Elsevier Ltd. C1 [Norton, Elizabeth B.; Bauer, David L.; Lawson, Louise B.; Clements, John D.] Tulane Univ, Sch Med, Dept Microbiol & Immunol, New Orleans, LA 70112 USA. [Weldon, William C.; Oberste, M. Steven] Ctr Dis Control & Prevent CDC, Div Viral Dis, Atlanta, GA 30333 USA. RP Clements, JD (reprint author), Tulane Univ, Sch Med, Dept Microbiol & Immunol, 1430 Tulane Ave SL38, New Orleans, LA 70112 USA. EM enorton@tulane.edu; dbauer3@tulane.edu; wiw4@cdc.gov; mbo2@cdc.gov; lbraud@tulane.edu; jclemen@tulane.edu FU Bill and Melinda Gates Foundation [OPP1031440] FX Support for this project was provided by the Bill and Melinda Gates Foundation (Grant No. OPP1031440). The authors would like to thank Monica Czapla, Carli Thompson, Rachel Hahn and Zaid Mandi for their help performing these studies, as well as Deborah Moore, Yiting Zhang, Sharla McDonald, William Hendley, Larin McDuffie, Patricia Mitchell, and Mario Nicolas for performing the serology tests. Robin Baudier is also thanked for writing assistance and proofreading manuscript drafts. NR 38 TC 9 Z9 9 U1 1 U2 18 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD APR 15 PY 2015 VL 33 IS 16 BP 1909 EP 1915 DI 10.1016/j.vaccine.2015.02.069 PG 7 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA CF6JC UT WOS:000352662000003 PM 25765967 ER PT J AU Russell, K Dunne, EF Kemper, AR Dolor, RJ Unger, ER Panicker, G Markowitz, LE Walter, EB AF Russell, Kate Dunne, Eileen F. Kemper, Alex R. Dolor, Rowena J. Unger, Elizabeth. R. Panicker, Gitika Markowitz, Lauri E. Walter, Emmanuel B. TI Antibody responses among adolescent females receiving the quadrivalent HPV vaccine series corresponding to standard or non-standard dosing intervals SO VACCINE LA English DT Article DE Human papillomavirus; Vaccine; Dosing; Immunity ID HUMAN-PAPILLOMAVIRUS; PARTICLE VACCINE; IMMUNOGENICITY; WOMEN; TRIAL; SCHEDULES; TYPE-11; SAFETY; MEN AB Quadrivalent human papillomavirus vaccine (HPV4) is recommended as a 3-dose series administered at 0, 1-2, and 6 months. However, this dosing schedule is often not followed leading to longer dosing intervals. We conducted a prospective study to assess antibody titers to HPV4 when dose 2 and/or dose 3 were administered on schedule or delayed. Healthy females (N=331) aged 9-18 years were enrolled at the time of receipt of HPV4 dose 2 or 3. Participants were classified as belonging to one of four groups depending upon timing of receipt of HPV4: both doses on time; only dose 2 delayed later than 90 days; only dose 3 delayed later than 180 days; or both doses 2 and 3 delayed. Pre- and post-dose 3 blood samples were assayed for HPV antibody titers (types 6, 11, 16, and 18). Post-dose 3 geometric mean titers (GMTs) for all HPV types were not significantly lower for any of the delayed dosing groups when compared to the on time group. When compared to the on time group, the post dose 3 GMTs in the delayed dose 3 group were significantly higher (p < 0.05) for HPV types 6, 11, and 16. Our findings suggest that delays of dose 2 or 3 do not interfere with immune responses after completion of the 3-dose series. These results support current recommendations to not administer additional doses of HPV4 vaccine if dose 2, dose 3, or both doses have been administered late. (C) 2015 Elsevier Ltd. All rights reserved. C1 [Russell, Kate; Kemper, Alex R.; Dolor, Rowena J.; Walter, Emmanuel B.] Duke Univ, Sch Med, Clin Vaccine Unit, Durham, NC 27705 USA. [Russell, Kate; Kemper, Alex R.; Dolor, Rowena J.; Walter, Emmanuel B.] Duke Univ, Sch Med, Primary Care Res Consortium, Durham, NC 27705 USA. [Dunne, Eileen F.; Markowitz, Lauri E.] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA 30329 USA. [Unger, Elizabeth. R.; Panicker, Gitika] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Atlanta, GA 30329 USA. RP Walter, EB (reprint author), Duke Univ, Sch Med, Clin Vaccine Unit, 2608 Erwin Rd Suite 210, Durham, NC 27705 USA. EM kate.russell@dm.duke.edu; dde9@CDC.GOV; alex.kemper@dm.duke.edu; rowena.dolor@dm.duke.edu; eru0@cdc.gov; dhv1@cdc.gov; lem2@cdc.gov; walte002@mc.duke.edu OI Russell, Kate/0000-0001-9343-3355 FU Duke University School of Medicine; AAMC-CDC [5U36CD319276] FX Support for this work was provided through a cooperative agreement between Duke University School of Medicine and AAMC-CDC: no. 5U36CD319276. NR 26 TC 0 Z9 0 U1 0 U2 3 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD APR 15 PY 2015 VL 33 IS 16 BP 1953 EP 1958 DI 10.1016/j.vaccine.2015.02.058 PG 6 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA CF6JC UT WOS:000352662000009 PM 25744229 ER PT J AU Haber, P Moro, PL Cano, M Lewis, P Stewart, B Shimabukuro, TT AF Haber, Penina Moro, Pedro L. Cano, Maria Lewis, Paige Stewart, Brock Shimabukuro, Tom T. TI Post-licensure surveillance of quadrivalent live attenuated influenza vaccine United States, Vaccine Adverse Event Reporting System (VAERS), July 2013-June 2014 SO VACCINE LA English DT Article DE Vaccine safety; Post-licensure surveillance; Live attenuated influenza vaccine; Vaccine Adverse Event Reporting System ID GUILLAIN-BARRE-SYNDROME; IMMUNIZATION SAFETY DATA; ADVISORY-COMMITTEE; SEASONAL INFLUENZA; RECOMMENDATIONS; PREVENTION; GUIDELINES; COLLECTION; CHILDREN; ADULTS AB Background: Quadrivalent live attenuated influenza vaccine (LAIV4) was approved in 2012 for healthy persons aged 2-49 years. Beginning with the 2013-2014 influenza season, LAIV4 replaced trivalent live attenuated influenza vaccine (LAIV3). Methods: We analyzed LAIV4 reports to VAERS, a national spontaneous reporting system. LAIV4 reports in 2013-2014 were compared to LAIV3 reports from the previous three influenza seasons. Medical records were reviewed for non-manufacturer serious reports (i.e., death, hospitalization, prolonged hospitalization, life-threatening illness, permanent disability) and reports of selected conditions of interest. We conducted Empirical Bayesian data mining to identify disproportional reporting for LAIV4. Results: In 2013-2014, 12.7 million doses of LAIV4 were distributed and VAERS received 779 reports in individuals aged 2-49 years; 95% were non-serious. Expired drug administered (42%), fever (13%) and cough (8%) were most commonly reported in children aged 2-17 years when LAIV4 was administered alone, while headache (18%), expired drug administered (15%) and exposure during pregnancy (12%) were most common in adults aged 18-49 years. We identified one death report in a child who died from complications of cerebellar vascular tumors. Among non-death serious reports, neurologic conditions were common in children and adults. In children, seizures (3) and Guillain-Barre. syndrome (2) were the most common serious neurologic outcomes. We identified three serious reports of asthma/wheezing following LAIV4 in children. Data mining detected disproportional reporting for vaccine administration errors and for influenza illness in children. Conclusions: Our analysis of VAERS reports for LAIV4 did not identify any concerning patterns. The data mining finding for reports of influenza illness is consistent with low LAIV4 vaccine effectiveness observed for influenza A disease in children in 2013-2014. Reports of LAIV4 administration to persons in whom the vaccine is not recommended (e.g., pregnant women) indicate the need for education, training and screening regarding indications. Published by Elsevier Ltd. C1 [Haber, Penina; Moro, Pedro L.; Cano, Maria; Lewis, Paige; Stewart, Brock; Shimabukuro, Tom T.] Ctr Dis Control & Prevent, Immunizat Safety Off, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. RP Haber, P (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS D-26, Atlanta, GA 30333 USA. EM phaber@cdc.gov NR 30 TC 11 Z9 11 U1 0 U2 7 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD APR 15 PY 2015 VL 33 IS 16 BP 1987 EP 1992 DI 10.1016/j.vaccine.2015.01.080 PG 6 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA CF6JC UT WOS:000352662000014 PM 25678241 ER PT J AU Lewis, RC Cantonwine, DE Del Toro, LVA Calafat, AM Valentin-Blasini, L Davis, MD Montesano, MA Alshawabkeh, AN Cordero, JF Meeker, JD AF Lewis, Ryan C. Cantonwine, David E. Del Toro, Liza V. Anzalota Calafat, Antonia M. Valentin-Blasini, Liza Davis, Mark D. Montesano, M. Angela Alshawabkeh, Akram N. Cordero, Jose F. Meeker, John D. TI Distribution and determinants of urinary biomarkers of exposure to organophosphate insecticides in Puerto Rican pregnant women SO SCIENCE OF THE TOTAL ENVIRONMENT LA English DT Article DE Biomarker; Pesticides; Pregnancy; Urine; Women ID PESTICIDE EXPOSURE; NONPERSISTENT INSECTICIDES; TEMPORAL VARIABILITY; METABOLITE CONCENTRATIONS; AGRICULTURAL HEALTH; PRENATAL EXPOSURE; PREVALENCE; PREDICTORS; CHILDREN; OBESITY AB Globally, human exposures to organophosphate (OP) insecticides may pose a significant burden to the health of mothers and their developing fetuses. Unfortunately, relevant data is limited in certain areas of the world concerning sources of exposure to OP insecticides in pregnant populations. To begin to address this gap in information for Puerto Rico, we studied repeated measures of urinary concentrations of 10 OP insecticide metabolites among 54 pregnant women from the northern karst region of the island. We also collected demographic data and self-reported information on the consumption of fruits, vegetables, and legumes in the past 48 h before urine collection and home pest-related issues. We calculated the distributions of the urinary biomarkers and compared them to women of reproductive age from the general U.S. population. We also used statistical models accounting for correlated data to assess within-subject temporal variability of the urinary biomarkers and to identify predictors of exposure. We found that for all but two metabolites (para-nitrophenol [PNP], diethylthiophosphate [DETP], 50th or 95th percentile urinary concentrations (the metric that was used for comparison was based on the biomarker's detection frequency) of the other eight metabolites (3,5,6-trichloro-2-pyridinol [TCPY], 2-isopropyl-4-methyl-6-hydroxy-pyrimidine, malathion dicarboxylic acid, diethylphosphate, diethyldithiophosphate, dimethylphosphate, dimethylthiophosphate [DMTP], dimethyldithiophosphate) were somewhat lower in our cohort compared with similarly aged women from the continental United States, TCPY, PNP, DETP, and DMTP, which were the only urinary metabolites detected in greater than 50% of the samples, had poor reproducibility (intraclass correlation coefficient range: 0.19-0.28) during pregnancy. Positive predictors of OP insecticide exposure included: age; marital or employment status; consumption of cherries, grape juice, peanuts, peanut butter, or raisins; and residential application of pesticides. Further research is needed to understand what aspects of the predictors identified influence OP insecticide exposure during pregnancy. (C) 2015 Elsevier B.V. All rights reserved. C1 [Lewis, Ryan C.; Meeker, John D.] Univ Michigan, Sch Publ Hlth, Dept Environm Hlth Sci, Ann Arbor, MI 48109 USA. [Cantonwine, David E.] Brigham & Womens Hosp, Dept Obstet & Gynecol, Boston, MA 02115 USA. [Del Toro, Liza V. Anzalota; Cordero, Jose F.] Univ Puerto Rico, Grad Sch Publ Hlth, San Juan, PR 00935 USA. [Calafat, Antonia M.; Valentin-Blasini, Liza; Davis, Mark D.; Montesano, M. Angela] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Sci Lab, Atlanta, GA 30341 USA. [Alshawabkeh, Akram N.] Northeastern Univ, Coll Engn, Boston, MA 02115 USA. RP Meeker, JD (reprint author), Univ Michigan, Sch Publ Hlth, Dept Environm Hlth Sci, 1415 Washington Hts, Ann Arbor, MI 48109 USA. EM rclewis@umich.edu; dcantonwine@partners.org; liza.anzalota@upr.edu; aic7@cdc.gov; Ivb5@cdc.gov; msd7@cdc.gov; ahm2@cdc.gov; aalsha@coe.neu.edu; jose.cordero6@upr.edu; meekerj@umich.edu OI Meeker, John/0000-0001-8357-5085 FU National Institute of Environmental Health Sciences, National Institutes of Health (NIH) [P42ES017198, R01 ES021465, P30ES017885]; National Institute on Minority Health and Health Disparities, NIH [G12MD007600, U54MD007587] FX Work was supported by grants P42ES017198, R01 ES021465 and P30ES017885 from the National Institute of Environmental Health Sciences, National Institutes of Health (NIH), and by grants G12MD007600 and U54MD007587 from the National Institute on Minority Health and Health Disparities, NIH. The content is solely the responsibility of the authors and does not necessarily represent the official position of NIH or CDC. We thank Carolina Fernandez, Do-Gyun Kim, William Roman, Erin Wade and Charlie Chambers of CDC for their technical support with the urinalysis. NR 43 TC 5 Z9 6 U1 2 U2 22 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0048-9697 EI 1879-1026 J9 SCI TOTAL ENVIRON JI Sci. Total Environ. PD APR 15 PY 2015 VL 512 BP 337 EP 344 DI 10.1016/j.scitotenv.2015.01.059 PG 8 WC Environmental Sciences SC Environmental Sciences & Ecology GA CD7CN UT WOS:000351248500035 PM 25634738 ER PT J AU McElroy, AK Akondy, RS Davis, CW Ellebedy, AH Mehta, AK Kraft, CS Lyon, GM Ribner, BS Varkey, J Sidney, J Sette, A Campbell, S Stroher, U Damon, I Nichol, ST Spiropoulou, CF Ahmed, R AF McElroy, Anita K. Akondy, Rama S. Davis, Carl W. Ellebedy, Ali H. Mehta, Aneesh K. Kraft, Colleen S. Lyon, G. Marshall Ribner, Bruce S. Varkey, Jay Sidney, John Sette, Alessandro Campbell, Shelley Stroeher, Ute Damon, Inger Nichol, Stuart T. Spiropoulou, Christina F. Ahmed, Rafi TI Human Ebola virus infection results in substantial immune activation SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE Ebola infection; human immune response; immune activation; plasmablasts; T cells ID T-CELL RESPONSES; HEMORRHAGIC-FEVER; LYMPHOCYTE APOPTOSIS; NONHUMAN-PRIMATES; DENDRITIC CELLS; MARBURG VIRUSES; IN-VITRO; CHALLENGE; VACCINES; KIKWIT AB Four Ebola patients received care at Emory University Hospital, presenting a unique opportunity to examine the cellular immune responses during acute Ebola virus infection. We found striking activation of both B and T cells in all four patients. Plasmablast frequencies were 10-50% of B cells, compared with less than 1% in healthy individuals. Many of these proliferating plasmablasts were IgG-positive, and this finding coincided with the presence of Ebola virus-specific IgG in the serum. Activated CD4 T cells ranged from 5 to 30%, compared with 1-2% in healthy controls. The most pronounced responses were seen in CD8 T cells, with over 50% of the CD8 T cells expressing markers of activation and proliferation. Taken together, these results suggest that all four patients developed robust immune responses during the acute phase of Ebola virus infection, a finding that would not have been predicted based on our current assumptions about the highly immunosuppressive nature of Ebola virus. Also, quite surprisingly, we found sustained immune activation after the virus was cleared from the plasma, observed most strikingly in the persistence of activated CD8 T cells, even 1 mo after the patients' discharge from the hospital. These results suggest continued antigen stimulation after resolution of the disease. From these convalescent time points, we identified CD4 and CD8 T-cell responses to several Ebola virus proteins, most notably the viral nucleoprotein. Knowledge of the viral proteins targeted by T cells during natural infection should be useful in designing vaccines against Ebola virus. C1 [McElroy, Anita K.; Campbell, Shelley; Stroeher, Ute; Damon, Inger; Nichol, Stuart T.; Spiropoulou, Christina F.] Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Atlanta, GA 30333 USA. [McElroy, Anita K.] Emory Univ, Sch Med, Div Pediat Infect Dis, Atlanta, GA 30322 USA. [Akondy, Rama S.; Davis, Carl W.; Ellebedy, Ali H.; Ahmed, Rafi] Emory Univ, Sch Med, Emory Vaccine Ctr, Atlanta, GA 30322 USA. [Akondy, Rama S.; Davis, Carl W.; Ellebedy, Ali H.; Ahmed, Rafi] Emory Univ, Sch Med, Dept Microbiol & Immunol, Atlanta, GA 30322 USA. [Mehta, Aneesh K.; Kraft, Colleen S.; Lyon, G. Marshall; Ribner, Bruce S.; Varkey, Jay] Emory Univ, Sch Med, Div Infect Dis, Atlanta, GA 30322 USA. [Kraft, Colleen S.] Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA. [Sidney, John; Sette, Alessandro] La Jolla Inst Allergy & Immunol, La Jolla, CA 92037 USA. RP Spiropoulou, CF (reprint author), Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Atlanta, GA 30333 USA. EM ccs8@cdc.gov; rahmed@emory.edu RI Mehta, Aneesh/B-8054-2012; OI Mehta, Aneesh/0000-0002-6552-9162; Akondy, Rama/0000-0003-4737-5240 FU Defense Advanced Research Projects Agency [W31P4Q-14-1-0010]; NIH [UL1TR000454, K12 HD072245]; Pediatric Infectious Disease Society/St. Jude's Fellowship Award; Burroughs Wellcome Career Award FX We are most grateful to the patients for participating in the study, and thank the Emory Serious Communicable Diseases Unit team for their assistance. We thank Tim Uyeki for providing coordination between the clinical and research staff, and Tatyana Klimova for help with the manuscript. This project is supported by funding from the Defense Advanced Research Projects Agency (W31P4Q-14-1-0010) and NIH (UL1TR000454). A.K. McElroy is supported by a Pediatric Infectious Disease Society/St. Jude's Fellowship Award, a Burroughs Wellcome Career Award, and NIH K12 HD072245. NR 29 TC 40 Z9 41 U1 1 U2 10 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD APR 14 PY 2015 VL 112 IS 15 BP 4719 EP 4724 DI 10.1073/pnas.1502619112 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CF9BO UT WOS:000352856800060 PM 25775592 ER PT J AU Tao, GY Hua, J Chen, JL AF Tao, Guoyu Hua, Jennifer Chen, Jessica L. TI Understanding Sexual Activity and Chlamydia Testing Rate Based on Linked National Survey and Medicaid Claims Data SO PLOS ONE LA English DT Article ID CARE-EFFECTIVENESS-DATA; UNITED-STATES; COVERAGE; WOMEN; CHILDREN AB Background Monitoring adherence to national recommendations for annual chlamydia screening of female adolescents and young adult women is important for targeting quality improvement interventions to improve low screening rates. However, accurate measurement of rates may vary depending on the data source used to determine eligible sexually-active women. Methods The 2001-2004 NHANES data linked with Medicaid administrative data by respondent's unique identifier, the 2011-2012 NHANES data, and the 2004 and 2010 Medicaid data were used in this cross-sectional analysis. We defined self-reported sexual activity by self-reported sexual behaviors, claim-identified sexual activity by reproductive-related claims among women who had >= one healthcare claim, HEDIS-defined sexual activity by reproductive-related claims among women who were enrolled in Medicaid for >= 330 days and had >= one healthcare claim, and chlamydia tests by claims submitted in the 12 months prior to the survey interview. Results Of Medicaid women aged 18-25 years, 91.5% self-reported to be sexually-active. Of self-reported sexually-active women aged 18-25 years, 92.0% had >= one healthcare claim in the 12 months prior to the survey interview; of this subpopulation, only 58.8% were enrolled in Medicaid for >= 330 days in the 12 months prior to the survey interview; of this further subpopulation, 74.1% had healthcare claims identifying them as sexually-active in the 12 months prior to the survey interview. Of HEDIS-defined sexually-active women, 42.4% had chlamydia testing. Conclusion Our study suggests that the number of sexually-active women aged 18-25 years used as the denominator in the chlamydia testing measure could be significantly different, depending upon the definition applied and the data used. Our data highlight the limited representativeness of Medicaid population in the current HEDIS measure on chlamydia testing when a high proportion of women who were enrolled in Medicaid for <330 days had been excluded from the measure. The interventions that can improve the proportion of women who were enrolled in Medicaid for >= 330 days among all young Medicaid women are needed not only for improving health care services, but also for measuring quality of healthcare. C1 [Tao, Guoyu; Hua, Jennifer; Chen, Jessica L.] Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. RP Tao, GY (reprint author), Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. EM gat3@cdc.gov NR 20 TC 1 Z9 1 U1 0 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD APR 13 PY 2015 VL 10 IS 4 AR e0122927 DI 10.1371/journal.pone.0122927 PG 12 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CF8XK UT WOS:000352845100119 PM 25875858 ER PT J AU Gazula, H Chang, CC Lu, ML Hsiang, SM AF Gazula, Harshvardhan Chang, Chien-Chi Lu, Ming-Lun Hsiang, Simon M. TI Using mutual information to capture major concerns of postural control in a tossing activity SO JOURNAL OF BIOMECHANICS LA English DT Article DE Tossing; Information theory; Chow-Liu tree ID DECISION-MAKING; COORDINATION; MOVEMENTS; NETWORKS; MODEL AB Human body motion for load-tossing activity was partitioned into three phases using four critical events based on the load position viz, lift-off, closest to body, peak and release. For each phase, three objective functions values, viz, mobilization, stabilization and muscular torque utilization, used to control the motion patterns, were then calculated. We hypothesize that the relationships between different objective functions can be extracted using information theory. The kinematic data obtained with 36 treatment combinations (2 tossing distances, 2 tossing heights, 3 weights, and 3 target clearances) was used to estimate the mutual information between each pair of objective functions and construct Chow-Liu trees. Results from this research indicate that there was no dominant concern in the first two phases of the activity; however, torque utilization and mobilization were found to be important factors in the third phase of the load tossing activity. (C) 2015 Elsevier Ltd. All rights reserved. C1 [Gazula, Harshvardhan; Hsiang, Simon M.] Texas Tech Univ, Dept Ind Engn, Lubbock, TX 79409 USA. [Chang, Chien-Chi] Natl Tsing Hua Univ, Dept Ind Engn & Engn Management, Hsinchu, Taiwan. [Lu, Ming-Lun] NIOSH, Cincinnati, OH 45226 USA. RP Gazula, H (reprint author), Texas Tech Univ, Dept Ind Engn, Lubbock, TX 79409 USA. EM harshvardhan.gazula@ttu.edu FU Intramural CDC HHS [CC999999] NR 24 TC 0 Z9 0 U1 0 U2 3 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0021-9290 EI 1873-2380 J9 J BIOMECH JI J. Biomech. PD APR 13 PY 2015 VL 48 IS 6 BP 1105 EP 1111 DI 10.1016/j.jbiomech.2015.01.022 PG 7 WC Biophysics; Engineering, Biomedical SC Biophysics; Engineering GA CF6MZ UT WOS:000352672100030 PM 25680297 ER PT J AU Orr, MF Wu, J Sloop, SL AF Orr, Maureen F. Wu, Jennifer Sloop, Sue L. TI Acute Chemical Incidents Surveillance - Hazardous Substances Emergency Events Surveillance, Nine States, 1999-2008 SO MMWR SURVEILLANCE SUMMARIES LA English DT Article AB Problem/Condition: Although they are infrequent, acute chemical incidents (i.e., uncontrolled or illegal release or threatened release of hazardous substances lasting <72 hours) with mass casualties or extraordinary levels of damage or disruption severely affecting the population, infrastructure, environment, and economy occur, and thousands of less damaging chemical incidents occur annually. Surveillance data enable public health and safety professionals to better understand the patterns and causes of these incidents, which can improve prevention efforts and preparation for future incidents. Reporting Period: 1999-2008. Description of System: The Hazardous Substances Emergency Events Surveillance (HSEES) system was operated by the Agency for Toxic Substances and Disease Registry (ATSDR) during January 1991-September 2009 to describe the public health consequences of chemical releases and to develop activities aimed at reducing the harm. This report provides a historical overview of HSEES and summarizes incidents from the nine states (Colorado, Iowa, Minnesota, New York, North Carolina, Oregon, Texas, Washington, and Wisconsin) that participated in HSEES during its last 10 full years of data collection (1999-2008). Results: During 1999-2008, a total of 57,975 chemical incidents occurred: 41,993 (72%) occurred at fixed facilities, and 15,981 (28%) were transportation related. Chemical manufacturing (NAICS 325) (23%) was the industry with the most incidents; however, the number of chemical incidents in chemical manufacturing decreased substantially over time (R-2 = 0.78), whereas the educational services category (R-2 = 0.65) and crop production category (R-2 = 0.61) had a consistently increasing trend. The most common contributing factors for an incident were equipment failure (n = 22,535, 48% of incidents) and human error (n = 16,534, 36%). The most frequently released chemical was ammonia 3,366 (6%). Almost 60% of all incidents occurred in two states, Texas and New York. A decreasing trend occurred in the number of incidents in Texas, Wisconsin, and Colorado, and an increasing trend occurred in Minnesota. Interpretation: Although chemical manufacturing accounted for the largest percentage of incidents in HSEES, the number of chemical incidents over time decreased substantially for this industry while heightened awareness and prevention measures were being implemented. However, incidents in educational services and crop production settings increased. Trends in incidents and number of incidents varied by state. Only a certain few chemicals, sectors, and areas were found to be related to the majority of incidents and injured persons. Equipment failure and human error, both common casual factors, are preventable. Public Health Implications: The findings in this collection of surveillance summaries underscore the need for educational institutions and the general public to receive more focused outreach. In addition, the select few chemicals and industries that result in numerous incidents can be the focus of prevention activities. The data in these surveillance summaries show that equipment maintenance, as well as training to prevent human error, could alleviate many of the incidents; NTSIP has begun work in these areas. State surveillance allows a state to identify its problem areas and industries and chemicals for prevention and preparedness. Beginning in 2010, ATSDR replaced HSEES with the National Toxic Substance Incidents Program (NTSIP) to expand on the work of HSEES. NTSIP helps states to collect surveillance data and to promote cost-effective, proactive measures such as converting to an inherently safer design, developing geographic mapping of chemically vulnerable areas, and adopting the principles of green chemistry (design of chemical products and processes that reduce or eliminate the generation of hazardous substances). Because the more populous states such as New York and Texas had the most incidents, areas with high population density should be carefully assessed for preparedness and prevention measures. NTSIP develops estimated incident numbers for states that do not collect data to help with state and national planning. NTSIP also collects more detailed data on chemical incidents with mass casualties. HSEES and NTSIP data can be used by public and environmental health and safety practitioners, worker representatives, emergency planners, preparedness coordinators, industries, emergency responders, and others to prepare for and prevent chemical incidents and injuries. C1 [Orr, Maureen F.; Wu, Jennifer] CDC, Div Toxicol & Human Hlth Sci, Agcy Toxic Subst & Dis Registry, Atlanta, GA 30333 USA. [Sloop, Sue L.] Ctr Medicare & Medicaid Serv, Off Informat Serv, Independence, MO USA. RP Orr, MF (reprint author), CDC, Div Toxicol & Human Hlth Sci, Agcy Toxic Subst & Dis Registry, Atlanta, GA 30333 USA. EM morr@cdc.gov NR 25 TC 0 Z9 0 U1 2 U2 6 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-8636 J9 MMWR SURVEILL SUMM JI MMWR Surv. Summ. PD APR 10 PY 2015 VL 64 IS 2 BP 1 EP 9 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CI4AN UT WOS:000354688800001 PM 25856532 ER PT J AU Ruckart, PZ Orr, MF AF Ruckart, Perri Zeitz Orr, Maureen F. TI Temporal Trends of Acute Chemical Incidents and Injuries - Hazardous Substances Emergency Events Surveillance, Nine States, 1999-2008 SO MMWR SURVEILLANCE SUMMARIES LA English DT Article AB Problem/Condition: Widespread use of hazardous chemicals in the United States is associated with unintentional acute chemical incidents (i.e., uncontrolled or illegal release or threatened release of hazardous substances lasting <72 hours). Efforts by industries, government agencies, academics, and others aim to reduce chemical incidents and the public health consequences, environmental damage, and economic losses; however, incidents are still prevalent. Reporting Period: 1999-2008. Description of System: The Hazardous Substances Emergency Events Surveillance (HSEES) system was operated by the Agency for Toxic Substances and Disease Registry (ATSDR) during January 1991-September 2009 to describe the public health consequences of chemical releases and to develop activities aimed at reducing the harm. This report summarizes temporal trends in the numbers of incidents, injured persons, deaths, and evacuations from the nine states (Colorado, Iowa, Minnesota, New York, North Carolina, Oregon, Texas, Washington, and Wisconsin) that participated in HSEES during its last 10 full years of data collection (1999-2008). Results: A total of 57,975 incidents and 15,506 injured persons, including 354 deaths, were reported. During the surveillance period, several trends were observed: a slight overall decrease occurred in incidents for fixed facilities (R-2 = 0.6) and an increasing trend in deaths (R-2 = 0.7) occurred, particularly for the general public (R-2 = 0.9). The number of incidents increased in the spring during March-June, and a decrease occurred in the remainder of the year (R-2 = 0.5). A decreasing trend in incidents occurred during Monday-Sunday (R-2 = 0.7) that was similar to that for the number of injured persons (R-2 = 0.6). The highest number of incidents occurred earlier in the day (6:00 a.m.-11:59 a.m.) and then decreased as the day went on (R-2 = 0.9); this trend was similar for the number of injured persons (R-2 = 1.0). Interpretation: Chemical incidents continue to affect public health and appear to be a growing problem for the general public. The number of incidents and injuries varied by month, day of week, and time of day and likely was influenced by other factors such as weather and the economy. Public Health Implications: Public and environmental health and safety practitioners, worker representatives, emergency planners, preparedness coordinators, industries, emergency responders, and others can use the findings in this report to prepare for and prevent chemical incidents and injuries. Specifically, knowing when to expect the most incidents and injuries can guide preparedness and prevention efforts. In addition, new or expanded efforts and outreach to educate consumers who could be exposed to chemicals are needed (e.g., education about the dangers of carbon monoxide poisoning for consumers in areas likely to experience weather-related power outages). Redirection of efforts such as promoting inherently safer technologies should be explored to reduce or eliminate the hazards completely. C1 [Ruckart, Perri Zeitz; Orr, Maureen F.] CDC, Div Toxicol & Human Hlth Sci, Agcy Toxic Subst & Dis Registry, Atlanta, GA 30333 USA. RP Ruckart, PZ (reprint author), CDC, Div Toxicol & Human Hlth Sci, Agcy Toxic Subst & Dis Registry, Atlanta, GA 30333 USA. EM afp4@cdc.gov NR 20 TC 0 Z9 0 U1 0 U2 4 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-8636 J9 MMWR SURVEILL SUMM JI MMWR Surv. Summ. PD APR 10 PY 2015 VL 64 IS 2 BP 10 EP 17 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CI4AN UT WOS:000354688800002 PM 25856533 ER PT J AU Duncan, MA Wu, J Neu, MC Orr, MF AF Duncan, Mary Anne Wu, Jennifer Neu, M. Caitlin Orr, Maureen F. TI Persons Injured During Acute Chemical Incidents - Hazardous Substances Emergency Events Surveillance, Nine States, 1999-2008 SO MMWR SURVEILLANCE SUMMARIES LA English DT Article ID POSTTRAUMATIC-STRESS AB Problem/Condition: Persons exposed to chemicals during acute chemical incidents (i.e., uncontrolled or illegal release or threatened release of hazardous substances lasting <72 hours) can experience both acute and chronic health effects. Surveillance of toxic substance incidents provides data that can be used to prevent future incidents and improve the emergency response to those that occur, leading to a decrease in morbidity and mortality from chemical releases. Reporting Period: 1999-2008 Description of System: The Hazardous Substances Emergency Events Surveillance (HSEES) system was operated by the Agency for Toxic Substances and Disease Registry (ATSDR) during January 1991-September 2009 to describe the public health consequences of chemical releases and to develop activities aimed at reducing the harm. This report summarizes the data collected on injured persons from the nine states (Colorado, Iowa, Minnesota, New York, North Carolina, Oregon, Texas, Washington, and Wisconsin) that participated in HSEES during its last 10 full years of data collection (1999-2008). Results: A total of 57,975 chemical incidents were reported by these states during the 10-year surveillance period. In 4,621 (8%) of these incidents, 15,506 persons were injured. Among them, 354 deaths occurred. The most commonly reported category of injured persons included employees of the responsible party (7,616 [49%]), members of the general public (4,737 [31%]), students exposed at school (1,730 [11%]), and responders to the incident (1,398 [9%]). Deaths occurred among members of the general public (190 [54%]), employees (154 [44%]), and responders (10 [3%]). The most frequent health effects experienced as a result of these incidents included respiratory irritation (7,443), dizziness or central nervous system problems (3,186), and headache (3,167). The three chemicals associated with the largest number of persons injured were carbon monoxide (2,364), ammonia (1,153), and chlorine (763). Interpretation: Company employees, followed by members of the general public, are frequently injured in acute chemical incidents. The chemicals most often associated with these injuries are carbon monoxide, ammonia, and chlorine, all of which are hazardous gases that can be found in various locations including schools and homes. Respiratory irritation is the most common health effect. Public Health Implications: By understanding the types of persons injured in chemical release incidents, as well as how they are injured and the injuries sustained, prevention outreach activities can be focused to protect the health of these groups in the future. Improved awareness among and training for not just employees but also the public is needed, particularly regarding carbon monoxide, ammonia, and chlorine. Appropriate measures to provide protection from respiratory effects of chemical incidents could prevent injuries. C1 [Duncan, Mary Anne; Wu, Jennifer; Neu, M. Caitlin; Orr, Maureen F.] CDC, Div Toxicol & Human Hlth Sci, Agcy Tox Subst & Dis Registry, Atlanta, GA 30333 USA. RP Duncan, MA (reprint author), CDC, Div Toxicol & Human Hlth Sci, Agcy Tox Subst & Dis Registry, Atlanta, GA 30333 USA. EM maduncan@cdc.gov NR 17 TC 3 Z9 3 U1 0 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-8636 J9 MMWR SURVEILL SUMM JI MMWR Surv. Summ. PD APR 10 PY 2015 VL 64 IS 2 BP 18 EP 24 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CI4AN UT WOS:000354688800003 PM 25856534 ER PT J AU Melnikova, N Wu, J Orr, MF AF Melnikova, Natalia Wu, Jennifer Orr, Maureen F. TI Public Health Response to Acute Chemical Incidents - Hazardous Substances Emergency Events Surveillance, Nine States, 1999-2008 SO MMWR SURVEILLANCE SUMMARIES LA English DT Article AB Problem/Condition: Acute chemical incidents (i.e., uncontrolled or illegal release or threatened release of hazardous substances lasting <72 hours) represent a substantial threat to the environment, public health and safety, and community well-being. Providing a timely and appropriate public health response can prevent or reduce the impact of these incidents. Reporting Period: 1999-2008. Description of System: The Hazardous Substances Emergency Events Surveillance (HSEES) system was operated by the Agency for Toxic Substances and Disease Registry (ATSDR) during January 1991-September 2009 to describe the public health consequences of chemical releases and to develop activities aimed at reducing the harm. This report summarizes types, frequency, and trends in public health actions taken in response to hazardous substance incidents in the nine states (Colorado, Iowa, Minnesota, New York, North Carolina, Oregon, Texas, Washington, and Wisconsin) that participated in HSEES during its last 10 full years of data collection (1999-2008). Results: Of the 57,975 HSEES incidents that occurred during 1999-2008, a total of 15,203 (26.2%) incidents resulted in at least one public health action taken to protect public health. Evacuations were ordered in 4,281 (7.4%) HSEES incidents, shelter in place was ordered in 509 (0.9%) incidents, and access to the affected area was restricted in 10,345 (25.9%) incidents. Decontamination occurred in 2,171 (3.7%) incidents; 13,461 persons were decontaminated, including 1,152 injured persons. Actions to protect public health (e.g., environmental sampling or issuance of health advisories) were taken in 6,693 (11.5%) incidents. The highest number of evacuations and orders to shelter in place occurred in Washington (n = 558 [16.1%] and n = 121 [3.2%], respectively). Carbon monoxide and ammonia releases resulted in the highest percentage of orders to evacuate and shelter in place. The most frequently reported responders to chemical incidents were company response teams. Interpretation: The most frequent public health response was restricting access to the area (26% of incidents), public health actions (12%), evacuation (7%), decontamination (4%), and shelter-in-place (1%). Ammonia and carbon monoxide were associated with adverse health effects in the population and the most public health response actions. Therefore, these chemicals can be considered a high priority for prevention and response efforts. Public Health Implications: States and communities can collaborate with facilities to use the information collected through community right-to-know legislation and this report to improve chemical safety and protect public health and the environment, such as being prepared to handle the most common chemicals in their area and probable public health actions. C1 [Melnikova, Natalia; Wu, Jennifer; Orr, Maureen F.] CDC, Div Toxicol & Human Hlth Sci, Agcy Tox Subst & Dis Registry, Atlanta, GA 30333 USA. RP Melnikova, N (reprint author), CDC, Div Toxicol & Human Hlth Sci, Agcy Tox Subst & Dis Registry, Atlanta, GA 30333 USA. EM nbm6@cdc.gov NR 7 TC 0 Z9 0 U1 1 U2 4 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-8636 J9 MMWR SURVEILL SUMM JI MMWR Surv. Summ. PD APR 10 PY 2015 VL 64 IS 2 BP 25 EP 31 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CI4AN UT WOS:000354688800004 PM 25856535 ER PT J AU Young, R AF Young, Randall TI Geographic Distribution of Acute Chemical Incidents - Hazardous Substances Emergency Events Surveillance, Nine States, 1999-2008 SO MMWR SURVEILLANCE SUMMARIES LA English DT Article AB Problem/Condition: Hazardous chemicals are transported and used widely in the United States, and acute chemical releases (lasting <72 hours) are not uncommon. Characterizing acute incidents within geographic areas can help researchers identify spatial patterns and differences and enable public and environmental health and safety practitioners, members of local emergency planning committees, preparedness coordinators, industry managers, emergency responders, and others to prepare for and respond to chemical incidents. Reporting Period: 1999-2008. Description of System: The Hazardous Substances Emergency Events Surveillance (HSEES) system was operated by the Agency for Toxic Substances and Disease Registry (ATSDR) during January 1991-September 2009 to collect data on hazardous chemical releases that would enable researchers to describe the public health consequences of these acute releases and to develop activities aimed at reducing the ensuing harm to the public. This report summarizes data for the geographic distribution of reported acute incidents by states, counties, and Metropolitan Statistical Areas (MSAs) from the nine states (Colorado, Iowa, Minnesota, New York, North Carolina, Oregon, Texas, Washington, and Wisconsin) that participated in HSEES during its last 10 full years of data collection (1999-2008). Results: A total of 57,975 acute incidents occurred during 1999-2008; five MSAs accounted for 40.1% of all incidents. Texas reported 41% of all incidents reported by the nine states during the 10-year study period, and Colorado reported the fewest incidents (3.4%). Interpretation: Storage, use, and transport of hazardous substances often are associated with unanticipated releases. In general, releases occurred more frequently in areas that use or store more hazardous chemicals and in urbanized areas compared with rural areas. In rural areas, most incidents were related to the transport of hazardous chemicals. The primary economic activities in an area had a strong influence on the frequency and type of chemicals released in the area. Public Health Implications: Exposure to hazardous chemicals can have immediate and serious health consequences. Harmful releases can occur wherever hazardous chemicals are used, stored, or transported. The time and location of releases is unpredictable. Taken together, these elements underscore the need for preparedness. A culture of safety, prevention, and preparedness can minimize the consequences of future incidents. C1 CDC, Div Toxicol & Human Hlth Sci, Agcy Toxic Subst & Dis Registry, Atlanta, GA 30333 USA. RP Young, R (reprint author), CDC, Div Toxicol & Human Hlth Sci, Agcy Toxic Subst & Dis Registry, Atlanta, GA 30333 USA. EM rby5@cdc.gov NR 12 TC 0 Z9 0 U1 1 U2 4 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-8636 J9 MMWR SURVEILL SUMM JI MMWR Surv. Summ. PD APR 10 PY 2015 VL 64 IS 2 BP 32 EP 38 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CI4AN UT WOS:000354688800005 PM 25856536 ER PT J AU Anderson, AR AF Anderson, Ayana R. TI Top Five Chemicals Resulting in Injuries from Acute Chemical Incidents - Hazardous Substances Emergency Events Surveillance, Nine States, 1999-2008 SO MMWR SURVEILLANCE SUMMARIES LA English DT Article ID EVACUATIONS AB Problem/Condition: The Toxic Substances Control Act Chemical Substance Inventory lists >84,000 chemicals used in commerce (http://www.epa.gov/oppt/existingchemicals/pubs/tscainventory/basic.html). With chemicals having a multitude of uses, persons are potentially at risk daily for exposure to chemicals as a result of an acute chemical incident (lasting <72 hours). Depending on the level of exposure and the type of chemical, exposure can result in morbidity and, in some cases, mortality. Reporting Period: 1999-2008. Description of System: The Hazardous Substances Emergency Events Surveillance (HSEES) system was operated by the Agency for Toxic Substances and Disease Registry during January 1991-September 2009 to collect data that would enable researchers to describe the public health consequences of chemical incidents and to develop activities aimed at reducing the harm from such incidents. This report identifies the top five chemicals that caused injuries in the nine states (Colorado, Iowa, Minnesota, New York, North Carolina, Oregon, Texas, Washington, and Wisconsin) that participated in HSEES during its last 10 full years of data collection (1999-2008). Results: Of the 57,975 incidents that were reported, 54,989 (95%) involved the release of only one chemical. The top five chemicals associated with injury were carbon monoxide (2,364), ammonia (1,153), chlorine (763), hydrochloric acid (326), and sulfuric acid (318). Carbon monoxide and ammonia by far caused the most injuries, deaths, and evacuations. Chlorine, while not in the top 10 chemicals released, was in the top five chemicals associated with injury because of its hazardous properties. Interpretation: Multiple measures can be taken to prevent injuries associated with the top five chemicals. Because many carbon monoxide releases occur in residential settings, use of carbon monoxide detectors can prevent injuries. Substituting chemicals with less lethal alternatives can result in mitigating injuries associated with ammonia. Routine maintenance of equipment and engineering controls can reduce injuries associated with chlorine and sulfuric acid, and proper chemical handling training can reduce injuries associated with hydrochloric acid. Public Health Implications: Understanding the most frequently reported locations where carbon monoxide, ammonia, chlorine, hydrochloric acid, and sulfuric acid are released along with the most frequently reported contributing factors can help mitigate injuries associated with these releases. Prevention initiatives should focus on educating the public and workers about the dangers of these chemicals and about proper handling of these chemicals along with routine maintenance of equipment. C1 CDC, Div Toxicol & Human Hlth Sci, Agcy Toxic Subst & Dis Registry, Atlanta, GA 30333 USA. RP Anderson, AR (reprint author), CDC, Div Toxicol & Human Hlth Sci, Agcy Toxic Subst & Dis Registry, Atlanta, GA 30333 USA. EM aranderson@cdc.gov NR 28 TC 1 Z9 1 U1 1 U2 6 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-8636 J9 MMWR SURVEILL SUMM JI MMWR Surv. Summ. PD APR 10 PY 2015 VL 64 IS 2 BP 39 EP 46 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CI4AN UT WOS:000354688800006 PM 25856537 ER PT J AU Anderson, AR Wu, J AF Anderson, Ayana R. Wu, Jennifer TI Top Five Industries Resulting in Injuries from Acute Chemical Incidents - Hazardous Substance Emergency Events Surveillance, Nine States, 1999-2008 SO MMWR SURVEILLANCE SUMMARIES LA English DT Article ID ACCIDENTS AB Problem/Condition: Because industries using and/or producing chemicals are located in close proximity to populated areas, U.S. residents are at risk for unintentional chemical exposures. Reporting Period: 1999-2008. Description of System: The Hazardous Substances Emergency Events Surveillance (HSEES) system was operated by the Agency for Toxic Substances and Disease Registry during January 1991-September 2009 to collect data that would enable researchers to describe the public health consequences of chemical releases and to develop activities aimed at reducing the harm from such releases. This report summarizes data for the top five industries resulting in injuries from an acute chemical incident (lasting <72 hours) occurring in the nine states (Colorado, Iowa, Minnesota, New York, North Carolina, Oregon, Texas, Washington, and Wisconsin) that participated in HSEES during its last 10 full years of data collection (1999-2008). Results: Five industries (truck transportation, educational services, chemical manufacturing, utilities, and food manufacturing) accounted for approximately one third of all incidents in which persons were injured as a result of unintentional release of chemicals; the same five industries were responsible for approximately one third of all persons injured as a result of such releases. Interpretation: Acute chemical incidents in these five industries resulted in serious public health implications including the need for evacuations, morbidity, and mortality. Public Health Implications: Targeting chemical incident prevention and preparedness activities towards these five industries provides an efficient use of resources for reducing chemical exposures. A variety of methods can be used to minimize chemical releases in industries. One example is the Occupational Safety and Health Administration's hierarchy of controls model, which focuses on controlling exposures to occupational hazards. The hierarchy includes elimination, substitution, engineering controls, administrative controls, and use of personal protective equipment. C1 [Anderson, Ayana R.; Wu, Jennifer] CDC, Div Toxicol & Human Hlth Sci, Agcy Tox Subst & Dis Registry, Atlanta, GA 30333 USA. RP Anderson, AR (reprint author), CDC, Div Toxicol & Human Hlth Sci, Agcy Tox Subst & Dis Registry, Atlanta, GA 30333 USA. EM aranderson@cdc.gov NR 22 TC 1 Z9 1 U1 0 U2 6 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-8636 J9 MMWR SURVEILL SUMM JI MMWR Surv. Summ. PD APR 10 PY 2015 VL 64 IS 2 BP 47 EP 53 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CI4AN UT WOS:000354688800007 PM 25856538 ER PT J AU Aliabadi, N Tate, JE Haynes, AK Parashar, UD AF Aliabadi, Negar Tate, Jacqueline E. Haynes, Amber K. Parashar, Umesh D. TI Sustained Decrease in Laboratory Detection of Rotavirus after Implementation of Routine Vaccination-United States, 2000-2014 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID CHILDREN; GASTROENTERITIS C1 [Aliabadi, Negar] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Aliabadi, Negar; Tate, Jacqueline E.; Haynes, Amber K.; Parashar, Umesh D.] CDC, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Aliabadi, N (reprint author), CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. EM ydh6@cdc.gov NR 10 TC 15 Z9 16 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD APR 10 PY 2015 VL 64 IS 13 BP 337 EP 342 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CG3KU UT WOS:000353179900001 PM 25856253 ER PT J AU Mazurek, JM White, GE AF Mazurek, Jacek M. White, Gretchen E. TI Work-Related Asthma-22 States, 2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID PUBLIC-HEALTH SURVEILLANCE; LANDLINE C1 [Mazurek, Jacek M.; White, Gretchen E.] CDC, Div Resp Dis Studies, Natl Inst Occupat Safety & Hlth, Atlanta, GA 30333 USA. RP Mazurek, JM (reprint author), CDC, Div Resp Dis Studies, Natl Inst Occupat Safety & Hlth, Atlanta, GA 30333 USA. EM jmazurek1@cdc.gov NR 10 TC 1 Z9 1 U1 1 U2 3 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD APR 10 PY 2015 VL 64 IS 13 BP 343 EP 346 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CG3KU UT WOS:000353179900002 PM 25856254 ER PT J AU Parham, M Edison, L Soetebier, K Feldpausch, A Kunkes, A Smith, W Guffey, T Fetherolf, R Sanlis, K Gabel, J Cowell, A Drenzek, C AF Parham, Mary Edison, Laura Soetebier, Karl Feldpausch, Amanda Kunkes, Audrey Smith, Wendy Guffey, Taylor Fetherolf, Romana Sanlis, Kathryn Gabel, Julie Cowell, Alex Drenzek, Cherie TI Ebola Active Monitoring System for Travelers Returning from West Africa - Georgia, 2014-2015 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Parham, Mary] CDC, Ctr Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA. [Edison, Laura; Soetebier, Karl; Feldpausch, Amanda; Kunkes, Audrey; Smith, Wendy; Guffey, Taylor; Gabel, Julie; Cowell, Alex; Drenzek, Cherie] Georgia Dept Publ Hlth, Atlanta, GA USA. [Edison, Laura; Sanlis, Kathryn] CDC, Div State & Local Readiness, Atlanta, GA 30333 USA. [Fetherolf, Romana] CDC, Off State Tribal Local & Terr Support, Atlanta, GA 30333 USA. RP Parham, M (reprint author), CDC, Ctr Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA. EM maparham@cdc.gov NR 5 TC 1 Z9 1 U1 0 U2 5 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD APR 10 PY 2015 VL 64 IS 13 BP 347 EP 350 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CG3KU UT WOS:000353179900003 PM 25856255 ER PT J AU Williams, TR Alam, S Gaffney, M AF Williams, Tonya R. Alam, Suhana Gaffney, Marcus TI Progress in Identifying Infants with Hearing Loss - United States, 2006-2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID CHILDREN; CARE C1 [Williams, Tonya R.; Alam, Suhana; Gaffney, Marcus] CDC, Div Human Dev & Disabil, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. RP Williams, TR (reprint author), CDC, Div Human Dev & Disabil, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. EM rwilliams10@cdc.gov NR 9 TC 5 Z9 5 U1 3 U2 3 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD APR 10 PY 2015 VL 64 IS 13 BP 351 EP 356 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CG3KU UT WOS:000353179900004 PM 25856256 ER PT J AU Takashima, Y Schluter, WW Mariano, KML Diorditsa, S Castro, MD Ou, AC Ducusin, MJU Garcia, LC Elfa, DC Dabbagh, A Rota, P Goodson, JL AF Takashima, Yoshihiro Schluter, W. William Mariano, Kayla Mae L. Diorditsa, Sergey de Quiroz Castro, Maricel Ou, Alan C. Ducusin, Maria Joyce U. Garcia, Luzviminda C. Elfa, Dulce C. Dabbagh, Alya Rota, Paul Goodson, James L. TI Progress Toward Measles Elimination - Philippines, 1998-2014 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID GENOTYPES C1 [Takashima, Yoshihiro; Schluter, W. William; Mariano, Kayla Mae L.; Diorditsa, Sergey] WHO, Expanded Programme Immunizat, Western Pacific Reg Off, Manila, Philippines. [de Quiroz Castro, Maricel; Ou, Alan C.] WHO, Representat Off, Manila, Philippines. [Ducusin, Maria Joyce U.; Garcia, Luzviminda C.; Elfa, Dulce C.] Dept Hlth, Natl Ctr Dis Prevent & Control, Manila, Philippines. [Dabbagh, Alya] WHO, Dept Immunizat Vaccines & Biol, CH-1211 Geneva, Switzerland. [Rota, Paul] CDC, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Goodson, James L.] CDC, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA 30333 USA. RP Goodson, JL (reprint author), CDC, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA 30333 USA. EM jgoodson@cdc.gov NR 10 TC 9 Z9 10 U1 0 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD APR 10 PY 2015 VL 64 IS 13 BP 357 EP 362 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CG3KU UT WOS:000353179900005 PM 25856257 ER PT J AU Romero, L Pazol, K Warner, L Gavin, L Moskosky, S Besera, G Briceno, ACL Jatlaoui, T Barfield, W AF Romero, Lisa Pazol, Karen Warner, Lee Gavin, Lorrie Moskosky, Susan Besera, Ghenet Briceno, Ana Carolina Loyola Jatlaoui, Tara Barfield, Wanda TI Vital Signs: Trends in Use of Long-Acting Reversible Contraception Among Teens Aged 15-19 Years Seeking Contraceptive Services - United States, 2005-2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID ADOLESCENT PREGNANCY; YOUNG AB Background: Nationally, the use of long-acting reversible contraception (LARC), specifically intrauterine devices (IUDs) and implants, by teens remains low, despite their effectiveness, safety, and ease of use. Methods: To examine patterns in use of LARC among females aged 15-19 years seeking contraceptive services, CDC and the U.S. Department of Health and Human Services' Office of Population Affairs analyzed 2005-2013 data from the Title X National Family Planning Program. Title X serves approximately 1 million teens each year and provides family planning and related preventive health services for low-income persons. Results: Use of LARC among teens* seeking contraceptive services at Title X service sites increased from 0.4% in 2005 to 7.1% in 2013 (p-value for trend <0.001). Of the 616,148 female teens seeking contraceptive services in 2013, 17,349 (2.8%) used IUDs, and 26,347 (4.3%) used implants. Use of LARC was higher among teens aged 18-19 years (7.6%) versus 15-17 years (6.5%) (p<0.001). The percentage of teens aged 15-19 years who used LARC varied widely by state, from 0.7% (Mississippi) to 25.8% (Colorado). Conclusions: Although use of LARC by teens remains low nationwide, efforts to improve access to LARC among teens seeking contraception at Title X service sites have increased use of these methods. Implications for public health practice: Health centers that provide quality contraceptive services can facilitate use of LARC among teens seeking contraception. Strategies to address provider barriers to offering LARC include: 1) educating providers that LARC is safe for teens; 2) training providers on LARC insertion and a client-centered counseling approach that includes discussing the most effective contraceptive methods first; and 3) providing contraception at reduced or no cost to the client. C1 [Romero, Lisa; Pazol, Karen; Warner, Lee; Besera, Ghenet; Jatlaoui, Tara; Barfield, Wanda] CDC, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Gavin, Lorrie; Moskosky, Susan; Briceno, Ana Carolina Loyola] US Dept HHS, Off Family Planning, Off Populat Affairs, Washington, DC USA. RP Romero, L (reprint author), CDC, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM eon1@cdc.gov NR 28 TC 13 Z9 14 U1 0 U2 4 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD APR 10 PY 2015 VL 64 IS 13 BP 363 EP 369 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CG3KU UT WOS:000353179900006 PM 25856258 ER PT J AU Catumbela, E Freitas, A Lopes, F Mendoza, MDT Costa, C Sarmento, A da Costa-Pereira, A AF Catumbela, Emanuel Freitas, Alberto Lopes, Fernando Torres Mendoza, Maria del Carmen Costa, Carlos Sarmento, Antonio da Costa-Pereira, Altamiro TI HIV disease burden, cost, and length of stay in Portuguese hospitals from 2000 to 2010: a cross-sectional study SO BMC HEALTH SERVICES RESEARCH LA English DT Article DE Advanced HIV infection; Administrative data; HIV epidemiology ID ANTIRETROVIRAL THERAPY; IMPACT; INFECTION; PATTERNS; TRENDS AB Background: The number of HIV-related hospitalizations has decreased worldwide in recent years owing to the availability of highly active antiretroviral therapy. However, the change in HIV-related hospitalizations in Portugal has not been studied. Using comprehensive hospital discharge data from mainland Portuguese hospitals, we examined trends in HIV-related inpatient admissions, length of stay (LOS), Elixhauser comorbidity measures, in-hospital mortality, and mean cost from 2000 to 2010. Methods: The hospital administrative data from inpatient admissions and discharges at 75 public acute care hospitals in the Portuguese National Health Service from 2000 to 2010 were included. HIV-related admissions were identified using the International Classification of Diseases, 9th Revision, Clinical Modification diagnosis codes 042.x-044.x. The effect of Elixhauser comorbidity measures on extending the LOS was assessed by comparing admissions in HIV patients with and without comorbidities using the Mann-Whitney U test. Multivariate logistic regression was performed to estimate the odds of having a decreased discharge. Results: A total of 57,027 hospital admissions were analyzed; 73% of patients were male, and the mean age was 39 years. The median LOS was 11 days, and the in-hospital mortality was 14%. The mean cost per hospitalization was 5,148.7(sic). A total of 83% of admissions were through the emergency room. During the period, inpatient HIV admissions decreased by 22%, LOS decreased by 9%, and in-hospital mortality dropped by 12%. Elixhauser comorbidities increased the median LOS in nearly all admissions. Conclusions: Despite small regional variations, a strong, consistent decrease was observed in the hospital admission rate, mean cost, length of stay, and mortality rate for HIV-related admissions in Portugal during 2000-2010. C1 [Catumbela, Emanuel; Freitas, Alberto; Lopes, Fernando; da Costa-Pereira, Altamiro] Univ Porto, Fac Med, Dept Hlth Informat & Decis Sci, P-4100 Oporto, Portugal. [Catumbela, Emanuel] Univ Agostinho Neto, Fac Med, Dept Pathol, Luanda, Angola. [Catumbela, Emanuel; Freitas, Alberto; Lopes, Fernando; da Costa-Pereira, Altamiro] Univ Porto, CINTESIS, Ctr Res Hlth Technol & Informat Syst, P-4100 Oporto, Portugal. [Torres Mendoza, Maria del Carmen] US Ctr Dis Control & Prevent CDC, Div Global HIV AIDS, Atlanta, GA USA. [Costa, Carlos] Univ Nova Lisboa, Natl Sch Publ Hlth, Lisbon, Portugal. [Sarmento, Antonio] Univ Porto, Fac Med, Dept Infect Dis, P-4100 Oporto, Portugal. [Catumbela, Emanuel] Univ Porto, Fac Med, Dept Ciencias Informacao & Decisao Saude, P-4200319 Oporto, Portugal. RP Catumbela, E (reprint author), Univ Porto, Fac Med, Dept Hlth Informat & Decis Sci, Rua Campo Alegre 823, P-4100 Oporto, Portugal. EM ecassoco@gmail.com RI FMUP, CINTESIS/C-6631-2014; Freitas, Alberto/C-1972-2012; Costa-Pereira, Altamiro/I-5987-2012; Catumbela, Emanuel/J-9224-2014 OI FMUP, CINTESIS/0000-0001-7248-2086; Freitas, Alberto/0000-0003-2113-9653; Costa-Pereira, Altamiro/0000-0001-8467-6398; Catumbela, Emanuel/0000-0002-3289-2643 NR 24 TC 1 Z9 1 U1 14 U2 23 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1472-6963 J9 BMC HEALTH SERV RES JI BMC Health Serv. Res. PD APR 8 PY 2015 VL 15 AR 144 DI 10.1186/s12913-015-0801-8 PG 10 WC Health Care Sciences & Services SC Health Care Sciences & Services GA CG2OQ UT WOS:000353114600001 PM 25889920 ER PT J AU Vishwanathan, SA Morris, MR Wolitski, RJ Luo, W Rose, CE Blau, DM Tsegaye, T Zaki, SR Garber, DA Jenkins, LT Henning, TC Patton, DL Hendry, RM McNicholl, JM Kersh, EN AF Vishwanathan, Sundaram A. Morris, Monica R. Wolitski, Richard J. Luo, Wei Rose, Charles E. Blau, Dianna M. Tsegaye, Theodros Zaki, Sherif R. Garber, David A. Jenkins, Leecresia T. Henning, Tara C. Patton, Dorothy L. Hendry, R. Michael McNicholl, Janet M. Kersh, Ellen N. TI Rectal Application of a Highly Osmolar Personal Lubricant in a Macaque Model Induces Acute Cytotoxicity but Does Not Increase Risk of SHIV Infection SO PLOS ONE LA English DT Article ID SEXUAL LUBRICANTS; ANAL INTERCOURSE; HIV; MEN; TRANSMISSION; MICROBICIDES; PREVENTION; SHIVSF162P3; EFFICACY; TRIALS AB Background Personal lubricant use is common during anal intercourse. Some water-based products with high osmolality and low pH can damage genital and rectal tissues, and the polymer polyquaternium 15 (PQ15) can enhance HIV replication in vitro. This has raised concerns that lubricants with such properties may increase STD/HIV infection risk, although in vivo evidence is scarce. We use a macaque model to evaluate rectal cytotoxicity and SHIV infection risk after use of a highly osmolar (>8,000 mOsm/kg) water-based lubricant with pH of 4.4, and containing PQ15. Methods Cytotoxicity was documented by measuring inflammatory cytokines and epithelial tissue sloughing during six weeks of repeated, non-traumatic lubricant or control buffer applications to rectum and anus. We measured susceptibility to SHIVSF162P3 infection by comparing virus doses needed for rectal infection in twenty-one macaques treated with lubricant or control buffer 30 minutes prior to virus exposure. Results Lubricant increased pro-inflammatory cytokines and tissue sloughing while control buffer (phosphate buffered saline; PBS) did not. However, the estimated AID(50) (50% animal infectious dose) was not different in lubricant-and control buffer-treated macaques (p = 0.4467; logistic regression models). Conclusions Although the test lubricant caused acute cytotoxicity in rectal tissues, it did not increase susceptibility to infection in this macaque model. Thus neither the lubricant-induced type/extent of inflammation nor the presence of PQ15 affected infection risk. This study constitutes a first step in the in vivo evaluation of lubricants with regards to HIV transmission. C1 [Vishwanathan, Sundaram A.; Morris, Monica R.; Wolitski, Richard J.; Luo, Wei; Rose, Charles E.; Tsegaye, Theodros; Garber, David A.; Jenkins, Leecresia T.; Henning, Tara C.; Hendry, R. Michael; McNicholl, Janet M.; Kersh, Ellen N.] Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30329 USA. [Blau, Dianna M.] Natl Ctr Emerging & Zoonot Infect Dis, Ctr Dis Control & Prevent, Atlanta, GA USA. [Patton, Dorothy L.] Univ Washington, Seattle, WA 98195 USA. RP Kersh, EN (reprint author), Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30329 USA. EM ekersh@cdc.gov FU Centers for Disease Control (CDC) FX This study was funded by the Centers for Disease Control (CDC). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 28 TC 1 Z9 1 U1 1 U2 6 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD APR 8 PY 2015 VL 10 IS 4 AR e0120021 DI 10.1371/journal.pone.0120021 PG 17 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CF3WA UT WOS:000352478400009 PM 25853710 ER PT J AU Lu, PJ Yankey, D Jeyarajah, J O'Halloran, A Elam-Evans, L Greby, SM Singleton, JA Murphy, TV AF Lu, Peng-jun Yankey, David Jeyarajah, Jenny O'Halloran, Alissa Elam-Evans, Laurie Greby, Stacie M. Singleton, James A. Murphy, Trudy V. TI Hepatitis B vaccination among adolescents 13-17 years, United States, 2006-2012 SO VACCINE LA English DT Article DE Hepatitis B vaccine; Vaccination; Coverage; Adolescent vaccination; The National Immunization Survey-Teen (NIS-Teen) ID HUMAN-PAPILLOMAVIRUS VACCINATION; CHILDREN PROGRAM; HEALTH-CARE; COVERAGE; IMMUNIZATION; RECOMMENDATIONS; REIMBURSEMENT; VACCINES AB Background: Hepatitis B (HepB) vaccination is the most effective measure to prevent HBV infection. Routine HepB vaccination was recommended for infants in 1991 and catch-up vaccination has been recommended for adolescents since in 1995. The purpose of this study is to assess HepB vaccination among adolescents 13-17 years. Methods: The 2006-2012 NIS-Teen were analyzed. Vaccination trends and coverage by birth cohort among adolescents were evaluated. Multivariable logistic regression and predictive marginal models are used to identify factors independently associated with HepB vaccination. Results: HepB vaccination coverage increased from 81.3% in 2006 to 92.8% in 2012. Coverage varied by birth cohort and 79-83% received vaccination before 2 years of age for those who were born during 1995 and 1999. Among those who had not received vaccination by 11 years of age, for the 1993-1995 birth cohorts, 9-15% were vaccinated during ages 11-12 years, and 27-37% had been vaccinated through age 16 years. Coverage among adolescents 13-17 years in 2012 ranged by state from 84.4% in West Virginia to 98.7% in Florida (median 93.3%). Characteristics independently associated with a higher likelihood of HepB vaccination included living more than 5 times above poverty level, living in Northeastern or Southern region of the United States, and having a mixed facility as their vaccination provider. Those with a hospital listed as their vaccination provider and those who did not have a well-child visit at age 11-12 years were independently associated with a lower likelihood of HepB vaccination. Conclusions: Efforts focused on groups with lower coverage may reduce disparities in coverage and prevent hepatitis B infection. Parents and providers should routinely review adolescent immunizations. Routine reminder/recall, expanded access in health care settings, and standing order programs should be incorporated into routine clinical care of adolescents. Published by Elsevier Ltd. C1 [Lu, Peng-jun; Yankey, David; Jeyarajah, Jenny; O'Halloran, Alissa; Elam-Evans, Laurie; Greby, Stacie M.; Singleton, James A.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Immunizat Serv Div, Atlanta, GA 30333 USA. [Murphy, Trudy V.] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div Viral Hepatitis, Atlanta, GA 30333 USA. RP Lu, PJ (reprint author), Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd,NE,Mail Stop A-19, Atlanta, GA 30333 USA. EM lhp8@cdc.gov NR 43 TC 2 Z9 2 U1 1 U2 4 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD APR 8 PY 2015 VL 33 IS 15 BP 1855 EP 1864 DI 10.1016/j.vaccine.2015.02.021 PG 10 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA CF6PL UT WOS:000352678500015 PM 25724820 ER PT J AU Pan, Q Pais, R Ohandjo, A He, C He, Q Omosun, Y Igietseme, JU Eko, FO AF Pan, Qing Pais, Roshan Ohandjo, Adaugo He, Cheng He, Qing Omosun, Yusuf Igietseme, J. U. Eko, F. O. TI Comparative evaluation of the protective efficacy of two formulations of a recombinant Chlamydia abortus subunit candidate vaccine in a mouse model SO VACCINE LA English DT Article DE Chlatnydia abortus; Pmp18D; Vaccine delivery; Cross protection; Immunity ID OVINE ENZOOTIC ABORTION; OUTER-MEMBRANE-PROTEIN; VIBRIO-CHOLERAE GHOSTS; CHLAMYDOPHILA-ABORTUS; DENDRITIC CELLS; INFECTION; MICE; TRACHOMATIS; RESOLUTION; IMMUNITY AB Chlamydia abortus (C. abortus) is the causative agent of ovine enzootic abortion (OEA) and poses a zoonotic risk to pregnant women. Current live attenuated 1B vaccines are efficacious but cause disease in vaccinated animals and inactivated vaccines are only marginally protective. We tested the ability of a new C. abortus subunit vaccine candidate based on the conserved and immunogenic polymorphic membrane protein D (Pmp18D) formulated in CpG1826 + FL (Fms-like tyrosine kinase 3 Ligand: Flt3L) or Vibrio cholerae ghosts (VCG) to induce innate and cross protective immunity against genital C. abortus infection. We found that delivery of rPmp18D with VCG was more effective than with CpG + FL in up-regulating the expression of molecules critically involved in T cell activation and differentiation, including MHC II, CD40, CD80, and CD86, activation of TLRs and NLRP3 inflammasome engagement, and secretion of IL-1 beta and TNF-alpha but not IL-10 and IL-4. rVCG-Pmp 18D-immunized mice elicited more robust antigen-specific IFN-alpha, IgA and IgG2c antibody responses compared to CpG + FL-delivered rPmp18D. Based on the number of mice with positive vaginal cultures, length of vaginal shedding, and number of inclusion forming units recovered following challenge with the heterologous C. abortus strain B577, vaccine delivery with VCG induced superior protective immunity than delivery with a combination of CpG1826 and FL, a nasal DC-targeting adjuvant. These results demonstrate that the ability of VCG to enhance protective immunity against genital C. abortus infection is superior to that of CpG + FL adjuvants. (C) 2015 Elsevier Ltd. All rights reserved. C1 [Pan, Qing; Pais, Roshan; Ohandjo, Adaugo; He, Qing; Omosun, Yusuf; Eko, F. O.] Morehouse Sch Med, Dept Microbiol Biochem & Immunol, Atlanta, GA 30310 USA. [Pan, Qing; He, Cheng] China Agr Univ, Coll Vet Med, Beijing 100094, Peoples R China. [Igietseme, J. U.] Ctr Dis Control & Prevent CDC, Atlanta, GA USA. RP Eko, FO (reprint author), Morehouse Sch Med, Dept Microbiol Biochem & Immunol, Atlanta, GA 30310 USA. EM feko@msm.edu OI Omosun, Yusuf/0000-0003-4759-6254 FU NIAID grant from the National Institutes of Health [AI41231]; National Center for Research Resources, National Institutes of Health [1 C06 RR18386] FX We are very grateful to Dr. Bernhard Kaltenboeck (Auburn University, Alabama) who provided the C. abortus strain B577 used in this study. This work was supported by an NIAID grant AI41231 from the National Institutes of Health. The investigation was conducted in a facility constructed with support from Research Facilities Improvement Grant no. 1 C06 RR18386 from the National Center for Research Resources, National Institutes of Health. NR 35 TC 4 Z9 5 U1 3 U2 12 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD APR 8 PY 2015 VL 33 IS 15 BP 1865 EP 1872 DI 10.1016/j.vaccine.2015.02.007 PG 8 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA CF6PL UT WOS:000352678500016 PM 25698486 ER PT J AU Kalb, SR Baudys, J Raphael, BH Dykes, JK Luquez, C Maslanka, SE Barr, JR AF Kalb, Suzanne R. Baudys, Jakub Raphael, Brian H. Dykes, Janet K. Luquez, Carolina Maslanka, Susan E. Barr, John R. TI Functional Characterization of Botulinum Neurotoxin Serotype H as a Hybrid of Known Serotypes F and A (BoNT F/A) SO ANALYTICAL CHEMISTRY LA English DT Article ID CLOSTRIDIUM-BOTULINUM; NEUROTRANSMITTER RELEASE; SNAP-25; CLEAVES; VAMP/SYNAPTOBREVIN; PROTEOLYSIS; DIVERSITY; ANTIBODY; TETANUS; PROTEIN AB A unique strain of Clostridium botulinum (IBCA10-7060) was recently discovered which produces two toxins: botulinum neurotoxin (BoNT) serotype B and a novel BoNT reported as serotype H. Previous molecular assessment showed that the light chain (LC) of the novel BoNT most resembled the bont of the light chain of known subtype F5, while the C-terminus of the heavy chain (H-C) most resembled the binding domain of serotype A. We evaluated the functionality of both toxins produced in culture by first incorporating an immunoaffinity step using monoclonal antibodies to purify BoNT from culture supernatants and tested each immune-captured neurotoxin with full-length substrates vesicle-associated membrane protein 2 (VAMP-2), synaptosomal-associated protein 25 (SNAP-25), syntaxin, and shortened peptides representing the substrates. The BoNT/B produced by this strain behaved as a typical BoNT/B, having immunoaffinity for anti-B monoclonal antibodies and cleaving both full length VAMP-2 and a peptide based on the sequence of VAMP-2 in the expected location. As expected, there was no activity toward SNAP-25 or syntaxin. The novel BoNT demonstrated immunoaffinity for anti-A monoclonal antibodies but did not cleave SNAP-25 as expected for BoNT/A. Instead, the novel BoNT cleaved VAMP-2 and VAMP-2-based peptides in the same location as BoNT/F5. This is the first discovery of a single botulinum neurotoxin with BoNT/A antigenicity and BoNT/F light chain function. This work suggests that the newly reported serotype H may actually be a hybrid of previously known BoNT serotype A and serotype F, specifically subtype F5. C1 [Kalb, Suzanne R.; Baudys, Jakub; Barr, John R.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Sci Lab, Atlanta, GA 30341 USA. [Raphael, Brian H.; Dykes, Janet K.; Luquez, Carolina; Maslanka, Susan E.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Enter Dis Lab Branch, Atlanta, GA 30329 USA. RP Barr, JR (reprint author), Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Sci Lab, 4770 Buford Hwy NE, Atlanta, GA 30341 USA. EM jbarr@cdc.gov OI Kalb, Suzanne/0000-0002-8067-136X; Raphael, Brian/0000-0003-2778-2623 FU Intramural CDC HHS [CC999999] NR 27 TC 22 Z9 22 U1 0 U2 9 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0003-2700 EI 1520-6882 J9 ANAL CHEM JI Anal. Chem. PD APR 7 PY 2015 VL 87 IS 7 BP 3911 EP 3917 DI 10.1021/ac504716v PG 7 WC Chemistry, Analytical SC Chemistry GA CF6ID UT WOS:000352659500051 PM 25731972 ER PT J AU Peasah, SK Purakayastha, DR Koul, PA Dawood, FS Saha, S Amarchand, R Broor, S Rastogi, V Assad, R Kaul, KA Widdowson, MA Lal, RB Krishnan, A AF Peasah, Samuel K. Purakayastha, Debjani Ram Koul, Parvaiz A. Dawood, Fatima S. Saha, Siddhartha Amarchand, Ritvik Broor, Shobha Rastogi, Vaibhab Assad, Romana Kaul, Kaisar Ahmed Widdowson, Marc-Alain Lal, Renu B. Krishnan, Anand TI The cost of acute respiratory infections in Northern India: a multi-site study SO BMC PUBLIC HEALTH LA English DT Article DE Acute respiratory infections; Costs; Outpatient; Inpatient; Direct; Indirect; Public; Private ID CHILDHOOD PNEUMONIA; TRACT INFECTIONS; ECONOMIC-IMPACT; YOUNG-CHILDREN; INFLUENZA; BURDEN; HEALTH; PREVENTION; COUNTRIES AB Background: Despite the high mortality and morbidity resulting from acute respiratory infections (ARI) globally, there are few data from low-income countries on costs of ARI to inform public health policy decisions We conducted a prospective survey to assess costs of ARI episodes in selected primary, secondary, and tertiary healthcare facilities in north India where no respiratory pathogen vaccine is routinely recommended. Methods: Face-to-face interviews were conducted among a purposive sample of patients with ARI from healthcare facilities. Data were collected on out-of-pocket costs of hospitalization, medical consultations, medications, diagnostics, transportation, lodging, and missed work days. Telephone surveys were conducted two weeks after medical encounters to ask about subsequent missed work and costs incurred. Costs of prescriptions and diagnostics in public facilities were supplemented with WHO-CHOICE estimates of hospital bed costs. Missed work days were assigned cost based on the national annual per capita income (US$1,104). Non-medically attended ARI cases were identified from an ongoing community-based ARI surveillance project in Faridabad. Results: During September 2012-March 2013, 1766 patients with ARI were enrolled, including 451 hospitalized patients, 1056 outpatients, and 259 non-medically attended patients. The total direct cost of an ARI episode requiring outpatient care was US$4-$6 for public and $3-$10 for private institutions based on age groups. The total direct cost of an ARI episode requiring hospitalized care was $54-$120 in public and $135-$355 in private institutions. The cost of ARI among those hospitalized was highest among persons aged > = 65 years and lowest among children aged < 5 years. Indirect costs due to missed work days were 16-25% of total costs. The direct out-of-pocket cost of hospitalized ARI was 34% of annual per capita income. Conclusions: The cost of hospitalized ARI episodes in India is high relative to median per capita income. Data from this study can inform evaluations of the cost effectiveness of proven ARI prevention strategies such as vaccination. C1 [Peasah, Samuel K.] Mercer Univ, Coll Pharm, Atlanta, GA 30341 USA. [Peasah, Samuel K.; Dawood, Fatima S.; Widdowson, Marc-Alain] Ctr Dis Control & Prevent, Atlanta, GA USA. [Purakayastha, Debjani Ram; Krishnan, Anand] All India Inst Med Sci, Ctr Community Med, New Delhi 110029, India. [Koul, Parvaiz A.] Sheri Kashmir Inst Med Sci, Dept Internal & Pulm Med, Srinagar 190011, Jammu & Kashmir, India. [Saha, Siddhartha; Lal, Renu B.] Ctr Dis Control & Prevent, US Embassy, Influenza Div, New Delhi 110021, India. [Amarchand, Ritvik; Broor, Shobha; Rastogi, Vaibhab] INCLEN Trust, New Delhi 110020, India. [Assad, Romana] Sheri Kashmir Inst Med Sci, Srinagar 190011, Jammu & Kashmir, India. [Kaul, Kaisar Ahmed] GB Pant Hosp, Srinagar, Jammu & Kashmir, India. RP Peasah, SK (reprint author), Mercer Univ, Coll Pharm, 3001 Mercer Univ Dr, Atlanta, GA 30341 USA. EM Peasah_SK@Mercer.edu FU US Centers for Disease Control and Prevention FX This study was funded by the US Centers for Disease Control and Prevention. NR 32 TC 5 Z9 5 U1 1 U2 5 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2458 J9 BMC PUBLIC HEALTH JI BMC Public Health PD APR 7 PY 2015 VL 15 AR 330 DI 10.1186/s12889-015-1685-6 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CF3SL UT WOS:000352468700001 PM 25880910 ER PT J AU Liang, J Duan, S Ma, YL Wang, JB Su, YZ Zhang, H Ou, CY Hao, L Qi, MS Bulterys, M Westerman, L Jiang, Y Xiao, Y AF Liang, Jun Duan, Song Ma, Yan-Ling Wang, Ji-Bao Su, Ying-Zhen Zhang, Hui Ou, Chin-Yih Hao, Ling Qi, Ming-Shan Bulterys, Marc Westerman, Larry Jiang, Yan Xiao, Yao TI Evaluation of PIMA Point-of-care CD4 Analyzer in Yunnan, China SO CHINESE MEDICAL JOURNAL LA English DT Article DE CD4 Counts; Finger-prick; HIV; Point-of-care; Venous Blood ID PERFORMANCE EVALUATION; SETTINGS; BLOOD AB Background: CD4 count is used to determine antiretroviral therapy (ART) eligibility. In China, flow cytometers are mostly located in urban areas with limited access by patients residing in remote areas. In an attempt to address this issue, we conducted a study to validate the performance of Alere PIMA point-of-care CD4 analyzer. Methods: Venous and finger-prick blood specimens were collected from HIV-positive participants from two voluntary counseling and testing sites in Yunnan Province. Both venous and finger-prick blood specimens were tested with the PIMA analyzer. Venous blood specimens tested with the Becton Dickinson FACSCalibur were used as a reference. Results: Venous specimens from 396 and finger-prick specimens from 387 persons were available for analysis. CD4 counts by PIMA correlated well with those from FACSCalibur with an R-2 of 0.91 for venous blood and 0.81 for finger-prick blood. Compared to FACSCalibur, the PIMA analyzer yielded lower counts with a mean bias of -47.0 cells/mu l (limit of agreement, [LOA]: -204-110 cells/mu l) for venous blood and -71.0 cells/mu l (LOA: -295-153 cells/mu l) for finger-prick blood. For a CD4 threshold of 350 cells/mu l, the positive predictive value (PPV) of PIMA was 84.2% and 75.7% and the negative predictive value (NPV) was 97.6% and 95.8% for venous and finger-prick blood, respectively. For an ART threshold of 500 cells/mu l, the corresponding PPV was 90.3% and 84.0% and NPV was 94.3% and 93.4%, respectively. Conclusions: CD4 counting using venous blood with PIMA analyzers is a feasible alternative to a large flow cytometer to determine ART eligibility. C1 [Liang, Jun; Zhang, Hui; Jiang, Yan; Xiao, Yao] Chinese Ctr Dis Control & Prevent, Natl Ctr AIDS STD Control & Prevent, Natl HIV HCV Reference Lab, Dept AIDS STD Prevent, Beijing 102206, Peoples R China. [Liang, Jun] Tongzhou Blood Ctr, Dept Lab, Beijing 101100, Peoples R China. [Duan, Song; Wang, Ji-Bao] Dehong Prefecture Ctr Dis Control & Prevent, Dept AIDS STD Prevent, Dehong 678400, Yunnan, Peoples R China. [Ma, Yan-Ling; Su, Ying-Zhen] Yunnan Prov Ctr Dis Control & Prevent, Dept AIDS STD Prevent, Kunming 650022, Yunnan, Peoples R China. [Ou, Chin-Yih; Hao, Ling; Qi, Ming-Shan; Bulterys, Marc] US Ctr Dis Control & Prevent, Global AIDS Program China Off, Beijing 100600, Peoples R China. [Westerman, Larry] US Ctr Dis Control & Prevent, Int Lab Branch, Div Global HIV AIDS, Ctr Global Hlth, Atlanta, GA 30329 USA. RP Xiao, Y (reprint author), Chinese Ctr Dis Control & Prevent, Natl Ctr AIDS STD Control & Prevent, Natl HIV HCV Reference Lab, Beijing 102206, Peoples R China. EM xiaoyao@chinaaids.cn FU President's Emergency Plan for AIDS Relief through US CDC Global AIDS Program [5U2GPS001188] FX This study was supported by the President's Emergency Plan for AIDS Relief through a cooperative agreement from the US CDC Global AIDS Program (No. 5U2GPS001188). The Alere company provided test reagents, equipment, and training of personnel. NR 14 TC 4 Z9 4 U1 1 U2 2 PU CHINESE MEDICAL ASSOC PI BEIJING PA 42 DONGSI XIDAJIE, BEIJING 100710, PEOPLES R CHINA SN 0366-6999 J9 CHINESE MED J-PEKING JI Chin. Med. J. PD APR 5 PY 2015 VL 128 IS 7 BP 890 EP 895 DI 10.4103/0366-6999.154283 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA CF4PW UT WOS:000352533500007 PM 25836608 ER PT J AU Roehler, DR Ear, C Parker, EM Sem, P Ballesteros, MF AF Roehler, Douglas R. Ear, Chariya Parker, Erin M. Sem, Panhavuth Ballesteros, Michael F. TI Fatal motorcycle crashes: a growing public health problem in Cambodia SO INTERNATIONAL JOURNAL OF INJURY CONTROL AND SAFETY PROMOTION LA English DT Article DE helmet; motorcycle; speeding; road safety; helmet wearing; Cambodia ID RISK; MORTALITY; BRAIN AB This study examines the risk characteristics of fatal motorcycle crashes in Cambodia over a 5-year period (2007-2011). Secondary data analyses were conducted using the Cambodia Road Crash and Victim Information System, the only comprehensive and integrated road crash surveillance system in the country. Researchers from the Centers for Disease Control and Prevention and Handicap International found that (1) males are dying in motorcycle crashes roughly seven times more frequently than females; (2) motorcyclist fatalities increased by about 30% from 2007 to 2011; (3) the motorcyclist death rates per 100,000 population increased from 7.4 to 8.7 deaths from 2007 to 2011; and (4) speed-related crashes and not wearing motorcycle helmet were commonly reported for motorcyclist fatalities at approximately 50% and over 80% through the study years, respectively. Additionally, this study highlights that Cambodia has the highest motorcycle death rate in South-East Asia, far surpassing Thailand, Malaysia, and Myanmar. By recognising the patterns of fatal motorcycle crashes in Cambodia, local road-safety champions and stakeholders can design targeted interventions and preventative measures to improve road safety among motorcyclists. C1 [Roehler, Douglas R.] Univ Michigan, Sch Publ Hlth, Hlth Behav & Hlth Educ, Ann Arbor, MI 48109 USA. [Ear, Chariya; Sem, Panhavuth] Handicap Int, Phnom Penh, Cambodia. [Parker, Erin M.] Ctr Dis Control & Prevent, Div Unintent Injury Prevent, Atlanta, GA 30329 USA. [Ballesteros, Michael F.] Ctr Dis Control & Prevent, Ctr Global Hlth, Atlanta, GA USA. RP Parker, EM (reprint author), Ctr Dis Control & Prevent, Div Unintent Injury Prevent, 4770 Buford Hwy, Atlanta, GA 30329 USA. EM eparker@cdc.gov NR 39 TC 0 Z9 0 U1 6 U2 6 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1745-7300 EI 1745-7319 J9 INT J INJ CONTROL SA JI Int. J. Inj. Control Saf. Promot. PD APR 3 PY 2015 VL 22 IS 2 BP 165 EP 171 DI 10.1080/17457300.2013.876050 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CN1BI UT WOS:000358150100011 PM 24499413 ER PT J AU Shults, RA Olsen, E Williams, AF AF Shults, Ruth A. Olsen, Emily Williams, Allan F. TI Driving Among High School Students - United States, 2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID LICENSING POLICIES; NATIONAL-SURVEY; TEENAGERS; VIEWS C1 [Shults, Ruth A.] CDC, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Bethesda, MD 20889 USA. [Olsen, Emily] CDC, Div Adolescent, Bethesda, MD USA. [Olsen, Emily] CDC, Sch Hlth Natl Ctr HIV AIDS Viral Hepatitis STD &, Bethesda, MD USA. [Williams, Allan F.] Allan F Williams, Bethesda, MD USA. RP Shults, RA (reprint author), CDC, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Bethesda, MD 20889 USA. EM rshults@cdc.gov NR 10 TC 1 Z9 1 U1 1 U2 4 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD APR 3 PY 2015 VL 64 IS 12 BP 313 EP 317 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CE8MO UT WOS:000352097000001 PM 25837240 ER PT J AU Bowen, A Hurd, J Hoover, C Khachadourian, Y Traphagen, E Harvey, E Libby, T Ehlers, S Ongpin, M Norton, JC Bicknese, A Kimura, A AF Bowen, Anna Hurd, Jacqueline Hoover, Cora Khachadourian, Yvette Traphagen, Elizabeth Harvey, Emily Libby, Tanya Ehlers, Sara Ongpin, Melissa Norton, J. Corbin Bicknese, Amelia Kimura, Akiko TI Importation and Domestic Transmission of Shigella sonnei Resistant to Ciprofloxacin - United States, May 2014-February 2015 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Bowen, Anna; Hurd, Jacqueline; Norton, J. Corbin] CDC, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging Zoonot & Infect Dis, Atlanta, GA 30333 USA. [Hoover, Cora; Ehlers, Sara; Ongpin, Melissa] San Francisco Dept Publ Hlth, San Francisco, CA USA. [Khachadourian, Yvette] Philadelphia Dept Publ Hlth, Div Dis Control, Philadelphia, PA USA. [Traphagen, Elizabeth; Harvey, Emily] Massachusetts Dept Publ Hlth, Boston, MA 02111 USA. [Libby, Tanya] Calif Emerging Infect Program, Oakland, CA USA. [Kimura, Akiko] Calif Dept Publ Hlth, Sacramento, CA USA. RP Bowen, A (reprint author), CDC, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging Zoonot & Infect Dis, Atlanta, GA 30333 USA. EM abowen@cdc.gov NR 7 TC 17 Z9 17 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD APR 3 PY 2015 VL 64 IS 12 BP 318 EP 320 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CE8MO UT WOS:000352097000002 PM 25837241 ER PT J AU Yacisin, K Balter, S Fine, A Weiss, D Ackelsberg, J Prezant, D Wilson, R Starr, D Rakeman, J Raphael, M Quinn, C Toprani, A Clark, N Link, N Daskalakis, D Maybank, A Layton, M Varma, JK AF Yacisin, Kari Balter, Sharon Fine, Annie Weiss, Don Ackelsberg, Joel Prezant, David Wilson, Ross Starr, David Rakeman, Jennifer Raphael, Marisa Quinn, Celia Toprani, Amita Clark, Nancy Link, Nathan Daskalakis, Demetre Maybank, Aletha Layton, Marcelle Varma, Jay K. TI Ebola Virus Disease in a Humanitarian Aid Worker - New York City, October 2014 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Yacisin, Kari] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Yacisin, Kari; Balter, Sharon; Fine, Annie; Weiss, Don; Ackelsberg, Joel; Starr, David; Rakeman, Jennifer; Raphael, Marisa; Quinn, Celia; Toprani, Amita; Clark, Nancy; Daskalakis, Demetre; Maybank, Aletha; Layton, Marcelle; Varma, Jay K.] New York City Dept Hlth & Mental Hyg, New York, NY USA. [Prezant, David] Fire Dept New York, New York, NY USA. [Wilson, Ross] New York City Hlth & Hosp Corp, New York, NY USA. [Quinn, Celia] CDC, Div State & Local Readiness, Off Publ Hlth Preparedness & Response, Atlanta, GA 30333 USA. [Link, Nathan] Bellevue Hosp Ctr, New York, NY 10016 USA. RP Yacisin, K (reprint author), CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. EM xfm3@cdc.gov NR 4 TC 9 Z9 9 U1 0 U2 11 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD APR 3 PY 2015 VL 64 IS 12 BP 321 EP 323 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CE8MO UT WOS:000352097000003 PM 25837242 ER PT J AU Thomas, CC Richards, TB Plescia, M Wong, FL Ballard, R Levin, TR Calonge, BN Brawley, OW Iskander, J AF Thomas, Cheryll C. Richards, Thomas B. Plescia, Marcus Wong, Faye L. Ballard, Rachel Levin, Theodore R. Calonge, Bruce N. Brawley, Otis W. Iskander, John TI CDC Grand Rounds: the Future of Cancer Screening SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID COLORECTAL-CANCER; UNITED-STATES; HEALTH C1 [Thomas, Cheryll C.; Richards, Thomas B.; Plescia, Marcus; Wong, Faye L.] CDC, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Ballard, Rachel] NCI, Bethesda, MD 20892 USA. [Levin, Theodore R.] Permanente Med Grp Inc, Oakland, CA USA. [Levin, Theodore R.] Kaiser Permanente Med Ctr, Walnut Creek, CA USA. [Brawley, Otis W.] Amer Canc Soc, Atlanta, GA USA. [Iskander, John] CDC, Off Associate Director Sci, Atlanta, GA 30333 USA. RP Thomas, CC (reprint author), CDC, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM ccthomas@cdc.gov NR 13 TC 0 Z9 0 U1 0 U2 3 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD APR 3 PY 2015 VL 64 IS 12 BP 324 EP 327 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CE8MO UT WOS:000352097000004 PM 25837243 ER PT J AU Lamb, E Satre, J Pon, S Hurd-Kundeti, G Liscek, B Hall, CJ Pinner, RW Conn, L Zajac, J Smallwood, M Smith, K AF Lamb, Emilie Satre, John Pon, Steve Hurd-Kundeti, Glorietta Liscek, Bonnie Hall, C. Jason Pinner, Robert W. Conn, Laura Zajac, Julie Smallwood, Megan Smith, Kaley TI Update on Progress in Electronic Reporting of Laboratory Results to Public Health Agencies - United States, 2014 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Lamb, Emilie] North Carolina Dept Hlth & Human Serv, Wilmington, NC 28403 USA. [Satre, John] Iowa Dept Hlth, Iowa City, IA USA. [Pon, Steve; Hurd-Kundeti, Glorietta] Calif Dept Publ Hlth, Sacramento, CA USA. [Liscek, Bonnie] Kansas Dept Hlth & Environm, Topeka, KS USA. [Hall, C. Jason; Smith, Kaley] Div Preparedness & Emerging Infect, Atlanta, GA USA. [Pinner, Robert W.] Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Conn, Laura] Off Publ Hlth Sci Serv, Atlanta, GA USA. [Zajac, Julie; Smallwood, Megan] CDC, Div Hlth Informat & Surveillance, Ctr Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA. RP Hall, CJ (reprint author), Div Preparedness & Emerging Infect, Atlanta, GA 30329 USA. EM cjhall@cdc.gov NR 4 TC 1 Z9 1 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD APR 3 PY 2015 VL 64 IS 12 BP 328 EP 330 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CE8MO UT WOS:000352097000005 PM 25837244 ER PT J AU McEligot, AJ Ziogas, A Pfeiffer, CM Fazili, Z Anton-Culver, H AF McEligot, Archana Jaiswal Ziogas, Argyrios Pfeiffer, Christine M. Fazili, Zia Anton-Culver, Hoda TI The Association Between Circulating Total Folate and Folate Vitamers With Overall Survival After Postmenopausal Breast Cancer Diagnosis SO NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL LA English DT Article ID TANDEM MASS-SPECTROMETRY; UNMETABOLIZED FOLIC-ACID; ONE-CARBON METABOLISM; OVARIAN-CANCER; LUNG-CANCER; PROSPECTIVE COHORT; SWEDISH WOMEN; PLASMA FOLATE; UNITED-STATES; HUMAN SERUM AB We studied the relationship between plasma total folate and folate vitamer concentrations [5-methyltetrahydrofolic acid, pteroylglutamic acid (folic acid) and tetrahydrofolic acid] with overall survival after breast cancer diagnosis. A secondary aim was to assess the relationship between folic acid supplement use with circulating total folate and folate vitamer concentrations. Participants were postmenopausal women diagnosed with breast cancer (n = 498) with an average follow-up of 6.7yr. Plasma total folate and folate vitamers were measured by isotope-dilution LC-MS/MS in samples collected at or postdiagnosis. Cox proportional multivariate hazards models (controlled for stage, age at diagnosis, body mass index, parity, hormone replacement therapy use, treatment, alcohol use, folic acid use, and energy intake), were used to assess overall survival after breast cancer diagnosis. We found that the relative risk of dying for women with plasma total folate concentrations in the highest quartile was 59% lower (hazard ratio: 0.41, 95% confidence interval: 0.19-0.90) compared with the lowest quartile. Data on supplement use showed that women taking folic acid supplements had significantly higher circulating total folate and folate vitamer concentrations (P < 0.0001), suggesting that increased folate consumption through diet and/or supplementation may improve prognosis after breast cancer diagnosis. C1 [McEligot, Archana Jaiswal] Calif State Univ Fullerton, Dept Hlth Sci, Fullerton, CA 92834 USA. [Ziogas, Argyrios; Anton-Culver, Hoda] Univ Calif Irvine, Dept Med, Div Epidemiol, Irvine, CA 92717 USA. [Pfeiffer, Christine M.; Fazili, Zia] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA USA. RP McEligot, AJ (reprint author), Calif State Univ Fullerton, Dept Hlth Sci, 800 N State Coll Blvd,Room KHS 121, Fullerton, CA 92834 USA. EM amceligot@fullerton.edu FU National Cancer Institute, NIH [5K07CA101964] FX The present study was supported by the National Cancer Institute, NIH grant, 5K07CA101964. NR 42 TC 3 Z9 3 U1 6 U2 11 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0163-5581 EI 1532-7914 J9 NUTR CANCER JI Nutr. Cancer PD APR 3 PY 2015 VL 67 IS 3 BP 442 EP 448 DI 10.1080/01635581.2015.1002623 PG 7 WC Oncology; Nutrition & Dietetics SC Oncology; Nutrition & Dietetics GA CF1OO UT WOS:000352316200007 PM 25647689 ER PT J AU Epstein, MP Duncan, R Ware, EB Jhun, MA Bielak, LF Zhao, W Smith, JA Peyser, PA Kardia, SLR Satten, GA AF Epstein, Michael P. Duncan, Richard Ware, Erin B. Jhun, Min A. Bielak, Lawrence F. Zhao, Wei Smith, Jennifer A. Peyser, Patricia A. Kardia, Sharon L. R. Satten, Glen A. TI A Statistical Approach for Rare-Variant Association Testing in Affected Sibships SO AMERICAN JOURNAL OF HUMAN GENETICS LA English DT Article ID FAMILY-BASED ASSOCIATION; QUANTITATIVE TRAITS; HUMAN GENOME; LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; AFRICAN-ANCESTRY; COMPLEX TRAITS; SEQUENCE DATA; HYPERTENSION; INDIVIDUALS AB Sequencing and exome-chip technologies have motivated development of novel statistical tests to identify rare genetic variation that influences complex diseases. Although many rare-variant association tests exist for case-control or cross-sectional studies, far fewer methods exist for testing association in families. This is unfortunate, because cosegregation of rare variation and disease status in families can amplify association signals for rare variants. Many researchers have begun sequencing (or genotyping via exome chips) familial samples that were either recently collected or previously collected for linkage studies. Because many linkage studies of complex diseases sampled affected sibships, we propose a strategy for association testing of rare variants for use in this study design. The logic behind our approach is that rare susceptibility variants should be found more often on regions shared identical by descent by affected sibling pairs than on regions not shared identical by descent. We propose both burden and variance-component tests of rare variation that are applicable to affected sibships of arbitrary size and that do not require genotype information from unaffected siblings or independent controls. Our approaches are robust to population stratification and produce analytic p values, thereby enabling our approach to scale easily to genome-wide studies of rare variation. We illustrate our methods by using simulated data and exome chip data from sibships ascertained for hypertension collected as part of the Genetic Epidemiology Network of Arteriopathy (GENOA) study. C1 [Epstein, Michael P.; Duncan, Richard] Emory Univ, Dept Human Genet, Atlanta, GA 30322 USA. [Ware, Erin B.; Jhun, Min A.; Bielak, Lawrence F.; Zhao, Wei; Smith, Jennifer A.; Peyser, Patricia A.; Kardia, Sharon L. R.] Univ Michigan, Dept Epidemiol, Ann Arbor, MI 48103 USA. [Satten, Glen A.] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. RP Epstein, MP (reprint author), Emory Univ, Dept Human Genet, Atlanta, GA 30322 USA. EM mpepste@emory.edu OI Smith, Jennifer/0000-0002-3575-5468; Ware, Erin/0000-0003-4731-8158 FU National Human Genome Research Institute [HG007508]; National Heart, Lung, and Blood Institute [HL086694, HL119443] FX We thank Dr. Karen Conneely and two anonymous reviewers for their constructive comments related to this work. This work was supported by HG007508 from the National Human Genome Research Institute. GENOA is supported by HL086694 and HL119443 from the National Heart, Lung, and Blood Institute. NR 51 TC 3 Z9 3 U1 0 U2 5 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 0002-9297 EI 1537-6605 J9 AM J HUM GENET JI Am. J. Hum. Genet. PD APR 2 PY 2015 VL 96 IS 4 BP 543 EP 554 DI 10.1016/j.ajhg.2015.01.020 PG 12 WC Genetics & Heredity SC Genetics & Heredity GA CF0DJ UT WOS:000352212600003 PM 25799106 ER PT J AU Hawkins, N Berkowitz, Z Rodriguez, JL AF Hawkins, Nikki Berkowitz, Zahava Rodriguez, Juan L. TI AWARENESS OF DIETARY GUIDELINES AND HEALTHY EATING PRACTICES AMONG COLORECTAL CANCER SURVIVORS SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Hawkins, Nikki; Rodriguez, Juan L.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Berkowitz, Zahava] CDC, Chamblee, GA USA. EM cyt4@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 EI 1532-4796 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2015 VL 49 SU 1 MA A061 BP S19 EP S19 PG 1 WC Psychology, Multidisciplinary SC Psychology GA DA5EH UT WOS:000367825001072 ER PT J AU Holman, D Pagoto, SL Asdigian, N Hillhouse, JJ Crane, LA Geller, A AF Holman, Dawn Pagoto, Sherry L. Asdigian, Nancy Hillhouse, Joel J. Crane, Lori A. Geller, Alan TI FROM AVAILABILITY TO ADVERTISEMENT: FACTORS PROMOTING FREQUENT INDOOR TANNING AMONG YOUNG ADULTS SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Holman, Dawn] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA USA. [Pagoto, Sherry L.] Univ Massachusetts, Sch Med, Worcester, MA USA. [Asdigian, Nancy] Colorado Sch Publ Hlth, Aurora, CO USA. [Hillhouse, Joel J.] E Tennessee State Univ, Johnson City, TN 37614 USA. [Crane, Lori A.] Univ Colorado, Colorado Sch Publ Hlth, Aurora, CO USA. [Geller, Alan] Harvard Univ, Sch Publ Hlth, Dept Social & Behav Sci, Boston, MA 02115 USA. EM sherry.pagoto@umassmed.edu; nancy.asdigian@ucdenver.edu; drhillhouse@tanningproject.org; lori.crane@ucdenver.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 EI 1532-4796 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2015 VL 49 SU 1 MA 17 BP S65 EP S65 PG 1 WC Psychology, Multidisciplinary SC Psychology GA DA5EH UT WOS:000367825001253 ER PT J AU Mielenz, T Winter, SJ Ory, MG Schneider, E Smith, ML Altpeter, M Bomberger, S Shubert, T Kharrazi, RJ Fauci, MA Castro, CM King, A Stevens, JA Caffarelli, AI AF Mielenz, Thelma Winter, Sandra J. Ory, Marcia G. Schneider, Ellen Smith, Matthew Lee Altpeter, Mary Bomberger, Stephanie Shubert, Tiffany Kharrazi, Rebekah J. Fauci, Mark A. Castro, Cynthia Marie King, Abby Stevens, Judy A. Caffarelli, Anna I. TI MULTI-LEVEL BEHAVIORAL CHANGE APPROACHES TO FALL PREVENTION: INDIVIDUAL, COMMUNITY AND POLICY SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Mielenz, Thelma] Columbia Univ, Mailman Sch Publ Hlth New, New York, NY USA. [Winter, Sandra J.] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA. [Ory, Marcia G.] Texas A&M, College Stn, TX USA. [Schneider, Ellen; Bomberger, Stephanie] Univ N Carolina, Chapel Hill, NC USA. [Smith, Matthew Lee] Univ Georgia, Athens, GA 30602 USA. [Altpeter, Mary] Univ N Carolina, Ctr Hlth Promot & Dis Prevent, Chapel Hill, NC USA. [Shubert, Tiffany] Univ N Carolina, Chapel Hill, NC USA. [Kharrazi, Rebekah J.] Columbia Univ, Mailman Sch Publ Hlth, Alameda, CA USA. [Castro, Cynthia Marie] Stanford Univ, Palo Alto, CA 94304 USA. [King, Abby] Stanford Univ, Sch Med, Stanford, CA USA. [Stevens, Judy A.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Caffarelli, Anna I.] NYC Dept Hlth & Mental Hyg, New York, NY USA. EM tjm2141@columbia.edu; sjwinter@stanford.edu; mory@sph.tamhsc.edu; mfauci@gen9.com NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 EI 1532-4796 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2015 VL 49 SU 1 MA 26 BP S126 EP S126 PG 1 WC Psychology, Multidisciplinary SC Psychology GA DA5EH UT WOS:000367825001495 ER PT J AU Violanti, JM Fekedulegn, D Andrew, M Hartley, TA Charles, LE MIller, DB Burchfiel, C AF Violanti, John M. Fekedulegn, Desta Andrew, Michael Hartley, Tara A. Charles, Luenda E. MIller, Diane B. Burchfiel, Cecil TI POLICE STRESSORS AND THE AWAKENING CORTISOL RESPONSE: COMPARING THE MOST AND LEAST SEVERE EVENTS SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Violanti, John M.] SUNY Buffalo, Buffalo, NY 14214 USA. [Fekedulegn, Desta; Andrew, Michael; Hartley, Tara A.; Charles, Luenda E.; MIller, Diane B.; Burchfiel, Cecil] NIOSH, CDC, Morgantown, WV USA. EM violanti@buffalo.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 EI 1532-4796 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2015 VL 49 SU 1 MA A139 BP S38 EP S38 PG 1 WC Psychology, Multidisciplinary SC Psychology GA DA5EH UT WOS:000367825001150 ER PT J AU Suthar, AB Vitoria, MA Nagata, JM Anglaret, X Mbori-Ngacha, D Sued, O Kaplan, JE Doherty, MC AF Suthar, Amitabh B. Vitoria, Marco A. Nagata, Jason M. Anglaret, Xavier Mbori-Ngacha, Dorothy Sued, Omar Kaplan, Jonathan E. Doherty, Meg C. TI Co-trimoxazole prophylaxis in adults, including pregnant women, with HIV: a systematic review and meta-analysis SO LANCET HIV LA English DT Review ID ACTIVE ANTIRETROVIRAL THERAPY; HUMAN-IMMUNODEFICIENCY-VIRUS; PNEUMOCYSTIS-CARINII-PNEUMONIA; RANDOMIZED CONTROLLED-TRIAL; SUB-SAHARAN AFRICA; TRIMETHOPRIM-SULFAMETHOXAZOLE; INFECTED PATIENTS; PREVENTIVE THERAPY; COTE-DIVOIRE; OPPORTUNISTIC INFECTIONS AB Introduction Co-trimoxazole prophylaxis is used to reduce morbidity and mortality in people with HIV. We systematically reviewed three topics related to co-trimoxazole prophylaxis to update WHO guidelines: initiation, discontinuation, and dose. Methods We searched PubMed, Embase, WHO Global Index Medicus, and clinical trial registries in November, 2013, for randomised controlled trials and observational studies including co-trimoxazole prophylaxis and a comparator group. Studies were eligible if they reported death, WHO clinical stage 3 or 4 events, admittance to hospital, severe bacterial infections, tuberculosis, pneumonia, diarrhoea, malaria, or treatment-limiting adverse events. Infant mortality, low birthweight, and placental malaria were additional outcomes for the comparison of co-trimoxazole prophylaxis and intermittent preventive treatment for malaria in pregnant women (IPTp). We compared a dose of 480 mg co-trimoxazole once a day with one of 960 mg co-trimoxazole once a day. We used a 10% margin for non-inferiority and equivalence analyses. We used random-effects models for all meta-analyses. This study is registered with PROSPERO, number CRD42014007163. Findings 19 articles, published from 1995 to 2014 and including 35 328 participants, met the inclusion criteria. Co-trimoxazole prophylaxis reduced rates of death (hazard ratio [HR] 0.40, 95% CI 0.26-0.64) when started at CD4 counts of 350 cells per mu L or lower with antiretroviral therapy (ART) worldwide. Co-trimoxazole prophylaxis started at higher than 350 cells per mu L without ART reduced rates of death (0.50, 0.30-0.83) and malaria (0.25, 0.10-0.57) in Africa. Co-trimoxazole prophylaxis was non-inferior to IPTp with respect to infant mortality (risk difference [RD] -0.05, 95% CI -0.12 to 0.02), low birthweight (0.00, -0.07 to 0.07), and placental malaria (0.00, -0.10 to 0.10). Co-trimoxazole prophylaxis continuation after ART-induced recovery with CD4 counts higher than 350 cells per mu L reduced admittances to hospital (HR 0.42, 95% CI 0.22-0.80), pneumonia (0.73, 0.61-0.88), malaria (0.03, 0.01-0.10), and diarrhoea (0.61, 0.48-0.78) in Africa. A dose of 480 mg co-trimoxazole prophylaxis once a day did not reduce treatment-limiting adverse events compared with 960 mg once a day (RD -0.07, 95% CI -0.52 to 0.39). Interpretation Co-trimoxazole prophylaxis should be given with ART in people with CD4 counts of 350 cells per mu L or lower in low-income and middle-income countries. Co-trimoxazole prophylaxis should be provided irrespective of CD4 count in settings with a high burden of infectious diseases. Pregnant women with HIV in Africa should use co-trimoxazole rather than IPTp to prevent malaria complications in infants. Further research is needed to inform dose optimisation and co-trimoxazole use in the context of expanded ART in different epidemiological settings. Copyright (C) 2015. World Health Organization. Published by Elsevier Ltd/Inc/BV. All rights reserved. C1 [Suthar, Amitabh B.; Vitoria, Marco A.; Doherty, Meg C.] WHO, Dept HIV AIDS, CH-1211 Geneva 27, Switzerland. [Nagata, Jason M.] Stanford Univ, Dept Pediat, Sch Med, Stanford, CA 94305 USA. [Anglaret, Xavier] Univ Victor Segalen, INSERM, Ctr 897, Bordeaux, France. [Mbori-Ngacha, Dorothy] United Nations Childrens Fund, Eastern & Southern Africa Reg Off, Pretoria, South Africa. [Sued, Omar] Fdn Huesped, Dept Clin Res, Buenos Aires, DF, Argentina. [Kaplan, Jonathan E.] Ctr Dis Control & Prevent, Div Global HIV AIDS, Atlanta, GA USA. RP Suthar, AB (reprint author), WHO, Dept HIV AIDS, CH-1211 Geneva 27, Switzerland. EM amitabh.suthar@gmail.com OI Nagata, Jason/0000-0002-6541-0604 NR 83 TC 13 Z9 13 U1 1 U2 2 PU ELSEVIER INC PI SAN DIEGO PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 2352-3018 J9 LANCET HIV JI Lancet HIV PD APR PY 2015 VL 2 IS 4 BP E137 EP E150 DI 10.1016/S2352-3018(15)00005-3 PG 14 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CU8KW UT WOS:000363792300009 PM 26424674 ER PT J AU Holmberg, SD Moorman, AC Tong, X Spradling, PR Teshale, EH Gordon, SC Boscarino, JA Vijayadeva, V Schmidt, MA Rupp, LB Lu, M Xu, F AF Holmberg, S. D. Moorman, A. C. Tong, X. Spradling, P. R. Teshale, E. H. Gordon, S. C. Boscarino, J. A. Vijayadeva, V. Schmidt, M. A. Rupp, L. B. Lu, M. Xu, F. CA CHeCS Investigators TI RENAL DISEASE PREVALENCE AND ASSOCIATION WITH HEPATIC FIBROSIS MEASURED BY FIB4 SCORE AMONG US PATIENTS WITH CHRONIC HEPATITIS C VIRUS (HCV) INFECTION IN THE CHRONIC HEPATITIS COHORT STUDY (CHECS) SO JOURNAL OF HEPATOLOGY LA English DT Meeting Abstract CT 50th International Liver Congress of the European-Association-for-the-Study-of-the-Liver CY APR 22-26, 2015 CL Vienna, AUSTRIA SP European Assoc Study Liver C1 [Holmberg, S. D.; Moorman, A. C.; Tong, X.; Spradling, P. R.; Teshale, E. H.; Xu, F.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA USA. [Gordon, S. C.; Rupp, L. B.; Lu, M.] Henry Ford Hlth Syst, Detroit, MI USA. [Boscarino, J. A.] Geisinger Hlth Syst, Danville, PA USA. [Vijayadeva, V.] Kaiser Permanente Hawaii, Honolulu, HI USA. [Schmidt, M. A.] Kaiser Permanente Northwest, Portland, OR USA. EM sdh1@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-8278 EI 1600-0641 J9 J HEPATOL JI J. Hepatol. PD APR PY 2015 VL 62 SU 2 MA P0729 BP S597 EP S598 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CT5EJ UT WOS:000362830600446 ER PT J AU Lara, J Thai, H Kitrinos, K Xia, G Gaggar, A Paulson, M Ganova-Raeva, L Khudyakov, Y AF Lara, J. Thai, H. Kitrinos, K. Xia, G. Gaggar, A. Paulson, M. Ganova-Raeva, L. Khudyakov, Y. TI ASSOCIATION OF HEPATITIS B VIRUS GENETIC DIVERSITY WITH TENOFOVIR DISOPROXIL FUMARATE RESPONSE RATES IN IMMUNE TOLERANT CHRONIC HEPATITIS B PATIENTS SO JOURNAL OF HEPATOLOGY LA English DT Meeting Abstract CT 50th International Liver Congress of the European-Association-for-the-Study-of-the-Liver CY APR 22-26, 2015 CL Vienna, AUSTRIA SP European Assoc Study Liver C1 [Lara, J.; Thai, H.; Xia, G.; Ganova-Raeva, L.; Khudyakov, Y.] Ctr Dis Control, Div Viral Hepatitis, Atlanta, GA 30333 USA. [Kitrinos, K.; Gaggar, A.; Paulson, M.] Gilead Sci Inc, Foster City, CA 94404 USA. EM katie.kitrinos@gilead.com NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-8278 EI 1600-0641 J9 J HEPATOL JI J. Hepatol. PD APR PY 2015 VL 62 SU 2 MA P0633 BP S556 EP S556 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CT5EJ UT WOS:000362830600350 ER PT J AU Layden, J Mora, N Phillips, RO Owusi-Ofori, S Sarfo, FS Kliethermes, S Owusu, D Nelson, K Dugas, L Luke, A Shoham, D Forbi, JC Khudyakov, YE Cooper, RS AF Layden, J. Mora, N. Phillips, R. O. Owusi-Ofori, S. Sarfo, F. S. Kliethermes, S. Owusu, D. Nelson, K. Dugas, L. Luke, A. Shoham, D. Forbi, J. C. Khudyakov, Y. E. Cooper, R. S. TI HIGH FREQUENCY OF ACTIVE HCV INFECTION AMONG SEROPOSITIVES IN WEST AFRICA AND EVIDENCE FOR MULTIPLE TRANSMISSION PATHWAYS SO JOURNAL OF HEPATOLOGY LA English DT Meeting Abstract CT 50th International Liver Congress of the European-Association-for-the-Study-of-the-Liver CY APR 22-26, 2015 CL Vienna, AUSTRIA SP European Assoc Study Liver C1 [Layden, J.; Mora, N.; Kliethermes, S.; Dugas, L.; Luke, A.; Shoham, D.; Cooper, R. S.] Loyola Univ Chicago, Publ Hlth Sci, Maywood, IL USA. [Layden, J.] Loyola Univ, Med Ctr, Dept Med, Div Infect Dis, Maywood, IL 60153 USA. [Phillips, R. O.; Owusi-Ofori, S.; Sarfo, F. S.; Owusu, D.] Komfo Anokye Teaching Hosp, Kumasi, Ghana. [Phillips, R. O.; Sarfo, F. S.] Kwame Nkrumah Univ Sci & Technol, Kumasi, Ghana. [Kliethermes, S.] Loyola Univ Chicago, Dept Med, Maywood, IL USA. [Nelson, K.] Johns Hopkins Sch Publ Hlth, Epidemiol & Int Hlth, Baltimore, MD USA. [Forbi, J. C.; Khudyakov, Y. E.] Ctr Dis Control, Mol Epidemiol & Bioinformat, Atlanta, GA 30333 USA. EM namora@luc.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-8278 EI 1600-0641 J9 J HEPATOL JI J. Hepatol. PD APR PY 2015 VL 62 SU 2 MA P0595 BP S539 EP S540 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CT5EJ UT WOS:000362830600312 ER PT J AU Lu, M Li, J Rupp, LB Holmberg, SD Moorman, AC Spradling, PR Tehale, E Xu, F Boscarino, JA Vijayadeva, V Schmidt, MA Lamerato, LE Gordon, S AF Lu, M. Li, J. Rupp, L. B. Holmberg, S. D. Moorman, A. C. Spradling, P. R. Tehale, E. Xu, F. Boscarino, J. A. Vijayadeva, V. Schmidt, M. A. Lamerato, L. E. Gordon, S. TI THE EFFECT OF HCV ANTIVIRAL THERAPY ON FIBROSIS PROGRESSION SO JOURNAL OF HEPATOLOGY LA English DT Meeting Abstract CT 50th International Liver Congress of the European-Association-for-the-Study-of-the-Liver CY APR 22-26, 2015 CL Vienna, AUSTRIA SP European Assoc Study Liver C1 [Lu, M.; Li, J.; Rupp, L. B.; Lamerato, L. E.; Gordon, S.] Henry Ford Hlth Syst, Detroit, MI USA. [Holmberg, S. D.; Moorman, A. C.; Spradling, P. R.; Tehale, E.; Xu, F.; Vijayadeva, V.] Ctr Dis Control, Atlanta, GA 30333 USA. [Boscarino, J. A.] Geisinger Hlth Syst, Danville, PA USA. [Schmidt, M. A.] Kaiser Permanente Northwest, Portland, OR USA. EM strudea1@hfhs.org NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-8278 EI 1600-0641 J9 J HEPATOL JI J. Hepatol. PD APR PY 2015 VL 62 SU 2 MA P0778 BP S622 EP S622 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CT5EJ UT WOS:000362830600495 ER PT J AU Lu, M Li, J Rupp, LB Holmberg, SD Moorman, AC Spradling, PR Teshale, E Xu, F Boscarino, JA Vijayadeva, V Schmidt, MA Lamerato, LE Gordon, S AF Lu, M. Li, J. Rupp, L. B. Holmberg, S. D. Moorman, A. C. Spradling, P. R. Teshale, E. Xu, F. Boscarino, J. A. Vijayadeva, V. Schmidt, M. A. Lamerato, L. E. Gordon, S. TI EFFECT OF HEPATITIS C ANTIVIRAL THERAPY ON ALL-CAUSE MORTALITY AND DEVELOPMENT OF CANCER IN THE CHRONIC HEPATITIS COHORT STUDY (CHECS) SO JOURNAL OF HEPATOLOGY LA English DT Meeting Abstract CT 50th International Liver Congress of the European-Association-for-the-Study-of-the-Liver CY APR 22-26, 2015 CL Vienna, AUSTRIA SP European Assoc Study Liver C1 [Lu, M.; Li, J.; Rupp, L. B.; Lamerato, L. E.; Gordon, S.] Henry Ford Hlth Syst, Detroit, MI USA. [Holmberg, S. D.; Moorman, A. C.; Spradling, P. R.; Teshale, E.; Xu, F.] Ctr Dis Control, Atlanta, GA 30333 USA. [Boscarino, J. A.] Geisinger Hlth Syst, Danville, PA USA. [Vijayadeva, V.] Kaiser Premanente Hawaii, Honolulu, HI USA. [Schmidt, M. A.] Kaiser Permanente Northwest, Portland, OR USA. EM strudea1@hfhs.org NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-8278 EI 1600-0641 J9 J HEPATOL JI J. Hepatol. PD APR PY 2015 VL 62 SU 2 MA P0770 BP S618 EP S619 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CT5EJ UT WOS:000362830600487 ER PT J AU Ashour, F Addo, Y Sullivan, K Suchdev, P Mei, ZG Temple, V Raiten, D Flores-Ayala, R AF Ashour, Fayrouz Addo, Yaw Sullivan, Kevin Suchdev, Parmi Mei, Zuguo Temple, Victor Raiten, Daniel Flores-Ayala, Rafael TI Associations Between Markers of Inflammation and Hemoglobin Concentration: Implications for Diagnosis of Anemia in Women of Reproductive Age SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology Meeting CY MAR 28-APR 01, 2015 CL Boston, MA SP Amer Assoc Anatomists, Amer Physiol Soc, Amer Soc Biochem & Mol Biol, ASIP, ASN, ASPET C1 [Ashour, Fayrouz; Addo, Yaw; Raiten, Daniel] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Pediat Growth & Nutr, NIH, Bethesda, MD USA. [Addo, Yaw; Sullivan, Kevin; Suchdev, Parmi] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Sullivan, Kevin; Suchdev, Parmi; Mei, Zuguo; Flores-Ayala, Rafael] Ctr Dis Control & Prevent, Div Nutr, Atlanta, GA USA. [Temple, Victor] Univ Papua New Guinea, Sch Med & Hlth Sci, Port Moresby, Papua N Guinea. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 EI 1530-6860 J9 FASEB J JI Faseb J. PD APR PY 2015 VL 29 SU 1 MA 913.3 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA CS0BT UT WOS:000361722706013 ER PT J AU Burke, R Revollo, R Iniguez, V Leon, J Suchdev, P AF Burke, Rachel Revollo, Rita Iniguez, Volga Leon, Juan Suchdev, Parmi TI Prevalence and Predictors of Iron Deficiency in Bolivian Infants SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology Meeting CY MAR 28-APR 01, 2015 CL Boston, MA SP Amer Assoc Anatomists, Amer Physiol Soc, Amer Soc Biochem & Mol Biol, ASIP, ASN, ASPET C1 [Burke, Rachel; Leon, Juan; Suchdev, Parmi] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Revollo, Rita] La Paz Serv Dept Salud, La Paz, Bolivia. [Iniguez, Volga] Univ Mayor San Andres, IBMB, La Paz, Bolivia. [Suchdev, Parmi] Ctr Dis Control & Prevent, Nutr, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 EI 1530-6860 J9 FASEB J JI Faseb J. PD APR PY 2015 VL 29 SU 1 MA 729.6 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA CS0BT UT WOS:000361722701463 ER PT J AU Cattran, A Burke, R Lipus, A Revollo, R Iniguez, V Leon, J Suchdev, P AF Cattran, Alexander Burke, Rachel Lipus, Adam Revollo, Rita Iniguez, Volga Leon, Juan Suchdev, Parminder TI Vitamin A Deficiency and Mother-Infant Correlations in Bolivia SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology Meeting CY MAR 28-APR 01, 2015 CL Boston, MA SP Amer Assoc Anatomists, Amer Physiol Soc, Amer Soc Biochem & Mol Biol, ASIP, ASN, ASPET C1 [Cattran, Alexander; Burke, Rachel; Lipus, Adam; Leon, Juan; Suchdev, Parminder] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Revollo, Rita] La Paz Serv Dept Salud, La Paz, Bolivia. [Iniguez, Volga] Univ Mayor San Andres, IBMB, La Paz, Bolivia. [Suchdev, Parminder] Ctr Dis Control & Prevent, Nutr, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 EI 1530-6860 J9 FASEB J JI Faseb J. PD APR PY 2015 VL 29 SU 1 MA 898.50 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA CS0BT UT WOS:000361722705297 ER PT J AU Crider, K Devine, O Qi, Y Tinker, S Berry, R AF Crider, Krista Devine, Owen Qi, Yan Tinker, Sarah Berry, R. TI Predicting the Impact of Folic Acid Fortification, Ready to Eat Cereals and Supplement Use on the Risk of Neural Tube Defects in the United States SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology Meeting CY MAR 28-APR 01, 2015 CL Boston, MA SP Amer Assoc Anatomists, Amer Physiol Soc, Amer Soc Biochem & Mol Biol, ASIP, ASN, ASPET C1 [Crider, Krista; Devine, Owen; Tinker, Sarah; Berry, R.] CDC, NCBDDD, Atlanta, GA 30333 USA. [Qi, Yan] Carter Consulting Inc, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 EI 1530-6860 J9 FASEB J JI Faseb J. PD APR PY 2015 VL 29 SU 1 MA 751.2 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA CS0BT UT WOS:000361722702233 ER PT J AU Fazili, Z Sternberg, M Pfeiffer, C AF Fazili, Zia Sternberg, Maya Pfeiffer, Christine TI Does the addition of ascorbic acid to freshly prepared serum samples improve the stability of folate forms during multiple analyses and long-term storage? SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology Meeting CY MAR 28-APR 01, 2015 CL Boston, MA SP Amer Assoc Anatomists, Amer Physiol Soc, Amer Soc Biochem & Mol Biol, ASIP, ASN, ASPET C1 [Fazili, Zia; Sternberg, Maya; Pfeiffer, Christine] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 EI 1530-6860 J9 FASEB J JI Faseb J. PD APR PY 2015 VL 29 SU 1 MA 919.6 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA CS0BT UT WOS:000361722706061 ER PT J AU Lee-Kwan, SH Pan, LP Kimmons, J Foltz, J Park, S AF Lee-Kwan, Seung Hee Pan, Liping Kimmons, Joel Foltz, Jennifer Park, Sohyun TI Employed US Adults' Support for Food and Beverage Worksite Wellness Strategies and Sugar-Sweetened Beverage Intake during the Workday SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology Meeting CY MAR 28-APR 01, 2015 CL Boston, MA SP Amer Assoc Anatomists, Amer Physiol Soc, Amer Soc Biochem & Mol Biol, ASIP, ASN, ASPET C1 [Lee-Kwan, Seung Hee; Pan, Liping; Kimmons, Joel; Foltz, Jennifer; Park, Sohyun] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 EI 1530-6860 J9 FASEB J JI Faseb J. PD APR PY 2015 VL 29 SU 1 MA 903.19 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA CS0BT UT WOS:000361722705402 ER PT J AU Onufrak, S Park, S Kimmons, J Harris, D AF Onufrak, Stephen Park, Sohyun Kimmons, Joel Harris, Diane TI Worksite Supports for Healthy Eating Reported by Employed Adults SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Onufrak, Stephen; Park, Sohyun; Kimmons, Joel; Harris, Diane] CDC, NCCDPHP, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 EI 1530-6860 J9 FASEB J JI Faseb J. PD APR PY 2015 VL 29 SU 1 MA 903.13 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA CS0BT UT WOS:000361722705396 ER PT J AU Pachon, H Spohrer, R Mei, ZG Serdula, M AF Pachon, Helena Spohrer, Rebecca Mei, Zuguo Serdula, Mary TI Evidence of the Effectiveness of Flour Fortification Programs on Iron Status and Anemia: A Systematic Review SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology Meeting CY MAR 28-APR 01, 2015 CL Boston, MA SP Amer Assoc Anatomists, Amer Physiol Soc, Amer Soc Biochem & Mol Biol, ASIP, ASN, ASPET C1 [Pachon, Helena] FFI, Washington, DC USA. [Pachon, Helena] Emory Univ, Hubert Dept Global Hlth, Atlanta, GA 30322 USA. [Spohrer, Rebecca] Global Alliance Improved Nutr, Geneva, Switzerland. [Mei, Zuguo; Serdula, Mary] US Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 EI 1530-6860 J9 FASEB J JI Faseb J. PD APR PY 2015 VL 29 SU 1 MA 729.4 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA CS0BT UT WOS:000361722701461 ER PT J AU Park, S McGuire, L Galuska, D AF Park, Sohyun McGuire, Lisa Galuska, Deborah TI Regional Differences in Sugar-sweetened Beverage Intake among US Adults SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology Meeting CY MAR 28-APR 01, 2015 CL Boston, MA SP Amer Assoc Anatomists, Amer Physiol Soc, Amer Soc Biochem & Mol Biol, ASIP, ASN, ASPET C1 [Park, Sohyun; McGuire, Lisa; Galuska, Deborah] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 EI 1530-6860 J9 FASEB J JI Faseb J. PD APR PY 2015 VL 29 SU 1 MA 902.1 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA CS0BT UT WOS:000361722705354 ER PT J AU Park, S Li, RW Birch, L AF Park, Sohyun Li, Ruowei Birch, Leann TI Mothers' Child-feeding Practices Are Associated with Children's Sugar-sweetened Beverage Intake SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology Meeting CY MAR 28-APR 01, 2015 CL Boston, MA SP Amer Assoc Anatomists, Amer Physiol Soc, Amer Soc Biochem & Mol Biol, ASIP, ASN, ASPET C1 [Park, Sohyun; Li, Ruowei] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA USA. [Birch, Leann] Univ Georgia, Dept Food & Nutr, Athens, GA 30602 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 EI 1530-6860 J9 FASEB J JI Faseb J. PD APR PY 2015 VL 29 SU 1 MA 901.1 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA CS0BT UT WOS:000361722705325 ER PT J AU Sullivan, K Suchdev, P Raiten, D Flores, R Namaste, S Temple, V Serdula, M Mei, ZG Jefferds, M Whitehead, R AF Sullivan, Kevin Suchdev, Parmi Raiten, Daniel Flores, Rafael Namaste, Sorrel Temple, Victor Serdula, Mary Mei, Zugou Jefferds, Maria Whitehead, Ralph TI Association between Two Acute Phase Proteins with Hemoglobin in Preschool Children SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology Meeting CY MAR 28-APR 01, 2015 CL Boston, MA SP Amer Assoc Anatomists, Amer Physiol Soc, Amer Soc Biochem & Mol Biol, ASIP, ASN, ASPET C1 [Sullivan, Kevin; Suchdev, Parmi; Flores, Rafael; Serdula, Mary; Mei, Zugou; Jefferds, Maria; Whitehead, Ralph] CDC, CCDPHP, Atl, GA USA. [Raiten, Daniel] NICHD, NIH, Bethesda, MD USA. [Namaste, Sorrel; Temple, Victor] UPNG, SMHS, Port Moresby, Papua N Guinea. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 EI 1530-6860 J9 FASEB J JI Faseb J. PD APR PY 2015 VL 29 SU 1 MA 757.6 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA CS0BT UT WOS:000361722702336 ER PT J AU Whitehead, R Perrine, C Mebrahtu, S Dahal, P Subedi, GR Jefferds, ME AF Whitehead, Ralph, Jr. Perrine, Cria Mebrahtu, Saba Dahal, Pradiumna Subedi, Giri Raj Jefferds, Maria Elena TI Defining a vitamin A deficiency cut-off for retinol binding protein in Nepal children 6-23 mo of age SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology Meeting CY MAR 28-APR 01, 2015 CL Boston, MA SP Amer Assoc Anatomists, Amer Physiol Soc, Amer Soc Biochem & Mol Biol, ASIP, ASN, ASPET C1 [Whitehead, Ralph, Jr.] Ctr Dis Control & Prevent, Div Lab Sci, Atlanta, GA USA. [Perrine, Cria; Jefferds, Maria Elena] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA USA. [Mebrahtu, Saba; Dahal, Pradiumna] UNICEF, Nutr Sect, Kathmandu, Nepal. [Subedi, Giri Raj] Minist Hlth & Populat, Nutr Sect, Kathmandu, Nepal. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 EI 1530-6860 J9 FASEB J JI Faseb J. PD APR PY 2015 VL 29 SU 1 MA 729.5 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA CS0BT UT WOS:000361722701462 ER PT J AU Addo, OY Ashour, F Namaste, S Sullivan, K Suchdev, P Mei, ZG Rohner, F Northrop-Clewes, C Flores-Ayala, R Raiten, D AF Addo, O. Yaw Ashour, Fayrouz Namaste, Sorrel Sullivan, Kevin Suchdev, Parminder Mei, Zuguo Rohner, Fabian Northrop-Clewes, Christine Flores-Ayala, Rafael Raiten, Daniel TI Relationship between Transferrin Receptor and Two Acute Phase Proteins in Women of Reproductive Age SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Addo, O. Yaw; Sullivan, Kevin; Suchdev, Parminder; Flores-Ayala, Rafael] Emory Univ, RSPH, Atlanta, GA 30322 USA. [Addo, O. Yaw; Ashour, Fayrouz; Namaste, Sorrel; Raiten, Daniel] NICHD, PGNB, Bethesda, MD USA. [Sullivan, Kevin; Suchdev, Parminder; Mei, Zuguo; Flores-Ayala, Rafael] CDC, Nutr Branch, Atlanta, GA 30333 USA. [Namaste, Sorrel] HKI, SPRING, Washington, DC USA. [Rohner, Fabian] GroundWork, Crans Pres Celigny, Switzerland. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 EI 1530-6860 J9 FASEB J JI Faseb J. PD APR PY 2015 VL 29 SU 1 MA 393.4 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA CR6PV UT WOS:000361470503029 ER PT J AU Ahluwalia, N Sternberg, M Raghavan, R Looker, A Pfeiffer, C AF Ahluwalia, Namanjeet Sternberg, Maya Raghavan, Ramkripa Looker, Anne Pfeiffer, Christine TI Race-Ethnic Patterns in Iron Intake and Status in US Women: Findings from NHANES 2003-06 SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Ahluwalia, Namanjeet; Looker, Anne] CDC, Natl Ctr Hlth Stat, Hyattsville, MD USA. [Sternberg, Maya; Pfeiffer, Christine] CDC, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. [Raghavan, Ramkripa] Johns Hopkins Univ, Baltimore, MD 21218 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 EI 1530-6860 J9 FASEB J JI Faseb J. PD APR PY 2015 VL 29 SU 1 MA 272.6 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA CR6PV UT WOS:000361470502273 ER PT J AU Deputy, N Sharma, A Kim, S AF Deputy, Nicholas Sharma, Andrea Kim, Shin TI Balancing the Risk of Infant Low Birth Weight and Macrosomia: an Examination of Gestational Weight Gain or Weight Loss among Obese Women SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Deputy, Nicholas] Emory Univ, Nutr & Hlth Sci Program, Atlanta, GA 30322 USA. [Deputy, Nicholas; Sharma, Andrea; Kim, Shin] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 EI 1530-6860 J9 FASEB J JI Faseb J. PD APR PY 2015 VL 29 SU 1 MA 590.3 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA CR6PV UT WOS:000361470505012 ER PT J AU Kuiper, H Vesper, H AF Kuiper, Heather Vesper, Hubert TI Trans Fatty Acids in Plasma, Serum, and Red Blood Cells SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Kuiper, Heather; Vesper, Hubert] Ctr Dis Control & Prevent, Clin Chem Branch, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 EI 1530-6860 J9 FASEB J JI Faseb J. PD APR PY 2015 VL 29 SU 1 MA 598.22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA CR6PV UT WOS:000361470505143 ER PT J AU Larson, L Addo, OY Sandalinas, F Baawo, K Faigao, K Kupka, R Flores-Ayala, R Suchdev, P AF Larson, Leila Addo, O. Yaw Sandalinas, Fanny Baawo, Kou Faigao, Katherine Kupka, Roland Flores-Ayala, Rafael Suchdev, Parminder TI Accounting for the Influence of Inflammation on Retinol Binding Protein in a Population Survey of Liberian Preschool-Aged Children SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Larson, Leila; Addo, O. Yaw; Flores-Ayala, Rafael; Suchdev, Parminder] Emory Univ, Nutr & Hlth Sci, Atlanta, GA 30322 USA. [Sandalinas, Fanny; Kupka, Roland] UNICEF, Reg Off West & Cent Africa, Yoff Dakar, Senegal. [Baawo, Kou] Minist Hlth & Social Welf MoH, Accra, Liberia. [Faigao, Katherine] UNICEF, Yoff Dakar, Liberia. [Flores-Ayala, Rafael; Suchdev, Parminder] Ctr Dis Control & Prevent, Nutr Branch, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 EI 1530-6860 J9 FASEB J JI Faseb J. PD APR PY 2015 VL 29 SU 1 MA 393.6 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA CR6PV UT WOS:000361470503031 ER PT J AU Lee-Kwan, SH Park, SY McGuire, L Maynard, L Blanck, H AF Lee-Kwan, Seung Hee Park, Sohyun McGuire, Lisa Maynard, Leah Blanck, Heidi TI Parents' Purchases of Kids' Meals for Children SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Lee-Kwan, Seung Hee; Park, Sohyun; McGuire, Lisa; Maynard, Leah; Blanck, Heidi] CDC, Div Nutr Phys Act & Obes, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 EI 1530-6860 J9 FASEB J JI Faseb J. PD APR PY 2015 VL 29 SU 1 MA LB320 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA CR6PV UT WOS:000361470500318 ER PT J AU Maalouf, J Barron, J Gunn, J Yuan, K Perrine, C Cogswell, M AF Maalouf, Joyce Barron, Jessica Gunn, Janelle Yuan, Keming Perrine, Cria Cogswell, Mary TI Iodized Salt Sales in the United States SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Maalouf, Joyce; Barron, Jessica; Gunn, Janelle; Yuan, Keming; Cogswell, Mary] Ctr Dis Control & Prevent CDC, Div Heart Dis & Stroke Prevent, Atlanta, GA USA. [Maalouf, Joyce] IHRC Inc, Atlanta, GA USA. [Perrine, Cria] CDC, Div Nutr Phys Act & Obes, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 EI 1530-6860 J9 FASEB J JI Faseb J. PD APR PY 2015 VL 29 SU 1 MA 272.3 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA CR6PV UT WOS:000361470502270 ER PT J AU Merrill, R Sullivan, K Northrop-Clewes, C Flores-Ayala, R Namaste, S Serdula, M Suchdev, P AF Merrill, Rebecca Sullivan, K. Northrop-Clewes, C. Flores-Ayala, R. Namaste, S. Serdula, M. Suchdev, P. TI Prevalence of Inflammation Varies among Preschool Aged Children across 12 Countries SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Merrill, Rebecca; Sullivan, K.; Flores-Ayala, R.; Serdula, M.; Suchdev, P.] CDC, IMMPaCt, Atlanta, GA 30333 USA. [Sullivan, K.; Suchdev, P.] Emory Univ, Atlanta, GA 30322 USA. [Namaste, S.] NIH, Bethesda, MD 20892 USA. [Namaste, S.] SPRING, Washington, DC USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 EI 1530-6860 J9 FASEB J JI Faseb J. PD APR PY 2015 VL 29 SU 1 MA 403.6 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA CR6PV UT WOS:000361470503071 ER PT J AU Nielsen, SJ Ogden, C AF Nielsen, Samara Joy Ogden, Cynthia TI Trends in Yogurt Consumption, US Adults, 1999-2012 SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Nielsen, Samara Joy; Ogden, Cynthia] Ctr Dis Control & Prevent, Div Hlth & Nutr Examinat Surveys, Natl Ctr Hlth Stat, Hyattsville, MD USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 EI 1530-6860 J9 FASEB J JI Faseb J. PD APR PY 2015 VL 29 SU 1 MA 587.17 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA CR6PV UT WOS:000361470504478 ER PT J AU Onufrak, S Moore, L Carlson, S Galuska, D AF Onufrak, Stephen Moore, Latetia Carlson, Susan Galuska, Deborah TI Prevalence and Characteristics of Written Nutrition Standards for Foods Served or Sold in Municipal Government Buildings or Worksites in the United States, 2014 SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Onufrak, Stephen; Moore, Latetia; Carlson, Susan; Galuska, Deborah] CDC, NCCDPHP, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 EI 1530-6860 J9 FASEB J JI Faseb J. PD APR PY 2015 VL 29 SU 1 MA 382.8 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA CR6PV UT WOS:000361470502469 ER PT J AU Pao, CI Rybak, M Sternberg, M Ahluwalia, N Pfeiffer, C AF Pao, Ching-I Rybak, Michael Sternberg, Maya Ahluwalia, Namanjeet Pfeiffer, Christine TI Principal Components Analysis of Urine Caffeine and Caffeine Metabolites in the US Population SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Pao, Ching-I; Rybak, Michael; Sternberg, Maya; Pfeiffer, Christine] CDC, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. [Ahluwalia, Namanjeet] CDC, Natl Ctr Hlth Stat, Hyattsville, MD USA. NR 0 TC 0 Z9 0 U1 2 U2 5 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 EI 1530-6860 J9 FASEB J JI Faseb J. PD APR PY 2015 VL 29 SU 1 MA 586.7 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA CR6PV UT WOS:000361470504459 ER PT J AU Pfeiffer, C Sternberg, M Rybak, M Lacher, D AF Pfeiffer, Christine Sternberg, Maya Rybak, Michael Lacher, David TI Race-Ethnic Differences in B-Vitamin Biomarkers and Intake Among US Adults in NHANES 2003-2006 SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Pfeiffer, Christine; Sternberg, Maya; Rybak, Michael] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. [Lacher, David] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 EI 1530-6860 J9 FASEB J JI Faseb J. PD APR PY 2015 VL 29 SU 1 MA 587.1 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA CR6PV UT WOS:000361470504462 ER PT J AU Pfeiffer, C Hughes, J Lacher, D Cogswell, M Wang, CY Johnson, C AF Pfeiffer, Christine Hughes, Jeffery Lacher, David Cogswell, Mary Wang, Chia-Yih Johnson, Clifford TI Estimated Average 24-h Urine Sodium Excretion in US Children SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Pfeiffer, Christine] CDC, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. [Hughes, Jeffery; Lacher, David; Wang, Chia-Yih; Johnson, Clifford] CDC, Natl Ctr Hlth Stat, Hyattsville, MD USA. [Cogswell, Mary] CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 EI 1530-6860 J9 FASEB J JI Faseb J. PD APR PY 2015 VL 29 SU 1 MA 272.4 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA CR6PV UT WOS:000361470502271 ER PT J AU Qi, YP Crider, K Tinker, S Berry, R AF Qi, Yan Ping Crider, Krista Tinker, Sarah Berry, Robert TI Unmetabolized Folic Acid by Sources of Folic Acid Intake Among US Adults in the National Health and Nutrition Examination Survey 2007-2008 SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Qi, Yan Ping] Carter Consulting Inc, Atlanta, GA USA. [Qi, Yan Ping; Crider, Krista; Tinker, Sarah; Berry, Robert] CDC, NCBDDD, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 EI 1530-6860 J9 FASEB J JI Faseb J. PD APR PY 2015 VL 29 SU 1 MA 134.5 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA CR6PV UT WOS:000361470501481 ER PT J AU Saldanha, L Dwyer, J Andrews, K Bailen, R Bailey, R Betz, J Costello, R Dang, P Gahche, J Gusev, P Han, F Palachuvattil, J Savarala, S Pehrsson, P AF Saldanha, L. Dwyer, J. Andrews, K. Bailen, R. Bailey, R. Betz, J. Costello, R. Dang, P. Gahche, J. Gusev, P. Han, F. Palachuvattil, J. Savarala, S. Pehrsson, P. TI Comparison of Labeled Composition and Strength of Prenatal Multivitamin/Mineral (MVM) Prescription (P) and Non-Prescription (N-P) Supplements SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Andrews, K.; Dang, P.; Gusev, P.; Han, F.; Palachuvattil, J.; Savarala, S.; Pehrsson, P.] ARS, USDA, Washington, DC USA. [Gahche, J.] CDC, NCHS, Atlanta, GA 30333 USA. RI Han, Fei/O-1980-2015 OI Han, Fei/0000-0003-2454-4187 NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 EI 1530-6860 J9 FASEB J JI Faseb J. PD APR PY 2015 VL 29 SU 1 MA 250.5 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA CR6PV UT WOS:000361470502156 ER PT J AU Unger, E McMullen, A Lin, JM Rajeevan, M Steinau, M Saraiya, M AF Unger, E. McMullen, A. Lin, J-M Rajeevan, M. Steinau, M. Saraiya, M. TI HPV 16 Variants in Invasive Cancers in the US Prior to HPV Vaccine Implementation SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Unger, E.; McMullen, A.; Lin, J-M; Rajeevan, M.; Steinau, M.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Atlanta, GA USA. [Saraiya, M.] CDC, Div Canc Prevent & Control, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 EI 1530-6860 J9 FASEB J JI Faseb J. PD APR PY 2015 VL 29 SU 1 MA LB450 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA CR6PV UT WOS:000361470500447 ER PT J AU Huang, YLA Lasry, A Hutchinson, AB Sansom, SL AF Huang, Ya-Lin A. Lasry, Arielle Hutchinson, Angela B. Sansom, Stephanie L. TI A Systematic Review on Cost Effectiveness of HIV Prevention Interventions in the United States SO APPLIED HEALTH ECONOMICS AND HEALTH POLICY LA English DT Review ID HUMAN-IMMUNODEFICIENCY-VIRUS; RANDOMIZED CONTROLLED-TRIAL; HEALTH-CARE SETTINGS; FOR-DISEASE-CONTROL; PARTNER-NOTIFICATION; EMERGENCY-DEPARTMENT; PREGNANT-WOMEN; PREEXPOSURE PROPHYLAXIS; TRANSMITTED-DISEASE; CLINICAL SETTINGS AB Background The Centers for Disease Control and Prevention (CDC) focus on funding HIV prevention interventions likely to have high impact on the HIV epidemic. In its most recent funding announcement to state and local health department grantees, CDC required that health departments allocate the majority of funds to four HIV prevention interventions: HIV testing, prevention with HIV-positives and their partners, condom distribution and policy initiatives. Objective We conducted a systematic review of the published literature to determine the extent of the cost-effectiveness evidence for each of those interventions. Methodology We searched for US-based studies published through October 2012. The studies that qualified for inclusion contained original analyses that reported costs per quality-adjusted life-year saved, life-year saved, HIV infection averted, or new HIV diagnosis. For each study, paired reviewers performed a detailed review and data extraction. We reported the number of studies related to each intervention and summarized key cost-effectiveness findings according to intervention type. Costs were converted to 2011 US dollars. Results Of the 50 articles that met the inclusion criteria, 33 related to HIV testing, 15 assessed prevention with HIV-positives and partners, three reported on condom distribution, and one reported on policy initiatives. Methodologies and cost-effectiveness metrics varied across studies and interventions, making them difficult to compare. Conclusion Our review provides an updated summary of the published evidence of cost effectiveness of four key HIV prevention interventions recommended by CDC. With the exception of testing-related interventions, including partner services, where economic evaluations suggest that testing often can be cost effective, more cost-effectiveness research is needed to help guide the most efficient use of HIV prevention funds. C1 [Huang, Ya-Lin A.; Lasry, Arielle; Hutchinson, Angela B.; Sansom, Stephanie L.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30329 USA. RP Huang, YLA (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, 1600 Clifton Rd NE,Mailstop E-48, Atlanta, GA 30329 USA. EM yhuang@cdc.gov NR 69 TC 5 Z9 5 U1 0 U2 0 PU SPRINGER INTERNATIONAL PUBLISHING AG PI CHAM PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND SN 1175-5652 EI 1179-1896 J9 APPL HEALTH ECON HEA JI Appl. Health Econ. Health Policy PD APR PY 2015 VL 13 IS 2 BP 149 EP 156 DI 10.1007/s40258-014-0142-5 PG 8 WC Health Policy & Services SC Health Care Sciences & Services GA CQ2YN UT WOS:000360468600005 PM 25536927 ER PT J AU Carlson, V Chilton, MJ Corso, LC Beitsch, LM AF Carlson, Valeria Chilton, Marita J. Corso, Liza C. Beitsch, Leslie M. TI Defining the Functions of Public Health Governance SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Editorial Material ID SYSTEMS RESEARCH; HOSPITAL BOARDS; DECISION-MAKING; RESEARCH AGENDA; STATE BOARDS; PERFORMANCE; DIRECTORS; SERVICES; OVERSIGHT; NATIONS AB We conducted a literature review in 2011 to determine if accepted governance functions continue to reflect the role of public health governing entities. Reviewing literature and other source documents, as well as consulting with practitioners, resulted in an iterative process that identified 6 functions of public health governance and established definitions for each of these: policy development; resource stewardship; continuous improvement; partner engagement; legal authority; and oversight of a health department. These functions provided context for the role of governing entities in public health practice and aligned well with existing public health accreditation standards. Public health systems research can build from this work in future explorations of the contributions of governance to health department performance. C1 [Carlson, Valeria] Ctr Dis Control & Prevent, Dept Hlth, Div Publ Hlth Performance Improvement, Off State Tribal Local & Terr Support, Atlanta, GA USA. [Carlson, Valeria] Ctr Dis Control & Prevent, Syst Dev Branch, Div Publ Hlth Performance Improvement, Off State Tribal Local & Terr Support, Atlanta, GA USA. [Chilton, Marita J.] Publ Hlth Accreditat Board, Alexandria, VA USA. [Corso, Liza C.] Ctr Dis Control & Prevent, Div Publ Hlth Performance Improvement, Off State Tribal Local & Terr Support, Atlanta, GA USA. [Beitsch, Leslie M.] Florida State Univ, Ctr Med & Publ Hlth, Coll Med, Tallahassee, FL 32306 USA. RP Carlson, V (reprint author), 4770 Buford Highway NE,MS E-19, Atlanta, GA 30341 USA. EM guz6@cdc.gov FU Centers for Disease Control and Prevention (CDC) [5U38HM000512]; National Association of Local Boards of Health (NALBOH) FX This review was supported in part by funds from the Centers for Disease Control and Prevention (CDC) Cooperative Agreement (5U38HM000512) with the National Association of Local Boards of Health (NALBOH). NR 96 TC 4 Z9 4 U1 0 U2 8 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD APR PY 2015 VL 105 SU 2 BP S159 EP S166 DI 10.2105/AJPH.2014.302198 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CN2ZS UT WOS:000358293300011 PM 25689187 ER PT J AU Krahn, GL Walker, DK Correa-De-Araujo, R AF Krahn, Gloria L. Walker, Deborah Klein Correa-De-Araujo, Rosaly TI Persons With Disabilities as an Unrecognized Health Disparity Population SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID PUBLIC-HEALTH; UNITED-STATES; SECONDARY CONDITIONS; NONFATAL INJURIES; CARE-NEEDS; ADULTS; LIMITATIONS; CANCER; BREAST; LEVEL AB Disability is an emerging field within public health; people with significant disabilities account formore than 12% of the US population. Disparity status for this group would allow federal and state governments to actively work to reduce inequities. We summarize the evidence and recommend that observed differences are sufficient to meet the criteria for health disparities: population-level differences in health outcomes that are related to a history of wide-ranging disadvantages, which are avoidable and not primarily caused by the underlying disability. We recommend future research and policy directions to address health inequities for individuals with disabilities; these include improved access to health care and human services, increased data to support decision-making, strengthened health and human services workforce capacity, explicit inclusion of disability in public health programs, and increased emergency preparedness. C1 [Krahn, Gloria L.] Ctr Dis Control & Prevent, Div Human Dev & Disabil, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Walker, Deborah Klein] Abt Associates Inc, Publ Hlth & Epidemiol Practice, Cambridge, MA USA. [Correa-De-Araujo, Rosaly] Dept Hlth & Human Serv, Washington, DC USA. RP Krahn, GL (reprint author), Oregon State Univ, Coll Publ Hlth & Human Sci, 2631 SW Campus Way, Corvallis, OR 97331 USA. EM Gloria.Krahn@Oregonstate.edu FU Intramural CDC HHS [CC999999] NR 75 TC 21 Z9 21 U1 3 U2 13 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD APR PY 2015 VL 105 SU 2 BP S198 EP S206 DI 10.2105/AJPH.2014.302182 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CN2ZS UT WOS:000358293300016 PM 25689212 ER PT J AU Kruk, ME Jakubowski, A Rabkin, M Kimanga, DO Kundu, F Lim, T Lumumba, V Oluoch, T Robinson, KA El-Sadr, W AF Kruk, Margaret E. Jakubowski, Aleksandra Rabkin, Miriam Kimanga, Davies O. Kundu, Francis Lim, Travis Lumumba, Vane Oluoch, Tom Robinson, Katherine A. El-Sadr, Wafaa TI Association Between HIV Programs and Quality of Maternal Health Inputs and Processes in Kenya SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID SUB-SAHARAN AFRICA; SCALE-UP; OF-CARE; SERVICES; MORTALITY; INTERVENTIONS; TRANSMISSION; PREVENTION; COUNTRIES; DELIVERY AB We assessed whether quality of maternal and newborn health services is influenced by presence of HIV programs at Kenyan health facilities using data from a national facility survey. Facilities that provided services to prevent mother-to-child HIV transmission had better prenatal and postnatal care inputs, such as infrastructure and supplies, and those providing antiretroviral therapy had better quality of prenatal and postnatal care processes. HIV-related programs may have benefits for quality of care for related services in the health system. C1 [Kruk, Margaret E.; Jakubowski, Aleksandra] Columbia Univ, Dept Hlth Policy & Management, Mailman Sch Publ Hlth, New York, NY USA. [Rabkin, Miriam; El-Sadr, Wafaa] Columbia Univ, Dept Epidemiol, New York, NY USA. [Rabkin, Miriam; El-Sadr, Wafaa] Columbia Univ, Dept Med, New York, NY USA. [Kimanga, Davies O.] Natl AIDS & STI Control Programme, Nairobi, Kenya. [Kundu, Francis; Lumumba, Vane] Natl Council Populat & Dev, Nairobi, Kenya. [Lim, Travis] Ctr Dis Control & Prevent CDC, Atlanta, GA USA. [Oluoch, Tom; Robinson, Katherine A.] CDC, Nairobi, Kenya. RP Kruk, ME (reprint author), Harvard Univ, TH Chan Sch Publ Hlth, Dept Global Hlth & Populat, Global Hlth, 665 Huntington Ave, Boston, MA 02115 USA. EM mkruk@hsph.harvard.edu OI Oluoch, Tom/0000-0001-9621-5900 FU CDC, Division of Global HIV/AIDS [5U2GPS001537] FX Funding for this research was provided by the US President's Emergency Plan for AIDS Relief through a cooperative agreement from the CDC, Division of Global HIV/AIDS (5U2GPS001537). NR 26 TC 3 Z9 3 U1 1 U2 1 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD APR PY 2015 VL 105 SU 2 BP S207 EP S210 DI 10.2105/AJPH.2014.302511 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CN2ZS UT WOS:000358293300017 PM 25689188 ER PT J AU McLees, AW Nawaz, S Thomas, C Young, A AF McLees, Anita W. Nawaz, Saira Thomas, Craig Young, Andrea TI Defining and Assessing Quality Improvement Outcomes: A Framework for Public Health SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Editorial Material ID LOS-ANGELES-COUNTY; LOCAL HEALTH; ACCREDITATION READINESS; NORTH-CAROLINA; DEPARTMENTS; EXPERIENCE; SYSTEMS AB We describe an evidence-based framework to define and assess the impact of quality improvement (QI) in public health. Developed to address programmatic and research-identified needs for articulating the value of public health QI in aggregate, this framework proposes a standardized set of measures to monitor and improve the efficiency and effectiveness of public health programs and operations. We reviewed the scientific literature and analyzed QI initiatives implemented through the Centers for Disease Control and Prevention's National Public Health Improvement Initiative to inform the selection of 5 efficiency and 8 effectiveness measures. This framework provides a model for identifying the types of improvement outcomes targeted by public health QI efforts and a means to understand QI's impact on the practice of public health. C1 [McLees, Anita W.; Thomas, Craig; Young, Andrea] Ctr Dis Control & Prevent, Div Publ Hlth Performance Improvement, Off State Tribal Local & Terr Support, Atlanta, GA USA. [Nawaz, Saira] Carter Consulting, Atlanta, GA USA. RP McLees, AW (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,NE,MS E-70, Atlanta, GA 30333 USA. EM zdu5@cdc.gov FU Intramural CDC HHS [CC999999] NR 49 TC 0 Z9 0 U1 0 U2 2 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD APR PY 2015 VL 105 SU 2 BP S167 EP S173 DI 10.2105/AJPH.2014.302533 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CN2ZS UT WOS:000358293300012 PM 25689185 ER PT J AU Thomas, CW Corso, L Monroe, JA AF Thomas, Craig W. Corso, Liza Monroe, Judith A. TI The Value of the "System" in Public Health Services and Systems Research SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Editorial Material ID PERFORMANCE; AGENDA C1 [Thomas, Craig W.; Corso, Liza; Monroe, Judith A.] Ctr Dis Control & Prevent, Off State Tribal Local & Terr Support, Atlanta, GA 30329 USA. RP Thomas, CW (reprint author), Ctr Dis Control & Prevent, Div Publ Hlth Performance & Improvement, Off State Tribal Local & Terr Support, 1600 Clifton Rd, Atlanta, GA 30329 USA. EM cht2@cdc.gov NR 15 TC 0 Z9 0 U1 1 U2 4 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD APR PY 2015 VL 105 SU 2 BP S147 EP S149 DI 10.2105/AJPH.2015.302625 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CN2ZS UT WOS:000358293300008 PM 25689189 ER PT J AU Hurley, LP Lindley, MC Allison, M Crane, LA Brtnikova, M Beaty, B Snow, M Bridges, C Kempe, A AF Hurley, Laura P. Lindley, Megan C. Allison, Mandy Crane, Lori A. Brtnikova, Michaela Beaty, Brenda Snow, Megan Bridges, Carolyn Kempe, Allison TI FINANCIAL BARRIERS TO ADULT VACCINE DELIVERY SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 38th Annual Meeting of the Society-of-General-Internal-Medicine (SGIM) CY APR 22-25, 2015 CL Toronto, CANADA SP Soc Gen Internal Med C1 [Bridges, Carolyn] CDC, Atlanta, GA 30333 USA. [Lindley, Megan C.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Brtnikova, Michaela] Childrens Outcomes Res Program, Aurora, CO USA. [Hurley, Laura P.] Denver Hlth, Denver, CO USA. [Allison, Mandy; Crane, Lori A.; Beaty, Brenda; Kempe, Allison] Univ Colorado, Aurora, CO USA. [Snow, Megan] Univ Colorado Denver, Aurora, CO USA. [Kempe, Allison] Childrens Hosp Colorado, Aurora, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2015 VL 30 SU 2 MA 2192476 BP S58 EP S58 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA CN4FV UT WOS:000358386900033 ER PT J AU Hurley, LP Bridges, C Allison, M Crane, LA Brtnikova, M O'Leary, S Beaty, B Snow, M Harpaz, R Kempe, A AF Hurley, Laura P. Bridges, Carolyn Allison, Mandy Crane, Lori A. Brtnikova, Michaela O'Leary, Sean Beaty, Brenda Snow, Megan Harpaz, Rafael Kempe, Allison TI PHYSICIAN ATTITUDES AND PRACTICES REGARDING ADULT VACCINES AND OTHER PREVENTION PRACTICES IN A SHIFTING PRACTICE ENVIRONMENT SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 38th Annual Meeting of the Society-of-General-Internal-Medicine (SGIM) CY APR 22-25, 2015 CL Toronto, CANADA SP Soc Gen Internal Med C1 [Bridges, Carolyn; Harpaz, Rafael] CDC, Atlanta, GA 30333 USA. [Brtnikova, Michaela] Childrens Outcomes Res Program, Aurora, CO USA. [Hurley, Laura P.] Denver Hlth, Denver, CO USA. [Allison, Mandy; Crane, Lori A.; Beaty, Brenda; Kempe, Allison] Univ Colorado, Aurora, CO USA. [Snow, Megan] Univ Colorado Denver, Aurora, CO USA. [O'Leary, Sean] Univ Colorado, Sch Med, Aurora, CO USA. [Hurley, Laura P.; Kempe, Allison] Childrens Hosp Colorado, Aurora, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2015 VL 30 SU 2 MA 2181305 BP S65 EP S66 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA CN4FV UT WOS:000358386900050 ER PT J AU Lundberg, E Lyman, MM Tomolo, A AF Lundberg, Erin Lyman, Meghan M. Tomolo, Anne TI A QUALITY IMPROVEMENT PROJECT: OPTIMIZING INPATIENT DISCHARGE FLOW SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 38th Annual Meeting of the Society-of-General-Internal-Medicine (SGIM) CY APR 22-25, 2015 CL Toronto, CANADA SP Soc Gen Internal Med C1 [Lundberg, Erin; Tomolo, Anne] Emory Univ, Sch Med, Atlanta, GA USA. [Tomolo, Anne] Atlanta VA Med Ctr, Atlanta, GA USA. [Lyman, Meghan M.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2015 VL 30 SU 2 MA 2196154 BP S521 EP S522 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA CN4FV UT WOS:000358386902185 ER PT J AU Tang, JW Moran, MR Allweiss, P Ackermann, RT AF Tang, Joyce W. Moran, Margaret R. Allweiss, Pamela Ackermann, Ronald T. TI WHY DO EMPLOYERS OFFER WELLNESS PROGRAMS AND HOW DO THEY MEASURE SUCCESS? SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 38th Annual Meeting of the Society-of-General-Internal-Medicine (SGIM) CY APR 22-25, 2015 CL Toronto, CANADA SP Soc Gen Internal Med C1 [Tang, Joyce W.; Moran, Margaret R.; Ackermann, Ronald T.] Northwestern Univ, Chicago, IL 60611 USA. [Allweiss, Pamela] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2015 VL 30 SU 2 MA 2196109 BP S304 EP S304 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA CN4FV UT WOS:000358386901189 ER PT J AU Damon, SA Tardif, RR AF Damon, Scott A. Tardif, Richard R. TI Asthma education: different viewpoints elicited by qualitative and quantitative methods SO JOURNAL OF ASTHMA LA English DT Article DE Asthma Action Plan; clinicians; docStyles; physicians; reimbursement ID PHYSICIAN AB Objective: This project began as a qualitative examination of how asthma education provided by health professionals could be improved. Unexpected qualitative findings regarding the use of Asthma Action Plans and the importance of insurance reimbursement for asthma education prompted further quantitative examination. Methods: Qualitative individual interviews were conducted with primary care physicians in private practice who routinely provide initial diagnoses of asthma and focus groups were conducted with other clinicians in private primary care practices who routinely provide asthma education. Using the DocStyles quantitative tool two questions regarding Asthma Action Plans and insurance reimbursement were asked of a representative sample of physicians and other clinicians. Results: The utility of Asthma Action Plans was questioned in the 2012 qualitative study. Qualitative findings also raised questions regarding whether reimbursement is the barrier to asthma education for patients performed by medical professionals it is thought to be. 2013 quantitative findings show that the majority of clinicians see Asthma Action Plans as useful. The question of whether reimbursement is a barrier to providing asthma education to patients was not resolved by the quantitative data. Conclusions: The majority of clinicians see Asthma Action Plans as a useful tool for patient education. Clinicians had less clear opinions on whether the lack of defined reimbursement codes acted as a barrier to asthma education. The study also provided useful audience data for design of new asthma educational tools developed by CDC. C1 [Damon, Scott A.] Ctr Dis Control, Natl Ctr Environm Hlth, Air Pollut & Resp Hlth Branch, Atlanta, GA 30341 USA. [Tardif, Richard R.] Oak Ridge Associated Univ, Oak Ridge, TN USA. RP Damon, SA (reprint author), Ctr Dis Control, Natl Ctr Environm Hlth, Air Pollut & Resp Hlth Branch, Atlanta, GA 30341 USA. EM scd3@cdc.gov FU Intramural CDC HHS [CC999999] NR 11 TC 1 Z9 1 U1 0 U2 0 PU INFORMA HEALTHCARE PI NEW YORK PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA SN 0277-0903 EI 1532-4303 J9 J ASTHMA JI J. Asthma PD APR PY 2015 VL 52 IS 3 BP 314 EP 317 DI 10.3109/02770903.2014.966112 PG 4 WC Allergy; Respiratory System SC Allergy; Respiratory System GA CN0DF UT WOS:000358082300014 PM 25243323 ER PT J AU Zahran, HS Bailey, CM Qin, XT Moorman, JE AF Zahran, Hatice S. Bailey, Cathy M. Qin, Xiaoting Moorman, Jeanne E. TI Assessing asthma control and associated risk factors among persons with current asthma - findings from the child and adult Asthma Call-back Survey SO JOURNAL OF ASTHMA LA English DT Article DE Asthma; comorbidity; environment; risk factors; obesity ID HEALTH-CARE UTILIZATION; QUALITY-OF-LIFE; PREDICTORS AB Introduction: Monitoring the level of asthma control is important in determining the effectiveness of current treatment which may decrease the frequency and intensity of symptoms and functional limitations. Uncontrolled asthma has been associated with decreased quality of life and increased health care use. The objectives of this study were to assess the level of asthma control and identify related risk factors among persons with current asthma. Methods: Using the 2006 to 2010 BRFSS child and adult Asthma Call-back Survey, asthma control was classified as well-controlled or uncontrolled (not-well-controlled or very-poorly-controlled) using three impairment measures: daytime symptoms, night-time symptoms, and taking short-acting beta 2-agonists for symptom control. Multivariate logistic regression identified predictors of asthma control. Results: Fifty percent of adults and 38.4% of children with current asthma had uncontrolled asthma. About 63% of children and 53% of adults with uncontrolled asthma were on long-term asthma control medications. Among children, uncontrolled asthma was significantly associated with being younger than 5 years, having annual household income <$15 000, and reporting cost as barriers to medical care. Among adults, it was significantly associated with being 45 years or older, having annual household income of <$25 000, being "other'' race, having less than a 4-year college degree, being a current or former smoker, reporting cost as barriers, being obese, and having chronic obstructive pulmonary disease or depression. Conclusion: Identifying and targeting modifiable predictors of uncontrolled asthma (low educational attainment, low income, cigarette smoking, and co-morbid conditions including obesity and depression) could improve asthma control. C1 [Zahran, Hatice S.; Bailey, Cathy M.; Qin, Xiaoting; Moorman, Jeanne E.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Environm Hazards & Hlth Effects, Atlanta, GA 30341 USA. RP Zahran, HS (reprint author), Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Environm Hazards & Hlth Effects, 4770 Buford Highway,NE,MS F-60, Atlanta, GA 30341 USA. EM HZahran@cdc.gov FU Intramural CDC HHS [CC999999] NR 23 TC 8 Z9 8 U1 0 U2 1 PU INFORMA HEALTHCARE PI NEW YORK PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA SN 0277-0903 EI 1532-4303 J9 J ASTHMA JI J. Asthma PD APR PY 2015 VL 52 IS 3 BP 318 EP 326 DI 10.3109/02770903.2014.956894 PG 9 WC Allergy; Respiratory System SC Allergy; Respiratory System GA CN0DF UT WOS:000358082300015 PM 25144551 ER PT J AU Fogel, CI Crandell, JL Neevel, AM Parker, SD Carry, M White, BL Fasula, AM Herbst, JH Gelaude, DJ AF Fogel, Catherine I. Crandell, Jamie L. Neevel, A. M. Parker, Sharon D. Carry, Monique White, Becky L. Fasula, Amy M. Herbst, Jeffrey H. Gelaude, Deborah J. TI Efficacy of an Adapted HIV and Sexually Transmitted Infection Prevention Intervention for Incarcerated Women: A Randomized Controlled Trial SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID BEHAVIORAL INTERVENTION; PSYCHOMETRIC EVALUATION; MINORITY WOMEN; RISK BEHAVIOR; PREVALENCE; CHLAMYDIA; PRISON; PARTNERSHIPS; GONORRHEA; ABUSE AB Objectives. We tested the efficacy of an adapted evidence-based HIV-sexually transmitted infection (STI) behavioral intervention (Providing Opportunities for Women's Empowerment, Risk-Reduction, and Relationships, or POWER) among incarcerated women. Methods. We conducted a randomized trial with 521 women aged 18 to 60 years in 2 correctional facilities in North Carolina in 2010 and 2011. Intervention participants attended 8 POWER sessions; control participants received a single standard-of-care STI prevention session. We followed up at 3 and 6 months after release. We examined intervention efficacy with mixed-effects models. Results. POWER participants reported fewer male sexual partners than did control participants at 3 months, although this finding did not reach statistical significance; at 6 months they reported significantly less vaginal intercourse without a condom outside of a monogamous relationship and more condom use with a main male partner. POWER participants also reported significantly fewer condom barriers, and greater HIV knowledge, health-protective communication, and tangible social support. The intervention had no significant effects on incident STIs. Conclusions. POWER is a behavioral intervention with potential to reduce risk of acquiring or transmitting HIV and STIs among incarcerated women returning to their communities. C1 [Fogel, Catherine I.; Crandell, Jamie L.; Neevel, A. M.; Parker, Sharon D.] Univ N Carolina, Sch Nursing, Chapel Hill, NC 27599 USA. [White, Becky L.] Univ N Carolina, Dept Med, Div Infect Dis, Chapel Hill, NC 27599 USA. [Carry, Monique; Fasula, Amy M.; Herbst, Jeffrey H.; Gelaude, Deborah J.] Ctr Dis Control & Prevent CDC, Prevent Res Branch, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. RP Fogel, CI (reprint author), Univ N Carolina, Sch Nursing, Carrington Hall,CB 7460, Chapel Hill, NC 27599 USA. EM cfogel@e-mail.unc.edu FU CDC [5UR6PS000670]; UNC Center for AIDS Research [P30AI0410] FX This study was funded by the CDC (cooperative agreement 5UR6PS000670). Catherine I. Fogel received support from the UNC Center for AIDS Research (grant P30AI0410). The POWER intervention videos were updated with support from The North Carolina Translational and Clinical Sciences Institute. NR 41 TC 7 Z9 7 U1 1 U2 9 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD APR PY 2015 VL 105 IS 4 BP 802 EP 809 DI 10.2105/AJPH.2014.302105 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CM0SE UT WOS:000357387800053 PM 25211714 ER PT J AU Breiding, MJ AF Breiding, Matthew J. TI Prevalence and Characteristics of Sexual Violence, Stalking, and Intimate Partner Violence Victimization-National Intimate Partner and Sexual Violence Survey, United States, 2011 SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article C1 CDC, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. RP Breiding, MJ (reprint author), CDC, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. EM dvi8@cdc.gov NR 0 TC 2 Z9 2 U1 1 U2 6 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD APR PY 2015 VL 105 IS 4 BP E11 EP E12 DI 10.2105/AJPH.2014.302321 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CM0SE UT WOS:000357387800010 ER PT J AU Fayer, R Esposito, DH Dubey, JP AF Fayer, Ronald Esposito, Douglas H. Dubey, Jitender P. TI Human Infections with Sarcocystis Species SO CLINICAL MICROBIOLOGY REVIEWS LA English DT Review ID MUSCULAR SARCOCYSTOSIS; SKELETAL-MUSCLE; TIOMAN ISLAND; RISK-FACTOR; MALAYSIA; NESBITTI; SARCOSPORIDIOSIS; MYOSITIS; PREVALENCE; OUTBREAK AB Recurrent outbreaks of muscular sarcocystosis among tourists visiting islands in Malaysia have focused international attention on sarcocystosis, a disease once considered rare in humans. Sarcocystis species require two hosts, definitive and intermediate, to complete their life cycle. Humans can serve as definitive hosts, with intestinal sarcocystosis for two species acquired from eating undercooked meat: Sarcocystis hominis, from beef, and Sarcocystis suihominis, from pork. Symptoms such as nausea, stomachache, and diarrhea vary widely depending on the number of cysts ingested but appear more severe with pork than with beef. Humans serve as intermediate hosts for Sarcocystis nesbitti, a species with a reptilian definitive host, and possibly other unidentified species, acquired by ingesting sporocysts from feces-contaminated food or water and the environment; infections have an early phase of development in vascular endothelium, with illness that is difficult to diagnose; clinical signs include fever, headache, and myalgia. Subsequent development of intramuscular cysts is characterized by myositis. Presumptive diagnosis based on travel history to tropical regions, elevated serum enzyme levels, and eosinophilia is confirmed by finding sarcocysts in muscle biopsy specimens. There is no vaccine or confirmed effective antiparasitic drug for muscular sarcocystosis, but anti-inflammatory drugs may reduce symptoms. Prevention strategies are also discussed. C1 [Fayer, Ronald] ARS, USDA, Beltsville, MD 20705 USA. [Dubey, Jitender P.] ARS, USDA, Anim Parasit Dis Lab, Beltsville, MD USA. [Esposito, Douglas H.] Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. RP Fayer, R (reprint author), ARS, USDA, Beltsville, MD 20705 USA. EM ronald.fayer@ars.usda.gov NR 88 TC 19 Z9 20 U1 4 U2 15 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0893-8512 EI 1098-6618 J9 CLIN MICROBIOL REV JI Clin. Microbiol. Rev. PD APR PY 2015 VL 28 IS 2 BP 295 EP 311 DI 10.1128/CMR.00113-14 PG 17 WC Microbiology SC Microbiology GA CK6SY UT WOS:000356359400002 PM 25715644 ER PT J AU Calancie, L Leeman, J Pitts, SBJ Khan, LK Fleischhacker, S Evenson, KR Schreiner, M Byker, C Owens, C McGuirt, J Barnidge, E Dean, W Johnson, D Kolodinsky, J Piltch, E Pinard, C Quinn, E Whetstone, L Ammerman, A AF Calancie, Larissa Leeman, Jennifer Pitts, Stephanie B. Jilcott Khan, Laura Kettel Fleischhacker, Sheila Evenson, Kelly R. Schreiner, Michelle Byker, Carmen Owens, Clint McGuirt, Jared Barnidge, Ellen Dean, Wesley Johnson, Donna Kolodinsky, Jane Piltch, Emily Pinard, Courtney Quinn, Emilee Whetstone, Lauren Ammerman, Alice TI Nutrition-Related Policy and Environmental Strategies to Prevent Obesity in Rural Communities: A Systematic Review of the Literature, 2002-2013 SO PREVENTING CHRONIC DISEASE LA English DT Review ID REDUCE CHILDHOOD OBESITY; ARKANSAS ACT 1220; DIABETES PREVENTION; PHYSICAL-ACTIVITY; 1ST NATIONS; PSYCHOSOCIAL FACTORS; DISEASE PREVENTION; UNITED-STATES; HEALTHY FOODS; INTERVENTION AB Introduction Residents of rural communities in the United States are at higher risk for obesity than their urban and suburban counterparts. Policy and environmental-change strategies supporting healthier dietary intake can prevent obesity and promote health equity. Evidence in support of these strategies is based largely on urban and suburban studies; little is known about use of these strategies in rural communities. The purpose of this review was to synthesize available evidence on the adaptation, implementation, and effectiveness of policy and environmental obesity-prevention strategies in rural settings. Methods The review was guided by a list of Centers for Disease Control and Prevention Recommended Community Strategies and Measurements to Prevent Obesity in the United States, commonly known as the "COCOMO" strategies. We searched PubMed, Cumulative Index of Nursing and Allied Health Literature, Public Affairs Information Service, and Cochrane databases for articles published from 2002 through 2013 that reported findings from research on nutrition-related policy and environmental strategies in rural communities in the United States and Canada. Two researchers independently abstracted data from each article, and resolved discrepancies by consensus. Results Of the 663 articles retrieved, 33 met inclusion criteria. The interventions most commonly focused on increasing access to more nutritious foods and beverages or decreasing access to less nutritious options. Rural adaptations included accommodating distance to food sources, tailoring to local food cultures, and building community partnerships. Conclusions Findings from this literature review provide guidance on adapting and implementing policy and environmental strategies in rural communities. C1 [Leeman, Jennifer; Evenson, Kelly R.; Schreiner, Michelle; Owens, Clint; McGuirt, Jared; Ammerman, Alice] Univ N Carolina, Chapel Hill, NC 27599 USA. [Pitts, Stephanie B. Jilcott; Whetstone, Lauren] E Carolina Univ, Elizabeth City, NC USA. [Khan, Laura Kettel] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA USA. [Fleischhacker, Sheila] NIH, Div Nutr Res Coordinat, Bethesda, MD 20892 USA. [Byker, Carmen] Montana State Univ, Billings, MT USA. [Barnidge, Ellen] St Louis Univ, St Louis, MO 63103 USA. [Dean, Wesley] Food & Nutr Serv, USDA, Washington, DC USA. [Johnson, Donna; Quinn, Emilee] Univ Washington, Seattle, WA 98195 USA. [Kolodinsky, Jane] Univ Vermont, Burlington, VT USA. [Piltch, Emily] Tufts Univ, Boston, MA 02111 USA. [Pinard, Courtney] Univ Nebraska, Lincoln, NE USA. RP Calancie, L (reprint author), Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Nutr, CB 7426,1700 MLK Airport Rd,Room 239, Chapel Hill, NC 27599 USA. EM lcalancie@unc.edu OI Byker Shanks, Carmen/0000-0002-9030-9938 FU CDC [5-37850, U48/DP000059]; National Institute of Nursing Research [T32NR007091, 5T32NR008856] FX This study was conducted as a joint project of the CDC-funded NOPREN Rural Food Access Working Group (grant no. 5-37850). This work was also supported by the CDC-funded University of North Carolina at Chapel Hill Prevention Research Center (no. U48/DP000059). Michelle Schreiner's and Clint Owens's work was supported by grants no. T32NR007091 and no. 5T32NR008856 from the National Institute of Nursing Research. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC, the USDA, or the National Institutes of Health. NR 60 TC 4 Z9 4 U1 2 U2 20 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD APR PY 2015 VL 12 AR 140540 DI 10.5888/pcd12.140540 PG 16 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CL0YS UT WOS:000356669600015 ER PT J AU Edwards, VJ Anderson, LA Deokar, AJ AF Edwards, Valerie J. Anderson, Lynda A. Deokar, Angela J. TI Proxy Reports About Household Members With Increased Confusion or Memory Loss, 2011 Behavioral Risk Factor Surveillance System SO PREVENTING CHRONIC DISEASE LA English DT Article AB To provide information about the effects of increased confusion or memory loss (ICML) in households in the United States, we describe primary respondents' reports (proxy reports) about another person in their household experiencing ICML, using 2011 Behavioral Risk Factor Surveillance System (BRFSS) data. We used proxy reports on type of assistance needed, effects on functioning in daily activities, and whether confusion or memory was discussed with a health care professional, stratifying by age of the household member with ICML (18-50 y vs >= 65 y). About 3% (n = 3,075 households) of primary respondents reported living with a household member with ICML; 75% of these household members needed some type of assistance, and nearly 60% had discussed ICML with a health care professional. Collecting proxy data about individuals in households may help paint a clearer picture of the characteristics of those experiencing cognitive decline and the potential needs of individuals and families. C1 [Edwards, Valerie J.; Anderson, Lynda A.; Deokar, Angela J.] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. [Anderson, Lynda A.] Emory Univ, Sch Publ Hlth, Atlanta, GA USA. RP Edwards, VJ (reprint author), Ctr Dis Control & Prevent, 4770 Buford Hwy NE,Mailstop K-45, Atlanta, GA 30341 USA. EM vae2@cdc.gov NR 7 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD APR PY 2015 VL 12 AR 140427 DI 10.5888/pcd12.140427 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CL0YS UT WOS:000356669600005 ER PT J AU Holt, JB Zhang, XY Sizov, N Croft, JB AF Holt, James B. Zhang, Xingyou Sizov, Natalia Croft, Janet B. TI Airport Noise and Self-Reported Sleep Insufficiency, United States, 2008 and 2009 SO PREVENTING CHRONIC DISEASE LA English DT Article ID ISCHEMIC-HEART-DISEASE; AIRCRAFT NOISE; ENVIRONMENTAL NOISE; TRANSPORTATION NOISE; HEALTH; EXPOSURE; DISTURBANCE; ANNOYANCE; METAANALYSIS; HYPERTENSION AB Introduction Sleep insufficiency is a major health risk factor. Exposure to environmental noise may affect sleep duration and quality. The objective of this study was to assess the relationship between airport noise exposure and insufficient sleep in the United States by using data from the Behavioral Risk Factor Surveillance System (BRFSS). Methods Data on the number of days without enough rest or sleep for approximately 750,000 respondents to the 2008 and 2009 BRFSS were linked with data on noise exposure modeled using the US Federal Aviation Administration's (FAA's) Integrated Noise Model for 95 major US airports for corresponding years. Noise exposure data were stratified into 3 groups depending on noise levels. People living outside airport noise exposure zones were included as a reference category. Results We found 8.6 mean days of insufficient sleep in the previous 30 days among 745,868 adults; 10.8% reported insufficient sleep for all 30 days; and 30.1% reported no days of insufficient sleep. After controlling for individual sociodemographics and ZIP Code-level socioeconomic status, we found no significant differences in sleep insufficiency between the 3 noise exposure zones and the zone outside. Conclusion This research demonstrates the feasibility of conducting a national study of airport noise and sleep using an existing public health surveillance dataset and recommends methods for improving the accuracy of such studies; some of these recommendations were implemented in recent FAA-sponsored studies. Validation of BRFSS sleep measures and refined ways of collecting data are needed to determine the optimal measures of sleep for such a large-scale survey and to establish the relationship between airport noise and sleep. C1 [Holt, James B.; Zhang, Xingyou; Croft, Janet B.] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. [Sizov, Natalia] FAA, Washington, DC USA. RP Holt, JB (reprint author), Ctr Dis Control & Prevent, 4770 Buford Hwy NE,Mailstop F-78, Atlanta, GA 30341 USA. EM jgh4@cdc.gov NR 33 TC 0 Z9 0 U1 1 U2 6 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD APR PY 2015 VL 12 AR 140551 DI 10.5888/pcd12.140551 PG 12 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CL0YS UT WOS:000356669600007 ER PT J AU Jones, SE Wendel, AM AF Jones, Sherry Everett Wendel, Arthur M. TI Characteristics of Joint Use Agreements in School Districts in the United States: Findings From the School Health Policies and Practices Study, 2012 SO PREVENTING CHRONIC DISEASE LA English DT Article ID PHYSICAL-ACTIVITY; SHARED USE; FACILITIES AB Introduction Joint use or shared use of public school facilities provides community access to facilities for varied purposes. We examined a nationally representative sample of school districts in the United States to identify characteristics associated with having a formal joint use agreement (JUA) and with the kinds of uses to which JUAs apply. Methods We analyzed data from the 2012 School Health Policies and Practices Study. The response rate for the module containing questions about formal JUAs was 60.1% (N = 630). We used multivariate logistic regression models to examine the adjusted odds of having a formal JUA and chi(2) analyses to examine differences in district characteristics associated with the uses of the JUA. Results Among the 61.6% of school districts with a formal JUA, more than 80% had an agreement for the use of indoor and outdoor recreation facilities; other uses also were identified. JUAs were more common in urban than rural areas, in large than small school districts, and in the West compared with the Midwest, South, and Northeast. Conclusion In many districts, school facilities appear to be an untapped resource for community members. Formal JUAs provide an opportunity for shared use while addressing issues of liability, cost, and logistics. C1 [Wendel, Arthur M.] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. RP Jones, SE (reprint author), Ctr Dis Control & Prevent, Sch Based Surveillance Branch, Div Adolescent & Sch Hlth, 1600 Clifton Rd NE,MS E75, Atlanta, GA 30329 USA. EM sce2@cdc.gov FU CDC FX The authors thank Nancy D. Brener, PhD, and Tim McManus, MS, with CDC and Bob Axelrad and Tim Torma with the US Environmental Protection Agency for their input and guidance. This work was supported solely through regular institution operating funds of CDC. NR 24 TC 2 Z9 2 U1 0 U2 3 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD APR PY 2015 VL 12 AR 140560 DI 10.5888/pcd12.140560 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CL0YS UT WOS:000356669600008 ER PT J AU Lee, AK Schieb, LJ Yuan, KM Maalouf, J Gillespie, C Cogswell, ME AF Lee, Alexandra K. Schieb, Linda J. Yuan, Keming Maalouf, Joyce Gillespie, Cathleen Cogswell, Mary E. TI Sodium Content in Packaged Foods by Census Division in the United States, 2009 SO PREVENTING CHRONIC DISEASE LA English DT Article ID BLOOD-PRESSURE; DIETARY-SODIUM; HYPERTENSION; TRENDS AB Excess sodium intake correlates positively with high blood pressure. Blood pressure varies by region, but whether sodium content of foods sold varies across regions is unknown. We combined nutrition and sales data from 2009 to assess the regional variation of sodium in packaged food products sold in 3 of the 9 US census divisions. Although sodium density and concentration differed little by region, fewer than half of selected food products met Food and Drug Administration sodium-per-serving conditions for labeling as "healthy." Regional differences in hypertension were not reflected in differences in the sodium content of packaged foods from grocery stores. C1 [Lee, Alexandra K.] Emory Univ, Atlanta, GA 30322 USA. [Yuan, Keming; Maalouf, Joyce; Gillespie, Cathleen; Cogswell, Mary E.] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. RP Schieb, LJ (reprint author), Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, 4770 Buford Hwy NE,MS F-72, Atlanta, GA 30341 USA. EM Ekf7@cdc.gov NR 10 TC 1 Z9 1 U1 0 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD APR PY 2015 VL 12 AR 140500 DI 10.5888/pcd12.140500 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CL0YS UT WOS:000356669600001 ER PT J AU Levings, JL Maalouf, J Tong, X Cogswell, ME AF Levings, Jessica Lee Maalouf, Joyce Tong, Xin Cogswell, Mary E. TI Reported Use and Perceived Understanding of Sodium Information on US Nutrition Labels SO PREVENTING CHRONIC DISEASE LA English DT Article ID DIETARY-INTAKE AB Introduction Comparing nutrition labels and choosing lower sodium foods are tactics to help reduce excessive sodium intake, a major risk factor for hypertension. Our objective was to assess US adult consumers' reported use and perceived understanding of sodium information on nutrition labels by sociodemographic and health status. Methods We analyzed responses to questions from 3,729 adults aged 18 years or older participating in 2 national cross-sectional mail panel surveys in 2010. Results We found that 19.3% (95% confidence interval [CI], 17.2%-21.6%) of respondents agreed they were confused about how to figure out how much sodium is in the foods they eat; 57.9% (95% CI, 55.4%-60.5%) reported that they or the person who shops for their food buy items labeled low salt or low sodium; and 46.8% (95% CI, 44.3%-49.4%) reported they check nutrition labels for sodium content as a tactic to limit salt. Consumers with a high school education or less were more likely than college graduates to report they were confused about sodium content on labels (adjusted odds ratio [AOR], 1.9; 95% CI, 1.4-2.8) and less likely to check labels for sodium as a tactic to limit salt intake (AOR, 0.7; 95% CI, 0.6-0.98). Conclusion Most survey respondents in our study reported buying low sodium food items. However, a higher proportion of respondents with low education than respondents with high education reported confusion with and less use of sodium content information, suggesting enhanced efforts may be needed to assist this group. Opportunity exists for health care professionals to educate patients about using and understanding nutrition labels and consuming a diet consistent with the Dietary Approaches to Stop Hypertension (DASH) eating plan. C1 [Maalouf, Joyce; Tong, Xin; Cogswell, Mary E.] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. RP Levings, JL (reprint author), Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, MS K-72,4770 Buford Hwy, Chamblee, GA 30341 USA. EM JLevings@cdc.gov NR 17 TC 0 Z9 0 U1 1 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD APR PY 2015 VL 12 AR 140522 DI 10.5888/pcd12.140522 PG 12 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CL0YS UT WOS:000356669600006 ER PT J AU Nielsen, J Bahendeka, SK Gregg, EW Whyte, SR Bygbjerg, IC Meyrowitsch, DW AF Nielsen, Jannie Bahendeka, Silver K. Gregg, Edward W. Whyte, Susan R. Bygbjerg, Ib C. Meyrowitsch, Dan W. TI A Comparison of Cardiometabolic Risk Factors in Households in Rural Uganda With and Without a Resident With Type 2 Diabetes, 2012-2013 SO PREVENTING CHRONIC DISEASE LA English DT Article ID PHYSICAL-ACTIVITY QUESTIONNAIRE; IMPAIRED GLUCOSE-TOLERANCE; LIFE-STYLE; WEIGHT-LOSS; FOLLOW-UP; PREVENTION; MELLITUS; OBESITY; INTERVENTION; RELIABILITY AB Introduction Few studies have examined the health consequences of living in a household with a person who has been diagnosed with type 2 diabetes (T2D). We assessed the association of sharing a household with a person with diagnosed T2D and risk factors for cardio-metabolic diseases in Uganda, a low-income country. Methods Ninety households with 437 residents in southwestern Uganda were studied from December 2012 through March 2013. Forty-five of the households had a member with diagnosed T2D (hereafter "diabetic household"), and 45 households had no member with diagnosed T2D (hereafter "nondiabetic household"). We compared glycosylated hemoglobin (HbA1c), fasting plasma glucose (FPG), hypertension, anthropometry, aerobic capacity, physical activity, nutrition, smoking, and diabetes-related knowledge of people without diagnosed T2D living in diabetic and nondiabetic households. Results People living in diabetic households had a significantly higher level of diabetes-related knowledge, lower levels of FPG (5.6 mmol/L vs 6.0 mmol/L), and fewer smoked (1.3% vs 12.9%) than residents of nondiabetic households. HbA1c was significantly lower in people aged 30 years or younger (5.2% vs 5.4%) and in males (5.2% vs 5.4%) living in diabetic households compared to residents of nondiabetic households. No differences were found between the 2 types of households in overweight and obesity, upper-arm fat area, intake of staple foods or cooking oil, or physical activity. Conclusions Sharing a household with a person with T2D may have unexpected benefits on the risk factor profile for cardio-metabolic diseases, probably because of improved health behaviors and a closer connection with the health care system. Thus, future studies should consider the household for interventions targeting primary and secondary prevention of T2D. C1 [Nielsen, Jannie; Bygbjerg, Ib C.; Meyrowitsch, Dan W.] Univ Copenhagen, Dept Publ Hlth, Global Hlth Sect, DK-1014 Copenhagen K, Denmark. [Bahendeka, Silver K.] St Francis Hosp Nsambya, Kampala, Uganda. [Gregg, Edward W.] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA USA. [Whyte, Susan R.] Univ Copenhagen, Dept Anthropol, DK-1014 Copenhagen K, Denmark. RP Nielsen, J (reprint author), Univ Copenhagen, Dept Publ Hlth, Global Hlth Sect, Oester Farimagsgade 5,Bldg 9,Mailbox 2099, DK-1014 Copenhagen K, Denmark. EM Jannien@sund.ku.dk OI Bygbjerg, Ib/0000-0001-9100-2754 FU Novo Nordisk Fonden [29847]; University of Copenhagen; Thorvald Madsens Fond; Aase and Ejnar Danielsens Fond; Christian and Otilia Brorsons Rejselegat FX Dr. Nielsen's PhD fellowship was partly funded by Novo Nordisk Fonden (grant no. 29847). The study was sponsored by University of Copenhagen, Thorvald Madsens Fond, Aase and Ejnar Danielsens Fond, and Christian and Otilia Brorsons Rejselegat. No sponsor had any influence on the study design; data collection, analysis, or interpretation; or the writing of this article. The remaining authors have declared no conflict of interest. We thank the people who opened their homes and took time to participate in this study, the field assistants for collecting data and carrying equipment up the mountain slopes, and the Kagando Hospital staff members for their hospitality and support. We also thank Professor Thomas Scheike, Department of Biostatistics, University of Copenhagen, for statistical analysis help; Associate Professor Pernille Kaestel and Ms Maria Pedersen of the University of Copenhagen for assistance with nutritional data; and Soren Brage, University of Cambridge, for assistance with step-test data. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 37 TC 2 Z9 2 U1 1 U2 3 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD APR PY 2015 VL 12 AR 140486 DI 10.5888/pcd12.140486 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CL0YS UT WOS:000356669600002 ER PT J AU Pratt, M Yin, SM Soler, R Njai, R Siegel, PZ Liao, YL AF Pratt, Michael Yin, Shaoman Soler, Robin Njai, Rashid Siegel, Paul Z. Liao, Youlian TI Does Perceived Neighborhood Walkability and Safety Mediate the Association Between Education and Meeting Physical Activity Guidelines? SO PREVENTING CHRONIC DISEASE LA English DT Article ID FACTOR SURVEILLANCE SYSTEM AB The role of neighborhood walkability and safety in mediating the association between education and physical activity has not been quantified. We used data from the 2010 and 2012 Communities Putting Prevention to Work Behavioral Risk Factor Surveillance System and structural equation modeling to estimate how much of the effect of education level on physical activity was mediated by perceived neighborhood walkability and safety. Neighborhood walkability accounts for 11.3% and neighborhood safety accounts for 6.8% of the effect. A modest proportion of the important association between education and physical activity is mediated by perceived neighborhood walkability and safety, suggesting that interventions focused on enhancing walkability and safety could reduce the disparity in physical activity associated with education level. C1 [Pratt, Michael; Soler, Robin; Njai, Rashid; Siegel, Paul Z.; Liao, Youlian] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Yin, Shaoman] SciMetrika LLC, Durham, NC USA. RP Pratt, M (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Mailstop F-80,4770 Buford Hwy NE, Atlanta, GA 30341 USA. EM mpratt@cdc.gov NR 11 TC 1 Z9 1 U1 0 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD APR PY 2015 VL 12 AR 140570 DI 10.5888/pcd12.140570 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CL0YS UT WOS:000356669600004 ER PT J AU Skarbinski, J Rosenberg, E Paz-Bailey, G Hall, HI Rose, CE Viall, AH Fagan, JL Lansky, A Mermin, JH AF Skarbinski, Jacek Rosenberg, Eli Paz-Bailey, Gabriela Hall, H. Irene Rose, Charles E. Viall, Abigail H. Fagan, Jennifer L. Lansky, Amy Mermin, Jonathan H. TI Human Immunodeficiency Virus Transmission at Each Step of the Care Continuum in the United States SO JAMA INTERNAL MEDICINE LA English DT Article ID RECEIVING MEDICAL-CARE; HIV-INFECTION; PERSONS AWARE; PREVENTION; RECOMMENDATIONS; UNAWARE; INTERVENTION; SURVEILLANCE; ASSOCIATION; GUIDELINES AB IMPORTANCE Human immunodeficiency virus (HIV) transmission risk is primarily dependent on behavior (sexual and injection drug use) and HIV viral load. National goals emphasize maximizing coverage along the HIV care continuum, but the effect on HIV prevention is unknown. OBJECTIVES To estimate the rate and number of HIV transmissions attributable to persons at each of the following 5 HIV care continuum steps: HIV infected but undiagnosed, HIV diagnosed but not retained in medical care, retained in care but not prescribed antiretroviral therapy, prescribed antiretroviral therapy but not virally suppressed, and virally suppressed. DESIGN, SETTING, AND PARTICIPANTS A multistep, static, deterministic model that combined population denominator data from the National HIV Surveillance System with detailed clinical and behavioral data from the National HIV Behavioral Surveillance System and the Medical Monitoring Project to estimate the rate and number of transmissions along the care continuum. This analysis was conducted January 2013 to June 2014. The findings reflect the HIV-infected population in the United States in 2009. MAIN OUTCOMES AND MEASURES Estimated rate and number of HIV transmissions. RESULTS Of the estimated 1 148 200 persons living with HIV in 2009, there were 207 600 (18.1%) who were undiagnosed, 519 414 (45.2%) were aware of their infection but not retained in care, 47 453 (4.1%) were retained in care but not prescribed ART, 82 809 (7.2%) were prescribed ART but not virally suppressed, and 290 924 (25.3%) were virally suppressed. Persons who are HIV infected but undiagnosed (18.1% of the total HIV-infected population) and persons who are HIV diagnosed but not retained in medical care (45.2% of the population) were responsible for 91.5%(30.2% and 61.3%, respectively) of the estimated 45 000 HIV transmissions in 2009. Compared with persons who are HIV infected but undiagnosed (6.6 transmissions per 100 person-years), persons who were HIV diagnosed and not retained in medical care were 19.0%(5.3 transmissions per 100 person-years) less likely to transmit HIV, and persons who were virally suppressed were 94.0%(0.4 transmissions per 100 person-years) less likely to transmit HIV. Men, those who acquired HIV via male-to-male sexual contact, and persons 35 to 44 years old were responsible for the most HIV transmissions by sex, HIV acquisition risk category, and age group, respectively. CONCLUSIONS AND RELEVANCE Sequential steps along the HIV care continuum were associated with reduced HIV transmission rates. Improvements in HIV diagnosis and retention in care, as well as reductions in sexual and drug use risk behavior, primarily for persons undiagnosed and not receiving antiretroviral therapy, would have a substantial effect on HIV transmission in the United States. C1 [Skarbinski, Jacek; Paz-Bailey, Gabriela; Hall, H. Irene; Rose, Charles E.; Viall, Abigail H.; Fagan, Jennifer L.; Lansky, Amy] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Rosenberg, Eli] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30322 USA. [Mermin, Jonathan H.] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. RP Skarbinski, J (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, 1600 Clifton Rd NE,Mail Stop E-46, Atlanta, GA 30333 USA. EM jskarbinski@cdc.gov FU Centers for Disease Control and Prevention FX The Centers for Disease Control and Prevention provides funds to all states and the District of Columbia to conduct the human immunodeficiency virus surveillance used in this study and to selected areas to conduct the Medical Monitoring Project and the National HIV Behavioral Surveillance System. NR 32 TC 84 Z9 84 U1 1 U2 8 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD APR PY 2015 VL 175 IS 4 BP 588 EP 596 DI 10.1001/jamainternmed.2014.8180 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA CK4FJ UT WOS:000356177100024 PM 25706928 ER PT J AU McDonald, LC AF McDonald, L. Clifford TI Uncovering the Role of Antibiotics in the Transmission of Multidrug-Resistant Organisms SO JAMA INTERNAL MEDICINE LA English DT Editorial Material ID CLOSTRIDIUM-DIFFICILE INFECTION C1 Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30329 USA. RP McDonald, LC (reprint author), Ctr Dis Control & Prevent, Div Healthcare Qual Promot, 1600 Clifton Rd,Mail Stop A35, Atlanta, GA 30329 USA. EM Cmcdonald1@cdc.gov FU Intramural CDC HHS [CC999999] NR 7 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD APR PY 2015 VL 175 IS 4 BP 633 EP 634 DI 10.1001/jamainternmed.2014.8279 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA CK4FJ UT WOS:000356177100033 PM 25706887 ER PT J AU B'Hymer, C Connor, T Stinson, D Pretty, J AF B'Hymer, Clayton Connor, Thomas Stinson, Derek Pretty, Jack TI Validation of an HPLC-MS/MS and Wipe Procedure for Mitomycin C Contamination SO JOURNAL OF CHROMATOGRAPHIC SCIENCE LA English DT Article ID INTRAOPERATIVE INTRAPERITONEAL CHEMOTHERAPY; OPERATING-ROOM; SAFETY; PORFIROMYCIN; STABILITY; AGENTS AB A high-performance liquid chromatography-tandem mass spectrometric (HPLC-MS/MS) method was developed for the determination of mitomycin C, an anticancer drug, from contamination on various surfaces. Mitomycin C is often used in various forms of intraperitoneal chemotherapy, and operating room healthcare worker exposure to this drug is possible. The surface testing method consisted of a wiping procedure utilizing a solution of 20/45/35 (v/v/v) of acetonitrile-isopropanol-water made 0.01 M in ammonium citrate (apparent pH 7.0). The wipe solutions were analyzed by means of HPLC-MS/MS using a reversed-phase gradient system and electrospray ionization in positive ion mode with a triple-quadrupole MS detector. Accuracy and precision of this method were demonstrated by a series of recovery studies of both spiked solutions and extracted wipes from various surfaces (stainless steel, vinyl and Formica (R)) spiked with known levels of mitomycin C. Recoveries of spiked solutions containing the analyte demonstrate mean recoveries (accuracy) ranged from 93 to 105%. Precision as measured by the relative standard deviation (% RSD) of multiple samples (n = 10) at each concentration level demonstrated values of 7.5% or less. The recoveries from spiked surfaces varied from 30 to 99%. The limit of detection for this methodology is similar to 2 ng/100 cm(2) equivalent surface area, and the limit of quantitation is similar to 6 ng/100 cm(2). C1 [B'Hymer, Clayton; Connor, Thomas; Stinson, Derek; Pretty, Jack] NIOSH, US Dept HHS, Ctr Dis Control, Div Appl Res & Technol,Taft Lab C 23, Cincinnati, OH 45226 USA. RP B'Hymer, C (reprint author), NIOSH, US Dept HHS, Ctr Dis Control, Div Appl Res & Technol,Taft Lab C 23, 4676 Columbia Pkwy, Cincinnati, OH 45226 USA. EM cbhymer@cdc.gov FU Intramural CDC HHS [CC999999] NR 24 TC 1 Z9 1 U1 1 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0021-9665 EI 1945-239X J9 J CHROMATOGR SCI JI J. Chromatogr. Sci. PD APR PY 2015 VL 53 IS 4 BP 619 EP 624 DI 10.1093/chromsci/bmu095 PG 6 WC Biochemical Research Methods; Chemistry, Analytical SC Biochemistry & Molecular Biology; Chemistry GA CK9XT UT WOS:000356593600025 PM 25129062 ER PT J AU El Bcheraoui, C Zhang, XJ Welty, LJ Abram, KM Teplin, LA Sutton, MY AF El Bcheraoui, Charbel Zhang, Xinjian Welty, Leah J. Abram, Karen M. Teplin, Linda A. Sutton, Madeline Y. TI HIV Knowledge Among a Longitudinal Cohort of Juvenile Detainees in an Urban Setting SO JOURNAL OF CORRECTIONAL HEALTH CARE LA English DT Article DE HIV; AIDS; knowledge; detainees; youth ID SEXUALLY-TRANSMITTED-DISEASES; US CORRECTIONAL FACILITIES; RISK BEHAVIORS; PSYCHIATRIC-DISORDERS; PUBLIC-HEALTH; AIDS KNOWLEDGE; ADOLESCENTS; INMATES; DETENTION; REINCARCERATION AB The authors investigated HIV knowledge change among a cohort of juvenile detainees. Participants completed an HIV knowledge survey at baseline and up to 4 more times over 6 years. The authors calculated knowledge scores; the time serial trend of scores was modeled using generalized estimating equations. A baseline survey was completed by 798 participants, ages 14 to 18 years; mean HIV knowledge scores ranged from 11.4 to 14.1 (maximum score = 18). Males had significantly lower HIV knowledge scores than females at baseline only. Over time, Hispanic participants had significantly lower scores than non-Hispanic Black and non-Hispanic White participants. Overall, HIV knowledge increased but was still suboptimal 5 years after baseline. These findings suggest the need to develop and strengthen HIV prevention education programs in youth detention settings. C1 [El Bcheraoui, Charbel] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Div Appl Sci, Sci Educ & Profess Dev Program,Off Surveillance E, Atlanta, GA USA. [El Bcheraoui, Charbel; Zhang, Xinjian; Sutton, Madeline Y.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. [El Bcheraoui, Charbel] Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98195 USA. [Welty, Leah J.; Abram, Karen M.; Teplin, Linda A.] Northwestern Univ, Feinberg Sch Med, Dept Psychiat & Behav Sci, Chicago, IL 60611 USA. [Welty, Leah J.] Northwestern Univ, Dept Prevent Med, Feinberg Sch Med, Chicago, IL 60611 USA. RP Sutton, MY (reprint author), CDC, DHAP, NCHHSTP, 1600 Clifton Rd NE,MS E-45, Atlanta, GA 30333 USA. EM msutton@cdc.gov FU NIMH; NIDA; NIAAA; OJJDP; CDC; CMHS; CSAP; CSAT; NIH Office of Rare Diseases; NIH Office of Minority Health and Health Disparities; NIH Office on Women's Health; Department of Labor; Robert Wood Johnson Foundation; William T. Grant Foundation FX The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This project is funded by NIMH, NIDA, NIAAA, OJJDP, CDC, CMHS, CSAP, CSAT, NIH Office of Rare Diseases, NIH Office of Minority Health and Health Disparities, NIH Office on Women's Health, Department of Labor, Robert Wood Johnson Foundation, and William T. Grant Foundation. NR 59 TC 0 Z9 0 U1 1 U2 4 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1078-3458 EI 1940-5200 J9 J CORRECT HEALTH CAR JI J. Correct. Health Care PD APR PY 2015 VL 21 IS 2 BP 112 EP 124 DI 10.1177/1078345815572596 PG 13 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CK7QT UT WOS:000356427900003 PM 25788607 ER PT J AU Edens, C Wong, J Lyman, M Nguyen, D Blain, M Rizzo, K Ayscue, P Arduino, M Moulton-Meissner, H Epson, E Rosenberg, J Patel, P AF Edens, Chris Wong, Jacklyn Lyman, Meghan Nguyen, Duc Blain, Michela Rizzo, Kyle Ayscue, Patrick Arduino, Matthew Moulton-Meissner, Heather Epson, Erin Rosenberg, Jon Patel, Priti TI GRAM-NEGATIVE BACTEREMIA OUTBREAK AND DIALYZER REUSE - CALIFORNIA, 2013-2014 SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Meeting Abstract CT Spring Clinical Meeting of National-Kidney-Foundation CY MAR 25-29, 2015 CL Grapevine, TX SP Natl Kidney Fdn C1 [Edens, Chris; Wong, Jacklyn; Lyman, Meghan; Nguyen, Duc; Blain, Michela; Arduino, Matthew; Moulton-Meissner, Heather; Patel, Priti] Ctr Dis Control & Prevent CDC, Atlanta, GA USA. [Wong, Jacklyn; Rizzo, Kyle; Ayscue, Patrick; Epson, Erin; Rosenberg, Jon] Calif Dept Publ Hlth, Richmond, CA USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 EI 1523-6838 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD APR PY 2015 VL 65 IS 4 MA 72 BP A32 EP A32 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA CJ9BE UT WOS:000355796500075 ER PT J AU Hung, J Bragg-Gresham, J Han, SW Yi, JH Yun, HJ Saydah, S Banerjee, T Powe, N Saran, R AF Hung, J. Bragg-Gresham, J. Han, S. W. Yi, J. H. Yun, H. J. Saydah, S. Banerjee, T. Powe, N. Saran, R. TI ASSOCIATION OF BLOOD CADMIUM AND LEAD WITH PREVALENCE OF CHRONIC KIDNEY DISEASE (CKD) IN THE KOREA AND US NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEYS (NHANES) SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Meeting Abstract CT Spring Clinical Meeting of National-Kidney-Foundation CY MAR 25-29, 2015 CL Grapevine, TX SP Natl Kidney Fdn C1 [Hung, J.; Bragg-Gresham, J.; Saran, R.] Univ Michigan, Ann Arbor, MI 48109 USA. [Han, S. W.; Yi, J. H.; Yun, H. J.] Hanyang Univ, Seoul 133791, South Korea. [Saydah, S.] CDC, Atlanta, GA 30333 USA. [Banerjee, T.; Powe, N.] UCSF, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 4 U2 5 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 EI 1523-6838 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD APR PY 2015 VL 65 IS 4 MA 116 BP A43 EP A43 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA CJ9BE UT WOS:000355796500119 ER PT J AU Zhu, Y Banerjee, T Burrows, NR Herman, WH Saran, R Powe, NR AF Zhu, Y. Banerjee, T. Burrows, N. R. Herman, W. H. Saran, R. Powe, N. R. TI TRENDS IN DIABETES PREVALENCE, AWARENESS, TREATMENT AND CONTROL IN OLDER ADULT GENERAL AND CKD POPULATIONS OF THE UNITED STATES, 1999-2012 SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Meeting Abstract CT Spring Clinical Meeting of National-Kidney-Foundation CY MAR 25-29, 2015 CL Grapevine, TX SP Natl Kidney Fdn C1 [Zhu, Y.; Banerjee, T.; Powe, N. R.] UCSF, San Francisco, CA USA. [Herman, W. H.; Saran, R.] UM, Ann Arbor, MI USA. [Burrows, N. R.] CDC, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 EI 1523-6838 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD APR PY 2015 VL 65 IS 4 MA 312 BP A92 EP A92 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA CJ9BE UT WOS:000355796500315 ER PT J AU Tamura, D Okomo-Adhiambo, M Mishin, VP Guo, Z Xu, XY Villanueva, J Fry, AM Stevens, J Gubareva, LV AF Tamura, Daisuke Okomo-Adhiambo, Margaret Mishin, Vasiliy P. Guo, Zhu Xu, Xiyan Villanueva, Julie Fry, Alicia M. Stevens, James Gubareva, Larisa V. TI Application of a Seven-Target Pyrosequencing Assay To Improve the Detection of Neuraminidase Inhibitor-Resistant Influenza A(H3N2) Viruses SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID DRUG SUSCEPTIBILITY ASSESSMENT; A/H3N2 VIRUS; IMMUNOCOMPROMISED CHILD; OSELTAMIVIR-RESISTANT; A VIRUSES; MUTATION; EMERGENCE; VARIANTS; PATIENT AB National U.S. influenza antiviral surveillance incorporates data generated by neuraminidase (NA) inhibition (NI) testing of isolates supplemented with NA sequence analysis and pyrosequencing analysis of clinical specimens. A lack of established correlates for clinically relevant resistance to NA inhibitors (NAIs) hinders interpretation of NI assay data. Nonetheless, A(H3N2) viruses are commonly monitored for moderately or highly reduced inhibition in the NI assay and/or for the presence of NA markers E119V, R292K, and N294S. In 2012 to 2013, three drug-resistant A(H3N2) viruses were detected by NI assay among isolates (n = 1,424); all showed highly reduced inhibition by oseltamivir and had E119V. In addition, one R292K variant was detected among clinical samples (n = 1,024) by a 3-target pyrosequencing assay. Overall, the frequency of NAI resistance was low (0.16% [ 4 of 2,448]). To screen for additional NA markers previously identified in viruses from NAI-treated patients, the pyrosequencing assay was modified to include Q136K, I222V, and deletions encompassing residues 245 to 248 (del245-248) and residues 247 to 250 (del247-250). The 7-target pyrosequencing assay detected NA variants carrying E119V, Q136, and del245-248 in an isolate from an oseltamivir-treated patient. Next, this assay was applied to clinical specimens collected from hospitalized patients and submitted for NI testing but failed cell culture propagation. Of the 27 clinical specimens tested, 4 (15%) contained NA changes: R292K (n = 2), E119V (n = 1), and del247-250 (n = 1). Recombinant NAs with del247-250 or del245-248 conferred highly reduced inhibition by oseltamivir, reduced inhibition by zanamivir, and normal inhibition by peramivir and laninamivir. Our results demonstrated the benefits of the 7-target pyrosequencing assay in conducting A(H3N2) antiviral surveillance and testing for clinical care. C1 [Tamura, Daisuke; Okomo-Adhiambo, Margaret; Mishin, Vasiliy P.; Guo, Zhu; Xu, Xiyan; Villanueva, Julie; Fry, Alicia M.; Stevens, James; Gubareva, Larisa V.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Influenza Div, Atlanta, GA 30333 USA. [Tamura, Daisuke] Oak Ridge Inst Sci & Educ, Oak Ridge, TN USA. RP Gubareva, LV (reprint author), Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Influenza Div, Atlanta, GA 30333 USA. EM lqg3@cdc.gov FU ge Institute for Science and Education (ORISE) Ridge, TN; Centers for Disease Control and Prevention FX D.T. received financial support for this work from the ge Institute for Science and Education (ORISE) Ridge, TN.; This work was supported by the Centers for Disease Control and Prevention. NR 29 TC 3 Z9 3 U1 0 U2 3 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 EI 1098-6596 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD APR PY 2015 VL 59 IS 4 BP 2374 EP 2379 DI 10.1128/AAC.04939-14 PG 6 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA CI8BY UT WOS:000354993700065 PM 25645846 ER PT J AU Pettus, K Sharpe, S Papp, JR AF Pettus, Kevin Sharpe, Samera Papp, John R. TI In Vitro Assessment of Dual Drug Combinations To Inhibit Growth of Neisseria gonorrhoeae SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID CEPHALOSPORINS; SYNERGY AB The development of resistance to first-line antimicrobial therapies has led to recommendations for combination therapies for the treatment of gonorrhea infection. Recent studies have shown the success of combination therapies in treating patients, but few have reported on the in vitro activities of these drug combinations. An in vitro assessment of azithromycin in combination with gentamicin demonstrated inhibition of growth and suggests that clinical trials may be warranted to assess the utility of this combination in treating gonorrhea infections. C1 [Pettus, Kevin; Sharpe, Samera; Papp, John R.] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. RP Papp, JR (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. EM jwp6@cdc.gov NR 8 TC 3 Z9 4 U1 1 U2 4 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 EI 1098-6596 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD APR PY 2015 VL 59 IS 4 BP 2443 EP 2445 DI 10.1128/AAC.04127-14 PG 3 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA CI8BY UT WOS:000354993700077 PM 25624328 ER PT J AU Robbins, HA Pfeiffer, RM Shiels, MS Li, JM Hall, HI Engels, EA AF Robbins, Hilary A. Pfeiffer, Ruth M. Shiels, Meredith S. Li, Jianmin Hall, H. Irene Engels, Eric A. TI Excess Cancers Among HIV-Infected People in the United States SO JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; ANTIRETROVIRAL THERAPY; LUNG-CANCER; EUROPEAN COUNTRIES; PROSPECTIVE COHORT; ANAL CANCER; AIDS; RISK; BURDEN; LESIONS AB Background: Nearly 900 000 people in the United States are living with diagnosed human immunodeficiency virus (HIV) infection and therefore increased cancer risk. The total number of cancers occurring among HIV-infected people and the excess number above expected background cases are unknown. Methods: We derived cancer incidence rates for the United States HIV-infected and general populations from Poisson models applied to linked HIV and cancer registry data and from Surveillance, Epidemiology, and End Results program data, respectively. We applied these rates to estimates of people living with diagnosed HIV at mid-year 2010 to estimate total and expected cancer counts, respectively. We subtracted expected from total cancers to estimate excess cancers. Results: An estimated 7760 (95% confidence interval [CI] = 7330 to 8320) cancers occurred in 2010 among HIV-infected people, of which 3920 cancers (95% CI = 3480 to 4470) or 50% (95% CI = 48 to 54%) were in excess of expected. The most common excess cancers were non-Hodgkin's lymphoma (NHL; n = 1440 excess cancers, occurring in 88% excess), Kaposi's sarcoma (KS, n = 910, 100% excess), anal cancer (n = 740, 97% excess), and lung cancer (n = 440, 52% excess). The proportion of excess cancers that were AIDS defining (ie, KS, NHL, cervical cancer) declined with age and time since AIDS diagnosis (both P < .001). For anal cancer, 83% of excess cases occurred among men who have sex with men, and 71% among those living five or more years since AIDS onset. Among injection drug users, 22% of excess cancers were lung cancer, and 16% were liver cancer. Conclusions: The excess cancer burden in the US HIV population is substantial, and patterns across groups highlight opportunities for cancer control initiatives targeted to HIV-infected people. C1 [Robbins, Hilary A.; Pfeiffer, Ruth M.; Shiels, Meredith S.; Engels, Eric A.] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA. [Li, Jianmin; Hall, H. Irene] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. RP Robbins, HA (reprint author), 9609 Med Ctr Dr,6-E228, Bethesda, MD 20892 USA. EM hilary.robbins@jhmi.edu FU Intramural Research Program of the National Cancer Institute at the National Institutes of Health; Surveillance, Epidemiology, and End Results Program of the National Cancer Institute: Connecticut [HHSN261201000024C]; Surveillance, Epidemiology, and End Results Program of the National Cancer Institute: New Jersey [HHSN261201300021I, N01-PC-2013-00021]; National Program of Cancer Registries of the Centers for Disease Control and Prevention: Colorado [U58 DP000848-04]; National Program of Cancer Registries of the Centers for Disease Control and Prevention: Georgia [5U58DP003875-01]; National Program of Cancer Registries of the Centers for Disease Control and Prevention: Michigan [5U58DP000812-03]; National Program of Cancer Registries of the Centers for Disease Control and Prevention: New Jersey [5U58/DP003931-02]; National Program of Cancer Registries of the Centers for Disease Control and Prevention: Texas [5U58DP000824-04]; state of New Jersey FX This research was supported by the Intramural Research Program of the National Cancer Institute at the National Institutes of Health. The following cancer registries were supported by the Surveillance, Epidemiology, and End Results Program of the National Cancer Institute: Connecticut (HHSN261201000024C) and New Jersey (HHSN261201300021I, N01-PC-2013-00021). The following cancer registries were supported by the National Program of Cancer Registries of the Centers for Disease Control and Prevention: Colorado (U58 DP000848-04), Georgia (5U58DP003875-01), Michigan (5U58DP000812-03), New Jersey (5U58/DP003931-02), and Texas (5U58DP000824-04). The New Jersey Cancer Registry was also supported by the state of New Jersey. NR 40 TC 25 Z9 25 U1 0 U2 4 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0027-8874 EI 1460-2105 J9 JNCI-J NATL CANCER I JI JNCI-J. Natl. Cancer Inst. PD APR PY 2015 VL 107 IS 4 AR dju503 DI 10.1093/jnci/dju503 PG 8 WC Oncology SC Oncology GA CI9IB UT WOS:000355082500001 ER PT J AU Schully, SD Carrick, DM Mechanic, LE Srivastava, S Anderson, GL Baron, JA Berg, CD Cullen, J Diamandis, EP Doria-Rose, VP Goddard, KAB Hankinson, SE Kushi, LH Larson, EB McShane, LM Schilsky, RL Shak, S Skates, SJ Urban, N Kramer, BS Khoury, MJ Ransohoff, DF AF Schully, Sheri D. Carrick, Danielle M. Mechanic, Leah E. Srivastava, Sudhir Anderson, Garnet L. Baron, John A. Berg, Christine D. Cullen, Jennifer Diamandis, Eleftherios P. Doria-Rose, V. Paul Goddard, Katrina A. B. Hankinson, Susan E. Kushi, Lawrence H. Larson, Eric B. McShane, Lisa M. Schilsky, Richard L. Shak, Steven Skates, Steven J. Urban, Nicole Kramer, Barnett S. Khoury, Muin J. Ransohoff, David F. TI Leveraging Biospecimen Resources for Discovery or Validation of Markers for Early Cancer Detection SO JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE LA English DT Editorial Material ID OVARIAN-CANCER; ALGORITHM ROCA; BIOMARKER; RISK; SPECIMENS; ACCURACY; OPINION; DESIGN; MODELS; LUNG AB Validation of early detection cancer biomarkers has proven to be disappointing when initial promising claims have often not been reproducible in diagnostic samples or did not extend to prediagnostic samples. The previously reported lack of rigorous internal validity (systematic differences between compared groups) and external validity (lack of generalizability beyond compared groups) may be effectively addressed by utilizing blood specimens and data collected within well-conducted cohort studies. Cohort studies with prediagnostic specimens (eg, blood specimens collected prior to development of clinical symptoms) and clinical data have recently been used to assess the validity of some early detection biomarkers. With this background, the Division of Cancer Control and Population Sciences (DCCPS) and the Division of Cancer Prevention (DCP) of the National Cancer Institute (NCI) held a joint workshop in August 2013. The goal was to advance early detection cancer research by considering how the infrastructure of cohort studies that already exist or are being developed might be leveraged to include appropriate blood specimens, including prediagnostic specimens, ideally collected at periodic intervals, along with clinical data about symptom status and cancer diagnosis. Three overarching recommendations emerged from the discussions: 1) facilitate sharing of existing specimens and data, 2) encourage collaboration among scientists developing biomarkers and those conducting observational cohort studies or managing healthcare systems with cohorts followed over time, and 3) conduct pilot projects that identify and address key logistic and feasibility issues regarding how appropriate specimens and clinical data might be collected at reasonable effort and cost within existing or future cohorts. C1 [Schully, Sheri D.; Carrick, Danielle M.; Mechanic, Leah E.; Doria-Rose, V. Paul; Khoury, Muin J.] NCI, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA. [Srivastava, Sudhir; Kramer, Barnett S.] NCI, Canc Prevent Div, Bethesda, MD 20892 USA. [McShane, Lisa M.] NCI, Div Canc Treatment & Diag, Bethesda, MD 20892 USA. [Anderson, Garnet L.; Urban, Nicole] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98104 USA. [Baron, John A.; Ransohoff, David F.] Univ N Carolina, Dept Med, Chapel Hill, NC USA. [Berg, Christine D.] Johns Hopkins Med, Dept Radiat Oncol, Baltimore, MD USA. [Cullen, Jennifer] Ctr Prostate Dis Res, Dept Def, Rockville, MD USA. [Diamandis, Eleftherios P.] Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada. [Goddard, Katrina A. B.] Kaiser Permanente, Ctr Hlth Res, Portland, OR USA. [Hankinson, Susan E.] Univ Massachusetts, Div Biostat & Epidemiol, Amherst, MA 01003 USA. [Kushi, Lawrence H.] Kaiser Permanente, Div Res, Oakland, CA USA. [Larson, Eric B.] Grp Hlth Res Inst, Seattle, WA USA. [Schilsky, Richard L.] Amer Soc Clin Oncol, Alexandria, VA USA. [Shak, Steven] Genom Hlth Inc, Redwood City, CA USA. [Skates, Steven J.] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA. [Khoury, Muin J.] Ctr Dis Control & Prevent, Off Publ Hlth Gen, Atlanta, GA USA. RP Schully, SD (reprint author), 9609 Med Ctr Dr 4E106, Rockville, MD 20850 USA. EM schullys@mail.nih.gov OI Doria-Rose, Vincent/0000-0002-8802-5143 NR 31 TC 7 Z9 7 U1 1 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0027-8874 EI 1460-2105 J9 JNCI-J NATL CANCER I JI JNCI-J. Natl. Cancer Inst. PD APR PY 2015 VL 107 IS 4 AR djv012 DI 10.1093/jnci/djv012 PG 7 WC Oncology SC Oncology GA CI9IB UT WOS:000355082500014 ER PT J AU Barbour, KE Hootman, JM Helmick, CG Murphy, LB Renner, JB Jordan, JM AF Barbour, K. E. Hootman, J. M. Helmick, C. G. Murphy, L. B. Renner, J. B. Jordan, J. M. TI BONE MINERAL DENSITY AND THE RISK OF KNEE OSTEOARTHRITIS: THE JOHNSTON COUNTY OSTEOARTHRITIS PROJECT SO OSTEOARTHRITIS AND CARTILAGE LA English DT Meeting Abstract CT World Congress of the Osteoarthritis-Research-Society-International (OARSI) on Osteoarthritis CY APR 30-MAY 03, 2015 CL Seattle, WA SP Osteoarthritis Res Soc Int C1 [Barbour, K. E.; Hootman, J. M.; Helmick, C. G.; Murphy, L. B.] CDC, Atlanta, GA 30333 USA. [Renner, J. B.; Jordan, J. M.] Univ N Carolina, Dept Radiol, Chapel Hill, NC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1063-4584 EI 1522-9653 J9 OSTEOARTHR CARTILAGE JI Osteoarthritis Cartilage PD APR PY 2015 VL 23 SU 2 MA 265 BP A173 EP A173 PG 1 WC Orthopedics; Rheumatology SC Orthopedics; Rheumatology GA CI8VC UT WOS:000355048800295 ER PT J AU Rhee, SY Blanco, JL Jordan, MR Taylor, J Lemey, P Varghese, V Hamers, RL Bertagnolio, S de Wit, TR Aghokeng, AF Albert, J Avi, R Avila-Rios, S Bessong, PO Brooks, JI Boucher, CAB Brumme, ZL Busch, MP Bussmann, H Chaix, ML Chin, BS D'Aquin, TT De Gascun, CF Derache, A Descamps, D Deshpande, AK Djoko, CF Eshleman, SH Fleury, H Frange, P Fujisaki, S Harrigan, PR Hattori, J Holguin, A Hunt, GM Ichimura, H Kaleebu, P Katzenstein, D Kiertiburanakul, S Kim, JH Kim, SS Li, YP Lutsar, I Morris, L Ndembi, N Peng, NGK Paranjape, RS Peeters, M Poljak, M Price, MA Ragonnet-Cronin, ML Reyes-Teran, G Rolland, M Sirivichayakul, S Smith, DM Soares, MA Soriano, VV Ssemwanga, D Stanojevic, M Stefani, MA Sugiura, W Sungkanuparph, S Tanuri, A Tee, KK Truong, HHM van de Vijver, DAMC Vidal, N Yang, CF Yang, RG Yebra, G Ioannidis, JPA Vandamme, AM Shafer, RW AF Rhee, Soo-Yon Blanco, Jose Luis Jordan, Michael R. Taylor, Jonathan Lemey, Philippe Varghese, Vici Hamers, Raph L. Bertagnolio, Silvia de Wit, TobiasF. Rinke Aghokeng, Avelin F. Albert, Jan Avi, Radko Avila-Rios, Santiago Bessong, Pascal O. Brooks, James I. Boucher, Charles A. B. Brumme, Zabrina L. Busch, Michael P. Bussmann, Hermann Chaix, Marie-Laure Chin, Bum Sik D'Aquin, Toni T. De Gascun, Cillian F. Derache, Anne Descamps, Diane Deshpande, Alaka K. Djoko, Cyrille F. Eshleman, Susan H. Fleury, Herve Frange, Pierre Fujisaki, Seiichiro Harrigan, P. Richard Hattori, Junko Holguin, Africa Hunt, Gillian M. Ichimura, Hiroshi Kaleebu, Pontiano Katzenstein, David Kiertiburanakul, Sasisopin Kim, Jerome H. Kim, Sung Soon Li, Yanpeng Lutsar, Irja Morris, Lynn Ndembi, Nicaise Peng, Kee N. G. Paranjape, Ramesh S. Peeters, Martine Poljak, Mario Price, Matt A. Ragonnet-Cronin, Manon L. Reyes-Teran, Gustavo Rolland, Morgane Sirivichayakul, Sunee Smith, Davey M. Soares, Marcelo A. Soriano, Vincent V. Ssemwanga, Deogratius Stanojevic, Maja Stefani, Mariane A. Sugiura, Wataru Sungkanuparph, Somnuek Tanuri, Amilcar Tee, Kok Keng Truong, Hong-Ha M. van de Vijver, David A. M. C. Vidal, Nicole Yang, Chunfu Yang, Rongge Yebra, Gonzalo Ioannidis, John P. A. Vandamme, Anne-Mieke Shafer, Robert W. TI Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis SO PLOS MEDICINE LA English DT Article ID RESOURCE-LIMITED SETTINGS; OLIGONUCLEOTIDE LIGATION ASSAY; TREATMENT-NAIVE INDIVIDUALS; SUB-SAHARAN AFRICA; REVERSE-TRANSCRIPTASE; VIROLOGICAL FAILURE; ANTIRETROVIRAL TREATMENT; TREATMENT PROGRAMS; META-REGRESSION; SOUTH-AFRICA AB Background Regional and subtype-specific mutational patterns of HIV-1 transmitted drug resistance (TDR) are essential for informing first-line antiretroviral (ARV) therapy guidelines and designing diagnostic assays for use in regions where standard genotypic resistance testing is not affordable. We sought to understand the molecular epidemiology of TDR and to identify the HIV-1 drug-resistance mutations responsible for TDR in different regions and virus subtypes. Methods and Findings We reviewed all GenBank submissions of HIV-1 reverse transcriptase sequences with or without protease and identified 287 studies published between March 1, 2000, and December 31, 2013, with more than 25 recently or chronically infected ARV-naive individuals. These studies comprised 50,870 individuals from 111 countries. Each set of study sequences was analyzed for phylogenetic clustering and the presence of 93 surveillance drug-resistance mutations (SDRMs). The median overall TDR prevalence in sub-Saharan Africa (SSA), south/southeast Asia (SSEA), upper-income Asian countries, Latin America/Caribbean, Europe, and North America was 2.8%, 2.9%, 5.6%, 7.6%, 9.4%, and 11.5%, respectively. In SSA, there was a yearly 1.09-fold (95% CI: 1.05-1.14) increase in odds of TDR since national ARV scale-up attributable to an increase in non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance. The odds of NNRTI-associated TDR also increased in Latin America/Caribbean (odds ratio [OR] = 1.16; 95% CI: 1.06-1.25), North America (OR = 1.19; 95% CI: 1.12-1.26), Europe (OR = 1.07; 95% CI: 1.01-1.13), and upper-income Asian countries (OR = 1.33; 95% CI: 1.12-1.55). In SSEA, there was no significant change in the odds of TDR since national ARV scale-up (OR = 0.97; 95% CI: 0.92-1.02). An analysis limited to sequences with mixtures at less than 0.5% of their nucleotide positions-a proxy for recent infection-yielded trends comparable to those obtained using the complete dataset. Four NNRTI SDRMs-K101E, K103N, Y181C, and G190A-accounted for > 80% of NNRTI-associated TDR in all regions and subtypes. Sixteen nucleoside reverse transcriptase inhibitor (NRTI) SDRMs accounted for > 69% of NRTI-associated TDR in all regions and subtypes. In SSA and SSEA, 89% of NNRTI SDRMs were associated with high-level resistance to nevirapine or efavirenz, whereas only 27% of NRTI SDRMs were associated with high-level resistance to zidovudine, lamivudine, tenofovir, or abacavir. Of 763 viruses with TDR in SSA and SSEA, 725 (95%) were genetically dissimilar; 38 (5%) formed 19 sequence pairs. Inherent limitations of this study are that some cohorts may not represent the broader regional population and that studies were heterogeneous with respect to duration of infection prior to sampling. Conclusions Most TDR strains in SSA and SSEA arose independently, suggesting that ARV regimens with a high genetic barrier to resistance combined with improved patient adherence may mitigate TDR increases by reducing the generation of new ARV-resistant strains. A small number of NNRTI-resistance mutations were responsible for most cases of high-level resistance, suggesting that inexpensive point-mutation assays to detect these mutations may be useful for pre-therapy screening in regions with high levels of TDR. In the context of a public health approach to ARV therapy, a reliable point-of-care genotypic resistance test could identify which patients should receive standard first-line therapy and which should receive a protease-inhibitor-containing regimen. C1 [Rhee, Soo-Yon; Varghese, Vici; Katzenstein, David; Shafer, Robert W.] Stanford Univ, Dept Med, Stanford, CA 94305 USA. [Blanco, Jose Luis] Univ Barcelona, Hosp Clin Univ, Inst Invest Biomed August Pi & Sunyer, Barcelona, Spain. [Jordan, Michael R.] Tufts Univ, Sch Med, Boston, MA 02111 USA. [Taylor, Jonathan] Stanford Univ, Dept Stat, Stanford, CA 94305 USA. [Lemey, Philippe; Vandamme, Anne-Mieke] Univ Leuven, KU Leuven, Dept Microbiol & Immunol, Rega Inst Med Res Clin & Epidemiol Virol, Leuven, Belgium. [Hamers, Raph L.; de Wit, TobiasF. Rinke] Univ Amsterdam, Acad Med Ctr, Dept Global Hlth & Internal Med, NL-1105 AZ Amsterdam, Netherlands. [Hamers, Raph L.; de Wit, TobiasF. Rinke] Amsterdam Inst Global Hlth & Dev, Amsterdam, Netherlands. [Bertagnolio, Silvia] WHO, CH-1211 Geneva, Switzerland. [Aghokeng, Avelin F.] Virol Lab CREMER IMPM, Yaounde, Cameroon. [Albert, Jan] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Stockholm, Sweden. [Albert, Jan] Karolinska Univ Hosp, Dept Clin Microbiol, Stockholm, Sweden. [Avi, Radko; Lutsar, Irja] Univ Tartu, Dept Microbiol, EE-50090 Tartu, Estonia. [Avila-Rios, Santiago; Reyes-Teran, Gustavo] Ctr Res Infect Dis, Natl Inst Resp Dis, Mexico City, DF, Mexico. [Bessong, Pascal O.] Univ Venda, Dept Microbiol, HIV AIDS & Global Hlth Res Programme, Thohoyandou, South Africa. [Brooks, James I.] Publ Hlth Agcy Canada, Natl HIV & Retrovirol Labs, Ottawa, ON, Canada. [Boucher, Charles A. B.; van de Vijver, David A. M. C.] Erasmus Univ, Erasmus Med Ctr, Dept Virosci, Rotterdam, Netherlands. [Brumme, Zabrina L.; Harrigan, P. Richard] British Columbia Ctr Excellence HIV AIDS, Vancouver, BC, Canada. [Brumme, Zabrina L.] Simon Fraser Univ, Fac Hlth Sci, Burnaby, BC V5A 1S6, Canada. [Busch, Michael P.] Blood Syst Res Inst, San Francisco, CA USA. [Bussmann, Hermann] Botswana Harvard AIDS Inst Partnership, Gaborone, Botswana. [Chaix, Marie-Laure] Univ Paris Diderot, Hop St Louis, Lab Virol, INSERM,U941, Paris, France. [Chin, Bum Sik] Natl Med Ctr, Ctr Infect Dis, Seoul, South Korea. [D'Aquin, Toni T.] CIRBA Programme PACCI, Abidjan, Cote Ivoire. [De Gascun, Cillian F.] Univ Coll Dublin, UCD Natl Virus Reference Lab, Dublin 2, Ireland. [Derache, Anne] Hop La Pitie Salpetriere, Dept Virol, Paris, France. [Descamps, Diane] Univ Paris Diderot, Hop Bichat Claude Bernard, AP HP, INSERM,UMR 1137,Lab Virol, Paris, France. [Deshpande, Alaka K.] Grant Med Coll, Dept Med, Mumbai, Maharashtra, India. [Deshpande, Alaka K.] Sir Jamshedjee Jeejeebhoy Grp Hosp, Mumbai, Maharashtra, India. [Djoko, Cyrille F.] EMAT CRESAR, Intendance Round About, Global Viral Cameroon, Yaounde, Cameroon. [Eshleman, Susan H.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA. [Fleury, Herve] Univ Bordeaux, Ctr Hosp Univ Bordeaux, CNRS, Lab Virol,UMR 5234, Bordeaux, France. [Frange, Pierre] Hop Necker Enfants Malad, Dept Microbiol, Paris, France. [Fujisaki, Seiichiro] Natl Inst Infect Dis, Influenza Virus Res Ctr, Tokyo, Japan. [Hattori, Junko; Sugiura, Wataru] Nagoya Med Ctr, Natl Hosp Org, Nagoya, Aichi, Japan. [Holguin, Africa; Yebra, Gonzalo] Hosp Univ Ramon y Cajal, Inst Ramon y Cajal Invest Sanitaria, Dept Microbiol, Madrid, Spain. [Hunt, Gillian M.; Morris, Lynn] Natl Inst Communicable Dis, Ctr HIV & STIs, Johannesburg, South Africa. [Ichimura, Hiroshi] Kanazawa Univ, Dept Viral Infect & Int Hlth, Grad Sch Med Sci, Kanazawa, Ishikawa, Japan. [Kaleebu, Pontiano; Ssemwanga, Deogratius] MRC UVRI Uganda Res Unit AIDS, Entebbe, Uganda. [Kiertiburanakul, Sasisopin; Sungkanuparph, Somnuek] Mahidol Univ, Ramathibodi Hosp, Fac Med, Bangkok 10400, Thailand. [Kim, Jerome H.; Rolland, Morgane] Walter Reed Army Inst Res, US Mil HIV Res Program, Silver Spring, MD USA. [Kim, Sung Soon] Korea Natl Inst Hlth, Div Aids, Osong, Chungcheongbuk, South Korea. [Li, Yanpeng; Yang, Rongge] Chinese Acad Sci, Wuhan Inst Virol, State Key Lab Virol, Wuhan, Peoples R China. [Ndembi, Nicaise] Inst Human Virol, Abuja, Nigeria. [Peng, Kee N. G.; Tee, Kok Keng] Univ Malaya, Fac Med, Dept Med, Kuala Lumpur, Malaysia. [Paranjape, Ramesh S.] Indian Council Med Res, Natl AIDS Res Inst, Pune, Maharashtra, India. [Peeters, Martine] INSERM, U1175, UMR 233, Inst Rech Dev, F-34394 Montpellier, France. [Peeters, Martine] Univ Montpellier, F-34394 Montpellier, France. [Peeters, Martine] Computat Biol Inst, Montpellier, France. [Poljak, Mario] Univ Ljubljana, Fac Med, Inst Microbiol, Ljubljana, Slovenia. [Price, Matt A.] Int AIDS Vaccine Initiat, Dept Med Affairs, New York, NY USA. [Price, Matt A.] Univ Calif San Francisco, Sch Med, Dept Epidemiol & Biostat, San Francisco, CA USA. [Ragonnet-Cronin, Manon L.] Univ Edinburgh, Edinburgh, Midlothian, Scotland. [Sirivichayakul, Sunee] Chulalongkorn Univ, Fac Med, Bangkok 10330, Thailand. [Smith, Davey M.] Univ Calif San Diego, La Jolla, CA 92093 USA. [Soares, Marcelo A.; Tanuri, Amilcar] Univ Fed Rio de Janeiro, Rio De Janeiro, Brazil. [Soriano, Vincent V.] Hosp Carlos III, Dept Infect Dis, Madrid, Spain. [Stanojevic, Maja] Univ Belgrade, Inst Microbiol & Immunol, Fac Med, Belgrade, Serbia. [Stefani, Mariane A.] Univ Fed Goias, Goiania, Go, Brazil. [Truong, Hong-Ha M.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Vidal, Nicole] Univ Montpellier I, Inst Rech Dev, Montpellier, France. [Yang, Chunfu] Ctr Dis Control & Prevent, Int Lab Branch, Div Global HIV AIDS, Ctr Global Hlth, Atlanta, GA USA. [Ioannidis, John P. A.] Stanford Univ, Dept Med, Stanford Prevent Res Ctr, Stanford, CA 94305 USA. [Ioannidis, John P. A.] Stanford Univ, Meta Res Innovat Ctr Stanford, Stanford, CA 94305 USA. [Vandamme, Anne-Mieke] Univ Nova Lisboa, Global Hlth & Trop Med, Unidade Microbiol, Inst Higiene Med & Trop, P-1200 Lisbon, Portugal. RP Rhee, SY (reprint author), Stanford Univ, Dept Med, Stanford, CA 94305 USA. EM syrhee@stanford.edu RI lutsar, irja/H-3177-2015; Tee, Kok Keng/A-8148-2008; Vandamme, Anne Mieke/I-4127-2012; OI Tee, Kok Keng/0000-0002-7923-5448; Vandamme, Anne Mieke/0000-0002-6594-2766; , Lynn/0000-0003-3961-7828; Yebra, Gonzalo/0000-0002-3472-3667 FU NIH [R01 AI068581]; Bill & Melinda Gates Foundation grant; CFAR [1P30A142853] FX SYR, VV, and RWS were supported in part from NIH grant R01 AI068581. SYR and RWS were supported in part from an Bill & Melinda Gates Foundation grant. MRJ is supported by CFAR grant 1P30A142853. No funding bodies had any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 49 TC 49 Z9 51 U1 6 U2 22 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1549-1676 J9 PLOS MED JI PLos Med. PD APR PY 2015 VL 12 IS 4 AR e1001810 DI 10.1371/journal.pmed.1001810 PG 29 WC Medicine, General & Internal SC General & Internal Medicine GA CI5UQ UT WOS:000354825700001 PM 25849352 ER PT J AU Ellis, EM Neatherlin, JC Delorey, M Ochieng, M Mohamed, AH Mogeni, DO Hunsperger, E Patta, S Gikunju, S Waiboic, L Fields, B Ofula, V Konongoi, SL Torres-Velasquez, B Marano, N Sang, R Margolis, HS Montgomery, JM Tomashek, KM AF Ellis, Esther M. Neatherlin, John C. Delorey, Mark Ochieng, Melvin Mohamed, Abdinoor Haji Mogeni, Daniel Ondari Hunsperger, Elizabeth Patta, Shem Gikunju, Stella Waiboic, Lilian Fields, Barry Ofula, Victor Konongoi, Samson Limbaso Torres-Velasquez, Brenda Marano, Nina Sang, Rosemary Margolis, Harold S. Montgomery, Joel M. Tomashek, Kay M. TI A Household Serosurvey to Estimate the Magnitude of a Dengue Outbreak in Mombasa, Kenya, 2013 SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID LINKED-IMMUNOSORBENT-ASSAY; ARBOVIRAL INFECTIONS; VIRUS-INFECTION; AEDES-AEGYPTI; CLINICAL-MANIFESTATIONS; HEMORRHAGIC-FEVER; WEST-AFRICA; MALARIA; DIAGNOSIS; OVIPOSITION AB Dengue appears to be endemic in Africa with a number of reported outbreaks. In February 2013, several individuals with dengue-like illnesses and negative malaria blood smears were identified in Mombasa, Kenya. Dengue was laboratory confirmed and an investigation was conducted to estimate the magnitude of local transmission including a serologic survey to determine incident dengue virus (DENV) infections. Consenting household members provided serum and were questioned regarding exposures and medical history. RTPCR was used to identify current DENV infections and IgM anti-DENV ELISA to identify recent infections. Of 1,500 participants from 701 households, 210 (13%) had evidence of current or recent DENV infection. Among those infected, 93 (44%) reported fever in the past month. Most (68, 73%) febrile infected participants were seen by a clinician and all but one of 32 participants who reportedly received a diagnosis were clinically diagnosed as having malaria. Having open windows at night (OR = 2.3; CI: 1.1-4.8), not using daily mosquito repellent (OR = 1.6; CI: 1.0-2.8), and recent travel outside of Kenya (OR = 2.5; CI: 1.1-5.4) were associated with increased risk of DENV infection. This survey provided a robust measure of incident DENV infections in a setting where cases were often unrecognized and misdiagnosed. C1 [Ellis, Esther M.; Hunsperger, Elizabeth; Torres-Velasquez, Brenda; Margolis, Harold S.; Tomashek, Kay M.] Ctr Dis Control & Prevent, Dengue Branch, Div Vector Borne Dis, San Juan, PR USA. [Neatherlin, John C.; Ochieng, Melvin; Waiboic, Lilian; Fields, Barry; Marano, Nina; Montgomery, Joel M.] Ctr Dis Control & Prevent, Div Global Hlth Protect, Ctr Global Hlth, Nairobi, Kenya. [Delorey, Mark; Gikunju, Stella] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO USA. [Mohamed, Abdinoor Haji; Mogeni, Daniel Ondari] Kenya Govt Med Res Ctr, Ctr Global Hlth Res, Nairobi, Kenya. [Patta, Shem] Minist Hlth, Mombasa, Kenya. [Ofula, Victor; Konongoi, Samson Limbaso; Sang, Rosemary] Kenya Govt Med Res Ctr, Ctr Virus Res, Nairobi, Kenya. RP Ellis, EM (reprint author), US Virgin Isl Dept Hlth, St Croix, VI 00820 USA. EM hsm1@cdc.gov FU Centers for Disease Control and Prevention FX This investigation was funded by Centers for Disease Control and Prevention. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 39 TC 8 Z9 8 U1 1 U2 5 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD APR PY 2015 VL 9 IS 4 AR e0003733 DI 10.1371/journal.pntd.0003733 PG 10 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA CI7VF UT WOS:000354972200067 PM 25923210 ER PT J AU Hampson, K Coudeville, L Lembo, T Sambo, M Kieffer, A Attlan, M Barrat, J Blanton, JD Briggs, DJ Cleaveland, S Costa, P Freuling, CM Hiby, E Knopf, L Leanes, F Meslin, FX Metlin, A Miranda, ME Muller, T Nel, LH Recuenco, S Rupprecht, CE Schumacher, C Taylor, L Vigilato, MAN Zinsstag, J Dushoff, J AF Hampson, Katie Coudeville, Laurent Lembo, Tiziana Sambo, Maganga Kieffer, Alexia Attlan, Michael Barrat, Jacques Blanton, Jesse D. Briggs, Deborah J. Cleaveland, Sarah Costa, Peter Freuling, Conrad M. Hiby, Elly Knopf, Lea Leanes, Fernando Meslin, Francois-Xavier Metlin, Artem Miranda, Mary Elizabeth Mueller, Thomas Nel, Louis H. Recuenco, Sergio Rupprecht, Charles E. Schumacher, Carolin Taylor, Louise Natal Vigilato, Marco Antonio Zinsstag, Jakob Dushoff, Jonathan CA Global Alliance Rabies Control Par TI Estimating the Global Burden of Endemic Canine Rabies SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID POSTEXPOSURE PROPHYLAXIS; COST-EFFECTIVENESS; DOMESTIC-ANIMALS; PUBLIC-HEALTH; LATIN-AMERICA; DOG RABIES; AFRICA; VACCINATION; TANZANIA; EPIDEMIOLOGY AB Background Rabies is a notoriously underreported and neglected disease of low-income countries. This study aims to estimate the public health and economic burden of rabies circulating in domestic dog populations, globally and on a country-by-country basis, allowing an objective assessment of how much this preventable disease costs endemic countries. Methodology/Principal Findings We established relationships between rabies mortality and rabies prevention and control measures, which we incorporated into a model framework. We used data derived from extensive literature searches and questionnaires on disease incidence, control interventions and preventative measures within this framework to estimate the disease burden. The burden of rabies impacts on public health sector budgets, local communities and livestock economies, with the highest risk of rabies in the poorest regions of the world. This study estimates that globally canine rabies causes approximately 59,000 (95% Confidence Intervals: 25-159,000) human deaths, over 3.7 million (95% CIs: 1.6-10.4 million) disability-adjusted life years (DALYs) and 8.6 billion USD (95% CIs: 2.9-21.5 billion) economic losses annually. The largest component of the economic burden is due to premature death (55%), followed by direct costs of post-exposure prophylaxis (PEP, 20%) and lost income whilst seeking PEP (15.5%), with only limited costs to the veterinary sector due to dog vaccination (1.5%), and additional costs to communities from livestock losses (6%). Conclusions/Significance This study demonstrates that investment in dog vaccination, the single most effective way of reducing the disease burden, has been inadequate and that the availability and affordability of PEP needs improving. Collaborative investments by medical and veterinary sectors could dramatically reduce the current large, and unnecessary, burden of rabies on affected communities. Improved surveillance is needed to reduce uncertainty in burden estimates and to monitor the impacts of control efforts. C1 [Hampson, Katie; Lembo, Tiziana; Cleaveland, Sarah] Univ Glasgow, Boyd Orr Ctr Populat & Ecosyst Hlth, Inst Biodivers Anim Hlth & Comparat Med, Glasgow, Lanark, Scotland. [Coudeville, Laurent; Kieffer, Alexia; Attlan, Michael] Sanofi Pasteur, Lyon, France. [Sambo, Maganga] Ifakara Hlth Inst, Ifakara, Tanzania. [Barrat, Jacques] ANSES French Agcy Food Environm & Occupat Hlth &, Rabies & Wildlife Lab Nancy, Atton, France. [Blanton, Jesse D.; Recuenco, Sergio] Ctr Dis Control & Prevent, Atlanta, GA USA. [Briggs, Deborah J.; Costa, Peter; Knopf, Lea; Miranda, Mary Elizabeth; Rupprecht, Charles E.; Taylor, Louise] Global Alliance Rabies Control, Manhattan, KS USA. [Freuling, Conrad M.; Mueller, Thomas] Fed Res Inst Anim Hlth, Friedrich Loeffler Inst, Greifswald, Germany. [Hiby, Elly] Int Compan Anim Management Coalit, Cambridge, England. [Leanes, Fernando; Natal Vigilato, Marco Antonio] Pan Amer Hlth Org, Rio De Janeiro, Brazil. [Metlin, Artem] Inst Pasteur Cambodia, Phnom Penh, Cambodia. [Nel, Louis H.] Univ Pretoria, ZA-0002 Pretoria, South Africa. [Rupprecht, Charles E.] Ross Univ, Sch Vet Med, Basseterre, St Kitts, W Ind Assoc St. [Schumacher, Carolin] Merial, Lyon, France. [Zinsstag, Jakob] Swiss Trop & Publ Hlth Inst, Basel, Switzerland. [Dushoff, Jonathan] McMaster Univ, Hamilton, ON, Canada. RP Hampson, K (reprint author), Univ Glasgow, Boyd Orr Ctr Populat & Ecosyst Hlth, Inst Biodivers Anim Hlth & Comparat Med, Glasgow, Lanark, Scotland. EM katie.hampson@glasgow.ac.uk RI Zinsstag, Jakob/A-8317-2008; OI Zinsstag, Jakob/0000-0002-8899-6097; Cleaveland, Sarah/0000-0002-0456-0959; Hampson, Katie/0000-0001-5392-6884; Recuenco-Cabrera, Sergio/0000-0002-8446-7411; Taylor, Louise/0000-0001-8141-2346 FU UBS Optimus Foundation; Wellcome Trust [095787/Z/11/Z] FX This study was funded by the UBS Optimus Foundation (http://www.ubs.com/optimus-foundation) and the Wellcome Trust (095787/Z/11/Z). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 50 TC 86 Z9 90 U1 6 U2 26 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD APR PY 2015 VL 9 IS 4 AR e0003709 DI 10.1371/journal.pntd.0003709 PG 20 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA CI7VF UT WOS:000354972200052 PM 25881058 ER PT J AU Rascoe, LN Price, C Shin, SH McAuliffe, I Priest, JW Handali, S AF Rascoe, Lisa N. Price, Courtney Shin, Sun Hee McAuliffe, Isabel Priest, Jeffrey W. Handali, Sukwan TI Development of Ss-NIE-1 Recombinant Antigen Based Assays for Immunodiagnosis of Strongyloidiasis SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID CRYPTOSPORIDIUM-PARVUM ANTIGENS; IMMUNOGLOBULIN-G ANTIBODIES; LINKED-IMMUNOSORBENT-ASSAY; STERCORALIS INFECTION; LYMPHATIC FILARIASIS; ENZYME-IMMUNOASSAY; TAENIA-SOLIUM; DIAGNOSIS; EFFICACY; HUMANS AB Strongyloides stercoralis is a widely distributed parasite that infects 30 to 100 million people worldwide. In the United States strongyloidiasis is recognized as an important infection in immigrants and refugees. Public health and commercial reference laboratories need a simple and reliable method for diagnosis of strongyloidiasis to identify and treat cases and to prevent transmission. The recognized laboratory test of choice for diagnosis of strongyloidiasis is detection of disease specific antibodies, most commonly using a crude parasite extract for detection of IgG antibodies. Recently, a luciferase tagged recombinant protein of S. stercoralis, Ss-NIE-1, has been used in a luciferase immunoprecipitation system (LIPS) to detect IgG and IgG(4) specific antibodies. To promote wider adoption of immunoassays for strongyloidiasis, we used the Ss-NIE-1 recombinant antigen without the luciferase tag and developed ELISA and fluorescent bead (Luminex) assays to detect S. stercoralis specific IgG(4). We evaluated the assays using well-characterized sera from persons with or without presumed strongyloidiasis. The sensitivity and specificity of Ss-NIE-1 IgG(4) ELISA were 95% and 93%, respectively. For the IgG(4) Luminex assay, the sensitivity and specificity were 93% and 95%, respectively. Specific IgG(4) antibody decreased after treatment in a manner that was similar to the decrease of specific IgG measured in the crude IgG ELISA. The sensitivities of the Ss-NIE-1 IgG(4) ELISA and Luminex assays were comparable to the crude IgG ELISA but with improved specificities. However, the Ss-NIE-1 based assays are not dependent on native parasite materials and can be performed using widely available laboratory equipment. In conclusion, these newly developed Ss-NIE-1 based immunoassays can be readily adopted by public health and commercial reference laboratories for routine screening and clinical diagnosis of S. stercoralis infection in refugees and immigrants in the United States. C1 [Rascoe, Lisa N.; Price, Courtney; McAuliffe, Isabel; Handali, Sukwan] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA 30329 USA. [Shin, Sun Hee] Emory Univ, Emory Coll, Atlanta, GA 30322 USA. [Priest, Jeffrey W.] Ctr Dis Controls & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA USA. RP Rascoe, LN (reprint author), Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA 30329 USA. EM ahi0@cdc.gov NR 30 TC 3 Z9 3 U1 1 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD APR PY 2015 VL 9 IS 4 AR e0003694 DI 10.1371/journal.pntd.0003694 PG 10 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA CI7VF UT WOS:000354972200044 PM 25860665 ER PT J AU Talundzic, E Okoth, SA Congpuong, K Plucinski, MM Morton, L Goldman, IF Kachur, PS Wongsrichanalai, C Satimai, W Barnwell, JW Udhayakumar, V AF Talundzic, Eldin Okoth, Sheila Akinyi Congpuong, Kanungnit Plucinski, Mateusz M. Morton, Lindsay Goldman, Ira F. Kachur, Patrick S. Wongsrichanalai, Chansuda Satimai, Wichai Barnwell, John W. Udhayakumar, Venkatachalam TI Selection and Spread of Artemisinin-Resistant Alleles in Thailand Prior to the Global Artemisinin Resistance Containment Campaign SO PLOS PATHOGENS LA English DT Article ID PLASMODIUM-FALCIPARUM MALARIA; ARTESUNATE-MEFLOQUINE; GENETIC DIVERSITY; WESTERN CAMBODIA; CLEARANCE; PROVINCES; PROJECT; ORIGINS; SWEEPS; BORDER AB The recent emergence of artemisinin resistance in the Greater Mekong Subregion poses a major threat to the global effort to control malaria. Tracking the spread and evolution of artemisinin-resistant parasites is critical in aiding efforts to contain the spread of resistance. A total of 417 patient samples from the year 2007, collected during malaria surveillance studies across ten provinces in Thailand, were genotyped for the candidate Plasmodium falciparum molecular marker of artemisinin resistance K13. Parasite genotypes were examined for K13 propeller mutations associated with artemisinin resistance, signatures of positive selection, and for evidence of whether artemisinin-resistant alleles arose independently across Thailand. A total of seven K13 mutant alleles were found (N458Y, R539T, E556D, P574L, R575K, C580Y, S621F). Notably, the R575K and S621F mutations have previously not been reported in Thailand. The most prevalent artemisinin resistance-associated K13 mutation, C580Y, carried two distinct haplotype profiles that were separated based on geography, along the Thai-Cambodia and Thai-Myanmar borders. It appears these two haplotypes may have independent evolutionary origins. In summary, parasites with K13 propeller mutations associated with artemisinin resistance were widely present along the Thai-Cambodia and Thai-Myanmar borders prior to the implementation of the artemisinin resistance containment project in the region. C1 [Talundzic, Eldin; Plucinski, Mateusz M.; Morton, Lindsay; Goldman, Ira F.; Kachur, Patrick S.; Barnwell, John W.; Udhayakumar, Venkatachalam] Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30329 USA. [Talundzic, Eldin; Okoth, Sheila Akinyi] Atlanta VA Med Ctr, Atlanta Res & Educ Fdn, Atlanta, GA USA. [Congpuong, Kanungnit; Satimai, Wichai] Minist Publ Hlth, Bur Vector Borne Dis, Nonthaburi, Thailand. [Congpuong, Kanungnit] Bansomdej Chaopraya Rajabhat Univ, Bangkok, Thailand. RP Talundzic, E (reprint author), Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, 4770 Buford Highway,Mail Stop F-12, Atlanta, GA 30329 USA. EM etalundzic@cdc.gov FU American Society for Microbiology (ASM); Centers for Disease Control and Prevention Postdoctoral Fellowship; Atlanta Research and Education Foundation, Atlanta, GA; CDC Antimicrobial Resistance Working Group FX Funding: ET is supported by an American Society for Microbiology (ASM) and Centers for Disease Control and Prevention Postdoctoral Fellowship. We acknowledge support from the Atlanta Research and Education Foundation, Atlanta, GA, and the CDC Antimicrobial Resistance Working Group. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 34 TC 24 Z9 27 U1 2 U2 10 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1553-7366 EI 1553-7374 J9 PLOS PATHOG JI PLoS Pathog. PD APR PY 2015 VL 11 IS 4 AR e1004789 DI 10.1371/journal.ppat.1004789 PG 14 WC Microbiology; Parasitology; Virology SC Microbiology; Parasitology; Virology GA CI7XE UT WOS:000354978000019 PM 25836766 ER PT J AU Olney, RS Ailes, EC Sontag, MK AF Olney, Richard S. Ailes, Elizabeth C. Sontag, Marci K. TI Detection of critical congenital heart defects: Review of contributions from prenatal and newborn screening SO SEMINARS IN PERINATOLOGY LA English DT Review DE Neonatal screening; Prenatal diagnosis; Heart defects; Congenital; Population surveillance; Public health ID PULSE OXIMETRY; UNITED-STATES; SURVEILLANCE PROGRAMS; SCIENTIFIC STATEMENT; DISEASE; INFANTS; ASSOCIATION; DIAGNOSIS; CHILDREN; MORTALITY C1 [Olney, Richard S.; Ailes, Elizabeth C.] Ctr Dis Control & Prevent CDC, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Sontag, Marci K.] Univ Colorado Denver, Colorado Sch Publ Hlth, Dept Epidemiol, Aurora, CO USA. RP Olney, RS (reprint author), Ctr Dis Control & Prevent CDC, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd,Mailstop E86, Atlanta, GA 30333 USA. EM rsolney@aap.net FU Intramural CDC HHS [CC999999] NR 47 TC 3 Z9 3 U1 1 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0146-0005 EI 1558-075X J9 SEMIN PERINATOL JI Semin. Perinatol. PD APR PY 2015 VL 39 IS 3 BP 230 EP 237 DI 10.1053/j.semperi.2015.03.007 PG 8 WC Obstetrics & Gynecology; Pediatrics SC Obstetrics & Gynecology; Pediatrics GA CI9AQ UT WOS:000355063200007 PM 25979782 ER PT J AU Ford, ES AF Ford, Earl S. TI Hospital Discharges, Readmissions, and ED Visits for COPD or Bronchiectasis Among US Adults Findings From the Nationwide Inpatient Sample 2001-2012 and Nationwide Emergency Department Sample 2006-2011 SO CHEST LA English DT Article ID OBSTRUCTIVE PULMONARY-DISEASE; UNITED-STATES; RISK-FACTORS; MORTALITY; TRENDS; PREDICTORS; INCREASES; VALIDITY; PROGRAM; RECORDS AB BACKGROUND: Numbers and rates of hospitalizations and ED visits by patients with COPD are important metrics for surveillance purposes. The objective of this study was to examine trends in these rates from 2001 to 2012 among adults aged >= 18 years in the United States. METHODS: Data from the Nationwide Inpatient Sample (NIS) and Nationwide Emergency Department Sample (NEDS) were examined for temporal trends in the numbers and rates of hospitalizations by patients with COPD or bronchiectasis, mean length of stay, in-hospital case-fatality rate, 30-day readmission rate, and numbers and rates of ED visits. RESULTS: The national number of discharges with COPD or bronchiectasis as the principal diagnosis was about 88,000 higher in 2012 than in 2001, but the age-adjusted rate of discharges did not change significantly (range, 242.7-286.0 per 100,000 population, P trend - .554). In contrast, hospitalization rates for common cardiovascular disorders, pneumonia, and lung cancer decreased significantly by 27% to 68%, whereas the mean charge doubled and mean cost increased by 40%. From 2006 to 2011, the numbers of ED visits increased from 1,480,363 to 1,787,612. The age-adjusted rate increased nonsignificantly from 654 to 725 per 100,000 population (P trend = .072). CONCLUSIONS: Despite many local and national efforts to reduce the burden of COPD, total hospitalizations and ED visits over the past decade have increased for COPD, and the ageadjusted rates of hospitalizations and ED visits for COPD or bronchiectasis have not changed significantly in the United States. C1 [Ford, Earl S.] Ctr Dis Control & Prevent, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP Ford, ES (reprint author), Ctr Dis Control & Prevent, 4770 Buford Hwy,MS F78, Atlanta, GA 30341 USA. EM eford@cdc.gov FU Intramural CDC HHS [CC999999] NR 24 TC 27 Z9 27 U1 1 U2 4 PU AMER COLL CHEST PHYSICIANS PI GLENVIEW PA 2595 PATRIOT BLVD, GLENVIEW, IL 60026 USA SN 0012-3692 J9 CHEST JI Chest PD APR PY 2015 VL 147 IS 4 BP 989 EP 998 DI 10.1378/chest.14-2146 PG 10 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA CI2VT UT WOS:000354606300028 PM 25375955 ER PT J AU Click, ES AF Click, Eleanor S. TI How Is TB Transmitted? SO CHEST LA English DT Letter C1 Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA 30329 USA. RP Click, ES (reprint author), Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA 30329 USA. EM eoc9@cdc.gov NR 5 TC 0 Z9 0 U1 1 U2 2 PU AMER COLL CHEST PHYSICIANS PI GLENVIEW PA 2595 PATRIOT BLVD, GLENVIEW, IL 60026 USA SN 0012-3692 J9 CHEST JI Chest PD APR PY 2015 VL 147 IS 4 BP E158 EP E158 DI 10.1378/chest.14-3111 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA CI2VT UT WOS:000354606300009 PM 25846543 ER PT J AU Petrosky, EY Hariri, S Markowitz, LE Panicker, G Unger, ER Dunne, EF AF Petrosky, Emiko Y. Hariri, Susan Markowitz, Lauri E. Panicker, Gitika Unger, Elizabeth R. Dunne, Eileen F. TI Is vaccine type seropositivity a marker for human papillomavirus vaccination? National Health and Nutrition Examination Survey, 2003-2010 SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE Human papillomavirus vaccine; National Health and Nutrition Examination; Survey; Seropositivity ID AGED 13-17 YEARS; UNITED-STATES; HPV VACCINE; COVERAGE; ADOLESCENTS; RESPONSES; ACCURACY; VALIDITY; IMMUNITY; MEASLES AB Objective: Since 2006, human papillomavirus (HPV) vaccination has been routinely recommended for adolescent females in the USA. The quadrivalent vaccine induces long-term seropositivity to HPV 6/11/16, which may be useful as a marker for HPV vaccine coverage. Methods: We evaluated vaccine type seropositivity (i.e., seropositivity to HPV 6/11/16 with or without HPV18) among females aged 14-59 years participating in the 2003-2010 National Health and Nutrition Examination Survey (cross-sectional, nationally representative surveys). We compared pre-vaccine era (2003-2006) to vaccine era (2007-2010) seropositivity and assessed agreement between vaccine era seropositivity and reported vaccination by kappa statistic. Results: Seropositivity was 1.0% among 2151 females in the pre-vaccine era and 22.1% among 1420 females in the vaccine era (p < 0.001); 23.1% of vaccine era females reported receipt of one or more HPV vaccine dose. Seropositivity and reported vaccination had high agreement (kappa = 0.79; 95% confidence interval 0.74-0.84). Among seropositive females, 14.5% reported no vaccination. Conclusion: The increase in vaccine era seropositivity likely reflects vaccination uptake. Our study suggests seropositivity to HPV 6/11/16 may be a useful marker for vaccination coverage in adolescent and young adult females. Discordance between seropositivity and reported vaccination may be explained by inaccurate reporting and/or natural exposure to HPV. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. C1 [Petrosky, Emiko Y.; Hariri, Susan; Markowitz, Lauri E.; Dunne, Eileen F.] Ctr Dis Control & Prevent, Div Sexually Transmitted Dis Prevent, Natl Ctr HIV AIDS Viral Hepatitis Sexually Transm, Atlanta, GA 30333 USA. [Panicker, Gitika; Unger, Elizabeth R.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. RP Petrosky, EY (reprint author), Ctr Dis Control & Prevent, Div Sexually Transmitted Dis Prevent, Natl Ctr HIV AIDS Viral Hepatitis Sexually Transm, 1600 Clifton Rd, Atlanta, GA 30333 USA. EM xfq7@cdc.gov FU Intramural CDC HHS [CC999999] NR 32 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1201-9712 EI 1878-3511 J9 INT J INFECT DIS JI Int. J. Infect. Dis. PD APR PY 2015 VL 33 BP 137 EP 141 DI 10.1016/j.ijid.2015.01.010 PG 5 WC Infectious Diseases SC Infectious Diseases GA CI0SQ UT WOS:000354448600033 PM 25596377 ER PT J AU Johnson, D Carter, MD Crow, BS Isenberg, SL Graham, LA Erol, HA Watson, CM Pantazides, BG van der Schans, MJ Langenberg, JP Noort, D Blake, TA Thomas, JD Johnson, RC AF Johnson, Darryl Carter, Melissa D. Crow, Brian S. Isenberg, Samantha L. Graham, Leigh Ann Erol, H. Akin Watson, Caroline M. Pantazides, Brooke G. van der Schans, Marcel J. Langenberg, Jan P. Noort, Daan Blake, Thomas A. Thomas, Jerry D. Johnson, Rudolph C. TI Quantitation of ortho-cresyl phosphate adducts to butyrylcholinesterase in human serum by immunomagnetic-UHPLC-MS/MS SO JOURNAL OF MASS SPECTROMETRY LA English DT Article DE tri-ortho-cresyl-phosphate; butyrylcholinesterase; cresyl saligenin phosphate; Jamaica ginger paralysis; organophosphate-induced delayed neuropathy ID ORGANOPHOSPHORUS NERVE AGENTS; AIRCRAFT CABIN AIR; AEROTOXIC SYNDROME; MASS-SPECTROMETRY; TRICRESYL PHOSPHATE; EXPOSURE; SAMPLES; OILS AB Tri-ortho-cresyl phosphate (ToCP) is an anti-wear, flame retardant additive used in industrial lubricants, hydraulic fluids and gasoline. cresyl saligenin phosphate or CBDP), which inhibits esterase enzymes including butyrylcholinesterase (BChE). Following BChE adduction, CBDP undergoes hydrolysis to form the aged adduct ortho-cresyl phosphoserine (oCP-BChE), thus providing a biomarker of CBDP exposure. Previous studies have identified ToCP in aircraft cabin and cockpit air, but assessing human exposure has been hampered by the lack of a laboratory assay to confirm exposure. This work presents the development of an wimmunomagnetic-UHPLC-MS/MS method for the quantitation of unadducted BChE and the long-term CBDP biomarker, oCP-BChE, in human serum. The method has a reportable range from 2.0 ng/ml to 150 ng/ml, which is consistent with the sensitivity of methods used to detect organophosphorus nerve agent protein adducts. The assay demonstrated high intraday and interday accuracy (>= 85%) and precision (RSD <= 15%) across the calibration range. The method was developed for future analyses of potential human exposure to CBDP. Analysis of human serum inhibited in vitro with CBDP demonstrated that the oCP-BChE adduct was stable for at least 72h at 4, 22 and 37 degrees C. Compared to a previously reported assay, this method requires 75% less sample volume, reduces analysis time by a factor of 20 and demonstrates a threefold improvement in sensitivity. Published 2015. This article is a U.S. Government work and is in the public domain in the USA. C1 [Johnson, Darryl; Isenberg, Samantha L.; Graham, Leigh Ann; Erol, H. Akin; Watson, Caroline M.] Ctr Dis Control & Prevent, Oak Ridge Inst Sci & Educ, Atlanta, GA 30341 USA. [Carter, Melissa D.; Crow, Brian S.; Pantazides, Brooke G.; Blake, Thomas A.; Thomas, Jerry D.; Johnson, Rudolph C.] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. [van der Schans, Marcel J.; Langenberg, Jan P.; Noort, Daan] CBRN Protect, Tech Sci, Netherlands Org Appl Sci Res TNO, Rijswijk, Netherlands. RP Carter, MD (reprint author), Ctr Dis Control & Prevent, Div Sci Lab, Atlanta, GA 30341 USA. EM vsm8@cdc.gov OI Blake, Thomas/0000-0001-8536-9998 FU Centers for Disease Control and Prevention; Defense Threat Reduction Agency; Oak Ridge Institute for Science and Education FX This work was supported by the Centers for Disease Control and Prevention, the Defense Threat Reduction Agency and the Oak Ridge Institute for Science and Education. The authors would like to thank Ms. Chariety Sapp of the CDC's Incident Response Laboratory (IRL) for dispensing convenience set serum samples prior to analysis. The authors would also like to express their gratitude for input from colleagues Professor Clement E. Furlong of The University of Washington and Professor Oksana Lockridge of The University of Nebraska Medical Center. NR 39 TC 3 Z9 3 U1 2 U2 22 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1076-5174 EI 1096-9888 J9 J MASS SPECTROM JI J. Mass Spectrom. PD APR PY 2015 VL 50 IS 4 BP 683 EP 692 DI 10.1002/jms.3576 PG 10 WC Biochemical Research Methods; Chemistry, Analytical; Spectroscopy SC Biochemistry & Molecular Biology; Chemistry; Spectroscopy GA CI3NR UT WOS:000354655000005 PM 26149113 ER PT J AU Kempe, A O'Leary, ST Kennedy, A Crane, LA Allison, MA Beaty, BL Hurley, LP Brtnikova, M Jimenez-Zambrano, A Stokley, S AF Kempe, Allison O'Leary, Sean T. Kennedy, Allison Crane, Lori A. Allison, Mandy A. Beaty, Brenda L. Hurley, Laura P. Brtnikova, Michaela Jimenez-Zambrano, Andrea Stokley, Shannon TI Physician Response to Parental Requests to Spread Out the Recommended Vaccine Schedule SO PEDIATRICS LA English DT Article ID DECISION-MAKING; CHILDHOOD IMMUNIZATIONS; PERTUSSIS INFECTION; YOUNG-CHILDREN; UNITED-STATES; SOCIAL NORMS; REFUSAL; ASSOCIATION; HESITANCY; TRUST AB OBJECTIVES: To assess among US physicians (1) frequency of requests to spread out recommended vaccination schedule for children <2 years, (2) attitudes regarding such requests, and (3) strategies used and perceived effectiveness in response to such requests. METHODS: An e-mail and mail survey of a nationally representative sample of pediatricians and family physicians from June 2012 through October 2012. RESULTS: The response rate was 66% (534 of 815). In a typical month, 93% reported some parents of children <2 years requested to spread out vaccines; 21% reported >= 10% of parents made this request. Most respondents thought these parents were putting their children at risk for disease (87%) and that it was more painful for children (84%), but if they agreed to requests, it would build trust with families (82%); further, they believed that if they did not agree, families might leave their practice (80%). Forty percent reported this issue had decreased their job satisfaction. Most agreed to spread out vaccines when requested, either often/always (37%) or sometimes (37%); 2% would often/always, 4% would sometimes, and 12% would rarely dismiss families from their practice if they wanted to spread out the primary series. Physicians reported using a variety of strategies in response to requests but did not think they were effective. CONCLUSIONS: Virtually all providers encounter requests to spread out vaccines in a typical month and, despite concerns, most are agreeing to do so. Providers are using many strategies in response but think few are effective. Evidence-based interventions to increase timely immunization are needed to guide primary care and public health practice. C1 [Kempe, Allison; O'Leary, Sean T.; Crane, Lori A.; Allison, Mandy A.; Beaty, Brenda L.; Hurley, Laura P.; Brtnikova, Michaela; Jimenez-Zambrano, Andrea] Childrens Hosp Colorado, Childrens Outcomes Res, Aurora, CO USA. [Kempe, Allison; O'Leary, Sean T.; Allison, Mandy A.] Univ Colorado, Dept Pediat, Aurora, CO 80045 USA. [Kennedy, Allison; Stokley, Shannon] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Crane, Lori A.] Colorado Sch Publ Hlth, Dept Community & Behav Hlth, Denver, CO USA. [Hurley, Laura P.] Denver Hlth, Div Gen Internal Med, Denver, CO USA. RP Kempe, A (reprint author), Univ Colorado, Dept Pediat, Mail Stop F443,13199 E Montview Blvd,Suite 300, Aurora, CO 80045 USA. EM allison.kempe@childrenscolorado.org FU Centers for Disease Control and Prevention [5U48DP001938] FX This investigation was funded by the Centers for Disease Control and Prevention and administered through the Rocky Mountain Prevention Research Center, University of Colorado Anschutz Medical Campus (grant 5U48DP001938). NR 55 TC 17 Z9 17 U1 5 U2 17 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD APR PY 2015 VL 135 IS 4 BP 666 EP 677 DI 10.1542/peds.2014-3474 PG 12 WC Pediatrics SC Pediatrics GA CH0QG UT WOS:000353726700055 PM 25733753 ER PT J AU Schechter, MS Liu, TB Soe, M Swanson, M Ward, E Thibadeau, J AF Schechter, Michael S. Liu, Tiebin Soe, Minn Swanson, Mark Ward, Elisabeth Thibadeau, Judy TI Sociodemographic Attributes and Spina Bifida Outcomes SO PEDIATRICS LA English DT Article ID NEURAL-TUBE DEFECTS; SOCIOECONOMIC-STATUS; SOCIAL CONDITIONS; PATIENT REGISTRY; HEALTH RESEARCH; CARE; ASSOCIATIONS; DISPARITIES AB BACKGROUND: A National Spina Bifida Patient Registry (NSBPR) was begun in 2009 to help understand the natural history of spina bifida (SB) and the effects of treatments provided by SB clinics. We used the NSBPR to explore the relationship of sociodemographic characteristics with SB outcomes. METHODS: Using NSBPR data collected in 2009 to 2012, we examined the unadjusted association between demographic characteristics and 4 SB outcomes: bowel continence, bladder continence, mobility, and presence of pressure sores. We then developed multivariable logistic models to explore these relationships while controlling for SB clinic, SB type, and level of lesion. RESULTS: Data were available on 2054 patients,22 years of age from 10 SB clinics. In the multivariable models, older age groups were more likely to have continence and pressure sores and less likely to be community ambulatory. Males and patients without private insurance were less likely to be continent and community ambulatory. Non-Hispanic blacks were less likely to be continent. Level of lesion was associated with all outcomes; SB type was associated with all but pressure sores; and all outcomes except community ambulation showed significant variation across clinic sites. CONCLUSIONS: Sociodemographic attributes are associated with SB outcomes. In particular, males, non-Hispanic blacks, and patients without private insurance have less favorable outcomes, and age has an impact as well. These characteristics need to be considered by clinicians who care for this patient population and factored into case-mix adjustment when evaluating variation in clinical and functional outcomes among different SB clinics. C1 [Schechter, Michael S.] Virginia Commonwealth Univ, Dept Pediat, Childrens Hosp Richmond, Richmond, VA USA. [Schechter, Michael S.; Liu, Tiebin; Soe, Minn; Swanson, Mark; Ward, Elisabeth; Thibadeau, Judy] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Div Human Dev & Disabil, Rare Disorders & Hlth Outcomes Team, Atlanta, GA USA. [Ward, Elisabeth] Carter Consulting Inc, Atlanta, GA USA. RP Schechter, MS (reprint author), 403 North 11th St,POB 980315, Richmond, VA 23298 USA. EM mschechter@vcu.edu FU National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention [1U01DDD000744.01] FX Funded by grant #1U01DDD000744.01, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention. NR 26 TC 2 Z9 2 U1 0 U2 2 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD APR PY 2015 VL 135 IS 4 BP E957 EP E964 DI 10.1542/peds.2014-2576 PG 8 WC Pediatrics SC Pediatrics GA CH0QG UT WOS:000353726700019 PM 25780069 ER PT J AU Gambhir, M Clark, TA Cauchemez, S Tartof, SY Swerdlow, L Ferguson, NM AF Gambhir, Manoj Clark, Thomas A. Cauchemez, Simon Tartof, Sara Y. Swerdlow, L. Ferguson, Neil M. TI A Change in Vaccine Efficacy and Duration of Protection Explains Recent Rises in Pertussis Incidence in the United States SO PLOS COMPUTATIONAL BIOLOGY LA English DT Article ID AGED 19-35 MONTHS; BORDETELLA-PERTUSSIS; COVERAGE; EPIDEMIOLOGY; RESURGENCE; CHILDREN; ADOLESCENTS; DIAGNOSIS; COMPLETENESS; PREVENTION AB Over the past ten years the incidence of pertussis in the United States (U.S.) has risen steadily, with 2012 seeing the highest case number since 1955. There has also been a shift over the same time period in the age group reporting the largest number of cases (aside from infants), from adolescents to 7-11 year olds. We use epidemiological modelling and a large case incidence dataset to explain the upsurge. We investigate several hypotheses for the upsurge in pertussis cases by fitting a suite of dynamic epidemiological models to incidence data from the National Notifiable Disease Surveillance System (NNDSS) between 1990-2009, as well as incidence data from a variety of sources from 1950-1989. We find that: 1) the best-fitting model is one in which vaccine efficacy and duration of protection of the acellular pertussis (aP) vaccine is lower than that of the whole-cell (wP) vaccine, (efficacy of the first three doses 80% [95% CI: 78%, 82%] versus 90% [95% CI: 87%, 94%]), 2) increasing the rate at which disease is reported to NNDSS is not sufficient to explain the upsurge and 3) 2010-2012 disease incidence is predicted well. In this study, we use all available U.S. surveillance data to: fit a set of mathematical models and determine which best explains these data and determine the epidemiological and vaccine-related parameter values of this model. We find evidence of a difference in efficacy and duration of protection between the two vaccine types, wP and aP (aP efficacy and duration lower than wP). Future refinement of the model presented here will allow for an exploration of alternative vaccination strategies such as different age-spacings, further booster doses, and cocooning. C1 [Gambhir, Manoj] Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia. [Gambhir, Manoj; Swerdlow, L.] Ctr Dis Control & Prevent CDC, Modeling Unit, Natl Ctr Immunizat & Resp Dis NCIRD, Atlanta, GA USA. [Gambhir, Manoj] IHRC Inc, Atlanta, GA USA. [Clark, Thomas A.] CDC, Meningitis & Vaccine Preventable Dis Branch, Div Bacterial Dis, NCIRD, Atlanta, GA 30333 USA. [Cauchemez, Simon; Ferguson, Neil M.] Univ London Imperial Coll Sci Technol & Med, MRC, Ctr Outbreak Anal & Modelling, London, England. [Cauchemez, Simon] Inst Pasteur, Math Modelling Infect Dis Unit, Paris, France. [Tartof, Sara Y.] Kaiser Permanente Res, Kaiser Permanente So Calif, Dept Res & Evaluat, Pasadena, CA USA. [Swerdlow, L.] CDC, Off Sci & Integrat Programs, NCIRD, Atlanta, GA 30333 USA. RP Gambhir, M (reprint author), Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia. EM manoj.gambhir@monash.edu RI Ferguson, Neil/B-8578-2008 OI Ferguson, Neil/0000-0002-1154-8093 FU UK Medical Research Council [MR/K010174/1]; UK National Institute of Health Research (Health Protection Research Unit funding) [HPRU-2012-10080]; U.S. National Insitutes of Health NIGMS MIDAS [1U01GM110721-01] FX This work was funded by: UK Medical Research Council (Centre funding), Grant Number MR/K010174/1, UK National Institute of Health Research (Health Protection Research Unit funding), Grant Number HPRU-2012-10080, U.S. National Insitutes of Health NIGMS MIDAS (Grant funding): Models for synthesising molecular, clinical and epidemiological data, and translation to public health response, Grant Number 1U01GM110721-01. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 49 TC 22 Z9 22 U1 0 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1553-734X EI 1553-7358 J9 PLOS COMPUT BIOL JI PLoS Comput. Biol. PD APR PY 2015 VL 11 IS 4 AR e1004138 DI 10.1371/journal.pcbi.1004138 PG 16 WC Biochemical Research Methods; Mathematical & Computational Biology SC Biochemistry & Molecular Biology; Mathematical & Computational Biology GA CI1PX UT WOS:000354517600018 PM 25906150 ER PT J AU Pitman, JP Bocking, A Wilkinson, R Postma, MJ Basavaraju, SV von Finckenstein, B Mataranyika, M Marfin, AA Lowrance, DW Sibinga, CTS AF Pitman, John P. Bocking, Adele Wilkinson, Robert Postma, Maarten J. Basavaraju, Sridhar V. von Finckenstein, Bjorn Mataranyika, Mary Marfin, Anthony A. Lowrance, David W. Sibinga, Cees Th. Smit TI The impact of external donor support through the US President's Emergency Plan for AIDS Relief on the cost of red cell concentrate in Namibia, 2004-2011 SO BLOOD TRANSFUSION LA English DT Article DE blood safety; Namibia; costing; PEPFAR ID SUB-SAHARAN AFRICA; BLOOD-TRANSFUSION; HEALTH; COUNTRIES; DONATIONS; PEPFAR AB Background. External assistance can rapidly strengthen health programmes in developing countries, but such funding can also create sustainability challenges. From 2004-2011, the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) provided more than $ 8 million to the Blood Transfusion Service of Namibia (NAMBTS) for supplies, equipment, and staff salaries. This analysis describes the impact that support had on actual production costs and the unit prices charged for red cell concentrate (RCC) units issued to public sector hospitals. Materials and methods. A costing system developed by NAMBTS to set public sector RCC unit prices was used to describe production costs and unit prices during the period of PEPFAR scale-up (2004-2009) and the 2 years in which PEPFAR support began to decline (2010-2011). Hypothetical production costs were estimated to illustrate differences had PEPFAR support not been available. Results. Between 2004-2006, NAMBTS sold 22,575 RCC units to public sector facilities. During this time, RCC unit prices exceeded per unit cost-recovery targets by between 40.3% (US$ 16.75 or N$ 109.86) and 168.3% (US$ 48.72 or N$ 333.28) per year. However, revenue surpluses dwindled between 2007 and 2011, the final year of the study period, when NAMBTS sold 20,382 RCC units to public facilities but lost US$23.31 (N$ 170.43) on each unit. Discussion. PEPFAR support allowed NAMBTS to leverage domestic cost-recovery revenue to rapidly increase blood collections and the distribution of RCC. However, external support kept production costs lower than they would have been without PEPFAR. If PEPFAR funds had not been available, RCC prices would have needed to increase by 20% per year to have met annual cost-recovery targets and funded the same level of investments as were made with PEPFAR support. Tracking the subsidising influence of external support can help blood services make strategic investments and plan for unit price increases as external funds are withdrawn. C1 [Pitman, John P.; Basavaraju, Sridhar V.; Marfin, Anthony A.] Ctr Dis Control & Prevent, Div Global HIV AIDS, Ctr Global Hlth, Atlanta, GA 30333 USA. [Bocking, Adele; Wilkinson, Robert; von Finckenstein, Bjorn] Blood Transfus Serv Namibia, Windhoek, Namibia. [Postma, Maarten J.] Univ Groningen, Dept Pharm, Unit PharmacoEpidemiol &PharmacoEcon PE2, Groningen, Netherlands. [Postma, Maarten J.] Univ Groningen, Univ Med Ctr Groningen, Inst Sci Hlth Aging & Hlth caRE SHARE, NL-9713 AV Groningen, Netherlands. [Mataranyika, Mary] Namibia Minist Hlth & Social Serv, Directorate Tertiary Hlth Care & Clin Support Ser, Windhoek, Namibia. [Lowrance, David W.] Ctr Dis Control & Prevent, Div Global HIV AIDS, Ctr Global Hlth, Windhoek, Namibia. [Sibinga, Cees Th. Smit] ID Consulting Int Dev Transfus Med, Groningen, Netherlands. RP Pitman, JP (reprint author), Ctr Dis Control & Prevent, HIV Prevent Branch, Div Global HIV AIDS, Ctr Global Hlth, 1600 Clifton Rd NE,MS E-04, Atlanta, GA 30333 USA. EM cgx5@cdc.gov OI Pitman, John/0000-0001-5983-7241 FU President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention FX This project was supported by the President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention. NR 27 TC 1 Z9 1 U1 0 U2 1 PU SIMITI SERVIZI SRL PI MILAN PA VIA DESIDERIO 21, MILAN, 20131, ITALY SN 1723-2007 J9 BLOOD TRANSFUS-ITALY JI Blood Transf. PD APR PY 2015 VL 13 IS 2 BP 240 EP 247 DI 10.2450/2014.0122-14 PG 8 WC Hematology SC Hematology GA CI2OG UT WOS:000354586300014 PM 25369616 ER PT J AU Wheaton, AG Ford, ES Cunningham, TJ Croft, JB AF Wheaton, Anne G. Ford, Earl S. Cunningham, Timothy J. Croft, Janet B. TI Chronic Obstructive Pulmonary Disease, Hospital Visits, and Comorbidities: National Survey of Residential Care Facilities, 2010 SO JOURNAL OF AGING AND HEALTH LA English DT Article DE chronic obstructive pulmonary disease; hospitalization; comorbidity; residential facilities ID ALZHEIMERS-DISEASE; UNITED-STATES; PARKINSON DISEASE; DIAGNOSED COPD; RISK-FACTOR; SMOKING; PREVALENCE; CONSUMPTION; MANAGEMENT; MORTALITY AB Objective: To characterize the prevalence of chronic obstructive pulmonary disease (COPD) among residential care facility (RCF) residents in the United States, and to compare patterns of hospital visits and comorbidities with residents without COPD. Method: Resident data from the 2010 National Survey of Residential Care Facilities were analyzed. Medical history and information on past-year hospital visits for 8,089 adult residents were obtained from interviews with RCF staff. Results: COPD prevalence was 12.4%. Compared with residents without COPD, emergency department visits or overnight hospital stays in the previous year were more prevalent (p < .05) among residents with COPD. Less than 3% of residents with COPD had no comorbidities. Arthritis, depression, congestive heart failure (CHF), diabetes, coronary heart disease, and asthma were more common (p < .05) among residents with COPD than those without COPD, but Alzheimer's disease was less common. Discussion: COPD is associated with more emergency department visits, hospital stays, and comorbidities among RCF residents. C1 [Wheaton, Anne G.; Ford, Earl S.; Cunningham, Timothy J.; Croft, Janet B.] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. RP Wheaton, AG (reprint author), Ctr Dis Control & Prevent, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy NE Mailstop F-78, Atlanta, GA 30341 USA. EM AWheaton@cdc.gov FU Intramural CDC HHS [CC999999] NR 36 TC 2 Z9 2 U1 0 U2 2 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0898-2643 EI 1552-6887 J9 J AGING HEALTH JI J. Aging Health PD APR PY 2015 VL 27 IS 3 BP 480 EP 499 DI 10.1177/0898264314552419 PG 20 WC Gerontology; Health Policy & Services SC Geriatrics & Gerontology; Health Care Sciences & Services GA CI2BO UT WOS:000354549800005 PM 25288588 ER PT J AU Fry, AM Zhong, WM Gubareva, LV AF Fry, Alicia M. Zhong, Weimin Gubareva, Larisa V. TI Advancing Treatment Options for Influenza: Challenges With the Human Influenza Challenge SO JOURNAL OF INFECTIOUS DISEASES LA English DT Editorial Material ID VIRUS M2 PROTEIN; A VIRUS; MONOCLONAL-ANTIBODIES; MATRIX PROTEIN-2; ECTODOMAIN; PROTECTION; EPITOPE; VACCINATION; DISEASE; MICE C1 [Fry, Alicia M.; Zhong, Weimin; Gubareva, Larisa V.] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Fry, AM (reprint author), 1600 Clifton Rd,MS A-32, Atlanta, GA 30329 USA. EM afry@cdc.gov NR 21 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD APR 1 PY 2015 VL 211 IS 7 BP 1033 EP 1035 DI 10.1093/infdis/jiu543 PG 3 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CI4DQ UT WOS:000354697500001 PM 25281756 ER PT J AU Chertow, DS Uyeki, TM DuPont, HL AF Chertow, Daniel S. Uyeki, Timothy M. DuPont, Herbert L. TI Loperamide Therapy for Voluminous Diarrhea in Ebola Virus Disease SO JOURNAL OF INFECTIOUS DISEASES LA English DT Editorial Material DE Ebola; loperamide; diarrhea; gastrointestinal losses; hypovolemia C1 [Chertow, Daniel S.] NIH, Dept Crit Care Med, Ctr Clin, Bethesda, MD 20892 USA. [Uyeki, Timothy M.] Ctr Dis Control & Prevent, Atlanta, GA USA. [DuPont, Herbert L.] Univ Texas Sch Publ Hlth, Ctr Infect Dis, Houston, TX USA. RP Chertow, DS (reprint author), NIH, Dept Crit Care Med, Ctr Clin, 10 Ctr Dr,2C-145, Bethesda, MD 20892 USA. EM chertowd@cc.nih.gov NR 11 TC 7 Z9 7 U1 0 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD APR 1 PY 2015 VL 211 IS 7 BP 1036 EP 1037 DI 10.1093/infdis/jiv001 PG 2 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CI4DQ UT WOS:000354697500002 PM 25573887 ER PT J AU Denkinger, CM Kik, SV Cirillo, DM Casenghi, M Shinnick, T Weyer, K Gilpin, C Boehme, CC Schito, M Kimerling, M Pai, M AF Denkinger, Claudia M. Kik, Sandra V. Cirillo, Daniela Maria Casenghi, Martina Shinnick, Thomas Weyer, Karin Gilpin, Chris Boehme, Catharina C. Schito, Marco Kimerling, Michael Pai, Madhukar TI Defining the Needs for Next Generation Assays for Tuberculosis SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE tuberculosis; diagnosis; target product profiles; prioritization; point-of-care ID XPERT MTB/RIF ASSAY; PULMONARY TUBERCULOSIS; DIAGNOSTIC-TESTS; EXTRAPULMONARY TUBERCULOSIS; INTRATHORACIC TUBERCULOSIS; MICROSCOPY CENTERS; COST-EFFECTIVENESS; GASTRIC LAVAGE; PRIMARY-CARE; CHILDREN AB To accelerate the fight against tuberculosis, major diagnostic challenges need to be addressed urgently. Post-2015 targets are unlikely to be met without the use of novel diagnostics that are more accurate and can be used closer to where patients first seek care in affordable diagnostic algorithms. This article describes the efforts by the stakeholder community that led to the identification of the high-priority diagnostic needs in tuberculosis. Subsequently target product profiles for the high-priority diagnostic needs were developed and reviewed in a World Health Organization (WHO)-led consensus meeting. The high-priority diagnostic needs included (1) a sputum-based replacement test for smear-microscopy; (2) a non-sputum-based biomarker test for all forms of tuberculosis, ideally suitable for use at levels below microscopy centers; (3) a simple, low cost triage test for use by first-contact care providers as a rule-out test, ideally suitable for use by community health workers; and (4) a rapid drug susceptibility test for use at the microscopy center level. The developed target product profiles, along with complimentary work presented in this supplement, will help to facilitate the interaction between the tuberculosis community and the diagnostics industry with the goal to lead the way toward the post-2015 global tuberculosis targets. C1 [Denkinger, Claudia M.; Boehme, Catharina C.] FIND, CH-1202 Geneva, Switzerland. [Denkinger, Claudia M.] Beth Israel Deaconess Med Ctr, Div Infect Dis, Boston, MA 02215 USA. [Kik, Sandra V.; Pai, Madhukar] McGill Univ, McGill Int TB Ctr, Montreal, PQ, Canada. [Kik, Sandra V.; Pai, Madhukar] McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, Canada. [Cirillo, Daniela Maria] IRCCS Osped San Raffaele, Milan, Italy. [Casenghi, Martina] Med Sans Frontieres, Geneva, Switzerland. [Shinnick, Thomas] Ctr Dis Control & Prevent, Atlanta, GA USA. [Weyer, Karin; Gilpin, Chris] WHO, CH-1211 Geneva, Switzerland. [Schito, Marco] HJF DAIDS, Bethesda, MD USA. [Kimerling, Michael] Bill & Melinda Gates Fdn, Seattle, WA USA. RP Denkinger, CM (reprint author), FIND, Campus Biotech,Chemin Mines 9,POB 87, CH-1202 Geneva, Switzerland. EM claudia.denkinger@finddiagnostics.org FU Bill and Melinda Gates Foundation [OPP1061487, OPP1018924]; Burroughs -Wellcome Fund from the American Society of Tropical Medicine and Hygiene; federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services [HHSN272200800014C] FX This work was supported by a grant of the Bill and Melinda Gates Foundation to McGill University (OPP1061487) and to FIND (OPP1018924). C. M. D. was supported by a postdoctoral fellowship of the Burroughs -Wellcome Fund from the American Society of Tropical Medicine and Hygiene. M. S. was supported by federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under contract number HHSN272200800014C. The funders had no role in the analysis of data and decision to publish. NR 47 TC 22 Z9 22 U1 0 U2 6 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD APR 1 PY 2015 VL 211 SU 2 BP S29 EP S38 DI 10.1093/infdis/jiu821 PG 10 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CI4DZ UT WOS:000354698600002 PM 25765104 ER PT J AU Salamon, H Yamaguchi, KD Cirillo, DM Miotto, P Schito, M Posey, J Starks, AM Niemann, S Alland, D Hanna, D Aviles, E Perkins, MD Dolinger, DL AF Salamon, Hugh Yamaguchi, Ken D. Cirillo, Daniela M. Miotto, Paolo Schito, Marco Posey, James Starks, Angela M. Niemann, Stefan Alland, David Hanna, Debra Aviles, Enrique Perkins, Mark D. Dolinger, David L. TI Integration of Published Information Into a Resistance-Associated Mutation Database for Mycobacterium tuberculosis SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE tuberculosis; drug resistance; resistance-associated mutations; genomic sequencing; drug susceptibility testing; database ID DRUG; LABORATORIES; PROFICIENCY; GENES AB Tuberculosis remains a major global public health challenge. Although incidence is decreasing, the proportion of drug-resistant cases is increasing. Technical and operational complexities prevent Mycobacterium tuberculosis drug susceptibility phenotyping in the vast majority of new and retreatment cases. The advent of molecular technologies provides an opportunity to obtain results rapidly as compared to phenotypic culture. However, correlations between genetic mutations and resistance to multiple drugs have not been systematically evaluated. Molecular testing of M. tuberculosis sampled from a typical patient continues to provide a partial picture of drug resistance. A database of phenotypic and genotypic testing results, especially where prospectively collected, could document statistically significant associations and may reveal new, predictive molecular patterns. We examine the feasibility of integrating existing molecular and phenotypic drug susceptibility data to identify associations observed across multiple studies and demonstrate potential for well-integrated M. tuberculosis mutation data to reveal actionable findings. C1 [Salamon, Hugh; Yamaguchi, Ken D.] Knowledge Synth Inc, Berkeley, CA 94710 USA. [Cirillo, Daniela M.; Miotto, Paolo] IRCCS San Raffaele Sci Inst, Milan, Italy. [Schito, Marco] NIH, HJF DAIDS, DHHS, Bethesda, MD 20892 USA. [Posey, James; Starks, Angela M.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Niemann, Stefan] Forschungszentrum Borstel, Borstel, Germany. [Alland, David] Rutgers State Univ, Piscataway, NJ 08855 USA. [Hanna, Debra; Aviles, Enrique] Crit Path Inst, Tucson, AZ USA. [Perkins, Mark D.; Dolinger, David L.] FIND, Geneva, Switzerland. RP Salamon, H (reprint author), Knowledge Synth Inc, 725 Folger Ave, Berkeley, CA 94710 USA. EM hugh@knowledgesynthesis.com RI Niemann, Stefan/C-9327-2011; Miotto, Paolo/E-3940-2017 OI Miotto, Paolo/0000-0003-4610-2427 FU Bill and Melinda Gates Foundation; Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services [HHSN272200800014C] FX This work was supported by the Bill and Melinda Gates Foundation. M. S. is funded with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract HHSN272200800014C. The funders had no role in the analysis of data and decision to publish. NR 17 TC 7 Z9 7 U1 1 U2 4 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD APR 1 PY 2015 VL 211 SU 2 BP S50 EP S57 DI 10.1093/infdis/jiu816 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CI4DZ UT WOS:000354698600004 PM 25765106 ER PT J AU Bradley, RD Schmidly, DJ Amman, BR Platt, RN Neumann, KM Huynh, HM Muniz-Martinez, R Lopez-Gonzalez, C Ordonez-Garza, N AF Bradley, Robert D. Schmidly, David J. Amman, Brian R. Platt, Roy N., II Neumann, Kathy M. Huynh, Howard M. Muniz-Martinez, Raul Lopez-Gonzalez, Celia Ordonez-Garza, Nicte TI Molecular and morphologic data reveal multiple species in Peromyscus pectoralis SO JOURNAL OF MAMMALOGY LA English DT Article DE cytochrome-b gene; DNA sequences; morphometrics; Peromyscus pectoralis; taxonomy ID CYTOCHROME-B SEQUENCES; PHYLOGENETIC TREES; DNA-SEQUENCES; MAMMALS; MEXICO; SYSTEMATICS; CRICETIDAE; INFERENCE; RODENTIA; MODEL AB DNA sequence and morphometric data were used to re-evaluate the taxonomy and systematics of Peromyscus pectoralis. Phylogenetic analyses (maximum likelihood and Bayesian inference) of DNA sequences from the mitochondrial cytochrome-b gene in 44 samples of P. pectoralis indicated 2 well-supported monophyletic clades. The 1st clade contained specimens from Texas historically assigned to P. p. laceianus; the 2nd was comprised of specimens previously referable to P. p. collinus, P. p. laceianus, and P. p. pectoralis obtained from northern and eastern Mexico. Levels of genetic variation (similar to 7%) between these 2 clades indicated that the genetic divergence typically exceeded that reported for other species of Peromyscus. Samples of P. p. laceianus north and south of the Rio Grande were not monophyletic. In addition, samples representing P. p. collinus and P. p. pectoralis formed 2 clades that differed genetically by 7.14%. Multivariate analyses of external and cranial measurements from 63 populations of P. pectoralis revealed 4 morpho-groups consistent with clades in the DNA sequence analysis: 1 from Texas and New Mexico assignable to P. p. laceianus; a 2nd from western and southern Mexico assignable to P. p. pectoralis; a 3rd from northern and central Mexico previously assigned to P. p. pectoralis but herein shown to represent an undescribed taxon; and a 4th from southeastern Mexico assignable to P. p. collinus. Based on the concordance of these results, populations from the United States are referred to as P. laceianus, whereas populations from Mexico are referred to as P. pectoralis (including some samples historically assigned to P. p. collinus, P. p. laceianus, and P. p. pectoralis). A new subspecies is described to represent populations south of the Rio Grande in northern and central Mexico. Additional research is needed to discern if P. p. collinus warrants species recognition. C1 [Bradley, Robert D.; Huynh, Howard M.; Ordonez-Garza, Nicte] Texas Tech Univ, Dept Biol Sci, Lubbock, TX 79409 USA. [Bradley, Robert D.] Texas Tech Univ Museum, Lubbock, TX 79409 USA. [Schmidly, David J.] Univ New Mexico, Dept Biol, Albuquerque, NM 87131 USA. [Amman, Brian R.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div High Consequence Pathogens & Pathol, Viral Special Pathogens Branch,Virus Host Ecol, Atlanta, GA 30329 USA. [Platt, Roy N., II] Mississippi State Univ, Inst Genom Biocomp & Biotechnol, Mississippi State, MS 39762 USA. [Muniz-Martinez, Raul; Lopez-Gonzalez, Celia] Inst Politecn Nacl, Ctr Interdisciplinario Invest Desarrollo Integral, Durango 34220, Mexico. RP Bradley, RD (reprint author), Texas Tech Univ, Dept Biol Sci, Lubbock, TX 79409 USA. EM robert.bradley@ttu.edu FU National Institutes of Health [DHHS A141435-01]; Instituto Politecnico Nacional [SIP-2013-0840] FX The first 2 authors contributed equally to this manuscript; however, RDB lost the debate with his former mentor (DJS) and was placed as 1st author. We thank M. S. Corley-Keith, C. D. Dunn, M. R. Mauldin, and E. K. Roberts for reviewing earlier versions of this manuscript. Tissue samples were kindly provided by the Centro de Interdisciplinario de Investigacion para el Desarrollo Integral Regional (CIIDIR) Unidad Durango, Instituto Politecnico Nacional, Natural Science Research Laboratory, Museum of Texas Tech University and Texas Cooperative Wildlife Collection, and Texas A&M University. Special thanks to the TTU Field Methods classes of 1995, 1997, 2000, 2005, and 2008 for assistance in collecting specimens and to A. Jones for helping prepare portions of the various drafts. Partial support for this research was provided by a National Institutes of Health grant (DHHS A141435-01 to RDB) and by Instituto Politecnico Nacional (SIP-2013-0840 to CL-G). NR 35 TC 0 Z9 0 U1 2 U2 11 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-2372 EI 1545-1542 J9 J MAMMAL JI J. Mammal. PD APR PY 2015 VL 96 IS 2 BP 446 EP 459 DI 10.1093/jmammal/gyv049 PG 14 WC Zoology SC Zoology GA CH7XG UT WOS:000354249300019 PM 26937045 ER PT J AU Bender, JB Barlam, TF Glore, RP Gumley, N Grayzel, SE Hoang, C Murphy, MJ Papich, MG Sykes, JE Watts, JL Whichard, JM AF Bender, Jeff B. Barlam, Tamar F. Glore, Reilly P. Gumley, Nigel Grayzel, Sharon E. Hoang, Christine Murphy, Michael J. Papich, Mark G. Sykes, Jane E. Watts, Jeffrey L. Whichard, Jean M. TI The AVMA Task Force for Antimicrobial Stewardship in Companion Animal Practice responds SO JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION LA English DT Letter C1 [Bender, Jeff B.] Univ Minnesota, Coll Vet Med, Dept Vet Populat Med, St Paul, MN 55108 USA. [Barlam, Tamar F.] Boston Med Ctr, Infect Dis Sect, Boston, MA USA. [Glore, Reilly P.] Brady Vet Hosp, Montesano, WA USA. [Gumley, Nigel] Canadian Vet Med Assoc, Ottawa, ON, Canada. [Grayzel, Sharon E.] Columbia Vet Ctr, Vancouver, WA USA. [Hoang, Christine] AVMA, Schaumburg, IL USA. [Murphy, Michael J.] US FDA, Ctr Vet Med, Rockville, MD 20857 USA. [Papich, Mark G.] N Carolina State Univ, Coll Vet Med, Dept Mol Biomed Sci, Raleigh, NC USA. [Sykes, Jane E.] Univ Calif Davis, Sch Vet Med, Dept Med & Epidemiol, Davis, CA 95616 USA. [Watts, Jeffrey L.] Zoetis, Antiinfect Res VMRD, Kalamazoo, MI USA. [Whichard, Jean M.] CDC, Atlanta, GA 30333 USA. RP Bender, JB (reprint author), Univ Minnesota, Coll Vet Med, Dept Vet Populat Med, St Paul, MN 55108 USA. NR 1 TC 1 Z9 1 U1 1 U2 4 PU AMER VETERINARY MEDICAL ASSOC PI SCHAUMBURG PA 1931 N MEACHAM RD SUITE 100, SCHAUMBURG, IL 60173-4360 USA SN 0003-1488 EI 1943-569X J9 JAVMA-J AM VET MED A JI JAVMA-J. Am. Vet. Med. Assoc. PD APR 1 PY 2015 VL 246 IS 7 BP 727 EP 728 PG 2 WC Veterinary Sciences SC Veterinary Sciences GA CH1KS UT WOS:000353780900022 PM 25958435 ER PT J AU Florschutz, AV Fagan, RP Matar, WY Sawyer, RG Berrios-Torres, SI AF Florschutz, Anthony V. Fagan, Ryan P. Matar, Wadih Y. Sawyer, Robert G. Berrios-Torres, Sandra I. TI Surgical Site Infection Risk Factors and Risk Stratification SO JOURNAL OF THE AMERICAN ACADEMY OF ORTHOPAEDIC SURGEONS LA English DT Article ID TOTAL JOINT ARTHROPLASTY; TOTAL HIP-REPLACEMENT; OPERATING-ROOM; KNEE ARTHROPLASTY; SURVEILLANCE; PROPHYLAXIS; PREVENTION; SURGERY; RATIO AB Preoperative identification of the risk factors for surgical site infection and patient risk stratification are essential for deciding whether surgery is appropriate, educating patients on their individual risk of complications, and managing postoperative expectations. Early identification of these factors is also necessary to help guide both patient medical optimization and perioperative care planning. Several resources are currently available to track and analyze healthcare-associated infections, including the Centers for Disease Control and Prevention's National Healthcare Safety Network. In addition, the Centers for Disease Control and Prevention and the American Academy of Orthopaedic Surgeons are exploring collaborative opportunities for the codevelopment of a hip and/or knee arthroplasty national quality measure for periprosthetic joint infection. C1 [Florschutz, Anthony V.] Orlando Reg Med Ctr Inc, Dept Orthopaed, Orlando, FL 32806 USA. [Fagan, Ryan P.; Berrios-Torres, Sandra I.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA USA. [Matar, Wadih Y.] Hull Hosp, Ctr Sante, Dept Orthopaed Surg, Gatineau, PQ, Canada. [Matar, Wadih Y.] Hull Hosp, Serv Sociaux Gatineau, Gatineau, PQ, Canada. [Sawyer, Robert G.] Univ Virginia, Dept Surg, Div Acute Care Surg, Charlottesville, VA USA. RP Florschutz, AV (reprint author), Orlando Reg Med Ctr Inc, Dept Orthopaed, Orlando, FL 32806 USA. NR 36 TC 3 Z9 3 U1 0 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1067-151X EI 1940-5480 J9 J AM ACAD ORTHOP SUR JI J. Am. Acad. Orthop. Surg. PD APR PY 2015 VL 23 SU 1 BP S8 EP S11 DI 10.5435/JAAOS-D-14-00447 PG 4 WC Orthopedics; Surgery SC Orthopedics; Surgery GA CH6ES UT WOS:000354129700002 PM 25808971 ER PT J AU Marchetta, CM Devine, OJ Crider, KS Tsang, BL Cordero, AM Qi, YP Guo, J Berry, RJ Rosenthal, J Mulinare, J Mersereau, P Hamner, HC AF Marchetta, Claire M. Devine, Owen J. Crider, Krista S. Tsang, Becky L. Cordero, Amy M. Qi, Yan Ping Guo, Jing Berry, Robert J. Rosenthal, Jorge Mulinare, Joseph Mersereau, Patricia Hamner, Heather C. TI Assessing the Association between Natural Food Folate Intake and Blood Folate Concentrations: A Systematic Review and Bayesian Meta-Analysis of Trials and Observational Studies SO NUTRIENTS LA English DT Article ID NEURAL-TUBE DEFECTS; FOLIC-ACID SUPPLEMENTATION; TOTAL HOMOCYSTEINE LEVELS; DISEASE RISK-FACTORS; BIO-RAD RADIOASSAY; YOUNG-WOMEN; METHYLENETETRAHYDROFOLATE REDUCTASE; CHILDBEARING AGE; DIETARY-FOLATE; NUTRITIONAL-STATUS AB Folate is found naturally in foods or as synthetic folic acid in dietary supplements and fortified foods. Adequate periconceptional folic acid intake can prevent neural tube defects. Folate intake impacts blood folate concentration; however, the dose-response between natural food folate and blood folate concentrations has not been well described. We estimated this association among healthy females. A systematic literature review identified studies (1 1992-3 2014) with both natural food folate intake alone and blood folate concentration among females aged 12-49 years. Bayesian methods were used to estimate regression model parameters describing the association between natural food folate intake and subsequent blood folate concentration. Seven controlled trials and 29 observational studies met the inclusion criteria. For the six studies using microbiologic assay (MA) included in the meta-analysis, we estimate that a 6% (95% Credible Interval (CrI): 4%, 9%) increase in red blood cell (RBC) folate concentration and a 7% (95% CrI: 1%, 12%) increase in serum/plasma folate concentration can occur for every 10% increase in natural food folate intake. Using modeled results, we estimate that a natural food folate intake of >= 450 mu g dietary folate equivalents (DFE)/day could achieve the lower bound of an RBC folate concentration (~1050 nmol/L) associated with the lowest risk of a neural tube defect. Natural food folate intake affects blood folate concentration and adequate intakes could help women achieve a RBC folate concentration associated with a risk of 6 neural tube defects/10,000 live births. C1 [Marchetta, Claire M.; Tsang, Becky L.; Qi, Yan Ping] Oak Ridge Inst Sci & Educ ORISE, Oak Ridge, TN 37831 USA. [Devine, Owen J.; Mulinare, Joseph] Carter Consulting Inc, Atlanta, GA 30345 USA. [Crider, Krista S.; Cordero, Amy M.; Berry, Robert J.; Rosenthal, Jorge] Ctr Dis Control & Prevent, Div Birth Defects & Dev Disabil DBDDD, Natl Ctr Birth Defects & Dev Disabil NCBDDD, Atlanta, GA 30329 USA. [Guo, Jing] Acentia, Falls Church, VA 22042 USA. [Mersereau, Patricia] SciMetrika LLC, Atlanta, GA 30329 USA. [Hamner, Heather C.] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes DNPAO, Natl Ctr Chron Dis Prevent & Hlth Promot NCCDPHP, Atlanta, GA 30329 USA. RP Hamner, HC (reprint author), Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes DNPAO, Natl Ctr Chron Dis Prevent & Hlth Promot NCCDPHP, Atlanta, GA 30329 USA. EM claire.marchetta@gmail.com; ojd1@cdc.gov; kvc3@cdc.gov; bltsang@gmail.com; iqt8@cdc.gov; rv7@cdc.gov; shashagj@gmail.com; rjb1@cdc.gov; jyr4@cdc.gov; jxm1@cdc.gov; pmersereau@comcast.net; hfc2@cdc.gov OI Berry, Robert/0000-0002-7162-5046 NR 78 TC 2 Z9 3 U1 2 U2 3 PU MDPI AG PI BASEL PA POSTFACH, CH-4005 BASEL, SWITZERLAND SN 2072-6643 J9 NUTRIENTS JI Nutrients PD APR PY 2015 VL 7 IS 4 BP 2663 EP 2686 DI 10.3390/nu7042663 PG 24 WC Nutrition & Dietetics SC Nutrition & Dietetics GA CH0KY UT WOS:000353709800035 PM 25867949 ER PT J AU Backer, LC Manassaram-Baptiste, D LePrell, R Bolton, B AF Backer, Lorraine C. Manassaram-Baptiste, Deana LePrell, Rebecca Bolton, Birgit TI Cyanobacteria and Algae Blooms: Review of Health and Environmental Data from the Harmful Algal Bloom-Related Illness Surveillance System (HABISS) 2007-2011 SO TOXINS LA English DT Article ID TIDE TOXINS BREVETOXINS; UNITED-STATES; AEROSOLIZED BREVETOXINS; DISEASE OUTBREAKS; EXPOSURE; EVENTS; ASTHMA AB Algae and cyanobacteria are present in all aquatic environments. We do not have a good sense of the extent of human and animal exposures to cyanobacteria or their toxins, nor do we understand the public health impacts from acute exposures associated with recreational activities or chronic exposures associated with drinking water. We describe the Harmful Algal Bloom-related Illness Surveillance System (HABISS) and summarize the collected reports describing bloom events and associated adverse human and animal health events. For the period of 2007-2011, Departments of Health and/or Environment from 11 states funded by the National Center for Environmental Health (NCEH), Centers for Disease Control and Prevention contributed reports for 4534 events. For 2007, states contributed 173 reports from historical data. The states participating in the HABISS program built response capacity through targeted public outreach and prevention activities, including supporting routine cyanobacteria monitoring for public recreation waters. During 2007-2010, states used monitoring data to support196 public health advisories or beach closures. The information recorded in HABISS and the application of these data to develop a wide range of public health prevention and response activities indicate that cyanobacteria and algae blooms are an environmental public health issue that needs continuing attention. C1 [Backer, Lorraine C.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Chamblee, GA 30341 USA. [Manassaram-Baptiste, Deana] Amer Canc Soc, Atlanta, GA 30303 USA. [LePrell, Rebecca] Virginia Dept Hlth, Richmond, VA 23219 USA. [Bolton, Birgit] Task Force Global Hlth, Int Trachoma Initiat, Decatur, GA 30030 USA. RP Backer, LC (reprint author), Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, 4770 Buford Highway NE, Chamblee, GA 30341 USA. EM lbacker@cdc.gov; deana.baptiste@cancer.org; rebecca.leprell@vdh.virginia.gov; bbolton@taskforce.org NR 20 TC 6 Z9 6 U1 12 U2 48 PU MDPI AG PI BASEL PA POSTFACH, CH-4005 BASEL, SWITZERLAND SN 2072-6651 J9 TOXINS JI Toxins PD APR PY 2015 VL 7 IS 4 BP 1048 EP 1064 DI 10.3390/toxins7041048 PG 17 WC Toxicology SC Toxicology GA CH3XG UT WOS:000353963700004 PM 25826054 ER PT J AU Lam, TK Chang, CQ Rogers, SD Khoury, MJ Schully, SD AF Lam, Tram Kim Chang, Christine Q. Rogers, Scott D. Khoury, Muin J. Schully, Sheri D. TI Evolution of the "Drivers" of Translational Cancer Epidemiology: Analysis of Funded Grants and the Literature SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Article DE cancer; cancer epidemiology; collaboration; consortia; epidemiologic methods; knowledge integration; translation ID KNOWLEDGE INTEGRATION; GENOMIC MEDICINE; 21ST-CENTURY; HEALTH; CONTINUUM; SCIENCE; CARE AB Concurrently with a workshop sponsored by the National Cancer Institute, we identified key "drivers" for accelerating cancer epidemiology across the translational research continuum in the 21st century: emerging technologies, a multilevel approach, knowledge integration, and team science. To map the evolution of these "drivers" and translational phases (T0-T4) in the past decade, we analyzed cancer epidemiology grants funded by the National Cancer Institute and published literature for 2000, 2005, and 2010. For each year, we evaluated the aims of all new/competing grants and abstracts of randomly selected PubMed articles. Compared with grants based on a single institution, consortium-based grants were more likely to incorporate contemporary technologies (P = 0.012), engage in multilevel analyses (P = 0.010), and incorporate elements of knowledge integration (P = 0.036). Approximately 74% of analyzed grants and publications involved discovery (T0) or characterization (T1) research, suggesting a need for more translational (T2-T4) research. Our evaluation indicated limited research in 1) a multilevel approach that incorporates molecular, individual, social, and environmental determinants and 2) knowledge integration that evaluates the robustness of scientific evidence. Cancer epidemiology is at the cusp of a paradigm shift, and the field will need to accelerate the pace of translating scientific discoveries in order to impart population health benefits. While multi-institutional and technology-driven collaboration is happening, concerted efforts to incorporate other key elements are warranted for the discipline to meet future challenges. C1 [Lam, Tram Kim; Chang, Christine Q.; Rogers, Scott D.; Khoury, Muin J.; Schully, Sheri D.] NCI, Epidemiol & Genom Res Program, Div Canc Control & Populat Sci, Rockville, MD 20850 USA. [Khoury, Muin J.] Ctr Dis Control & Prevent, Off Publ Hlth Genom, Atlanta, GA USA. RP Lam, TK (reprint author), NCI, Epidemiol & Genom Res Program, Div Canc Control & Populat Sci, 9609 Med Ctr Dr,Room 4E124, Rockville, MD 20850 USA. EM lamt@mail.nih.gov FU Intramural CDC HHS [CC999999] NR 18 TC 3 Z9 3 U1 0 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 EI 1476-6256 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD APR 1 PY 2015 VL 181 IS 7 BP 451 EP 458 DI 10.1093/aje/kwu479 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CH1XD UT WOS:000353815100001 PM 25767265 ER PT J AU Lam, TK Chang, CQ Rogers, SD Khoury, MJ Schully, SD AF Lam, Tram Kim Chang, Christine Q. Rogers, Scott D. Khoury, Muin J. Schully, Sheri D. TI Lam et al. Respond to "Driving for Further Evolution" SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Editorial Material C1 [Lam, Tram Kim; Chang, Christine Q.; Rogers, Scott D.; Khoury, Muin J.; Schully, Sheri D.] NCI, Epidemiol & Genom Res Program, Div Canc Control & Populat Sci, Rockville, MD 20850 USA. [Khoury, Muin J.] Ctr Dis Control & Prevent, Off Publ Hlth Genom, Atlanta, GA USA. RP Lam, TK (reprint author), NCI, Epidemiol & Genom Res Program, Div Canc Control & Populat Sci, 9609 Med Ctr Dr,Room 4E124, Rockville, MD 20850 USA. EM lamt@mail.nih.gov NR 2 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 EI 1476-6256 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD APR 1 PY 2015 VL 181 IS 7 BP 463 EP 463 DI 10.1093/aje/kwu478 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CH1XD UT WOS:000353815100003 PM 25767264 ER PT J AU Layden, JE Phillips, RO Owusu-Ofori, S Sarfo, FS Kliethermes, S Mora, N Owusu, D Nelson, K Opare-Sem, O Dugas, L Luke, A Shoham, D Forbi, JC Khudyakov, YE Cooper, RS AF Layden, Jennifer E. Phillips, Richard O. Owusu-Ofori, Shirley Sarfo, Fred Stephen Kliethermes, Stephanie Mora, Nallely Owusu, Dorcas Nelson, Kenrad Opare-Sem, Ohene Dugas, Lara Luke, Amy Shoham, David Forbi, Joseph C. Khudyakov, Yury E. Cooper, Richard S. TI High Frequency of Active HCV Infection Among Seropositive Cases in West Africa and Evidence for Multiple Transmission Pathways SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE HCV; Africa; prevalence; transmission ID HEPATITIS-C VIRUS; GENOTYPE 2 INFECTION; SUB-SAHARAN AFRICA; BLOOD-TRANSFUSION; UNITED-STATES; BURKINA-FASO; HEPATOCELLULAR-CARCINOMA; HIV-INFECTION/; RISK-FACTORS; PREVALENCE AB Background. Sub-Saharan Africa (SSA) has one of the highest global hepatitis C virus (HCV) prevalence estimates. However, reports that suggest high rates of serologic false positives and low levels of viremia have led to uncertainty regarding the burden of active infection in this region. Additionally, little is known about the predominant transmission risk factors in SSA. Methods. We prospectively recalled 363 past blood donors (180 who were rapid screen assay [RSA] positive and 183 who were RSA negative at time of donation) to identify the level of active infection and risk factors for infection at a teaching hospital in Kumasi, Ghana. Participants had repeat blood testing and were administered a questionnaire on risk factors. Results. The frequency of HCV active infection ranged from 74.4% to 88% depending on the criteria used to define serologically positive cases. Individuals with active disease had biochemical evidence of liver inflammation and median viral loads of 5.7 log copies/mL. Individuals from the northern and upper regions of Ghana had greater risks of infection compared with participants from other areas. Additional risk factors included traditional circumcision, home birth, tribal scarring, and hepatitis B virus coinfection. Conclusions. Viremic infection was common among serologically confirmed cases. Attention to testing algorithms is needed in order to define the true HCV burden in SSA. These data also suggest that several transmission modes are likely contributing to the current HCV epidemic in Ghana and that the distribution of these practices may result in substantial regional variation in prevalence. C1 [Layden, Jennifer E.; Kliethermes, Stephanie; Mora, Nallely; Dugas, Lara; Luke, Amy; Shoham, David; Cooper, Richard S.] Loyola Univ Chicago, Stritch Sch Med, Dept Publ Hlth Sci, Maywood, IL USA. [Layden, Jennifer E.; Kliethermes, Stephanie] Loyola Univ Chicago, Stritch Sch Med, Dept Med, Maywood, IL USA. [Phillips, Richard O.; Owusu-Ofori, Shirley; Sarfo, Fred Stephen; Owusu, Dorcas; Opare-Sem, Ohene] Komfo Anokye Teaching Hosp, Kumasi, Ghana. [Phillips, Richard O.; Sarfo, Fred Stephen; Opare-Sem, Ohene] Kwame Nkrumah Univ Sci & Technol, Kumasi, Ghana. [Nelson, Kenrad] Johns Hopkins Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Nelson, Kenrad] Johns Hopkins Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA. [Forbi, Joseph C.; Khudyakov, Yury E.] Ctr Dis Control, Div Viral Hepatitis, Mol Epidemiol & Bioinformat Lab, Atlanta, GA 30333 USA. RP Layden, JE (reprint author), Loyola Univ, Med Ctr, Dept Med, Div Infect Dis, 2160 S First Ave, Maywood, IL 60153 USA. EM jlayden@lumc.edu FU Loyola University FX Internal funding was provided to J. E. L. from Loyola University. NR 47 TC 6 Z9 6 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD APR 1 PY 2015 VL 60 IS 7 BP 1033 EP 1041 DI 10.1093/cid/ciu965 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CH0MH UT WOS:000353714000008 PM 25477425 ER PT J AU Shulman, LM Martin, J Sofer, D Burns, CC Manor, Y Hindiyeh, M Gavrilin, E Wilton, T Moran-Gilad, J Gamzo, R Mendelson, E Grotto, I AF Shulman, Lester M. Martin, Javier Sofer, Danit Burns, Cara C. Manor, Yossi Hindiyeh, Musa Gavrilin, Eugene Wilton, Thomas Moran-Gilad, Jacob Gamzo, Ronni Mendelson, Ella Grotto, Itamar CA GPI Genotype Phenotype TI Genetic Analysis and Characterization of Wild Poliovirus Type 1 During Sustained Transmission in a Population With > 95% Vaccine Coverage, Israel 2013 SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE wild type 1 poliovirus; neurovirulence; neutralizing antigenic epitopes; poliovirus receptor; environmental surveillance ID ENVIRONMENTAL SURVEILLANCE; PARALYTIC POLIOMYELITIS; MOLECULAR EPIDEMIOLOGY; MUCOSAL IMMUNITY; OUTBREAK; CIRCULATION; EXCRETION; VIRUS; CONGO AB Background. Israel has >95% polio vaccine coverage with the last 9 birth cohorts immunized exclusively with inactivated polio vaccine (IPV). Using acute flaccid paralysis and routine, monthly countrywide environmental surveillance, no wild poliovirus circulation was detected between 1989 and February 2013, after which wild type 1 polioviruses South Asia genotype (WPV1-SOAS) have persistently circulated in southern Israel and intermittently in other areas without any paralytic cases as determined by intensified surveillance of environmental and human samples. We aimed to characterize antigenic and neurovirulence properties of WPV1-SOAS silently circulating in a highly vaccinated population. Methods. WPV1-SOAS capsid genes from environmental and stool surveillance isolates were sequenced, their neurovirulence was determined using transgenic mouse expressing the human poliovirus receptor (Tg21-PVR) mice, and their antigenicity was characterized by in vitro neutralization using human sera, epitope-specific monoclonal murine anti-oral poliovirus vaccine (OPV) antibodies, and sera from IPV-immunized rats and mice. Results. WPV1 amino acid sequences in neutralizing epitopes varied from Sabin 1 and Mahoney, with little variation among WPV1 isolates. Neutralization by monoclonal antibodies against 3 of 4 OPV epitopes was lost. Three-fold lower geometric mean titers (Z = -4.018; P < .001, Wilcoxon signed-rank test) against WPV1 than against Mahoney in human serum correlated with 4- to 6-fold lower neutralization titers in serum from IPV-immunized rats and mice. WPV1-SOAS isolates were neurovirulent (50% intramuscular paralytic dose in Tg21-PVR mice: log10(7.0)). IPV-immunized mice were protected against WPV1-induced paralysis. Conclusions. Phenotypic and antigenic profile changes of WPV1-SOAS may have contributed to the intense silent transmission, whereas the reduced neurovirulence may have contributed to the absence of paralytic cases in the background of high population immunity. C1 [Shulman, Lester M.; Sofer, Danit; Manor, Yossi; Hindiyeh, Musa; Mendelson, Ella] Israel Minist Hlth, Publ Hlth Serv, Cent Virol Lab, Sheba Med Ctr, IL-52621 Tel Hashomer, Israel. [Martin, Javier; Wilton, Thomas] Natl Inst Biol Stand & Controls, Div Virol, Potters Bar, Herts, England. [Burns, Cara C.] Ctr Dis Control & Prevent, Div Viral Dis, Polio & Picornavirus Lab Branch, Atlanta, GA USA. [Gavrilin, Eugene] World Hlth Org EUROPE, Reg Polio Lab Network, Copenhagen, Denmark. [Moran-Gilad, Jacob; Gamzo, Ronni; Grotto, Itamar] Minist Hlth, Jerusalem, Israel. RP Shulman, LM (reprint author), Israel Minist Hlth, Publ Hlth Serv, Cent Virol Lab, Sheba Med Ctr, IL-52621 Tel Hashomer, Israel. EM lester.shulman@sheba.health.gov.il FU World Health Organization [001] NR 38 TC 6 Z9 6 U1 5 U2 8 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD APR 1 PY 2015 VL 60 IS 7 BP 1057 EP 1064 DI 10.1093/cid/ciu1136 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CH0MH UT WOS:000353714000011 PM 25550350 ER PT J AU Premkumar, PS Parashar, UD Gastanaduy, PA McCracken, JP de Oliveira, LH Payne, DC Patel, MM Tate, JE Lopman, BA AF Premkumar, Prasanna S. Parashar, Umesh D. Gastanaduy, Paul A. McCracken, John P. de Oliveira, Lucia Helena Payne, Daniel C. Patel, Manish M. Tate, Jacqueline E. Lopman, Ben A. TI Reduced Rotavirus Vaccine Effectiveness Among Children Born During the Rotavirus Season: A Pooled Analysis of 5 Case-Control Studies From the Americas SO CLINICAL INFECTIOUS DISEASES LA English DT Editorial Material DE rotavirus disease; birth seasons; rotavirus vaccines; pooled analysis ID CHILDHOOD DIARRHEA; PENTAVALENT; DISEASE; EFFICACY; INFANTS; TRIALS AB Using data from rotavirus vaccine effectiveness (VE) studies, we assessed whether rotavirus season modifies rotavirus VE in infants. In the first year of life, adjusted VE was 72% for children born during rotavirus season and 84% for children born in other months (P = .01). Seasonal factors may interfere with vaccine performance. C1 [Premkumar, Prasanna S.; Parashar, Umesh D.; Gastanaduy, Paul A.; Payne, Daniel C.; Patel, Manish M.; Tate, Jacqueline E.; Lopman, Ben A.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Premkumar, Prasanna S.] Christian Med Coll & Hosp, Div Gastrointestinal Sci, Wellcome Trust Res Lab, Vellore, Tamil Nadu, India. [McCracken, John P.] Univ Valle Guatemala, Ctr Hlth Studies, Guatemala City, Guatemala. [de Oliveira, Lucia Helena] Pan Amer Hlth Org, Washington, DC USA. RP Premkumar, PS (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,MS A-34, Atlanta, GA 30333 USA. EM wpl6@cdc.gov NR 26 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD APR 1 PY 2015 VL 60 IS 7 BP 1075 EP 1078 DI 10.1093/cid/ciu956 PG 4 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CH0MH UT WOS:000353714000014 PM 25452592 ER PT J AU Esposito, DH Rosenthal, BM Slesak, G Tappe, D Fayer, R Bottieau, E Brown, C Grobusch, MP Malvy, D von Sonnenburg, F Sotir, MJ Steiner, F Zanger, P Kozarsky, PE AF Esposito, Douglas H. Rosenthal, Benjamin M. Slesak, Guenther Tappe, Dennis Fayer, Ronald Bottieau, Emmanuel Brown, Clive Grobusch, Martin P. Malvy, Denis von Sonnenburg, Frank Sotir, Mark J. Steiner, Florian Zanger, Philipp Kozarsky, Phyllis E. TI Avoid Haste in Defining Human Muscular Sarcocystosis Reply SO CLINICAL INFECTIOUS DISEASES LA English DT Letter ID TIOMAN ISLAND; OUTBREAK; MALAYSIA; INFECTION; NESBITTI; MYOSITIS C1 [Esposito, Douglas H.; Brown, Clive; Sotir, Mark J.; Kozarsky, Phyllis E.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div Global Migrat & Quarantine, Atlanta, GA 30333 USA. [Rosenthal, Benjamin M.; Fayer, Ronald] US DOE, Beltsville Agr Res Ctr, Beltsville, MD USA. [Slesak, Guenther] Tropenklin Paul Lechler Krankenhaus, Tubingen, Germany. [Tappe, Dennis] Bernhard Nocht Inst Trop Med, D-20359 Hamburg, Germany. [Bottieau, Emmanuel] Inst Trop Med, Dept Clin Sci, B-2000 Antwerp, Belgium. [Grobusch, Martin P.] Univ Amsterdam, Acad Med Ctr, Dept Infect Dis, Ctr Trop Med & Travel Med, NL-1012 WX Amsterdam, Netherlands. [Malvy, Denis] Univ Hosp Ctr, Div Trop Med & Clin Int Hlth, Bordeaux, France. [von Sonnenburg, Frank] Univ Munich, Dept Infect Dis & Trop Med, D-81377 Munich, Germany. [Steiner, Florian] Charite Univ Med Berlin, Inst Trop Med & Int Hlth, Berlin, Germany. [Zanger, Philipp] Univ Tubingen, Inst Trop Med, Tubingen, Germany. [Kozarsky, Phyllis E.] Emory Univ, Dept Med, Div Infect Dis, Atlanta, GA 30322 USA. RP Esposito, DH (reprint author), Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Travelers Hlth Branch, Div Global Migrat & Quarantine, 1600 Clifton Rd NE,MS E-03, Atlanta, GA 30333 USA. EM hgj4@cdc.gov RI Zanger, Philipp/B-8033-2010 FU Intramural CDC HHS [CC999999] NR 10 TC 0 Z9 0 U1 0 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD APR 1 PY 2015 VL 60 IS 7 BP 1135 EP U198 DI 10.1093/cid/ciu1165 PG 2 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CH0MH UT WOS:000353714000025 PM 25537874 ER PT J AU Tian, N Shaw, EC Zack, M Kobau, R Dykstra, H Covington, TM AF Tian, Niu Shaw, Esther C. Zack, Matthew Kobau, Rosemarie Dykstra, Heather Covington, Theresa M. TI Cause-specificmortality among children and young adults with epilepsy: Results from the US National Child Death Review Case Reporting System SO EPILEPSY & BEHAVIOR LA English DT Article DE Epilepsy; Mortality; Death; Infant; Child ID ONSET EPILEPSY; MORTALITY AB We investigated causes of death in children and young adults with epilepsy by using data from the U.S. National Child Death Review Case Reporting System(NCDR-CRS), a passive surveillance system composed of comprehensive information related to deaths reviewed by local child death review teams. Information on a total of 48,697 deaths in children and young adults 28 days to 24 years of age, including 551 deaths with epilepsy and 48,146 deaths without epilepsy, was collected from 2004 through 2012 in 32 states. In a proportionate mortality analysis by official manner of death, decedents with epilepsy had a significantly higher percentage of natural deaths but significantly lower percentages of deaths due to accidents, homicide, and undetermined causes compared with persons without epilepsy. With respect to underlying causes of death, decedents with epilepsy had significantly higher percentages of deaths due to drowning and most medical conditions including pneumonia and congenital anomalies but lower percentages of deaths due to asphyxia, weapon use, and unknown causes compared with decedents without epilepsy. The increased percentages of deaths due to pneumonia and drowning in children and young adults with epilepsy suggest preventive interventions including immunization and better instruction and monitoring before or during swimming. State-specific and national population-based mortality studies of children and young adults with epilepsy are recommended. Published by Elsevier Inc. C1 [Tian, Niu; Zack, Matthew; Kobau, Rosemarie] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Populat Hlth, Epilepsy Program, Atlanta, GA 30341 USA. [Shaw, Esther C.; Dykstra, Heather; Covington, Theresa M.] Natl Ctr Review & Prevent Child Deaths, Michigan Publ Hlth Inst, Okemos, MI 48864 USA. RP Tian, N (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Populat Hlth, Epilepsy Program, 4770 Buford Highway NE,Mailstop F-78, Atlanta, GA 30341 USA. EM vii9@cdc.gov FU Maternal and Child Health Bureau, Health Resources and Services Administration; U.S. Department of Health and Human Services [U49 MC00225] FX The NCDR-CRS is partially funded by the Maternal and Child Health Bureau, Health Resources and Services Administration, and U.S. Department of Health and Human Services (grant U49 MC00225). We gratefully acknowledge the child death review coordinators in the participating states for their enthusiastic support of this project. The authors are grateful to Dr. Yao-Hua Luo for statistical assistance. NR 17 TC 1 Z9 1 U1 0 U2 3 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1525-5050 EI 1525-5069 J9 EPILEPSY BEHAV JI Epilepsy Behav. PD APR PY 2015 VL 45 BP 31 EP 34 DI 10.1016/j.yebeh.2015.02.006 PG 4 WC Behavioral Sciences; Clinical Neurology; Psychiatry SC Behavioral Sciences; Neurosciences & Neurology; Psychiatry GA CH2BY UT WOS:000353830700005 PM 25794682 ER PT J AU Aroda, VR Christophi, CA Edelstein, SL Zhang, P Herman, WH Barrett-Connor, E Delahanty, LM Montez, MG Ackermann, RT Zhuo, X Knowler, WC Ratner, RE AF Aroda, V. R. Christophi, C. A. Edelstein, S. L. Zhang, P. Herman, W. H. Barrett-Connor, E. Delahanty, L. M. Montez, M. G. Ackermann, R. T. Zhuo, X. Knowler, W. C. Ratner, R. E. CA Diabet Prevention Program Res Grp TI The Effect of Lifestyle Intervention and Metformin on Preventing or Delaying Diabetes Among Women With and Without Gestational Diabetes: The Diabetes Prevention Program Outcomes Study 10-Year Follow-Up SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID ORAL GLUCOSE-TOLERANCE; CLINICAL-TRIAL; MELLITUS; MODELS AB Context: Gestational diabetes (GDM) confers a high risk of type 2 diabetes. In the Diabetes Prevention Program (DPP), intensive lifestyle (ILS) and metformin prevented or delayed diabetes in women with a history of GDM. Objective: The objective of the study was to evaluate the impact of ILS and metformin intervention over 10 years in women with and without a history of GDM in the DPP/Diabetes Prevention Program Outcomes Study. Design: This was a randomized controlled clinical trial with an observational follow-up. Setting: The study was conducted at 27 clinical centers. Participants: Three hundred fifty women with a history of GDM and 1416 women with previous live births but no history of GDM participated in the study. The participants had an elevated body mass index and fasting glucose and impaired glucose tolerance at study entry. Interventions: Interventions included placebo, ILS, or metformin. Outcomes Measure: Outcomes measure was diabetes mellitus. Results: Over 10 years, women with a history of GDM assigned to placebo had a 48% higher risk of developing diabetes compared with women without a history of GDM. In women with a history of GDM, ILS and metformin reduced progression to diabetes compared with placebo by 35% and 40%, respectively. Among women without a history of GDM, ILS reduced the progression to diabetes by 30%, and metformin did not reduce the progression to diabetes. Conclusions: Women with a history of GDM are at an increased risk of developing diabetes. In women with a history of GDM in the DPP/Diabetes Prevention Program Outcomes Study, both lifestyle and metformin were highly effective in reducing progression to diabetes during a 10-year follow-up period. Among women without a history of GDM, lifestyle but not metformin reduced progression to diabetes. C1 [Aroda, V. R.; Ratner, R. E.] MedStar Hlth Res Inst, Hyattsville, MD 20782 USA. [Christophi, C. A.; Edelstein, S. L.] George Washington Univ, Ctr Biostat, Rockville, MD 20852 USA. [Zhang, P.; Zhuo, X.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Herman, W. H.] Univ Michigan, Ann Arbor, MI 48109 USA. [Barrett-Connor, E.] Univ Calif San Diego, La Jolla, CA 92093 USA. [Delahanty, L. M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Delahanty, L. M.] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Montez, M. G.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Ackermann, R. T.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Knowler, W. C.] NIDDK, Phoenix, AZ 85014 USA. RP Aroda, VR (reprint author), George Washington Univ, Ctr Biostat, Diabet Prevent Program Coordinating Ctr, 6110 Execut Blvd,Suite 750, Rockville, MD 20852 USA. RI Uwaifo, Gabriel/M-2361-2016 OI Uwaifo, Gabriel/0000-0002-6962-9304 FU National Institutes of Health, NIDDK [U01-DK048489] FX This work was supported by the National Institutes of Health, NIDDK, under U01-DK048489. NR 17 TC 30 Z9 33 U1 2 U2 10 PU ENDOCRINE SOC PI WASHINGTON PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA SN 0021-972X EI 1945-7197 J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD APR PY 2015 VL 100 IS 4 BP 1646 EP 1653 DI 10.1210/jc.2014-3761 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CG5UN UT WOS:000353361500076 PM 25706240 ER PT J AU Gittelman, S Lange, V Crawford, CAG Okoro, CA Lieb, E Dhingra, SS Trimarchi, E AF Gittelman, Steven Lange, Victor Crawford, Carol A. Gotway Okoro, Catherine A. Lieb, Eugene Dhingra, Satvinder S. Trimarchi, Elaine TI A New Source of Data for Public Health Surveillance: Facebook Likes SO JOURNAL OF MEDICAL INTERNET RESEARCH LA English DT Article DE big data; social networks; surveillance; chronic illness ID SOCIAL NETWORKING; DISEASE DETECTION; RISK-FACTORS; BEHAVIOR; MEDICINE; WEB; EPIDEMIOLOGY; ATTRIBUTES; INTERNET; POWER AB Background: Investigation into personal health has become focused on conditions at an increasingly local level, while response rates have declined and complicated the process of collecting data at an individual level. Simultaneously, social media data have exploded in availability and have been shown to correlate with the prevalence of certain health conditions. Objective: Facebook likes may be a source of digital data that can complement traditional public health surveillance systems and provide data at a local level. We explored the use of Facebook likes as potential predictors of health outcomes and their behavioral determinants. Methods: We performed principal components and regression analyses to examine the predictive qualities of Facebook likes with regard to mortality, diseases, and lifestyle behaviors in 214 counties across the United States and 61 of 67 counties in Florida. These results were compared with those obtainable from a demographic model. Health data were obtained from both the 2010 and 2011 Behavioral Risk Factor Surveillance System (BRFSS) and mortality data were obtained from the National Vital Statistics System. Results: Facebook likes added significant value in predicting most examined health outcomes and behaviors even when controlling for age, race, and socioeconomic status, with model fit improvements (adjusted R-2) of an average of 58% across models for 13 different health-related metrics over basic sociodemographic models. Small area data were not available in sufficient abundance to test the accuracy of the model in estimating health conditions in less populated markets, but initial analysis using data from Florida showed a strong model fit for obesity data (adjusted R-2=.77). Conclusions: Facebook likes provide estimates for examined health outcomes and health behaviors that are comparable to those obtained from the BRFSS. Online sources may provide more reliable, timely, and cost-effective county-level data than that obtainable from traditional public health surveillance systems as well as serve as an adjunct to those systems. C1 [Gittelman, Steven; Lange, Victor; Trimarchi, Elaine] Mktg Inc, East Islip, NY 11730 USA. [Crawford, Carol A. Gotway] USDA Natl Agr Stat Serv, Div Res & Dev, Washington, DC USA. [Okoro, Catherine A.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Populat Hlth, Atlanta, GA USA. [Lieb, Eugene] Custom Decis Support, Los Angeles, CA USA. [Dhingra, Satvinder S.] Northrop Grumman, Atlanta, GA USA. RP Gittelman, S (reprint author), Mktg Inc, 200 Carleton Ave, East Islip, NY 11730 USA. EM Steve@Mktginc.com NR 50 TC 4 Z9 5 U1 4 U2 34 PU JMIR PUBLICATIONS, INC PI TORONTO PA 59 WINNERS CIRCLE, TORONTO, ON M4L 3Y7, CANADA SN 1438-8871 J9 J MED INTERNET RES JI J. Med. Internet Res. PD APR PY 2015 VL 17 IS 4 AR e98 DI 10.2196/jmir.3970 PG 10 WC Health Care Sciences & Services; Medical Informatics SC Health Care Sciences & Services; Medical Informatics GA CH3KC UT WOS:000353928600004 PM 25895907 ER PT J AU Nakazawa, Y Mauldin, MR Emerson, GL Reynolds, MG Lash, RR Gao, JX Zhao, H Li, Y Muyembe, JJ Kingebeni, PM Wemakoy, O Malekani, J Karem, KL Damon, IK Carroll, DS AF Nakazawa, Yoshinori Mauldin, Matthew R. Emerson, Ginny L. Reynolds, Mary G. Lash, R. Ryan Gao, Jinxin Zhao, Hui Li, Yu Muyembe, Jean-Jacques Kingebeni, Placide Mbala Wemakoy, Okito Malekani, Jean Karem, Kevin L. Damon, Inger K. Carroll, Darin S. TI A Phylogeographic Investigation of African Monkeypox SO VIRUSES-BASEL LA English DT Article ID CLIMATE-CHANGE; GEOGRAPHIC-DISTRIBUTION; SPECIES DISTRIBUTIONS; PLEISTOCENE REFUGIA; UNITED-STATES; NORTH-AMERICA; DAHOMEY GAP; RAIN-FOREST; CONGO; VIRUS AB Monkeypox is a zoonotic disease caused by a virus member of the genus Orthopoxvirus and is endemic to Central and Western African countries. Previous work has identified two geographically disjuct clades of monkeypox virus based on the analysis of a few genomes coupled with epidemiological and clinical analyses; however, environmental and geographic causes of this differentiation have not been explored. Here, we expand previous phylogenetic studies by analyzing a larger set of monkeypox virus genomes originating throughout Sub-Saharan Africa to identify possible biogeographic barriers associated with genetic differentiation; and projected ecological niche models onto environmental conditions at three periods in the past to explore the potential role of climate oscillations in the evolution of the two primary clades. Analyses supported the separation of the Congo Basin and West Africa clades; the Congo Basin clade shows much shorter branches, which likely indicate a more recent diversification of isolates within this clade. The area between the Sanaga and Cross Rivers divides the two clades and the Dahomey Gap seems to have also served as a barrier within the West African clade. Contraction of areas with suitable environments for monkeypox virus during the Last Glacial Maximum, suggests that the Congo Basin clade of monkeypox virus experienced a severe bottleneck and has since expanded its geographic range. C1 [Nakazawa, Yoshinori; Mauldin, Matthew R.; Emerson, Ginny L.; Reynolds, Mary G.; Lash, R. Ryan; Gao, Jinxin; Zhao, Hui; Li, Yu; Karem, Kevin L.; Damon, Inger K.; Carroll, Darin S.] Ctr Dis Control & Prevent, Poxvirus & Rabies Branch, Atlanta, GA 30333 USA. [Mauldin, Matthew R.] Oak Ridge Inst Sci & Educ ORISE, CDC Fellowship Program, Oak Ridge, TN 37831 USA. [Muyembe, Jean-Jacques; Kingebeni, Placide Mbala] INRB Lab, Lemba, DEM REP CONGO. [Wemakoy, Okito] Univ Kinshasa, Kinshasa Sch Publ Hlth, Kinshasa 11850, DEM REP CONGO. [Malekani, Jean] Univ Kinshasa, Dept Biol, Lemba, DEM REP CONGO. RP Nakazawa, Y (reprint author), Ctr Dis Control & Prevent, Poxvirus & Rabies Branch, 1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM ynakazawa@cdc.gov; mmauldin@cdc.gov; gemerson@cdc.gov; mreynolds3@cdc.gov; rlash@cdc.gov; jgao2@cdc.gov; hzhao1@cdc.gov; yuli@cdc.gov; muyembejj@gmail.com; mbalaplacide@gmail.com; okitow@yahoo.fr; jean.malekani@unikin.ac.cd; kkarem@cdc.gov; idamon@cdc.gov; dcarroll@cdc.gov FU CDC FX The authors thank the Emory University Core facility for assistance with genomic sequencing and Chris Upton and Nick Tang in the Department of Biochemistry and Microbiology at the University of Victoria for their assistance with annotation and submission of genomes. Isolation of MPXV from recent DRC cases was the result of research and surveillance efforts led by the Kinshasa School of Public Health, the Institut National de Recherche Biomedicale (INRB), and the Department of Biology at the University of Kinshasa in DRC. Annotation was performed with tools at the Viral Bioinformatics Resource Center (www.virology.ca). This research was supported in part by the appointment of MRM to the Research Participation Program at the CDC, administered by the Oak Ridge Institute for Science and Education (ORISE) through an interagency agreement between the US Department of Energy and the CDC. NR 75 TC 0 Z9 0 U1 2 U2 10 PU MDPI AG PI BASEL PA POSTFACH, CH-4005 BASEL, SWITZERLAND SN 1999-4915 J9 VIRUSES-BASEL JI Viruses-Basel PD APR PY 2015 VL 7 IS 4 BP 2168 EP 2184 DI 10.3390/v7042168 PG 17 WC Virology SC Virology GA CH0OH UT WOS:000353720400031 PM 25912718 ER PT J AU Fang, X Fry, DA Brown, DS Mercy, JA Dunne, MP Butchart, AR Corso, PS Maynzyuk, K Dzhygyr, Y Chen, Y Mccoy, A Swales, DM AF Fang, Xiangming Fry, Deborah A. Brown, Derek S. Mercy, James A. Dunne, Michael P. Butchart, Alexander R. Corso, Phaedra S. Maynzyuk, Kateryna Dzhygyr, Yuriy Chen, Yu McCoy, Amalee Swales, Diane M. TI The burden of child maltreatment in the East Asia and Pacific region SO CHILD ABUSE & NEGLECT LA English DT Article DE Child maltreatment; Economic burden; Lifelong consequences; Disability-Adjusted Life Years; East Asia and Pacific region ID SEXUAL-ABUSE; MENTAL-HEALTH; VIOLENCE; OUTCOMES; RISK; ASSOCIATION; PREVALENCE; EXPOSURE; TRENDS; STATES AB This study estimated the health and economic burden of child maltreatment in the East Asia and Pacific region, addressing a significant gap in the current evidence base. Systematic reviews and meta-analyses were conducted to estimate the prevalence of child physical abuse, sexual abuse, emotional abuse, neglect, and witnessing parental violence. Population Attributable Fractions were calculated and Disability-Adjusted Life Years (DALYs) lost from physical and mental health outcomes and health risk behaviors attributable to child maltreatment were estimated using the most recent comparable Global Burden of Disease data. DALY losses were converted into monetary value by assuming that one DALY is equal to the sub-region's per capita GDP. The estimated economic value of DALYs lost to violence against children as a percentage of GDP ranged from 1.24% to 3.46% across sub-regions defined by the World Health Organization. The estimated economic value of DALYs (in constant 2000 US$) lost to child maltreatment in the EAP region totaled US $151 billion, accounting for 1.88% of the region's GDP. Updated to 2012 dollars, the estimated economic burden totaled US $194 billion. In sensitivity analysis, the aggregate costs as a percentage of GDP range from 1.36% to 2.52%. The economic burden of child maltreatment in the East Asia and Pacific region is substantial, indicating the importance of preventing and responding to child maltreatment in this region. More comprehensive research into the impact of multiple types of childhood adversity on a wider range of putative health outcomes is needed to guide policy and programs for child protection in the region, and globally. (c) 2015 Elsevier Ltd. All rights reserved. C1 [Fang, Xiangming; Chen, Yu] China Agr Univ, Int Ctr Appl Econ & Policy, Coll Econ & Management, Beijing 100083, Peoples R China. [Fry, Deborah A.] Univ Edinburgh, Moray House Sch Educ, Edinburgh EH8 9YL, Midlothian, Scotland. [Brown, Derek S.] Washington Univ, Brown Sch, St Louis, MO USA. [Mercy, James A.] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA. [Dunne, Michael P.] Queensland Univ Technol, Children & Youth Res Ctr, Sch Publ Hlth & Social Work, Kelvin Grove, Australia. [Butchart, Alexander R.] World Hlth Org, Dept Violence & Injury Prevent & Disabil, Noncommunicable Dis & Mental Hlth, Geneva, Switzerland. [Corso, Phaedra S.] Univ Georgia, Coll Publ Hlth, Dept Hlth Policy & Management, Athens, GA 30602 USA. [McCoy, Amalee; Swales, Diane M.] UNICEF East Asia & Pacific Reg Off, Bangkok, Thailand. RP Fang, X (reprint author), China Agr Univ, Int Ctr Appl Econ & Policy, Coll Econ & Management, 17 Qinghuadong Rd, Beijing 100083, Peoples R China. RI Fang, Xiangming/O-1653-2014; Brown, Derek/J-3035-2013 OI Fang, Xiangming/0000-0001-9922-8977; Brown, Derek/0000-0001-9908-9882 FU UNICEF East Asia and Pacific Regional Office [43123767] FX This study was funded by a grant (Contract No.43123767) from the UNICEF East Asia and Pacific Regional Office. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of UNICEF East Asia and Pacific Regional Office. NR 41 TC 13 Z9 13 U1 3 U2 20 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0145-2134 EI 1873-7757 J9 CHILD ABUSE NEGLECT JI Child Abuse Negl. PD APR PY 2015 VL 42 BP 146 EP 162 DI 10.1016/j.chiabu.2015.02.012 PG 17 WC Family Studies; Psychology, Social; Social Work SC Family Studies; Psychology; Social Work GA CG1CK UT WOS:000353010400014 PM 25757367 ER PT J AU Romano, ME Webster, GM Vuong, AM Zoeller, RT Chen, AM Hoofnagle, AN Calafat, AM Karagas, MR Yolton, K Lanphear, BP Braun, JM AF Romano, Megan E. Webster, Glenys M. Vuong, Ann M. Zoeller, R. Thomas Chen, Aimin Hoofnagle, Andrew N. Calafat, Antonia M. Karagas, Margaret R. Yolton, Kimberly Lanphear, Bruce P. Braun, Joseph M. TI Gestational urinary bisphenol A and maternal and newborn thyroid hormone concentrations: The HOME Study SO ENVIRONMENTAL RESEARCH LA English DT Article DE Bisphenol A; Thyroid hormones; Thyroid stimulating hormone; Thyroxine; Triiodothyronine; Pregnant women; Newborns; Endocrine disruptors; Epidemiology ID POLYCHLORINATED-BIPHENYLS; PRENATAL EXPOSURE; NATIONAL-HEALTH; PREGNANCY; BEHAVIOR; CHILDHOOD; CHILDREN; SERUM; POPULATION; PREVALENCE AB Bisphenol A (BPA), an endocrine disruptor used in consumer products, may perturb thyroid function. Prenatal BPA exposure may have sex-specific effects on thyroid hormones (THs). Our objectives were to investigate whether maternal urinary BPA concentrations during pregnancy were associated with THs in maternal or cord serum, and whether these associations differed by newborn sex or maternal iodine status. We measured urinary BPA concentrations at 16 and 26 weeks gestation among pregnant women in the HOME Study (2003-2006, Cincinnati, Ohio). Thyroid stimulating hormone (TSH) and free and total thyroxine (T-4) and triiodothyronine (T-3) were measured in maternal serum at 16 weeks (n=181) and cord serum at delivery (n=249). Associations between BPA concentrations and maternal or cord serum TH levels were estimated by multivariable linear regression. Mean maternal urinary BPA was not associated with cord THs in all newborns, but a 10-fold increase in mean BPA was associated with lower cord TSH in girls (percent change=-36.0%; 95% confidence interval (CI): -58.4, -1.7%), but not boys (7.8%; 95% CI: -28.5, 62.7%; p-for-effect modification=0.09). We observed no significant associations between 16-week BPA and THs in maternal or cord serum, but 26-week maternal BPA was inversely associated with TSH in girls ( -42.9%; 95% CI: -59.9, -18.5%), but not boys (7.6%; 95% CI: -17.3,40.2%; p-for-effect modification=0.005) at birth. The inverse BPA-TSH relation among girls was stronger, but less precise, among iodine deficient versus sufficient mothers. Prenatal BPA exposure may reduce TSH among newborn girls, particularly when exposure occurs later in gestation. (C) 2015 Elsevier Inc. All rights reserved. C1 [Romano, Megan E.; Braun, Joseph M.] Brown Univ, Sch Publ Hlth, Dept Epidemiol, Providence, RI 02912 USA. [Webster, Glenys M.; Lanphear, Bruce P.] Simon Fraser Univ, BC Childrens & Womens Hosp, Child & Family Res Inst, Vancouver, BC, Canada. [Webster, Glenys M.; Lanphear, Bruce P.] Simon Fraser Univ, Fac Hlth Sci, Vancouver, BC, Canada. [Vuong, Ann M.; Chen, Aimin] Univ Cincinnati, Coll Med, Dept Environm Hlth, Div Epidemiol & Biostat, Cincinnati, OH 45267 USA. [Zoeller, R. Thomas] Univ Massachusetts, Dept Biol, Amherst, MA 01003 USA. [Hoofnagle, Andrew N.] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA. [Calafat, Antonia M.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Sci Lab, Atlanta, GA USA. [Karagas, Margaret R.] Geisel Sch Med Dartmouth, Childrens Environm Hlth & Dis Prevent Res Ctr, Hanover, NH USA. [Karagas, Margaret R.] Geisel Sch Med Dartmouth, Dept Community & Family Med, Hanover, NH USA. [Yolton, Kimberly] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Gen & Community Pediat, Cincinnati, OH 45229 USA. RP Romano, ME (reprint author), Brown Univ, Dept Epidemiol, Box G-S-121-2, Providence, RI 02912 USA. EM megan_romano@brown.edu RI Braun, Joseph/H-8649-2014 FU [R00-ES020346]; [R01-ES020349]; [P01-ES11261]; [P01ES022832-02]; [RD-83544201] FX This research was supported by R00-ES020346, R01-ES020349, P01-ES11261, P01ES022832-02, and RD-83544201. The authors have no conflicts of interest to declare. The authors thank the HOME Study personnel for their skillful assistance and acknowledge the Centers for Disease Control and Prevention (CDC) laboratory staff who performed the measurements of BPA, creatinine, PCBs, and cotinine. NR 45 TC 18 Z9 18 U1 2 U2 17 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0013-9351 EI 1096-0953 J9 ENVIRON RES JI Environ. Res. PD APR PY 2015 VL 138 BP 453 EP 460 DI 10.1016/j.envres.2015.03.003 PG 8 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA CG1CT UT WOS:000353011300048 PM 25794847 ER PT J AU Correa, A Levis, DM Tinker, SC Cragan, JD AF Correa, Adolfo Levis, Denise M. Tinker, Sarah C. Cragan, Janet D. TI Maternal Cigarette Smoking and Congenital Heart Defects SO JOURNAL OF PEDIATRICS LA English DT Editorial Material ID METROPOLITAN ATLANTA; DISEASE; METAANALYSIS; ASSOCIATION; PREGNANCY; RISK; PREVALENCE; MOTHERS; UPDATE; HEALTH C1 [Correa, Adolfo] Univ Mississippi, Med Ctr, Dept Med, Jackson, MS 39216 USA. [Correa, Adolfo] Univ Mississippi, Med Ctr, Dept Pediat, Jackson, MS 39216 USA. [Levis, Denise M.; Tinker, Sarah C.; Cragan, Janet D.] Ctr Dis Control & Prevent, Div Birth Defects & Dev Disabil, Atlanta, GA USA. RP Correa, A (reprint author), Univ Mississippi, Med Ctr, Dept Med, 2500 North State St, Jackson, MS 39216 USA. EM acorrea@umc.edu FU Intramural CDC HHS [CC999999]; NCCIH NIH HHS [U01 AT006239, 1U01AT006239-01]; NHLBI NIH HHS [HHSN268201300047C, HHSN268201300046C, HHSN268201300049C]; NIMHD NIH HHS [P60MD002249-01, P60 MD002249]; PHS HHS [HHSN268201300046C, HHSN268201300049C, HHSN268201300047C] NR 25 TC 3 Z9 3 U1 2 U2 4 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-3476 EI 1097-6833 J9 J PEDIATR-US JI J. Pediatr. PD APR PY 2015 VL 166 IS 4 BP 801 EP 804 DI 10.1016/j.jpeds.2015.01.013 PG 5 WC Pediatrics SC Pediatrics GA CG6DL UT WOS:000353385700007 PM 25681204 ER PT J AU Wang, Y Liu, G Canfield, MA Mai, CT Gilboa, SM Meyer, RE Anderka, M Copeland, GE Kucik, JE Nembhard, WN Kirby, RS AF Wang, Ying Liu, Gang Canfield, Mark A. Mai, Cara T. Gilboa, Suzanne M. Meyer, Robert E. Anderka, Marlene Copeland, Glenn E. Kucik, James E. Nembhard, Wendy N. Kirby, Russell S. CA Natl Birth Defects Prevention Netw TI Racial/Ethnic Differences in Survival of United States Children with Birth Defects: A Population-Based Study SO JOURNAL OF PEDIATRICS LA English DT Article ID CONGENITAL HEART-DEFECTS; ATRIOVENTRICULAR SEPTAL-DEFECT; DOWN-SYNDROME; MATERNAL RACE/ETHNICITY; METROPOLITAN ATLANTA; CHILDHOOD MORTALITY; 1ST-YEAR SURVIVAL; GESTATIONAL-AGE; REGISTRY DATA; SPINA-BIFIDA AB Objectives To examine racial/ethnic-specific survival of children with major birth defects in the US. Study design We pooled data on live births delivered during 1999-2007 with any of 21 birth defects from 12 population-based birth defects surveillance programs. We used the Kaplan-Meier method to calculate cumulative survival probabilities and Cox proportional hazards models to estimate mortality risk. Results For most birth defects, there were small-to-moderate differences in neonatal (<28 days) survival among racial/ethnic groups. However, compared with children born to non-Hispanic white mothers, postneonatal infant (28 days to <1 year) mortality risk was significantly greater among children born to non-Hispanic black mothers for 13 of 21 defects (hazard ratios [HRs] 1.3-2.8) and among children born to Hispanic mothers for 10 of 21 defects (HRs 1.3-1.7). Compared with children born to non-Hispanic white mothers, a significantly increased childhood (<= 8 years) mortality risk was found among children born to Asian/Pacific Islander mothers for encephalocele (HR 2.6), tetralogy of Fallot, and atrioventricular septal defect (HRs 1.6-1.8) and among children born to American Indian/Alaska Native mothers for encephalocele (HR 2.8), whereas a significantly decreased childhood mortality risk was found among children born to Asian/Pacific Islander mothers for cleft lip with or without cleft palate (HR 0.6). Conclusion Children with birth defects born to non-Hispanic black and Hispanic mothers carry a greater risk of mortality well into childhood, especially children with congenital heart defect. Understanding survival differences among racial/ethnic groups provides important information for policy development and service planning. C1 [Wang, Ying] NYU, Dept Hlth, Off Primary Care & Hlth Syst Management, Div Data Management Anal & Res, Albany, NY 12237 USA. [Liu, Gang] SUNY Albany, Sch Publ Hlth, Dept Epidemiol & Biostat, Albany, NY 12222 USA. [Canfield, Mark A.] Texas Dept State Hlth Serv, Austin, TX USA. [Mai, Cara T.; Gilboa, Suzanne M.; Kucik, James E.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Meyer, Robert E.] North Carolina Birth Defects Monitoring Program, Raleigh, NC USA. [Anderka, Marlene] Massachusetts Dept Publ Hlth, Boston, MA USA. [Copeland, Glenn E.] Michigan Dept Community Hlth, Michigan Birth Defects Registry, Lansing, MI USA. [Nembhard, Wendy N.] Arkansas Childrens Hosp, Res Inst, Arkansas Reprod Hlth Monitoring Syst, Little Rock, AR 72202 USA. [Nembhard, Wendy N.] Univ Arkansas Med Sci, Little Rock, AR 72205 USA. [Kirby, Russell S.] Univ S Florida, Coll Publ Hlth, Dept Community & Family Hlth, Tampa, FL USA. RP Wang, Y (reprint author), NYU, Dept Hlth, Off Primary Care & Hlth Syst Management, Div Data Management Anal & Res, Empire State Plaza,Corning Tower,Room 1695, Albany, NY 12237 USA. EM ying.wang@health.ny.gov OI Liu, Gang/0000-0003-1928-2047 FU Intramural CDC HHS [CC999999] NR 35 TC 13 Z9 15 U1 0 U2 9 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-3476 EI 1097-6833 J9 J PEDIATR-US JI J. Pediatr. PD APR PY 2015 VL 166 IS 4 BP 819 EP U94 DI 10.1016/j.jpeds.2014.12.025 PG 10 WC Pediatrics SC Pediatrics GA CG6DL UT WOS:000353385700010 PM 25641238 ER PT J AU Moro, PL Jankosky, C Menschik, D Lewis, P Duffy, J Stewart, B Shimabukuro, TT AF Moro, Pedro L. Jankosky, Christopher Menschik, David Lewis, Paige Duffy, Jonathan Stewart, Brock Shimabukuro, Tom T. TI Adverse Events following Haemophilus influenzae Type b Vaccines in the Vaccine Adverse Event Reporting System, 1990-2013 SO JOURNAL OF PEDIATRICS LA English DT Article ID INFANT-DEATH-SYNDROME; IMMUNIZATION SAFETY DATA; CONJUGATE VACCINE; UNITED-STATES; ACELLULAR PERTUSSIS; FEBRILE SEIZURES; CASE-DEFINITION; RISK; IMMUNOGENICITY; TETANUS AB Objective To characterize adverse events (AEs) after Haemophilus influenzae type b (Hib) vaccines reported to the US Vaccine Adverse Event Reporting System (VAERS), a spontaneous reporting surveillance system. Study design We searched VAERS for US reports after Hib vaccines among reports received from January 1, 1990, to December 1, 2013. We reviewed a random sample of reports and accompanying medical records for reports classified as serious. All reports of death were reviewed. Physicians assigned a primary clinical category to each reviewed report. We used empirical Bayesian data mining to identify AEs that were disproportionally reported after Hib vaccines. Results VAERS received 29 747 reports after Hib vaccines; 5179 (17%) were serious, including 896 reports of deaths. Median age was 6 months (range 0-1022 months). Sudden infant death syndrome was the stated cause of death in 384 (51%) of 749 death reports with autopsy/death certificate records. The most common nondeath serious AE categories were neurologic (80; 37%), other noninfectious (46; 22%) (comprising mainly constitutional signs and symptoms); and gastrointestinal (39; 18%) conditions. No new safety concerns were identified after clinical review of reports of AEs that exceeded the data mining statistical threshold. Conclusion Review of VAERS reports did not identify any new or unexpected safety concerns for Hib vaccines. C1 [Moro, Pedro L.; Lewis, Paige; Duffy, Jonathan; Stewart, Brock; Shimabukuro, Tom T.] Ctr Dis Control & Prevent, Immunizat Safety Off, Atlanta, GA 30333 USA. [Jankosky, Christopher; Menschik, David] US FDA, Ctr Biol Evaluat & Res, Silver Spring, MD USA. RP Moro, PL (reprint author), Ctr Dis Control & Prevent, Immunizat Safety Off, Div Healthcare Qual Promot, 1600 Clifton Rd,MS D26, Atlanta, GA 30333 USA. EM pmoro@cdc.gov FU Centers for Disease Control and Prevention (CDC); Food and Drug Administration (FDA) FX Funded by the Centers for Disease Control and Prevention (CDC) and Food and Drug Administration (FDA). The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC or the FDA. The authors declare no conflicts of interest. NR 34 TC 4 Z9 4 U1 0 U2 7 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-3476 EI 1097-6833 J9 J PEDIATR-US JI J. Pediatr. PD APR PY 2015 VL 166 IS 4 BP 992 EP 997 DI 10.1016/j.jpeds.2014.12.014 PG 6 WC Pediatrics SC Pediatrics GA CG6DL UT WOS:000353385700039 PM 25598306 ER PT J AU Mody, RK Gu, WD Griffin, PM Jones, TF Rounds, J Shiferaw, B Tobin-D'Angelo, M Smith, G Spina, N Hurd, S Lathrop, S Palmer, A Boothe, E Luna-Gierke, RE Hoekstra, RM AF Mody, Rajal K. Gu, Weidong Griffin, Patricia M. Jones, Timothy F. Rounds, Josh Shiferaw, Beletshachew Tobin-D'Angelo, Melissa Smith, Glenda Spina, Nancy Hurd, Sharon Lathrop, Sarah Palmer, Amanda Boothe, Effie Luna-Gierke, Ruth E. Hoekstra, Robert M. TI Postdiarrheal Hemolytic Uremic Syndrome in United States Children: Clinical Spectrum and Predictors of In-Hospital Death SO JOURNAL OF PEDIATRICS LA English DT Article ID ESCHERICHIA-COLI; RELATIVE NEPHROPROTECTION; VOLUME EXPANSION; RISK-FACTORS; INFECTIONS; DIARRHEA; LEUKOCYTOSIS; ADMISSION; COUNT AB Objective To assess the clinical spectrum of postdiarrheal hemolytic uremic syndrome (D+HUS) hospitalizations and sought predictors of in-hospital death to help identify children at risk of poor outcomes. Study design We assessed clinical variables collected through population-based surveillance of D+HUS in children <18 years old hospitalized in 10 states during 1997-2012 as predictors of in-hospital death by using tree modeling. Results We identified 770 cases. Of children with information available, 56.5% (430 of 761) required dialysis, 92.6% (698 of 754) required a transfusion, and 2.9% (22 of 770) died; few had a persistent dialysis requirement (52 [7.3%] of 716) at discharge. The tree model partitioned children into 5 groups on the basis of 3 predictors (highest leukocyte count and lowest hematocrit value during the 7 days before to 3 days after the diagnosis of hemolytic uremic syndrome, and presence of respiratory tract infection [RTI] within 3 weeks before diagnosis). Patients with greater leukocyte or hematocrit values or a recent RTI had a greater probability of in-hospital death. The largest group identified (n = 533) had none of these factors and had the lowest odds of death. Many children with RTI had recent antibiotic treatment for nondiarrheal indications. Conclusion Most children with D+HUS have good hospitalization outcomes. Our findings support previous reports of increased leukocyte count and hematocrit as predictors of death. Recent RTI could be an additional predictor, or a marker of other factors such as antibiotic exposure, that may warrant further study. C1 [Mody, Rajal K.; Gu, Weidong; Griffin, Patricia M.; Luna-Gierke, Ruth E.; Hoekstra, Robert M.] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30333 USA. [Jones, Timothy F.; Boothe, Effie] Tennessee Dept Hlth, Nashville, TN USA. [Rounds, Josh] Minnesota Dept Hlth, St Paul, MN USA. [Shiferaw, Beletshachew] Oregon Publ Hlth Div, Portland, OR USA. [Tobin-D'Angelo, Melissa] Georgia Dept Publ Hlth, Atlanta, GA USA. [Smith, Glenda; Spina, Nancy] New York State Emerging Infect Program, Albany, NY USA. [Hurd, Sharon] Connecticut Emerging Infect Program, New Haven, CT USA. [Lathrop, Sarah] New Mexico Emerging Infect Program, Albuquerque, NM USA. [Palmer, Amanda] Maryland Dept Hlth & Mental Hyg, Baltimore, MD USA. RP Mody, RK (reprint author), Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30333 USA. FU Centers for Disease Control and Prevention FX Funded by the Centers for Disease Control and Prevention. FoodNet is a collaborative project among the Centers for Disease Control and Prevention, participating state health departments, the US Department of Agriculture, and the US Food and Drug Administration. The authors declare no conflicts of interest. NR 29 TC 3 Z9 3 U1 0 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-3476 EI 1097-6833 J9 J PEDIATR-US JI J. Pediatr. PD APR PY 2015 VL 166 IS 4 BP 1022 EP 1029 DI 10.1016/j.jpeds.2014.12.064 PG 8 WC Pediatrics SC Pediatrics GA CG6DL UT WOS:000353385700044 PM 25661408 ER PT J AU Ng, TFF Miller, MA Kondov, NO Dodd, EM Batac, F Manzer, M Ives, S Saliki, JT Deng, XT Delwart, E AF Terry Fei Fan Ng Miller, Melissa A. Kondov, Nikola O. Dodd, Erin M. Batac, Francesca Manzer, Mike Ives, Sarah Saliki, Jeremiah T. Deng, Xutao Delwart, Eric TI ORAL PAPILLOMATOSIS CAUSED BY ENHYDRA LUTRIS PAPILLOMAVIRUS 1 (EIPV-1) IN SOUTHERN SEA OTTERS (ENHYDRA LUTRIS NEREIS) IN CALIFORNIA, USA SO JOURNAL OF WILDLIFE DISEASES LA English DT Article DE Enhydra lutris; Enhydra lutris papillomavirus 1 (ElPV-1); next-generation sequencing; oral papillomatosis; papillomavirus; papillomaviral immunohistochemistry; sea otter; viral metagenomics ID CARCINOMA IN-SITU; CETACEAN PAPILLOMAVIRUSES; CANINE PAPILLOMAVIRUS; BOWENS-DISEASE; INFECTION; NORTHERN; RECOMBINATION; METASTASIS; TYPE-16; ALASKA AB The southern sea otter (Enhydralutris nereis) is a threatened marine sentinel. During postmortem investigations of stranded sea otters from 2004 to 2013 in California, US, papillomas were detected in the oral cavity of at least seven otters via necropsy and histopathology. Next-generation sequencing of viral particles purified from a single papilloma revealed a novel papillomavirus, Enhydra lutris papillomavirus 1 (ElPV-1). The genome of ElPV-1 was obtained, representing the first fully sequenced viral genome from southern sea otters. Phylogenetic analysis of the entire L1 gene, as well as a concatenated protein identities plot of all papillomaviral genes revealed that ElPV-1 is a X-papillomavirus, related to a raccoon papillomavirus (Procyon lotor papillomavirus type 1) and a canine oral papillomavirus. Immunohistochemical staining, using a cross-reactive bovine papillomavirus antibody, suggested that ElPV-1 is present in intranuclear inclusions and intracytoplasmic keratin granules. Virus-infected cells were scattered throughout the stratum granulosum and stratum spinosum of the gingival and buccal papillomas. Using ElPV-1 specific PCR, we confirmed viral DNA in oral papillomas from all seven stranded sea otters, with identical Li sequences. This virus is associated with the development of oral papillomatosis in southern sea otters. C1 [Terry Fei Fan Ng; Kondov, Nikola O.; Ives, Sarah; Deng, Xutao; Delwart, Eric] Blood Syst Res Inst, San Francisco, CA 94118 USA. [Terry Fei Fan Ng; Deng, Xutao; Delwart, Eric] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA. [Miller, Melissa A.; Dodd, Erin M.; Batac, Francesca] Calif Dept Fish & Wildlife, Marine Wildlife Vet Care & Res Ctr, Santa Cruz, CA 95060 USA. [Miller, Melissa A.; Manzer, Mike] Univ Calif Davis, Vet Med Teaching Hosp, Davis, CA 95616 USA. [Saliki, Jeremiah T.] Univ Georgia, Coll Vet Med, Athens Vet Diagnost Lab, Athens, GA 30602 USA. RP Ng, TFF (reprint author), Ctr Dis Control & Prevent, NCIRD, 1600 Clifton Rd, Atlanta, GA 30333 USA. EM terryfeifan@gmail.com; delwarte@medicine.ucsf.edu OI Ng, Terry Fei Fan/0000-0002-4815-8697 NR 36 TC 1 Z9 1 U1 1 U2 11 PU WILDLIFE DISEASE ASSOC, INC PI LAWRENCE PA 810 EAST 10TH ST, LAWRENCE, KS 66044-8897 USA SN 0090-3558 EI 1943-3700 J9 J WILDLIFE DIS JI J. Wildl. Dis. PD APR PY 2015 VL 51 IS 2 BP 446 EP 453 DI 10.7589/2014-06-152 PG 8 WC Veterinary Sciences SC Veterinary Sciences GA CF9XT UT WOS:000352921800015 PM 25647597 ER PT J AU Eads, DA Biggins, DE Antolin, MF Long, DH Huyvaert, KP Gage, KL AF Eads, David A. Biggins, Dean E. Antolin, Michael F. Long, Dustin H. Huyvaert, Kathryn P. Gage, Kenneth L. TI Prevalence of the Generalist Flea Pulex simulans on Black-tailed Prairie Dogs (Cynomys ludovicianus) in New Mexico, USA: The Importance of Considering Imperfect Detection SO JOURNAL OF WILDLIFE DISEASES LA English DT Article DE Cynomys; flea; occupancy modeling; Oropsylla hirsuta; plague; Pulex simulans; vector; Yersinia pestis ID PLAGUE; ABUNDANCE AB If a parasite is not detected during a survey, one of two explanations is possible: the parasite was truly absent or it was present but not detected. We fit occupancy models to account for imperfect detection when combing fleas (Siphonaptera) from black-tailed prairie dogs (Cynomys ludovicianus) during June August 2012 in the Vermejo Park Ranch, New Mexico, USA. With the use of detection histories from combing events during monthly trapping sessions, we fit occupancy models for two flea species: Oropsylla 1-drusta (a prairie dog specialist) and Pule% simulans (a generalist). Detection probability was <100% for both species and about 21% lower for P. simulans. Pulex simulans may be especially difficult to detect because it is about half the size of O. hirusta. Monthly occupancy (prevalence) for P. simulans was estimated at 24% (June, 95% confidence interval=19-30), 39% (July, 32-47), and 56% (August, 49-64) in new prairie dog colonies, and 43% (32-54), 61% (49-71), and 79% (70-87) in old colonies. These results suggest P. simulans can attain high prevalence on prairie dogs, especially in old colonies. If P. simulans is highly prevalent on prairie dogs, it may serve as a "bridge vector" between Cynomys and other mammalian hosts of the plague bacterium Yersinia pestis, and even function as a reservoir of Y. pestis between outbreaks. C1 [Eads, David A.; Biggins, Dean E.; Antolin, Michael F.] Colorado State Univ, Grad Degree Program Ecol, Ft Collins, CO 80523 USA. [Eads, David A.; Antolin, Michael F.; Gage, Kenneth L.] Colorado State Univ, Dept Biol, Ft Collins, CO 80523 USA. [Biggins, Dean E.] US Geol Survey, Ft Collins Sci Ctr, Ft Collins, CO 80526 USA. [Long, Dustin H.] Turner Endangered Species Fund, Cimarron, NM 87714 USA. [Huyvaert, Kathryn P.] Colorado State Univ, Dept Fish Wildlife & Conservat Biol, Ft Collins, CO 80523 USA. [Gage, Kenneth L.] Ctr Dis Control & Prevent, Bacterial Dis Branch, Div Vector Borne Infect Dis, Natl Ctr Infect Dis, Ft Collins, CO USA. RP Eads, DA (reprint author), Colorado State Univ, Grad Degree Program Ecol, 1878 Campus Delivery, Ft Collins, CO 80523 USA. EM David.Eads@colostate.edu FU US Geological Survey; Turner Endangered Species Fund; Turner Enterprises Incorporated; Colorado State University; Centers for Disease Control and Prevention; Shortgrass Steppe Long-Term Ecological Research Project [DEB 021763, 0823405]; National Science Foundation [1027319] FX Funding and logistical support were provided by the US Geological Survey, Turner Endangered Species Fund, Turner Enterprises Incorporated, Colorado State University, the Centers for Disease Control and Prevention, and the Shortgrass Steppe Long-Term Ecological Research Project (DEB 021763 and 0823405). This material is also based upon work supported by the National Science Foundation under grant 1027319. We thank S. Molina, J. Neill, and L. White for help with trapping prairie dogs, and H. Britten, three anonymous reviewers, and M. D. Samuel for constructive comments on the manuscript. NR 21 TC 3 Z9 3 U1 2 U2 11 PU WILDLIFE DISEASE ASSOC, INC PI LAWRENCE PA 810 EAST 10TH ST, LAWRENCE, KS 66044-8897 USA SN 0090-3558 EI 1943-3700 J9 J WILDLIFE DIS JI J. Wildl. Dis. PD APR PY 2015 VL 51 IS 2 BP 498 EP 502 DI 10.7589/2014-07-178 PG 5 WC Veterinary Sciences SC Veterinary Sciences GA CF9XT UT WOS:000352921800024 PM 25588009 ER PT J AU Forman-Hoffman, VL Ault, KL Anderson, WL Weiner, JM Stevens, A Campbell, VA Armour, BS AF Forman-Hoffman, Valerie L. Ault, Kimberly L. Anderson, Wayne L. Weiner, Joshua M. Stevens, Alissa Campbell, Vincent A. Armour, Brian S. TI Disability Status, Mortality, and Leading Causes of Death in the United States Community Population SO MEDICAL CARE LA English DT Article DE disability; mortality; cause of death ID SELF-RATED HEALTH; MENTAL-ILLNESS; PHYSICAL-DISABILITIES; PREDICTING MORTALITY; SECONDARY CONDITIONS; FUNCTIONAL ABILITY; CANCER-MORTALITY; OLDER-ADULTS; WOMEN; PEOPLE AB Objective: We examined the effect of functional disability on all-cause mortality and cause-specific deaths among community-dwelling US adults. Methods: We used data from 142,636 adults who participated in the 1994-1995 National Health Interview Survey-Disability Supplement eligible for linkage to National Death Index records from 1994 to 2006 to estimate the effects of disability on mortality and leading causes of death. Results: Adults with any disability were more likely to die than adults without disability (19.92% vs. 10.94%; hazard ratio = 1.51, 95% confidence interval, 1.45-1.57). This association was statistically significant for most causes of death and for most types of disability studied. The leading cause of death for adults with and without disability differed (heart disease and malignant neoplasms, respectively). Conclusions: Our results suggest that all-cause mortality rates are higher among adults with disabilities than among adults without disabilities and that significant associations exist between several types of disability and cause-specific mortality. Interventions are needed that effectively address the poorer health status of people with disabilities and reduce the risk of death. C1 [Forman-Hoffman, Valerie L.; Ault, Kimberly L.; Anderson, Wayne L.; Weiner, Joshua M.] RTI Int, Res Triangle Pk, NC 27709 USA. [Stevens, Alissa; Campbell, Vincent A.; Armour, Brian S.] Ctr Dis Control & Prevent, Div Human Dev & Disabil, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. RP Forman-Hoffman, VL (reprint author), RTI Int, 3040 W Cornwallis Rd, Res Triangle Pk, NC 27709 USA. EM vhoffman@rti.org FU Intramural CDC HHS [CC999999] NR 36 TC 4 Z9 4 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0025-7079 EI 1537-1948 J9 MED CARE JI Med. Care PD APR PY 2015 VL 53 IS 4 BP 346 EP 354 PG 9 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA CG3EE UT WOS:000353160100011 PM 25719432 ER PT J AU Mizuno, Y Purcell, DW Knowlton, AR Wilkinson, JD Gourevitch, MN Knight, KR AF Mizuno, Yuko l Purcell, David W. Knowlton, Amy R. Wilkinson, James D. Gourevitch, Marc N. Knight, Kelly R. TI Syndemic Vulnerability, Sexual and Injection Risk Behaviors, and HIV Continuum of Care Outcomes in HIV-Positive Injection Drug Users SO AIDS AND BEHAVIOR LA English DT Article DE Syndemics; HIV-positive injection drug users; HIV risk behaviors; HIV continuum of care ID PSYCHOSOCIAL HEALTH-PROBLEMS; UNITED-STATES; ANTIRETROVIRAL THERAPY; BISEXUAL MEN; ADHERENCE; PREVENTION; INTERVENTION; ASSOCIATIONS; WOMEN; GAY AB Limited investigations have been conducted on syndemics and HIV continuum of care outcomes. Using baseline data from a multi-site, randomized controlled study of HIV-positive injection drug users (n = 1,052), we examined whether psychosocial factors co-occurred, and whether these factors were additively associated with behavioral and HIV continuum of care outcomes. Experiencing one type of psychosocial problem was significantly (p < 0.05) associated with an increased odds of experiencing another type of problem. Persons with 3 or more psychosocial problems were significantly more likely to report sexual and injection risk behaviors and were less likely to be adherent to HIV medications. Persons with 4 or more problems were less likely to be virally suppressed. Reporting any problems was associated with not currently taking HIV medications. Our findings highlight the association of syndemics not only with risk behaviors, but also with outcomes related to the continuum of care for HIV-positive persons. C1 [Mizuno, Yuko l; Purcell, David W.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Knowlton, Amy R.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Behav & Soc, Baltimore, MD 21205 USA. [Wilkinson, James D.] Batchelor Childrens Res Inst, Leonard M Miller Sch Med, Div Pediat Clin Res, Miami, FL 33101 USA. [Gourevitch, Marc N.] NYU, Sch Med, Dept Populat Hlth, New York, NY 10016 USA. [Knight, Kelly R.] Univ Calif San Francisco, Dept Anthropol Hist & Social Med, San Francisco, CA 94143 USA. RP Mizuno, Y (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, 1600 Clifton Rd,NE Mail Stop E37, Atlanta, GA 30333 USA. EM ybm2@cdc.gov OI Purcell, David/0000-0001-8125-5168; Gourevitch, Marc/0000-0001-6865-2126 FU Centers for Disease Control and Prevention; Health Resources and Services Administration FX The INSPIRE Team includes the following people: Carl Latkin, Amy Knowlton, and Karin Tobin (Baltimore); Lisa Metsch, Eduardo Valverde, James Wilkinson, and Martina DeVarona (Miami); Mary Latka, Dave Vlahov, Phillip Coffin, Marc Gourevitch, Julia Arnsten, and Robert Gern (New York); Cynthia Gomez, Kelly Knight, Carol Dawson Rose, Starley Shade, and Sonja Mackenzie (San Francisco); David Purcell, Yuko Mizuno, Scott Santibanez, Richard Garfein, and Ann O'Leary (Centers for Disease Control and Prevention [CDC]); Lois Eldred, Kathleen Handley (Health Resources and Services Administration). We would also like to acknowledge the following people for their contributions to this research: Susan Sherman, Roeina Marvin, Joanne Jenkins, Donny Gann, and Tonya Johnson (Baltimore); Clyde McCoy, Rob Malow, Wei Zhao, Lauren Gooden, Sam Comerford, Virginia Locascio, Curtis Delford, Laurel Hall, Henry Boza, Cheryl Riles, Faye Yeomans (Miami); George Fesser, Carol Gerran, Diane Thornton (New York); Caryn Pelegrino, Barbara Garcia, Jeff Moore, Erin Rowley, Debra Allen, Dinah Iglesia-Usog, Gilda Mendez, Paula Lum, and Greg Austin (San Francisco); Gladys Ibanez, Hae-Young Kim, Toni McWhorter, Jan Moore, Lynn Paxton, and John Williamson (CDC); Lee Lam, Jeanne Urban, Stephen Soroka, Zilma Rey, Astrid Ortiz, Sheila Bashirian, Marjorie Hubbard, Karen Tao, Bharat Parekh, Thomas Spira (CDC Laboratory). This study was supported by the Centers for Disease Control and Prevention and the Health Resources and Services Administration. NR 52 TC 8 Z9 8 U1 1 U2 2 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 EI 1573-3254 J9 AIDS BEHAV JI AIDS Behav. PD APR PY 2015 VL 19 IS 4 BP 684 EP 693 DI 10.1007/s10461-014-0890-0 PG 10 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA CF6AI UT WOS:000352638400013 PM 25249392 ER PT J AU Garnes, NJMD Moore, ZS Cadwell, BL Fleischauer, AT Leone, P AF Garnes, Natalie J. M. Dailey Moore, Zack S. Cadwell, Betsy L. Fleischauer, Aaron T. Leone, Peter TI Previously Undiagnosed HIV Infections Identified Through Cluster Investigation, North Carolina, 2002-2007 SO AIDS AND BEHAVIOR LA English DT Article DE Contact tracing; HIV infections; Prevention and control; Male; Sexual behavior ID ACTIVE ANTIRETROVIRAL THERAPY; IMMUNODEFICIENCY-VIRUS INFECTION; PARTNER-NOTIFICATION; UNITED-STATES; COST-EFFECTIVENESS; SEXUAL TRANSMISSION; PERSONS AWARE; SAN-FRANCISCO; BLACK-MEN; SYPHILIS AB During cluster investigation, index patients name social contacts that are not sex or drug-sharing partners. The likelihood of identifying new HIV infections among social contacts is unknown. We hypothesized greater odds of identifying new infections among social contacts identified by men who report sex with men (MSM). We reviewed North Carolina HIV diagnoses during 2002-2005 and used logistic regression to compare testing results among social contacts of MSM, men who report sex with women only (MSW) and women. HIV was newly diagnosed among 54/601 (9.0 %) social contacts tested named by MSM, 16/522 (3.1 %) named by MSW, and 23/639 (3.6 %) named by women. Compared with those named by MSW, odds of new HIV diagnosis were greater among MSM social contacts (adjusted odds ratio: 2.5; 95 % confidence interval: 1.3-4.7). Testing social contacts identified previously undiagnosed HIV infections and could provide an opportunity to interrupt transmission. C1 [Garnes, Natalie J. M. Dailey; Cadwell, Betsy L.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Field Assignments Branch, Atlanta, GA USA. [Garnes, Natalie J. M. Dailey; Moore, Zack S.; Fleischauer, Aaron T.; Leone, Peter] North Carolina Dept Hlth & Human Serv, Raleigh, NC USA. [Garnes, Natalie J. M. Dailey] Feigin Ctr, Houston, TX 77030 USA. [Fleischauer, Aaron T.] Ctr Dis Control & Prevent, Career Epidemiol Field Officer Program, Atlanta, GA USA. [Leone, Peter] Univ N Carolina, Sch Publ Hlth, Dept Epidemiol, Chapel Hill, NC USA. [Leone, Peter] Univ N Carolina, Sch Med, Div Infect Dis, Chapel Hill, NC USA. RP Garnes, NJMD (reprint author), Feigin Ctr, 1102 Bates St,Suite 1120, Houston, TX 77030 USA. EM dailey@bcm.edu NR 38 TC 0 Z9 0 U1 1 U2 2 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 EI 1573-3254 J9 AIDS BEHAV JI AIDS Behav. PD APR PY 2015 VL 19 IS 4 BP 723 EP 731 DI 10.1007/s10461-014-0913-x PG 9 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA CF6AI UT WOS:000352638400017 ER PT J AU Lucien, MAB Schaad, N Steenland, MW Mintz, ED Emmanuel, R Freeman, N Boncy, J Adrien, P Joseph, GA Katz, MA AF Lucien, Mentor Ali Ber Schaad, Nicolas Steenland, Maria W. Mintz, Eric D. Emmanuel, Rossignol Freeman, Nicole Boncy, Jacques Adrien, Paul Joseph, Gerard A. Katz, Mark A. TI Identifying the Most Sensitive and Specific Sign and Symptom Combinations for Cholera: Results from an Analysis of Laboratory-Based Surveillance Data from Haiti, 2012-2013 SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID ACUTE DIARRHEA; BURDEN; BANGLADESH; ROTAVIRUS; EPIDEMIC; DISEASE AB Since October 2010, over 700,000 cholera cases have been reported in Haiti. We used data from laboratory-based surveillance for diarrhea in Haiti to evaluate the sensitivity, specificity, and positive (PPV) and negative predictive values (NPV) of the cholera case definitions recommended by the World Health Organization (WHO). From April 2012 to May 2013, we tested 1,878 samples from hospitalized patients with acute watery diarrhea; 1,178 (62.7%) yielded Vibrio cholerae O1. The sensitivity and specificity of the WHO case definition for cholera in an epidemic setting were 91.3% and 43.1%, respectively, and the PPV and NPV were 72.8% and 74.8%, respectively. The WHO case definition for cholera in an area where cholera is not known to be present had lower sensitivity (63.1%) and NPV (55.1%) but higher specificity (74.2%) and PPV (80.0%). When laboratory diagnostic testing is not immediately available, clinicians can evaluate signs and symptoms to more accurately identify cholera patients. C1 [Lucien, Mentor Ali Ber; Emmanuel, Rossignol; Freeman, Nicole; Boncy, Jacques; Joseph, Gerard A.] Minist Publ Hlth & Populat, Natl Publ Hlth Lab, Port Au Prince, Haiti. Ctr Dis Control & Prevent, Div Global Hlth Protect, Ctr Global Hlth, Atlanta, GA USA. Ctr Dis Control & Prevent, Div Foodborne Water & Environm Dis, Natl Ctr Emerging & Zoonot Infect, Atlanta, GA USA. [Adrien, Paul] Minist Publ Hlth & Populat, Directorate Epidemiol Lab & Res, Port Au Prince, Haiti. [Katz, Mark A.] Ctr Dis Control & Prevent Haiti, Port Au Prince, Haiti. [Schaad, Nicolas] Ctr Dis Control & Prevent, Div Global Hlth Protect, Atlanta, GA USA. [Steenland, Maria W.; Mintz, Eric D.] Ctr Dis Control & Prevent, Div Foodborne Water & Environm Dis, Atlanta, GA USA. RP Lucien, MAB (reprint author), 667 WI, Turgeau, Port Au Prince, Haiti. EM lucienmentor@gmail.com; ick2@cdc.gov; maria.steenland@gmail.com; edml@cdc.gov; emmarossignol@yahoo.fr; nicolemfreeman@gmail.com; jboncy2001@yahoo.fr; padrien2004@yahoo.fr; gerardajo944@gmail.com; markakatz@gmail.com NR 20 TC 3 Z9 3 U1 1 U2 5 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD APR PY 2015 VL 92 IS 4 BP 758 EP 764 DI 10.4269/ajtmh.14-0429 PG 7 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA CF8QY UT WOS:000352828200015 PM 25732682 ER PT J AU Wong, J Shah, MP Mwandama, D Gimnig, JE Lindblade, KA Mathanga, DP AF Wong, Jacklyn Shah, Monica P. Mwandama, Dyson Gimnig, John E. Lindblade, Kim A. Mathanga, Don P. TI Home Visits to Assess the Reliability of Caregiver-Reported Use of Insecticide-Treated Bednets by Children in Machinga District, Malawi SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID BED-NETS; HIGH AGREEMENT; WESTERN KENYA; LOW KAPPA; HOUSEHOLDS; PARADOXES; MALARIA AB A malaria cohort study was conducted among young children in Machinga District, Malawi, following distribution of insecticide-treated bednets (ITNs) in May 2012. To assess ITN use, two independently sampled subsets of children (211 during survey 1 [December 2012 January 2013] and 325 during survey 2 [September October 2013]) were randomly selected to compare the proportions of positive and negative agreement between caregiver verbal reports at monthly interviews with visual observation of the ITN at home visits. Caregiver-reported ITN use was consistently high during both surveys (98.1% and 96.0%, respectively; P = 0.17). Home visit-based ITN use fell significantly (P < 0.001) from survey 1 (98.6%) to survey 2(88.6%). The proportions of positive agreement between caregiver report and home visit in the first and second surveys were 98.8% (95% confidence interval [CI] 97.6-99.8%) and 93.3% (95% CI 91.2-95.3%), respectively. The proportions of negative agreement in the first and second surveys were 28.6% (95% Cl 0-75.0%) and 20.0% (95% CI 0.1-35.0%), respectively. ITN use by children was high in Machinga District, and caregiver reports and home visits with visual confirmation of the net demonstrated a high level of agreement for use of ITNs, but a low level of agreement when ITNs were not used. C1 [Wong, Jacklyn; Shah, Monica P.; Gimnig, John E.] Ctr Dis Control & Prevent, Entomol Branch, Div Parasit Dis & Malaria, Atlanta, GA 30309 USA. [Wong, Jacklyn; Shah, Monica P.; Gimnig, John E.] Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, Atlanta, GA 30309 USA. [Mwandama, Dyson; Mathanga, Don P.] Coll Med, Malaria Alert Ctr, Blantyre, Malawi. [Lindblade, Kim A.] Ctr Dis Control & Prevent, Epidemiol & Prevent Branch, Influenza Div, Bangkok, Thailand. RP Shah, MP (reprint author), Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, 1600 Clifton Rd NE,MS A-06, Atlanta, GA 30309 USA. EM vsm0@cdc.gov; mshah2@cdc.gov; dmwandama@mac.medcol.mw; hzg1@cdc.gov; ki12@cdc.gov; dmathang@mac.medcol.mw FU U.S. President's Malaria Initiative; U.S. Agency for International Development; Centers for Disease Control and Prevention (CDC) [U01CK000135]; Malaria Alert Centre, College of Medicine FX This work was made possible through support provided by the U.S. President's Malaria Initiative, U.S. Agency for International Development, under the terms of an Interagency Agreement with the Centers for Disease Control and Prevention (CDC) and through a Cooperative Agreement (No. U01CK000135) between the CDC and the Malaria Alert Centre, College of Medicine. NR 13 TC 0 Z9 0 U1 0 U2 3 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD APR PY 2015 VL 92 IS 4 BP 825 EP 827 DI 10.4269/ajtmh.14-0768 PG 3 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA CF8QY UT WOS:000352828200027 PM 25667055 ER PT J AU Ajumobi, O Sabitu, K Nguku, P Kwaga, J Ntadom, G Gitta, S Elizeus, R Oyibo, W Nsubuga, P Maire, M Poggensee, G AF Ajumobi, Olufemi Sabitu, Kabir Nguku, Patrick Kwaga, Jacob Ntadom, Godwin Gitta, Sheba Elizeus, Rutebemberwa Oyibo, Wellington Nsubuga, Peter Maire, Mark Poggensee, Gabriele TI Performance of an HRP-2 Rapid Diagnostic Test in Nigerian Children Less Than 5 Years of Age SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID PLASMODIUM-FALCIPARUM; MALARIA INFECTION; BURKINA-FASO; TRANSMISSION; ACCURACY; MICROSCOPY AB The diagnostic performance of histidine-rich protein 2 (HRP-2) based malaria rapid diagnostic test (RDT) was evaluated in a mesoendemic area for malaria, Kaduna, Nigeria. We compared RDT results with expert microscopy results of blood samples from 295 febrile children under 5 years. Overall, 11.9% (35/295) tested positive with RDT compared with 10.5% (31/295) by microscopy: sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were 100%, 98.5%, 88.6%, and 100%, respectively. The RDT sensitivity was not affected by transmission season, parasite density, and age. Specificity and positive PV decreased slightly during the high-transmission season (97.5% and 83.3%). The RDT test positivity rates in the low- and high-transmission seasons were 9.4% and 13.5%, respectively. Overall, the test performance of this RDT was satisfactory. The findings of a low proportion of RDT false positives, no invalid and no false-negative results should validate the performance of RDTs in this context. C1 [Ajumobi, Olufemi; Nguku, Patrick; Poggensee, Gabriele] Nigeria Field Epidemiol & Lab Training Programme, Abuja, Nigeria. [Sabitu, Kabir; Kwaga, Jacob] Ahmadu Bello Univ, Zaria, Nigeria. [Ajumobi, Olufemi; Ntadom, Godwin] Fed Minist Hlth, Natl Malaria Control Programme, Abuja, Nigeria. [Gitta, Sheba] African Field Epidemiol Network, Kampala, Uganda. [Elizeus, Rutebemberwa] Makerere Univ, Kampala, Uganda. [Oyibo, Wellington] Univ Lagos, Coll Med, Lagos, Nigeria. Global Publ Hlth Solut, Atlanta, GA USA. [Maire, Mark] Ctr Dis Control & Prevent, Div Global Hlth Protect, Ctr Global Hlth, Atlanta, GA USA. [Maire, Mark] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA USA. [Nsubuga, Peter] Global Hlth Solut, Atlanta, GA USA. RP Ajumobi, O (reprint author), Nigeria Field Epidemiol & Lab Training Programme, 50 Haile Selassie St, Abuja, Nigeria. EM femiajumobi@gmail.com; kssabitu@yahoo.com; drnguku@yahoo.com; jacobkwaga@yahoo.com; ntadomg@yahoo.com; sgitta@afenet.net; ellie@musph.ac.ug; wellao@yahoo.com; pnsubuga@globalphsolutions.com; vlq8@cdc.gov; gapo.nigeria@gmail.com FU AFENET/USAID/CDC FX We acknowledge and appreciate the staff and patients of Makarfi General Hospital and members of Makarfi and Kuruntumawa communities, Makarfi Local Government Area, Kaduna state for their immense support and cooperation toward the success of this study. We are indebted to AFENET/USAID/CDC for providing financial support. The malaria rapid test kit used in this study was provided at no cost by the standard diagnostics South Korea through Codix Pharmaceuticals Limited, Nigeria. We have not received any financial incentives from these organizations. NR 37 TC 6 Z9 6 U1 0 U2 3 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD APR PY 2015 VL 92 IS 4 BP 828 EP 833 DI 10.4269/ajtmh.13-0558 PG 6 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA CF8QY UT WOS:000352828200028 PM 25711608 ER PT J AU Watt, G Lacroix, A Pachirat, O Baggett, HC Raoult, D Fournier, PE Tattevin, P AF Watt, George Lacroix, Adele Pachirat, Orathai Baggett, Henry C. Raoult, Didier Fournier, Pierre-Edouard Tattevin, Pierre TI Prospective Comparison of Infective Endocarditis in Khon Kaen, Thailand and Rennes, France SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID CULTURE-NEGATIVE ENDOCARDITIS; RHEUMATIC HEART-DISEASE; BARTONELLA-QUINTANA; STREPTOCOCCUS-SUIS; EPIDEMIOLOGY; PREVENTION; MANAGEMENT; DIAGNOSIS; TUNISIA AB Prospectively collected, contemporary data are lacking on how the features of infective endocarditis (IE) vary according to region. We, therefore, compared IE in Rennes, France and Khon Kaen, Thailand. Fifty-eight patients with confirmed IE were enrolled at each site during 2011 and 2012 using a common protocol. Compared with French patients, Thais had a lower median age (47 versus 70 years old; P < 0.001) and reported more animal contact (86% versus 21%; P < 0.001). There were more zoonotic infections among Thai than France patients (6 and 1 cases; P = 0.017) and fewer staphylococcal infections (4 versus 15 cases; P = 0.011). Underlying rheumatic heart disease was more prevalent in Thai than in French patients (31% and 4%; P = 0.001), whereas prosthetic heart valves were less prevalent (9% and 35%; P = 0.001). Our data strengthen previous observations that IE in the tropics has distinctive demographic characteristics, risk factors, and etiologies and underscore the need for improved prevention and control strategies. C1 [Watt, George; Baggett, Henry C.] Thailand Minist Publ Hlth US Ctr Dis Control & Pr, Global Dis Detect Ctr, Nonthaburi, Thailand. [Lacroix, Adele] Univ Rennes 1, Infect Dis & Intens Care Unit, Pontchaillou Univ Hosp, Rennes, France. [Pachirat, Orathai] Khon Kaen Univ, Fac Med, Dept Med, Khon Kaen, Thailand. [Baggett, Henry C.] US Ctr Dis Control & Prevent, Div Global Hlth Protect, Atlanta, GA USA. [Raoult, Didier; Fournier, Pierre-Edouard] Univ Mediterranean, Fac Med, Unite Rech Malad Infect & Trop Emergentes, Marseille, France. [Tattevin, Pierre] Univ Rennes 1, Infect Dis & Intens Care Unit, Pontchaillou Univ Hosp, INSERM,U835, Rennes, France. RP Watt, G (reprint author), Thailand Minist Publ Hlth US Ctr Dis Control & Pr, Global Dis Detect Ctr, Nonthaburi, Thailand. EM gwattth@yahoo.com; adele.lacroix@chu-rennes.fr; orathai@hotmail.com; Hfb8@cdc.gov; Didier.Raoult@gmail.com; pierre-edouard.fournier@univ-amu.fr; pierre.tattevin@chu-rennes.fr FU Global Disease Detection Program; Division of Vector Borne Infectious Diseases at the Centers for Disease Control and Prevention; Mediterranee-Infection Foundation FX This work was supported by the Global Disease Detection Program, the Division of Vector Borne Infectious Diseases at the Centers for Disease Control and Prevention, and the Mediterranee-Infection Foundation. NR 26 TC 2 Z9 2 U1 2 U2 3 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD APR PY 2015 VL 92 IS 4 BP 871 EP 874 DI 10.4269/ajtmh.14-0689 PG 4 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA CF8QY UT WOS:000352828200034 PM 25646262 ER PT J AU Schantz, MM Benner, BA Heckert, NA Sander, LC Sharpless, KE Vander Pol, SS Vasquez, Y Villegas, M Wise, SA Alwis, KU Blount, BC Calafat, AM Li, Z Silva, MJ Ye, X Gaudreau, E Patterson, DG Sjodin, A AF Schantz, Michele M. Benner, Bruce A., Jr. Heckert, N. Alan Sander, Lane C. Sharpless, Katherine E. Vander Pol, Stacy S. Vasquez, Y. Villegas, M. Wise, Stephen A. Alwis, K. Udeni Blount, Benjamin C. Calafat, Antonia M. Li, Zheng Silva, Manori J. Ye, Xiaoyun Gaudreau, Eric Patterson, Donald G., Jr. Sjoedin, Andreas TI Development of urine standard reference materials for metabolites of organic chemicals including polycyclic aromatic hydrocarbons, phthalates, phenols, parabens, and volatile organic compounds SO ANALYTICAL AND BIOANALYTICAL CHEMISTRY LA English DT Article DE Reference materials; Urine; PAHs; Phthalates; Phenols; VOCs ID MASS-SPECTROMETRY; EXPOSURE; QUANTIFICATION; NAPHTHALENE; EXTRACTION; BIOMARKERS; NICOTINE; SERUM; MILK; ACID AB Two new Standard Reference Materials (SRMs), SRM 3672 Organic Contaminants in Smokers' Urine (Frozen) and SRM 3673 Organic Contaminants in Non-Smokers' Urine (Frozen), have been developed in support of studies for assessment of human exposure to select organic environmental contaminants. Collaborations among three organizations resulted in certified values for 11 hydroxylated polycyclic aromatic hydrocarbons (OH-PAHs) and reference values for 11 phthalate metabolites, 8 environmental phenols and parabens, and 24 volatile organic compound (VOC) metabolites. Reference values are also available for creatinine and the free forms of caffeine, theobromine, ibuprofen, nicotine, cotinine, and 3-hydroxycotinine. These are the first urine Certified Reference Materials characterized for metabolites of organic environmental contaminants. Noteworthy, the mass fractions of the environmental organic contaminants in the two SRMs are within the ranges reported in population survey studies such as the National Health and Nutrition Examination Survey (NHANES) and the Canadian Health Measures Survey (CHMS). These SRMs will be useful as quality control samples for ensuring compatibility of results among population survey studies and will fill a void to assess the accuracy of analytical methods used in studies monitoring human exposure to these organic environmental contaminants. C1 [Schantz, Michele M.; Benner, Bruce A., Jr.; Sander, Lane C.; Sharpless, Katherine E.; Vander Pol, Stacy S.; Vasquez, Y.; Villegas, M.; Wise, Stephen A.] NIST, Div Chem Sci, Gaithersburg, MD 20899 USA. [Heckert, N. Alan] NIST, Stat Engn Div, Charleston, SC 29412 USA. [Alwis, K. Udeni; Blount, Benjamin C.; Calafat, Antonia M.; Li, Zheng; Silva, Manori J.; Ye, Xiaoyun; Sjoedin, Andreas] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. [Gaudreau, Eric] Inst Natl Sante Publ Quebec, Toxicol Lab, Quebec City, PQ G1V 5B3, Canada. [Patterson, Donald G., Jr.] Environ Solut Consulting Inc, Auburn, GA 30011 USA. [Vasquez, Y.; Villegas, M.] Fdn Chile, Ctr Metrol Quim, Santiago 8320000, Chile. RP Schantz, MM (reprint author), NIST, Div Chem Sci, Gaithersburg, MD 20899 USA. EM michele.schantz@nist.gov FU Intramural CDC HHS [CC999999] NR 34 TC 7 Z9 8 U1 9 U2 35 PU SPRINGER HEIDELBERG PI HEIDELBERG PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY SN 1618-2642 EI 1618-2650 J9 ANAL BIOANAL CHEM JI Anal. Bioanal. Chem. PD APR PY 2015 VL 407 IS 11 BP 2945 EP 2954 DI 10.1007/s00216-014-8441-0 PG 10 WC Biochemical Research Methods; Chemistry, Analytical SC Biochemistry & Molecular Biology; Chemistry GA CF1GJ UT WOS:000352292000002 PM 25651899 ER PT J AU Mineva, EM Zhang, M Rabinowitz, DJ Phinney, KW Pfeiffer, CM AF Mineva, Ekaterina M. Zhang, Mindy Rabinowitz, Daniel J. Phinney, Karen W. Pfeiffer, Christine M. TI An LC-MS/MS method for serum methylmalonic acid suitable for monitoring vitamin B12 status in population surveys SO ANALYTICAL AND BIOANALYTICAL CHEMISTRY LA English DT Article DE MMA; Method comparison; GC/MS; Anticoagulant types; NHANES; NIST SRM1950; Vitamin B-12 ID TANDEM MASS-SPECTROMETRY; STABLE-ISOTOPE-DILUTION; TOTAL HOMOCYSTEINE; COBALAMIN DEFICIENCY; AUTOMATED-ASSAY; PLASMA; URINE; QUANTIFICATION AB Methylmalonic acid (MMA), a functional indicator of vitamin B-12 insufficiency, was measured in the US population in the National Health and Nutrition Examination Survey (NHANES) from 1999 to 2004 using a GC/MS procedure that required 275 mu L of sample and had a low throughput (36 samples/run). Our objective was to introduce a more efficient yet highly accurate LC-MS/MS method for NHANES 2011-2014. We adapted the sample preparation with some modifications from a published isotope-dilution LC-MS/MS procedure. The procedure utilized liquid-liquid extraction and generation of MMA dibutyl ester. Reversed-phase chromatography with isocratic elution allowed baseline resolution of MMA from its naturally occurring structural isomer succinic acid within 4.5 min. Our new method afforded an increased throughput (a parts per thousand currency sign160 samples/run) and measured serum MMA with high sensitivity (LOD = 22.1 nmol/L) in only 75 mu L of sample. Mean (+/- SD) recovery of MMA spiked into serum (2 d, 4 levels, 2 replicates each) was 94 % +/- 5.5 %. Total imprecision (41 d, 2 replicates each) for three serum quality control pools was 4.9 %-7.9 % (97.1-548 nmol/L). The LC-MS/MS method showed excellent correlation (n = 326, r = 0.99) and no bias (Deming regression, Bland-Altman analysis) compared to the previous GC/MS method. Both methods produced virtually identical mean (+/- SD) MMA concentrations [LC-MS/MS: 18.47 +/- 0.71 ng/mL (n = 17), GC/MS: 18.18 +/- 0.67 ng/mL (n = 11)] on a future plasma reference material compared with a GC/MS method procedure from the National Institute of Standards and Technology [18.41 +/- 0.70 ng/mL (n = 15)]. No adjustment will be necessary to compare previous (1999-2004) to future (2011-2014) NHANES MMA data. C1 [Mineva, Ekaterina M.; Zhang, Mindy; Rabinowitz, Daniel J.; Pfeiffer, Christine M.] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. [Phinney, Karen W.] NIST, Biomol Measurement Div, Gaithersburg, MD 20899 USA. RP Pfeiffer, CM (reprint author), Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. EM cfp8@cdc.gov FU Intramural CDC HHS [CC999999] NR 29 TC 2 Z9 2 U1 3 U2 27 PU SPRINGER HEIDELBERG PI HEIDELBERG PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY SN 1618-2642 EI 1618-2650 J9 ANAL BIOANAL CHEM JI Anal. Bioanal. Chem. PD APR PY 2015 VL 407 IS 11 BP 2955 EP 2964 DI 10.1007/s00216-014-8148-2 PG 10 WC Biochemical Research Methods; Chemistry, Analytical SC Biochemistry & Molecular Biology; Chemistry GA CF1GJ UT WOS:000352292000003 PM 25258283 ER PT J AU Mack, KA Liller, KD Baldwin, G Sleet, D AF Mack, Karin A. Liller, Karen D. Baldwin, Grant Sleet, David TI Preventing Unintentional Injuries in the Home Using the Health Impact Pyramid SO HEALTH EDUCATION & BEHAVIOR LA English DT Article DE falls; fire; Health Impact Pyramid; injury prevention; poisonings ID UNITED-STATES; EMERGENCY-DEPARTMENTS; META-REGRESSION; YOUNG-CHILDREN; SAFETY; PROMOTION; FALLS; METAANALYSIS; EXPERIENCE; REDUCTION AB Injuries continue to be the leading cause of death for the first four decades of life. These injuries result from a confluence of behavioral, physical, structural, environmental, and social factors. Taken together, these illustrate the importance of taking a broad and multileveled approach to injury prevention. Using examples from fall, fire, scald, and poisoning-related injuries, this article illustrates the utility of an approach that incorporates a social-environmental perspective in identifying and selecting interventions to improve the health and safety of individuals. Injury prevention efforts to prevent home injuries benefit from multilevel modifications of behavior, public policy, laws and enforcement, the environment, consumer products and engineering standards, as demonstrated with Frieden's Health Impact Pyramid. A greater understanding, however, is needed to explain the associations between tiers. While interventions that include modifications of the social environment are being field-tested, much more work needs to be done in measuring social-environmental change and in evaluating these programs to disentangle what works best. C1 [Mack, Karin A.; Baldwin, Grant; Sleet, David] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. [Liller, Karen D.] Univ S Florida, Tampa, FL USA. RP Mack, KA (reprint author), Ctr Dis Control & Prevent, 4770 Buford Highway NE,F62, Atlanta, GA 30341 USA. EM kmack@cdc.gov FU Intramural CDC HHS [CC999999] NR 56 TC 4 Z9 4 U1 2 U2 9 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1090-1981 EI 1552-6127 J9 HEALTH EDUC BEHAV JI Health Educ. Behav. PD APR PY 2015 VL 42 SU 1 BP 115S EP 122S DI 10.1177/1090198114568306 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CF4UN UT WOS:000352547800013 PM 25829110 ER PT J AU Guy, GP Berkowitz, Z Jones, SE Holman, DM Garnett, E Watson, M AF Guy, Gery P., Jr. Berkowitz, Zahava Jones, Sherry Everett Holman, Dawn M. Garnett, Erin Watson, Meg TI Trends in Indoor Tanning Among US High School Students, 2009-2013 SO JAMA DERMATOLOGY LA English DT Letter ID METAANALYSIS C1 [Guy, Gery P., Jr.; Berkowitz, Zahava; Holman, Dawn M.; Watson, Meg] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent Hlth Promot, Atlanta, GA 30341 USA. [Jones, Sherry Everett] Ctr Dis Control & Prevent, Div Adolescent & Sch Hlth, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30341 USA. [Garnett, Erin] Adv Technol Logist Inc, Atlanta, GA USA. RP Guy, GP (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent Hlth Promot, 4770 Buford Hwy NE,MS F-76, Atlanta, GA 30341 USA. EM irm2@cdc.gov FU Intramural CDC HHS [CC999999] NR 5 TC 9 Z9 9 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6068 EI 2168-6084 J9 JAMA DERMATOL JI JAMA Dermatol. PD APR PY 2015 VL 151 IS 4 BP 448 EP 450 DI 10.1001/jamadermatol.2014.4677 PG 4 WC Dermatology SC Dermatology GA CF6FI UT WOS:000352652000023 PM 25535810 ER PT J AU Patel, P DiPette, DJ AF Patel, Pragna DiPette, Donald J. TI Hypertension-Related Congestive Heart Failure in West Africa: A Framework for Global Blood Pressure Control SO JOURNAL OF CLINICAL HYPERTENSION LA English DT Editorial Material ID RISK-FACTORS; SYSTEMATIC ANALYSIS; COUNTRIES; BURDEN; DISEASE; STROKE; AGE C1 [Patel, Pragna] Ctr Dis Control & Prevent, Ctr Global Hlth, Div Global Hlth Protect, Global Noncommunicable Dis Unit, Atlanta, GA USA. [DiPette, Donald J.] Univ S Carolina, Columbia, SC 29203 USA. [DiPette, Donald J.] Univ S Carolina, Sch Med, Columbia, SC USA. RP DiPette, DJ (reprint author), Univ S Carolina, 2 Med Pk,Suite 502, Columbia, SC 29203 USA. EM Donald.DiPette@uscmed.sc.edu NR 16 TC 1 Z9 1 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1524-6175 EI 1751-7176 J9 J CLIN HYPERTENS JI J. Clin. Hypertens. PD APR PY 2015 VL 17 IS 4 BP 260 EP 262 DI 10.1111/jch.12494 PG 3 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA CF5BY UT WOS:000352571400003 PM 25688849 ER PT J AU Haddad, L Achadi, E Bendech, MA Ahuja, A Bhatia, K Bhutta, Z Blossner, M Borghi, E Colecraft, E de Onis, M Eriksen, K Fanzo, J Flores-Ayala, R Fracassi, P Kimani-Murage, E Koukoubou, EN Krasevec, J Newby, H Nugent, R Oenema, S Martin-Prevel, Y Randel, J Requejo, J Shyam, T Udomkesmalee, E Reddy, KS AF Haddad, Lawrence Achadi, Endang Bendech, Mohamed Ag Ahuja, Arti Bhatia, Komal Bhutta, Zulfiqar Bloessner, Monika Borghi, Elaine Colecraft, Esi de Onis, Mercedes Eriksen, Kamilla Fanzo, Jessica Flores-Ayala, Rafael Fracassi, Patrizia Kimani-Murage, Elizabeth Koukoubou, Eunice Nago Krasevec, Julia Newby, Holly Nugent, Rachel Oenema, Stineke Martin-Prevel, Yves Randel, Judith Requejo, Jennifer Shyam, Tara Udomkesmalee, Emorn Reddy, K. Srinath TI The Global Nutrition Report 2014: Actions and Accountability to Accelerate the World's Progress on Nutrition SO JOURNAL OF NUTRITION LA English DT Article DE malnutrition; SDGs; accountability; progress; indicators ID DEVELOPING-COUNTRIES; CHILD NUTRITION; WEIGHT-GAIN; INTERVENTIONS; UNDERNUTRITION; HEALTH; POPULATION; PREVALENCE; OVERWEIGHT; CONTRIBUTE AB In 2013, the Nutrition for Growth Summit called for a Global Nutrition Report (GNR) to strengthen accountability in nutrition so that progress in reducing malnutrition could be accelerated. This article summarizes the results of the first GNR. By focusing on undernutrition and overweight, the GNR puts malnutrition in a new light. Nearly every country in the world is affected by malnutrition, and multiple malnutrition burdens are the "new normal." Unfortunately, the world is off track to meet the 2025 World Health Assembly (WHA) targets for nutrition. Many countries are, however, making good progress on WHA indicators, providing inspiration and guidance for others. Beyond the WHA goals, nutrition needs to be more strongly represented in the Sustainable Development Goal (SDG) framework. At present, it is only explicitly mentioned in 1 of 169 SDG targets despite the many contributions improved nutritional status will make to their attainment. To achieve improvements in nutrition status, it is vital to scale up nutrition programs. We identify bottlenecks in the scale-up of nutrition-specific and nutrition-sensitive approaches and highlight actions to accelerate coverage and reach. Holding stakeholders to account for delivery on nutrition actions requires a well-functioning accountability infrastructure, which is lacking in nutrition. New accountability mechanisms need piloting and evaluation, financial resource flows to nutrition need to be made explicit, nutrition spending targets should be established, and some key data gaps need to be filled. For example, many UN member states cannot report on their WHA progress and those that can often rely on data >5 y old. The world can accelerate malnutrition reduction substantially, but this will require stronger accountability mechanisms to hold all stakeholders to account. C1 [Haddad, Lawrence] Int Food Policy Res Inst, Washington, DC 20036 USA. [Achadi, Endang] Univ Indonesia, Jakarta, Indonesia. [Bendech, Mohamed Ag] UN, Food & Agr Org, Rome, Italy. [Ahuja, Arti] Women & Child Dev, Bhubaneswar, Odisha, India. [Bhatia, Komal; Shyam, Tara] Univ Sussex, Inst Dev Studies, Brighton, E Sussex, England. [Bhutta, Zulfiqar] Hosp Sick Children, Ctr Global Child Hlth, Toronto, ON M5G 1X8, Canada. [Bhutta, Zulfiqar] Aga Khan Univ, Ctr Excellence Women & Child Hlth, Karachi, Pakistan. [Bloessner, Monika; Borghi, Elaine; de Onis, Mercedes] WHO, CH-1211 Geneva, Switzerland. [Colecraft, Esi] Univ Ghana, Accra, Ghana. [Eriksen, Kamilla] Univ Cambridge, Cambridge, England. [Fanzo, Jessica] Columbia Univ, New York, NY USA. [Flores-Ayala, Rafael] CDC, Atlanta, GA 30333 USA. [Fracassi, Patrizia] Scaling Nutr Secretariat, Geneva, Switzerland. [Kimani-Murage, Elizabeth] APHRC, Nairobi, Kenya. [Koukoubou, Eunice Nago] Univ Abomey Calavi, Cotonou, Benin. [Krasevec, Julia; Newby, Holly] UNICEF, New York, NY USA. [Nugent, Rachel] Univ Washington, Seattle, WA 98195 USA. [Oenema, Stineke] Interchurch Org Dev Cooperat ICCO Alliance, Utrecht, Netherlands. [Martin-Prevel, Yves] Inst Dev Res, Marseille, France. [Randel, Judith] Dev Initiat, Bristol, Avon, England. [Requejo, Jennifer] WHO, Partnership Maternal Newborn & Child Hlth, CH-1211 Geneva, Switzerland. [Udomkesmalee, Emorn] Mahidol Univ, Inst Nutr, Nakhon Pathom, Thailand. [Reddy, K. Srinath] Publ Hlth Fdn India, New Delhi, India. RP Haddad, L (reprint author), Int Food Policy Res Inst, Washington, DC 20036 USA. RI Martin-Prevel, Yves/E-7637-2011 OI Martin-Prevel, Yves/0000-0002-4689-7867 FU 1000 Days; Bill & Melinda Gates Foundation; Children's Investment Fund Foundation; European Commission; Government of Canada; Irish Aid; UK Department for International Development; CGIAR Agriculture for Nutrition and Health Programme FX Supported by 1000 Days, the Bill & Melinda Gates Foundation, the Children's Investment Fund Foundation, the European Commission, the Government of Canada, Irish Aid, the UK Department for International Development, and the CGIAR Agriculture for Nutrition and Health Programme. This is a free access article, distributed under terms (http://www.nutrition.org/publications/guidelines-and-policies/license/) that permit unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited. NR 44 TC 8 Z9 9 U1 2 U2 21 PU AMER SOC NUTRITION-ASN PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-3166 EI 1541-6100 J9 J NUTR JI J. Nutr. PD APR PY 2015 VL 145 IS 4 BP 663 EP 671 DI 10.3945/jn.114.206078 PG 9 WC Nutrition & Dietetics SC Nutrition & Dietetics GA CE9RG UT WOS:000352180500001 PM 25740908 ER PT J AU Rybak, ME Sternberg, MR Pao, CI Ahluwalia, N Pfeiffer, CM AF Rybak, Michael E. Sternberg, Maya R. Pao, Ching-I Ahluwalia, Namanjeet Pfeiffer, Christine M. TI Urine Excretion of Caffeine and Select Caffeine Metabolites Is Common in the US Population and Associated with Caffeine Intake SO JOURNAL OF NUTRITION LA English DT Article DE NHANES; urine; caffeine; metabolites; dietary intake; biomarkers; phenotyping; LC-MS/MS ID DIETARY EXPOSURE; RISK; METAANALYSIS; BIOMARKERS; DISEASE; YOUNG; MEN AB Background: Caffeine is a widely consumed psychoactive stimulant and is of epidemiologic interest. Major sources of caffeine are challenging to standardize, and the use of biomarkers is proposed as an alternative means of assessing intake. Objective: We described urine caffeine and caffeine metabolite concentrations (n=2466) and excretion rates (n=2261) in the US population >= 6 y by age, sex, race-ethnicity, and caffeine intake (from foods, beverages, and dietary supplements). Methods: We measured caffeine and 14 of its metabolites in spot urine samples from the cross-sectional NHANES 2009 2010 by use of LC-tandem mass spectrometry. Results: Caffeine and its metabolites were detectable in the urine of most persons, generally at concentrations >= 1 mu mol/L. Median concentrations (95% Cl) ranged from 0.560 (0.497, 0.620) mu mol/L to 58.6 (48.6, 67.2) mu mol/L; median excretion rates from 0.423 (0.385, 0.468) nmol/min to 46.0 (40.7, 50.2) nmol/min. Urine concentrations and excretion rates for 9 analytes (caffeine, theophylline, paraxanthine, 1-methylxanthine, 1-methyluric acid, 1,3-dimethyluric acid, 1,7-dimethyluric acid, 1,3,7-trimethyluric acid, and 5-acetylamino-6-amino-3-methyluracil) had moderate correlations with caffeine intake (Spearman rho = 0.55-0.68, P < 0.0001); the remaining analytes had low correlations (rho =0.15-0.33, P < 0.0001). We observed larger differences in geometric mean concentrations and excretion rates between the highest vs. lowest Quartiles of caffeine intake for these 9 compounds than the rest. Consistent with dietary caffeine intake, we observed that urine concentrations and excretion rates for most compounds were significantly (P < 0.05) higher in men than women, non-Hispanic whites than Hispanics and non-Hispanic blacks, and highest in persons aged 40-59 y. Conclusion: Excretion of caffeine and its metabolites in urine is common in the US population. According to the observed associations between spot urine concentrations or excretion rates with caffeine intake, several of these compounds show promise as potential biomarkers of caffeine intake. C1 [Rybak, Michael E.; Sternberg, Maya R.; Pao, Ching-I; Pfeiffer, Christine M.] CDC, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. [Ahluwalia, Namanjeet] CDC, Natl Ctr Hlth Stat, Hyattsville, MD USA. RP Rybak, ME (reprint author), CDC, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. EM mrybak@cdc.gov OI Rybak, Michael/0000-0003-1650-8581 NR 31 TC 2 Z9 2 U1 6 U2 14 PU AMER SOC NUTRITION-ASN PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-3166 EI 1541-6100 J9 J NUTR JI J. Nutr. PD APR PY 2015 VL 145 IS 4 BP 766 EP 774 DI 10.3945/jn.114.205476 PG 9 WC Nutrition & Dietetics SC Nutrition & Dietetics GA CE9RG UT WOS:000352180500014 PM 25833779 ER PT J AU Park, S Li, RW Birch, L AF Park, Sohyun Li, Ruowei Birch, Leann TI Mothers' Child-Feeding Practices Are Associated with Children's Sugar-Sweetened Beverage Intake SO JOURNAL OF NUTRITION LA English DT Article DE child-feeding practices; sugar-sweetened beverage; children; Infant Feeding Practice Study; obesity; sweet foods ID HIGH-SCHOOL-STUDENTS; EATING BEHAVIORS; UNITED-STATES; RESTRICTING ACCESS; YOUNG-CHILDREN; WEIGHT STATUS; US CHILDREN; SODA INTAKE; CONSUMPTION; ADOLESCENTS AB Background: Sugar-sweetened beverage (SSB) intake is a substantial source of energy in the diet of US children. Objective: We examined the associations between mothers' child-feeding practices and SSB intake among 6-y-old children. Methods: We analyzed data from the Year 6 Follow-up of the Infant Feeding Practices Study II in 1350 US children aged 6 y. The outcome variable was child's SSB intake. The exposure variables were 4 child-feeding practices of mothers: setting limits on sweets or junk foods, regulating their child's favorite food intake to prevent overconsumption, pressuring their child to eat enough, and pressuring their child to "clean the plate." We used multinomial logistic regression and controlled for child and maternal characteristics. Analyses were stratified on child weight status. Results: The consumption of SSBs >= time/d was observed among 17.1% of underweight/normal-weight children and in 23.2% of overweight/obese children. Adjusted ORs (aORs) of consuming SSBs >= time/d (vs. no SSB consumption) were significantly lower in children whose mothers reported setting limits on sweets/junk foods (aOR: 0.29; 95% Cl: 0.15, 0.58 for underweight/normal-weight children; aOR: 0.16; 95% 01:.0.03, 0.79 for overweight/obese children). SSB intake was higher among underweight/normal-weight children whose mothers reported trying to'keep the child from eating too much of their favorite foods (aOR: 2.03; 95% Cl: 1.25, 3.29). Mothers' tendency to pressure their children to consume more food or to "clean the plate" was not associated with child's SSB intake. Conclusions: SSBs were commonly consumed by young children. The odds of daily SSB' intake were lower among children whose mothers set limits on sweets/junk foods regardless of child's weight but were higher among underweight/normal-weight children whose mothers restricted the child's favorite food intake. Future studies can investigate the impact of alternatives to restrictive feeding practices that could reduce children's SSB intake. C1 [Park, Sohyun; Li, Ruowei] CDC, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Birch, Leann] Univ Georgia, Dept Foods & Nutr, Athens, GA 30602 USA. RP Park, S (reprint author), CDC, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM spark3@cdc.gov FU US FDA; CDC; Office on Women's Health, NIH; Maternal and Child Health Bureau in the US Department of Health and Human Services FX Supported by the US FDA, CDC, Office on Women's Health, NIH, and Maternal and Child Health Bureau in the US Department of Health and Human Services. NR 36 TC 1 Z9 1 U1 6 U2 15 PU AMER SOC NUTRITION-ASN PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-3166 EI 1541-6100 J9 J NUTR JI J. Nutr. PD APR PY 2015 VL 145 IS 4 BP 806 EP 812 DI 10.3945/jn.114.207233 PG 7 WC Nutrition & Dietetics SC Nutrition & Dietetics GA CE9RG UT WOS:000352180500019 PM 25833783 ER PT J AU Albert, M McCaig, LF AF Albert, M. McCaig, L. F. TI A comparison of emergency department utilization for injury and illness in older adults: United States, 2010-2011 SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society (AGS) CY MAY 10-17, 2015 CL National Harbor, MD SP Amer Geriatr Soc C1 [Albert, M.; McCaig, L. F.] CDC, Natl Ctr Hlth Stat, Hyattsville, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2015 VL 63 SU 1 SI SI MA A69 BP S42 EP S42 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA CF5EL UT WOS:000352578900115 ER PT J AU Caffrey, C Harris-Kojetin, L Park-Lee, E Rome, V AF Caffrey, C. Harris-Kojetin, L. Park-Lee, E. Rome, V. TI Hospitalizations and Subsequent Hospital Readmissions within Residential Care Communities: Findings from the 2012 National Study of Long-Term Care Providers SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society (AGS) CY MAY 10-17, 2015 CL National Harbor, MD SP Amer Geriatr Soc C1 [Caffrey, C.; Harris-Kojetin, L.; Park-Lee, E.; Rome, V.] CDC, NCHS, Hyattsville, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2015 VL 63 SU 1 SI SI MA C144 BP S210 EP S210 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA CF5EL UT WOS:000352578900590 ER PT J AU Chung, KW Harvey, A Basavaraju, SV Kuehnert, MJ AF Chung, Koo-Whang Harvey, Alexis Basavaraju, Sridhar V. Kuehnert, Matthew J. TI How is national recipient hemovigilance conducted in the United States? SO TRANSFUSION LA English DT Article ID TRANSFUSION AB A national recipient hemovigilance system was introduced in the United States in 2010, when voluntary enrollment began as part of the National Healthcare Safety Network (NHSN) Hemovigilance Module. NHSN is a secure, Web-based surveillance system operated by the Centers for Disease Control and Prevention and used by US health care facilities to report a variety of patient safety information. The Hemovigilance Module is used for comprehensive monitoring of transfusion-related adverse events. Participating facilities can utilize analytic tools available within the module to identify opportunities for enhancing transfusion safety, evaluate the effectiveness of interventions, and compare facility specific transfusion-related data to aggregate national estimates. Data may be voluntarily shared by facilities with external partners for patient safety improvement initiatives and to fulfill reporting mandates. We describe the key characteristics of the Hemovigilance Module, highlight the benefits for participating facilities, and discuss the use of reported data for establishing national estimates of transfusion-associated adverse events to identify gaps in transfusion safety and opportunities for interventions. National hemovigilance systems are essential to recognize gaps in transfusion safety and identify opportunities for interventions to improve patient safety and outcomes. C1 [Chung, Koo-Whang; Harvey, Alexis; Basavaraju, Sridhar V.; Kuehnert, Matthew J.] US Ctr Dis Control & Prevent, Off Blood Organ & Other Tissue Safety, Div Healthcare Qual Promot, Natl Ctr Emerging Zoonot & Infect Dis, Atlanta, GA USA. RP Chung, KW (reprint author), Ctr Dis Control & Prevent, Off Blood Organ & Other Tissue Safety, 1600 Clifton Rd NE,MS A-07, Atlanta, GA 30329 USA. EM jeq4@cdc.gov FU Intramural CDC HHS [CC999999] NR 16 TC 2 Z9 3 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0041-1132 EI 1537-2995 J9 TRANSFUSION JI Transfusion PD APR PY 2015 VL 55 IS 4 BP 703 EP 707 DI 10.1111/trf.12980 PG 5 WC Hematology SC Hematology GA CF7KN UT WOS:000352735200004 PM 25565577 ER PT J AU Harvey, AR Basavaraju, SV Chung, KW Kuehnert, MJ AF Harvey, Alexis R. Basavaraju, Sridhar V. Chung, Koo-Whang Kuehnert, Matthew J. TI Transfusion-related adverse reactions reported to the National Healthcare Safety Network Hemovigilance Module, United States, 2010 to 2012 SO TRANSFUSION LA English DT Article ID HAEMOVIGILANCE SYSTEM; SURVEILLANCE; BLOOD; IMPLEMENTATION; VALIDATION; RATES; ORGANIZATION AB BackgroundIn 2010, health care facilities in the United States began voluntary enrollment in the National Healthcare Safety Network (NHSN) Hemovigilance Module. Participants report transfusion practices; red blood cell, platelet (PLT), plasma, and cryoprecipitate units transfused; and transfusion-related adverse reactions and process errors to the Centers for Disease Control and Prevention through a secure, Internet-accessible surveillance application available to transfusing facilities. Study Design and MethodsFacilities submitting at least 1month of transfused components data and adverse reactions from January 1, 2010, to December 31, 2012, were included in this analysis. Adverse reaction rates for transfused components, stratified by component type and collection and modification methods, were calculated. ResultsIn 2010 to 2012, a total of 77 facilities reported 5136 adverse reactions among 2,144,723 components transfused (239.5/100,000). Allergic (46.8%) and febrile nonhemolytic (36.1%) reactions were most frequent; 7.2% of all reactions were severe or life-threatening and 0.1% were fatal. PLT transfusions (421.7/100,000) had the highest adverse reaction rate. ConclusionAdverse transfusion reaction rates from the NHSN Hemovigilance Module in the United States are comparable to early hemovigilance reporting from other countries. Although severe reactions are infrequent, the numbers of transfusion reactions in US hospitals suggest that interventions to prevent these reactions are important for patient safety. Further investigation is needed to understand the apparent increased risk of reactions from apheresis-derived blood components. Comprehensive evaluation, including data validation, is important to continued refinement of the module. C1 [Harvey, Alexis R.; Basavaraju, Sridhar V.; Chung, Koo-Whang; Kuehnert, Matthew J.] US Ctr Dis Control & Prevent, Off Blood Organ & Other Tissue Safety, Div Healthcare Qual Promot, Natl Ctr Emerging Zoonot & Infect Dis, Atlanta, GA USA. RP Harvey, AR (reprint author), Ctr Dis Control & Prevent, Off Blood Organ & Other Tissue Safety, 1600 Clifton Rd NE,MS A-07, Atlanta, GA 30329 USA. EM ARHarvey@cdc.gov NR 34 TC 12 Z9 12 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0041-1132 EI 1537-2995 J9 TRANSFUSION JI Transfusion PD APR PY 2015 VL 55 IS 4 BP 709 EP 718 DI 10.1111/trf.12918 PG 10 WC Hematology SC Hematology GA CF7KN UT WOS:000352735200006 PM 25371300 ER PT J AU Neuman, R Hayek, S Rahman, A Poole, JC Menon, V Sher, S Newman, JL Karatela, S Polhemus, D Lefer, DJ De Staercke, C Hooper, C Quyyumi, AA Roback, JD AF Neuman, Robert Hayek, Salim Rahman, Ayaz Poole, Joseph C. Menon, Vivek Sher, Salman Newman, James L. Karatela, Sulaiman Polhemus, David Lefer, David J. De Staercke, Christine Hooper, Craig Quyyumi, Arshed A. Roback, John D. TI Effects of storage-aged red blood cell transfusions on endothelial function in hospitalized patients SO TRANSFUSION LA English DT Article ID FLOW-MEDIATED DILATION; OLDER STORED-BLOOD; NITRIC-OXIDE; S-NITROSOHEMOGLOBIN; HEALTHY-VOLUNTEERS; FREE HEMOGLOBIN; CRITICALLY-ILL; MOUSE MODEL; MORTALITY; RISK AB BackgroundClinical and animal studies indicate that transfusions of older stored red blood cells (RBCs) impair clinical outcomes as compared to fresh RBC transfusions. It has been suggested that this effect is due to inhibition of nitric oxide (NO)-mediated vasodilation after transfusion of older RBC units. However, to date this effect has not been identified in human transfusion recipients. Study Design and MethodsForty-three hospitalized patients with transfusion orders were randomly assigned to receive either fresh (<14 days) or older stored (>21 days) RBC units. Before transfusion, and at selected time points after the start of transfusion, endothelial function was assessed using noninvasive flow-mediated dilation assays. ResultsAfter transfusion of older RBC units, there was a significant reduction in NO-mediated vasodilation at 24 hours after transfusion (p=0.045), while fresh RBC transfusions had no effect (p=0.231). ConclusionsThis study suggests for the first time a significant inhibitory effect of transfused RBC units stored more than 21 days on NO-mediated vasodilation in anemic hospitalized patients. This finding lends further support to the hypothesis that deranged NO signaling mediates adverse clinical effects of older RBC transfusions. Future investigations will be necessary to address possible confounding factors and confirm these results. C1 [Neuman, Robert; Hayek, Salim; Rahman, Ayaz; Poole, Joseph C.; Menon, Vivek; Sher, Salman; Quyyumi, Arshed A.] Emory Univ, Sch Med, Div Cardiol, Atlanta, GA 30322 USA. [Newman, James L.; Karatela, Sulaiman; Roback, John D.] Emory Univ, Sch Med, Dept Pathol & Lab Med, Ctr Transfus & Cellular Therapies, Atlanta, GA 30322 USA. [Polhemus, David; Lefer, David J.] Louisiana State Univ, Dept Pharmacol, Hlth Sci Ctr, New Orleans, LA USA. [De Staercke, Christine; Hooper, Craig] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Div Blood Disorders, Atlanta, GA USA. RP Roback, JD (reprint author), Emory Univ, Sch Med, Dept Pathol & Lab Med, Ctr Transfus & Cellular Therapies, EUH D655,1364 Clifton Rd NE, Atlanta, GA 30322 USA. EM jroback@emory.edu FU NHLBI [R01 HL095479-01]; NIH [UL1 RR025008]; National Blood Foundation FX Support for these studies was provided by NHLBI (R01 HL095479-01 and administrative supplement to JDR), NIH Grant UL1 RR025008, and the National Blood Foundation (to AR). NR 62 TC 18 Z9 18 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0041-1132 EI 1537-2995 J9 TRANSFUSION JI Transfusion PD APR PY 2015 VL 55 IS 4 BP 782 EP 790 DI 10.1111/trf.12919 PG 9 WC Hematology SC Hematology GA CF7KN UT WOS:000352735200014 PM 25393772 ER PT J AU Amek, N Vounatsou, P Obonyo, B Hamel, M Odhiambo, F Slutsker, L Laserson, K AF Amek, Nyaguara Vounatsou, Penelope Obonyo, Benson Hamel, Mary Odhiambo, Frank Slutsker, Laurence Laserson, Kayla TI Using health and demographic surveillance system (HDSS) data to analyze geographical distribution of socio-economic status; an experience from KEMRI/CDC HDSS SO ACTA TROPICA LA English DT Article DE Socio-economic status; Multiple correspondence analysis; Health and demographic surveillance system; Quintiles map AB Continuous monitoring in health and demographic surveillance sites (HDSS) allows for collection of longitudinal demographic data, health related, and socio-economic indicators of the site population. We sought to use household survey data collected between 2002 and 2006 in the Kenya Medical Research Institute in collaboration with Centers for Disease Control and prevention (KEMRI/CDC) HDSS site in Asembo and Gem Western Kenya to estimate socio-economic status (SES) and assess changes of SES over time and space. Data on household assets and characteristics, mainly source of drinking water, cooking fuel, and occupation of household head was annually collected from 44,313 unique households during the study period. An SES index was calculated as a weighted average of assets using weights generated via Principal Component Analysis (PCA), Polychoric PCA, and Multiple Correspondence Analysis (MCA) methods applied to the pooled data. The index from the best method was used to rank households into SES quintiles and assess their transition over time across SES categories. Kriging was employed to produce SES maps at the start and the end of the study period. First component of PCA, Polychoric PCA, and MCA accounted for 13.7%, 31.8%, and 47.3%, respectively of the total variance of all variables. The gap between the poorest and the least poor increased from 1% at the start to 6% at the end of the study period. Spatial analysis revealed that the increase in least poor households was centered in the lower part of study area (Asembo) over time. No significant changes were observed in Gem. The HDSS sites can provide a platform to assess spatial-temporal changes in the SES status of the population. Evidence on how SES varied over time and space within the same geographical area may provide a useful tool to design interventions in health and other areas that have a close bearing to the SES of the population. (C) 2015 Elsevier B.V. All rights reserved. C1 [Amek, Nyaguara; Obonyo, Benson; Hamel, Mary; Odhiambo, Frank; Laserson, Kayla] Kenya Govt Med Res Ctr, Ctr Dis Control & Prevent CDC, Res & Publ Hlth Collaborat, Kisumu, Kenya. [Amek, Nyaguara; Vounatsou, Penelope; Obonyo, Benson] Swiss Trop & Publ Hlth Inst, Basel, Switzerland. [Amek, Nyaguara; Vounatsou, Penelope; Obonyo, Benson] Univ Basel, Basel, Switzerland. [Hamel, Mary; Slutsker, Laurence] Ctr Dis Control & Prevent, Atlanta, GA 30301 USA. RP Vounatsou, P (reprint author), Swiss Trop & Publ Hlth Inst, Socinstr 57,POB 4002, Basel, Switzerland. EM Penelope.Vounatsou@unibas.ch FU Swiss National Science Foundation [325200_118379] FX The authors are grateful to the KEMRI/CDC HDSS for providing the socio-economic data. Amek Nyaguara was funded by Swiss National Science Foundation (Project Nr. 325200_118379). The KEMRI/CDC HDSS is a member of the INDEPTH network. The findings and conclusions in this study are those of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention. This paper is published with the permission of the Director of the Kenya Medical Research Institute. NR 13 TC 3 Z9 3 U1 2 U2 5 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0001-706X EI 1873-6254 J9 ACTA TROP JI Acta Trop. PD APR PY 2015 VL 144 BP 24 EP 30 DI 10.1016/j.actatropica.2015.01.006 PG 7 WC Parasitology; Tropical Medicine SC Parasitology; Tropical Medicine GA CE9SY UT WOS:000352184900004 PM 25602533 ER PT J AU Fang, J George, MG Gindi, RM Hong, YL Yang, QH Ayala, C Ward, BW Loustalot, F AF Fang, Jing George, Mary G. Gindi, Renee M. Hong, Yuling Yang, Quanhe Ayala, Carma Ward, Brian W. Loustalot, Fleetwood TI Use of Low-Dose Aspirin as Secondary Prevention of Atherosclerotic Cardiovascular Disease in US Adults (from the National Health Interview Survey, 2012) SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Article ID ACUTE MYOCARDIAL-INFARCTION; AMERICAN-HEART-ASSOCIATION; CORONARY-ARTERY-DISEASE; RISK; GUIDELINE; ADHERENCE; PROGRAM; UPDATE AB Current guidelines recommend that adults with atherosclerotic cardiovascular disease take low-dose aspirin or other antiplatelet medications as secondary prevention of recurrent cardiovascular events. Yet, no national level assessment of low-dose aspirin use for secondary prevention of cardiovascular disease has been reported in a community-based population. Using data from the 2012 National Health Interview Survey, we assessed low-dose aspirin use in those with atherosclerotic cardiovascular disease. We estimated the prevalence ratios of low-dose aspirin use, adjusting for sociodemographic status, health insurance, and cardiovascular risk factors. In those with atherosclerotic cardiovascular disease (n = 3,068), 76% had been instructed to take aspirin and 88% of those were following this advice. Of those not advised, 11% took aspirin on their own. Overall, 70% were taking aspirin (including those who followed their health care provider's advice and those who were not advised but took aspirin on their own). Logistic regression models showed that women, non-Hispanic blacks and Hispanics, those aged 40 to 64 years, with a high school education or with some college, or with fewer cardiovascular disease risk factors were less likely to take aspirin than men, non-Hispanic whites, those aged 65 years, with a college education or higher, or with all 4 selected cardiovascular disease risk factors, respectively. Additional analyses conducted in those with coronary heart disease only (n = 2,007) showed similar patterns. In conclusion, use of low-dose aspirin for secondary prevention was 70%, with high reported adherence to health care providers' advice to take low-dose aspirin (88%) and significant variability within subgroups. Published by Elsevier Inc. C1 [Fang, Jing; George, Mary G.; Hong, Yuling; Yang, Quanhe; Ayala, Carma; Loustalot, Fleetwood] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Heart Dis & Stroke Prevent, Atlanta, GA 30333 USA. [Gindi, Renee M.; Ward, Brian W.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Div Hlth Interview Stat, Hyattsville, MD 20782 USA. RP Fang, J (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Heart Dis & Stroke Prevent, Atlanta, GA 30333 USA. EM jfang@cdc.gov FU Intramural CDC HHS [CC999999] NR 22 TC 8 Z9 8 U1 0 U2 4 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9149 EI 1879-1913 J9 AM J CARDIOL JI Am. J. Cardiol. PD APR 1 PY 2015 VL 115 IS 7 BP 895 EP 900 DI 10.1016/j.amjcard.2015.01.014 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CF0RX UT WOS:000352253000008 PM 25670639 ER PT J AU Meaney-Delman, D Koonin, LM Jamieson, DJ AF Meaney-Delman, Dana Koonin, Lisa M. Jamieson, Denise J. TI US hospital preparedness for obstetrics patients with possible Ebola SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY LA English DT Editorial Material ID VIRUS DISEASE C1 [Meaney-Delman, Dana] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Koonin, Lisa M.] Ctr Dis Control & Prevent, Influenza Coordinat Unit, Off Infect Dis, Atlanta, GA USA. [Jamieson, Denise J.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. RP Meaney-Delman, D (reprint author), Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. EM vmo0@cdc.gov FU Intramural CDC HHS [CC999999] NR 22 TC 1 Z9 1 U1 0 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9378 EI 1097-6868 J9 AM J OBSTET GYNECOL JI Am. J. Obstet. Gynecol. PD APR PY 2015 VL 212 IS 4 BP 417 EP 419 DI 10.1016/j.ajog.2015.01.018 PG 3 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA CE9EQ UT WOS:000352147100001 PM 25656019 ER PT J AU Ellington, SR Flowers, L Legardy-Williams, JK Jamieson, DJ Kourtis, AP AF Ellington, Sascha R. Flowers, Lisa Legardy-Williams, Jennifer K. Jamieson, Denise J. Kourtis, Athena P. TI Recent trends in hepatic diseases during pregnancy in the United States, 2002-2010 SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY LA English DT Article DE hepatic disease; hepatitis; liver disease; pregnancy ID LIVER-DISEASE; CHOLECYSTECTOMY; MANAGEMENT; INFECTION; CIRRHOSIS AB OBJECTIVE: While pregnancy-related severe liver disorders are rare, when they occur morbidity and mortality rates are increased for mothers and infants. The objective of this study was to examine the prevalence and trends of hepatic diseases during pregnancy hospitalizations from 2002 through 2010 in the United States. STUDY DESIGN: Hospital discharge data were obtained from the Nationwide Inpatient Sample, the largest all-payer hospital inpatient care database in the United States that provides nationally representative estimates. Pregnancy hospitalizations with the following diagnoses were identified: hepatitis B, hepatitis C, gallbladder disease/cholelithiasis, liver disorders of pregnancy, chronic/alcohol-related liver disease, biliary tract disease, and HELLP (hemolysis, elevated liver enzymes, low platelet count) syndrome. Age, insurance status, hospital location, and hospital region were compared among women with and without hepatic diseases using a chi(2) test. Trends in rates of pregnancy hospitalizations and mean charges were analyzed using multi-variable logistic and linear regression, respectively. RESULTS: From 2002 through 2010 there were an estimated 41,479,358 pregnancy hospitalizations in the United States. Gallbladder disease and liver disorders of pregnancy were the most common hepatic diseases (rates = 7.18 and 4.65/1000 pregnancy hospitalizations, respectively). Adjusted rates and mean charges significantly increased for all hepatic diseases during pregnancy over the study period. All hepatic diseases were associated with significantly higher charges compared to all pregnancy hospitalizations. HELLP syndrome was associated with the highest mean charges. CONCLUSION: This large study among a representative sample of the US population provides valuable information that can aid policy planning and management of these hepatic diseases during pregnancy in the United States. C1 [Ellington, Sascha R.; Flowers, Lisa; Legardy-Williams, Jennifer K.; Jamieson, Denise J.; Kourtis, Athena P.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Reprod Hlth, Womens Hlth & Fertil Branch, Atlanta, GA 30333 USA. RP Ellington, SR (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Reprod Hlth, Womens Hlth & Fertil Branch, Atlanta, GA 30333 USA. EM sellington@cdc.gov FU Intramural CDC HHS [CC999999] NR 23 TC 1 Z9 1 U1 0 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9378 EI 1097-6868 J9 AM J OBSTET GYNECOL JI Am. J. Obstet. Gynecol. PD APR PY 2015 VL 212 IS 4 AR 524.e1 DI 10.1016/j.ajog.2014.10.1093 PG 7 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA CE9EQ UT WOS:000352147100032 PM 25448511 ER PT J AU Adam, BW Flores, SR Hou, Y Allen, TW De Jesus, VR AF Adam, Barbara W. Flores, Sharon R. Hou, Yu Allen, Todd W. De Jesus, Victor R. TI Galactose-1-phosphate uridyltransferase dried blood spot quality control materials for newborn screening tests SO CLINICAL BIOCHEMISTRY LA English DT Article DE Galactose-1-phosphate uridyltransferase; Galactosemia; Newborn screening; Blood spots; Quality control; Sample integrity ID GALACTOSEMIA AB Objectives: We aimed to prepare dried-blood-spot (DBS) quality control (QC) materials for galactose-1-phosphate uridyltransferase (GALT), to evaluate their stability during storage and use, and to evaluate their performance in five DBS GALT test methods. Design and methods: We prepared and characterized GALT-normal and GALT-deficient DBS materials and compared GALT activities in DBSs after predetermined storage intervals at controlled temperatures and humidities. External evaluators documented the suitability of the DBS QC materials for use in five GALT test methods. Results: GALT activity losses from DBSs stored in low (<30%) humidity for 14 days at 45 degrees C, 35 days at 37 degrees C, 91 days at room temperature, 182 days at 4 degrees C, and 367 days at -20 degrees C were 54%, 53%, 52% 23%, and 7% respectively. In paired DBSs stored in high humidity (>50%) for identical intervals, losseswere: 45 degrees C-68%; 37 degrees C-79%; room temperature-72%, and 4 degrees C-63%. GALT activities in DBSs stored at 4 degrees C were stable throughout 19 excursions to room temperature. Twenty-five of 26 external evaluators, using five different GALT test methods, classified the GALT-deficient DBSs as "outside normal limits". All evaluators classified the GALT-normal DBSs as "within normal limits". Conclusions: Most of the GALT activity loss from DBSs stored at elevated or room temperature was attributable to the effects of storage temperature. Most of the loss from DBSs stored at 4 degrees C was attributable to the effects of elevated humidity. Loss from DBSs stored at -20 degrees C was insignificant. The DBS materials were suitable for monitoring performance of all five GALT test methods. (C) 2014 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved. C1 [Adam, Barbara W.; Flores, Sharon R.; De Jesus, Victor R.] Ctr Dis Control & Prevent CDC, Atlanta, GA 30341 USA. [Hou, Yu] Calif Dept Publ Hlth, Genet Dis Lab Branch, Richmond, CA 94804 USA. [Allen, Todd W.] Astoria Pacific Inc, Clackamas, OR 97015 USA. RP Adam, BW (reprint author), Ctr Dis Control & Prevent CDC, 4770 Buford Highway NE, Atlanta, GA 30341 USA. EM barbaraadam@att.net FU Intramural CDC HHS [CC999999] NR 15 TC 0 Z9 0 U1 1 U2 10 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0009-9120 EI 1873-2933 J9 CLIN BIOCHEM JI Clin. Biochem. PD APR PY 2015 VL 48 IS 6 BP 437 EP 442 DI 10.1016/j.clinbiochem.2014.12.009 PG 6 WC Medical Laboratory Technology SC Medical Laboratory Technology GA CF4GE UT WOS:000352506000013 PM 25528144 ER PT J AU Hays, SM Aylward, LL Blount, BC AF Hays, Sean M. Aylward, Lesa L. Blount, Benjamin C. TI Variation in Urinary Flow Rates According to Demographic Characteristics and Body Mass Index in NHANES: Potential Confounding of Associations between Health Outcomes and Urinary Biomarker Concentrations SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Article ID BISPHENOL-A CONCENTRATION; CREATININE CONCENTRATIONS; US CHILDREN; VARIABILITY; OBESITY; ADULTS; RISK; POPULATION; EXCRETION; PHTHALATE AB Background: Urinary analyte concentrations are affected both by exposure level and by urinary flow rate (UFR). Systematic variations in UFR with demographic characteristics or body mass index (BMI) could confound assessment of associations between health outcomes and biomarker concentrations. Objectives: We assessed patterns of UFR (milliliters per hour) and body weight-adjusted UFR (UFRBW; milliliters per kilogram per hour) across age, sex, race/ethnicity, and BMI category in the NHANES (National Health and Nutrition Examination Survey) 2009-2012 data sets. Methods: Geometric mean (GM) UFR and UFRBW were compared across age-stratified (6-11, 12-19, 20-39, 40-59, and >= 60 years) subgroups (sex, race/ethnicity, and BMI category). Patterns of analyte urinary concentration or mass excretion rates (nanograms per hour and nanograms per kilogram per hour BW) were assessed in sample age groups for case study chemicals bisphenol A and 2,5-dichlorophenol. Results: UFR increased from ages 6 to 60 years and then declined with increasing age. UFRBW varied inversely with age. UFR, but not UFRBW, differed significantly by sex (males > females after age 12 years). Differences in both metrics were observed among categories of race/ethnicity. UFRBW, but not UFR, varied inversely with BMI category and waist circumference in all age groups. Urinary osmolality increased with increasing BMI. Case studies demonstrated different exposure-outcome relationships depending on exposure metric. Conventional hydration status adjustments did not fully address the effect of flow rate variations. Conclusions: UFR and UFRBW exhibit systematic variations with age, sex, race/ethnicity, and BMI category. These variations can confound assessments of potential exposure-health outcome associations based on urinary concentration. Analyte excretion rates are valuable exposure metrics in such assessments. C1 [Hays, Sean M.] Summit Toxicol LLP, Lyons, CO USA. [Aylward, Lesa L.] Summit Toxicol LLP, Falls Church, VA 22044 USA. [Aylward, Lesa L.] Univ Queensland, Natl Res Ctr Environm Toxicol Entox, Brisbane, Qld, Australia. [Blount, Benjamin C.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. RP Aylward, LL (reprint author), Summit Toxicol LLP, 6343 Carolyn Dr, Falls Church, VA 22044 USA. EM laylward@summittoxicology.com RI Aylward, Lesa/F-7418-2012 OI Aylward, Lesa/0000-0003-3191-8175 FU American Chemistry Council FX S.M.H. and L.L.A. are independent partners in Summit Toxicology LLP, a toxicology, risk assessment and pharmaceutical consulting firm, and received funding from the American Chemistry Council to conduct the analyses and prepare the manuscript. B.C.B. declares he has no actual or potential competing financial interests. NR 31 TC 10 Z9 10 U1 2 U2 13 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 EI 1552-9924 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD APR PY 2015 VL 123 IS 4 BP 293 EP 300 DI 10.1289/ehp.1408944 PG 8 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA CE9ML UT WOS:000352168000013 PM 25625328 ER PT J AU Lonnroth, K Migliori, GB Abubakar, I D'Ambrosio, L de Vries, G Diel, R Douglas, P Falzon, D Gaudreau, MA Goletti, D Ochoa, ERG Lobue, P Matteelli, A Njoo, H Solovic, I Story, A Tayeb, T van der Werf, MJ Weil, D Zellweger, JP Aziz, MA Al Lawati, MRM Aliberti, S de Onate, WA Barreira, D Bhatia, V Blasi, F Bloom, A Bruchfeld, J Castelli, F Centis, R Chemtob, D Cirillo, DM Colorado, A Dadu, A Dahle, UR De Paoli, L Dias, HM Duarte, R Fattorini, L Gaga, M Getahun, H Glaziou, P Goguadze, L del Granado, M Haas, W Jarvinen, A Kwon, GY Mosca, D Nahid, P Nishikiori, N Noguer, I O'Donnell, J Pace-Asciak, A Pompa, MG Popescu, GG Cordeiro, CR Ronning, K Ruhwald, M Sculier, JP Simunovic, A Smith-Palmer, A Sotgiu, G Sulis, G Torres-Duque, CA Umeki, K Uplekar, M van Weezenbeek, C Vasankari, T Vitillo, RJ Voniatis, C Wanlin, M Raviglione, MC AF Loennroth, Knut Migliori, Giovanni Battista Abubakar, Ibrahim D'Ambrosio, Lia de Vries, Gerard Diel, Roland Douglas, Paul Falzon, Dennis Gaudreau, Marc-Andre Goletti, Delia Ochoa, Edilberto R. Gonzalez LoBue, Philip Matteelli, Alberto Njoo, Howard Solovic, Ivan Story, Alistair Tayeb, Tamara van der Werf, Marieke J. Weil, Diana Zellweger, Jean-Pierre Aziz, Mohamed Abdel Al Lawati, Mohamed R. M. Aliberti, Stefano de Onate, Wouter Arrazola Barreira, Draurio Bhatia, Vineet Blasi, Francesco Bloom, Amy Bruchfeld, Judith Castelli, Francesco Centis, Rosella Chemtob, Daniel Cirillo, Daniela M. Colorado, Alberto Dadu, Andrei Dahle, Ulf R. De Paoli, Laura Dias, Hannah M. Duarte, Raquel Fattorini, Lanfranco Gaga, Mina Getahun, Haileyesus Glaziou, Philippe Goguadze, Lasha del Granado, Mirtha Haas, Walter Jarvinen, Asko Kwon, Geun-Yong Mosca, Davide Nahid, Payam Nishikiori, Nobuyuki Noguer, Isabel O'Donnell, Joan Pace-Asciak, Analita Pompa, Maria G. Popescu, Gilda G. Cordeiro, Carlos Robalo Ronning, Karin Ruhwald, Morten Sculier, Jean-Paul Simunovic, Aleksandar Smith-Palmer, Alison Sotgiu, Giovanni Sulis, Giorgia Torres-Duque, Carlos A. Umeki, Kazunori Uplekar, Mukund van Weezenbeek, Catharina Vasankari, Tuula Vitillo, Robert J. Voniatis, Constantia Wanlin, Maryse Raviglione, Mario C. TI Towards tuberculosis elimination: an action framework for low-incidence countries SO EUROPEAN RESPIRATORY JOURNAL LA English DT Article ID DRUG-RESISTANT TUBERCULOSIS; LOW-BURDEN-COUNTRY; CALMETTE-GUERIN VACCINATION; COST-EFFECTIVENESS ANALYSIS; CAPTURE-RECAPTURE ANALYSIS; LONG-TERM-CARE; LATENT TUBERCULOSIS; PULMONARY TUBERCULOSIS; UNITED-STATES; BCG VACCINATION AB This paper describes an action framework for countries with low tuberculosis (TB) incidence (<100 TB cases per million population) that are striving for TB elimination. The framework sets out priority interventions required for these countries to progress first towards "pre-elimination" (<10 cases per million) and eventually the elimination of TB as a public health problem (less than one case per million). TB epidemiology in most low-incidence countries is characterised by a low rate of transmission in the general population, occasional outbreaks, a majority of TB cases generated from progression of latent TB infection (LTBI) rather than local transmission, concentration to certain vulnerable and hard-toreach risk groups, and challenges posed by cross-border migration. Common health system challenges are that political commitment, funding, clinical expertise and general awareness of TB diminishes as TB incidence falls. The framework presents a tailored response to these challenges, grouped into eight priority action areas: 1) ensure political commitment, funding and stewardship for planning and essential services; 2) address the most vulnerable and hard-to-reach groups; 3) address special needs of migrants and cross-border issues; 4) undertake screening for active TB and LTBI in TB contacts and selected high-risk groups, and provide appropriate treatment; 5) optimise the prevention and care of drug-resistant TB; 6) ensure continued surveillance, programme monitoring and evaluation and case-based data management; 7) invest in research and new tools; and 8) support global TB prevention, care and control. The overall approach needs to be multisectorial, focusing on equitable access to high-quality diagnosis and care, and on addressing the social determinants of TB. Because of increasing globalisation and population mobility, the response needs to have both national and global dimensions. C1 [Loennroth, Knut; Falzon, Dennis; Matteelli, Alberto; Weil, Diana; Bhatia, Vineet; Dias, Hannah M.; Getahun, Haileyesus; Glaziou, Philippe; Sulis, Giorgia; Uplekar, Mukund] WHO, Global TB Programme, CH-1211 Geneva 27, Switzerland. [Migliori, Giovanni Battista; D'Ambrosio, Lia; Centis, Rosella] Fdn S Maugeri, WHO Collaborating Ctr TB & Lung Dis, IRCCS, Tradate, Italy. [Abubakar, Ibrahim] UCL, TB Sect, London, England. [Abubakar, Ibrahim] Publ Hlth England, London, England. [de Vries, Gerard; van Weezenbeek, Catharina] KNCV TB Fdn, The Hague, Netherlands. [Diel, Roland] Univ Hosp Schleswig Holstein, Inst Epidemiol, Kiel, Germany. [Douglas, Paul] Dept Immigrat & Border Protect, Global Hlth Borders Refugee & Onshore Serv, Sydney, NSW, Australia. [Gaudreau, Marc-Andre; Njoo, Howard] Publ Hlth Agcy Canada, Ctr Communicable Dis & Infect Control, Montreal, PQ, Canada. [Goletti, Delia] Natl Inst Infect Dis, Rome, Italy. [Ochoa, Edilberto R. Gonzalez] Inst Trop Med Pedro Kouri, Epidemiol Board, Res & Surveillance Grp TB Leprosy & ARI, Havana, Cuba. [LoBue, Philip] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA USA. [Solovic, Ivan] Catholic Univ, TB Dept, Natl Inst TB Resp Dis & Thorac Surg, Ruzomberok, Slovakia. [Story, Alistair] Find & Treat, London, England. [Tayeb, Tamara] Minist Hlth, Natl TB Control Programme, Riyadh, Saudi Arabia. [van der Werf, Marieke J.] European Ctr Dis Prevent & Control ECDC, Stockholm, Sweden. [Zellweger, Jean-Pierre] Swiss Lung Assoc, Bern, Switzerland. [Aziz, Mohamed Abdel] WHO Reg Off Eastern Mediterranean, Cairo, Egypt. [Al Lawati, Mohamed R. M.] Minist Hlth, Muscat, Oman. [Aliberti, Stefano] Univ Milano Bicocca, UO Clin Pneumol, AO San Gerardo, Monza, Italy. [de Onate, Wouter Arrazola] Belgian Lung & TB Assoc, Brussels, Belgium. [Barreira, Draurio] Minist Hlth, Brasilia, DF, Brazil. [Blasi, Francesco] Univ Milan, IRCCS Fdn Ca Granda, Dipartimento Fisiopatol Med Chirurg Trapianti, Milan, Italy. [Bloom, Amy] US Agcy Int Dev, Washington, DC 20523 USA. [Bruchfeld, Judith] Karolinska Inst Solna, Inst Med, Infect Dis Unit, Stockholm, Sweden. [Bruchfeld, Judith] Karolinska Univ Hosp, Stockholm, Sweden. [Castelli, Francesco] Univ Brescia, Brescia, Italy. [Chemtob, Daniel] Minist Hlth, Jerusalem, Israel. [Cirillo, Daniela M.] IRCCS, San Raffaele Sci Inst, Milan, Italy. [Colorado, Alberto] Advocates Hlth Int, San Diego, CA USA. [Dadu, Andrei] WHO Reg Off Europe, TB & M XDR TB Control Programme, Copenhagen, Denmark. [Dahle, Ulf R.; Ronning, Karin] Norwegian Inst Publ Hlth, Oslo, Norway. [De Paoli, Laura] Med Sans Frontieres, Rome, Italy. [Duarte, Raquel] Gen Directorate Hlth, Lisbon, Portugal. [Fattorini, Lanfranco] Ist Super Sanita, I-00161 Rome, Italy. [Gaga, Mina] Minist Hlth, Athens Chest Hosp, Natl Referral Ctr Mycobacteria, Athens, Greece. [Goguadze, Lasha] Int Federat Red Cross & Red Crescent Soc, Geneva, Switzerland. [del Granado, Mirtha] WHO Reg Off Amer, Washington, DC USA. [Haas, Walter] Robert Koch Inst, Dept Infect Dis Epidemiol, Berlin, Germany. [Jarvinen, Asko; Vasankari, Tuula] Finnish Lung Hlth Assoc, Helsinki, Finland. [Jarvinen, Asko] Helsinki Univ Cent Hosp, Div Infect Dis, Helsinki, Finland. [Kwon, Geun-Yong] Minist Hlth & Welf, Korea Ctr Dis Control & Prevent KCDC, Seoul, South Korea. [Mosca, Davide] Int Org Migrat, Geneva, Switzerland. [Nahid, Payam] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Nahid, Payam] Amer Thorac Soc, New York, NY USA. [Nishikiori, Nobuyuki] WHO Reg Off Western Pacific, Stop TB & Leprosy Eliminat, Manila, Philippines. [Noguer, Isabel] Inst Salud Carlos III, Madrid, Spain. [O'Donnell, Joan] HSE Hlth Protect Surveillance Ctr, Dublin, Ireland. [Pace-Asciak, Analita] Minist Hlth, Valletta, Malta. [Pompa, Maria G.] Minist Hlth, Rome, Italy. [Popescu, Gilda G.] Pneumol Inst Marius Nasta, Bucharest, Romania. [Cordeiro, Carlos Robalo] Coimbra Univ Hosp, Coimbra, Portugal. [Ruhwald, Morten] State Serum Inst, Copenhagen, Denmark. [Sculier, Jean-Paul] Inst Jules Bordet ULB, Brussels, Belgium. [Simunovic, Aleksandar] Croatian Natl Inst Publ Hlth, Zagreb, Croatia. [Smith-Palmer, Alison] Hlth Protect Scotland, Glasgow, Lanark, Scotland. [Sotgiu, Giovanni] Univ Sassari, Clin Epidemiol & Med Stat Unit, Dept Biomed Sci, Res Med Educ & Profess Dev Unit,AOU Sassari, I-07100 Sassari, Italy. [Torres-Duque, Carlos A.] Asociac Latinoamer Torax ALAT Fdn Neumol Colombia, Bogota, Colombia. [Umeki, Kazunori] Minist Hlth Labour & Welf, Tokyo, Japan. [Vitillo, Robert J.] Caritas Int, Geneva, Switzerland. [Voniatis, Constantia] Minist Hlth, Nicosia, Cyprus. [Wanlin, Maryse] Fonds Affect Resp FARES, Brussels, Belgium. RP Raviglione, MC (reprint author), WHO, Global TB Programme, 20 Ave Appia, CH-1211 Geneva 27, Switzerland. EM raviglionem@who.int RI Matteelli, Alberto/M-8784-2015; Lonnroth, Knut/L-2339-2014; Aliberti, Stefano/K-9115-2016; Robalo Cordeiro, Carlos Manuel da Silva/I-4864-2012; OI Sulis, Giorgia/0000-0001-6641-0094; Matteelli, Alberto/0000-0001-5109-9248; Lonnroth, Knut/0000-0001-5054-8240; Aliberti, Stefano/0000-0002-0090-4531; Glaziou, Philippe/0000-0002-0649-1272; van der Werf, Marieke J./0000-0001-8021-1358; Robalo Cordeiro, Carlos Manuel da Silva/0000-0002-8264-3856; Migliori, Giovanni Battista/0000-0002-2597-574X; SOTGIU, Giovanni/0000-0002-1600-4474; Duarte, Raquel/0000-0003-2257-3099; Blasi, Francesco/0000-0002-2285-9970; Goletti, Delia/0000-0001-8360-4376 FU European Respiratory Society FX This work was supported by core funding from the European Respiratory Society. NR 185 TC 146 Z9 148 U1 5 U2 23 PU EUROPEAN RESPIRATORY SOC JOURNALS LTD PI SHEFFIELD PA 442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND SN 0903-1936 EI 1399-3003 J9 EUR RESPIR J JI Eur. Resp. J. PD APR PY 2015 VL 45 IS 4 BP 928 EP 952 DI 10.1183/09031936.00214014 PG 25 WC Respiratory System SC Respiratory System GA CE7MB UT WOS:000352023800008 PM 25792630 ER PT J AU Kissin, DM Kulkarni, AD Mneimneh, A Warner, L Boulet, SL Crawford, S Jamieson, DJ AF Kissin, Dmitry M. Kulkarni, Aniket D. Mneimneh, Allison Warner, Lee Boulet, Sheree L. Crawford, Sara Jamieson, Denise J. CA Natl ART Surveillance Syst NASS Gr TI Embryo transfer practices and multiple births resulting from assisted reproductive technology: an opportunity for prevention SO FERTILITY AND STERILITY LA English DT Article DE Assisted reproductive technology (ART); in vitro fertilization (IVF); multiple birth; embryo transfer guidelines ID IN-VITRO FERTILIZATION; UNITED-STATES; MONOZYGOTIC TWINS; NUMBER; RISK; PREGNANCIES; TRENDS AB Objective: To evaluate assisted reproductive technology (ART) ET practices in the United States and assess the impact of these practices on multiple births, which pose health risks for both mothers and infants. Design: Retrospective cohort analysis using the National ART Surveillance System data. Setting: US fertility centers reporting to the National ART Surveillance System. Patient(s): Noncanceled ART cycles conducted in the United States in 2012. Intervention(s): None. Main Outcome Measure(s): Multiple birth (birth of two or more infants, at least one of whom was live-born). Result(s): Of 134,381 ART transfer cycles performed in 2012, 51,262 resulted in live births, of which 13,563 (26.5%) were multiple births: 13,123 twin and 440 triplet and higher order births. Almost half (46.1%) of these multiple births resulted from the following four cycle types: two fresh blastocyst transfers among favorable or average prognosis patients less than 35 years (1,931 and 1,341 multiple births, respectively), two fresh blastocyst transfers among donor-oocyte recipients (1,532 multiple births), and two frozen/thawed ETs among patients less than 35 years (1,452 multiple births). More than half of triplet or higher order births resulted from the transfer of two embryos (52.5% of births among fresh autologous transfers, 67.2% of births among donor-oocyte recipient transfers, and 42.9% among frozen/thawed autologous transfers). Conclusion(s): A substantial reduction of ART-related multiple (both twin and triplet or higher order) births in the United States could be achieved by single blastocyst transfers among favorable and average prognosis patients less than 35 years of age and donor-oocyte recipients. (C) 2015 by American Society for Reproductive Medicine. C1 [Kissin, Dmitry M.; Kulkarni, Aniket D.; Mneimneh, Allison; Warner, Lee; Boulet, Sheree L.; Crawford, Sara; Jamieson, Denise J.; Natl ART Surveillance Syst NASS Gr] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP Kissin, DM (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, 4770 Buford Highway NE,Mailstop F-74, Atlanta, GA 30341 USA. EM DKissin@cdc.gov FU Intramural CDC HHS [CC999999] NR 35 TC 18 Z9 19 U1 2 U2 9 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0015-0282 EI 1556-5653 J9 FERTIL STERIL JI Fertil. Steril. PD APR PY 2015 VL 103 IS 4 BP 954 EP 961 DI 10.1016/j.fertnstert.2014.12.127 PG 8 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA CE8QZ UT WOS:000352110400023 PM 25637480 ER PT J AU Dunietz, GL Holzman, C McKane, P Li, CX Boulet, SL Todem, D Kissin, DM Copeland, G Bernson, D Sappenfield, WM Diamond, MP AF Dunietz, Galit Levi Holzman, Claudia McKane, Patricia Li, Chenxi Boulet, Sheree L. Todem, David Kissin, Dmitry M. Copeland, Glenn Bernson, Dana Sappenfield, William M. Diamond, Michael P. TI Assisted reproductive technology and the risk of preterm birth among primiparas SO FERTILITY AND STERILITY LA English DT Article DE Assisted reproductive technology (ART); infertility; preterm birth ID SERUM RELAXIN CONCENTRATIONS; IN-VITRO FERTILIZATION; PERINATAL OUTCOMES; SINGLETON PREGNANCIES; METAANALYSIS; STIMULATION; INFERTILITY; STATES; WOMEN; TERM AB Objective: To investigate the risk of preterm birth among liveborn singletons to primiparas who conceived with assisted reproductive technology (ART) using four mutually exclusive categories of infertility (female infertility only, male infertility only, female and male infertility, and unexplained infertility) and to examine preterm birth risk along the gestational age continuum. Design: Retrospective cohort study. Setting: Not applicable. Patient(s): Singletons born to primiparas who conceived with or without ART. Intervention(s): None. Main Outcome Measure(s): Preterm (<37 weeks' gestation) and preterm/early term birth <39 weeks' gestation). Result(s): For the male infertility only, female infertility only, combined male and female infertility, and unexplained infertility groups, ART-conceived singletons were significantly more likely than non-ART singletons to be born preterm: adjusted odds ratio (aOR) 1.24 (95% CI, 1.13, 1.37), aOR 1.60 (95% CI, 1.50, 1.70), aOR 1.49 (95% CI, 1.35, 1.64), and aOR 1.26 (1.12, 1.43) respectively. Among infants whose mothers were diagnosed with infertility, the odds of preterm birth were highest between 28-30 weeks [female infertility only, aOR 1.95 (95% CI, 1.59, 2.39); male and female infertility: 2.21 (95% CI, 1.62, 3.00)] compared with infants in the general population. Within the ART population, singletons of couples with female infertility only were more likely to be born preterm than singletons born to couples with other infertility diagnoses. Conclusion(s): Among singleton births to primiparas, those conceived with ART had an increased risk for preterm birth, even when only the male partner had been diagnosed with infertility. The risk of preterm birth for ART-conceived infants whose mothers were diagnosed with infertility included the earliest deliveries. (C) 2015 by American Society for Reproductive Medicine. C1 [Dunietz, Galit Levi; Holzman, Claudia; Li, Chenxi; Todem, David] Michigan State Univ, Dept Epidemiol & Biostat, E Lansing, MI 48824 USA. [McKane, Patricia] Michigan Dept Community Hlth, Maternal & Child Hlth Sect, Lansing, MI USA. [Boulet, Sheree L.; Kissin, Dmitry M.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA. [Copeland, Glenn] Michigan Dept Community Hlth, Lansing, MI USA. [Bernson, Dana] Massachusetts Dept Publ Hlth, Boston, MA USA. [Sappenfield, William M.] Univ S Florida, Dept Community & Family Hlth, Tampa, FL USA. [Diamond, Michael P.] Georgia Regents Univ, Dept Obstet & Gynecol, Augusta, GA USA. RP Dunietz, GL (reprint author), Michigan State Univ, Epidemiol & Biostatist, 909 Fee Rd, E Lansing, MI 48824 USA. EM galit@msu.edu OI Diamond, Michael/0000-0001-6353-4489 FU Eunice Kennedy Shriver National Institute of Child Health and Human Development [T32-HD046377]; Centers for Disease Control and Prevention; Florida Department of Public Health; NIH/NICHD Cooperative Reproductive Medicine Network FX This work was supported in part by a T32 grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (T32-HD046377).; G.L.D. has nothing to disclose. C.H. has nothing to disclose. P.M. has nothing to disclose. C.L. has nothing to disclose. S.L.B. has nothing to disclose. D.T. has nothing to disclose. D.M.K. has nothing to disclose. G.C. has received a grant from the Centers for Disease Control and Prevention. D.B. has nothing to disclose. W.M.S. has received a grant from the Florida Department of Public Health. M.P.D. is a stockholder in and on the board of directors of Advanced Reproductive Care, and has received a grant from the NIH/NICHD Cooperative Reproductive Medicine Network. NR 25 TC 5 Z9 5 U1 1 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0015-0282 EI 1556-5653 J9 FERTIL STERIL JI Fertil. Steril. PD APR PY 2015 VL 103 IS 4 BP 974 EP U150 DI 10.1016/j.fertnstert.2015.01.015 PG 7 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA CE8QZ UT WOS:000352110400025 PM 25707336 ER PT J AU Leduc-Galindo, D Rincon-Herrera, U Ramos-Jimenez, J Garcia-Luna, S Arellanos-Soto, D Mendoza-Tavera, N Tavitas-Aguilar, I Garcia-Garcia, E Galindo-Galindo, E Villarreal-Perez, J Fernandez-Salas, I Santiago, GA Munoz-Jordan, J Rivas-Estilla, AM AF Leduc-Galindo, D. Rincon-Herrera, U. Ramos-Jimenez, J. Garcia-Luna, S. Arellanos-Soto, D. Mendoza-Tavera, N. Tavitas-Aguilar, I. Garcia-Garcia, E. Galindo-Galindo, E. Villarreal-Perez, J. Fernandez-Salas, I. Santiago, G. A. Munoz-Jordan, J. Rivas-Estilla, A. M. TI Characterization of the dengue outbreak in Nuevo Leon state, Mexico, 2010 SO INFECTION LA English DT Article DE Dengue fever (DF); Dengue hemorrhagic fever (DHF); Dengue virus (DENV); Breteau index (BI); Mexico ID SEVERITY; CHILDREN; VIRUS AB We studied serotypes circulating dengue virus (DENV) cases, entomological Breteau index, rain-fall index and epidemiology of groups affected during the 2010 outbreak in Nuevo Leon, Mexico. From 2,271 positive cases, 94 % were dengue classic and 6 % dengue hemorrhagic fever; DENV1 was mainly isolated (99 %) (Central-American lineage of American-African-genotype). We found correlation between two environmental phenomena (Increment of rainfall and vector-indexes) (p a parts per thousand currency sign 0.05) with epidemiological, clinical and risk of DENV-1 ongoing transmission. C1 [Leduc-Galindo, D.; Rincon-Herrera, U.; Garcia-Luna, S.; Arellanos-Soto, D.; Rivas-Estilla, A. M.] Univ Autonoma Nuevo Leon, Fac Med, Dept Biochem & Mol Med, Monterrey 64460, Nuevo Leon, Mexico. [Leduc-Galindo, D.; Rincon-Herrera, U.; Ramos-Jimenez, J.; Garcia-Luna, S.; Arellanos-Soto, D.; Mendoza-Tavera, N.; Villarreal-Perez, J.; Rivas-Estilla, A. M.] Univ Autonoma Nuevo Leon, Hosp Univ Dr Jose E Gonzalez, Monterrey 64460, Nuevo Leon, Mexico. [Ramos-Jimenez, J.; Mendoza-Tavera, N.; Villarreal-Perez, J.] Univ Autonoma Nuevo Leon, Fac Med, Dept Internal Med, Monterrey 64460, Nuevo Leon, Mexico. [Tavitas-Aguilar, I.; Garcia-Garcia, E.; Galindo-Galindo, E.; Villarreal-Perez, J.] Nuevo Leon Reference Lab Secretariat Hlth, Monterrey, Nuevo Leon, Mexico. [Fernandez-Salas, I.] Univ Autonoma Nuevo Leon, Sch Biol Sci, Dept Entomol, Monterrey 64460, Nuevo Leon, Mexico. [Santiago, G. A.; Munoz-Jordan, J.] Ctr Dis Control & Prevent, Div Vector Borne Infect Dis, Natl Ctr Zoonot Vector Borne & Enter Dis, San Juan, PR USA. RP Rivas-Estilla, AM (reprint author), Univ Autonoma Nuevo Leon, Fac Med, Dept Biochem & Mol Med, Ave Francisco I Madero & Eduardo Aguirre Pequeno, Monterrey 64460, Nuevo Leon, Mexico. EM amrivas1@yahoo.ca OI Villarreal-Perez, Jesus Zacarias/0000-0002-6814-062X FU CONACYT [SALUD-01-2010-1-141409]; PAICYT-UANL FX We thank Sergio Lozano-Rodriguez, M.D. (UANL) for his assistance in reviewing the manuscript. Financial support was provided by CONACYT Grant Number SALUD-01-2010-1-141409 and PAICYT-UANL-2011 to JRJ. NR 9 TC 2 Z9 2 U1 1 U2 3 PU SPRINGER HEIDELBERG PI HEIDELBERG PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY SN 0300-8126 EI 1439-0973 J9 INFECTION JI Infection PD APR PY 2015 VL 43 IS 2 BP 201 EP 206 DI 10.1007/s15010-014-0700-7 PG 6 WC Infectious Diseases SC Infectious Diseases GA CF1HN UT WOS:000352295600011 PM 25573274 ER PT J AU Leduc-Galindo, D Gloria-Herrera, U Ramos-Jimenez, J Garcia-Luna, S Arellanos-Soto, D Mendoza-Tavera, N Tavitas-Aguilar, I Garcia-Garcia, E Galindo-Galindo, E Villarreal-Perez, J Fernandez-Salas, I Santiago, GA Munoz-Jordan, J Rivas-Estilla, AM AF Leduc-Galindo, D. Gloria-Herrera, U. Ramos-Jimenez, J. Garcia-Luna, S. Arellanos-Soto, D. Mendoza-Tavera, N. Tavitas-Aguilar, I. Garcia-Garcia, E. Galindo-Galindo, E. Villarreal-Perez, J. Fernandez-Salas, I. Santiago, G. A. Munoz-Jordan, J. Rivas-Estilla, A. M. TI Characterization of the dengue outbreak in Nuevo Leon state, Mexico, 2010 (vol 43, pg 201, 2015) SO INFECTION LA English DT Correction C1 [Leduc-Galindo, D.; Gloria-Herrera, U.; Garcia-Luna, S.; Arellanos-Soto, D.; Rivas-Estilla, A. M.] Univ Autonoma Nuevo Leon, Fac Med, Dept Biochem & Mol Med, Monterrey 64460, Nuevo Leon, Mexico. [Leduc-Galindo, D.; Gloria-Herrera, U.; Ramos-Jimenez, J.; Garcia-Luna, S.; Arellanos-Soto, D.; Mendoza-Tavera, N.; Villarreal-Perez, J.; Rivas-Estilla, A. M.] Univ Autonoma Nuevo Leon, Hosp Univ Dr Jose E Gonzalez, Monterrey 64460, Nuevo Leon, Mexico. [Ramos-Jimenez, J.; Mendoza-Tavera, N.; Villarreal-Perez, J.] Univ Autonoma Nuevo Leon, Fac Med, Dept Internal Med, Monterrey 64460, Nuevo Leon, Mexico. [Tavitas-Aguilar, I.; Garcia-Garcia, E.; Galindo-Galindo, E.; Villarreal-Perez, J.] Nuevo Leon Reference Lab Secretariat Hlth, Monterrey, Nuevo Leon, Mexico. [Fernandez-Salas, I.] Univ Autonoma Nuevo Leon, Sch Biol Sci, Dept Entomol, Monterrey 64460, Nuevo Leon, Mexico. [Santiago, G. A.; Munoz-Jordan, J.] Ctr Dis Control & Prevent, Div Vector Borne Infect Dis, Natl Ctr Zoonot Vector Borne & Enter Dis, San Juan, PR USA. RP Rivas-Estilla, AM (reprint author), Univ Autonoma Nuevo Leon, Fac Med, Dept Biochem & Mol Med, Ave Francisco I Madero & Eduardo Aguirre Pequeno, Monterrey 64460, Nuevo Leon, Mexico. EM amrivas1@yahoo.ca NR 1 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER HEIDELBERG PI HEIDELBERG PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY SN 0300-8126 EI 1439-0973 J9 INFECTION JI Infection PD APR PY 2015 VL 43 IS 2 BP 259 EP 259 DI 10.1007/s15010-015-0739-0 PG 1 WC Infectious Diseases SC Infectious Diseases GA CF1HN UT WOS:000352295600026 PM 25701220 ER PT J AU Nyaga, MM Jere, KC Esona, MD Seheri, ML Stucker, KM Halpin, RA Akopov, A Stockwell, TB Peenze, I Diop, A Ndiaye, K Boula, A Maphalala, G Berejena, C Mwenda, JM Steele, AD Wentworth, DE Mphahlele, MJ AF Nyaga, Martin M. Jere, Khuzwayo C. Esona, Mathew D. Seheri, Mapaseka L. Stucker, Karla M. Halpin, Rebecca A. Akopov, Asmik Stockwell, Timothy B. Peenze, Ina Diop, Amadou Ndiaye, Kader Boula, Angeline Maphalala, Gugu Berejena, Chipo Mwenda, Jason M. Steele, A. Duncan Wentworth, David E. Mphahlele, M. Jeffrey TI Whole genome detection of rotavirus mixed infections in human, porcine and bovine samples co-infected with various rotavirus strains collected from sub-Saharan Africa SO INFECTION GENETICS AND EVOLUTION LA English DT Article DE Rotavirus; Mixed infections; Reassortants; Whole genome; Africa ID GROUP-A ROTAVIRUSES; SEQUENCE-INDEPENDENT AMPLIFICATION; POLYMERASE-CHAIN-REACTION; THAN 5 YEARS; MOLECULAR EPIDEMIOLOGY; IMMUNIZATION PROGRAM; VACCINATION PROGRAMS; CHILDREN YOUNGER; SEVERE DIARRHEA; NUCLEIC-ACID AB Group A rotaviruses (RVA) are among the main global causes of severe diarrhea in children under the age of 5 years. Strain diversity, mixed infections and untypeable RVA strains are frequently reported in Africa. We analysed rotavirus-positive human stool samples (n = 13) obtained from hospitalised children under the age of 5 years who presented with acute gastroenteritis at sentinel hospital sites in six African countries, as well as bovine and porcine stool samples (n = 1 each), to gain insights into rotavirus diversity and evolution. Polyacrylamide gel electrophoresis (PAGE) analysis and genotyping with G-(VP7) and P-specific (VP4) typing primers suggested that 13 of the 15 samples contained more than 11 segments and/or mixed G/P genotypes. Full-length amplicons for each segment were generated using RVA-specific primers and sequenced using the Ion Torrent and/or Illumina MiSeq next-generation sequencing platforms. Sequencing detected at least one segment in each sample for which duplicate sequences, often having distinct genotypes, existed. This supported and extended the PAGE and RT-PCR genotyping findings that suggested these samples were collected from individuals that had mixed rotavirus infections. The study reports the first porcine (MRC-DPRU1567) and bovine (MRC-DPRU3010) mixed infections. We also report a unique genome segment 9 (VP7), whose G9 genotype belongs to lineage VI and clusters with porcine reference strains. Previously, African G9 strains have all been in lineage III. Furthermore, additional RVA segments isolated from humans have a clear evolutionary relationship with porcine, bovine and ovine rotavirus sequences, indicating relatively recent interspecies transmission and reassortment. Thus, multiple RVA strains from sub-Saharan Africa are infecting mammalian hosts with unpredictable variations in their gene segment combinations. Whole-genome sequence analyses of mixed RVA strains underscore the considerable diversity of rotavirus sequences and genome segment combinations that result from a complex evolutionary history involving multiple host species. (C) 2015 Elsevier B.V. All rights reserved. C1 [Nyaga, Martin M.; Jere, Khuzwayo C.; Esona, Mathew D.; Seheri, Mapaseka L.; Peenze, Ina; Steele, A. Duncan; Mphahlele, M. Jeffrey] Sefako Makgatho Hlth Sci Univ, Fac Hlth Sci, South African Med Res Council, Diarrhoeal Pathogens Res Unit, Pretoria, South Africa. [Jere, Khuzwayo C.] Univ Liverpool, Dept Clin Infect Microbiol & Immunol, Inst Infect & Global Hlth, Liverpool L69 3BX, Merseyside, England. [Esona, Mathew D.] CDC, Gastroenteritis & Resp Viruses Lab Branch, Div Viral Dis, NCIRD, Atlanta, GA 30333 USA. [Stucker, Karla M.; Halpin, Rebecca A.; Akopov, Asmik; Stockwell, Timothy B.; Wentworth, David E.] J Craig Venter Inst, Rockville, MD USA. [Diop, Amadou] Albert Royer Natl Paediat Hosp Lab, Dakar, Senegal. [Ndiaye, Kader] Inst Pasteur, Unite Virol Med, Dakar, Senegal. [Boula, Angeline] Chantal Biya Fdn, Mother & Child Ctr, Yaounde, Cameroon. [Maphalala, Gugu] Natl Clin Lab Serv, Mbabane, Swaziland. [Berejena, Chipo] Univ Zimbabwe, Dept Med Microbiol, Virol Sect, Harare, Zimbabwe. [Mwenda, Jason M.] WHO, Reg Off Africa, Brazzaville, Congo. [Steele, A. Duncan] Bill & Melinda Gates Fdn, Enter & Diarrhoeal Dis Programme, Global Hlth Program, Seattle, WA USA. RP Mphahlele, MJ (reprint author), Sefako Makgatho Hlth Sci Univ, Fac Hlth Sci, South African Med Res Council, Diarrhoeal Pathogens Res Unit, Pretoria, South Africa. EM wamodylan@gmail.com; Khuzwayo.Jere@liverpool.ac.uk; mdi4@cdc.gov; mpasi.seheri@gmail.com; kstucker@jcvi.org; RHalpin@jcvi.org; aakopov@jcvi.org; tstockwell@jcvi.org; inapeenze@yahoo.com; amadoudioplaba@yahoo.fr; kadern@pasteur.sn; boulaayc@yahoo.fr; gpmaphalala@gmail.com; cberejena@gmail.com; mwendaj@afro.who.int; duncan.steele@gatesfoundation.org; DWentworth@cdc.gov; jeffrey.mphahlele@mrc.ac.za OI Jere, Khuzwayo/0000-0003-3376-8529; Wentworth, David/0000-0002-5190-980X FU National Research Foundation (NRF); South African Medical Research Council (MRC); Poliomyelitis Research Foundation (PRF) [PRF14/05, PRF13/62]; US federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services [HHSN272200900007C] FX The financial assistance of the National Research Foundation (NRF), the South African Medical Research Council (MRC) and the Poliomyelitis Research Foundation (PRF), under grant numbers PRF14/05 (Major Impact) and PRF13/62 (PhD) are hereby acknowledged. The project was also funded in part by US federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services under contract number HHSN272200900007C (Genome Sequencing Center for Infectious Diseases). Opinions expressed and conclusions arrived at, are those of the authors and are not necessarily to be attributed to the sponsors. NR 65 TC 8 Z9 8 U1 0 U2 7 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1567-1348 EI 1567-7257 J9 INFECT GENET EVOL JI Infect. Genet. Evol. PD APR PY 2015 VL 31 BP 321 EP 334 DI 10.1016/j.meegid.2015.02.011 PG 14 WC Infectious Diseases SC Infectious Diseases GA CE9SE UT WOS:000352182900044 PM 25701122 ER PT J AU Wesolowski, LG Wroblewski, K Bennett, SB Parker, MM Hagan, C Ethridge, SF Rhodes, J Sullivan, TJ Ignacio-Hernando, I Werner, BG Owen, SM AF Wesolowski, Laura G. Wroblewski, Kelly Bennett, Spencer B. Parker, Monica M. Hagan, Celia Ethridge, Steven F. Rhodes, Jeselyn Sullivan, Timothy J. Ignacio-Hernando, Imelda Werner, Barbara G. Owen, S. Michele TI Nucleic acid testing by public health referral laboratories for public health laboratories using the US HIV diagnostic testing algorithm SO JOURNAL OF CLINICAL VIROLOGY LA English DT Article DE HIV; Algorithms; Nucleic acid amplification test; Diagnostic tests ID PERFORMANCE; INFECTION; ASSAY; AMPLIFICATION; TRANSMISSION; RATES AB Background: Many public health laboratories adopting the U.S. HIV laboratory testing algorithm do not have a nucleic acid test (NAT), which is needed when the third- or fourth-generation HIV screening immunoassay is reactive and the antibody-based supplemental test is non-reactive or indeterminate. Objectives: Among public health laboratories utilizing public health referral laboratories for NAT conducted as part of the algorithm, we evaluated the percentage of screening immunoassays needing NAT, the number of specimens not meeting APTIMA (NAT) specifications, time to APTIMA result, the proportion of acute infections (i.e., reactive APTIMA) among total infections, and screening immunoassay specificity. Study design: From August 2012 to April 2013, 22 laboratories enrolled to receive free APTIMA (NAT) at New York or Florida public health referral laboratories. Data were analyzed for testing conducted until June 2013. Results: Submitting laboratories conducted a median of 4778 screening immunoassays; 0-1.3% (median 0.2%) needed NAT. Of 140 specimens received, 9 (6.4%) did not meet NAT specifications. The median time from specimen collection to reporting the 11 reactive NAT results was ten days, including six days from receipt in the submitting laboratory to shipment to the referral laboratory. Acute infections ranged from 0 to 12.5% (median 0%) of total infections. Third-and fourth-generation immunoassays met package insert specificity values. Conclusions: Public health referral laboratories provide a feasible option for conducting NAT. Reducing the time from specimen collection to submission of specimens for NAT is an important step toward maximizing the public health impact of identifying acute infections. Published by Elsevier B.V. C1 [Wesolowski, Laura G.; Ethridge, Steven F.; Owen, S. Michele] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. [Wroblewski, Kelly; Hagan, Celia] Assoc Publ Hlth Labs, Silver Spring, MD 20910 USA. [Bennett, Spencer B.; Ignacio-Hernando, Imelda] Florida Dept Hlth, Bur Publ Hlth Labs, Jacksonville, FL 32202 USA. [Parker, Monica M.; Sullivan, Timothy J.] New York State Dept Hlth, Wadsworth Ctr, Albany, NY 12208 USA. [Rhodes, Jeselyn] ICF Int Inc, Atlanta, GA 30329 USA. [Werner, Barbara G.] MA Dept Publ Hlth, Bur Infect Dis, Jamaica, MA 02130 USA. RP Wesolowski, LG (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, 1600 Clifton Rd,MS E-46, Atlanta, GA 30333 USA. EM lig7@cdc.gov OI Sullivan, Timothy/0000-0003-3144-9188; Rhodes, Jeselyn/0000-0002-5776-2386 FU CDC [U60HM000803]; APHL FX The project was funded through CDC Cooperative Agreement # U60HM000803 with APHL. NR 15 TC 2 Z9 2 U1 2 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1386-6532 EI 1873-5967 J9 J CLIN VIROL JI J. Clin. Virol. PD APR PY 2015 VL 65 BP 6 EP 10 DI 10.1016/j.jcv.2015.01.017 PG 5 WC Virology SC Virology GA CF6XZ UT WOS:000352701500002 PM 25766979 ER PT J AU Oliveira, DBL Iwane, MK Prill, MM Weinberg, GA Williams, JV Griffin, MR Szilagyi, PG Edwards, KM Staat, MA Hall, CB Durigon, EL Erdman, DD AF Oliveira, Danielle B. L. Iwane, Marika K. Prill, Mila M. Weinberg, Geoffrey A. Williams, John V. Griffin, Marie R. Szilagyi, Peter G. Edwards, Kathryn M. Staat, Mary A. Hall, Caroline B. Durigon, Edison L. Erdman, Dean D. TI Molecular characterization of respiratory syncytial viruses infecting children reported to have received palivizumab immunoprophylaxis SO JOURNAL OF CLINICAL VIROLOGY LA English DT Article DE Respiratory syncytial virus; Palivizumab resistance; Pyrosequencing ID F-GLYCOPROTEIN; IN-VITRO; RESISTANT; NEUTRALIZATION; VARIANTS; INFANTS AB Background: Respiratory syncytial virus (RSV) is a major cause of respiratory infections in children. Palivizumab (PZ) is the only RSV-specific immunoprophylaxis approved by the U.S.Food and Drug Administration. Mutations leading to amino acid substitutions in the PZ binding site of the RSV F protein have been associated with breakthrough RSV infections in patients receiving PZ. Objective: To detect PZ resistance conferring mutations in RSV strains from children who received PZ. Study design: Children aged <= 24 months on October 31 who were hospitalized or had outpatient visits for respiratory illness and/or fever during October-May 2001-2008 in 3 US counties were included. PZ receipt was obtained from parent interviews and medical records among children subsequently infected with RSV. Archived nasal/throat swab specimens were tested for RSV by real-time RT-PCR. The coding region of the PZ binding site of the RSV F protein was sequenced using both Sanger and pyrosequencing methods. Results: Of 8762 enrolled children, 375 (4.3%) were tested for RSV and had a history of PZ receipt, of which 56 (14.9%) were RSV-positive and 45 of these had available archived specimens. Molecular typing identified 42 partial F gene sequences in specimens from 39 children: 19 single RSV subgroup A, 17 subgroup B and 3 mixed infections. Nucleotide substitutions were identified in 12/42 (28.6%) RSV strains. PZ resistance mutations were identified in 4 (10.2%) of the 39 children, of which one had documented PZ receipt. Conclusions: Although RSV PZ resistance mutations were infrequent, most RSV-associated illnesses in children with a history of PZ receipt were not due to strain resistance. Published by Elsevier B.V. C1 [Oliveira, Danielle B. L.; Durigon, Edison L.] Univ Sao Paulo, BR-05508 Sao Paulo, Brazil. [Iwane, Marika K.; Prill, Mila M.; Erdman, Dean D.] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA 30333 USA. [Weinberg, Geoffrey A.; Szilagyi, Peter G.; Hall, Caroline B.] Univ Rochester, Sch Med, Rochester, NY USA. [Williams, John V.; Griffin, Marie R.; Edwards, Kathryn M.] Vanderbilt Univ, Med Ctr, Nashville, TN USA. [Staat, Mary A.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA. RP Erdman, DD (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM dde1@cdc.gov OI Durigon, Edison/0000-0003-4898-6553 FU Centers for Disease Control and Prevention [U38CCU217969, U01 IP000017, U38CCU417958, U01 IP000022, U38CCU522352, U01 IP000147] FX Supported by the Centers for Disease Control and Prevention (cooperative agreements U38CCU217969, U01 IP000017, U38CCU417958, U01 IP000022, U38CCU522352, and U01 IP000147). NR 21 TC 2 Z9 2 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1386-6532 EI 1873-5967 J9 J CLIN VIROL JI J. Clin. Virol. PD APR PY 2015 VL 65 BP 26 EP 31 DI 10.1016/j.jcv.2015.01.016 PG 6 WC Virology SC Virology GA CF6XZ UT WOS:000352701500006 PM 25766983 ER PT J AU Tarkhashvili, N Chokheli, M Chubinidze, M Abazashvili, N Chakvetadze, N Imnadze, P Kretsinger, K Varma, J Sobel, J AF Tarkhashvili, N. Chokheli, M. Chubinidze, M. Abazashvili, N. Chakvetadze, N. Imnadze, P. Kretsinger, K. Varma, J. Sobel, J. TI Regional Variations in Home Canning Practices and the Risk of Foodborne Botulism in the Republic of Georgia, 2003 SO JOURNAL OF FOOD PROTECTION LA English DT Article ID CLOSTRIDIUM-BOTULINUM; TOXIN PRODUCTION; TOMATO JUICE; GROWTH; ACID; FOOD; PH AB Foodborne botulism is a severe, paralytic illness caused by ingestion of preformed neurotoxins produced by Clostridium botulinum. In 2003, we conducted a population-based household survey of home canning practices to explore marked regional variations in botulism incidence in the Republic of Georgia (ROG). We designed a cluster sampling scheme and subdivided each of the 10 regions of the ROG into a variable number of strata. Households were selected from each stratum using a two-step cluster sampling methodology. We administered a questionnaire about home canning practices to household members responsible for food preparation. Using multivariate logistic regression analysis, we modeled high (eastern ROG) against low (western ROG) incidence areas. Overall, we surveyed 2,742 households nationwide. Home canning with a capping device hermetically sealing the lid covering the jar was practiced by 1,909 households (65.9%; 95% confidence interval [CI]: 59.8 to 72.1%). Canning was more prevalent in regions of low botulism incidence (34 versus 32%; P < 0.01). When compared with low-botulism areas, the following practices were associated with an increased risk in high-botulism areas: >= 6 months between canning vegetables and consuming them (adjusted odds ratio [aOR] = 2.1; 95% CI: 1.3 to 3.5) and adding any of the following ingredients to the jar at time of preparation: >1 tablespoon of salt per liter (aOR = 5.1; 95% CI: 1.2 to 22.6); vinegar (aOR = 2.2; 95% CI: 1.3 to 3.7), and greens (aOR = 5.6; 95% CI: 1.7 to 18.2). The following practices were associated with a decreased risk in high-botulism areas: >57 jars canned per household annually (aOR = 0.5; 95% CI: 0.3 to 0.9), covering or immersing vegetables in boiling water before placing them into the jar (aOR = 0.3 95% CI: 0.2 to 0.6), covering or immersing vegetables in boiling water after placing them into the jar (aOR = 0.4; 95% CI: 0.2 to 0.9), or adding garlic (aOR = 0.2; 95% CI: 0.1 to 0.5) or aspirin (aOR = 0.1; 95% CI: 0.1 to 0.2) to the jar at the time of preparation. C1 [Tarkhashvili, N.; Kretsinger, K.; Varma, J.; Sobel, J.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Chokheli, M.; Chubinidze, M.; Abazashvili, N.; Chakvetadze, N.; Imnadze, P.] Natl Ctr Dis Control, Tbilisi, Rep of Georgia. RP Tarkhashvili, N (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM nato.tarkhashvili@state.sd.us FU U.S. Department of Health and Human Services, Biotechnology Engagement Program FX This study was funded by the U.S. Department of Health and Human Services, Biotechnology Engagement Program. The funding source played no role in designing the study; collecting, analyzing, and interpreting the data; writing the report; or deciding to submit the results for publication. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 12 TC 0 Z9 0 U1 1 U2 4 PU INT ASSOC FOOD PROTECTION PI DES MOINES PA 6200 AURORA AVE SUITE 200W, DES MOINES, IA 50322-2863 USA SN 0362-028X EI 1944-9097 J9 J FOOD PROTECT JI J. Food Prot. PD APR PY 2015 VL 78 IS 4 BP 746 EP 750 DI 10.4315/0362-028X.JFP-14-533 PG 5 WC Biotechnology & Applied Microbiology; Food Science & Technology SC Biotechnology & Applied Microbiology; Food Science & Technology GA CF3QM UT WOS:000352463600015 PM 25836400 ER PT J AU Schaffner, DW Brown, LG Ripley, D Reimann, D Koktavy, N Blade, H Nicholas, D AF Schaffner, Donald W. Brown, Laura Green Ripley, Danny Reimann, Dave Koktavy, Nicole Blade, Henry Nicholas, David TI Quantitative Data Analysis To Determine Best Food Cooling Practices in US Restaurants SO JOURNAL OF FOOD PROTECTION LA English DT Article ID FOODBORNE-DISEASE OUTBREAKS; CLOSTRIDIUM-PERFRINGENS; PEA SOUP; GROWTH AB Data collected by the Centers for Disease Control and Prevention (CDC) show that improper cooling practices contributed to more than 500 foodborne illness outbreaks associated with restaurants or delis in the United States between 1998 and 2008. CDC's Environmental Health Specialists Network (EHS-Net) personnel collected data in approximately 50 randomly selected restaurants in nine EHS-Net sites in 2009 to 2010 and measured the temperatures of cooling food at the beginning and the end of the observation period. Those beginning and ending points were used to estimate cooling rates. The most common cooling method was refrigeration, used in 48% of cooling steps. Other cooling methods included ice baths (19%), room-temperature cooling (17%), ice-wand cooling (7%), and adding ice or frozen food to the cooling food as an ingredient (2%). Sixty-five percent of cooling observations had an estimated cooling rate that was compliant with the 2009 Food and Drug Administration Food Code guideline (cooling to 41 degrees F [5 degrees C] in 6 h). Large cuts of meat and stews had the slowest overall estimated cooling rate, approximately equal to that specified in the Food Code guideline. Pasta and noodles were the fastest cooling foods, with a cooling time of just over 2 h. Foods not being actively monitored by food workers were more than twice as likely to cool more slowly than recommended in the Food Code guideline. Food stored at a depth greater than 7.6 cm (3 in.) was twice as likely to cool more slowly than specified in the Food Code guideline. Unventilated cooling foods were almost twice as likely to cool more slowly than specified in the Food Code guideline. Our data suggest that several best cooling practices can contribute to a proper cooling process. Inspectors unable to assess the full cooling process should consider assessing specific cooling practices as an alternative. Future research could validate our estimation method and study the effect of specific practices on the full cooling process. C1 [Schaffner, Donald W.] Rutgers State Univ, Food Sci Dept, New Brunswick, NJ 08901 USA. [Brown, Laura Green] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Chamblee, GA 30341 USA. [Ripley, Danny] Metro Nashville Davidson Cty Publ Hlth Dept, Nashville, TN 37203 USA. [Reimann, Dave] Minnesota Dept Hlth, Mankato, MN 56001 USA. [Koktavy, Nicole] Minnesota Dept Hlth, St Paul, MN 55164 USA. [Blade, Henry] Rhode Isl Dept Hlth, Providence, RI 02908 USA. [Nicholas, David] New York State Dept Hlth, Bur Community Environm Hlth & Food Protect, Albany, NY 12237 USA. RP Schaffner, DW (reprint author), Rutgers State Univ, Food Sci Dept, 65 Dudley Rd, New Brunswick, NJ 08901 USA. EM schaffner@aesop.rutgers.edu NR 13 TC 1 Z9 1 U1 0 U2 4 PU INT ASSOC FOOD PROTECTION PI DES MOINES PA 6200 AURORA AVE SUITE 200W, DES MOINES, IA 50322-2863 USA SN 0362-028X EI 1944-9097 J9 J FOOD PROTECT JI J. Food Prot. PD APR PY 2015 VL 78 IS 4 BP 778 EP 783 DI 10.4315/0362-028X.JFP-14-252 PG 6 WC Biotechnology & Applied Microbiology; Food Science & Technology SC Biotechnology & Applied Microbiology; Food Science & Technology GA CF3QM UT WOS:000352463600020 PM 25836405 ER PT J AU Yang, H Carney, PJ Chang, JC Villanueva, JM Stevens, J AF Yang, Hua Carney, Paul J. Chang, Jessie C. Villanueva, Julie M. Stevens, James TI Structure and Receptor Binding Preferences of Recombinant Hemagglutinins from Avian and Human H6 and H10 Influenza A Virus Subtypes SO JOURNAL OF VIROLOGY LA English DT Article ID HUMAN INFECTION; H7N9 VIRUS; HONG-KONG; MOLECULAR CHARACTERIZATION; MEMBRANE-FUSION; INTERNAL GENES; UNITED-STATES; H5N1 VIRUSES; ORIGIN; SPECIFICITY AB During 2013, three new avian influenza A virus subtypes, A(H7N9), A(H6N1), and A(H10N8), resulted in human infections. While the A(H7N9) virus resulted in a significant epidemic in China across 19 provinces and municipalities, both A(H6N1) and A(H10N8) viruses resulted in only a few human infections. This study focuses on the major surface glycoprotein hemagglutinins from both of these novel human viruses. The detailed structural and glycan microarray analyses presented here highlight the idea that both A(H6N1) and A(H10N8) virus hemagglutinins retain a strong avian receptor binding preference and thus currently pose a low risk for sustained human infections. IMPORTANCE Human infections with zoonotic influenza virus subtypes continue to be a great public health concern. We report detailed structural analysis and glycan microarray data for recombinant hemagglutinins from A(H6N1) and A(H10N8) viruses, isolated from human infections in 2013, and compare them with hemagglutinins of avian origin. This is the first structural report of an H6 hemagglutinin, and our results should further the understanding of these viruses and provide useful information to aid in the continuous surveillance of these zoonotic influenza viruses. C1 [Yang, Hua; Carney, Paul J.; Chang, Jessie C.; Villanueva, Julie M.; Stevens, James] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Influenza Div, Atlanta, GA 30333 USA. RP Stevens, J (reprint author), Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Influenza Div, Atlanta, GA 30333 USA. EM fwb4@cdc.gov FU Centers for Disease Control and Prevention; U.S. Department of Energy, Office of Science, Office of Basic Energy Sciences [DE-AC02-06CH11357]; National Institute of General Medical Sciences [GM62116] FX This study was funded by the Centers for Disease Control and Prevention. Use of the Advanced Photon Source at Argonne National Laboratory was supported by the U.S. Department of Energy, Office of Science, Office of Basic Energy Sciences, under contract DE-AC02-06CH11357. Glycan microarrays were produced for the Centers for Disease Control by the Consortium for Functional Glycomics (CFG), funded by National Institute of General Medical Sciences grant GM62116. NR 68 TC 5 Z9 5 U1 0 U2 6 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X EI 1098-5514 J9 J VIROL JI J. Virol. PD APR PY 2015 VL 89 IS 8 BP 4612 EP 4623 DI 10.1128/JVI.03456-14 PG 12 WC Virology SC Virology GA CF0FL UT WOS:000352218400048 PM 25673707 ER PT J AU Zeng, H Belser, JA Goldsmith, CS Gustin, KM Veguilla, V Katz, JM Tumpey, TM AF Zeng, Hui Belser, Jessica A. Goldsmith, Cynthia S. Gustin, Kortney M. Veguilla, Vic Katz, Jacqueline M. Tumpey, Terrence M. TI A(H7N9) Virus Results in Early Induction of Proinflammatory Cytokine Responses in both Human Lung Epithelial and Endothelial Cells and Shows Increased Human Adaptation Compared with Avian H5N1 Virus SO JOURNAL OF VIROLOGY LA English DT Article ID INFLUENZA-A H7N9; RESPIRATORY-DISTRESS-SYNDROME; HUMAN INFECTIONS; RECEPTOR-BINDING; OCULAR TROPISM; HOST RESPONSES; AMINO-ACID; TRANSMISSION; FERRETS; PATHOGENESIS AB Similar to H5N1 viruses, A( H7N9) influenza viruses have been associated with severe respiratory disease and fatal outcomes in humans. While high viral load, hypercytokinemia, and pulmonary endothelial cell involvement are known to be hallmarks of H5N1 virus infection, the pathogenic mechanism of the A(H7N9) virus in humans is largely unknown. In this study, we assessed the ability of A(H7N9) virus to infect, replicate, and elicit innate immune responses in both human bronchial epithelial cells and pulmonary microvascular endothelial cells, compared with the abilities of seasonal H3N2, avian H7N9, and H5N1 viruses. In epithelial cells, A(H7N9) virus replicated efficiently but did not elicit robust induction of cytokines like that observed for H5N1 virus. In pulmonary endothelial cells, A(H7N9) virus efficiently initiated infection; however, no released infectious virus was detected. The magnitudes of induction of host cytokine responses were comparable between A(H7N9) and H5N1 virus infection. Additionally, we utilized differentiated human primary bronchial and tracheal epithelial cells to investigate cellular tropism using transmission electron microscopy and the impact of temperature on virus replication. Interestingly, A(H7N9) virus budded from the surfaces of both ciliated and mucin-secretory cells. Furthermore, A(H7N9) virus replicated to a significantly higher titer at 37 degrees C than at 33 degrees C, with improved replication capacity at 33 degrees C compared to that of H5N1 virus. These findings suggest that a high viral load from lung epithelial cells coupled with induction of host responses in endothelial cells may contribute to the severe pulmonary disease observed following H7N9 virus infection. Improved adaptation of A(H7N9) virus to human upper airway poses an important threat to public health. IMPORTANCE A(H7N9) influenza viruses have caused over 450 documented human infections with a 30% fatality rate since early 2013. However, these novel viruses lack many molecular determinants previously identified with mammalian pathogenicity, necessitating a closer examination of how these viruses elicit host responses which could be detrimental. This study provides greater insight into the interaction of this virus with host lung epithelial cells and endothelial cells, which results in high viral load, epithelial cell death, and elevated immune response in the lungs, revealing the mechanism of pathogenesis and disease development among A(H7N9)-infected patients. In particular, we characterized the involvement of pulmonary endothelial cells, a cell type in the human lung accessible to influenza virus following damage of the epithelial monolayer, and its potential role in the development of severe pneumonia caused by A(H7N9) infection in humans. C1 [Zeng, Hui; Belser, Jessica A.; Gustin, Kortney M.; Veguilla, Vic; Katz, Jacqueline M.; Tumpey, Terrence M.] Ctr Dis Control & Prevent, Immunol & Pathogenesis Branch, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Goldsmith, Cynthia S.] Ctr Dis Control & Prevent, Infect Dis Pathol Branch, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. RP Tumpey, TM (reprint author), Ctr Dis Control & Prevent, Immunol & Pathogenesis Branch, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM tft9@cdc.gov NR 51 TC 10 Z9 11 U1 3 U2 10 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X EI 1098-5514 J9 J VIROL JI J. Virol. PD APR PY 2015 VL 89 IS 8 BP 4655 EP 4667 PG 13 WC Virology SC Virology GA CF0FL UT WOS:000352218400052 PM 25673714 ER PT J AU Ahmed, K Vaid, I May, D Manheim, D AF Ahmed, Kaha Vaid, Isam May, Dianne Manheim, Diane TI Community-Clinical Linkages in the WISEWOMAN Program SO JOURNAL OF WOMENS HEALTH LA English DT Meeting Abstract C1 [Ahmed, Kaha; Vaid, Isam; May, Dianne; Manheim, Diane] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 2 U2 4 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 EI 1931-843X J9 J WOMENS HEALTH JI J. Womens Health PD APR 1 PY 2015 VL 24 IS 4 MA P1 BP 2 EP 2 DI 10.1089/jwh.2015.Ab02.abstracts PG 1 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA CF5YE UT WOS:000352632500002 ER PT J AU Paykov, ME Nelson, RG Knowler, WC Cheng, YL Krolewski, AS Niewczas, MA AF Paykov, Meda E. Nelson, Robert G. Knowler, William C. Cheng, Yiling Krolewski, Andrzej S. Niewczas, Monika A. TI Elevation of circulating TNF receptors 1 and 2 increases the risk of end-stage renal disease in American Indians with type 2 diabetes SO KIDNEY INTERNATIONAL LA English DT Article DE diabetic nephropathy; ESRD; TNF ID TUMOR-NECROSIS-FACTOR; APOPTOSIS-INDUCING LIGAND; INSULIN-RESISTANCE; KIDNEY-FUNCTION; ADIPOSE-TISSUE; HUMAN OBESITY; PIMA-INDIANS; FACTOR-ALPHA; NEPHROPATHY; EXPRESSION AB In Caucasians with type 2 diabetes, circulating TNF receptors 1 (TNFR1) and 2 (INFR2) predict end-stage renal disease (ESRD). Here we examined this relationship in a longitudinal cohort study of American Indians with type 2 diabetes with measured glomerular filtration rate (mGFR, iothalamate) and urinary albumin-to-creatinine ratio (ACR). ESRD was defined as dialysis, kidney transplant, or death attributed to diabetic kidney disease. Age-gender-adjusted incidence rates and incidence rate ratios of ESRD were computed by Mantel-Haenszel stratification. The hazard ratio of ESRD was assessed per interquartile range increase in the distribution of each TNFR after adjusting for baseline age, gender, mean blood pressure, HbA1c, ACR, and mGFR. Among the 193 participants, 62 developed ESRD and 25 died without E5RD during a median follow-up of 9.5 years. The age-gender-adjusted incidence rate ratio of ESRD was higher among participants in the highest versus lowest quartile for TNFR1 (6.6, 95% confidence interval (Cl) 3.3-13.3) or TNFR2 (8.8, 95% Cl 4.3-18.0). In the fully adjusted model, the risk of ESRD per interquartile range increase was 1.6 times (95% Cl 1.1-2.2) as high for TNFR1 and 1.7 times (95% CI 1.2-2.3) as high for TNFR2. Thus, elevated serum concentrations of TNFR1 or TNFR2 are associated with increased risk of ESRD in American Indians with type 2 diabetes after accounting for traditional risk factors including ACR and mGFR. C1 [Paykov, Meda E.; Cheng, Yiling] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA USA. [Nelson, Robert G.; Knowler, William C.] NIDDK, Diabet Epidemiol & Clin Res Sect, NIH, Phoenix, AZ 85014 USA. [Krolewski, Andrzej S.; Niewczas, Monika A.] Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA. [Krolewski, Andrzej S.; Niewczas, Monika A.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. RP Nelson, RG (reprint author), NIDDK, Diabet Epidemiol & Clin Res Sect, NIH, 1550 East Indian Sch Rd, Phoenix, AZ 85014 USA. EM rnelson@nih.gov FU Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases; National Institutes of Health (NIH) [DRC P30DK036836, DK41526, DK67638] FX This study was supported in part by the Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases and by grants from the National Institutes of Health (NIH): DRC P30DK036836 to MAN; DK41526 and DK67638 to ASK. NR 48 TC 0 Z9 1 U1 1 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0085-2538 EI 1523-1755 J9 KIDNEY INT JI Kidney Int. PD APR PY 2015 VL 87 IS 4 BP 812 EP 819 DI 10.1038/ki.2014.330 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA CE9QZ UT WOS:000352179800020 ER PT J AU Smith, RM Parrott, DJ Swartout, KM Tharp, AT AF Smith, Rachel M. Parrott, Dominic J. Swartout, Kevin M. Tharp, Andra Teten TI Deconstructing Hegemonic Masculinity: The Roles of Antifemininity, Subordination to Women, and Sexual Dominance in Men's Perpetration of Sexual Aggression SO PSYCHOLOGY OF MEN & MASCULINITY LA English DT Article DE sexual aggression; hegemonic masculinity; masculine gender role stress; antifemininity; sexual dominance ID GENDER-ROLE STRESS; VIOLENCE PREVENTION PROGRAM; TEST-RETEST RELIABILITY; TACTICS-SCALES CTS2; MALE-ROLE NORMS; RESEARCHING VIOLENCE; CONSTRUCT-VALIDITY; CONFLUENCE MODEL; NATIONAL SAMPLE; ROLE-CONFLICT AB The aim of this investigation was to examine a theoretically based mechanism by which men's adherence to antifeminine norms is associated with their perpetration of sexual aggression toward intimate partners. Participants were 208 heterosexual men between the ages of 21-35 who had consumed alcohol in the past year. They were recruited from a large southeastern United States city. Participants completed self-report measures of hegemonic masculinity (i. e., antifemininity, sexual dominance), masculine gender role stress, and sexual aggression toward an intimate partner during the past 12 months. Results indicated that adherence to the antifemininity norm and the tendency to experience stress when in subordinate positions to women were indirectly related to sexual aggression perpetration via adherence to the sexual dominance norm. Thus, the men who adhere strongly to these particular hegemonic masculine norms may feel compelled to be sexually aggressive and/or coercive toward an intimate partner in order to maintain their need for dominance within their intimate relationship. Implications for future research and sexual aggression prevention programming are discussed. C1 [Smith, Rachel M.; Parrott, Dominic J.; Swartout, Kevin M.] Georgia State Univ, Dept Psychol, Atlanta, GA 30302 USA. [Tharp, Andra Teten] Ctr Dis Control & Prevent, Div Violence Prevent, Atlanta, GA USA. RP Parrott, DJ (reprint author), Georgia State Univ, Dept Psychol, POB 5010, Atlanta, GA 30302 USA. EM parrott@gsu.edu FU Centers for Disease Control and Georgia State University FX This article is based in part on a Georgia State University Honors College undergraduate thesis conducted by Rachel M. Smith under the direction of Dominic J. Parrott. This research was supported by a joint grant by the Centers for Disease Control and Georgia State University. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. We are grateful to Sarah Cook for her helpful comments. NR 67 TC 4 Z9 4 U1 6 U2 18 PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 1524-9220 EI 1939-151X J9 PSYCHOL MEN MASCULIN JI Psychol. Men Masculinity PD APR PY 2015 VL 16 IS 2 BP 160 EP 169 DI 10.1037/a0035956 PG 10 WC Psychology, Social SC Psychology GA CF7LX UT WOS:000352739100007 ER PT J AU Niolon, PH Kuperminc, GP Allen, JP AF Niolon, Phyllis Holditch Kuperminc, Gabriel P. Allen, Joseph P. TI Autonomy and Relatedness in Mother-Teen Interactions As Predictors of Involvement in Adolescent Dating Aggression SO PSYCHOLOGY OF VIOLENCE LA English DT Article DE adolescents; dating aggression; autonomy; relatedness; parental relationships ID FAMILY INTERACTIONS; SUBSTANCE USE; PARTNER VIOLENCE; RISK; ATTACHMENT; PERPETRATION; CONFLICT; CHILDREN; SCALES AB Objective: This multimethod longitudinal study examines the negotiation of autonomy and relatedness between teens and their mothers as etiologic predictors of perpetration and victimization of dating aggression 2 years later. Method: Observations of 87 mid-adolescents and their mothers discussing a topic of disagreement were coded for each individual's demonstrations of autonomy and relatedness using a validated coding system. Adolescents self-reported on perpetration and victimization of physical and psychological dating aggression 2 years later. We hypothesized that mothers' and adolescents' behaviors supporting autonomy and relatedness would longitudinally predict lower reporting of dating aggression, and that their behaviors inhibiting autonomy and relatedness would predict higher reporting of dating aggression. Results: Hypotheses were not supported; main findings were characterized by interactions of sex and risk status with autonomy. Maternal behaviors supporting autonomy predicted higher reports of perpetration and victimization of physical dating aggression for girls, but not for boys. Adolescent behaviors supporting autonomy predicted higher reports of perpetration of physical dating aggression for high-risk adolescents, but not for low-risk adolescents. Conclusions: Results indicate that autonomy is a dynamic developmental process, operating differently as a function of social contexts in predicting dating aggression. Examination of these and other developmental processes within parentchild relationships is important in predicting dating aggression, but may depend on social context. C1 [Niolon, Phyllis Holditch] Ctr Dis Control & Prevent, Div Violence Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA. [Kuperminc, Gabriel P.] Georgia State Univ, Dept Psychol, Atlanta, GA 30303 USA. [Allen, Joseph P.] Univ Virginia, Dept Psychol, Charlottesville, VA 22903 USA. RP Niolon, PH (reprint author), Ctr Dis Control & Prevent, Div Violence Prevent, 4770 Buford Highway,MS F-63, Atlanta, GA 30341 USA. EM pniolon@cdc.gov FU NICHD NIH HHS [R01 HD058305] NR 42 TC 0 Z9 0 U1 3 U2 9 PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 2152-0828 EI 2152-081X J9 PSYCHOL VIOLENCE JI Psychol. Violence PD APR PY 2015 VL 5 IS 2 BP 133 EP 143 DI 10.1037/a0036557 PG 11 WC Psychology, Clinical; Criminology & Penology; Family Studies SC Psychology; Criminology & Penology; Family Studies GA CF1QP UT WOS:000352323000004 PM 25914852 ER PT J AU Barile, JP Edwards, VJ Dhingra, SS Thompson, WW AF Barile, John P. Edwards, Valerie J. Dhingra, Satvinder S. Thompson, William W. TI Associations Among County-Level Social Determinants of Health, Child Maltreatment, and Emotional Support on Health-Related Quality of Life in Adulthood SO PSYCHOLOGY OF VIOLENCE LA English DT Article DE child abuse; family conflict; multilevel analysis; quality of life; social environment; social support ID MENTAL-HEALTH; SOCIOECONOMIC CONTEXT; RETROSPECTIVE REPORTS; INCOME INEQUALITY; MULTILEVEL SEM; EXPERIENCES; ADVERSE; DEPRESSION; RISK; BEHAVIORS AB Objective: This study determined whether county-level social determinants of health and adverse childhood experiences (ACE) were associated with emotional support and health-related quality of life (HRQOL) in adulthood. This study represents the largest population-based investigation on ACE to include county-level indicators of the social ecology. Method: We used data from the 2009 Behavioral Risk Factor Surveillance System (BRFSS) survey (29,212 adults from 5 states) and the American Community Survey (2010; 304 counties). Multilevel structural equation models were employed to test direct and indirect associations between county-level social determinants of health, ACEs and indicators of adult HRQOL. Results: At the individual level, ACEs were associated with lower emotional support, and lower emotional support was associated with worse physical and mental HRQOL. Parental divorce was associated with better mental HRQOL for individuals who reported >= 2 forms of childhood maltreatment and/or negative household environments during childhood. At the county-level, low median income and high county-level unemployment were associated with low emotional support, and high median income and high unemployment were directly associated with poor physical and mental HRQOL. Conclusion: Findings from this study suggest that intervention efforts designed to promote positive emotional supports for adults who have experienced ACEs, particularly for those living in disadvantaged counties, may ameliorate potential health consequences during adulthood. C1 [Barile, John P.] Univ Hawaii Manoa, Dept Psychol, Honolulu, HI 96822 USA. [Edwards, Valerie J.] US Ctr Dis Control & Prevent, Div Populat Hlth, Atlanta, GA USA. [Dhingra, Satvinder S.] US Ctr Dis Control & Prevent, Div Behav Surveillance, Atlanta, GA USA. [Thompson, William W.] US Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. RP Barile, JP (reprint author), Univ Hawaii Manoa, Dept Psychol, 2530 Dole St,Sakamaki Hall C404, Honolulu, HI 96822 USA. EM Barile@Hawaii.edu RI Barile, John/F-9456-2015 OI Barile, John/0000-0003-4098-0640 NR 62 TC 0 Z9 0 U1 2 U2 10 PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 2152-0828 EI 2152-081X J9 PSYCHOL VIOLENCE JI Psychol. Violence PD APR PY 2015 VL 5 IS 2 BP 183 EP 191 DI 10.1037/a0038202 PG 9 WC Psychology, Clinical; Criminology & Penology; Family Studies SC Psychology; Criminology & Penology; Family Studies GA CF1QP UT WOS:000352323000009 ER PT J AU Sue, PK Pisanic, N Heaney, CD Mixson-Hayden, T Kamili, S Nelson, K Schwarz, KB Forman, M Valsamakis, A Ticehurst, J Karnsakul, W AF Sue, P. K. Pisanic, N. Heaney, C. D. Mixson-Hayden, T. Kamili, S. Nelson, K. Schwarz, K. B. Forman, M. Valsamakis, A. Ticehurst, J. Karnsakul, W. TI Variability of hepatitis E serologic assays in a pediatric liver transplant recipient: challenges to diagnosing hepatitis E virus infection in the United States SO TRANSPLANT INFECTIOUS DISEASE LA English DT Article DE hepatitis E virus; liver transplantation; viral diagnostics ID DEVELOPED-COUNTRIES; EPIDEMIOLOGY; PERFORMANCE; KITS; IGM AB Hepatitis E virus (HEV) is an emerging cause of viral hepatitis among immunocompromised individuals in developed countries. Yet the diagnosis of HEV infection in the United States remains challenging, because of the variable sensitivity and specificity of currently available tests, and the lack of a US Food and Drug Administration-approved test. We report a case of multiple discordant HEV serology results in a pediatric liver transplant recipient with idiopathic hepatitis, and review the challenges to diagnosis of HEV infection in the United States. C1 [Sue, P. K.] Johns Hopkins Univ, Sch Med, Dept Pediat, Div Pediat Infect Dis, Baltimore, MD 21205 USA. [Pisanic, N.; Heaney, C. D.] Johns Hopkins Univ, Dept Environm Hlth Sci, Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA. [Heaney, C. D.; Nelson, K.; Ticehurst, J.] Johns Hopkins Univ, Dept Epidemiol, Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Mixson-Hayden, T.; Kamili, S.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA USA. [Schwarz, K. B.; Karnsakul, W.] Johns Hopkins Univ, Sch Med, Dept Pediat, Div Pediat Gastroenterol, Baltimore, MD 21205 USA. [Forman, M.; Valsamakis, A.; Ticehurst, J.] Johns Hopkins Univ, Sch Med, Dept Pathol, Div Med Microbiol, Baltimore, MD 21205 USA. RP Karnsakul, W (reprint author), Johns Hopkins Univ Hosp, Dept Pediat, 600 N Wolfe St, Baltimore, MD 21287 USA. EM wkarnsa1@jhmi.edu FU National Institutes of Health [T32 AI052071] FX Support for this study was provided by the National Institutes of Health training grant (T32 AI052071). NR 19 TC 2 Z9 2 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1398-2273 EI 1399-3062 J9 TRANSPL INFECT DIS JI Transpl. Infect. Dis. PD APR PY 2015 VL 17 IS 2 BP 284 EP 288 DI 10.1111/tid.12366 PG 5 WC Immunology; Infectious Diseases; Transplantation SC Immunology; Infectious Diseases; Transplantation GA CF0FV UT WOS:000352219400015 PM 25648626 ER PT J AU Carmichael, SL Ma, C Rasmussen, SA Cunningham, ML Browne, ML Dosiou, C Lammer, EJ Shaw, GM AF Carmichael, S. L. Ma, C. Rasmussen, S. A. Cunningham, M. L. Browne, M. L. Dosiou, C. Lammer, E. J. Shaw, G. M. TI Craniosynostosis and Risk Factors Related to Thyroid Dysfunction SO AMERICAN JOURNAL OF MEDICAL GENETICS PART A LA English DT Article DE craniosynostosis; thyroid; birth defects ID OVERT AUTOIMMUNE HYPOTHYROIDISM; BIRTH-DEFECTS PREVENTION; SURVEY NHANES-III; BODY-MASS INDEX; MATERNAL SMOKING; EARLY-PREGNANCY; PREMATURE CRANIOSYNOSTOSIS; CONGENITAL-MALFORMATION; ALCOHOL-CONSUMPTION; ANTITHYROID DRUGS AB Thyroid disease is a common problem among women of reproductive age but often goes undiagnosed. Maternal thyroid disease has been associated with increased risk of craniosynostosis. We hypothesized that known risk factors for thyroid disease would be associated with risk of craniosynostosis among women not diagnosed with thyroid disease. Analyses included mothers of 1,067 cases and 8,494 population-based controls who were interviewed for the National Birth Defects Prevention Study. We used multivariable logistic regression to estimate adjusted odds ratios (AOR) and 95% confidence intervals (CI). After excluding women with diagnosed thyroid disease, younger maternal age (AOR 0.7, 95% CI 0.6-0.9, for <25 years versus 25-29), black or other race-ethnicity (AOR 0.3, 95% CI 0.2-0.4 and AOR 0.6, 95% CI 0.4-0.8, respectively, relative to non-Hispanic whites), fertility medications or procedures (AOR 1.5, 95% CI 1.2-2.0), and alcohol consumption (AOR 0.8, 95% CI 0.7-0.9) were associated with risk of craniosynostosis, based on confidence intervals that excluded 1.0. These associations with craniosynostosis are consistent with the direction of their association with thyroid dysfunction (i.e., younger age, black race-ethnicity and alcohol consumption are associated with reduced risk and fertility problems are associated with increased risk of thyroid disease). This study thus provides support for the hypothesis that risk factors associated with thyroid dysfunction are also associated with risk of craniosynostosis. Improved understanding of the potential association between maternal thyroid function and craniosynostosis among offspring is important given that craniosynostosis carries significant morbidity and that thyroid disease is under-diagnosed and potentially modifiable. (c) 2015 Wiley Periodicals, Inc. C1 [Carmichael, S. L.; Ma, C.; Shaw, G. M.] Stanford Univ, Dept Pediat, Div Neonatol & Dev Med, Sch Med, Stanford, CA 94305 USA. [Rasmussen, S. A.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Cunningham, M. L.] Univ Washington, Sch Med, Dept Pediat, Seattle, WA 98195 USA. [Cunningham, M. L.] Seattle Childrens Craniofacial Ctr, Seattle, WA USA. [Browne, M. L.] New York State Dept Hlth, Congenital Malformat Registry, Albany, NY USA. [Browne, M. L.] Univ Albany, Sch Publ Hlth, Rensselaer, NY USA. [Dosiou, C.] Stanford Univ, Dept Med, Div Endocrinol Gerontol & Metab, Sch Med, Stanford, CA 94305 USA. [Lammer, E. J.] UCSF Benioff Childrens Hosp Oakland, Oakland, CA USA. RP Carmichael, SL (reprint author), Stanford Univ, Pediat, 1265 Welch Rd X111, Stanford, CA 94305 USA. EM scarmichael@stanford.edu FU Centers for Disease Control; Prevention Centers of Excellence [U50/CCU925286, U01DD001033]; NIH [R03 DE019521] FX Grant sponsor: Centers for Disease Control; Grant sponsor: Prevention Centers of Excellence; Grant number: Award No. U50/CCU925286 and U01DD001033; Grant sponsor: NIH; Grant number: R03 DE019521. NR 48 TC 2 Z9 2 U1 0 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1552-4825 EI 1552-4833 J9 AM J MED GENET A JI Am. J. Med. Genet. A PD APR PY 2015 VL 167 IS 4 BP 701 EP 707 DI 10.1002/ajmg.a.36953 PG 7 WC Genetics & Heredity SC Genetics & Heredity GA CE7KQ UT WOS:000352019000007 PM 25655789 ER PT J AU Kim, DK Bridges, CB Harriman, KH AF Kim, David K. Bridges, Carolyn B. Harriman, Kathleen H. TI Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older-United States, 2015 SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Editorial Material ID PRACTICES ACIP C1 [Kim, David K.; Bridges, Carolyn B.] CDC, Natl Ctr Immunizat & Resp Dis, Immunizat Serv Div, Atlanta, GA 30333 USA. [Harriman, Kathleen H.] Calif Dept Publ Hlth, San Francisco, CA USA. RP Kim, DK (reprint author), CDC, Natl Ctr Immunizat & Resp Dis, Immunizat Serv Div, Atlanta, GA 30333 USA. EM dkim@cdc.gov NR 4 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD APR PY 2015 VL 15 IS 4 BP 1114 EP 1115 DI 10.1111/ajt.13292 PG 2 WC Surgery; Transplantation SC Surgery; Transplantation GA CE2US UT WOS:000351675600034 ER PT J AU Strikas, RA AF Strikas, Raymond A. TI Advisory Committee on Immunization Practices Recommended Immunization Schedules for Persons Aged 0 Through 18 Years-United States, 2015 SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Editorial Material C1 CDC, Natl Ctr Immunizat & Resp, Immunizat Serv Div, Atlanta, GA 30333 USA. RP Strikas, RA (reprint author), CDC, Natl Ctr Immunizat & Resp, Immunizat Serv Div, Atlanta, GA 30333 USA. EM ras8@cdc.gov NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD APR PY 2015 VL 15 IS 4 BP 1116 EP 1117 DI 10.1111/ajt.13293 PG 2 WC Surgery; Transplantation SC Surgery; Transplantation GA CE2US UT WOS:000351675600035 ER PT J AU West, BS Pouget, ER Tempalski, B Cooper, HLF Hall, HI Hu, XH Friedman, SR AF West, Brooke S. Pouget, Enrique R. Tempalski, Barbara Cooper, Hannah L. F. Hall, H. Irene Hu, Xiaohong Friedman, Samuel R. TI Female and male differences in AIDS diagnosis rates among people who inject drugs in large US metro areas from 1993 to 2007 SO ANNALS OF EPIDEMIOLOGY LA English DT Article DE Injection drug use; AIDS; Gender; Health status disparities ID ACTIVE ANTIRETROVIRAL THERAPY; METROPOLITAN-AREAS; UNITED-STATES; HIV; USERS; GENDER; DISPARITIES; CARE; PREVALENCE; INFECTION AB Purpose: We estimated female and male incident AIDS diagnosis rates (IARs) among people who inject drugs (PWID) in U.S. metropolitan statistical areas (MSAs) over time to assess whether declines in IARs varied by sex after combination antiretroviral therapy (cART) dissemination. Methods: We compared IARs and 95% confidence ihtervals for female and male PWID in 95 of the most populous MSAs. To stabilize estimates, we aggregated data across three-year periods, selecting a period immediately preceding cART (1993-1995) and the most recent after the introduction of cART for which data were available (2005-2007). We assessed disparities by comparing IAR 95% confidence intervals for overlap, female-to-male risk ratios, and disparity change scores. Results: IARs declined an average of 58% for female PWID and 67% for male PWID between the pre-cART and cART periods. Among female PWID, IARs were significantly lower in the later period relative to the pre-cART period in 48% of MSAs. Among male PWID, IARs were significantly lower over time in 86% of MSAs. Conclusions: IARs among female PWID in large U.S. MSAs have declined more slowly than among male PWID. This suggests a need for increased targeting of prevention and treatment programs and for research on MSA level conditions that may drive differences in declining AIDS rates among female and male PWID. (C) 2015 Elsevier Inc. All rights reserved. C1 [West, Brooke S.] Univ Calif San Diego, Div Global Publ Hlth, Sch Med, San Diego, CA 92093 USA. [Pouget, Enrique R.; Tempalski, Barbara; Friedman, Samuel R.] Natl Dev & Res Inst Inc, New York, NY USA. [Cooper, Hannah L. F.] Emory Univ, Rollins Sch Publ Hlth, Dept Behav Sci & Hlth Educ, Atlanta, GA 30322 USA. [Hall, H. Irene; Hu, Xiaohong] Ctr Dis Control & Prevent, Atlanta, GA USA. RP West, BS (reprint author), Univ Calif San Diego, Div Global Publ Hlth, Sch Med, 9500 Gilman Dr 0507, San Diego, CA 92093 USA. EM bswest@ucsd.edu OI Tempalski, Barbara/0000-0002-6128-2510 FU U.S. National Institute on Drug Abuse [R01 DA013336, R01 DA037568]; NIH [P30 DA121041] FX This study was supported by grants from the U.S. National Institute on Drug Abuse (R01 DA013336 and R01 DA037568). The authors acknowledge the NIH-funded Center for Drug Use and HIV Research (P30 DA121041) for its support and assistance. NR 34 TC 1 Z9 1 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1047-2797 EI 1873-2585 J9 ANN EPIDEMIOL JI Ann. Epidemiol. PD APR PY 2015 VL 25 IS 4 BP 218 EP 225 DI 10.1016/j.annepidem.2015.01.006 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CE8UA UT WOS:000352118400002 PM 25724830 ER PT J AU Sellers, CJ Lee, H Chasela, C Kayira, D Soko, A Mofolo, I Ellington, S Hudgens, MG Kourtis, AP King, CC Jamieson, DJ van der Horst, C AF Sellers, Christopher J. Lee, Hana Chasela, Charles Kayira, Dumbani Soko, Alice Mofolo, Innocent Ellington, Sascha Hudgens, Michael G. Kourtis, Athena P. King, Caroline C. Jamieson, Denise J. van der Horst, Charles CA BAN Study Team TI Reducing lost to follow-up in a large clinical trial of prevention of mother-to-child transmission of HIV: The Breastfeeding, Antiretrovirals and Nutrition study experience SO CLINICAL TRIALS LA English DT Article DE Antiretroviral therapy; human immunodeficiency virus; lost to follow-up; prevention of mother-to-child transmission; retention; tracing ID SUB-SAHARAN AFRICA; RANDOMIZED-TRIAL; MALAWI; CARE; LILONGWE; THERAPY; PROGRAM; RETENTION; OUTCOMES; BAN AB Background/Aims Retaining patients in prevention of mother-to-child transmission of HIV studies can be challenging in resource-limited settings, where high lost to follow-up rates have been reported. In this article, we describe the effectiveness of methods used to encourage retention in the Breastfeeding, Antiretrovirals, and Nutrition study and analyze factors associated with lost to follow-up in the study. Methods The Breastfeeding, Antiretrovirals, and Nutrition clinical trial was designed to evaluate the efficacy of three different mother-to-child HIV transmission prevention strategies. Lower than expected participant retention prompted enhanced efforts to reduce lost to follow-up during the conduct of the trial. Following study completion, we employed regression modeling to determine predictors of perfect attendance and variables associated with being lost to follow-up. Results During the study, intensive tracing efforts were initiated after the first 1686 mother infant pairs had been enrolled, and 327 pairs were missing. Of these pairs, 60 were located and had complete data obtained. Among the 683 participants enrolling after initiation of intensive tracing efforts, the lost to follow-up rate was 3.4%. At study's end, 290 (12.2%) of the 2369 mother infant pairs were lost to follow-up. Among successfully traced missing pairs, relocation was common and three were deceased. Log-binomial regression modeling revealed higher maternal hemoglobin and older maternal age to be significant predictors of perfect attendance. These factors and the presence of food insecurity were also significantly associated with lower rates of lost to follow-up. Conclusion In this large HIV prevention trial, intensive tracing efforts centered on reaching study participants at their homes succeeded in finding a substantial proportion of lost to follow-up participants and were very effective in preventing further lost to follow-up during the remainder of the trial. The association between food insecurity and lower rates of lost to follow-up is likely related to the study's provision of nutritional support, including a family maize supplement, which may have contributed to patient retention. C1 [Sellers, Christopher J.; van der Horst, Charles] Univ N Carolina, Sch Med, Div Infect Dis, Chapel Hill, NC 27599 USA. [Lee, Hana] Brown Univ, Dept Biostat, Sch Publ Hlth, Providence, RI 02912 USA. [Chasela, Charles; Kayira, Dumbani; Soko, Alice; Mofolo, Innocent] UNC Project, Lilongwe, Malawi. [Ellington, Sascha; Kourtis, Athena P.; King, Caroline C.; Jamieson, Denise J.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Hudgens, Michael G.] Univ N Carolina, Sch Med, Dept Biostat, Chapel Hill, NC 27599 USA. [Chasela, Charles] Univ Witwatersrand, Sch Publ Hlth, Fac Hlth Sci, Div Epidemiol & Biostat, Johannesburg, South Africa. RP van der Horst, C (reprint author), Univ N Carolina, Sch Med, Div Infect Dis, Chapel Hill, NC 27599 USA. EM cvdh@med.unc.edu FU Prevention Research Centers Special Interest Project of the Centers for Disease Control and Prevention [SIP 13-01 U48-CCU409660-09, SIP 26-04 U48-DP000059-01, SIP 22-09 U48-DP001944-01]; National Institute of Allergy and Infectious Diseases; University of North Carolina Center for AIDS Research [P30-AI50410]; National Institutes of Health Fogarty AIDS International Training and Research Program (DHHS/NIH/FIC) [2-D43 Tw01039-06]; Fogarty International Clinical Research Scholars Program [R24 Tw00798]; American Recovery and Reinvestment Act; Ad Astra Fellowship from University College Dublin, Ireland; Bill and Melinda Gates Foundation [OPP53107]; Gilead Foundation; National Institutes of Health/National Institute of Allergy and Infectious Diseases Training in Infectious Disease Epidemiology Grant [NIH 5T32AI070114-08]; Elizabeth Glaser Pediatric AIDS Foundation; United Nations Children's Fund; World Food Program; Malawi Ministry of Health and Population; Johnson Johnson; U.S. Agency for International Development FX The Breastfeeding, Antiretrovirals, and Nutrition Study was supported by the Prevention Research Centers Special Interest Project of the Centers for Disease Control and Prevention (SIP 13-01 U48-CCU409660-09, SIP 26-04 U48-DP000059-01, and SIP 22-09 U48-DP001944-01); the National Institute of Allergy and Infectious Diseases; the University of North Carolina Center for AIDS Research (P30-AI50410); the National Institutes of Health Fogarty AIDS International Training and Research Program (DHHS/NIH/FIC 2-D43 Tw01039-06); the Fogarty International Clinical Research Scholars Program (R24 Tw00798); the American Recovery and Reinvestment Act; Ad Astra Fellowship from University College Dublin, Ireland; the Bill and Melinda Gates Foundation (Grant number OPP53107); a grant from the Gilead Foundation in support of our trainees; the National Institutes of Health/National Institute of Allergy and Infectious Diseases Training in Infectious Disease Epidemiology Grant (Grant number NIH 5T32AI070114-08). The antiretrovirals used in the BAN study were donated by Abbott Laboratories, GlaxoSmithKline, Boehringer Ingelheim, Roche Pharmaceuticals, and Bristol-Myers Squibb. The Call to Action Prevention of Mother-to-Child Transmission (PMTCT) program was supported by the Elizabeth Glaser Pediatric AIDS Foundation, the United Nations Children's Fund, the World Food Program, the Malawi Ministry of Health and Population, Johnson & Johnson, and the U.S. Agency for International Development. NR 28 TC 3 Z9 3 U1 0 U2 4 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1740-7745 EI 1740-7753 J9 CLIN TRIALS JI Clin. Trials PD APR PY 2015 VL 12 IS 2 BP 62 EP 71 DI 10.1177/1740774514562031 PG 10 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA CE9OQ UT WOS:000352173700013 PM 25518956 ER PT J AU Schoffelen, T Self, JS Fitzpatrick, KA Netea, MG van Deuren, M Joosten, LAB Kersh, GJ AF Schoffelen, Teske Self, Joshua S. Fitzpatrick, Kelly A. Netea, Mihai G. van Deuren, Marcel Joosten, Leo A. B. Kersh, Gilbert J. TI Early cytokine and antibody responses against Coxiella burnetii in aerosol infection of BALB/c mice SO DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE LA English DT Article DE Coxiella burnetii; Q fever; Cellular immunity; Serology; Interferon-gamma; Cytokines ID CHRONIC Q-FEVER; TUMOR-NECROSIS-FACTOR; INTERFERON-GAMMA; PHASE-I; COMPARATIVE VIRULENCE; MONONUCLEAR-CELLS; T-CELLS; ENDOCARDITIS; INTERLEUKIN-10; VACCINATION AB Coxiella burnetii, a Gram-negative intracellular bacterium, can give rise to Q fever in humans and is transmitted mainly by inhalation of infected aerosols from animal reservoirs. Serology is commonly used to diagnose Q fever, but the early cellular immune response-i.e., C. burnetii-specific interferon gamma (IFN-gamma) production in response to antigen challenge might be an additional diagnostic. Detection of IFN-gamma responses has been used to identify past and chronic Q fever infections, but the IFN-gamma response in acute Q fever has not been described. By challenging immunocompetent BALB/c mice with aerosols containing phase I C. burnetii, the timing and extent of IFN-gamma recall responses were evaluated in an acute C burnetii infection. Other cytokines were also measured in an effort to identify other potential diagnostic markers. The data show that after initial expansion of bacteria first in lungs and then in other tissues, the infection was cleared from day 10 onwards as reflected by the decreasing number of bacteria. The antigen-induced IFN-gamma production by splenocytes coincided with emergence of IgM phase II antibodies at day 10 postinfection and preceded appearance of IgG antibodies. This was accompanied by the production of proinflammatory cytokines including interleukin (IL) 6, keratinocyte-derived cytokine, and IFN-gamma-induced protein 10, followed by monocyte chemotactic protein 1, but not by IL-1 beta and tumor necrosis factor alpha, and only very low production of the anti-inflammatory cytokine IL-10. These data suggest that analysis of antigen-specific IFN-gamma responses could be a useful tool for diagnosis of acute Q fever. Moreover, the current model of C burnetii infection could be used to give new insights into immunological factors that predispose to development of persistent infection. Published by Elsevier Inc. C1 [Schoffelen, Teske; Netea, Mihai G.; van Deuren, Marcel; Joosten, Leo A. B.] Radboud Univ Nijmegen, Med Ctr, Dept Internal Med, NL-6525 GA Nijmegen, Netherlands. [Self, Joshua S.; Fitzpatrick, Kelly A.; Kersh, Gilbert J.] Ctr Dis Control & Prevent, Rickettsial Zoonoses Branch, Atlanta, GA 30333 USA. RP Kersh, GJ (reprint author), Ctr Dis Control & Prevent, Rickettsial Zoonoses Branch, 1600 Clifton Rd,MS G13, Atlanta, GA 30333 USA. EM gkersh@cdc.gov RI Joosten, Leo/H-3138-2015; Netea, Mihai/N-5155-2014 FU Netherlands Organisation for Health Research and Development [205520002]; ERC [310371] FX TS was financially supported by a grant of The Netherlands Organisation for Health Research and Development (grant number 205520002). MGN was supported by an ERC Consolidator Grant (310371). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the CDC or the Department of Health and Human Services. NR 35 TC 4 Z9 4 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0732-8893 EI 1879-0070 J9 DIAGN MICR INFEC DIS JI Diagn. Microbiol. Infect. Dis. PD APR PY 2015 VL 81 IS 4 BP 234 EP 239 DI 10.1016/j.diagmicrobio.2014.12.008 PG 6 WC Infectious Diseases; Microbiology SC Infectious Diseases; Microbiology GA CE8TO UT WOS:000352117200002 PM 25618420 ER PT J AU Smith, TM Pinard, CA Shanks, CB Wethington, H Blanck, HM Yaroch, AL AF Smith, Teresa M. Pinard, Courtney A. Shanks, Carmen Byker Wethington, Holly Blanck, Heidi M. Yaroch, Amy L. TI Fruits and vegetables as a healthier snack throughout the day among families with older children: Findings from a survey of parent-child dyads SO EATING BEHAVIORS LA English DT Article DE Snacking; Older children; Adolescents; Fruits and vegetables; ConsumerStyles ID UNITED-STATES; US CHILDREN; SOLID FATS; CONSUMPTION; ENERGY; AVAILABILITY; ADOLESCENTS; SUGARS; TRENDS; SCHOOL AB Most U.S. youth fail to eat the recommended amount of fruits and vegetables (FV) however many consume too many calories as added sugars and solid fats, often as snacks. The aim of this study was to assess factors associated with serving FV as snacks and with meals using parent-child dyads. A cross-sectional sample of U.S. children aged 9 to 18, and their caregiver/parent (n = 1522) were part of a Consumer Panel of households for the 2008 YouthStyles mail survey. Chi-square test of independence and multivariable logistic regression were used to assess associations between serving patterns of FV as snacks with variations in serving patterns, and covariates including dietary habits. Most parents (72%) reported serving FV at meals and as snacks. Fruit was most frequently served as a snack during the day (52%) and vegetables were most frequently served as a snack during the day (22%) but rarely in the morning. Significant differences in child FV intake existed among FV as a snack serving patterns by parents. Compared to children whose parents served FV only at meals, children whose parents reported serving FV as snacks in addition to meals were significantly more likely to have consumed FV the day before (using a previous day screener), P < 0.05. Contributing to the growing collection of literature describing parent-child dyad dietary behaviors, these findings suggest promoting FV access and intake throughout the day, not only at meals, by including serving as snacks, may increase FV intake among older children and adolescents. (C) 2015 Elsevier Ltd. All rights reserved. C1 [Smith, Teresa M.; Pinard, Courtney A.; Yaroch, Amy L.] Gretchen Swanson Ctr Nutr, Omaha, NE 68114 USA. [Shanks, Carmen Byker] Montana State Univ, Dept Hlth & Human Dev, Bozeman, MT 59717 USA. [Wethington, Holly; Blanck, Heidi M.] CDC, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Smith, Teresa M.; Pinard, Courtney A.; Yaroch, Amy L.] Univ Nebraska Med Ctr, Dept Hlth Promot Social & Behav Hlth, UNMC Coll Publ Hlth, Omaha, NE 68198 USA. RP Smith, TM (reprint author), 8401 West Dodge Rd,Suite 100, Omaha, NE 68114 USA. EM tsmith@centerfornutrition.org OI Byker Shanks, Carmen/0000-0002-9030-9938 NR 18 TC 1 Z9 1 U1 3 U2 6 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1471-0153 EI 1873-7358 J9 EAT BEHAV JI Eat. Behav. PD APR PY 2015 VL 17 BP 136 EP 139 DI 10.1016/j.eatbeh.2015.01.006 PG 4 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA CE4XP UT WOS:000351834000029 PM 25706949 ER PT J AU Gautret, P Harvey, K Pandey, P Lim, PL Leder, K Piyaphanee, W Shaw, M McDonald, SC Schwartz, E Esposito, DH Parola, P AF Gautret, Philippe Harvey, Kira Pandey, Prativa Lim, Poh Lian Leder, Karin Piyaphanee, Watcharapong Shaw, Marc McDonald, Susan C. Schwartz, Eli Esposito, Douglas H. Parola, Philippe CA GeoSentinel Surveillance Network TI Animal-Associated Exposure to Rabies Virus among Travelers, 1997-2012 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID POSTEXPOSURE PROPHYLAXIS; GEOSENTINEL SURVEILLANCE; RETURNED TRAVELERS; CHINA; RISK; VACCINATION; SCHEDULES; COUNTRIES; INDONESIA; EPIDEMIC AB Among travelers, rabies cases are rare, but animal bites are relatively common. To determine which travelers are at highest risk for rabies, we studied 2,697 travelers receiving care for animal-related exposures and requiring rabies postexposure prophylaxis at GeoSentinel clinics during 1997-2012. No specific demographic characteristics differentiated these travelers from other travelers seeking medical care, making it challenging to identify travelers who might benefit from reinforced pretravel rabies prevention counseling. Median travel duration was short for these travelers: 15 days for those seeking care after completion of travel and 20 days for those seeking care during travel. This finding contradicts the view that preexposure rabies vaccine recommendations should be partly based on longer travel durations. Over half of exposures occurred in Thailand, Indonesia, Nepal, China, and India. International travelers to rabies-endemic regions, particularly Asia, should be informed about potential rabies exposure and benefits of pretravel vaccination, regardless of demographics or length of stay. C1 [Gautret, Philippe; Parola, Philippe] Aix Marseille Univ, F-15915 Marseille 20, France. [Gautret, Philippe; Parola, Philippe] Inst Hosp Univ Mediterranee Infect, Marseille, France. [Harvey, Kira; Esposito, Douglas H.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Pandey, Prativa] CIWEC Clin Travel Med Ctr, Kathmandu, Nepal. [Lim, Poh Lian] Tan Tock Seng Hosp, Singapore, Singapore. [Lim, Poh Lian] Lee Kong Chian Sch Med, Singapore, Singapore. [Leder, Karin] Monash Univ, Melbourne, Vic 3004, Australia. [Leder, Karin] Royal Melbourne Hosp, Parkville, Vic 3050, Australia. [Piyaphanee, Watcharapong] Mahidol Univ, Bangkok 10700, Thailand. [Shaw, Marc] Travellers Hlth & Vaccinat Ctr, Auckland, New Zealand. [McDonald, Susan C.] Univ Hosp Northern British Columbia, Prince George, BC, Canada. [Schwartz, Eli] Tel Hashomer & Sackler Sch Med, Tel Aviv, Israel. RP Gautret, P (reprint author), Aix Marseille Univ, Hop Nord, Serv Malad Infect, Chemin Bourrelys 15915, F-15915 Marseille 20, France. EM philippe.gautret@club-internet.fr OI Leder, Karin/0000-0003-1368-1039; Aoun, Olivier/0000-0001-9554-8439; Gkrania-Klotsas, Effrossyni/0000-0002-0930-8330 FU CDC [U50 CK000189] FX This work was supported by CDC (cooperative agreement U50 CK000189). NR 38 TC 2 Z9 2 U1 6 U2 16 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD APR PY 2015 VL 21 IS 4 BP 569 EP 577 DI 10.3201/eid2104.141479 PG 9 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CE2NK UT WOS:000351652100003 PM 25811076 ER PT J AU Arwady, MA Bawo, L Hunter, JC Massaquoi, M Matanock, A Dahn, B Ayscue, P Nyenswah, T Forrester, JD Hensley, LE Monroe, B Schoepp, RJ Chen, TH Schaecher, KE George, T Rouse, E Schafer, IJ Pillai, SK De Cock, KM AF Arwady, M. Allison Bawo, Luke Hunter, Jennifer C. Massaquoi, Moses Matanock, Almea Dahn, Bernice Ayscue, Patrick Nyenswah, Tolbert Forrester, Joseph D. Hensley, Lisa E. Monroe, Benjamin Schoepp, Randal J. Chen, Tai-Ho Schaecher, Kurt E. George, Thomas Rouse, Edward Schafer, Ilana J. Pillai, Satish K. De Cock, Kevin M. TI Evolution of Ebola Virus Disease from Exotic Infection to Global Health Priority, Liberia, Mid-2014 SO EMERGING INFECTIOUS DISEASES LA English DT Article AB Over the span of a few weeks during July and August 2014, events in West Africa changed perceptions of Ebola virus disease (EVD) from an exotic tropical disease to a priority for global health security. We describe observations during that time of a field team from the Centers for Disease Control and Prevention and personnel of the Liberian Ministry of Health and Social Welfare. We outline the early epidemiology of EVD within Liberia, including the practical limitations on surveillance and the effect on the country's health care system, such as infections among health care workers. During this time, priorities included strengthening EVD surveillance; establishing safe settings for EVD patient care (and considering alternative isolation and care models when Ebola Treatment Units were overwhelmed); improving infection control practices; establishing an incident management system; and working with Liberian airport authorities to implement EVD screening of departing passengers. C1 [Arwady, M. Allison; Hunter, Jennifer C.; Matanock, Almea; Ayscue, Patrick; Forrester, Joseph D.; Monroe, Benjamin; Chen, Tai-Ho; George, Thomas; Rouse, Edward; Schafer, Ilana J.; Pillai, Satish K.; De Cock, Kevin M.] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. [Bawo, Luke; Massaquoi, Moses; Dahn, Bernice; Nyenswah, Tolbert] Minist Hlth & Social Welf, Monrovia, Liberia. [Hensley, Lisa E.] Natl Inst Hlth, Bethesda, MD USA. [Schoepp, Randal J.; Schaecher, Kurt E.] US Army Med Res Inst Infect Dis, Frederick, MD USA. RP Arwady, MA (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop E92, Atlanta, GA 30329 USA. EM xdr3@cdc.gov NR 5 TC 13 Z9 14 U1 3 U2 52 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD APR PY 2015 VL 21 IS 4 BP 578 EP 584 DI 10.3201/eid2104.141940 PG 7 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CE2NK UT WOS:000351652100004 PM 25811176 ER PT J AU Verhoef, L Hewitt, J Barclay, L Ahmed, SM Lake, R Hall, AJ Lopman, B Kroneman, A Vennema, H Vinje, J Koopmans, M AF Verhoef, Linda Hewitt, Joanne Barclay, Leslie Ahmed, Sharia M. Lake, Rob Hall, Aron J. Lopman, Ben Kroneman, Annelies Vennema, Harry Vinje, Jan Koopmans, Marion TI Norovirus Genotype Profiles Associated with Foodborne Transmission, 1999-2012 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID INFECTIOUS INTESTINAL DISEASE; GASTROENTERITIS OUTBREAKS; UNITED-STATES; FOOD; VIRUSES; EPIDEMIOLOGY; SURVEILLANCE; NETWORK; ENGLAND; WALES AB Worldwide, noroviruses are a leading cause of gastroenteritis. They can be transmitted from person to person directly or indirectly through contaminated food, water, or environments. To estimate the proportion of foodborne infections caused by noroviruses on a global scale, we used norovirus transmission and genotyping information from multiple international outbreak surveillance systems (Noronet, CaliciNet, EpiSurv) and from a systematic review of peer-reviewed literature. The proportion of outbreaks caused by food was determined by genotype and/or genogroup. Analysis resulted in the following final global profiles: foodborne transmission is attributed to 10% (range 9%-11%) of all genotype GII.4 outbreaks, 27% (25%-30%) of outbreaks caused by all other single genotypes, and 37% (24%-52%) of outbreaks caused by mixtures of GII.4 and other noroviruses. When these profiles are applied to global outbreak surveillance data, results indicate that approximate to 14% of all norovirus outbreaks are attributed to food. C1 [Verhoef, Linda; Kroneman, Annelies; Vennema, Harry; Koopmans, Marion] Natl Inst Publ Hlth & Environm, NL-3720 BA Bilthoven, Netherlands. [Hewitt, Joanne; Lake, Rob] Inst Environm Sci & Res, Porirua, New Zealand. [Barclay, Leslie; Ahmed, Sharia M.; Hall, Aron J.; Lopman, Ben; Vinje, Jan] Ctr Dis Control & Prevent, Atlanta, GA USA. [Koopmans, Marion] Erasmus MC, Rotterdam, Netherlands. RP Verhoef, L (reprint author), Natl Inst Publ Hlth & Environm RIVM, Postbak 75,POB 1, NL-3720 BA Bilthoven, Netherlands. EM linda.verhoef@rivm.nl RI Verhoef, Linda/P-9066-2015 OI Verhoef, Linda/0000-0001-5988-8946 FU New Zealand Ministry of Health; Foodborne Disease Burden Epidemiology Reference Group of the World Health Organization; Government of the Netherlands FX The New Zealand Ministry of Health funded the work conducted by the ESR. This study was commissioned and paid for in part by the Foodborne Disease Burden Epidemiology Reference Group of the World Health Organization, the New Zealand Ministry of Health, and by the Government of the Netherlands on behalf of the Foodborne Disease Burden Epidemiology Reference Group. NR 38 TC 22 Z9 24 U1 3 U2 50 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD APR PY 2015 VL 21 IS 4 BP 592 EP 599 DI 10.3201/eid2104.141073 PG 8 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CE2NK UT WOS:000351652100006 PM 25811368 ER PT J AU Tempia, S Walaza, S Viboud, C Cohen, AL Madhi, SA Venter, M von Mollendorf, C Moyes, J McAnerney, JM Cohen, C AF Tempia, Stefano Walaza, Sibongile Viboud, Cecile Cohen, Adam L. Madhi, Shabir A. Venter, Marietjie von Mollendorf, Claire Moyes, Jocelyn McAnerney, Johanna M. Cohen, Cheryl TI Deaths Associated with Respiratory Syncytial and Influenza Viruses among Persons >= 5 Years of Age in HIV-Prevalent Area, South Africa, 1998-2009 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID UNITED-STATES; TRACT INFECTION; PANDEMIC INFLUENZA; MORTALITY BURDEN; HOSPITALIZATIONS; CHILDREN; ADULTS; EPIDEMIOLOGY; SURVEILLANCE; SEVERITY AB We estimated deaths attributable to influenza and respiratory syncytial virus (RSV) among persons >= 5 years of age in South Africa during 1998-2009 by applying regression models to monthly deaths and laboratory surveillance data. Rates were expressed per 100,000 person-years. The mean annual number of seasonal influenza associated deaths was 9,093 (rate 21.6). Persons >= 65 years of age and HIV-positive persons accounted for 50% (n = 4,552) and 28% (n = 2,564) of overall seasonal influenza-associated deaths, respectively. In 2009, we estimated 4,113 (rate 9.2) influenza A(H1N1) pdm09-associated deaths. The mean of annual RSV-associated deaths during the study period was 511 (rate 1.2); no RSV-associated deaths were estimated in persons >= 45 years of age. Our findings support the recommendation for influenza vaccination of older persons and HIV-positive persons. Surveillance for RSV should be strengthened to clarify the public health implications and severity of illness associated with RSV infection in South Africa. C1 [Tempia, Stefano; Walaza, Sibongile; Madhi, Shabir A.; von Mollendorf, Claire; Moyes, Jocelyn; McAnerney, Johanna M.; Cohen, Cheryl] Natl Hlth Lab Serv, Johannesburg, South Africa. [Tempia, Stefano; Cohen, Adam L.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Tempia, Stefano; Cohen, Adam L.; Venter, Marietjie] Ctr Dis Control & Prevent, Pretoria, South Africa. [Viboud, Cecile] NIH, Bethesda, MD 20892 USA. [Madhi, Shabir A.; Moyes, Jocelyn; Cohen, Cheryl] Univ Witwatersrand, Johannesburg, South Africa. RP Tempia, S (reprint author), Natl Inst Communicable Dis, US Ctr Dis Control & Prevent, Private Bag X4, ZA-2131 Johannesburg, Gauteng, South Africa. EM wlu4@cdc.gov RI Venter, Marietjie/P-9604-2016 OI Venter, Marietjie/0000-0003-2696-824X FU GlaxoSmithKline; Novartis; Pfizer FX Stefano Tempia, DVM, MSc, PhD; Sibongile Walaza, MB BCh; Cede Viboud, PhD; Adam L. Cohen, MD, MPH; Marietjie Venter, PhD; Claire von Mollendorf, MB BCh, MSc; Jocelyn Moyes, MB BCh, MSc (Med); Johanna M. McAnerney; and Cheryl Cohen, PhD, have disclosed no relevant financial relationships. Shabir A. Madhi, MD, PhD, has disclosed the following relevant financial relationships: served as an advisor or consultant for GlaxoSmithKline, Pfizer; served as a speaker or a member of a speakers bureau for GlaxoSmithKline, Pfizer, Sanofi Pasteur; received grants for clinical research from GlaxoSmithKline, Novartis, Pfizer. NR 39 TC 4 Z9 4 U1 0 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD APR PY 2015 VL 21 IS 4 BP 600 EP 608 DI 10.3201/eid2104.141033 PG 9 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CE2NK UT WOS:000351652100007 PM 25811455 ER PT J AU Nasreen, S Khan, SU Luby, SP Gurley, ES Abedin, J Zaman, RU Sohel, BM Rahman, M Hancock, K Levine, MZ Veguilla, V Wang, D Holiday, C Gillis, E Sturm-Ramirez, K Bresee, JS Rahman, M Uyeki, TM Katz, JM Azziz-Baumgartner, E AF Nasreen, Sharifa Khan, Salah Uddin Luby, Stephen P. Gurley, Emily S. Abedin, Jaynal Zaman, Rashid Uz Sohel, Badrul Munir Rahman, Mustafizur Hancock, Kathy Levine, Min Z. Veguilla, Vic Wang, David Holiday, Crystal Gillis, Eric Sturm-Ramirez, Katharine Bresee, Joseph S. Rahman, Mahmudur Uyeki, Timothy M. Katz, Jacqueline M. Azziz-Baumgartner, Eduardo TI Highly Pathogenic Avian Influenza A(H5N1) Virus Infection among Workers at Live Bird Markets, Bangladesh, 2009-2010 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID A H5N1 VIRUS; TO-HUMAN TRANSMISSION; POULTRY WORKERS; CHINA; ANTIBODIES; PROVINCE; CULLERS AB The risk for influenza A(H5N1) virus infection is unclear among poultry workers in countries where the virus is endemic. To assess H5N1 seroprevalence and seroconversion among workers at live bird markets (LBMs) in Bangladesh, we followed a cohort of workers from 12 LBMs with existing avian influenza surveillance. Serum samples from workers were tested for H5N1 antibodies at the end of the study or when LBM samples first had H5N1 virus-positive test results. Of 404 workers, 9 (2%) were seropositive at baseline. Of 284 workers who completed the study and were seronegative at baseline, 6 (2%) seroconverted (7 cases/100 poultry worker-years). Workers who frequently fed poultry, cleaned feces from pens, cleaned food/water containers, and did not wash hands after touching sick poultry had a 7.6 times higher risk for infection compared with workers who infrequently performed these behaviors. Despite frequent exposure to H5N1 virus, LBM workers showed evidence of only sporadic infection. C1 [Nasreen, Sharifa; Khan, Salah Uddin; Luby, Stephen P.; Gurley, Emily S.; Abedin, Jaynal; Zaman, Rashid Uz; Sohel, Badrul Munir; Rahman, Mustafizur; Sturm-Ramirez, Katharine; Azziz-Baumgartner, Eduardo] Icddr B, Dhaka, Bangladesh. [Luby, Stephen P.; Hancock, Kathy; Levine, Min Z.; Veguilla, Vic; Wang, David; Holiday, Crystal; Gillis, Eric; Sturm-Ramirez, Katharine; Bresee, Joseph S.; Uyeki, Timothy M.; Katz, Jacqueline M.; Azziz-Baumgartner, Eduardo] Ctr Dis Control & Prevent, Atlanta, GA USA. [Rahman, Mahmudur] Inst Epidemiol Dis Control & Res, Dhaka, Bangladesh. RP Nasreen, S (reprint author), Ctr Communicable Dis, Icddr B, 68 Shaheed Tajuddin Ahmed Sarani, Dhaka 1212, Bangladesh. EM drsharifa74@gmail.com RI Gurley, Emily/B-7903-2010; OI Gurley, Emily/0000-0002-8648-9403; Khan, M. Salah Uddin Khan/0000-0001-5928-9257; Luby, Stephen/0000-0001-5385-899X FU CDC; icddr,b [1-U01-CI000298]; government of Australia; government of Bangladesh; government of Canada; government of Sweden; government of United Kingdom FX This research study was funded by the CDC through their cooperative agreement with icddr,b (grant no. 1-U01-CI000298). icddr,b is thankful to the governments of Australia, Bangladesh, Canada, Sweden, and the United Kingdom for providing core/unrestricted support. NR 39 TC 6 Z9 6 U1 0 U2 6 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD APR PY 2015 VL 21 IS 4 BP 629 EP 637 DI 10.3201/eid2104.141281 PG 9 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CE2NK UT WOS:000351652100010 PM 25811942 ER PT J AU Cutland, CL Schrag, SJ Thigpen, MC Velaphi, SC Wadula, J Adrian, PV Kuwanda, L Groome, MJ Buchmann, E Madhi, SA AF Cutland, Clare L. Schrag, Stephanie J. Thigpen, Michael C. Velaphi, Sithembiso C. Wadula, Jeannette Adrian, Peter V. Kuwanda, Locadiah Groome, Michelle J. Buchmann, Eckhart Madhi, Shabir A. TI Increased Risk for Group B Streptococcus Sepsis in Young Infants Exposed to HIV, Soweto, South Africa, 2004-2008 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID DEVELOPING-COUNTRIES; UNINFECTED INFANTS; UNITED-STATES; DISEASE; INFECTION; BURDEN; EPIDEMIOLOGY; TRANSMISSION; METAANALYSIS; POPULATION AB Although group B Streptococcus (GBS) is a leading cause of severe invasive disease in young infants worldwide, epidemiologic data and knowledge about risk factors for the disease are lacking from low- to middle-income countries. To determine the epidemiology of invasive GBS disease among young infants in a setting with high maternal HIV infection, we conducted hospital-based surveillance during 2004-2008 in Soweto, South Africa. Overall GBS incidence was 2.72 cases/1,000 live births (1.50 and 1.22, respectively, among-infants with early-onset disease [EOD] and late-onset [LOD] disease). Risk for EOD and LOD was higher for HIV-exposed than HIV-unexposed infants. GBS serotypes Ia and III accounted for 84.0% of cases, and 16.9% of infected infants died. We estimate that use of trivalent GBS vaccine (serotypes Ia, Ib, and III) could prevent 2,105 invasive GBS cases and 278 deaths annually among infants in South Africa; therefore, vaccination of all pregnant women in this country should be explored. C1 [Cutland, Clare L.; Velaphi, Sithembiso C.; Wadula, Jeannette; Adrian, Peter V.; Kuwanda, Locadiah; Groome, Michelle J.; Buchmann, Eckhart; Madhi, Shabir A.] Univ Witwatersrand, Johannesburg, South Africa. [Cutland, Clare L.; Adrian, Peter V.; Kuwanda, Locadiah; Groome, Michelle J.; Madhi, Shabir A.] MRC, Resp & Meningeal Pathogens Res Unit, Johannesburg, South Africa. [Schrag, Stephanie J.; Thigpen, Michael C.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Velaphi, Sithembiso C.; Wadula, Jeannette; Buchmann, Eckhart] Chris Hani Baragwanath Acad Hosp, Johannesburg, South Africa. [Madhi, Shabir A.] Natl Inst Communicable Dis, Johannesburg, South Africa. RP Cutland, CL (reprint author), Resp & Meningeal Pathogens Res Unit, POB 90753, ZA-2013 Johannesburg, South Africa. EM cutlandc@rmpru.co.za FU United States Agency for International Development; National Vaccine Program Office; Antimicrobial Resistance Working Group of the Centers for Disease Control and Prevention [U50/CCU021960, 5U01CI000318]; Bill and Melinda Gates Foundation [39415]; Respiratory and Meningeal Pathogens Research Unit of the South African Medical Research Council; Novartis FX This study was supported by the United States Agency for International Development, the National Vaccine Program Office, and the Antimicrobial Resistance Working Group of the Centers for Disease Control and Prevention (cooperative agreement nos. U50/CCU021960 and 5U01CI000318), and the Bill and Melinda Gates Foundation (grant no. 39415). Additional funding was provided by the Respiratory and Meningeal Pathogens Research Unit of the South African Medical Research Council.; The CHBAH Respiratory and Meningeal Pathogens Research Unit receives institutional grant support related to GBS from Novartis. S.A.M., C.L.C., and M.J.G. are clinical investigators in the Novartis GBS conjugate vaccine program. NR 34 TC 19 Z9 20 U1 4 U2 7 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD APR PY 2015 VL 21 IS 4 BP 638 EP 645 DI 10.3201/eid2104.141562 PG 8 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CE2NK UT WOS:000351652100011 PM 25812061 ER PT J AU Breedlove, B AF Breedlove, Byron TI "Welcome to the World of the Plastic Beach" SO EMERGING INFECTIOUS DISEASES LA English DT Editorial Material ID INVASIONS; DEBRIS C1 Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. RP Breedlove, B (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop C12, Atlanta, GA 30329 USA. EM wbb1@cdc.gov OI Breedlove, Byron/0000-0002-1026-1963 NR 9 TC 0 Z9 0 U1 3 U2 20 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD APR PY 2015 VL 21 IS 4 BP 736 EP 737 DI 10.3201/eid2104.AC2104 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CE2NK UT WOS:000351652100042 ER PT J AU Berger, RP Parks, S Fromkin, J Rubin, P Pecora, PJ AF Berger, Rachel P. Parks, Sharyn Fromkin, Janet Rubin, Pamela Pecora, Peter J. TI Assessing the accuracy of the International Classification of Diseases codes to identify abusive head trauma: a feasibility study SO INJURY PREVENTION LA English DT Article ID OPERATIONAL CASE-DEFINITION; HOSPITAL INPATIENT DATA; SHAKEN BABY SYNDROME; BRAIN-INJURY; CHILDREN; SURVEILLANCE; USA AB Objective To assess the accuracy of an International Classification of Diseases (ICD) code-based operational case definition for abusive head trauma (AHT). Methods Subjects were children <5 years of age evaluated for AHT by a hospital-based Child Protection Team (CPT) at a tertiary care paediatric hospital with a completely electronic medical record (EMR) system. Subjects were designated as non-AHT traumatic brain injury (TBI) or AHT based on whether the CPT determined that the injuries were due to AHT. The sensitivity and specificity of the ICD-based definition were calculated. Results There were 223 children evaluated for AHT: 117 AHT and 106 non-AHT TBI. The sensitivity and specificity of the ICD-based operational case definition were 92% (95% CI 85.8 to 96.2) and 96% (95% CI 92.3 to 99.7), respectively. All errors in sensitivity and three of the four specificity errors were due to coder error; one specificity error was a physician error. Conclusions In a paediatric tertiary care hospital with an EMR system, the accuracy of an ICD-based case definition for AHT was high. Additional studies are needed to assess the accuracy of this definition in all types of hospitals in which children with AHT are cared for. C1 [Berger, Rachel P.; Fromkin, Janet; Rubin, Pamela] Childrens Hosp Pittsburgh UPMC, Dept Pediat, Pittsburgh, PA 15224 USA. [Parks, Sharyn] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA. [Pecora, Peter J.] Univ Washington, Sch Social Work, Casey Family Programs, Seattle, WA 98195 USA. RP Berger, RP (reprint author), Childrens Hosp Pittsburgh UPMC, 4401 Penn Ave, Pittsburgh, PA 15224 USA. EM Rachel.berger@chp.edu FU NIH [R01HD055986]; Matty Eappen Foundation; Casey Family Foundation FX This project was funded, in part, by NIH R01HD055986 (RB), the Matty Eappen Foundation (RB) and the Casey Family Foundation. Neither NIH nor Matty Eappen Foundation had any role in (1) the study design; (2) the collection, analysis and interpretation of the data; (3) the writing of the report and (4) the decision to submit the article for publication. Casey Family Foundation assisted with study design, interpretation of the data, writing of the report and gave approval for submission. NR 24 TC 9 Z9 9 U1 1 U2 3 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1353-8047 EI 1475-5785 J9 INJURY PREV JI Inj. Prev. PD APR PY 2015 VL 21 IS E1 BP E133 EP E137 DI 10.1136/injuryprev-2013-040924 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CE2ZS UT WOS:000351693200024 PM 24167034 ER PT J AU Lindan, CP Anglemyer, A Hladik, W Barker, J Lubwama, G Rutherford, G Ssenkusu, J Opio, A Campbell, J AF Lindan, Christina P. Anglemyer, Andrew Hladik, Wolfgang Barker, Joseph Lubwama, George Rutherford, George Ssenkusu, John Opio, Alex Campbell, James CA Crane Survey Grp TI High-risk motorcycle taxi drivers in the HIV/AIDS era: a respondent-driven sampling survey in Kampala, Uganda SO INTERNATIONAL JOURNAL OF STD & AIDS LA English DT Article DE Men; HIV; AIDS; sexually transmitted infections; prevalence; screening; transportation; taxi drivers; boda-boda; Uganda; Africa; epidemiology ID DISTANCE TRUCK DRIVERS; SEXUALLY-TRANSMITTED INFECTIONS; CROSS-SECTIONAL SURVEY; FEMALE SEX WORKERS; ALCOHOL-USE; GENERAL-POPULATION; HIV PREVALENCE; AFRICA; BEHAVIOR; KENYA AB We evaluated motorcycle taxi (boda-boda') drivers in Kampala for the prevalence of HIV/sexually transmitted infections. We used respondent-driven sampling to recruit a cross-sectional sample of boda-boda drivers. We collected data through audio computer-assisted self-administered interviews. Men were tested for HIV, syphilis serology using Rapid Plasma Reagin and enzyme immunoassay, and Chlamydia and gonorrhoea using urine polymerase chain reaction. We recruited 683 men. Median age was 26 years; 59.4% were single. The prevalence of HIV was 7.5% (95% CI 5.2-10.0), of positive syphilis serology was 6.1% (95% CI 4.3-8.1), of Chlamydia was 1.1% (95% CI 0.4-2.0), and of gonorrhoea was 1.2% (95% CI 0.1-1.2). Many men (67.8%) had both casual and regular partners, sex with other men (8.7%), and commercial sex (33.1%). Factors associated with having HIV included reporting a genital ulcer (odds ratio [OR] =2.4, 95% CI 1.4-4.4), drinking alcohol during last sex (OR 2.0, 95% CI 1.1-3.7), having 4-6 lifetime partners (OR 2.2, 95% CI 1.0-4.8), and having one's last female partner be >24 years of age (OR 2.8, 95% CI 1.2-6.6). Independent predictors of HIV included age 31 (adjusted OR (aOR) 5.8, 95% CI 1.5-48.5), having 4-6 partners (aOR 2.2, 95%CI 1.0-5.1), and self-report of a genital ulcer (OR 2.3, 95% CI 1.2-4.1). Only 39.2% of men were circumcised, and 36.9% had been HIV tested in the past. Male boda-boda drivers have a higher prevalence of HIV than the general population, and low frequency of preventive behaviours, such as circumcision and HIV testing. Targeted and intensified interventions for this group are warranted. C1 [Lindan, Christina P.; Anglemyer, Andrew; Rutherford, George] Univ Calif San Francisco, Global Hlth Sci, San Francisco, CA 94105 USA. [Lindan, Christina P.; Anglemyer, Andrew; Rutherford, George] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94105 USA. [Hladik, Wolfgang] Ctr Dis Control & Prevent, Div Global HIV AIDS, Ctr Global Hlth, Atlanta, GA USA. [Barker, Joseph] US Dept State, Off Global AIDS Coordinator, Washington, DC 20520 USA. [Lubwama, George] Makerere Univ, Sch Publ Hlth, Kampala, Uganda. [Ssenkusu, John] Ctr Dis Control & Prevent, Div Global HIV AIDS, Ctr Global Hlth, Entebbe, Uganda. [Opio, Alex] Minist Hlth, Kampala, Uganda. [Campbell, James] Univ Maryland, Dept Pediat, Bethesda, MD USA. RP Lindan, CP (reprint author), Univ Calif San Francisco, Global Hlth Sci, 50 Beale St,12th Floor, San Francisco, CA 94105 USA. EM klindan@psg.ucsf.edu FU President's Emergency Plan for AIDS Relief (PEPFAR) through CDC-Uganda [U2GPS000971] FX The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was supported by the President's Emergency Plan for AIDS Relief (PEPFAR) through CDC-Uganda (Cooperative Agreement U2GPS000971). NR 29 TC 4 Z9 4 U1 0 U2 7 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0956-4624 EI 1758-1052 J9 INT J STD AIDS JI Int. J. STD AIDS PD APR PY 2015 VL 26 IS 5 BP 336 EP 345 DI 10.1177/0956462414538006 PG 10 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CE3EP UT WOS:000351709100006 PM 24970473 ER PT J AU Dunne, EF Stokley, S Chen, WW Zhou, FJ AF Dunne, Eileen F. Stokley, Shannon Chen, Weiwei Zhou, Fangjun TI Human Papillomavirus Vaccination of Females in a Large Health Claims Database in the United States, 2006-2012 SO JOURNAL OF ADOLESCENT HEALTH LA English DT Article DE HPV vaccine; Administrative data; Vaccine coverage; Missed opportunities for vaccination ID AGED 13-17 YEARS; ADOLESCENT VACCINATION; INTERVIEW SURVEY; YOUNG-WOMEN; COVERAGE; GIRLS; PHYSICIANS; RECOMMENDATIONS; IMMUNIZATION; COMPLETION AB Purpose: Information on vaccine utilization from a variety of sources is useful to give a status of the vaccine program and define opportunities to improve uptake. We evaluated MarketScan Commercial Claims and Encounters database on human papillomavirus (HPV) vaccine initiation and completion of all three doses among girls/women from 2006 to 2012. Methods: Data were obtained from the 2006-2012 MarketScan Commercial Claims and Encounters database. The study population included female enrollees aged 11-26 years who were continuously enrolled in the same private insurance plan from 2006 to 2012 (n = 407,371). We evaluated overall and yearly vaccine initiation and completion, demographic characteristics associated with vaccine initiation, clinical visits in which vaccine was given, and missed opportunities for vaccination. Results: By the end of 2012, 36.9% of females aged 11-26 years had received at least one HPV vaccine dose. Vaccination coverage was highest among females aged 17-18 years (49.3%) and aged 15-16 years (43.1%) and lowest among females aged 11-12 years (16.8%). Between 2007 and 2012, 96.1% of the 246,192 unvaccinated females had at least one missed opportunity (a heath care visit without HPV vaccine administered). Conclusions: Over a 6 year period, HPV vaccine initiation was lowest in the girls aged 11-12 years. Importantly, most (96.1%) unvaccinated females had at least one missed vaccination opportunity, and providers and health systems should focus efforts on using existing visits for vaccination. Published by Elsevier Inc. on behalf of Society for Adolescent Health and Medicine. C1 [Dunne, Eileen F.] CDC, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA. [Stokley, Shannon; Chen, Weiwei; Zhou, Fangjun] CDC, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Dunne, EF (reprint author), CDC Box 68, APO, AA 96546 USA. EM dde9@cdc.gov OI Chen, Weiwei/0000-0002-2162-0941 NR 30 TC 4 Z9 4 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X EI 1879-1972 J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD APR PY 2015 VL 56 IS 4 BP 408 EP 413 DI 10.1016/j.jadohealth.2015.01.004 PG 6 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA CE3BC UT WOS:000351698100010 PM 25797632 ER PT J AU Ahluwalia, IB Harrison, L Simpson, P Wako, E Shealy, KH Kapaya, M Williams, T Williams, L D'Angelo, D AF Ahluwalia, Indu B. Harrison, Leslie Simpson, Patrick Wako, Etobssie Shealy, Kristen Helms Kapaya, Martha Williams, Tanya Williams, Letitia D'Angelo, Denise TI Pregnancy Risk Assessment Monitoring System and the W.K. Kellogg Foundation Joint Project to Enhance Maternal and Child Health Surveillance: Focus on Collaboration SO JOURNAL OF WOMENS HEALTH LA English DT Article ID OUTCOMES AB Maternal and child health (MCH) surveillance data are important for understanding gaps in services and disparities in burden of disease, access to care, risk behaviors, and health outcomes. However, national and state surveillance systems are not always designed to gather sufficient data for calculating reliable estimates of the health conditions among high-risk or underrepresented population subgroups living in smaller geographic areas. The Centers for Disease Control and Prevention's Pregnancy Risk Assessment Monitoring System (PRAMS) has conducted surveillance for over 25 years in collaboration with state and city health departments. In 2012, PRAMS embarked on a multiyear collaboration with the W.K. Kellogg Foundation (WKKF) to include oversampling of minority and low-income women in selected geographic areas in four states (Louisiana, Michigan, Mississippi, and New Mexico) where the WKKF funded extensive place-based initiatives are located. The PRAMS-WKKF collaboration has broad implications for promoting meaningful collaboration between public, private, local, state, and federal organizations to address MCH data gaps on disparities, and for improving the availability of information needed for MCH programs, policy makers, and women. C1 [Ahluwalia, Indu B.; Harrison, Leslie; Williams, Tanya; Williams, Letitia; D'Angelo, Denise] Ctr Dis Control & Prevent, Pregnancy Risk Assessment Monitoring Syst, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Simpson, Patrick] WK Kellogg Fdn, Detroit, MI USA. [Wako, Etobssie; Shealy, Kristen Helms; Kapaya, Martha] DB Consulting Grp Inc, Silver Spring, MD USA. RP Ahluwalia, IB (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, 4770 Buford Highway,NE Mailstop F-74, Atlanta, GA 30341 USA. EM iaa2@cdc.gov NR 5 TC 0 Z9 0 U1 1 U2 3 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 EI 1931-843X J9 J WOMENS HEALTH JI J. Womens Health PD APR 1 PY 2015 VL 24 IS 4 BP 257 EP 260 DI 10.1089/jwh.2015.5260 PG 4 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA CF5YG UT WOS:000352632700001 PM 25860106 ER PT J AU Bar-Zen, N Kapanda, L Tate, JE Jere, KC Iturriza-Gomara, M Nakagomi, O Mwansambo, C Costello, A Parashar, UD Heyderman, RS French, N Cunliffe, NA AF Bar-Zen, Naor Kapanda, Lester Tate, Jacqueline E. Jere, Khuzwayo C. Iturriza-Gomara, Miren Nakagomi, Osamu Mwansambo, Charles Costello, Anthony Parashar, Umesh D. Heyderman, Robert S. French, Neil Cunliffe, Nigel A. CA VacSurv Consortium TI Effectiveness of a monovalent rotavirus vaccine in infants in Malawi after programmatic roll-out: an observational and case-control study SO LANCET INFECTIOUS DISEASES LA English DT Article ID UNITED-STATES; INDIRECT PROTECTION; AFRICAN INFANTS; SEVERE DIARRHEA; CHILDREN; GASTROENTERITIS; IMPACT; MORTALITY; BLANTYRE; STRAINS AB Background Rotavirus is the main cause of severe acute gastroenteritis in children in Africa. Monovalent human rotavirus vaccine (RV1) was added into Malawi's infant immunisation schedule on Oct 29, 2012. We aimed to assess the impact and effectiveness of RV1 on rotavirus gastroenteritis in the 2 years after introduction. Methods From Jan 1, 2012, to June 30, 2014, we recruited children younger than 5 years who were admitted into Queen Elizabeth Central Hospital, Blantyre, Malawi, with acute gastroenteritis. We assessed stool samples from these children for presence of rotavirus with use of ELISA and we genotyped rotaviruses with use of RT-PCR. We compared rotavirus detection rates in stool samples and incidence of hospital admittance for rotavirus in children from Jan 1 to June 30, in the year before vaccination (2012) with the same months in the 2 years after vaccination was introduced (2013 and 2014). In the case-control portion of our study, we recruited eligible rotavirus-positive children from the surveillance platform and calculated vaccine effectiveness (one minus the odds ratio of vaccination) by comparing infants with rotavirus gastroenteritis with infants who tested negative for rotavirus, and with community age-matched and neighbourhood-matched controls. Findings We enrolled 1431 children, from whom we obtained 1417 stool samples (99%). We detected rotavirus in 79 of 157 infants (50%) before the vaccine, compared with 57 of 219 (40%) and 52 of 170 (31%) in successive calendar years after vaccine introduction (p=0.0002). In the first half of 2012, incidence of rotavirus hospital admission was 269 per 100 000 infants compared with 284 in the same months of 2013 (rise of 5.8%, 95% CI -23.1 to 45.4; p=0.73) and 153 in these months in 2014 (a reduction from the prevaccine period of 43.2%, 18.0-60-7; p=0.003). We recruited 118 vaccine-eligible rotavirus cases (median age 8.9 months; IQR 6.6-11.1), 317 rotavirus-test-negative controls (9.4 months; 6.9-11.9), and 380 community controls (8.8 months; 6.5-11.1). Vaccine effectiveness for two doses of RV1 in rotavirus-negative individuals was 64% (95% CI 24-83) and community controls was 63% (23-83). The point estimate of effectiveness was higher against genotype G1 than against G2 and G12. Interpretation Routine use of RV1 reduced hospital admissions for several genotypes of rotavirus in children younger than 5 years, especially in infants younger than 1 year. Our data support introduction of rotavirus vaccination at the WHO recommended schedule, with continuing surveillance in high-mortality countries. Copyright (C) Bar-Zeev, et al. Open Access article distributed under the terms of CC BY. C1 [Bar-Zen, Naor; Kapanda, Lester; Jere, Khuzwayo C.; Heyderman, Robert S.; French, Neil] Univ Malawi, Coll Med, Malawi Liverpool Wellcome Trust Clin Res Programm, Blantyre, Malawi. [Bar-Zen, Naor; Jere, Khuzwayo C.; Iturriza-Gomara, Miren; French, Neil; Cunliffe, Nigel A.] Univ Liverpool, Inst Infect & Global Hlth, Liverpool L69 3BX, Merseyside, England. [Tate, Jacqueline E.; Parashar, Umesh D.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Div Viral Dis, Epidemiol Branch, Atlanta, GA USA. [Nakagomi, Osamu] Nagasaki Univ, Grad Sch Biomed Sci, Nagasaki 852, Japan. [Mwansambo, Charles] Minist Hlth & Populat, Lilongwe, Malawi. [Costello, Anthony] UCL, Inst Global Hlth, London, England. [Heyderman, Robert S.] Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England. RP Cunliffe, NA (reprint author), Univ Liverpool, Inst Infect & Global Hlth, Liverpool L69 3BX, Merseyside, England. EM n.a.cunliffe@liv.ac.uk OI Cunliffe, Nigel/0000-0002-5449-4988; Jere, Khuzwayo/0000-0003-3376-8529 FU Wellcome Trust; GlaxoSmithKline Biologicals FX Wellcome Trust, GlaxoSmithKline Biologicals. NR 32 TC 32 Z9 32 U1 1 U2 5 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1473-3099 EI 1474-4457 J9 LANCET INFECT DIS JI Lancet Infect. Dis. PD APR PY 2015 VL 15 IS 4 BP 422 EP 428 DI 10.1016/S1473-3099(14)71060-6 PG 7 WC Infectious Diseases SC Infectious Diseases GA CE6WA UT WOS:000351977700038 PM 25638521 ER PT J AU Lin, SW Freedman, ND Shi, JX Gail, MH Vogtmann, E Yu, GQ Klepac-Ceraj, V Paster, BJ Dye, BA Wang, GQ Wei, WQ Fan, JH Qiao, YL Dawsey, SM Abnet, CC AF Lin, Shih-Wen Freedman, Neal D. Shi, Jianxin Gail, Mitchell H. Vogtmann, Emily Yu, Guoqin Klepac-Ceraj, Vanja Paster, Bruce J. Dye, Bruce A. Wang, Guo-Qing Wei, Wen-Qiang Fan, Jin-Hu Qiao, You-Lin Dawsey, Sanford M. Abnet, Christian C. TI Beta-Diversity Metrics of the Upper Digestive Tract Microbiome Are Associated with Body Mass Index SO OBESITY LA English DT Article ID HUMAN GUT MICROBIOTA; OBESITY; ECOLOGY; DISEASE; LACTOBACILLUS; PERIODONTITIS; OVERWEIGHT; CHILDREN; LINXIAN; CANCER AB ObjectiveStudies of the fecal microbiome have implicated the gut microbiota in obesity, but few studies have examined the microbial diversity at other sites. The association between obesity and the upper gastrointestinal (UGI) microbial diversity was explored. MethodsThe UGI microbiome of 659 healthy Chinese adults with a measured body mass index (BMI) range of 15.0 to 35.7 was characterized using the 16S rRNA gene DNA microarray (HOMIM). ResultsIn multivariate-adjusted models, alpha diversity was not associated with BMI. However, beta diversity, assessed by principal coordinate vectors generated from an unweighted UniFrac distance matrix of pairwise comparisons, was associated with BMI (third and fourth vectors, P=0.01 and P=0.03, respectively). Moreover, beta diversity, assessed by cluster membership (three clusters), was also associated with BMI; individuals in the first cluster [median BMI 22.35, odds ratio (OR)=0.48, 95% confidence interval (CI) = 0.05-4.34] and second cluster [median BMI 22.55, OR=0.26, 95% CI=0.09-0.75] were significantly less likely to be obese (BMI27.5) than those in the third cluster (median BMI 23.59). ConclusionsA beta-diversity metric of the UGI microbiome is associated with a four fold difference in obesity risk in this Asian population. Future studies should address whether the UGI microbiome plays a causal role in obesity. C1 [Lin, Shih-Wen; Freedman, Neal D.; Shi, Jianxin; Gail, Mitchell H.; Vogtmann, Emily; Yu, Guoqin; Dawsey, Sanford M.; Abnet, Christian C.] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA. [Klepac-Ceraj, Vanja; Paster, Bruce J.] Forsyth Inst, Dept Microbiol, Boston, MA USA. [Klepac-Ceraj, Vanja] Wellesley Coll, Dept Biol Sci, Wellesley, MA 02181 USA. [Dye, Bruce A.] Ctr Dis Control & Prevent, Hyattsville, MD USA. [Wang, Guo-Qing; Wei, Wen-Qiang; Fan, Jin-Hu; Qiao, You-Lin] Chinese Acad Med Sci, Canc Inst & Hosp, Beijing 100730, Peoples R China. RP Lin, SW (reprint author), NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA. EM lins4@mail.nih.gov RI Freedman, Neal/B-9741-2015; Abnet, Christian/C-4111-2015; Qiao, You-Lin/B-4139-2012 OI Freedman, Neal/0000-0003-0074-1098; Abnet, Christian/0000-0002-3008-7843; Qiao, You-Lin/0000-0001-6380-0871 FU Intramural Research Program, Division of Cancer Epidemiology & Genetics, National Cancer Institute FX Supported by the Intramural Research Program, Division of Cancer Epidemiology & Genetics, National Cancer Institute. NR 40 TC 1 Z9 1 U1 1 U2 12 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1930-7381 EI 1930-739X J9 OBESITY JI Obesity PD APR PY 2015 VL 23 IS 4 BP 862 EP 869 DI 10.1002/oby.21020 PG 8 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA CE4XA UT WOS:000351832400022 PM 25755147 ER PT J AU Leelawiwat, W Rutvisuttinunt, W Arroyo, M Mueanpai, F Kongpechsatit, O Chonwattana, W Chaikummao, S de Souza, M vanGriensven, F McNicholl, JM Curlin, ME AF Leelawiwat, Wanna Rutvisuttinunt, Wiriya Arroyo, Miguel Mueanpai, Famui Kongpechsatit, Oranuch Chonwattana, Wannee Chaikummao, Supaporn de Souza, Mark vanGriensven, Frits McNicholl, Janet M. Curlin, Marcel E. TI Increasing HIV-1 Molecular Complexity Among Men Who Have Sex with Men in Bangkok SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Article ID INJECTING DRUG-USERS; CIRCULATING RECOMBINANT FORM; TYPE-1 SUBTYPE E; NEUTRALIZING ANTIBODIES; NORTHERN THAILAND; GENETIC DIVERSITY; INFECTION; EPIDEMIOLOGY; CHINA; MSM AB In Thailand, new HIV-1 infections are largely concentrated in certain risk groups such as men who have sex with men (MSM), where annual incidence may be as high as 12% per year. The paucity of information on the molecular epidemiology of HIV-1 in Thai MSM limits progress in understanding the epidemic and developing new prevention methods. We evaluated HIV-1 subtypes in seroincident and seroprevalent HIV-1-infected men enrolled in the Bangkok MSM Cohort Study (BMCS) between 2006 and 2011. We characterized HIV-1 subtype in 231 seroprevalent and 194 seroincident subjects using the multihybridization assay (MHA). Apparent dual infections, recombinant strains, and isolates found to be nontypeable by MHA were further characterized by targeted genomic sequencing. Most subjects were infected with HIV-1 CRF01_AE (82%), followed by infections with recombinants (11%, primarily CRF01_AE/B recombinants), subtype B (5%), and dual infections (2%). More than 11 distinct chimeric patterns were observed among CRF01B_AE/B recombinants, most involving recombination within integrase. A significant increase in the proportion of nontypeable strains was observed among seroincident MSM between 2006 and 2011. CRF01_AE and subtype B were the most and least common infecting strains, respectively. The predominance of CRF01_AE among HIV-1 infections in Thai MSM participating in the BMCS parallels trends observed in Thai heterosexuals and injecting drug users. The presence of complex recombinants and a significant rise in nontypeable strains suggest ongoing changes in the genetic makeup of the HIV-1 epidemic in Thailand, which may pose challenges for HIV-1 prevention efforts and vaccine development. C1 [Leelawiwat, Wanna; Mueanpai, Famui; Kongpechsatit, Oranuch; Chonwattana, Wannee; Chaikummao, Supaporn; vanGriensven, Frits; McNicholl, Janet M.; Curlin, Marcel E.] Thailand MOPH US CDC Collaborat, Nonthaburi 11000, Thailand. [Rutvisuttinunt, Wiriya; Arroyo, Miguel] Armed Forces Res Inst Med Sci, Dept Retrovirol, Bangkok 10400, Thailand. [de Souza, Mark] Thai Red Cross AIDS Res Ctr, SEARCH Thailand, Bangkok, Thailand. [vanGriensven, Frits; McNicholl, Janet M.; Curlin, Marcel E.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. RP Leelawiwat, W (reprint author), Thailand MOPH US CDC Collaborat, DMSC Bldg 2,Tivanon Rd, Nonthaburi 11000, Thailand. EM wannal@cdc.gov OI Arroyo, Miguel/0000-0001-7416-8867 FU U.S. military HIV-1 Research; Henry M. Jackson Foundation FX The authors would like to thank the participants in this study, and acknowledge the support and funding from the U.S. military HIV-1 Research and the Henry M. Jackson Foundation. We also thank Viseth Ngauy, Vatcharin Assawadarachai, Kultida Poltavee, Hathairat Savadsuk, and Suwittra Chaemchuen of the Armed Forces Research Institute of Medical Sciences, Thailand for their support of this study; Sodsai Tovanabutra, Gustavo Kijak, Eric Sander-Buell, Morgane Rolland, Francine McCutcheon, and Jerome Kim of the U.S. Military HIV Research Program for their technical and intellectual input; Jaray Tongtoyai, Atittaya Sangiamkittikul, Punneeporn Wasinrapee, Natthaga Sakulploy, Kusuma Auethavoranan, and Wanna Suwanaphan of the Thai MOPH US-CDC Collaboration (TUC) laboratory for processing and testing all the samples; Sarika Pattanasin, Boonyos Raengsakulrach, and Chonticha Kittinunvorakoon for helpful advice; and the remaining members of our collaborative study group. NR 53 TC 1 Z9 1 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD APR 1 PY 2015 VL 31 IS 4 BP 393 EP 400 DI 10.1089/aid.2014.0139 PG 8 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA CE5JR UT WOS:000351869400007 PM 25366819 ER PT J AU Audu, R Onwuamah, C Salu, O Okwuraiwe, A Ou, CY Bolu, O Bond, KB Diallo, K Lu, L Jelpe, T Okoye, M Ngige, E Vertefeuille, J AF Audu, Rosemary Onwuamah, Chika Salu, Olumuyiwa Okwuraiwe, Azuka Ou, Chin-Yih Bolu, Omotayo Bond, Kyle B. Diallo, Karidia Lu, Lydia Jelpe, Tapdiyel Okoye, McPaul Ngige, Evelyn Vertefeuille, John TI Development and Implementation Challenges of a Quality Assured HIV Infant Diagnosis Program in Nigeria Using Dried Blood Spots and DNA Polymerase Chain Reaction SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; INVITRO ANTIBODY-PRODUCTION; TO-CHILD TRANSMISSION; UNITED-STATES; INFECTION; ELIMINATION AB Nigeria has one of the highest HIV burdens as well as mother-to-infant transmission rates in the world. A pilot program using polymerase chain reaction (PCR)-based testing of dried blood spot (DBS) specimens was implemented to enable early identification of HIV-infected infants and timely referral and linkage to care. From February 2007 to October 2008, whole blood was collected by finger prick to prepare DBS from infants <18 months presenting in six public mother-and-child health facilities in Lagos, Nigeria. The DBS were tested using the Roche Amplicor HIV-1 DNA Test, v1.5. To monitor laboratory testing quality, all of the PCR-positive and 10% of the PCR-negative DBS were retested by the same method at another reference laboratory. Three hundred and sixty-five randomly selected infants were screened using HIV rapid tests (RT) according to the national algorithm and RT-negative and PCR-positive specimens were also tested using Genscreen enzyme-linked immunosorbent assay (EIA) (Bio-Rad, France). The turnaround time (TAT) from sample collection, testing, and dispatching of results from each health facility was monitored. A total of 1,273 infants with a median age of 12.6 weeks (1 day to 71.6 weeks) participated in the program and 280 (22.0%) were PCR positive. HIV transmission levels varied greatly in the different health facilities ranging from 7.1% to 38.4%. Infants aged 48 to 72 weeks had the highest level of PCR positivity (41.1%). All PCR-positive specimens were confirmed by retesting. The mean turnaround time from DBS collection to returning of the laboratory result to the health facilities was 25 days. Three infants were found to be HIV antibody negative by rapid tests but were positive by both PCR and the fourth generation EIA. The DBS-based PCR program accurately identified all of the HIV-infected infants. However, many programmatic challenges related to the laboratory and TAT were identified. C1 [Audu, Rosemary; Onwuamah, Chika; Salu, Olumuyiwa; Okwuraiwe, Azuka] Nigerian Inst Med Res, Lagos, Nigeria. [Ou, Chin-Yih] CDC, Global AIDS Program Beijing, Beijing, Peoples R China. [Bolu, Omotayo; Diallo, Karidia; Lu, Lydia] CDC, Div Global HIV AIDS, Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Bond, Kyle B.; Jelpe, Tapdiyel; Vertefeuille, John] CDC, Global AIDS Program Abuja, Abuja, Nigeria. [Okoye, McPaul] US Agcy Int Dev, Abuja, Nigeria. [Ngige, Evelyn] Fed Minist Hlth, HIV & AIDS Div, Abuja, Nigeria. RP Audu, R (reprint author), Nigerian Inst Med Res, Human Virol Lab, 6 Edmond Crescent,PMB 2013, Lagos, Nigeria. EM rosemaryaudu@yahoo.com FU U.S. CDC, Division of Global AIDS in Atlanta; U.S. CDC, Division of Global AIDS in Nigeria FX We wish to acknowledge the support provided by U.S. CDC, Division of Global AIDS in Atlanta and Nigeria. We appreciate the principal collaborators from the Federal Ministry of Health, USAID, UNICEF, Clinton Foundation, Global HIV/AIDS Initiative, Institute of Human Virology/ACTION project, AIDS Prevention Initiative, Family Health International/GHAIN project, Nigerian Institute of Medical Research, and the staff and clients from the clinical sites in Lagos where the children were recruited. We also appreciate the assistance of Nora Kleinman, MPH, of the Association of School and Program of Public Health in the preparation of this article. NR 29 TC 3 Z9 3 U1 0 U2 2 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD APR 1 PY 2015 VL 31 IS 4 BP 433 EP 438 DI 10.1089/aid.2014.0159 PG 6 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA CE5JR UT WOS:000351869400012 PM 25381805 ER PT J AU Masterson, EA Deddens, JA Themann, CL Bertke, S Calvert, GM AF Masterson, Elizabeth A. Deddens, James A. Themann, Christa L. Bertke, Stephen Calvert, Geoffrey M. TI Trends in Worker Hearing Loss by Industry Sector, 1981-2010 SO AMERICAN JOURNAL OF INDUSTRIAL MEDICINE LA English DT Article DE occupational hearing loss; material hearing impairment; hazardous noise; noise-induced hearing loss; surveillance; trends; prevalence; incidence ID NATIONAL RESEARCH AGENDA; PREVALENCE RATIOS; UNITED-STATES; RISK-FACTORS; NOISE; HEALTH; COMPENSATION; PREVENTION; OCCUPATION; INJURY AB BackgroundThe purpose of this study was to estimate the incidence and prevalence of hearing loss for noise-exposed U.S. workers by industry sector and 5-year time period, covering 30 years. MethodsAudiograms for 1.8 million workers from 1981-2010 were examined. Incidence and prevalence were estimated by industry sector and time period. The adjusted risk of incident hearing loss within each time period and industry sector as compared with a reference time period was also estimated. ResultsThe adjusted risk for incident hearing loss decreased over time when all industry sectors were combined. However, the risk remained high for workers in Healthcare and Social Assistance, and the prevalence was consistently high for Mining and Construction workers. ConclusionsWhile progress has been made in reducing the risk of incident hearing loss within most industry sectors, additional efforts are needed within Mining, Construction and Healthcare and Social Assistance. Am. J. Ind. Med. 58:392-401, 2015. (c) 2015 Wiley Periodicals, Inc. C1 [Masterson, Elizabeth A.; Deddens, James A.; Themann, Christa L.; Bertke, Stephen; Calvert, Geoffrey M.] Ctr Dis Control & Prevent, NIOSH, Cincinnati, OH USA. RP Masterson, EA (reprint author), NIOSH, Div Surveillance, Hazard Evaluat & Field Studies, 1090 Tusculum Ave,MS-R17, Cincinnati, OH 45226 USA. EM EMasterson@cdc.gov FU Intramural CDC HHS [CC999999] NR 37 TC 5 Z9 5 U1 0 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0271-3586 EI 1097-0274 J9 AM J IND MED JI Am. J. Ind. Med. PD APR PY 2015 VL 58 IS 4 BP 392 EP 401 DI 10.1002/ajim.22429 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CD6AF UT WOS:000351169600003 PM 25690583 ER PT J AU Hoerger, TJ Crouse, WL Zhuo, XH Gregg, EW Albright, AL Zhang, P AF Hoerger, Thomas J. Crouse, Wesley L. Zhuo, Xiaohui Gregg, Edward W. Albright, Ann L. Zhang, Ping TI Medicare's Intensive Behavioral Therapy for Obesity An Exploratory Cost-Effectiveness Analysis SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID DIABETES PREVENTION PROGRAM; LIFE-STYLE INTERVENTION; WEIGHT-LOSS; PRIMARY-CARE; ADULTS; RISK; REDUCTION; METFORMIN; MELLITUS; TRIAL AB Introduction: Medicare coverage recently was expanded to include intensive behavioral therapy for obese individuals in primary care settings. Purpose: To examine the potential cost effectiveness of Medicare's intensive behavioral therapy for obesity, accounting for uncertainty in effectiveness and utilization. Methods: A Markov simulation model of type 2 diabetes was used to estimate long-term health benefits and healthcare system costs of intensive behavioral therapy for obesity in the Medicare population without diabetes relative to an alternative of usual care. Cohort statistics were based on the 2005-2008 National Health and Nutrition Examination Survey. Model parameters were derived from the literature. Analyses were conducted in 2014 and reported in 2012 U.S. dollars. Results: Based on assumptions for the maximal intervention effectiveness, intensive behavioral therapy is likely to be cost saving if costs per session equal the current reimbursement rate ($25.19) and will provide a cost-effectiveness ratio of $20,912 per quality-adjusted life-year if costs equal the rate for routine office visits. The intervention is less cost effective if it is less effective in primary care settings or if fewer intervention sessions are supplied by providers or used by participants. Conclusions: If the effectiveness of the intervention is similar to lifestyle interventions tested in other settings and costs per session equal the current reimbursement rate, intensive behavioral therapy for obesity offers good value. However, intervention effectiveness and the pattern of implementation and utilization strongly influence cost effectiveness. Given uncertainty regarding these factors, additional data might be collected to validate the modeling results. (C) 2015 American Journal of Preventive Medicine. All rights reserved. C1 [Hoerger, Thomas J.; Crouse, Wesley L.] RTI Int, Res Triangle Pk, NC 27709 USA. [Zhuo, Xiaohui; Gregg, Edward W.; Albright, Ann L.; Zhang, Ping] CDC, Atlanta, GA 30333 USA. RP Hoerger, TJ (reprint author), RTI Int, 3040 E Cornwallis Rd,POB 12194, Res Triangle Pk, NC 27709 USA. EM tjh@rti.org FU CDC [200-2008-27958] FX This study was supported by contract number 200-2008-27958 from CDC to RTI International. Employees of the study sponsor (CDC) participated in the study as coauthors and thus had roles in study design: collection, analysis, and interpretation of data; report writing; and the decision to submit the report for publication. The manuscript was reviewed by CDC as part of its normal clearance process for scientific papers; the decision to submit the manuscript was made solely by the authors. The findings and conclusions of this study are those of the authors and do not necessarily represent the official position of RTI International or CDC. NR 20 TC 2 Z9 2 U1 2 U2 12 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD APR PY 2015 VL 48 IS 4 BP 419 EP 425 DI 10.1016/j.amepre.2014.11.008 PG 7 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA CD7DM UT WOS:000351251000007 PM 25703178 ER PT J AU Boyer, AE Gallegos-Candela, M Quinn, CP Woolfitt, AR Brumlow, JO Isbell, K Hoffmaster, AR Lins, RC Barr, JR AF Boyer, Anne E. Gallegos-Candela, Maribel Quinn, Conrad P. Woolfitt, Adrian R. Brumlow, Judith O. Isbell, Katherine Hoffmaster, Alex R. Lins, Renato C. Barr, John R. TI High-sensitivity MALDI-TOF MS quantification of anthrax lethal toxin for diagnostics and evaluation of medical countermeasures SO ANALYTICAL AND BIOANALYTICAL CHEMISTRY LA English DT Article DE Anthrax; MALDI-TOFMS; Quantification; Lethal toxin; Lethal factor; Protective antigen; Diagnostic; Bacillus anthracis ID TIME-RESOLVED FLUORESCENCE; PROTECTIVE ANTIGEN PA; INHALATION ANTHRAX; BACILLUS-ANTHRACIS; MASS-SPECTROMETRY; SERUM; RECEPTOR; BINDING; INTERNALIZATION; IMMUNOASSAY AB Inhalation anthrax has a rapid progression and high fatality rate. Pathology and death from inhalation of Bacillus anthracis spores are attributed to the actions of secreted protein toxins. Protective antigen (PA) binds and imports the catalytic component lethal factor (LF), a zinc endoprotease, and edema factor (EF), an adenylyl cyclase, into susceptible cells. PA-LF is termed lethal toxin (LTx) and PA-EF, edema toxin. As the universal transporter for both toxins, PA is an important target for vaccination and immunotherapeutic intervention. However, its quantification has been limited to methods of relatively low analytic sensitivity. Quantification of LTx may be more clinically relevant than LF or PA alone because LTx is the toxic form that acts on cells. A method was developed for LTx-specific quantification in plasma using anti-PA IgG magnetic immunoprecipitation of PA and quantification of LF activity that co-purified with PA. The method was fast (< 4 h total time to detection), sensitive at 0.033 ng/mL LTx in plasma for the fast analysis (0.0075 ng/mL LTx in plasma for an 18 h reaction), precise (6.3-9.9 % coefficient of variation), and accurate (0.1-12.7 %error; n a parts per thousand yenaEuro parts per thousand 25). Diagnostic sensitivity was 100 % (n = 27 animal/clinical cases). Diagnostic specificity was 100 % (n = 141). LTx was detected post-antibiotic treatment in 6/6 treated rhesus macaques and 3/3 clinical cases of inhalation anthrax and as long as 8 days post-treatment. Over the course of infection in two rhesus macaques, LTx was first detected at 0.101 and 0.237 ng/mL at 36 h post-exposure and increased to 1147 and 12,107 ng/mL in late-stage anthrax. This demonstrated the importance of LTx as a diagnostic and therapeutic target. This method provides a sensitive, accurate tool for anthrax toxin detection and evaluation of PA-directed therapeutics. C1 [Boyer, Anne E.; Gallegos-Candela, Maribel; Quinn, Conrad P.; Woolfitt, Adrian R.; Isbell, Katherine; Hoffmaster, Alex R.; Barr, John R.] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. [Brumlow, Judith O.; Lins, Renato C.] Battelle Tech On Site Profess Serv, Atlanta, GA 30329 USA. RP Barr, JR (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. EM jbarr@cdc.gov NR 36 TC 5 Z9 5 U1 0 U2 18 PU SPRINGER HEIDELBERG PI HEIDELBERG PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY SN 1618-2642 EI 1618-2650 J9 ANAL BIOANAL CHEM JI Anal. Bioanal. Chem. PD APR PY 2015 VL 407 IS 10 BP 2847 EP 2858 DI 10.1007/s00216-015-8509-5 PG 12 WC Biochemical Research Methods; Chemistry, Analytical SC Biochemistry & Molecular Biology; Chemistry GA CE0QQ UT WOS:000351509900018 PM 25673244 ER PT J AU Dong, J Porter, DW Batteli, LA Wolfarth, MG Richardson, DL Ma, Q AF Dong, Jie Porter, Dale W. Batteli, Lori A. Wolfarth, Michael G. Richardson, Diana L. Ma, Qiang TI Pathologic and molecular profiling of rapid-onset fibrosis and inflammation induced by multi-walled carbon nanotubes SO ARCHIVES OF TOXICOLOGY LA English DT Article DE Nanotoxicity; Lung fibrosis; Inflammation; Cytokine; Growth factor; Animal model ID IDIOPATHIC PULMONARY-FIBROSIS; COAL-WORKERS PNEUMOCONIOSIS; INHALATION EXPOSURE; SYSTEMIC-SCLEROSIS; FIBROTIC RESPONSE; LUNG-DISEASE; EXPRESSION; PARTICLES; MICE; INTERLEUKIN-6 AB Multi-walled carbon nanotubes (MWCNT) are new materials with a wide range of industrial and commercial applications. However, their nano-scaled size and fiber-like shape render them respirable and potentially fibrogenic if inhaled into the lungs. To understand MWCNT fibrogenesis, we analyzed the pathologic and molecular aspects of the early phase response to MWCNT in mouse lungs. MWCNT induced rapid and pronounced lesions in the lungs characterized by increased cellularity and formation of fibrotic foci, most notably near where MWCNT deposited, within 14 days post-exposure. Deposition of collagen fibers was markedly increased in the alveolar septa and fibrotic foci, accompanied by elevated expression of fibrotic genes Col1a1, Col1a2, and Fn1 at both mRNA and protein levels. Fibrosis was induced rapidly at 40 mu g, wherein fibrotic changes were detected on day 1 and reached a maximal intensity on day 7 through day 14. Induction of fibrosis was dose-dependent at the dose range of 5-40 mu g, 7 days post-exposure. MWCNT elicited rapid and prominent infiltrations of neutrophils and macrophages alongside fibrosis implicating acute inflammation in the fibrotic response. At the molecular level, MWCNT induced elevated expression of proinflammatory cytokines TNF alpha, IL1 alpha, IL1 beta, IL6, and CCL2 in lung tissues as well as the bronchoalveolar lavage fluid, in a dose- and time-dependent manner. MWCNT also increased the expression of fibrogenic growth factors TGF-beta 1 and PDGF-A in the lungs significantly. These findings underscore the interplay between acute inflammation and the early fibrotic response in the initiation and propagation of pulmonary fibrosis induced by MWCNT. C1 [Dong, Jie; Ma, Qiang] NIOSH, Receptor Biol Lab, Toxicol & Mol Biol Branch, Hlth Effects Lab Div,Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. [Porter, Dale W.; Batteli, Lori A.; Wolfarth, Michael G.] NIOSH, Pathol & Physiol Res Branch, Hlth Effects Lab Div, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. [Richardson, Diana L.] NIOSH, Pathol Core, Hlth Effects Lab Div, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. RP Ma, Q (reprint author), NIOSH, Receptor Biol Lab, Toxicol & Mol Biol Branch, Hlth Effects Lab Div,Ctr Dis Control & Prevent, 1095 Willowdale Rd,Mailstop 3014, Morgantown, WV 26505 USA. EM qam1@cdc.gov FU National Institute for Occupational Safety and Health, Health Effects Laboratory Division FX The study was supported by a grant to QM from National Institute for Occupational Safety and Health, Health Effects Laboratory Division. The anti-MBP antibody was kindly offered by Drs. Nancy A. Lee and James J. Lee at Mayo Clinic (Scottsdale, AZ, USA). NR 40 TC 16 Z9 16 U1 1 U2 11 PU SPRINGER HEIDELBERG PI HEIDELBERG PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY SN 0340-5761 EI 1432-0738 J9 ARCH TOXICOL JI Arch. Toxicol. PD APR PY 2015 VL 89 IS 4 BP 621 EP 633 DI 10.1007/s00204-014-1428-y PG 13 WC Toxicology SC Toxicology GA CD5UC UT WOS:000351152600011 PM 25510677 ER PT J AU Tan, XJ Li, L Zhang, BM Jorba, J Su, X Ji, TJ Yang, DJ Lv, LK Li, JM Xu, WB AF Tan, Xiaojuan Li, Li Zhang, Baomin Jorba, Jaume Su, Xu Ji, Tianjiao Yang, Dongjing Lv, Likun Li, Jiameng Xu, Wenbo TI Molecular epidemiology of coxsackievirus A6 associated with outbreaks of hand, foot, and mouth disease in Tianjin, China, in 2013 SO ARCHIVES OF VIROLOGY LA English DT Article ID ENTEROVIRUS 71; MAXIMUM-LIKELIHOOD; PCR AMPLIFICATION; INFECTIONS; IDENTIFICATION; TAIWAN; ONYCHOMADESIS; SUBSTITUTION; CIRCULATION; SEQUENCES AB Since 2008, Mainland China has undergone widespread outbreaks of hand, foot, and mouth disease (HFMD). In order to determine the characteristics of epidemics and enteroviruses (EV) associated with HFMD in Tianjin, in northern China, epidemiological and virological data from routine surveillance were collected and analyzed. In Tianjin, a persistent epidemic of HFMD was demonstrated during 2008-2013, involving 102,705 mild, 179 severe, and 16 fatal cases. Overall, 8234 specimens were collected from 7829 HFMD patients for EV detection during 2008-2013. Enterovirus 71 (EV-A71) and coxsackievirus A16 (CV-A16) were the dominant serotypes during 2008-2012, and they were replaced by CV-A6 as the major causative agent in 2013. Phylogenetic analysis based on complete VP1 nucleotide sequences revealed that multiple CV-A6 lineages co-circulated in Tianjin, which grouped together with strains from China and other countries and split into two distinct clusters (clusters 1 and 2). Most Tianjin strains grouped in cluster 1 and were closely related to strains from several eastern and southern provinces of China during 2012 and 2013. Estimates from Bayesian MCMC analysis suggested that multiple lineages had been transmitted silently before the outbreaks at an estimated evolutionary rate of 4.10 x 10(-3) substitutions per site per year without a specific distribution of rate variances among lineages. The sudden outbreak of CV-A6 in Tianjin during 2013 is attributed to indigenous CV-A6 lineages, which were linked to the wide spread of endemic strains around eastern and southern China. C1 [Tan, Xiaojuan; Zhang, Baomin; Ji, Tianjiao; Xu, Wenbo] Chinese Ctr Dis Control & Prevent, Minist Hlth, Key Lab Med Virol, Inst Viral Dis Control & Prevent, Beijing 102206, Peoples R China. [Li, Li; Su, Xu; Yang, Dongjing; Lv, Likun; Li, Jiameng] Tianjin Municipal Ctr Dis Control & Prevent, Tianjin 300171, Peoples R China. [Jorba, Jaume] Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Xu, WB (reprint author), Chinese Ctr Dis Control & Prevent, Minist Hlth, Key Lab Med Virol, Inst Viral Dis Control & Prevent, 155 Changbai Rd, Beijing 102206, Peoples R China. EM suxu@cdctj.gov.cn; wenbo_xu1@aliyun.com FU Key Technologies Research and Development Program from the Ministry of Science and Technology [2013ZX10004-202, 2012ZX10004201-003]; Tianjin Municipal Center for Disease Control and Prevention [CDCKY1303] FX We appreciate the pediatricians reporting cases to the surveillance system for HFMD in the Tianjin metropolitan area. We thank all the staff members who were responsible for specimen collection and shipment at the CDCs of all districts of Tianjin for their excellent assistance. We also thank Dr. Steve Oberste (CDC, Atlanta) for the revision of this manuscript. This work was supported by grants from the Key Technologies Research and Development Program from the Ministry of Science and Technology (grant numbers: 2013ZX10004-202, 2012ZX10004201-003) and Tianjin Municipal Center for Disease Control and Prevention (Grant number: CDCKY1303). NR 32 TC 10 Z9 17 U1 1 U2 9 PU SPRINGER WIEN PI WIEN PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA SN 0304-8608 EI 1432-8798 J9 ARCH VIROL JI Arch. Virol. PD APR PY 2015 VL 160 IS 4 BP 1097 EP 1104 DI 10.1007/s00705-015-2340-3 PG 8 WC Virology SC Virology GA CE0RW UT WOS:000351514100022 PM 25680566 ER PT J AU Vogtmann, E Flores, R Yu, GQ Freedman, ND Shi, JX Gail, MH Dye, BA Wang, GQ Klepac-Ceraj, V Paster, BJ Wei, WQ Guo, HQ Dawsey, SM Qiao, YL Abnet, CC AF Vogtmann, Emily Flores, Roberto Yu, Guoqin Freedman, Neal D. Shi, Jianxin Gail, Mitchell H. Dye, Bruce A. Wang, Guo-Qing Klepac-Ceraj, Vanja Paster, Bruce J. Wei, Wen-Qiang Guo, Hui-Qin Dawsey, Sanford M. Qiao, You-Lin Abnet, Christian C. TI Association between tobacco use and the upper gastrointestinal microbiome among Chinese men SO CANCER CAUSES & CONTROL LA English DT Article DE China; Microbiome; Tobacco; Upper gastrointestinal tract ID BIOFILM FORMATION; ORAL BACTERIA; SMOKING; PERIODONTITIS; SMOKERS; MICROARRAY; NONSMOKERS; PROFILES; CANCER; ADULTS AB Tobacco causes many adverse health conditions and may alter the upper gastrointestinal (UGI) microbiome. However, the few studies that studied the association between tobacco use and the microbiome were small and underpowered. Therefore, we investigated the association between tobacco use and the UGI microbiome in Chinese men. We included 278 men who underwent esophageal cancer screening in Henan Province, China. Men were categorized as current, former, or never smokers from questionnaire data. UGI tract bacterial cells were characterized using the Human Oral Microbial Identification Microarray. Counts of unique bacterial species and genera estimated alpha diversity. For beta diversity, principal coordinate (PCoA) vectors were generated from an unweighted UniFrac distance matrix. Polytomous logistic regression models were used for most analyses. Of the 278 men in this study, 46.8 % were current smokers and 12.6 % were former smokers. Current smokers tended to have increased alpha diversity (mean 42.3 species) compared to never smokers (mean 38.9 species). For a 10 species increase, the odds ratio (OR) for current smoking was 1.29 (95 % CI 1.04-1.62). Beta diversity was also associated with current smoking. The first two PCoA vectors were strongly associated with current smoking (PCoA1 OR 0.66; 95 % CI 0.51-0.87; PCoA2 OR 0.73; 95 % CI 0.56-0.95). Furthermore, Dialister invisus and Megasphaera micronuciformis were more commonly detected in current smokers than in never smokers. Current smoking was associated with both alpha and beta diversity in the UGI tract. Future work should consider how the UGI microbiome is associated with smoking-related diseases. C1 [Vogtmann, Emily; Yu, Guoqin; Freedman, Neal D.; Shi, Jianxin; Gail, Mitchell H.; Dawsey, Sanford M.; Abnet, Christian C.] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA. [Vogtmann, Emily; Flores, Roberto] NCI, Canc Prevent Div, NIH, Bethesda, MD 20892 USA. [Vogtmann, Emily] NCI, Nutr Epidemiol Branch, DCEG, Bethesda, MD 20892 USA. [Dye, Bruce A.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. [Wang, Guo-Qing; Wei, Wen-Qiang; Guo, Hui-Qin; Qiao, You-Lin] Chinese Acad Med Sci, Inst Canc, Beijing 100021, Peoples R China. [Klepac-Ceraj, Vanja; Paster, Bruce J.] Forsyth Inst, Cambridge, MA USA. [Klepac-Ceraj, Vanja] Wellesley Coll, Wellesley, MA 02181 USA. [Paster, Bruce J.] Harvard Univ, Sch Dent Med, Boston, MA 02115 USA. RP Vogtmann, E (reprint author), NCI, Nutr Epidemiol Branch, DCEG, 9609 Med Ctr Dr,6E404,MSC 9768, Bethesda, MD 20892 USA. EM emily.vogtmann@nih.gov RI Freedman, Neal/B-9741-2015; Abnet, Christian/C-4111-2015; Qiao, You-Lin/B-4139-2012 OI Freedman, Neal/0000-0003-0074-1098; Abnet, Christian/0000-0002-3008-7843; Qiao, You-Lin/0000-0001-6380-0871 FU Intramural Research Program of the National Institutes of Health; Cancer Prevention Fellowship Program of the National Institutes of Health; National Cancer Institute FX We would like to thank the staff in Linzhou, China. This work was supported by the Intramural Research Program and the Cancer Prevention Fellowship Program of the National Institutes of Health and the National Cancer Institute. NR 34 TC 3 Z9 3 U1 1 U2 9 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0957-5243 EI 1573-7225 J9 CANCER CAUSE CONTROL JI Cancer Causes Control PD APR PY 2015 VL 26 IS 4 BP 581 EP 588 DI 10.1007/s10552-015-0535-2 PG 8 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA CE0YG UT WOS:000351536400008 PM 25701246 ER PT J AU Zhuo, XH Zhang, P Kahn, HS Bardenheier, BH Li, R Gregg, EW AF Zhuo, Xiaohui Zhang, Ping Kahn, Henry S. Bardenheier, Barbara H. Li, Rui Gregg, Edward W. TI Change in Medical Spending Attributable to Diabetes: National Data From 1987 to 2011 SO DIABETES CARE LA English DT Article ID UNITED-STATES; GLYCEMIC CONTROL; US ADULTS; LONG-TERM; CARE; COMPLICATIONS; MELLITUS; TRENDS; COST; GROWTH AB OBJECTIVEDiabetes care has changed substantially in the past 2 decades. We examined the change in medical spending and use related to diabetes between 1987 and 2011.RESEARCH DESIGN AND METHODSUsing the 1987 National Medical Expenditure Survey and the Medical Expenditure Panel Surveys in 2000-2001 and 2010-2011, we compared per person medical expenditures and uses among adults 18 years of age with or without diabetes at the three time points. Types of medical services included inpatient care, emergency room (ER) visits, outpatient visits, prescription drugs, and others. We also examined the changes in unit cost, defined by the expenditure per encounter for medical services.RESULTSThe excess medical spending attributed to diabetes was $2,588 (95% CI, $2,265 to $3,104), $4,205 ($3,746 to $4,920), and $5,378 ($5,129 to $5,688) per person, respectively, in 1987, 2000-2001, and 2010-2011. Of the $2,790 increase, prescription medication accounted for 55%; inpatient visits accounted for 24%; outpatient visits accounted for 15%; and ER visits and other medical spending accounted for 6%. The growth in prescription medication spending was due to the increase in both the volume of use and unit cost, whereas the increase in outpatient expenditure was almost entirely driven by more visits. In contrast, the increase in inpatient and ER expenditures was caused by the rise of unit costs.CONCLUSIONSIn the past 2 decades, managing diabetes has become more expensive, mostly due to the higher spending on drugs. Further studies are needed to assess the cost-effectiveness of increased spending on drugs. C1 [Zhuo, Xiaohui; Zhang, Ping; Kahn, Henry S.; Bardenheier, Barbara H.; Li, Rui; Gregg, Edward W.] Ctr Dis Control & Prevent, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Zhuo, XH (reprint author), Ctr Dis Control & Prevent, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM xiaohui.zhuo@gmail.com NR 31 TC 14 Z9 14 U1 1 U2 5 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 EI 1935-5548 J9 DIABETES CARE JI Diabetes Care PD APR PY 2015 VL 38 IS 4 BP 581 EP 587 DI 10.2337/dc14-1687 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CE2FX UT WOS:000351630900019 PM 25592194 ER PT J AU Pastor, PN Reuben, CA Kobau, R Helmers, SL Lukacs, S AF Pastor, Patricia N. Reuben, Cynthia A. Kobau, Rosemarie Helmers, Sandra L. Lukacs, Susan TI Functional difficulties and school limitations of children with epilepsy: Findings from the 2009-2010 National Survey of Children with Special-Health Care Needs SO DISABILITY AND HEALTH JOURNAL LA English DT Article DE Epilepsy; Disability; Comorbid conditions ID NEWLY-DIAGNOSED EPILEPSY; CHILDHOOD EPILEPSY; PEDIATRIC EPILEPSY; YOUNG-CHILDREN; SEIZURE; PSYCHOPATHOLOGY; PERFORMANCE; PREVALENCE; DISABILITY; DISORDERS AB Background: Epilepsy is a common serious neurologic disorder in children. However, most studies of children's functional difficulties and school limitations have used samples from tertiary care or other clinical settings. Objective: To compare functional difficulties and school limitations of a national sample of US children with special health care needs (CSHCN) with and without epilepsy. Methods: Data from the 2009-2010 National Survey of CSHCN for 31,897 children aged 6-17 years with and without epilepsy were analyzed for CSHCN in two groups: 1) CSHCN with selected comorbid conditions (intellectual disability, cerebral palsy, autism, or traumatic brain injury) and 2) CSHCN without these conditions. Functional difficulties and school limitations, adjusted for the effect of sociodemographic characteristics, were examined by epilepsy and comorbid conditions. Results: Three percent of CSHCN had epilepsy. Among CSHCN with epilepsy 53% had comorbid conditions. Overall CSHCN with epilepsy, both with and without comorbid conditions, had more functional difficulties than CSHCN without epilepsy. For example, after adjustment for sociodemographic characteristics a higher percentage of children with epilepsy, compared to children without epilepsy, had difficulty with communication (with conditions: 53% vs. 37%, without conditions: 13% vs. 5%). Results for school limitations were similar. After adjustment, a higher percentage of children with epilepsy, compared to children without epilepsy, missed 11 + school days in the past year (with conditions: 36% vs. 18%, without conditions: 21% vs. 15%). Conclusion: CSHCN with epilepsy, compared to CSHCN without epilepsy, were more likely to have functional difficulties and limitations in school attendance regardless of comorbid conditions. Published by Elsevier Inc. C1 [Pastor, Patricia N.; Reuben, Cynthia A.; Lukacs, Susan] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. [Kobau, Rosemarie] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Helmers, Sandra L.] Emory Univ, Sch Med, Atlanta, GA USA. RP Pastor, PN (reprint author), Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, 3311 Toledo Rd, Hyattsville, MD 20782 USA. EM php3@cdc.gov NR 35 TC 3 Z9 3 U1 1 U2 11 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1936-6574 EI 1876-7583 J9 DISABIL HEALTH J JI Disabil. Health J. PD APR PY 2015 VL 8 IS 2 BP 231 EP 239 DI 10.1016/j.dhjo.2014.09.002 PG 9 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health; Rehabilitation SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Rehabilitation GA CD7YY UT WOS:000351313400011 PM 25312691 ER PT J AU Bruce, MG Bruden, DL Morris, JM Reasonover, AL Sacco, F Hurlburt, D Hennessy, TW Gove, J Parkinson, A Sahagun, G Davis, P Klejka, J Mcmahon, BJ AF Bruce, M. G. Bruden, D. L. Morris, J. M. Reasonover, A. L. Sacco, F. Hurlburt, D. Hennessy, T. W. Gove, J. Parkinson, A. Sahagun, G. Davis, P. Klejka, J. Mcmahon, B. J. TI Reinfection after successful eradication of Helicobacter pylori in three different populations in Alaska SO EPIDEMIOLOGY AND INFECTION LA English DT Article DE Alaska Natives; Helicobacter pylori; indigenous; reinfection ID TERM-FOLLOW-UP; DUODENAL-ULCER; HIGH PREVALENCE; TRIPLE THERAPY; UNITED-STATES; INFECTION; RECURRENCE; WATER; ADULTS; RISK AB We performed a study to determine rates of reinfection in three groups followed for 2 years after successful treatment: American Indian/Alaska Native (AI/AN) persons living in urban (group 1) and rural (group 2) communities, and urban Alaska non-Native persons (group 3). We enrolled adults diagnosed with H. pylori infection based on a positive urea breath test (C-13-UBT). After successful treatment was documented at 2 months, we tested each patient by C-13-UBT at 4, 6, 12 and 24 months. At each visit, participants were asked about medication use, illnesses and risk factors for reinfection. We followed 229 persons for 2 years or until they became reinfected. H. pylori reinfection occurred in 36 persons; cumulative reinfection rates were 14.5%, 22.1%, and 12.0% for groups 1, 2, and 3, respectively. Study participants who became reinfected were more likely to have peptic ulcer disease (P=0.02), low education level (P=0.04), or have a higher proportion of household members infected with H. pylori compared to participants who did not become reinfected (P=0.03). Among all three groups, reinfection occurred at rates higher than those reported for other US populations (< 5% at 2 years); rural AI/AN individuals appear to be at highest risk for reinfection. C1 [Bruce, M. G.; Bruden, D. L.; Morris, J. M.; Reasonover, A. L.; Hurlburt, D.; Hennessy, T. W.; Parkinson, A.; Mcmahon, B. J.] Natl Ctr Emerging Zoonot & Infect Dis, Centers Dis Control & Prevent CDC, Div Preparedness & Emerging Infect, Arct Invest Program, Anchorage, AK 99508 USA. [Sacco, F.; Davis, P.] Alaska Native Med Ctr, Anchorage, AK USA. [Gove, J.; Mcmahon, B. J.] Alaska Native Tribal Hlth Consortium, Div Community Hlth Serv, Liver Dis & Hepatitis Program, Anchorage, AK USA. [Sahagun, G.] Internal Med Associate Inc, Anchorage, AK USA. [Klejka, J.] Yukon Kuskokwim Hlth Corp, Bethel, AK USA. RP Bruce, MG (reprint author), Natl Ctr Emerging Zoonot & Infect Dis, CDC, Div Preparedness & Emerging Infect, Arct Invest Program, Anchorage, AK 99508 USA. EM zwa8@cdc.gov FU Centers for Disease Control and Prevention; North American Research Centers for Health (NARCH) [1 U26 94 00005]; Alaska Science and Technology Foundation FX This study was funded by the Centers for Disease Control and Prevention, a North American Research Centers for Health (NARCH) grant no.: 1 U26 94 00005, and a grant from the Alaska Science and Technology Foundation. NR 36 TC 7 Z9 7 U1 0 U2 2 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0950-2688 EI 1469-4409 J9 EPIDEMIOL INFECT JI Epidemiol. Infect. PD APR PY 2015 VL 143 IS 6 BP 1236 EP 1246 DI 10.1017/S0950268814001770 PG 11 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA CD9JW UT WOS:000351415600014 PM 25068917 ER PT J AU Kostova, D Chaloupka, FJ Shang, C AF Kostova, Deliana Chaloupka, Frank J. Shang, Ce TI A duration analysis of the role of cigarette prices on smoking initiation and cessation in developing countries SO EUROPEAN JOURNAL OF HEALTH ECONOMICS LA English DT Article DE Cigarette prices; Tobacco use; Smoking initiation; Smoking cessation; Duration analysis ID YOUTH SMOKING; QUITTING SMOKING; TOBACCO TAXES; EXCISE; BEHAVIOR; DEMAND AB This study evaluates the impact of cigarette prices on smoking initiation and cessation among adults in two pooled samples of 6 low- to lower-middle income countries (LMICs) and 8 upper-middle income countries (UMICs). We find that, while higher prices reduce smoking across the board, this reduction occurs through different behavioral mechanisms in lower versus higher income countries. Specifically, cigarette prices reduce smoking rates by deterring initiation in LMICs while in UMICs they act primarily by promoting cessation. Because current smoking rates are relatively lower in LMICs and relatively higher in UMICs, this differential mechanism underscores the adaptability of tobacco prices as a tool for regulating tobacco use across countries at different levels of development; it shows that prices can be used to sustain the relatively low rates of smoking in LMICs by preventing entry of new smokers, and can reduce the relatively high rates of smoking in UMICs by encouraging exit of existing smokers. Using split-population duration models and controlling for fixed and time-varying unobserved country characteristics, we estimate that the price elasticity of initiation in LMICs is -0.74 and the price elasticity of cessation in UMICs is 0.51. C1 [Kostova, Deliana] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Chaloupka, Frank J.] Univ Illinois, Dept Econ, Chicago, IL 60680 USA. [Chaloupka, Frank J.; Shang, Ce] Univ Illinois, Inst Hlth Res & Policy, Ctr Hlth Policy, Chicago, IL USA. RP Kostova, D (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. EM kiv0@cdc.gov RI Shang, Ce/L-3617-2016 NR 27 TC 6 Z9 6 U1 3 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1618-7598 EI 1618-7601 J9 EUR J HEALTH ECON JI Eur. J. Health Econ. PD APR PY 2015 VL 16 IS 3 BP 279 EP 288 DI 10.1007/s10198-014-0573-9 PG 10 WC Economics; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA CD9IA UT WOS:000351410500006 PM 24610323 ER PT J AU Grosse, SD Chaugule, SS Hay, JW AF Grosse, Scott D. Chaugule, Shraddha S. Hay, Joel W. TI Estimates of utility weights in hemophilia: implications for cost-utility analysis of clotting factor prophylaxis SO EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH LA English DT Review DE health utilities; hemophilia; prophylaxis; quality-adjusted life-years; quality of life ID QUALITY-OF-LIFE; PREFERENCE-BASED MEASURES; ON-DEMAND TREATMENT; TOOL CHO-KLAT; ECONOMIC-EVALUATION; SECONDARY PROPHYLAXIS; TREATMENT STRATEGIES; CANADIAN HEMOPHILIA; DECISION-MAKING; HEALTH-STATUS AB Estimates of preference-weighted health outcomes or health state utilities are needed to assess improvements in health in terms of quality-adjusted life-years. Gains in quality-adjusted life-years are used to assess the cost-effectiveness of prophylactic use of clotting factor compared with on-demand treatment among people with hemophilia, a congenital bleeding disorder. Published estimates of health utilities for people with hemophilia vary, contributing to uncertainty in the estimates of cost-effectiveness of prophylaxis. Challenges in estimating utility weights for the purpose of evaluating hemophilia treatment include selection bias in observational data, difficulty in adjusting for predictors of health-related quality of life and lack of preference-based data comparing adults with lifetime or primary prophylaxis versus no prophylaxis living within the same country and healthcare system. C1 [Grosse, Scott D.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Chaugule, Shraddha S.; Hay, Joel W.] Univ So Calif, Leonard Schaeffer Ctr Hlth Policy & Econ, Los Angeles, CA 90089 USA. RP Grosse, SD (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd NE,Mail Stop E-64, Atlanta, GA 30333 USA. EM sgrosse@cdc.gov FU Intramural CDC HHS [CC999999] NR 96 TC 1 Z9 1 U1 3 U2 5 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1473-7167 EI 1744-8379 J9 EXPERT REV PHARM OUT JI Expert Rev. Pharmacoecon. Outcomes Res. PD APR PY 2015 VL 15 IS 2 BP 267 EP 283 DI 10.1586/14737167.2015.1001372 PG 17 WC Health Care Sciences & Services; Health Policy & Services; Pharmacology & Pharmacy SC Health Care Sciences & Services; Pharmacology & Pharmacy GA CD6YK UT WOS:000351236700010 PM 25585817 ER PT J AU Taylor, MM Newman, DR Gonzalez, J Skinner, J Khurana, R Mickey, T AF Taylor, M. M. Newman, D. R. Gonzalez, J. Skinner, J. Khurana, R. Mickey, T. TI HIV status and viral loads among men testing positive for rectal gonorrhoea and chlamydia, Maricopa County, Arizona, USA, 2011-2013 SO HIV MEDICINE LA English DT Article DE chlamydia; gonorrhea; HIV aquisition; HIV transmission; HIV; rectal infection; STD; viral load ID UNITED-STATES; INFECTIONS; PREVENTION; SEX AB ObjectivesMen diagnosed with rectal gonorrhoea (GC) and chlamydia (CT) have engaged in unprotected receptive anal intercourse. We reviewed the HIV positivity and HIV viral loads (VLs) of men who had rectal GC and CT testing to evaluate potential HIV acquisition and transmission risk. MethodsRectal GC and CT testing data for men attending the Maricopa County STD clinic during the period from 1 October 2011 to 30 September 2013 were cross-matched with HIV surveillance data to identify men with HIV coinfection. We examined HIV status, HIV diagnosis date, and the values of VL collected nearest to the date of reported rectal infection. ResultsDuring the 2-year time period, 1591 men were tested for rectal GC and CT. Of the men tested, 506 (31.8%) were positive for GC (13.2%), CT (12.2%) or both (6.4%); 119 (23.5%) of those with rectal GC or CT were coinfected with HIV. Among the 275 men with HIV at the time of rectal testing, 54 (19.6%) had no reported VL; 63 (22.9%) had an undetectable VL (<20 HIV-1 RNA copies/mL) and 158 (57.4%) had a detectable VL collected within 1 year of rectal diagnosis. Mean VL was higher among HIV and rectal GC/CT coinfected cases compared with men with HIV alone (174316 vs. 57717copies/mL, respectively; P=0.04). ConclusionsApproximately one-third of men undergoing rectal testing were positive for GC or CT and one-quarter of men with rectal GC or CT also had HIV infection. Of the HIV-infected men tested for rectal GC or CT, more than half had a detectable VL collected near the time of rectal testing, demonstrating a risk for transmitting HIV. C1 [Taylor, M. M.; Newman, D. R.] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. [Taylor, M. M.; Khurana, R.; Mickey, T.] Maricopa Cty Dept Publ Hlth, Phoenix, AZ USA. [Taylor, M. M.] Arizona Dept Hlth Serv, STD Program, Phoenix, AZ 85007 USA. [Gonzalez, J.; Skinner, J.] Arizona Dept Hlth Serv, HIV Surveillance Program, Phoenix, AZ 85007 USA. RP Taylor, MM (reprint author), CDC NCHHSTP DSTDP, 1645 East Roosevelt, Phoenix, AZ 85006 USA. EM mdt7@cdc.gov NR 24 TC 1 Z9 1 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1464-2662 EI 1468-1293 J9 HIV MED JI HIV Med. PD APR PY 2015 VL 16 IS 4 BP 249 EP 254 DI 10.1111/hiv.12192 PG 6 WC Infectious Diseases SC Infectious Diseases GA CD8QD UT WOS:000351359900006 PM 25230929 ER PT J AU Bennett, DH Moran, RE Wu, X Tulve, NS Clifton, MS Colon, M Weathers, W Sjodin, A Jones, R Hertz-Picciotto, I AF Bennett, D. H. Moran, R. E. Wu, X. (May) Tulve, N. S. Clifton, M. S. Colon, M. Weathers, W. Sjoedin, A. Jones, R. Hertz-Picciotto, I. TI Polybrominated diphenyl ether (PBDE) concentrations and resulting exposure in homes in California: relationships among passive air, surface wipe and dust concentrations, and temporal variability SO INDOOR AIR LA English DT Article DE Polybrominated diphenyl ethers; Residential environment; Air concentration; Wipe; Dust; Temporal variability ID PERSISTENT ORGANIC POLLUTANTS; BROMINATED FLAME RETARDANTS; HOUSE-DUST; INDOOR AIR; OUTDOOR AIR; HEXABROMOCYCLODODECANE; MICROENVIRONMENTS; PHOTODEGRADATION; ASSOCIATIONS; PRODUCTS AB Polybrominated diphenyl ethers (PBDEs) are used as flame retardants in furniture foam, electronics, and other home furnishings. A field study was conducted that enrolled 139 households from California, which has had more stringent flame retardant requirements than other countries and areas. The study collected passive air, floor and indoor window surface wipes, and dust samples (investigator collected using an HVS3 and vacuum cleaner) in each home. PentaBDE and BDE209 were detected in the majority of the dust samples and many floor wipe samples, but the detection in air and window wipe samples was relatively low. Concentrations of each PBDE congener in different indoor environmental media were moderately correlated, with correlation coefficients ranging between 0.42 and 0.68. Correlation coefficients with blood levels were up to 0.65 and varied between environmental media and age group. Both investigator-collected dust and floor wipes were correlated with serum levels for a wide range of congeners. These two sample types also had a relatively high fraction of samples with adequate mass for reliable quantification. In 42 homes, PBDE levels measured in the same environmental media in the same home 1year apart were statistically correlated (correlation coefficients: 0.57-0.90), with the exception of BDE209 which was not well correlated longitudinally. C1 [Bennett, D. H.; Moran, R. E.; Wu, X. (May); Hertz-Picciotto, I.] Univ Calif Davis, Dept Publ Hlth Sci, Davis, CA 95616 USA. [Tulve, N. S.; Clifton, M. S.; Colon, M.; Weathers, W.] US EPA, Human Exposure & Atmospher Sci Div, Natl Exposure Res Lab, Off Res & Dev, Res Triangle Pk, NC 27711 USA. [Sjoedin, A.; Jones, R.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. RP Bennett, DH (reprint author), Univ Calif Davis, Dept Publ Hlth Sci, MS1C,One Shields Ave, Davis, CA 95616 USA. EM dhbennett@ucdavis.edu FU United States Environmental Protection Agency through its Office of Research and Development [RD-83154001-0]; International Society of Exposure Analysis Young Investigator Award FX The United States Environmental Protection Agency through its Office of Research and Development partially funded and collaborated in the research described here under STAR Grant # RD-83154001-0 to Irva Hertz-Picciotto. It has been subjected to Agency review and approved for publication. Environmental sample analysis was conducted by the USEPA's Office of Research and Development's National Exposure Research Laboratory. Blood sample analysis was conducted by the Centers for Disease Control and Prevention Laboratory. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. Data analysis was supported by the International Society of Exposure Analysis Young Investigator Award. We thank all our study participants and field staff (Colleen Phillips, Esther Rivera, Amanda Eberle, Robin Joseph, Candice Teague, Elizabeth Marder and Ashley Ratcliffe). NR 40 TC 9 Z9 11 U1 10 U2 68 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0905-6947 EI 1600-0668 J9 INDOOR AIR JI Indoor Air PD APR PY 2015 VL 25 IS 2 BP 220 EP 229 DI 10.1111/ina.12130 PG 10 WC Construction & Building Technology; Engineering, Environmental; Public, Environmental & Occupational Health SC Construction & Building Technology; Engineering; Public, Environmental & Occupational Health GA CD9RZ UT WOS:000351437300009 PM 24832910 ER PT J AU Hartley, S Valley, S Kuhn, L Washer, LL Gandhi, T Meddings, J Chenoweth, C Malani, AN Saint, S Srinivasan, A Flanders, SA AF Hartley, Sarah Valley, Staci Kuhn, Latoya Washer, Laraine L. Gandhi, Tejal Meddings, Jennifer Chenoweth, Carol Malani, Anurag N. Saint, Sanjay Srinivasan, Arjun Flanders, Scott A. TI Overtreatment of Asymptomatic Bacteriuria: Identifying Targets for Improvement SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID URINARY-TRACT-INFECTION; CLINICAL-PRACTICE GUIDELINES; HOSPITALIZED-PATIENTS; DISEASES-SOCIETY; DIAGNOSIS; AMERICA; ADULTS AB Treatment of asymptomatic bacteriuria contributes to antimicrobial overuse in hospitalized patients. Indications for urine culture, treatment, and targets for improvement were evaluated in 153 patients. Drivers of antimicrobial overuse included fever with an alternative source, altered mental status, and leukocytosis, which led 435 excess days of antimicrobial therapy. C1 [Hartley, Sarah; Valley, Staci; Washer, Laraine L.; Gandhi, Tejal; Meddings, Jennifer; Chenoweth, Carol; Saint, Sanjay; Flanders, Scott A.] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA. [Malani, Anurag N.] St Joseph Mercy Hosp, Ann Arbor, MI 48104 USA. [Kuhn, Latoya; Saint, Sanjay] Ann Arbor Vet Affairs Med Ctr, Patient Safety Enhancement Program, Ann Arbor, MI USA. [Kuhn, Latoya; Saint, Sanjay] Ann Arbor Vet Affairs Med Ctr, Hosp Outcomes Program Excellence, Ann Arbor, MI USA. [Washer, Laraine L.] Univ Michigan, Dept Infect Control & Epidemiol, Ann Arbor, MI 48109 USA. [Srinivasan, Arjun] Ctr Dis Control & Prevent, Healthcare Associated Infect Prevent Programs, Div Healthcare Qual Promot, Atlanta, GA USA. RP Hartley, S (reprint author), Univ Michigan Hlth Syst, 1500 E Med Ctr Dr,SPC 5736, Ann Arbor, MI 48109 USA. EM hartsara@med.umich.edu FU CDC Foundation FX Support for this study was provided by the CDC Foundation. NR 11 TC 3 Z9 3 U1 0 U2 3 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0899-823X EI 1559-6834 J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD APR PY 2015 VL 36 IS 4 BP 470 EP 473 DI 10.1017/ice.2014.73 PG 4 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA CE0GQ UT WOS:000351482900016 PM 25782904 ER PT J AU Gardner, LI Marks, G Wilson, TE Giordano, TP Sullivan, M Raper, JL Rodriguez, AE Keruly, J Malitz, F AF Gardner, Lytt I. Marks, Gary Wilson, Tracey E. Giordano, Thomas P. Sullivan, Meg Raper, James L. Rodriguez, Allan E. Keruly, Jeanne Malitz, Faye TI Clinic-wide Intervention Lowers Financial Risk and Improves Revenue to HIV Clinics Through Fewer Missed Primary Care Visits SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE clinic-wide intervention; missed visits; insurance revenue ID EARLY RETENTION AB We calculated the financial impact in 6 HIV clinics of a low-effort retention in care intervention involving brief motivational messages from providers, patient brochures, and posters. We used a linear regression model to calculate absolute changes in kept primary care visits from the preintervention year (2008-2009) to the intervention year (2009-2010). Revenue from patients' insurance was also assessed by clinic. Kept visits improved significantly in the intervention year versus the preintervention year (P < 0.0001). We found a net-positive effect on clinic revenue of +$24,000/year for an average-size clinic (7400 scheduled visits/year). We encourage HIV clinic administrators to consider implementing this low-effort intervention. C1 [Gardner, Lytt I.; Marks, Gary] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Off Infect Dis, Atlanta, GA 30333 USA. [Wilson, Tracey E.] Suny Downstate Med Ctr, Sch Publ Hlth, Dept Community Hlth Sci, Brooklyn, NY 11203 USA. [Giordano, Thomas P.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Giordano, Thomas P.] Michael E DeBakey VA Med Ctr, Dev Ctr Excellence, Houston, TX USA. [Sullivan, Meg] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA. [Raper, James L.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. [Rodriguez, Allan E.] Univ Miami, Miller Sch Med, Div Infect Dis, Miami, FL 33136 USA. [Keruly, Jeanne] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA. [Malitz, Faye] Hlth Resources & Serv Adm, Div Sci & Policy, Rockville, MD USA. RP Gardner, LI (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, MS E-45,1600 Clifton Rd, Atlanta, GA 30333 USA. EM lig0@cdc.gov FU Centers for Disease Control and Prevention [200-2007-23685, 200-2007-23690, 200-2007-23689, 200-2007-23687, 200-2007-23684, 200-2007-23692]; Health Resources and Services Administration FX Supported by the Centers for Disease Control and Prevention Contracts 200-2007-23685 (Baylor College of Medicine), 200-2007-23690 (Boston Medical Center), 200-2007-23689 (Johns Hopkins University School of Medicine), 200-2007-23687 (Research Foundation of the State University of New York, SUNY Downstate Medical Center), 200-2007-23684 (The University of Alabama at Birmingham), and 200-2007-23692 (University of Miami, Miller School of Medicine); and by the Health Resources and Services Administration. NR 16 TC 0 Z9 0 U1 1 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD APR 1 PY 2015 VL 68 IS 4 BP 472 EP 476 PG 5 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CE1RC UT WOS:000351588600020 PM 25559605 ER PT J AU Titchmarsh, L Zeh, C Verpoort, T Allain, JP Lee, H AF Titchmarsh, Logan Zeh, Clement Verpoort, Thierry Allain, Jean-Pierre Lee, Helen TI Leukodepletion as a Point-of-Care Method for Monitoring HIV-1 Viral Load in Whole Blood SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID IMMUNODEFICIENCY-VIRUS TYPE-1; NUCLISENS EASYQ HIV-1; ANTIRETROVIRAL THERAPY; RNA; SPOTS; ASSAY; PLASMA; QUANTIFICATION; AMPLIFICATION; DIAGNOSIS AB In order to limit the interference of HIV-1 cellular nucleic acids in estimating viral load (VL), the feasibility of leukodepletion of a small whole-blood (WB) volume to eliminate only leukocyte cell content was investigated, using a selection of filters. The efficacy of leukocyte filtration was evaluated by counting, CD45 quantitative PCR, and HIV-1 DNA quantification. Plasma HIV-1 was tested by real-time reverse transcription (RT)-PCR. A specific, miniaturized filter was developed and tested for leukocyte and plasma virus retention, WB sample dilution, and filtration parameters in HIV-1-spiked WB samples. This device proved effective to retain >99.9% of white blood cells in 100 mu l of WB without affecting plasma VL. The Samba sample preparation chemistry was adapted to use a leukodepleted WB sample for VL monitoring using the point-of-care Samba-1 semiautomated system. The clinical performance of the assay was evaluated by testing 207 consecutive venous EDTA WB samples from HIV-1-infected patients attending a CD4 testing clinic. Most patients were on antiretroviral treatment (ART), but their VL status was unknown. Compared to the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 test, the new Samba assay had a concordance of 96.5%. The use of the Samba system with a VL test for WB might contribute to HIV-1 ART management and reduce loss-to-follow-up rates in resource-limited settings. C1 [Titchmarsh, Logan; Lee, Helen] Univ Cambridge, Dept Haematol, Diagnost Dev Unit, Cambridge, England. [Zeh, Clement] US Ctr Dis Control & Prevent, HIV Res Branch, Kisumu, Kenya. [Zeh, Clement] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [Verpoort, Thierry] Macopharma, Dept Res & Dev, Tourcoing, France. [Allain, Jean-Pierre] Univ Cambridge, Dept Haematol, Div Transfus Med, Cambridge, England. RP Lee, H (reprint author), Univ Cambridge, Dept Haematol, Diagnost Dev Unit, Cambridge, England. EM hl207@cam.ac.uk FU National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services [HHSN272200800014C, HHSN2722009000028C] FX This project has been funded in part with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under contract no. HHSN272200800014C and HHSN2722009000028C. NR 20 TC 2 Z9 2 U1 0 U2 4 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 EI 1098-660X J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD APR PY 2015 VL 53 IS 4 BP 1080 EP 1086 DI 10.1128/JCM.02853-14 PG 7 WC Microbiology SC Microbiology GA CD8QA UT WOS:000351359500006 PM 25428162 ER PT J AU Nguyen, S Ramos, A Chang, J Li, B Shanmugam, V Boeras, D Nkengasong, JN Yang, CF Ellenberger, D AF Nguyen, Shon Ramos, Artur Chang, Joy Li, Bin Shanmugam, Vedapuri Boeras, Debrah Nkengasong, John N. Yang, Chunfu Ellenberger, Dennis TI Monitoring the Quality of HIV-1 Viral Load Testing through a Proficiency Testing Program Using Dried Tube Specimens in Resource-Limited Settings SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; TYPE-1 RNA; PLASMA; QUANTIFICATION; PANELS AB HIV-1 viral load (VL) levels are used for monitoring disease progression and antiretroviral therapy outcomes in HIV-infected patients. To assess the performance of laboratories conducting HIV-1 VL testing in resource-limited settings, the U.S. Centers for Disease Control and Prevention implemented a voluntary, free-of-charge, external quality assurance program using dried tube specimens (DTSs). Between 2010 and 2012, DTS proficiency testing (PT) panels consisting of 5 specimens were distributed at ambient temperature to participants. The results from the participants (n >= 6) using the same assay were grouped, analyzed, and graded as acceptable within a group mean +/- 3 standard deviations. Mean proficiency scores were calculated by dividing the combined PT scores by the number of testing cycles using a linear regression model. Between 2010 and 2012, the number of participants enrolled increased from 32 in 16 countries to 114 in 44 countries. A total of 78.2% of the participants reported results using 10 different VL assays. The rates of reporting of acceptable results by the participants were 96.6% for the Abbott assay, 96.3% for the Roche Cobas assay, 94.5% for the Roche Amplicor assay, 93.0% for the Biocentric assay, and 89.3% for the NucliSens assay. The overall mean proficiency scores improved over time (P = 0.024). DTSs are a good alternative specimen type to plasma specimens for VL PT programs, as they do not require cold chain transportation and can be used on PCR-based assays. Our data suggest that the CDC HIV-1 VL PT program using DTSs positively impacts the testing performance of the participants, which might translate into better and more accurate VL testing services for patients. C1 [Nguyen, Shon; Ramos, Artur; Chang, Joy; Shanmugam, Vedapuri; Boeras, Debrah; Nkengasong, John N.; Yang, Chunfu; Ellenberger, Dennis] Ctr Dis Control & Prevent, Div Global HIV AIDS, Ctr Global Hlth, Atlanta, GA 30333 USA. [Li, Bin] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV Hepatitis STD & TB Prevent, Atlanta, GA USA. RP Yang, CF (reprint author), Ctr Dis Control & Prevent, Div Global HIV AIDS, Ctr Global Hlth, Atlanta, GA 30333 USA. EM CYang1@cdc.gov FU President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention FX This research has been supported by the President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention. NR 18 TC 5 Z9 5 U1 0 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 EI 1098-660X J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD APR PY 2015 VL 53 IS 4 BP 1129 EP 1136 DI 10.1128/JCM.02780-14 PG 8 WC Microbiology SC Microbiology GA CD8QA UT WOS:000351359500012 PM 25609733 ER PT J AU Kondas, AV Olson, VA Li, Y Abel, J Laker, M Rose, L Wilkins, K Turner, J Kline, R Damon, IK AF Kondas, Ashley V. Olson, Victoria A. Li, Yu Abel, Jason Laker, Miriam Rose, Laura Wilkins, Kimberly Turner, Jonathan Kline, Richard Damon, Inger K. TI Variola Virus-Specific Diagnostic Assays: Characterization, Sensitivity, and Specificity SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID SMALLPOX VACCINATION; ORTHOPOXVIRUS DNA; DIFFERENTIATION; IDENTIFICATION; COMPLICATIONS AB A public health response relies upon rapid and reliable confirmation of disease by diagnostic assays. Here, we detail the design and validation of two variola virus-specific real-time PCR assays, since previous assays cross-reacted with newly identified cowpox viruses. The assay specificity must continually be reassessed as other closely related viruses are identified. C1 [Kondas, Ashley V.; Olson, Victoria A.; Li, Yu; Abel, Jason; Laker, Miriam; Rose, Laura; Wilkins, Kimberly; Turner, Jonathan; Kline, Richard; Damon, Inger K.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. RP Damon, IK (reprint author), Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. EM iad7@cdc.gov FU U.S. Department of Energy; CDC FX This research was supported in part by an appointment to the Research Participation Program at the Centers for Disease Control and Prevention administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the U.S. Department of Energy and CDC. NR 13 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 EI 1098-660X J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD APR PY 2015 VL 53 IS 4 BP 1406 EP 1410 DI 10.1128/JCM.03613-14 PG 5 WC Microbiology SC Microbiology GA CD8QA UT WOS:000351359500060 PM 25673790 ER PT J AU McDade-Montez, E Wallander, J Elliott, M Grunbaum, JA Tortolero, S Cuccaro, P Schuster, MA AF McDade-Montez, Elizabeth Wallander, Jan Elliott, Marc Grunbaum, Jo Anne Tortolero, Susan Cuccaro, Paula Schuster, Mark A. TI TV Viewing, Perceived Similarity, Coviewing, and Mental Well-Being Among African American, Latino, and White Children SO JOURNAL OF EARLY ADOLESCENCE LA English DT Article DE children; media; television; mental health; coviewing; parental mediation ID SELF-PERCEPTION PROFILE; GENERIC CORE SCALES; MEDIA LITERACY; CONCURRENT VALIDITY; PARENTAL MEDIATION; ESTEEM SCALE; ADOLESCENTS; TELEVISION; HEALTH; RELIABILITY AB Research among adults has demonstrated concurrent and prospective negative associations between TV viewing and mental health, yet little research has examined these associations among African American and Latino youth or examined the role of children's involvement with TV and parental mediation of TV viewing via coviewing. The purpose of the present study is to examine associations between TV viewing, perceived similarity, and coviewing and mental well-being in African American, Latino, and White children. Results from Healthy Passages, a study of 4,824 African American (30%), Latino (47%), and White (23%) fifth graders, indicated that TV viewing and perceived similarity were negatively associated with mental well-being among most groups of children, and coviewing was positively associated with mental well-being among Latinos. This study extends findings from adult research on media exposure and mental well-being into a diverse sample of fifth graders and illuminates the role of perceived similarity and coviewing. C1 [McDade-Montez, Elizabeth] Univ Calif, Merced, CA USA. [Wallander, Jan] Univ Calif, Psychol Sci, Merced, CA USA. [Elliott, Marc] RAND Corp, Santa Monica, CA USA. [Grunbaum, Jo Anne] Ctr Dis Control, Atlanta, GA 30333 USA. [Tortolero, Susan; Cuccaro, Paula] Univ Texas Sch Publ Hlth, Ctr Hlth Promot & Prevent Res, Houston, TX USA. [Schuster, Mark A.] Harvard Univ, Sch Med, Pediat, Boston, MA USA. RP McDade-Montez, E (reprint author), ETR Associates, 4 Carbonero Way, Scotts Valley, CA 95066 USA. EM liz.mcdade@gmail.com RI Dey, Kamalesh/E-6568-2017; OI Cuccaro, Paula/0000-0002-9551-4789 FU Centers for Disease Control and Prevention (CDC) [U19DP002663, U19DP002664, U19DP002665] FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was funded through cooperative agreements (U19DP002663, U19DP002664, and U19DP002665) from the Centers for Disease Control and Prevention (CDC). The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC. NR 51 TC 2 Z9 2 U1 5 U2 16 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0272-4316 EI 1552-5449 J9 J EARLY ADOLESCENCE JI J. Early Adolesc. PD APR PY 2015 VL 35 IS 3 BP 329 EP 352 DI 10.1177/0272431614531655 PG 24 WC Family Studies; Psychology, Developmental SC Family Studies; Psychology GA CD7BH UT WOS:000351244700005 ER PT J AU Treadwell, MJ Anie, KA Grant, AM Ofori-Acquah, SF Ohene-Frempong, K AF Treadwell, Marsha J. Anie, Kofi A. Grant, Althea M. Ofori-Acquah, Solomon F. Ohene-Frempong, Kwaku TI Using Formative Research to Develop a Counselor Training Program for Newborn Screening in Ghana SO JOURNAL OF GENETIC COUNSELING LA English DT Article DE Genetic counseling; newborn infant screening; formative research; counselor training; sickle cell disease; Ghana ID SICKLE-CELL-DISEASE; CRITICAL INCIDENT TECHNIQUE; CHILDHOOD MORTALITY; CHILDREN; AFRICA; ANEMIA; HEALTH; PERSPECTIVE; UNIVERSITY; QUALITY AB Sickle cell disease (SCD), sickle cell trait (SCT) and related conditions are highly prevalent in sub-Saharan Africa. Despite the public health implications, there is limited understanding of the unique needs regarding establishing and implementing extensive screening for newborns and appropriate family counseling. We sought to gain understanding of community attitudes and beliefs about SCD/SCT from counselors and potential counselors in Ghana; obtain their input about goals for counseling following newborn screening; and obtain guidance about developing effective counselor education. Five focus groups with 32 health care providers and health educators from 9 of 10 regions in Ghana were conducted by trained facilitators according to a structured protocol. Qualitative data were coded and categorized to reflect common themes. Saturation was achieved in themes related to genetics/inheritance; common complications of SCD; potential for stigmatization; marital strain; and emotional stress. Misconceptions about SCT as a form of SCD were prevalent as were cultural and spiritual beliefs about the causes of SCD/SCT. Potential positive aspects included affected children's academic achievement as compensation for physical limitations, and family cohesion. This data informed recommendations for content and structure of a counselor training program that was provided to the Ministry of Health in Ghana. C1 [Treadwell, Marsha J.] UCSF Benioff Childrens Hosp Oakland, Hematol Oncol Dept, Oakland, CA 94609 USA. [Anie, Kofi A.] Natl Hlth Serv NHS Trust, Haematol & Sickle Cell Ctr, North West London Hosp, London NW10 7NS, England. [Grant, Althea M.] Ctr Dis Control & Prevent, Epidemiol & Surveillance Branch, Natl Ctr Birth Defects & Dev Disabil, Div Blood Disorders, Atlanta, GA 30333 USA. [Ofori-Acquah, Solomon F.] Univ Pittsburgh, Ctr Translat & Int Hematol, Vasc Med Inst, Pittsburgh, PA 15262 USA. [Ohene-Frempong, Kwaku] Sickle Cell Fdn Ghana, Kumasi, Ghana. RP Treadwell, MJ (reprint author), UCSF Benioff Childrens Hosp Oakland, Hematol Oncol Dept, 747 52nd St, Oakland, CA 94609 USA. EM mtreadwell@mail.cho.org; kofi.anie@nhs.net; agrant@cdc.gov; sfo2@pitt.edu; ohene@sicklecellghana.org FU National Center for Research Resources, a component of the National Institutes of Health (NIH, USA) [UL 1RR024131]; NIH Roadmap for Medical Research FX This study was made possible by Grant Number UL 1RR024131 from the National Center for Research Resources, a component of the National Institutes of Health (NIH, USA) and NIH Roadmap for Medical Research. The authors wish to thank the Sickle Cell Foundation of Ghana, the Ghana Health Service and Ministry of Health of Ghana, UCSF Benioff Children's Hospital Oakland (USA), the North West London Hospitals (NHS) Trust (UK), Mr. Edward Tettey, Mrs. Mary Lamptey, Mrs. Mabel Asafo, Mr. Gregory Miller, Ms. Kimpreet Kaur, Ms. Hannah Grocott, Mr. John Nides, Ms. Natasha Dean, Jemima Dennis-Antwi, PhD and the focus group participants, for their invaluable contributions to the research. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 43 TC 2 Z9 2 U1 2 U2 6 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1059-7700 EI 1573-3599 J9 J GENET COUNS JI J. Genet. Couns. PD APR PY 2015 VL 24 IS 2 BP 267 EP 277 DI 10.1007/s10897-014-9759-7 PG 11 WC Genetics & Heredity SC Genetics & Heredity GA CE0UK UT WOS:000351522500009 PM 25193810 ER PT J AU Kambhampati, A Koopmans, M Lopman, BA AF Kambhampati, A. Koopmans, M. Lopman, B. A. TI Burden of norovirus in healthcare facilities and strategies for outbreak control SO JOURNAL OF HOSPITAL INFECTION LA English DT Article DE Antiviral agents; Gastroenteritis; Genogroup II type 4; Infection control; Norovirus ID VIRUS-LIKE PARTICLES; UNITED-STATES; VACCINE DEVELOPMENT; NORWALK VIRUS; ACUTE GASTROENTERITIS; IMMUNOCOMPROMISED PATIENTS; NOSOCOMIAL TRANSMISSION; INFECTION-CONTROL; EXCESS MORTALITY; CLINICAL IMPACT AB Norovirus is the most frequently occurring cause of community-acquired acute gastroenteritis in people of all ages. It is also one of the most frequent causes of outbreaks in healthcare settings, affecting both long-term care facilities and acute care hospitals. Whereas norovirus gastroenteritis is typically mild and resolves without medical attention, healthcare-associated infections often affect vulnerable populations, resulting in severe infections and disruption of healthcare services. Globally, most norovirus outbreaks in hospitals and residential care institutions are associated with genogroup II type 4 (GII.4) strains. Recent data demonstrate that excess mortality occurs during outbreak periods in healthcare facilities. Nosocomial outbreaks can result in large economic and societal costs. Current control measures for norovirus are largely based on general infection control principles, and treatment is mainly supportive and non-specific. While neither vaccines nor antiviral agents are currently available, both are being developed with encouraging results. Published by Elsevier Ltd on behalf of the Healthcare Infection Society. C1 [Kambhampati, A.; Lopman, B. A.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Koopmans, M.] Natl Inst Publ Hlth & Environm, NL-3720 BA Bilthoven, Netherlands. [Koopmans, M.] Erasmus MC, Dept Virol, Rotterdam, Netherlands. RP Lopman, BA (reprint author), 1600 Clifton Rd,MS A34, Atlanta, GA 30333 USA. EM blopman@cdc.gov FU US Department of Energy; CDC FX This research was supported in part by an appointment to the Research Participation Program at the Centers for Disease Control and Prevention administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the US Department of Energy and CDC. NR 79 TC 12 Z9 14 U1 5 U2 39 PU W B SAUNDERS CO LTD PI LONDON PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND SN 0195-6701 EI 1532-2939 J9 J HOSP INFECT JI J. Hosp. Infect. PD APR PY 2015 VL 89 IS 4 BP 296 EP 301 DI 10.1016/j.jhin.2015.01.011 PG 6 WC Infectious Diseases SC Infectious Diseases GA CE5FV UT WOS:000351857400015 PM 25726433 ER PT J AU Ostergaard, SD Butler, K Ritter, JM Johnson, R Sanders, J Powell, N Lathrop, G Zaki, SR McNicholl, JM Kersh, EN AF Ostergaard, Sharon Dietz Butler, Katherine Ritter, Jana M. Johnson, Ryan Sanders, Jeanine Powell, Nathaniel Lathrop, George Zaki, Sherif R. McNicholl, Janet M. Kersh, Ellen N. TI A combined oral contraceptive affects mucosal SHIV susceptibility factors in a pigtail macaque (Macaca nemestrina) model SO JOURNAL OF MEDICAL PRIMATOLOGY LA English DT Article DE contraception; non-human primate (NHP); SHIV; susceptibility; transmission risk ID DEPOT-MEDROXYPROGESTERONE ACETATE; MENSTRUAL-CYCLE; HORMONAL CONTRACEPTIVES; VAGINAL EPITHELIUM; HIV ACQUISITION; CYNOMOLGUS MONKEYS; RHESUS-MONKEYS; PILL USE; WOMEN; TRANSMISSION AB BackgroundInjectable hormonal contraception may increase women's risk of HIV acquisition and can affect biological risk factors in animal models of HIV. We established, for the first time, a model to investigate whether combined oral contraceptives (COC) alter SHIV susceptibility in macaques. MethodsSeven pigtail macaques were administered a monophasic levonorgestrel (LNG)/ethinyl estradiol (EE) COC at 33% or 66% of the human dose for 60days. Menstrual cycling, vaginal epithelial thickness, and other SHIV susceptibility factors were monitored for a mean of 18weeks. ResultsMean vaginal epithelial thicknesses were 290.8m at baseline and 186.2m during COC (P=0.0141, Mann-Whitney U-test). Vaginal pH decreased from 8.5 during treatment to 6.5 post-treatment (0.0176 two-tailed t-test). Measured microflora was unchanged. ConclusionsCOC caused thinning of the vaginal epithelium and vaginal pH changes, which may increase SHIV susceptibility. 0.033mg LNG+.0066mg EE appeared effective in suppressing ovulation. C1 [Ostergaard, Sharon Dietz; Johnson, Ryan; Powell, Nathaniel; Lathrop, George] CDC, Anim Resources Branch, Div Sci Resources, Natl Ctr Emerging Zoonot & Infect Dis, Atlanta, GA 30333 USA. [Butler, Katherine; McNicholl, Janet M.; Kersh, Ellen N.] CDC, Branch Lab, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis Sexually Transm, Atlanta, GA 30333 USA. [Ritter, Jana M.; Sanders, Jeanine; Zaki, Sherif R.] CDC, Infect Dis Pathol Branch, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. RP Kersh, EN (reprint author), 1600 Clifton Rd NE MS A25, Atlanta, GA 30333 USA. EM ekersh@cdc.gov FU CDC [Y1-A1-0681-02] FX We would like to thank Brianna Skinner, Yvonne Reed, David Garber, James Mitchell, Shannon Ellis, Julian Jolly, and the Animal Resources Branch care staff for all of their help and support with this research project. An additional thanks to Toni Zeigler and Amita Kapoor at the Wisconsin National Primate Research Center for providing the LNG/EE assays. This work was funded by CDC and an interagency agreement (Y1-A1-0681-02) between CDC and NIH. NR 40 TC 3 Z9 3 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0047-2565 EI 1600-0684 J9 J MED PRIMATOL JI J. Med. Primatol. PD APR PY 2015 VL 44 IS 2 BP 97 EP 107 DI 10.1111/jmp.12157 PG 11 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA CD5ZP UT WOS:000351168000006 ER PT J AU Tang, L Lyles, RH King, CC Hogan, JW Lo, YT AF Tang, Li Lyles, Robert H. King, Caroline C. Hogan, Joseph W. Lo, Yungtai TI Regression analysis for differentially misclassified correlated binary outcomes SO JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES C-APPLIED STATISTICS LA English DT Article DE Bias; Differential misclassification; Non-linear mixed model; Validation ID LINEAR MIXED MODELS; LOGISTIC-REGRESSION; RELATIVE RISK; PREDICTIVE-VALUE; ODDS RATIOS; VALIDATION; INFERENCE; SUBJECT; BIAS AB In many epidemiological and clinical studies, misclassification may arise in one or several variables, resulting in potentially invalid analytic results (e.g. estimates of odds ratios of interest) when no correction is made. Here we consider the situation in which correlated binary response variables are subject to misclassification. Building on prior work, we provide an approach to adjust for potentially complex differential misclassification via internal validation sampling applied at multiple study time points. We seek to estimate the parameters of a primary generalized linear mixed model that accounts for baseline and/or time-dependent covariates. The misclassification process is modelled via a second generalized linear model that captures variations in sensitivity and specificity parameters according to time and a set of subject-specific covariates that may or may not overlap with those in the primary model. Simulation studies demonstrate the precision and validity of the method proposed. An application is presented based on longitudinal assessments of bacterial vaginosis conducted in the HIV epidemiology research' study. C1 [Tang, Li] St Jude Childrens Res Hosp, Memphis, TN 38105 USA. [Lyles, Robert H.] Emory Univ, Atlanta, GA 30322 USA. [King, Caroline C.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Hogan, Joseph W.] Brown Univ, Providence, RI 02912 USA. [Lo, Yungtai] Albert Einstein Coll Med, New York, NY USA. RP Tang, L (reprint author), St Jude Childrens Res Hosp, Dept Biostat, 262 Danny Thomas Pl, Memphis, TN 38105 USA. EM li.tang@stjude.org OI Hogan, Joseph/0000-0001-7959-7361 FU National Institute of Nursing Research [1RC4NR012527-01]; National Institute of Environmental Health Sciences [5R01 ES012458-07]; National Center for Advancing Translational Sciences [UL1TR000454]; Centers for Disease Control and Prevention [U64/CCU106795, U64/CCU206798, U64/CCU306802, U64/CCU506831] FX This research was supported in part by grants from the National Institute of Nursing Research (1RC4NR012527-01), the National Institute of Environmental Health Sciences (5R01 ES012458-07) and the National Center for Advancing Translational Sciences (UL1TR000454). The HER study was supported by the Centers for Disease Control and Prevention: grants U64/CCU106795, U64/CCU206798, U64/CCU306802 and U64/CCU506831. The content is solely the responsibility of the authors and does not necessarily represent the official position of the National Institutes of Health or the Centers for Disease Control and Prevention. The authors especially thank the participants of the HER study and the Study Research Group. The HER Study Research Group consists of Robert S. Klein, MD, Ellie Schoenbaum, MD, Julia Arnsten, MD, MPH, Robert D. Burk, MD, Chee Jen Chang, PhD, Penelope Demas, PhD, and Andrea Howard, MD, MSc, from Montefiore Medical Center and the Albert Einstein College of Medicine, Paula Schuman, MD, and Jack Sobel, MD, from the Wayne State University School of Medicine, Anne Rompalo, MD, David Vlahov, PhD, and David Celentano, PhD, from the Johns Hopkins University School of Medicine, Charles Carpenter, MD, and Kenneth Mayer, MD, from the Brown University School of Medicine, Ann Duerr, MD, Caroline C. King, PhD, Lytt I. Gardner, PhD, Charles M. Heilig, PhD, Scott Holmberg, MD, Denise Jamieson, MD, Jan Moore, PhD, Ruby Phelps, BS, Dawn Smith, MD, and Dora Warren, PhD, from the Centers for Disease Control and Prevention, and Katherine Davenny, PhD, from the National Institute of Drug Abuse. NR 31 TC 1 Z9 1 U1 2 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0035-9254 EI 1467-9876 J9 J R STAT SOC C-APPL JI J. R. Stat. Soc. Ser. C-Appl. Stat. PD APR PY 2015 VL 64 IS 3 BP 433 EP 449 DI 10.1111/rssc.12081 PG 17 WC Statistics & Probability SC Mathematics GA CD4MD UT WOS:000351056000002 PM 26005223 ER PT J AU de Ravello, L Folkema, A Tulloch, S Taylor, M Reilley, B Hoover, K Holman, R Creanga, A AF de Ravello, Lori Folkema, Arianne Tulloch, Scott Taylor, Melanie Reilley, Brigg Hoover, Karen Holman, Robert Creanga, Andreea TI Ectopic Pregnancy Among American Indian and Alaska Native Women, 2002-2009 SO MATERNAL AND CHILD HEALTH JOURNAL LA English DT Article DE Ectopic pregnancy; North American Indians ID UNITED-STATES; TRENDS; PEOPLE AB To examine rates of ectopic pregnancy (EP) among American Indian and Alaska Native (AI/AN) women aged 15-44 years seeking care at Indian Health Service (IHS), Tribal, and urban Indian health facilities during 2002-2009. We used 2002-2009 inpatient and outpatient data from the IHS National Patient Information Reporting System to identify EP-associated visits and obtain the number of pregnancies among AI/AN women. Repeat visits for the same EP were determined by calculating the interval between visits; if more than 90 days between visits, the visit was considered related to a new EP. We identified 229,986 pregnancies among AI/AN women 15-44 years receiving care at IHS-affiliated facilities during 2002-2009. Of these, 2,406 (1.05 %) were coded as EPs, corresponding to an average annual rate of 10.5 per 1,000 pregnancies. The EP rate among AI/AN women was lowest in the 15-19 years age group (5.5 EPs per 1,000 pregnancies) and highest among 35-39 year olds (18.7 EPs per 1,000 pregnancies). EP rates varied by geographic region, ranging between 6.9 and 24.4 per 1,000 pregnancies in the Northern Plains East and the East region, respectively. The percentage of ectopic pregnancies found among AI/AN women is within the national 1-2 % range. We found relatively stable annual rates of EP among AI/AN women receiving care at IHS-affiliated facilities during 2002-2009, but considerable variation by age group and geographic region. Coupling timely diagnosis and management with public health interventions focused on tobacco use and sexually transmitted diseases may provide opportunities for reducing EP and EP-associated complications among AI/AN women. C1 [de Ravello, Lori; Creanga, Andreea] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Folkema, Arianne; Holman, Robert] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Tulloch, Scott; Hoover, Karen] Ctr Dis Control & Prevent, Div Sexually Transmitted Dis Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Taylor, Melanie] Ctr Dis Control & Prevent, Div Sexually Transmitted Dis Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Phoenix, AZ 85006 USA. [Reilley, Brigg] Indian Hlth Serv, HIV AIDS Prevent Program, Div Epidemiol & Dis Prevent, Albuquerque, NM 87110 USA. RP de Ravello, L (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway NE MS F-74, Atlanta, GA 30341 USA. EM leb8@cdc.gov; AFolkema@regionofwaterloo.ca; sdt2@cdc.gov; mdt7@cdc.gov; Brigg.reilley@ihs.gov; ffw6@cdc.gov; rch1@cdc.gov; igb4@cdc.gov FU Intramural CDC HHS [CC999999] NR 40 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1092-7875 EI 1573-6628 J9 MATERN CHILD HLTH J JI Matern. Child Health J. PD APR PY 2015 VL 19 IS 4 BP 733 EP 738 DI 10.1007/s10995-014-1558-0 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CD5PR UT WOS:000351140800005 PM 25023759 ER PT J AU Cannon, MJ Guo, J Denny, CH Green, PP Miracle, H Sniezek, JE Floyd, RL AF Cannon, Michael J. Guo, Jing Denny, Clark H. Green, Patricia P. Miracle, Heidi Sniezek, Joseph E. Floyd, R. Louise TI Prevalence and Characteristics of Women at Risk for an Alcohol-Exposed Pregnancy (AEP) in the United States: Estimates from the National Survey of Family Growth SO MATERNAL AND CHILD HEALTH JOURNAL LA English DT Article DE Pregnancy; Alcohol-induced disorders; Fetal alcohol syndrome ID BINGE DRINKING; SPECTRUM DISORDERS; SCHOOL; CARE; AGE AB Non-pregnant women can avoid alcohol-exposed pregnancies (AEPs) by modifying drinking and/or contraceptive practices. The purpose of this study was to estimate the number and characteristics of women in the United States who are at risk of AEPs. We analyzed data from in-person interviews obtained from a national probability sample (i.e., the National Survey of Family Growth) of reproductive-aged women conducted from January 2002 to March 2003. To be at risk of AEP, a woman had to have met the following criteria in the last month: (1) was drinking; (2) had vaginal intercourse with a man; and (3) did not use contraception. During a 1-month period, nearly 2 million U.S. women were at risk of an AEP (95 % confidence interval 1,760,079-2,288,104), including more than 600,000 who were binge drinking. Thus, 3.4 %, or 1 in 30, of all non-pregnant women were at risk of an AEP. Most demographic and behavioral characteristics were not clearly associated with AEP risk. However, pregnancy intention was strongly associated with AEP risk (prevalence ratio = 12.0, P < 0.001) because women often continued to drink even after they stopped using contraception. Nearly 2 million U.S. women are at AEP risk and therefore at risk of having children born with fetal alcohol spectrum disorders. For pregnant women and women intending a pregnancy, there is an urgent need for wider implementation of prevention programs and policy approaches that can reduce the risk for this serious public health problem. C1 [Cannon, Michael J.; Guo, Jing; Denny, Clark H.; Green, Patricia P.; Miracle, Heidi; Sniezek, Joseph E.; Floyd, R. Louise] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. RP Cannon, MJ (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd NE,Mailstop E-86, Atlanta, GA 30333 USA. EM mcannon@cdc.gov FU Intramural CDC HHS [CC999999] NR 23 TC 3 Z9 3 U1 1 U2 9 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1092-7875 EI 1573-6628 J9 MATERN CHILD HLTH J JI Matern. Child Health J. PD APR PY 2015 VL 19 IS 4 BP 776 EP 782 DI 10.1007/s10995-014-1563-3 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CD5PR UT WOS:000351140800010 PM 24996954 ER PT J AU Nerlander, LM Callaghan, WM Smith, RA Barfield, WD AF Nerlander, Lina M. Callaghan, William M. Smith, Ruben A. Barfield, Wanda D. TI Short Interpregnancy Interval Associated with Preterm Birth in US Adolescents SO MATERNAL AND CHILD HEALTH JOURNAL LA English DT Article DE Interpregnancy interval; Preterm birth; Teen pregnancy; Birth intervals; Premature birth; Pregnancy in adolescence; Contraception; Rapid repeat pregnancy ID ACTING REVERSIBLE CONTRACEPTION; RAPID-REPEAT PREGNANCY; RACIAL DISPARITIES; PERINATAL OUTCOMES; INFANT-MORTALITY; TEENAGE MOTHERS; UNITED-STATES; RISK; METAANALYSIS; WEIGHT AB A short interpregnancy interval (IPI) is a risk factor for preterm delivery among women of reproductive age. As limited data exist concerning adolescents, we aimed to examine the association between short IPIs and preterm birth among adolescents using a majority of US births. Using 2007-2008 US natality data, we assessed the relationship between IPIs < 3, 3-5, 6-11, and 12-17 months and moderately (32-36 weeks) and very (< 32 weeks) preterm singleton live births among mothers < 20 years, relative to IPIs 18-23 months. Adjusted odds ratios (aORs) and 95 % confidence intervals (95 % CIs) adjusted for maternal race, age, previous preterm deliveries, marital status, smoking and prenatal care were determined from a multivariable multinomial logistic regression model. In 2007-2008, there were 85,077 singleton live births to women aged < 20 who had one previous live birth, 69 % of which followed IPIs a parts per thousand currency sign18 months. Compared with IPIs 18-23 months, short IPIs were associated with moderately preterm birth for IPIs < 3 months (aOR 1.89, 95 % CI 1.70-2.10), 3-5 months (aOR 1.33, 95 % CI 1.22-1.47), and 6-12 months (aOR 1.11, 95 % CI 1.02-1.21). IPIs < 3 and < 6 months were also associated with very preterm birth, with aORs of 2.52 (95 % CI 1.98-3.22) and 1.68 (95 % CI 1.35-2.10) respectively. Many adolescent mothers with repeat births have short IPIs, and shorter IPIs are associated with preterm birth in a dose-dependent fashion. Increasing adolescent mothers' use of effective contraception postpartum can address both unintended adolescent births and preterm birth. C1 [Nerlander, Lina M.; Callaghan, William M.; Smith, Ruben A.; Barfield, Wanda D.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30333 USA. [Nerlander, Lina M.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. [Nerlander, Lina M.; Smith, Ruben A.; Barfield, Wanda D.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP Nerlander, LM (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, 1600 Clifton Rd,MS-E46, Atlanta, GA 30333 USA. EM LNerlander@cdc.gov; WCallaghan@cdc.gov; RASmith@cdc.gov; WBarfield@cdc.gov NR 39 TC 4 Z9 5 U1 0 U2 5 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1092-7875 EI 1573-6628 J9 MATERN CHILD HLTH J JI Matern. Child Health J. PD APR PY 2015 VL 19 IS 4 BP 850 EP 858 DI 10.1007/s10995-014-1583-z PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CD5PR UT WOS:000351140800018 PM 25062997 ER PT J AU Hawkins, PA Chochua, S Jackson, D Beall, B McGee, L AF Hawkins, Paulina A. Chochua, Sopio Jackson, Delois Beall, Bernard McGee, Lesley TI Mobile Elements and Chromosomal Changes Associated with MLS Resistance Phenotypes of Invasive Pneumococci Recovered in the United States SO MICROBIAL DRUG RESISTANCE LA English DT Article ID 23S RIBOSOMAL-RNA; STREPTOCOCCUS-PNEUMONIAE ISOLATE; IN-VITRO ACTIVITIES; MACROLIDE RESISTANCE; CONJUGATE VACCINE; QUINUPRISTIN-DALFOPRISTIN; ANTIBACTERIAL SUSCEPTIBILITY; ANTIMICROBIAL RESISTANCE; ERYTHROMYCIN RESISTANCE; PROTEKT 1999-2000 AB Pneumococcal macrolide resistance is usually expressed as one of two phenotypes: the M phenotype conferred by the mef gene or the MLSB phenotype caused by modification of ribosomal targets, most commonly mediated by an erm methylase. Target-site modification leading to antibiotic resistance can also occur due to sequence mutations within the 23S rRNA or the L4 and L22 riboproteins. We screened 4,535 invasive isolates resistant to erythromycin and 18 invasive isolates nonsusceptible to quinupristin-dalfopristin (Q-D) to deduce the potential mechanisms involved. Of 4,535 erythromycin-resistant isolates, 66.2% were polymerase chain reaction (PCR)-positive for mef alone, 17.8% for ermB alone, and 15.1% for both mef and ermB. Thirty-seven isolates (0.9%) were PCR negative for both determinants. Of these, 3 were positive for ermA (subclass ermTR) and 25 had chromosomal mutations. No chromosomal mutations (in 23S rRNA, rplD, or rplV) nor any of the macrolides/lincosamides/streptogramin (MLS) resistance genes screened for (ermT, ermA, cfr, lsaC, and vgaA) were found in the remaining nine isolates. Of 18 Q-D nonsusceptible isolates, 14 had chromosomal mutations and one carried both mef and ermB; no chromosomal mutations or other resistance genes were found in 3 isolates. Overall, we found 28 mutations, 13 of which have not been previously described in Streptococcus pneumoniae. The role of these mutations remains to be confirmed by transformation assays. C1 [Hawkins, Paulina A.; Chochua, Sopio] Emory Univ, Rollins Sch Publ Hlth, Hubert Dept Global Hlth, Atlanta, GA 30322 USA. [Jackson, Delois; Beall, Bernard; McGee, Lesley] Ctr Dis Control & Prevent, Resp Dis Branch, Atlanta, GA 30329 USA. RP McGee, L (reprint author), Ctr Dis Control & Prevent, Resp Dis Branch, 1600 Clifton Rd, Atlanta, GA 30329 USA. EM lmcgee@cdc.gov NR 57 TC 7 Z9 7 U1 0 U2 3 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1076-6294 EI 1931-8448 J9 MICROB DRUG RESIST JI Microb. Drug Resist. PD APR 1 PY 2015 VL 21 IS 2 BP 121 EP 129 DI 10.1089/mdr.2014.0086 PG 9 WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy GA CE5BD UT WOS:000351843800001 PM 25115711 ER PT J AU Deputy, NP Sharma, AJ Kim, SY Hinkle, SN AF Deputy, Nicholas P. Sharma, Andrea J. Kim, Shin Y. Hinkle, Stefanie N. TI Prevalence and Characteristics Associated With Gestational Weight Gain Adequacy SO OBSTETRICS AND GYNECOLOGY LA English DT Article ID BIRTH-WEIGHT; RACIAL-DIFFERENCES; PREGNANCY; PREPREGNANCY; HEALTH; INADEQUATE; EXERCISE; WOMEN; RISK AB OBJECTIVE: To estimate the prevalence of gestational weight gain adequacy according to the 2009 Institute of Medicine recommendations and examine demographic, behavioral, psychosocial, and medical characteristics associated with inadequate and excessive gain stratified by prepregnancy body mass index (BMI) category. METHODS: We used cross-sectional, population-based data on women delivering full-term (37 weeks of gestation or greater), singleton neonates in 28 states who participated in the 2010 or 2011 Pregnancy Risk Assessment Monitoring System. We estimated adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for inadequate and excessive compared with adequate gain, stratified by prepregnancy BMI. RESULTS: Overall, 20.9%, 32.0%, and 47.2% of women gained inadequate, adequate, and excessive gestational weight, respectively. Prepregnancy BMI was strongly associated with weight gain outside recommendations. Compared with normal-weight women (prevalence 51.8%), underweight women (4.2%) had decreased odds of excessive gain (adjusted OR 0.50, CI 0.40-0.61), whereas overweight and obese class I, II, and III (23.6%, 11.7%, 5.4%, and 3.5%, respectively) women had increased odds of excessive gain (adjusted OR range 2.07, CI 1.63-2.62 to adjusted OR 2.99, CI 2.63-3.40). Underweight and obese class II and III women had increased odds of inadequate gain (adjusted OR 1.25, CI 1.01-1.55 to 1.86, CI 1.45-2.36). Most characteristics associated with weight gain adequacy were demographic such as racial or ethnic minority status and education and varied by prepregnancy BMI. Notably, one behavioral characteristic-smoking cessation-was associated with excessive gain among normal-weight and obese women. CONCLUSION: Most women gained weight outside recommendations. Understanding characteristics associated with inadequate or excessive weight gain may identify potentially at-risk women and inform much-needed interventions. C1 Emory Univ, Nutr & Hlth Sci Program, Laney Grad Sch, Atlanta, GA 30322 USA. Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. US Publ Hlth Serv Commissioned Corps, Atlanta, GA USA. Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Epidemiol Branch, Div Intramural Populat Hlth Res, NIH, Bethesda, MD USA. RP Sharma, AJ (reprint author), Ctr Dis Control & Prevent, 4770 Buford Highway NE,MS-F74, Atlanta, GA 30341 USA. EM ajsharma@cdc.gov RI Hinkle, Stefanie/F-8253-2013 OI Hinkle, Stefanie/0000-0003-4312-708X FU National Institutes of Health [T32-DK007734]; Centers for Disease Control and Prevention; Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health FX Mr. Deputy was supported in part by a National Institutes of Health training grant (T32-DK007734) and an appointment to the Research Participation Program at the Centers for Disease Control and Prevention administered by the Oak Ridge Institute for Science Education through an interagency agreement between the U.S. Department of Energy and the Centers for Disease Control and Prevention. Stefanie N. Hinkle was supported by the intramural research program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health. NR 30 TC 21 Z9 21 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0029-7844 J9 OBSTET GYNECOL JI Obstet. Gynecol. PD APR PY 2015 VL 125 IS 4 BP 773 EP 781 DI 10.1097/AOG.0000000000000739 PG 9 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA CE1TP UT WOS:000351595200003 PM 25751216 ER PT J AU Meaney-Delman, D Bartlett, LA Gravett, MG Jamieson, DJ AF Meaney-Delman, Dana Bartlett, Linda A. Gravett, Michael G. Jamieson, Denise J. TI Oral and Intramuscular Treatment Options for Early Postpartum Endometritis in Low-Resource Settings A Systematic Review SO OBSTETRICS AND GYNECOLOGY LA English DT Review ID CESAREAN-SECTION ENDOMETRITIS; CLINDAMYCIN PLUS GENTAMICIN; GENITAL-TRACT INFECTIONS; PELVIC-INFLAMMATORY-DISEASE; GYNECOLOGIC INFECTIONS; POSTCESAREAN ENDOMETRITIS; ANAEROBIC-BACTERIA; CLAVULANIC ACID; DOUBLE-BLIND; CEPHALOSPORIN PROPHYLAXIS AB OBJECTIVE: To suggest options for oral and intramuscular antibiotic treatment of early postpartum endometritis in low-resource community settings where intravenous antibiotics are unavailable. DATA SOURCES: Studies were identified through MEDLINE from inception through December 2014. Search terms included [("anti-bacterial agents [MeSH]" or "anti-infective agents [MeSH]") and ("endometritis [MeSH]" or "puerperal infection [MeSH]")]. A second search using the terms [("endometritis or endomyometritis or puerperal infection) and ("antibiotics or antimicrobials or anti-bacterial agents or anti-infective agents)"] was also used. Additionally, all references from selected articles were reviewed, a hand-search of a subject matter expert library was conducted, and a search of ClinicalTrials.gov was performed. METHODS OF STUDY SELECTION: We conducted a systematic review of the literature in two phases. Phase I provides a summary of clinical cure data from prospective studies of oral and intramuscular antimicrobial regimens as well as summarizes evidence from trials of intravenous antimicrobials. Phase II is a quantitative analysis of pathogens from intrauterine postpartum endometritis samples. Based on these results, and with consideration of existing recommendations for antibiotic use during breastfeeding, we suggest oral and intramuscular antimicrobial options for the treatment of early postpartum endometritis after vaginal delivery in low-resource settings. TABULATION, INTEGRATION, AND RESULTS: Reports involving oral or intramuscular antimicrobial treatment of postpartum endometritis are rare and of generally poor quality. Antimicrobial trials of postpartum endometritis treatment and intrauterine microbiology studies suggest five antimicrobial regimens may be effective: oral clindamycin plus intramuscular gentamicin, oral amoxicillin-clavulanate, intramuscular cefotetan, intramuscular meropenem or imipenem-cilastatin, and oral amoxicillin in combination with oral metronidazole. ONCLUSION: This review provides suggestions for oral, intramuscular, and combined antimicrobial regimens that may warrant additional study. Experimental trials should consider clinical effectiveness, safety and side effects profiles, and feasibility of community-based treatment. C1 [Meaney-Delman, Dana] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30345 USA. Johns Hopkins Sch Publ Hlth, Baltimore, MD USA. GAPPS, Seattle, WA USA. RP Meaney-Delman, D (reprint author), Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, 1600 Clifton Rd,Mailstop C12, Atlanta, GA 30345 USA. EM Vmo0@cdc.gov NR 90 TC 4 Z9 4 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0029-7844 J9 OBSTET GYNECOL JI Obstet. Gynecol. PD APR PY 2015 VL 125 IS 4 BP 789 EP 800 DI 10.1097/AOG.0000000000000732 PG 12 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA CE1TP UT WOS:000351595200006 PM 25751198 ER PT J AU Creanga, AA Syverson, C Seed, K Bruce, FC Callaghan, WM AF Creanga, Andreea A. Syverson, Carla Seed, Kristi Bruce, F. Carol Callaghan, William M. TI Advanced Reproductive Age and Maternal Mortality Reply SO OBSTETRICS AND GYNECOLOGY LA English DT Letter C1 [Creanga, Andreea A.; Syverson, Carla; Seed, Kristi; Bruce, F. Carol; Callaghan, William M.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30333 USA. RP Creanga, AA (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30333 USA. NR 4 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0029-7844 J9 OBSTET GYNECOL JI Obstet. Gynecol. PD APR PY 2015 VL 125 IS 4 BP 984 EP 985 PG 4 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA CE1TP UT WOS:000351595200043 PM 25798970 ER PT J AU Flagg, EW Weinstock, HS Frazier, EL Valverde, EE Heffelfinger, JD Skarbinski, J AF Flagg, Elaine W. Weinstock, Hillard S. Frazier, Emma L. Valverde, Eduardo E. Heffelfinger, James D. Skarbinski, Jacek TI Bacterial Sexually Transmitted Infections Among HIV-Infected Patients in the United States: Estimates From the Medical Monitoring Project SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; PRIMARY-CARE GUIDELINES; DISEASES SOCIETY; SYPHILIS INFECTION; SECONDARY SYPHILIS; SAN-FRANCISCO; VIRAL LOAD; SEX; MEN; RECOMMENDATIONS AB Background: Bacterial sexually transmitted infections may facilitate HIV transmission. Bacterial sexually transmitted infection testing is recommended for sexually active HIV-infected patients annually and more frequently for those at elevated sexual risk. We estimated percentages of HIV-infected patients in the United States receiving at least one syphilis, gonorrhea, or chlamydia test, and repeat (>= 2 tests, >= 3 months apart) tests for any of these sexually transmitted infections from mid-2008 through mid-2010. Design: The Medical Monitoring Project collects behavioral and clinical characteristics of HIV-infected adults receiving medical care in the United States using nationally representative sampling. Methods: Sexual activity included self-reported oral, vaginal, or anal sex in the past 12 months. Participants reporting more than 1 sexual partner or illicit drug use before/during sex in the past year were classified as having elevated sexual risk. Among participants with only 1 sex partner and no drug use before/during sex, those reporting consistent condom use were classified as low risk; those reporting sex without a condom (or for whom this was unknown) were classified as at elevated sexual risk only if they considered their sex partner to be a casual partner, or if their partner was HIV-negative or partner HIV status was unknown. Bacterial sexually transmitted infection testing was ascertained through medical record abstraction. Results: Among sexually active patients, 55% were tested at least once in 12 months for syphilis, whereas 23% and 24% received at least one gonorrhea and chlamydia test, respectively. Syphilis testing did not vary by sex/sexual orientation. Receipt of at least 3 CD4+ T-lymphocyte cell counts and/or HIV viral load tests in 12 months was associated with syphilis testing in men who have sex with men (MSM), men who have sex with women only, and women. Chlamydia testing was significantly higher in sexually active women (30%) compared with men who have sex with women only (19%), but not compared with MSM (22%). Forty-six percent of MSM were at elevated sexual risk; 26% of these MSM received repeat syphilis testing, whereas repeat testing for gonorrhea and chlamydia was only 7% for each infection. Conclusions: Bacterial sexually transmitted infection testing among sexually active HIV-infected patients was low, particularly for those at elevated sexual risk. Patient encounters in which CD4+ T-lymphocyte cell counts and/or HIV viral load testing occurs present opportunities for increased bacterial sexually transmitted infection testing. C1 [Flagg, Elaine W.; Weinstock, Hillard S.] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA 30333 USA. [Frazier, Emma L.; Valverde, Eduardo E.; Heffelfinger, James D.; Skarbinski, Jacek] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. RP Flagg, EW (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS E-63, Atlanta, GA 30333 USA. EM eflagg@cdc.gov; jskarbinski@cdc.gov FU Centers for Disease Control and Prevention FX This work was supported by the Centers for Disease Control and Prevention. NR 34 TC 8 Z9 8 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD APR PY 2015 VL 42 IS 4 BP 171 EP 179 DI 10.1097/OLQ.0000000000000260 PG 9 WC Infectious Diseases SC Infectious Diseases GA CD3UY UT WOS:000351009100003 PM 25763669 ER PT J AU Kraft, JM Whiteman, MK Carter, MW Snead, MC DiClemente, RJ Murray, CC Hatfield-Timajchy, K Kottke, M AF Kraft, Joan Marie Whiteman, Maura K. Carter, Marion W. Snead, M. Christine DiClemente, Ralph J. Murray, Collen Crittenden Hatfield-Timajchy, Kendra Kottke, Melissa TI Identifying Psychosocial and Social Correlates of Sexually Transmitted Diseases Among Black Female Teenagers SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID AMERICAN ADOLESCENT FEMALES; INFECTIONS; RISK; SEX; STD; PREVALENCE; BEHAVIOR; RATES AB Background: Black teenagers have relatively high rates of sexually transmitted diseases (STDs), and recent research suggests the role of contextual factors, as well as risk behaviors. We explore the role of 4 categories of risk and protective factors on having a biologically confirmed STD among black, female teenagers. Methods: Black teenage girls (14-19 years old) accessing services at a publicly funded family planning clinic provided a urine specimen for STD testing and completed an audio computer-assisted self-interview that assessed the following: risk behaviors, relationship characteristics, social factors, and psychosocial factors. We examined bivariate associations between each risk and protective factor and having gonorrhea and/or chlamydia, as well as multivariate logistic regression among 339 black female teenagers. Results: More than one-fourth (26.5%) of participants had either gonorrhea and/or chlamydia. In multivariate analyses, having initiated sex before age 15 (adjusted odds ratio [aOR], 1.87) and having concurrent sex partners in the past 6 months (aOR, 1.55) were positively associated with having an STD. Living with her father (aOR, 0.44), believing that an STD is the worst thing that could happen (aOR, 0.50), and believing she would feel dirty and embarrassed about an STD (aOR, 0.44) were negatively associated with having an STD. Conclusions: Social factors and attitudes toward STDs and select risk behaviors were associated with the risk for STDs, suggesting the need for interventions that address more distal factors. Future studies should investigate how such factors influence safer sexual behaviors and the risk for STDs among black female teenagers. C1 [Kraft, Joan Marie; Whiteman, Maura K.; Carter, Marion W.; Snead, M. Christine; Hatfield-Timajchy, Kendra] US Ctr Dis Control & Prevent, Atlanta, GA USA. [DiClemente, Ralph J.; Kottke, Melissa] Emory Univ, Atlanta, GA 30322 USA. [Murray, Collen Crittenden] ICF Int, Fairfax, VA USA. RP Kraft, JM (reprint author), CDC, Div Reprod Hlth, 4770 Buford Highway NE,MS F74, Atlanta, GA 30341 USA. EM jik4@cdc.gov FU US Centers for Disease Control and Prevention [U48DP001909-01] FX Supported by the US Centers for Disease Control and Prevention through Cooperative Agreement No. U48DP001909-01. NR 28 TC 0 Z9 0 U1 1 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD APR PY 2015 VL 42 IS 4 BP 192 EP 197 DI 10.1097/OLQ.0000000000000254 PG 6 WC Infectious Diseases SC Infectious Diseases GA CD3UY UT WOS:000351009100006 PM 25763671 ER PT J AU Cooley, LA Pearl, ML Flynn, C Ross, C Hart-Cooper, G Elmore, K Blythe, D Morgan, J Oster, AM AF Cooley, Laura A. Pearl, Marcia L. Flynn, Colin Ross, Christine Hart-Cooper, Geoffrey Elmore, Kim Blythe, David Morgan, James Oster, Alexandra M. TI Low Viral Suppression and High HIV Diagnosis Rate Among Men Who Have Sex With Men With Syphilis - Baltimore, Maryland SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID SEXUALLY-TRANSMITTED-DISEASES; UNITED-STATES; EPIDEMIOLOGIC SYNERGY; HEALTH; INFECTION; RECOMMENDATIONS; ADOLESCENTS; GUIDELINES; CITIES; ADULTS AB Background: The burden of syphilis and HIV among gay, bisexual, and other men who have sex with men (MSM) in Baltimore, Maryland, is substantial. Syphilis and HIV surveillance data were analyzed to characterize MSM with syphilis, including those with repeat infection and HIV coinfection, to strengthen prevention efforts. Methods: MSM 15 years or older from Baltimore City or County diagnosed as having early syphilis in 2010 to 2011 were included. Those previously treated for syphilis in 2007 to 2011 were considered to have repeat syphilis infection. HIV surveillance data were used to identify HIV coinfection and assess viral suppression. For MSM not diagnosed as having HIV at or before their syphilis diagnosis, annual HIV diagnosis rates were estimated, using Baltimore City data. Results: Of 460 MSM with early syphilis in 2010 or 2011, 92 (20%) had repeat infection; 55% of MSM with a single diagnosis and 86% with repeat infection were HIV coinfected. Among MSM diagnosed as having HIV, viral suppression was low (25%, or 46% of those with a viral load reported). Among Baltimore City MSM without a prior HIV diagnosis, estimated annual HIV diagnosis rates were high (5% for those with 1 syphilis diagnosis, 23% for those with repeat infection). Conclusions: Baltimore-area MSM with syphilis, particularly those with repeat infection, represent a unique population for whom coinfection with HIV is high. Increasing frequency of syphilis and HIV testing among Baltimore area MSM with a syphilis diagnosis and prioritizing HIV infected MSM with syphilis in efforts to achieve viral suppression may improve outcomes locally for both infections. C1 [Cooley, Laura A.; Elmore, Kim; Oster, Alexandra M.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30329 USA. [Cooley, Laura A.; Ross, Christine] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30329 USA. [Pearl, Marcia L.; Flynn, Colin; Blythe, David] Maryland Dept Hlth & Mental Hyg, Baltimore, MD USA. [Ross, Christine; Hart-Cooper, Geoffrey] CDC, Div STD Prevent, Atlanta, GA 30333 USA. [Hart-Cooper, Geoffrey] CDC, Atlanta, GA 30333 USA. [Morgan, James] Baltimore Cty Dept Hlth & Human Serv, Towson, MD USA. RP Cooley, LA (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, 1600 Clifton Rd NE,Mailstop E-46, Atlanta, GA 30329 USA. EM LCooley@cdc.gov NR 32 TC 5 Z9 5 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD APR PY 2015 VL 42 IS 4 BP 226 EP 231 DI 10.1097/OLQ.0000000000000256 PG 6 WC Infectious Diseases SC Infectious Diseases GA CD3UY UT WOS:000351009100012 PM 25763676 ER PT J AU Nelson, RE Grosse, SD Waitzman, NJ Lin, JJ DuVall, SL Patterson, O Tsai, J Reyes, N AF Nelson, Richard E. Grosse, Scott D. Waitzman, Norman J. Lin, Junji DuVall, Scott L. Patterson, Olga Tsai, James Reyes, Nimia TI Using multiple sources of data for surveillance of postoperative venous thromboembolism among surgical patients treated in Department of Veterans Affairs hospitals, 2005-2010 SO THROMBOSIS RESEARCH LA English DT Article DE Venous thromboembolism; Deep vein thrombosis; Pulmonary embolism; Veterans; Surgery ID DEEP-VEIN THROMBOSIS; QUALITY IMPROVEMENT PROGRAM; PULMONARY-EMBOLISM; KNEE ARTHROPLASTY; RISK-FACTORS; TOTAL HIP; SURGERY; COMPLICATIONS; MORTALITY; MEDICARE AB Background: There are limitations to using administrative data to identify postoperative venous thromboembolism (VTE). We used a novel approach to quantify postoperative VTE events among Department of Veterans Affairs (VA) surgical patients during 2005-2010. Methods: We used VA administrative data to exclude patients with VTE during 12 months prior to surgery. We identified probable postoperative VTE events within 30 and 90 days post-surgery in three settings: 1) pre-discharge inpatient, using a VTE diagnosis code and a pharmacy record for anticoagulation; 2) post-discharge inpatient, using a VTE diagnosis code followed by a pharmacy record for anticoagulation within 7 days; and 3) outpatient, using a VTE diagnosis code and either anticoagulation or a therapeutic procedure code with natural language processing (NLP) to confirm acute VTE in clinical notes. Results: Among 468,515 surgeries without prior VTE, probable VTEs were documented within 30 and 90 days in 3,931 (0.8%) and 5,904 (1.3%), respectively. Of probable VTEs within 30 or 90 days post-surgery, 47.8% and 62.9%, respectively, were diagnosed post-discharge. Among post-discharge VTE diagnoses, 86% resulted in a VA hospital readmission. Fewer than 25% of outpatient records with both VTE diagnoses and anticoagulation prescriptions were confirmed by NLP as acute VTE events. Conclusion: More than half of postoperative VTE events were diagnosed post-discharge; analyses of surgical discharge records are inadequate to identify postoperative VTE. The NLP results demonstrate that the combination of VTE diagnoses and anticoagulation prescriptions in outpatient administrative records cannot be used to validly identify postoperative VTE events. (C) 2015 Published by Elsevier Ltd. C1 [Nelson, Richard E.; Lin, Junji; DuVall, Scott L.; Patterson, Olga] Vet Affairs Salt Lake City Hlth Care Syst, Salt Lake City, UT USA. [Nelson, Richard E.; DuVall, Scott L.; Patterson, Olga] Univ Utah, Dept Internal Med, Salt Lake City, UT 84112 USA. [Grosse, Scott D.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Off Director, Atlanta, GA USA. [Waitzman, Norman J.] Univ Utah, Dept Econ, Salt Lake City, UT USA. [Lin, Junji; DuVall, Scott L.] Univ Utah, Dept Pharmacotherapy, Salt Lake City, UT USA. [Tsai, James] Ctr Dis Control & Prevent, Off Smoking & Hlth, Atlanta, GA USA. [Reyes, Nimia] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Div Blood Disorders, Atlanta, GA USA. RP Nelson, RE (reprint author), 500 Foothill Blvd,182, Salt Lake City, UT 84148 USA. EM richard.nelson@utah.edu OI Patterson, Olga V/0000-0002-8717-5975 FU National Cancer Institute [KM1CA156723]; VA Health Services Research Development [CDA 11-210] FX We thank Richard White for thoughtful comments on an earlier draft. We acknowledge the contributions of the other members of the CDC clotting disorders surveillance group-Michele Beckman, Althea Grant, and Karon Abe-for helping to clarify the VTE case definition. We also thank Philip Kithas for insights into VTE diagnosis in the VA. This study was supported using resources and facilities at the VA Salt Lake City Health Care System. The work in this paper was conducted through a contract between the Centers for Disease Control and Prevention and the Western Institute for Biomedical Research, Salt Lake City, UT. Dr. Nelson received additional funding from grant KM1CA156723 from the National Cancer Institute and VA Health Services Research & Development grant CDA 11-210. NR 38 TC 2 Z9 2 U1 3 U2 4 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0049-3848 J9 THROMB RES JI Thromb. Res. PD APR PY 2015 VL 135 IS 4 BP 636 EP 642 DI 10.1016/j.thromres.2015.01.026 PG 7 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA CD4WJ UT WOS:000351086000012 PM 25666908 ER PT J AU Lewis, DA Suchindran, S Beckman, MG Hooper, WC Grant, AM Heit, JA Manco-Johnson, M Moll, S Philipp, CS Kenney, K De Staercke, C Pyle, ME Chi, JT Ortel, TL AF Lewis, Deborah A. Suchindran, Sunil Beckman, Michele G. Hooper, W. Craig Grant, Althea M. Heit, John A. Manco-Johnson, Marilyn Moll, Stephan Philipp, Claire S. Kenney, Kristy De Staercke, Christine Pyle, Meredith E. Chi, Jen-Tsan Ortel, Thomas L. TI Whole blood gene expression profiles distinguish clinical phenotypes of venous thromboembolism SO THROMBOSIS RESEARCH LA English DT Article DE venous thrombosis; deep-vein thrombosis; gene expression profiling ID SYMPTOMATIC PULMONARY-EMBOLISM; DEEP-VEIN THROMBOSIS; RISK-FACTORS; INTEGRATIVE ANALYSIS; COMPLEMENT; GENOMICS; REGULARIZATION; ANTICOAGULANT; COAGULATION; VALIDATION AB Introduction: Recurrent venous thromboembolism (VTE) occurs infrequently following a provoked event but occurs in up to 30% of individuals following an initial unprovoked event. There is limited understanding of the biological mechanisms that predispose patients to recurrent VTE. Objectives: To identify whole blood gene expression profiles that distinguished patients with clinically distinct patterns of VTE. Patients/Methods: We studied 107 patients with VTE separated into 3 groups: (1) 'low-risk' patients had one or more provoked VTE; (2) 'moderate-risk' patients had a single unprovoked VTE; (3) 'high-risk' patients had >= 2 unprovoked VTE. Each patient group was also compared to twenty-five individuals with no personal history of VTE. Total RNA from whole blood was isolated and hybridized to Illumina HT-12 V4 Beadchips to assay whole genome expression. Results: Using class prediction analysis, we distinguished high-risk patients from low-risk patients and healthy controls with good receiver operating curve characteristics (AUC=0.81 and 0.84, respectively). We also distinguished moderate-risk individuals and low-risk individuals from healthy controls with AUC's of 0.69 and 0.80, respectively. Using differential expression analysis, we identified several genes previously implicated in thrombotic disorders by genetic analyses, including SELP, KLKB1, ANXA5, and CD46. Protein levels for several of the identified genes were not significantly different between the different groups. Conclusion: Gene expression profiles are capable of distinguishing patients with different clinical presentations of VTE, and genes relevant to VTE risk are frequently differentially expressed in these comparisons. (C) 2015 Elsevier Ltd. All rights reserved. C1 [Lewis, Deborah A.; Ortel, Thomas L.] Duke Univ, Med Ctr, Div Hematol, Ctr Thrombosis & Hemostasis, Durham, NC USA. [Suchindran, Sunil] Duke Univ, Sch Med, Ctr Appl Genom, Durham, NC USA. [Beckman, Michele G.; Hooper, W. Craig; Grant, Althea M.; Kenney, Kristy; De Staercke, Christine; Pyle, Meredith E.] Ctr Dis Control & Prevent, Div Cardiovasc Dis, Atlanta, GA USA. [Heit, John A.] Mayo Clin, Rochester, MN USA. [Manco-Johnson, Marilyn] Univ Colorado, Aurora, CO USA. [Manco-Johnson, Marilyn] Childrens Hosp, Aurora, CO USA. [Moll, Stephan] Univ N Carolina, Chapel Hill, NC USA. [Philipp, Claire S.] Rutgers Robert Wood Johnson Med Sch, New Brunswick, NJ USA. [Chi, Jen-Tsan] Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Durham, NC USA. [Chi, Jen-Tsan] Duke Univ, Med Ctr, Ctr Genom & Computat Biol, Durham, NC USA. RP Ortel, TL (reprint author), Duke Thrombosis & Hemostasis Ctr, Box 3422 DUMC, Durham, NC 27710 USA. EM thomas.ortel@duke.edu FU Centers for Disease Control and Prevention [DD000014, DD000016, DD000017, DD000235, DD000292] FX This study was supported by grants from the Centers for Disease Control and Prevention (DD000014 to T. L. Ortel; DD000016 to M. Manco-Johnson; DD000017 to C. S. Philipp; DD000235 to J. A. Heit; and DD000292 to S. Moll). The Centers for Disease Control and Prevention had a collaborative role in the entire study. NR 43 TC 3 Z9 3 U1 0 U2 4 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0049-3848 J9 THROMB RES JI Thromb. Res. PD APR PY 2015 VL 135 IS 4 BP 659 EP 665 DI 10.1016/j.thromres.2015.02.003 PG 7 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA CD4WJ UT WOS:000351086000016 PM 25684211 ER PT J AU Murray, A Pierre-Louis, J Joseph, F Sylvain, G Patrick, M Lantagne, D AF Murray, Anna Pierre-Louis, Jocelyne Joseph, Flaurine Sylvain, Ginelove Patrick, Molly Lantagne, Daniele TI Need for certification of household water treatment products: examples from Haiti SO TROPICAL MEDICINE & INTERNATIONAL HEALTH LA English DT Article DE drinking water; water treatment; developing countries; regulation; household water treatment ID POINT-OF-USE; DRINKING-WATER; WESTERN KENYA; DIARRHEA; CHLORINATION; METAANALYSIS; COUNTRIES; QUALITY; IMPACT AB ObjectiveTo evaluate four household water treatment (HWT) products currently seeking approval for distribution in Haiti, through the application of a recently-developed national HWT product certification process. MethodsFour chemical treatment products were evaluated against the certification process validation stage by verifying international product certifications confirming treatment efficacy and reviewing laboratory efficacy data against WHO HWT microbiological performance targets; and against the approval stage by confirming product composition, evaluating treated water chemical content against national and international drinking water quality guidelines and reviewing packaging for dosing ability and usage directions in Creole. ResultsNone of the four evaluated products fulfilled validation or approval stage requirements. None was certified by an international agency as efficacious for drinking water treatment, and none had data demonstrating its ability to meet WHO HWT performance targets. All product sample compositions differed from labelled composition by >20%, and no packaging included complete usage directions in Creole. ConclusionsProduct manufacturers provided information that was inapplicable, did not demonstrate product efficacy, and was insufficient to ensure safe product use. Capacity building is needed with country regulatory agencies to objectively evaluate HWT products. Products should be internationally assessed against WHO performance targets and also locally approved, considering language, culture and usability, to ensure effective HWT. ObjectifEvaluer quatre produits de traitement chimique recherchant actuellement une approbation en Haiti. MethodesLes produits de traitement de l'eau des menages (TEM) ont ete evalues a l'etape de la validation du processus de certification en verifiant les certifications de produits internationaux confirmant l'efficacite du traitement et en examinant les donnees d'efficacite de laboratoire selon les objectifs de performance microbiologique de l'OMS pour le TEM, et a l'etape de l'approbation en confirmant la composition du produit, en evaluant la teneur chimique de l'eau traitee selon les directives nationales et internationales de qualite de l'eau potable, et en examinant l'emballage pour les dosages indiques et les instructions d'utilisation en creole. ResultatsAucun des quatre produits evalues ne remplissait les exigences de l'etape de validation ou d'approbation. Aucun n'etait certifie par un organisme international comme etant efficace pour le traitement de l'eau potable et aucun ne possedait des donnees demontrant sa capacite a atteindre les objectifs de performance de l'OMS pour le TEM. Les compositions de tous les echantillons des produits differaient de > 20% de la composition indiquee et aucun emballage ne portait des instructions completes d'utilisation en creole. ConclusionsLes fabricants de produits ont fourni des informations qui n'etaient pas applicables, ne demontraient pas l'efficacite du produit et n'etaient pas suffisantes pour assurer une utilisation adequate des produits. Le renforcement des capacites est necessaire pour les organismes de reglementation des pays pour pouvoir evaluer objectivement les produits de TEM. Les produits doivent etre evalues a l'echelle internationale selon les objectifs de performance de l'OMS et egalement approuves localement, en tenant compte de la langue, la culture et la convivialite, afin d'assurer un TEM efficace. ObjetivoEvaluar cuatro tratamientos con productos quimicos actualmente pendientes de aprobacion en Haiti. MetodosSe evaluaron los productos para el tratamiento de agua en hogares (TAH) que estaban en la etapa de validacion dentro del proceso de certificacion, verificando las certificaciones internacionales del producto que confirmasen la eficacia del tratamiento y revisando los datos de eficacia en el laboratorio frente a los objetivos de la OMS en el desempeno microbiologico para el TAH; y en la etapa de aprobacion, mediante la confirmacion de la composicion del producto, evaluando el contenido quimico del agua tratada frente a las normas internacionales de calidad del agua potable, y revisando el empaquetado segun dosificacion y las instrucciones de uso en Creole. ResultadosNinguno de los cuatro productos evaluados alcanzaba los requisitos para las etapas de validacion o aprobacion. Ninguno estaba certificado por una agencia internacional como un tratamiento eficaz para agua potable, y ninguno tenia datos que demostraran su capacidad de alcanzar los objetivos de desempeno de la OMS para el TAH. La composicion de todas las muestras de productos diferian de los componentes referenciados en la etiqueta en >20%, y ninguno de los empaques tenian instrucciones de uso completas en Creole. ConclusionesLos fabricantes de producto daban informacion que no era aplicable, no demostraban la eficacia de los productos, y era insuficiente para asegurar un uso seguro del producto. Se requiere formar al personal con las agencias reguladoras nacionales para evaluar de forma objetiva los TAH. Los productos deberian evaluarse a nivel internacional segun los objetivos de desempeno de la OMS y ser tambien aprobados a nivel local, teniendo en consideracion el idioma, la cultura y el uso, con el fin de asegurar un TAH efectivo. C1 [Murray, Anna; Lantagne, Daniele] Tufts Univ, Dept Civil & Environm Engn, Medford, MA 02155 USA. [Pierre-Louis, Jocelyne; Joseph, Flaurine; Sylvain, Ginelove] Minist Sante Publ & Populat, Port Au Prince, Haiti. [Patrick, Molly] Ctr Dis Control & Prevent, Emergency Response & Refugee Branch, Atlanta, GA USA. RP Murray, A (reprint author), Tufts Univ, Dept Civil & Environm Engn, 200 Coll Ave, Medford, MA 02155 USA. EM anna.murray@tufts.edu FU Intramural CDC HHS [CC999999] NR 36 TC 1 Z9 1 U1 4 U2 12 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1360-2276 EI 1365-3156 J9 TROP MED INT HEALTH JI Trop. Med. Int. Health PD APR PY 2015 VL 20 IS 4 BP 462 EP 470 DI 10.1111/tmi.12445 PG 9 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA CD0IV UT WOS:000350755800007 PM 25441711 ER PT J AU Tussing-Humphreys, LM Thomson, JL Onufrak, SJ AF Tussing-Humphreys, Lisa M. Thomson, Jessica L. Onufrak, Stephen J. TI A Church-Based Pilot Study Designed to Improve Dietary Quality for Rural, Lower Mississippi Delta, African American Adults SO JOURNAL OF RELIGION & HEALTH LA English DT Article DE Diet; Mississippi; African Americans; Adult; Church ID WEIGHT-LOSS INTERVENTION; FOOD-INTAKE; PHYSICAL-ACTIVITY; HEALTH-PROMOTION; LOSS MAINTENANCE; LOSS PROGRAM; US ADULTS; WOMEN; PROJECT; PREVENTION AB We piloted a 6-month, church-based, behavioral intervention, Delta Body and Soul (DBS), for African American (AA) adults in the Lower Mississippi Delta (LMD). DBS was designed to improve overall dietary quality in LMD AA adults. The intervention included six once monthly group-based educational sessions implemented by trained church members. Program implementation, session attendance, congregational feedback, and baseline and post-intervention, demographic, health, behavioral, and clinical parameters were assessed. Participants were predominately AA, female, and overweight or obese. Retention rate was 79 %. High adherence, defined as attendance at four or more educational sessions, was associated with dietary quality improvement and reduced blood glucose. Implementation of the DBS pilot intervention was feasible and may result in dietary quality and clinical improvements. C1 [Tussing-Humphreys, Lisa M.] Univ Illinois, Dept Med, Div Hlth Promot Res, Chicago, IL 60608 USA. [Tussing-Humphreys, Lisa M.] Univ Illinois, Ctr Canc, Chicago, IL 60608 USA. [Thomson, Jessica L.] ARS, Mid South Area, USDA, Stoneville, MS 38776 USA. [Onufrak, Stephen J.] Ctr Dis Control & Prevent, Obes Prevent & Control Branch, Atlanta, GA 30341 USA. RP Tussing-Humphreys, LM (reprint author), Univ Illinois, Dept Med, Div Hlth Promot Res, Chicago, IL 60608 USA. EM ltussing@uic.edu NR 37 TC 6 Z9 6 U1 1 U2 9 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0022-4197 EI 1573-6571 J9 J RELIG HEALTH JI J. Relig. Health PD APR PY 2015 VL 54 IS 2 BP 455 EP 469 DI 10.1007/s10943-014-9823-5 PG 15 WC Public, Environmental & Occupational Health; Religion SC Public, Environmental & Occupational Health; Religion GA CB4NO UT WOS:000349604800008 PM 24442772 ER PT J AU Miles, SR Tharp, AT Stanford, M Sharp, C Menefee, D Kent, TA AF Miles, Shannon R. Tharp, Andra Teten Stanford, Matthew Sharp, Carla Menefee, Deleene Kent, Thomas A. TI Emotion dysregulation mediates the relationship between traumatic exposure and aggression in healthy young women SO PERSONALITY AND INDIVIDUAL DIFFERENCES LA English DT Article DE Impulsive Aggression; Premeditated Aggression; Emotion dysregulation; Trauma exposure ID POSTTRAUMATIC-STRESS-DISORDER; INTIMATE PARTNER VIOLENCE; IMPULSIVE AGGRESSION; EXPERIENCES; PREVALENCE; VETERANS; BEHAVIOR; COLLEGE AB Research has linked trauma-sequelae, such as posttraumatic stress disorder, to aggression. However, not all who experience a trauma become violent, suggesting non-trauma factors, such as emotion dysregulation, influence aggression expression and if confirmed, may influence treatment approaches. Aggression can be considered a multifaceted construct with Impulsive Aggression (IA) as emotional, reactive, and uncontrolled and Premeditated Aggression (PA) as deliberate, planned, and instrumental. We hypothesized that parceling apart IA and PA may further refine predictors of aggression in the context of trauma exposure. We tested this hypothesis in undergraduate women (N = 208) who completed trauma, emotion, and aggression measures. Path analysis indicated that Borderline Features, including emotion dysregulation, mediated the relationship between trauma exposure and IA and PA. The finding extends clinical literature by providing evidence that emotion dysregulation influences both IA and PA in a non-clinical sample, while clinical sample research shows emotion dysregulation more specifically mediated the relationship between trauma and IA. Factors responsible for these differences are discussed. Published by Elsevier Ltd. C1 [Miles, Shannon R.; Menefee, Deleene; Kent, Thomas A.] Michael E DeBakey Vet Affairs VA Med Ctr, Houston, TX 77030 USA. [Miles, Shannon R.; Menefee, Deleene] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA. [Miles, Shannon R.; Menefee, Deleene; Kent, Thomas A.] South Cent Mental Illness Res Educ & Clin Ctr MIR, Dept VA 152, Houston, TX 77021 USA. [Tharp, Andra Teten] Ctr Dis Control & Prevent, Div Violence Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA. [Stanford, Matthew] Baylor Univ, Dept Psychol Neurosci & Biomed Studies, Waco, TX 76798 USA. [Sharp, Carla] Univ Houston, Dept Psychol, Houston, TX 77204 USA. [Kent, Thomas A.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA. RP Miles, SR (reprint author), Michael E DeBakey Vet Affairs VA Med Ctr 152, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM shannon.miles@va.gov OI Kent, Thomas/0000-0002-9877-7584; Sharp, Carla/0000-0001-8349-4701 FU Department of Veterans Affairs, Veterans Health Administration; South Central Mental Illness Research, Education and Clinical Centers (SCMIRECC); Traumatic Brain Injury, Center of Excellence; Houston VA HSR&D Center for Innovations in Quality, Effectiveness, and Safety, Houston TX [CIN13-413] FX The authors report no financial conflicts of interest. This material is based upon work supported (or supported in part) by the Department of Veterans Affairs, Veterans Health Administration, the South Central Mental Illness Research, Education and Clinical Centers (SCMIRECC), the Traumatic Brain Injury, Center of Excellence, and the Houston VA HSR&D Center for Innovations in Quality, Effectiveness, and Safety (CIN13-413), Houston TX. The funding sources had no role in the study design; in the collection, analysis, or interpretation of the data; in the writing of the manuscript; or in the decision to submit the paper for publication. The views expressed, findings, and conclusions in this report are those of the authors and do not necessarily represent the official position or policy of the Centers for Disease Control and Prevention, the Department of Veterans Affairs, the South Central MIRECC, Baylor College of Medicine, or the United States government. NR 34 TC 4 Z9 4 U1 0 U2 11 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0191-8869 J9 PERS INDIV DIFFER JI Pers. Individ. Differ. PD APR PY 2015 VL 76 BP 222 EP 227 DI 10.1016/j.paid.2014.11.058 PG 6 WC Psychology, Social SC Psychology GA CA9TU UT WOS:000349268500038 ER PT J AU Adjuik, MA Allan, R Anvikar, AR Ashley, EA Ba, MS Barennes, H Barnes, KI Bassat, Q Baudin, E Bjoorkman, A Bompart, F Bonnet, M Borrmann, S Brasseur, P Bukirwa, H Checchi, F Cot, M Dahal, P D'Alessandro, U Deloron, P Desai, M Diap, G Djimde, AA Dorsey, G Doumbo, OK Espiee, E Etard, JF Fanello, CI Faucher, JF Faye, B Flegg, JA Gaye, O Gething, PW Gonzalez, R Grandesso, F Guerin, PJ Guthmann, JP Hamour, S Hasugian, AR Hay, SI Humphreys, GS Jullien, V Juma, E Kamya, MR Karema, C Kiechel, JR Kremsner, PG Krishna, S Lameyre, V Ibrahim, LM Lee, SJ Lell, B Martensson, A Massougbodji, A Menan, H Menard, D Menendez, C Meremikwu, M Moreira, C Nabasumba, C Nambozi, M Ndiaye, JL Nikiema, F Nsanzabana, C Ntoumi, F Ogutu, BR Olliaro, P Osorio, L Ouedraogo, JB Penali, LK Pene, M Pinoges, L Piola, P Price, RN Roper, C Rosenthal, PJ Rwagacondo, CE Same-Ekobo, A Schramm, B Seck, A Sharma, B Sibley, CH Sinou, V Sirima, SB Smith, JJ Smithuis, F Some, FA Sow, D Staedke, SG Stepniewska, K Swarthout, TD Sylla, K Talisuna, AO Tarning, J Taylor, WRJ Temu, EA Thwing, JI Tjitra, E Tine, RCK Tinto, H Vaillant, MT Valecha, N Van den Broek, I White, NJ Yeka, A Zongo, I AF Adjuik, Martin A. Allan, Richard Anvikar, Anupkumar R. Ashley, Elizabeth A. Ba, Mamadou S. Barennes, Hubert Barnes, Karen I. Bassat, Quique Baudin, Elisabeth Bjorkman, Anders Bompart, Francois Bonnet, Maryline Borrmann, Steffen Brasseur, Philippe Bukirwa, Hasifa Checchi, Francesco Cot, Michel Dahal, Prabin D'Alessandro, Umberto Deloron, Philippe Desai, Meghna Diap, Graciela Djimde, Abdoulaye A. Dorsey, Grant Doumbo, Ogobara K. Espie, Emmanuelle Etard, Jean-Francois Fanello, Caterina I. Faucher, Jean-Francois Faye, Babacar Flegg, Jennifer A. Gaye, Oumar Gething, Peter W. Gonzalez, Raquel Grandesso, Francesco Guerin, Philippe J. Guthmann, Jean-Paul Hamour, Sally Hasugian, Armedy Ronny Hay, Simon I. Humphreys, Georgina S. Jullien, Vincent Juma, Elizabeth Kamya, Moses R. Karema, Corine Kiechel, Jean R. Kremsner, Peter G. Krishna, Sanjeev Lameyre, Valerie Ibrahim, Laminou M. Lee, Sue J. Lell, Bertrand Martensson, Andreas Massougbodji, Achille Menan, Herve Menard, Didier Menendez, Clara Meremikwu, Martin Moreira, Clarissa Nabasumba, Carolyn Nambozi, Michael Ndiaye, Jean-Louis Nikiema, Frederic Nsanzabana, Christian Ntoumi, Francine Ogutu, Bernhards R. Olliaro, Piero Osorio, Lyda Ouedraogo, Jean-Bosco Penali, Louis K. Pene, Mbaye Pinoges, Loretxu Piola, Patrice Price, Ric N. Roper, Cally Rosenthal, Philip J. Rwagacondo, Claude Emile Same-Ekobo, Albert Schramm, Birgit Seck, Amadou Sharma, Bhawna Sibley, Carol Hopkins Sinou, Veronique Sirima, Sodiomon B. Smith, Jeffery J. Smithuis, Frank Some, Fabrice A. Sow, Doudou Staedke, Sarah G. Stepniewska, Kasia Swarthout, Todd D. Sylla, Khadime Talisuna, Ambrose O. Tarning, Joel Taylor, Walter R. J. Temu, Emmanuel A. Thwing, Julie I. Tjitra, Emiliana Tine, Roger C. K. Tinto, Halidou Vaillant, Michel T. Valecha, Neena Van den Broek, Ingrid White, Nicholas J. Yeka, Adoke Zongo, Issaka CA WorldWide Antimalarial Resistance TI The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient data SO BMC Medicine LA English DT Article DE Malaria; Plasmodium falciparum; Drug resistance; Artesunate; Amodiaquine; Dosing; Efficacy ID PLASMODIUM-FALCIPARUM MALARIA; PLUS SULFADOXINE-PYRIMETHAMINE; CHLOROQUINE-RESISTANCE TRANSPORTER; FIXED-DOSE COMBINATION; ARTEMISININ-BASED COMBINATIONS; ANTIMALARIAL-DRUG RESISTANCE; MULTICENTER CLINICAL-TRIALS; NON-INFERIORITY TRIAL; ARTEMETHER-LUMEFANTRINE; IN-VIVO AB Background: Artesunate-amodiaquine (AS-AQ) is one of the most widely used artemisinin-based combination therapies (ACTs) to treat uncomplicated Plasmodium falciparum malaria in Africa. We investigated the impact of different dosing strategies on the efficacy of this combination for the treatment of falciparum malaria. Methods: Individual patient data from AS-AQ clinical trials were pooled using the WorldWide Antimalarial Resistance Network (WWARN) standardised methodology. Risk factors for treatment failure were identified using a Cox regression model with shared frailty across study sites. Results: Forty-three studies representing 9,106 treatments from 1999-2012 were included in the analysis; 4,138 (45.4%) treatments were with a fixed dose combination with an AQ target dose of 30 mg/kg (FDC), 1,293 (14.2%) with a non-fixed dose combination with an AQ target dose of 25 mg/kg (loose NFDC-25), 2,418 (26.6%) with a non-fixed dose combination with an AQ target dose of 30 mg/kg (loose NFDC-30), and the remaining 1,257 (13.8%) with a co-blistered non-fixed dose combination with an AQ target dose of 30 mg/kg (co-blistered NFDC). The median dose of AQ administered was 32.1 mg/kg [IQR: 25.9-38.2], the highest dose being administered to patients treated with co-blistered NFDC (median = 35.3 mg/kg [IQR: 30.6-43.7]) and the lowest to those treated with loose NFDC-25 (median = 25.0 mg/kg [IQR: 22.7-25.0]). Patients treated with FDC received a median dose of 32.4 mg/kg [IQR: 27-39.0]. After adjusting for reinfections, the corrected antimalarial efficacy on day 28 after treatment was similar for co-blistered NFDC (97.9% [95% confidence interval (CI): 97.0-98.8%]) and FDC (98.1% [95% CI: 97.6%-98.5%]; P = 0.799), but significantly lower for the loose NFDC-25 (93.4% [95% CI: 91.9%-94.9%]), and loose NFDC-30 (95.0% [95% CI: 94.1%-95.9%]) (P < 0.001 for all comparisons). After controlling for age, AQ dose, baseline parasitemia and region; treatment with loose NFDC-25 was associated with a 3.5-fold greater risk of recrudescence by day 28 (adjusted hazard ratio, AHR = 3.51 [95% CI: 2.02-6.12], P < 0.001) compared to FDC, and treatment with loose NFDC-30 was associated with a higher risk of recrudescence at only three sites. Conclusions: There was substantial variation in the total dose of amodiaquine administered in different AS-AQ combination regimens. Fixed dose AS-AQ combinations ensure optimal dosing and provide higher antimalarial treatment efficacy than the loose individual tablets in all age categories. C1 [Adjuik, Martin A.] INDEPTH NETWORK Secretariat, Accra, Ghana. [Allan, Richard] MENTOR Initiat, Crawley, England. [Anvikar, Anupkumar R.; Valecha, Neena] Natl Inst Malaria Res, New Delhi, India. [Ashley, Elizabeth A.; Baudin, Elisabeth; Checchi, Francesco; Guthmann, Jean-Paul; Pinoges, Loretxu] Epictr, Paris, France. [Ba, Mamadou S.; Faye, Babacar; Ndiaye, Jean-Louis; Pene, Mbaye; Sow, Doudou; Tine, Roger C. K.] Univ Cheikh Anta Diop, Fac Med, Dept Parasitol, Dakar, Senegal. [Barennes, Hubert] Ctr Muraz, Unite Epidemiol Intervent, Bobo Dioulasso, Burkina Faso. [Barennes, Hubert] French Foreign Affairs, Biarritz, France. [Barnes, Karen I.; Yeka, Adoke] WWARN, Pharmacol Module, Cape Town, South Africa. [Barnes, Karen I.] Univ Cape Town, Dept Med, Div Clin Pharmacol, ZA-7925 Cape Town, South Africa. [Bassat, Quique; Gonzalez, Raquel; Menendez, Clara] Ctr Invest Saude Manhica, Manhica, Mozambique. [Bassat, Quique; Gonzalez, Raquel; Menendez, Clara] Univ Barcelona, Hosp Clin, Barcelona Ctr Int Hlth Res CRESIB, ISGlobal, Barcelona, Spain. [Bjorkman, Anders; Martensson, Andreas] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Stockholm, Sweden. [Bompart, Francois] Direct AccEs Med Access Med, Gentilly, France. [Bonnet, Maryline] Epictr, Geneva, Switzerland. [Borrmann, Steffen] Univ Tubingen, Inst Trop Med, Tubingen, Germany. [Borrmann, Steffen] German Ctr Infect Res, Tubingen, Germany. [Brasseur, Philippe] IRD, Dakar, Senegal. [Bukirwa, Hasifa; Yeka, Adoke] Uganda Malaria Surveillance Project, Kampala, Uganda. [Cot, Michel; Deloron, Philippe] IRD, Mother & Child Hlth Trop Res Unit, Paris, France. [Cot, Michel; Deloron, Philippe] Univ Paris 05, Sorbonne Paris Cite, PRES, Paris, France. [Dahal, Prabin; Flegg, Jennifer A.; Guerin, Philippe J.; Humphreys, Georgina S.; Moreira, Clarissa; Nsanzabana, Christian; Sibley, Carol Hopkins; Stepniewska, Kasia] WWARN, Oxford, England. [Dahal, Prabin; Fanello, Caterina I.; Guerin, Philippe J.; Humphreys, Georgina S.; Lee, Sue J.; Moreira, Clarissa; Nsanzabana, Christian; Olliaro, Piero; Price, Ric N.; Tarning, Joel; White, Nicholas J.] Univ Oxford, Nuffield Dept Clin Med, Ctr Trop Med & Global Hlth, Oxford, England. [D'Alessandro, Umberto] Inst Trop Med, B-2000 Antwerp, Belgium. [D'Alessandro, Umberto] MRC Unit, Fajara, Gambia. [Desai, Meghna; Thwing, Julie I.] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA USA. [Diap, Graciela; Kiechel, Jean R.] Drugs Neglected Dis initiat, Geneva, Switzerland. [Djimde, Abdoulaye A.] Univ Bamako, Fac Med Pharm & Odontostomatol, Dept Epidemiol Parasit Dis, Malaria Res & Training Ctr, Bamako, Mali. [Dorsey, Grant; Rosenthal, Philip J.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Espie, Emmanuelle] Inst Pasteur, Dakar, Senegal. [Etard, Jean-Francois] IRD, Montpellier, France. [Fanello, Caterina I.] Mahidol Univ, Fac Trop Med, Mahidol Oxford Trop Med Res Unit MORU, Bangkok 10700, Thailand. [Faucher, Jean-Francois] Basancon Univ, Med Ctr, Dept Infect Dis, Besancon, France. [Flegg, Jennifer A.] Monash Univ, Sch Math Sci, Melbourne, Vic 3004, Australia. [Flegg, Jennifer A.] Monash Univ, Monash Acad Cross & Interdisciplinary Math Applic, Melbourne, Vic 3004, Australia. [Gething, Peter W.; Hay, Simon I.] Univ Oxford, Dept Zool, Spatial Ecol & Epidemiol Grp, Oxford, England. [Hamour, Sally] Royal Free Hosp, UCL Ctr Nephrol, London NW3 2QG, England. [Hasugian, Armedy Ronny; Tjitra, Emiliana] Nat Inst Hlth Res & Dev, Minist Hlth, Jakarta, Indonesia. [Jullien, Vincent] Univ Paris 05, Assistance Publ Hop Paris, Paris, France. [Juma, Elizabeth] Kenya Govt Med Res Ctr, Clin Res Ctr, Nairobi, Kenya. [Kamya, Moses R.] Makerere Univ, Coll Hlth Sci, Kampala, Uganda. [Karema, Corine] Minist Hlth, Malaria & Other Parasit Dis Div RBC, Kigali, Rwanda. [Kremsner, Peter G.; Lell, Bertrand] Ctr Rech Med Lambarene, Lambarene, Gabon. [Kremsner, Peter G.; Lell, Bertrand; Ntoumi, Francine] Univ Tubingen, Inst Tropenmed, Tubingen, Germany. [Krishna, Sanjeev] Univ London, Inst Infect & Immun St Georges, London, England. [Ibrahim, Laminou M.] Ctr Rech Med & Sanitaire, Niamey, Niger. [Martensson, Andreas] Karolinska Inst, Dept Publ Hlth Sci, Stockholm, Sweden. [Martensson, Andreas] Uppsala Univ, Ctr Clin Res Sormland, S-75105 Uppsala, Sweden. [Massougbodji, Achille] Univ Abomey Calavi, FSS, CERPAGE, Cotonou, Benin. [Menan, Herve] Univ Cocody, Fac Pharm, Dept Parasitol, Abidjan, Cote Ivoire. [Menard, Didier] Inst Pasteur Cambodge, Unite Epidemiol Mol Paludisme, Phnom Penh, Cambodia. [Meremikwu, Martin] Univ Calabar, Dept Paediat, Calabar, Nigeria. [Meremikwu, Martin] Inst Trop Dis Res & Prevent, Calabar, Nigeria. [Nabasumba, Carolyn] Mbarara Univ Sci & Technol, Fac Med, Mbarara, Uganda. [Nambozi, Michael] Trop Dis Res Ctr, Ndola, Zambia. [Nikiema, Frederic; Ouedraogo, Jean-Bosco; Tinto, Halidou; Zongo, Issaka] Inst Rech Sci Sante, Bobo Dioulasso, Burkina Faso. [Ntoumi, Francine] Univ Marien Ngouabi, Fac Sci Sante, FCRM, Brazzaville, Congo. [Ogutu, Bernhards R.] Kenya Govt Med Res Ctr, United States Army Med Res Unit, Kisumu, Kenya. [Olliaro, Piero; Taylor, Walter R. J.] UNDP, UNICEF, World Bank WHO Special Programme, Res & Training Trop Dis TDR, Geneva, Switzerland. [Osorio, Lyda] Int Ctr Med Res & Training CIDEIM, Cali, Colombia. [Ouedraogo, Jean-Bosco; Tinto, Halidou] Ctr Muraz, Bobo Dioulasso, Burkina Faso. [Penali, Louis K.; Seck, Amadou] WWARN, West Africa Reg Ctr, Dakar, Senegal. [Piola, Patrice] Inst Pasteur Madagascar, Antananarivo, Madagascar. [Price, Ric N.] Menzies Sch Hlth Res, Darwin, NT, Australia. [Price, Ric N.] Charles Darwin Univ, Darwin, NT 0909, Australia. [Roper, Cally] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, Dept Pathogen Mol Biol, London WC1, England. [Rwagacondo, Claude Emile] UNICEF WCARO, RBM Focal Point, Dakar, Senegal. [Same-Ekobo, Albert] Univ Yaounde, Ctr Hosp, Yaounde, Cameroon. [Sharma, Bhawna] Drugs Neglected Dis initiat, New Delhi, India. [Sibley, Carol Hopkins] Univ Washington, Dept Gen Sci, Seattle, WA 98195 USA. [Sinou, Veronique] Aix Marseille Univ, Fac Pharm, UMR MD3, Marseille, France. [Sirima, Sodiomon B.] CNRFP, Ouagadougou, Burkina Faso. [Smith, Jeffery J.; Tarning, Joel] WWARN, Asia Reg Ctr, Bangkok, Thailand. [Smith, Jeffery J.] Univ Maryland, Sch Med, Ctr Vaccine Dev, Baltimore, MD 21201 USA. [Smithuis, Frank] Med Sans Frontieres Holland, Yangon, Myanmar. [Smithuis, Frank] Med Act Myanmar, Yangon, Myanmar. [Staedke, Sarah G.] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, Dept Clin Res, London WC1, England. [Staedke, Sarah G.] Infect Dis Res Collaborat, Kampala, Uganda. [Swarthout, Todd D.] Med Sans Frontieres, London, England. [Talisuna, Ambrose O.] WWARN, East Africa Reg Ctr, Nairobi, Kenya. [Talisuna, Ambrose O.] Univ Oxford, KEMRI, Wellcome Trust Res Programme, Nairobi, Kenya. [Taylor, Walter R. J.] Hop Univ Geneva, Serv Med Int & Humanitaire, Geneva, Switzerland. [Temu, Emmanuel A.] Swiss Trop & Publ Hlth Inst, Basel, Switzerland. [Temu, Emmanuel A.] Univ Basel, Basel, Switzerland. [Vaillant, Michel T.] CRP Sante, Ctr Hlth Studies, Methodol & Stat Unit, Luxembourg, Luxembourg. [Vaillant, Michel T.] Univ Victor Segalen Bordeaux 2, Bases Therapeut Inflammat & Infect, Unite 3677, Bordeaux, France. [Van den Broek, Ingrid] Natl Inst Publ Hlth & Environm, Ctr Infect Dis Control, NL-3720 BA Bilthoven, Netherlands. [Yeka, Adoke] Makerere Univ, Sch Publ Hlth, Kampala, Uganda. RP Guerin, PJ (reprint author), Univ Oxford, Nuffield Dept Clin Med, Ctr Trop Med & Global Hlth, Oxford, England. EM philippe.guerin@wwarn.org; christian.nsanzabana@wwarn.org RI Roper, Cally/K-2989-2013; Hay, Simon/F-8967-2015; OI Humphreys, Georgina/0000-0001-9947-0034; Roper, Cally/0000-0002-6545-309X; Hay, Simon/0000-0002-0611-7272; Flegg, Jennifer/0000-0002-8809-726X; Dahal, Prabin/0000-0002-2158-846X; Krishna, Sanjeev/0000-0003-0066-0634; Price, Richard/0000-0003-2000-2874; Osorio, Lyda/0000-0002-5121-4741; Gething, Peter/0000-0001-6759-5449; Guerin, Philippe/0000-0002-6008-2963 FU Bill and Melinda Gates Foundation FX WWARN is funded by a Bill and Melinda Gates Foundation grant. The funder did not participate in the study protocol development and the writing of the paper. NR 78 TC 2 Z9 2 U1 2 U2 13 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1741-7015 J9 BMC MED JI BMC Med. PD MAR 31 PY 2015 VL 13 AR 66 DI 10.1186/s12916-015-0301-z PG 19 WC Medicine, General & Internal SC General & Internal Medicine GA CG8CY UT WOS:000353536000001 ER PT J AU Petrick, JL Steck, SE Bradshaw, PT Trivers, KF Abrahamson, PE Engel, LS He, K Chow, WH Mayne, ST Risch, HA Vaughan, TL Gammon, MD AF Petrick, J. L. Steck, S. E. Bradshaw, P. T. Trivers, K. F. Abrahamson, P. E. Engel, L. S. He, K. Chow, W-H Mayne, S. T. Risch, H. A. Vaughan, T. L. Gammon, M. D. TI Dietary intake of flavonoids and oesophageal and gastric cancer: incidence and survival in the United States of America (USA) SO BRITISH JOURNAL OF CANCER LA English DT Article DE diet; epidemiologic studies; oesophageal cancer; flavonoids; gastric cancer; survival ID GASTROESOPHAGEAL-REFLUX; RISK-FACTORS; ADENOCARCINOMA; POLYPHENOLS; BERRIES; EPIDEMIOLOGY; METAANALYSIS; CONSUMPTION; VEGETABLES; CARCINOMA AB Background: Flavonoids, polyphenolic compounds concentrated in fruits and vegetables, have experimentally demonstrated chemopreventive effects against oesophageal and gastric cancer. Few epidemiologic studies have examined flavonoid intake and incidence of these cancers, and none have considered survival. Methods: In this USA multicentre population-based study, case participants (diagnosed during 1993-1995 with oesophageal adenocarcinoma (OEA, n = 274), gastric cardia adenocarcinoma (GCA, n = 248), oesophageal squamous cell carcinoma (OES, n = 191), and other gastric adenocarcinoma (OGA, n = 341)) and frequency-matched controls (n = 662) were interviewed. Food frequency questionnaire responses were linked with USDA Flavonoid Databases and available literature for six flavonoid classes and lignans. Case participants were followed until 2000 for vital status. Multivariable-adjusted odds ratios (ORs) and hazard ratios (HRs) (95% confidence intervals (CIs)) were estimated, comparing highest with lowest intake quartiles, using polytomous logistic and proportional hazards regressions, respectively. Results: Little or no consistent association was found for total flavonoid intake (main population sources: black tea, orange/grapefruit juice, and wine) and incidence or survival for any tumour type. Intake of anthocyanidins, common in wine and fruit juice, was associated with a 57% reduction in the risk of incident OEA (OR = 0.43, 95% CI = 0.29-0.66) and OES (OR = 0.43, 95% CI = 0.26-0.70). The ORs for isoflavones, for which coffee was the main source, were increased for all tumours, except OES. Anthocyanidins were associated with decreased risk of mortality for GCA (HR = 0.63, 95% CI = 0.42-0.95) and modestly for OEA (HR = 0.87, 95% CI = 0.60-1.26), but CIs were wide. Conclusions: Our findings, if confirmed, suggest that increased dietary anthocyanidin intake may reduce incidence and improve survival for these cancers. C1 [Petrick, J. L.; Engel, L. S.; Gammon, M. D.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27599 USA. [Steck, S. E.] Univ S Carolina, Dept Epidemiol & Biostat, Columbia, SC 29208 USA. [Bradshaw, P. T.] Univ N Carolina, Dept Nutr, Chapel Hill, NC 27599 USA. [Trivers, K. F.] Ctr Dis Control, Div Canc Prevent & Control, Atlanta, GA 30333 USA. [Abrahamson, P. E.] Salmon Bay Consulting Inc, Seattle, WA USA. [He, K.] Indiana Univ, Dept Epidemiol & Biostat, Bloomington, IN USA. [Chow, W-H] Univ Texas MD Anderson Canc Ctr, Dept Epidemiol, Houston, TX 77030 USA. [Mayne, S. T.; Risch, H. A.] Yale Univ, Sch Publ Hlth, Dept Chron Dis Epidemiol, New Haven, CT USA. [Mayne, S. T.; Risch, H. A.] Yale Canc Ctr, New Haven, CT USA. [Vaughan, T. L.] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98104 USA. RP Petrick, JL (reprint author), Univ N Carolina, Dept Epidemiol, CB 7435, Chapel Hill, NC 27599 USA. EM jessica.petrick@unc.edu OI Engel, Lawrence/0000-0001-9268-4830 FU National Institutes of Health [R03-CA159409, T32-CA009330, T32-ES007018, U01-CA057983, U01-CA057949, U01-CA057923, P30-ES10126] FX This research was supported in part by grants from the National Institutes of Health (R03-CA159409, T32-CA009330, T32-ES007018, U01-CA057983, U01-CA057949, U01-CA057923, and P30-ES10126). We thank Eric Meier, Lynn Onstad, and Patricia Christopherson from the FHCRC for FFQ expertise; Dr Linda Liao from the National Cancer Institute for providing the parent study data; and Shelley Niwa from Westat for data preparation. NR 49 TC 10 Z9 10 U1 1 U2 26 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0007-0920 EI 1532-1827 J9 BRIT J CANCER JI Br. J. Cancer PD MAR 31 PY 2015 VL 112 IS 7 BP 1291 EP 1300 DI 10.1038/bjc.2015.25 PG 10 WC Oncology SC Oncology GA CE9DZ UT WOS:000352145300019 PM 25668011 ER PT J AU Budgell, E Cohen, AL McAnerney, J Walaza, S Madhi, SA Blumberg, L Dawood, H Kahn, K Tempia, S Venter, M Cohen, C AF Budgell, Eric Cohen, Adam L. McAnerney, Jo Walaza, Sibongile Madhi, Shabir A. Blumberg, Lucille Dawood, Halima Kahn, Kathleen Tempia, Stefano Venter, Marietjie Cohen, Cheryl TI Evaluation of Two Influenza Surveillance Systems in South Africa SO PLOS ONE LA English DT Article ID CASE DEFINITIONS; ILLNESS; EPIDEMIOLOGY; PERFORMANCE; DIAGNOSIS AB Background The World Health Organisation recommends outpatient influenza-like illness (ILI) and inpatient severe acute respiratory illness (SARI) surveillance. We evaluated two influenza surveillance systems in South Africa: one for ILI and another for SARI. Methodology The Viral Watch (VW) programme has collected virological influenza surveillance data voluntarily from patients with ILI since 1984 in private and public clinics in all 9 South African provinces. The SARI surveillance programme has collected epidemiological and virological influenza surveillance data since 2009 in public hospitals in 4 provinces by dedicated personnel. We compared nine surveillance system attributes from 2009-2012. Results We analysed data from 18,293 SARI patients and 9,104 ILI patients. The annual proportion of samples testing positive for influenza was higher for VW (mean 41%) than SARI (mean 8%) and generally exceeded the seasonal threshold from May to September (VW: weeks 21-40; SARI: weeks 23-39). Data quality was a major strength of SARI (most data completion measures > 90%; adherence to definitions: 88-89%) and a relative weakness of the VW programme (62% of forms complete, with limited epidemiologic data collected; adherence to definitions: 65-82%). Timeliness was a relative strength of both systems (e.g. both collected > 93% of all respiratory specimens within 7 days of symptom onset). ILI surveillance was more nationally representative, financially sustainable and expandable than the SARI system. Though the SARI programme is not nationally representative, the high quality and detail of SARI data collection sheds light on the local burden and epidemiology of severe influenza-associated disease. Conclusions To best monitor influenza in South Africa, we propose that both ILI and SARI should be under surveillance. Improving ILI surveillance will require better quality and more systematic data collection, and SARI surveillance should be expanded to be more nationally representative, even if this requires scaling back on information gathered. C1 [Budgell, Eric] Univ Oxford, Nuffield Dept Populat Hlth, Oxford, England. [Cohen, Adam L.; Tempia, Stefano] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. [Cohen, Adam L.; Tempia, Stefano] Ctr Dis Control & Prevent South Africa, Influenza Program, Pretoria, South Africa. [McAnerney, Jo; Walaza, Sibongile; Madhi, Shabir A.; Blumberg, Lucille; Venter, Marietjie; Cohen, Cheryl] Natl Inst Communicable Dis, Natl Hlth Lab Serv, Ctr Resp Dis & Meningitis, Johannesburg, South Africa. [Madhi, Shabir A.] Univ Witwatersrand, Dept Sci & Technol, Natl Res Fdn Vaccine Preventable Dis, Johannesburg, South Africa. [Dawood, Halima] Pietermaritzburg Metropolitan Hosp Complex, Dept Med, Kwa Zulu, South Africa. [Dawood, Halima] Univ KwaZulu Natal, Pietermaritzburg, South Africa. [Kahn, Kathleen] Univ Witwatersrand, Fac Hlth Sci, MRC Wits Rural Publ Hlth & Hlth Transit Res Unit, Sch Publ Hlth, Johannesburg, South Africa. [Tempia, Stefano] CTS Global Inc, Los Angeles, CA USA. [Venter, Marietjie] Univ Pretoria, Dept Med Virol, Zoonoses Res Unit, ZA-0001 Pretoria, South Africa. [Cohen, Cheryl] Univ Witwatersrand, Sch Publ Hlth, Johannesburg, South Africa. [Cohen, Cheryl] Univ Witwatersrand, Sch Pathol, Johannesburg, South Africa. RP Budgell, E (reprint author), Univ Oxford, Nuffield Dept Populat Hlth, Oxford, England. EM ebudgell@heroza.org RI Venter, Marietjie/P-9604-2016 OI Venter, Marietjie/0000-0003-2696-824X FU National Institute for Communicable Diseases of the National Health Laboratory Service [U51/IP000155-04]; United States Centers for Disease Control and Prevention (CDC), Atlanta, Georgia Preparedness and Response to Avian and Pandemic Influenza in South Africa [U51/IP000155-04] FX This study received funding from the National Institute for Communicable Diseases of the National Health Laboratory Service and was supported in part by funds from the United States Centers for Disease Control and Prevention (CDC), Atlanta, Georgia Preparedness and Response to Avian and Pandemic Influenza in South Africa (Cooperative Agreement Number: U51/IP000155-04). The contents are solely the responsibility of the authors and do not necessarily represent the official views of the CDC. The funders had no role in study design, implementation, manuscript writing or the decision to submit for publication. The corresponding author had full access to all the data in the study and takes final responsibility for the decision to submit for publication. NR 20 TC 2 Z9 2 U1 0 U2 1 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAR 30 PY 2015 VL 10 IS 3 AR e0120226 DI 10.1371/journal.pone.0120226 PG 13 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CE9AD UT WOS:000352134700058 PM 25822719 ER PT J AU Cleveland, AA Harrison, LH Farley, MM Hollick, R Stein, B Chiller, TM Lockhart, SR Park, BJ AF Cleveland, Angela Ahlquist Harrison, Lee H. Farley, Monica M. Hollick, Rosemary Stein, Betsy Chiller, Tom M. Lockhart, Shawn R. Park, Benjamin J. TI Declining Incidence of Candidemia and the Shifting Epidemiology of Candida Resistance in Two US Metropolitan Areas, 2008-2013: Results from Population-Based Surveillance SO PLOS ONE LA English DT Article ID BLOOD-STREAM INFECTIONS; INTENSIVE-CARE-UNIT; SUSCEPTIBILITY; GLABRATA; TRENDS; ECHINOCANDINS; MUTATIONS; HOSPITALS; CLSI AB Background Recent reports have demonstrated a decline in bacterial bloodstream infections (BSIs) following adherence to central line insertion practices; however, declines have been less evident for BSIs due to Candida species. Methods We conducted active, population-based laboratory surveillance for candidemia in metropolitan Atlanta, GA and Baltimore, MD over a 5-year period. We calculated annual candidemia incidence and antifungal drug resistance rates. Results We identified 3,848 candidemia cases from 2008-2013. Compared with 2008, candidemia incidence per 100,000 person-years decreased significantly by 2013 in both locations (GA: 14.1 to 9.5, p< 0.001; MD: 30.9 to 14.4, p< 0.001). A total of 3,255 cases (85%) had a central venous catheter (CVC) in place within 2 days before the BSI culture date. In both locations, the number of CVC-associated cases declined (GA: 473 to 294; MD: 384 to 151). Candida albicans (CA, 36%) and Candida glabrata (CG, 27%) were the most common species recovered. In both locations, the proportion of cases with fluconazole resistance decreased (GA: 8.0% to 7.1%, -10%; MD: 6.6% to 4.9%, -25%), while the proportion of cases with an isolate resistant to an echinocandin increased (GA: 1.2% to 2.9%, +147%; MD: 2.0% to 3.5%, +77%). Most (74%) echinocandin-resistant isolates were CG; 17 (< 1%) isolates were resistant to both drug categories (multidrug resistant [MDR], 16/17 were CG). The proportion of CG cases with MDR Candida increased from 1.8% to 2.6%. Conclusions We observed a significant decline in the incidence of candidemia over a five-year period, and increases in echinocandin-resistant and MDR Candida. Efforts to strengthen infection control practices may be preventing candidemia among high-risk patients. Further surveillance for resistant Candida is warranted. C1 [Cleveland, Angela Ahlquist; Chiller, Tom M.; Lockhart, Shawn R.; Park, Benjamin J.] Ctr Dis Control & Prevent, Mycot Dis Branch, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30333 USA. [Harrison, Lee H.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA. [Farley, Monica M.; Stein, Betsy] Emory Univ, Sch Med, Atlanta Vet Affairs Med Ctr, Georgia Emerging Infect Program, Atlanta, GA USA. [Farley, Monica M.; Stein, Betsy] Emory Univ, Sch Med, Dept Med, Atlanta, GA USA. RP Cleveland, AA (reprint author), Ctr Dis Control & Prevent, Mycot Dis Branch, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30333 USA. EM ara0@cdc.gov NR 29 TC 24 Z9 26 U1 2 U2 7 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAR 30 PY 2015 VL 10 IS 3 AR e0120452 DI 10.1371/journal.pone.0120452 PG 12 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CE9AD UT WOS:000352134700064 PM 25822249 ER PT J AU Supervie, V Archibald, CP Costagliola, D Delpech, V Hall, HI Lot, F van Sighem, A Wilson, DP AF Supervie, Virginie Archibald, Chris P. Costagliola, Dominique Delpech, Valerie Hall, H. Irene Lot, Florence van Sighem, Ard Wilson, David P. TI GBD 2013 and HIV incidence in high income countries SO LANCET LA English DT Letter ID NUMBER C1 [Supervie, Virginie; Costagliola, Dominique] Univ Paris 04, INSERM, Pierre Louis Inst Epidemiol & Publ Hlth, UMR S 1136, F-75013 Paris, France. [Archibald, Chris P.] Publ Hlth Agcy Canada, Ctr Communicable Dis & Infect Control, Ottawa, ON, Canada. [Delpech, Valerie] Hlth Protect Agcy, Hlth Protect Serv, London, England. [Hall, H. Irene] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [Lot, Florence] French Inst Publ Hlth Surveillance, St Maurice, France. [van Sighem, Ard] Stichting HIV Monitoring, Amsterdam, Netherlands. [Wilson, David P.] Univ New S Wales, Kirby Inst, Sydney, NSW, Australia. RP Supervie, V (reprint author), Univ Paris 04, INSERM, Pierre Louis Inst Epidemiol & Publ Hlth, UMR S 1136, F-75013 Paris, France. EM virginie.supervie@inserm.fr RI Supervie, Virginie/N-8032-2015; Costagliola, Dominique/H-5849-2011 OI Supervie, Virginie/0000-0003-0399-1957; Costagliola, Dominique/0000-0003-0765-0869 NR 5 TC 3 Z9 3 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0140-6736 EI 1474-547X J9 LANCET JI Lancet PD MAR 28 PY 2015 VL 385 IS 9974 BP 1177 EP 1177 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA CE3GQ UT WOS:000351715100019 PM 25845784 ER PT J AU Ercumen, A Naser, AM Unicomb, L Arnold, BF Colford, JM Luby, SP AF Ercumen, Ayse Naser, Abu Mohd. Unicomb, Leanne Arnold, Benjamin F. Colford, John M., Jr. Luby, Stephen P. TI Effects of Source- versus Household Contamination of Tubewell Water on Child Diarrhea in Rural Bangladesh: A Randomized Controlled Trial SO PLOS ONE LA English DT Article ID DICHLOROISOCYANURATE NADCC TABLETS; SAFE DRINKING-WATER; POINT-OF-USE; DEVELOPING-COUNTRIES; ESCHERICHIA-COLI; WELL-WATER; FECAL CONTAMINATION; ROUTINE TREATMENT; QUALITY; CHOLERA AB Background Shallow tubewells are the primary drinking water source for most rural Bangladeshis. Fecal contamination has been detected in tubewells, at low concentrations at the source and at higher levels at the point of use. We conducted a randomized controlled trial to assess whether improving the microbiological quality of tubewell drinking water by household water treatment and safe storage would reduce diarrhea in children <2 years in rural Bangladesh. Methods We randomly assigned 1800 households with a child aged 6-18 months (index child) into one of three arms: chlorine plus safe storage, safe storage and control. We followed households with monthly visits for one year to promote the interventions, track their uptake, test participants' source and stored water for fecal contamination, and record caregiver-reported child diarrhea prevalence (primary outcome). To assess reporting bias, we also collected data on health outcomes that are not expected to be impacted by our interventions. Findings Both interventions had high uptake. Safe storage, alone or combined with chlorination, reduced heavy contamination of stored water. Compared to controls, diarrhea in index children was reduced by 36% in the chlorine plus safe storage arm (prevalence ratio, PR = 0.64, 0.55-0.73) and 31% in the safe storage arm (PR = 0.69, 0.60-0.80), with no difference between the two intervention arms. One limitation of the study was the non-blinded design with self-reported outcomes. However, the prevalence of health outcomes not expected to be impacted by water interventions did not differ between study arms, suggesting minimal reporting bias. Conclusions Safe storage significantly improved drinking water quality at the point of use and reduced child diarrhea in rural Bangladesh. There was no added benefit from combining safe storage with chlorination. Efforts should be undertaken to implement and evaluate long-term efforts for safe water storage in Bangladesh. C1 [Ercumen, Ayse; Arnold, Benjamin F.; Colford, John M., Jr.] Univ Calif Berkeley, Sch Publ Hlth, Div Epidemiol, Berkeley, CA 94720 USA. [Naser, Abu Mohd.; Unicomb, Leanne; Luby, Stephen P.] Int Ctr Diarrhoeal Dis Res, Ctr Communicable Dis, Dhaka 1000, Bangladesh. [Luby, Stephen P.] Stanford Univ, Sch Med, Stanford, CA 94305 USA. [Luby, Stephen P.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Ercumen, A (reprint author), Univ Calif Berkeley, Sch Publ Hlth, Div Epidemiol, Berkeley, CA 94720 USA. EM aercumen@berkeley.edu OI Luby, Stephen/0000-0001-5385-899X FU United States Agency for International Development (USAID) FX This work was funded by the United States Agency for International Development (USAID). *icddr,b acknowledges with gratitude the commitment of USAID to its research efforts. The contents of this manuscript are the sole responsibility of icddr,b and do not necessarily reflect the views of USAID, CDC or the United States Government. *Medentech provided the NaDCC tablets used in the study free of charge. USAID or Medentech had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 56 TC 10 Z9 10 U1 1 U2 5 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAR 27 PY 2015 VL 10 IS 3 AR UNSP e0121907 DI 10.1371/journal.pone.0121907 PG 22 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CE8ZT UT WOS:000352133600126 PM 25816342 ER PT J AU Vale, VV Vilhena, TC Trindade, RCS Ferreira, MRC Percario, S Soares, LF Pereira, WLA Brandao, GC Oliveira, AB Dolabela, MF De Vasconcelos, F AF Vale, Valdicley V. Vilhena, Thyago C. Trindade, Rafaela C. Santos Ferreira, Marlia Regina C. Percario, Sandro Soares, Luciana F. Pereira, Washington Luiz A. Brandao, Geraldo C. Oliveira, Alaide B. Dolabela, Maria F. De Vasconcelos, Flavio TI Anti-malarial activity and toxicity assessment of Himatanthus articulatus, a plant used to treat malaria in the Brazilian Amazon SO MALARIA JOURNAL LA English DT Article DE Himatanthus articulatus; Malaria; Toxicity; Plumieride; Oxidative stress ID PLASMODIUM-FALCIPARUM; ANTIPLASMODIAL ACTIVITY; DRUG RESISTANCE; APOCYNACEAE; ALKALOIDS; SUCUUBA; CULTURE; BIOSYNTHESIS; IRIDOIDS; WOODSON AB Background: Plasmodium falciparum has become resistant to some of the available drugs. Several plant species are used for the treatment of malaria, such as Himatanthus articulatus in parts of Brazil. The present paper reports the phyto-chemistry, the anti-plasmodial and anti-malarial activity, as well as the toxicity of H. articulatus. Methods: Ethanol and dichloromethane extracts were obtained from the powder of stem barks of H. articulatus and later fractionated and analysed. The anti-plasmodial activity was assessed against a chloroquine resistant strain P. falciparum (W2) in vitro, whilst in vivo anti-malarial activity against Plasmodium berghei (ANKA strain) was tested in mice, evaluating the role of oxidative stress (total antioxidant capacity - TEAC; lipid peroxidation - TBARS, and nitrites and nitrates - NN). In addition, cytotoxicity was evaluated using the HepG2 A16 cell-line. The acute oral and sub-chronic toxicity of the ethanol extract were evaluated in both male and female mice. Results: Plumieride was isolated from the ethyl acetate fraction of ethanol extract, Only the dichloromethane extract was active against clone W2. Nevertheless, both extracts reduced parasitaemia in P. berghei-infected mice. Besides, a significant reduction in pulmonary and cerebral levels of NN (nitrites and nitrates) was found, as well as in pulmonary TBARS, indicating a reduced oxidative damage to these organs. The ethanol extract showed low cytotoxicity to HepG2 A16 cells in the concentrations used. No significant changes were observed in the in vivo toxicity studies. Conclusions: The ethanol extract of H. articulatus proved to be promising as anti-malarial medicine and showed low toxicity. C1 [Vale, Valdicley V.; Vilhena, Thyago C.; Oliveira, Alaide B.; Dolabela, Maria F.; De Vasconcelos, Flavio] UFPA, ICS, Programa Posgrad Ciencias Farmaceut, BR-68075110 Belem, PA, Brazil. [Trindade, Rafaela C. Santos; Ferreira, Marlia Regina C.] Museu Paraense Emilio Goeldi, Dept Bot, Belem, PA, Brazil. [Percario, Sandro] UFPA, ICB, Lab Pesquisa Estresse Oxidat, BR-68075110 Belem, PA, Brazil. [Soares, Luciana F.; Oliveira, Alaide B.] Univ Fed Minas Gerais, Fac Farm, Belo Horizonte, MG, Brazil. [Pereira, Washington Luiz A.] Univ Fed Rural Amazonia, ISPA, Dept Patol Vet & Med Prevent, Belem, PA, Brazil. [Dolabela, Maria F.] UFPA, ICS, Programa Posgrad Inovacao Farmaceut, BR-68075110 Belem, PA, Brazil. [Percario, Sandro] US Ctr Dis Control & Prevent CDC, Atlanta, GA USA. [Brandao, Geraldo C.] Univ Fed Ouro Preto, Escola Farm, Ouro Preto, MG, Brazil. RP De Vasconcelos, F (reprint author), UFPA, ICS, Programa Posgrad Ciencias Farmaceut, Rua Augusto Correa 1, BR-68075110 Belem, PA, Brazil. EM flavio@ufpa.br OI Percario, Sandro/0000-0002-9528-0361 FU National Counsel of Technological and Scientific Development (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico - CNPq); PRONEX-CNPq; Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG); Fundacao Amazonia Paraense de Amparo a Pesquisa (FAPESPA); PPSUS-FAPESPA FX The authors gratefully acknowledge the financial support from National Counsel of Technological and Scientific Development (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico - CNPq), PRONEX-CNPq, Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG), Fundacao Amazonia Paraense de Amparo a Pesquisa (FAPESPA), PPSUS-FAPESPA. NR 51 TC 2 Z9 2 U1 1 U2 15 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1475-2875 J9 MALARIA J JI Malar. J. PD MAR 27 PY 2015 VL 14 AR 132 DI 10.1186/s12936-015-0643-1 PG 10 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA CE8PZ UT WOS:000352107300001 PM 25888719 ER PT J AU Wheaton, AG Cunningham, TJ Ford, ES Croft, JB AF Wheaton, Anne G. Cunningham, Timothy J. Ford, Earl S. Croft, Janet B. TI Employment and Activity Limitations Among Adults with Chronic Obstructive Pulmonary Disease - United States, 2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Editorial Material ID BURDEN; COPD C1 [Wheaton, Anne G.; Cunningham, Timothy J.; Ford, Earl S.; Croft, Janet B.] CDC, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Wheaton, AG (reprint author), CDC, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM awheaton@cdc.gov NR 10 TC 14 Z9 14 U1 0 U2 3 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 27 PY 2015 VL 64 IS 11 BP 289 EP 295 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CE2HJ UT WOS:000351635900001 PM 25811677 ER PT J AU Hastings, DL Harrington, KJ Kutty, PK Rayman, RJ Spindola, D Diaz, MH Thurman, KA Winchell, JM Safranek, TJ AF Hastings, Deborah L. Harrington, Kari J. Kutty, Preeta K. Rayman, Rebecca J. Spindola, Dana Diaz, Maureen H. Thurman, Kathleen A. Winchell, Jonas M. Safranek, Thomas J. TI Mycoplasma pneumoniae Outbreak in a Long-Term Care Facility - Nebraska, 2014 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Editorial Material ID COMMUNITY-ACQUIRED PNEUMONIA; ATYPICAL PATHOGENS C1 [Hastings, Deborah L.] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Hastings, Deborah L.; Safranek, Thomas J.] Nebraska Dept Hlth & Human Serv, Columbus, NE USA. [Harrington, Kari J.; Rayman, Rebecca J.; Spindola, Dana] East Cent Dist Hlth Dept, Columbus, NE USA. [Kutty, Preeta K.; Diaz, Maureen H.; Thurman, Kathleen A.; Winchell, Jonas M.] CDC, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Hastings, DL (reprint author), CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. EM dkh5@cdc.gov NR 10 TC 4 Z9 4 U1 0 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 27 PY 2015 VL 64 IS 11 BP 296 EP 299 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CE2HJ UT WOS:000351635900002 PM 25811678 ER PT J AU Petrosky, E Bocchini, JA Hariri, S Chesson, H Curtis, CR Saraiya, M Unger, ER Markowitz, LE AF Petrosky, Emiko Bocchini, Joseph A., Jr. Hariri, Susan Chesson, Harrell Curtis, C. Robinette Saraiya, Mona Unger, Elizabeth R. Markowitz, Lauri E. TI Use of 9-Valent Human Papillomavirus (HPV) Vaccine: Updated HPV Vaccination Recommendations of the Advisory Committee on Immunization Practices SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Editorial Material ID CERVICAL-CANCER; PRACTICES ACIP; DISEASE; PREVENTION; BURDEN C1 [Petrosky, Emiko] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Petrosky, Emiko; Hariri, Susan; Chesson, Harrell; Markowitz, Lauri E.] CDC, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Bocchini, Joseph A., Jr.] Louisiana State Univ, Hlth Sci Ctr, Shreveport, LA 71105 USA. [Curtis, C. Robinette] CDC, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Saraiya, Mona] CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Unger, Elizabeth R.] CDC, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. RP Petrosky, E (reprint author), CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. EM xfq7@cdc.gov NR 19 TC 186 Z9 190 U1 1 U2 17 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 27 PY 2015 VL 64 IS 11 BP 300 EP 304 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CE2HJ UT WOS:000351635900003 PM 25811679 ER PT J AU Jackson, BR Iqbal, S Mahon, B AF Jackson, Brendan R. Iqbal, Shahed Mahon, Barbara TI Updated Recommendations for the Use of Typhoid Vaccine - Advisory Committee on Immunization Practices, United States, 2015 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Editorial Material ID PARATYPHOID FEVER; SALMONELLA-TYPHI; VI CONJUGATE; TRAVELERS; PREVENTION; CHILDREN; SAFETY; TRIAL C1 [Jackson, Brendan R.; Mahon, Barbara] CDC, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Iqbal, Shahed] CDC, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. RP Jackson, BR (reprint author), CDC, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. EM iyn0@cdc.gov NR 24 TC 5 Z9 5 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 27 PY 2015 VL 64 IS 11 BP 305 EP 308 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CE2HJ UT WOS:000351635900004 PM 25811680 ER PT J AU Joyner, C Barnwell, JW Galinski, MR AF Joyner, Chester Barnwell, John W. Galinski, Mary R. TI No more monkeying around: primate malaria model systems are key to understanding Plasmodium vivax liver-stage biology, hypnozoites, and relapses SO FRONTIERS IN MICROBIOLOGY LA English DT Article DE malaria; Plasmodium; P vivax; P cynomolgi; liver; hypnozoite; dormancy; non-human primate animal models ID HOST-PARASITE INTERACTIONS; CAVEOLA-VESICLE COMPLEXES; EXTRACELLULAR VESICLES; AOTUS MONKEYS; SCHUFFNERS DOTS; EL-SALVADOR; CYNOMOLGI; STRAIN; METABOLOMICS; SPOROZOITES AB Plasmodium vivax is a human malaria parasite responsible for significant morbidity worldwide and potentially death. This parasite possesses formidable liver-stage biology that involves the formation of dormant parasites known as hypnozoites. Hypnozoites are capable of activating weeks, months, or years after a primary blood-stage infection causing relapsing bouts of illness. Elimination of this dormant parasitic reservoir will be critical for global malaria eradication. Although hypnozoites were first discovered in 1982, few advancements have been made to understand their composition and biology. Until recently, in vitro models did not exist to study these forms and studying them from human ex vivo samples was virtually impossible. Today, non-human primate (NHP) models and modern systems biology approaches are poised as tools to enable the in-depth study of P vivax liver-stage biology, including hypnozoites and relapses. NHP liver-stage model systems for P vivax and the related simian malaria species P cynomolgi are discussed along with perspectives regarding metabolite biomarker discovery, putative roles of extracellular vesicles, and relapse immunobiology. C1 [Joyner, Chester; Barnwell, John W.; Galinski, Mary R.] Emory Univ, Yerkes Natl Primate Res Ctr, Emory Vaccine Ctr, Malaria Host Pathogen Interact Ctr, Atlanta, GA 30329 USA. [Barnwell, John W.] Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, Atlanta, GA USA. [Galinski, Mary R.] Emory Univ, Dept Med, Div Infect Dis, Atlanta, GA 30329 USA. RP Galinski, MR (reprint author), Emory Univ, Yerkes Natl Primate Res Ctr, Emory Vaccine Ctr, Malaria Host Pathogen Interact Ctr, 954 Gatewood Rd, Atlanta, GA 30329 USA. EM mary.galinski@emory.edu FU Federal funds from the US National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services [HHSN272201200031C]; ORIP/OD (Yerkes National Primate Research Center) [P510D011132] FX This project was funded, in part, by Federal funds from the US National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services under contract it HHSN272201200031C as well as ORIP/OD P510D011132 (Yerkes National Primate Research Center). Special thanks are given to Dr. Jorge L. Salinas for a critical review of this article. NR 72 TC 10 Z9 10 U1 1 U2 7 PU FRONTIERS MEDIA SA PI LAUSANNE PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND SN 1664-302X J9 FRONT MICROBIOL JI Front. Microbiol. PD MAR 26 PY 2015 VL 6 AR 145 DI 10.3389/fmicb.2015.00145 PG 8 WC Microbiology SC Microbiology GA CF4PQ UT WOS:000352532800001 PM 25859242 ER PT J AU Vora, NM Li, Y Geleishvili, M Emerson, GL Khmaladze, E Maghlakelidze, G Navdarashvili, A Zakhashvili, K Kokhreidze, M Endeladze, M Mokverashvili, G Satheshkumar, PS Gallardo-Romero, N Goldsmith, CS Metcalfe, MG Damon, I Maes, EF Reynolds, MG Morgan, J Carroll, DS AF Vora, Neil M. Li, Yu Geleishvili, Marika Emerson, Ginny L. Khmaladze, Ekaterine Maghlakelidze, Giorgi Navdarashvili, Archil Zakhashvili, Khatuna Kokhreidze, Maka Endeladze, Marina Mokverashvili, Gela Satheshkumar, P. S. Gallardo-Romero, Nadia Goldsmith, Cynthia S. Metcalfe, Maureen G. Damon, Inger Maes, Edmond F. Reynolds, Mary G. Morgan, Juliette Carroll, Darin S. TI Human Infection with a Zoonotic Orthopoxvirus in the Country of Georgia SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID COWPOX VIRUS-INFECTION; TIME PCR ASSAYS; MONKEYPOX-VIRUS; UNITED-STATES; WILD RODENTS; POXVIRUS; AFRICAN AB During 2013, cutaneous lesions developed in two men in the country of Georgia after they were exposed to ill cows. The men had never received vaccination against smallpox. Tests of lesion material with the use of a quantitative real-time polymerase-chain-reaction assay for non-variola virus orthopoxviruses were positive, and DNA sequence analysis implicated a novel orthopoxvirus species. During the ensuing epidemiologic investigation, no additional human cases were identified. However, serologic evidence of exposure to an orthopoxvirus was detected in cows in the patients' herd and in captured rodents and shrews. A third case of human infection that occurred in 2010 was diagnosed retrospectively during testing of archived specimens that were originally submitted for tests to detect anthrax. Orthopoxvirus infection should be considered in persons in whom cutaneous lesions develop after contact with animals. C1 [Vora, Neil M.] Ctr Dis Control & Prevent CDC, Epidem Intelligence Serv, Atlanta, GA USA. [Vora, Neil M.; Li, Yu; Emerson, Ginny L.; Satheshkumar, P. S.; Gallardo-Romero, Nadia; Goldsmith, Cynthia S.; Metcalfe, Maureen G.; Damon, Inger; Reynolds, Mary G.; Carroll, Darin S.] Ctr Dis Control & Prevent CDC, Div High Consequence Pathogens & Pathol, Atlanta, GA USA. [Vora, Neil M.; Geleishvili, Marika; Maes, Edmond F.; Morgan, Juliette] Ctr Dis Control & Prevent CDC, Div Global Hlth Protect, Atlanta, GA USA. [Geleishvili, Marika; Morgan, Juliette] CDC Georgia Country Off, Tbilisi, Rep of Georgia. [Khmaladze, Ekaterine; Navdarashvili, Archil; Zakhashvili, Khatuna] Natl Ctr Dis Control & Publ Hlth, Tbilisi, Rep of Georgia. [Maghlakelidze, Giorgi; Kokhreidze, Maka] Lab Minist Agr, Tbilisi, Rep of Georgia. [Endeladze, Marina] Infect Dis AIDS & Clin Immunol Res Ctr, Tbilisi, Rep of Georgia. [Mokverashvili, Gela] Natl Food Agcy, Tianeti, Rep of Georgia. RP Carroll, DS (reprint author), CDC, Div High Consequence Pathogens & Pathol, 1600 Clifton Rd NE,Mailstop G43, Atlanta, GA 30333 USA. EM zuz4@cdc.gov FU Intramural CDC HHS [CC999999] NR 32 TC 4 Z9 4 U1 1 U2 12 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD MAR 26 PY 2015 VL 372 IS 13 BP 1223 EP 1230 DI 10.1056/NEJMoa1407647 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA CE1QD UT WOS:000351585900008 PM 25806914 ER PT J AU Lindegren, ML Griffin, MR Williams, JV Edwards, KM Zhu, YW Mitchel, E Fry, AM Schaffner, W Talbot, HK AF Lindegren, Mary Louise Griffin, Marie R. Williams, John V. Edwards, Kathryn M. Zhu, Yuwei Mitchel, Ed Fry, Alicia M. Schaffner, William Talbot, H. Keipp TI Antiviral Treatment among Older Adults Hospitalized with Influenza, 2006-2012 SO PLOS ONE LA English DT Article ID RESPIRATORY SYNCYTIAL VIRUS; HIGH-RISK ADULTS; UNITED-STATES; SEASONAL INFLUENZA; RAPID INFLUENZA; MANAGEMENT; INFECTION; IMPACT; METAANALYSIS; DIAGNOSIS AB Objective To describe antiviral use among older, hospitalized adults during six influenza seasons (2006-2012) in Davidson County, Tennessee, USA. Methods Among adults >= 50 years old hospitalized with symptoms of respiratory illness or non-localizing fever, we collected information on provider-initiated influenza testing and nasal/throat swabs for influenza by RT-PCR in a research laboratory, and calculated the proportion treated with antivirals. Results We enrolled 1753 adults hospitalized with acute respiratory illness. Only 26% (457/1753) of enrolled patients had provider-initiated influenza testing. Thirty-eight patients had a positive clinical laboratory test, representing 2.2% of total patients and 8.3% of tested patients. Among the 38 subjects with clinical laboratory-confirmed influenza, 26.3% received antivirals compared to only 4.5% of those with negative clinical influenza tests and 0.7% of those not tested (p< 0.001). There were 125 (7.1%) patients who tested positive for influenza in the research laboratory. Of those with research laboratory-confirmed influenza, 0.9%, 2.7%, and 2.8% received antivirals (p = .046) during pre-pandemic, pandemic, and post-pandemic influenza seasons, respectively. Both research laboratory-confirmed influenza (adjusted odds ratio [AOR] 3.04 95% CI 1.26-7.35) and clinical laboratory-confirmed influenza (AOR 3.05, 95% CI 1.07-8.71) were independently associated with antiviral treatment. Severity of disease, presence of a high-risk condition, and symptom duration were not associated with antiviral use. Conclusions In urban Tennessee, antiviral use was low in patients recognized to have influenza by the provider as well as those unrecognized to have influenza. The use of antivirals remained low despite recommendations to treat all hospitalized patients with confirmed or suspected influenza. C1 [Lindegren, Mary Louise; Williams, John V.; Edwards, Kathryn M.] Vanderbilt Univ, Sch Med, Dept Pediat, Nashville, TN 37212 USA. [Griffin, Marie R.; Schaffner, William; Talbot, H. Keipp] Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37212 USA. [Griffin, Marie R.; Schaffner, William] Vanderbilt Univ, Sch Med, Dept Hlth Policy, Nashville, TN 37212 USA. [Griffin, Marie R.] VA TN Valley Hlth Care Syst, Midsouth Geriatr Res Educ & Clin Ctr, Nashville, TN USA. [Williams, John V.] Vanderbilt Univ, Sch Med, Dept Pathol Microbiol & Immunol, Nashville, TN 37212 USA. [Edwards, Kathryn M.] Vanderbilt Univ, Sch Med, Dept Pediat, Vanderbilt Vaccine Res Program, Nashville, TN 37212 USA. [Zhu, Yuwei; Mitchel, Ed] Vanderbilt Univ, Sch Med, Dept Biostat, Nashville, TN 37212 USA. [Fry, Alicia M.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Lindegren, ML (reprint author), Vanderbilt Univ, Sch Med, Dept Pediat, Nashville, TN 37212 USA. EM Marylou.lindegren@Vanderbilt.edu FU VTEU [N01 AI25462, 1U181P000184-01]; Centers for Disease Control and Prevention [200-2008-24624]; NIH/NCRR [5 K12 RR017697-05]; NIAID [1K23AI074863-01]; CTSA from the National Center for Advancing Translational Sciences [UL1TR000445] FX Funding for this study was through multiple sources: Surveillance for the first two years was funded by the VTEU (N01 AI25462) (Kathryn M. Edwards MD, site PI), during years 3-5 by CDC (1U181P000184-01) (Marie Griffin MD, site PI), and in the final year by the Centers for Disease Control and Prevention (contract 200-2008-24624 to RTI International). Dr. Talbot received salary support and career development from the NIH/NCRR (5 K12 RR017697-05), and from the NIAID (1K23AI074863-01). This project was also supported by CTSA award No. UL1TR000445 from the National Center for Advancing Translational Sciences. Its contents are solely the responsibility of the authors and do not necessarily represent official views of the National Center for Advancing Translational Sciences or the National Institutes of Health or the views of the Centers for Disease Control and Prevention. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 38 TC 2 Z9 2 U1 0 U2 0 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAR 25 PY 2015 VL 10 IS 3 AR e0121952 DI 10.1371/journal.pone.0121952 PG 16 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CE5MO UT WOS:000351880000191 PM 25807314 ER PT J AU Hazen, TH Lafon, PC Garrett, NM Lowe, TM Silberger, DJ Rowe, LA Frace, M Parsons, MB Bopp, CA Rasko, DA Sobecky, PA AF Hazen, Tracy H. Lafon, Patricia C. Garrett, Nancy M. Lowe, Tiffany M. Silberger, Daniel J. Rowe, Lori A. Frace, Michael Parsons, Michele B. Bopp, Cheryl A. Rasko, David A. Sobecky, Patricia A. TI Insights into the environmental reservoir of pathogenic Vibrio parahaemolyticus using comparative genomics SO FRONTIERS IN MICROBIOLOGY LA English DT Article DE genomics; Vibrio parahaemolyticus; environment; phylogenomics; O3:K6 ID MULTILOCUS SEQUENCE-ANALYSIS; III SECRETION SYSTEM; EVOLUTIONARY GENETICS ANALYSIS; THERMOSTABLE DIRECT HEMOLYSIN; FIELD GEL-ELECTROPHORESIS; GULF-OF-MEXICO; ESCHERICHIA-COLI; MAXIMUM-LIKELIHOOD; O3-K6 CLONE; STRAINS AB Vibrio parahaemolyticus is an aquatic halophilic bacterium that occupies estuarine and coastal marine environments, and is a leading cause of seafood-borne food poisoning cases. To investigate the environmental reservoir and potential gene flow that occurs among V. parahaemolyticus isolates, the virulence-associated gene content and genome diversity of a collection of 133 V. parahaemolyticus isolates were analyzed. Phylogenetic analysis of housekeeping genes, and pulsed-field gel electrophoresis, demonstrated that there is genetic similarity among V. parahaemolyticus clinical and environmental isolates. Whole-genome sequencing and comparative analysis of six representative V. parahaemolyticus isolates was used to identify genes that are unique to the clinical and environmental isolates examined. Comparative genomics demonstrated an O3:K6 environmental isolate, AF91, which was cultured from sediment collected in Florida in 2006, has significant genomic similarity to the post-1995 O3:K6 isolates. However, AF91 lacks the majority of the virulence-associated genes and genomic islands associated with these highly virulent post-1995 O3:K6 genomes. These findings demonstrate that although they do not contain most of the known virulence-associated regions, some V. parahaemolyticus environmental isolates exhibit significant genetic similarity to clinical isolates. This highlights the dynamic nature of the V. parahaemolyticus genome allowing them to transition between aquatic and host-pathogen states. C1 [Hazen, Tracy H.; Lowe, Tiffany M.; Silberger, Daniel J.; Sobecky, Patricia A.] Georgia Inst Technol, Sch Biol, Atlanta, GA 30332 USA. [Hazen, Tracy H.; Lafon, Patricia C.; Garrett, Nancy M.; Parsons, Michele B.; Bopp, Cheryl A.] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Rowe, Lori A.; Frace, Michael] Ctr Dis Control & Prevent, Div Sci Resources, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Rasko, David A.] Univ Maryland, Sch Med, Inst Genome Sci, Baltimore, MD 21201 USA. [Rasko, David A.] Univ Maryland, Dept Microbiol & Immunol, Baltimore, MD 21201 USA. RP Hazen, TH (reprint author), Univ Maryland, Sch Med, Inst Genome Sci, 801 W Baltimore St, Baltimore, MD 21201 USA. EM thazen@som.umaryland.edu OI David, Rasko/0000-0002-7337-7154; Lowe-Power, Tiffany/0000-0003-2681-3563 FU GT/CDC seed grant [1241326]; NSF [DBI-0304606] FX We thank C. Lovell for kindly providing V. parahaemolyticus environmental isolates from NC. We thank S. Chen for laboratory assistance. This project was supported by a GT/CDC seed grant no. 1241326 to PS and CB. Instrumentation for sequencing of PCR amplicons at Georgia Tech was supported by NSF grant DBI-0304606. NR 81 TC 7 Z9 8 U1 4 U2 15 PU FRONTIERS MEDIA SA PI LAUSANNE PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND SN 1664-302X J9 FRONT MICROBIOL JI Front. Microbiol. PD MAR 24 PY 2015 VL 6 AR 204 DI 10.3389/fmicb.2015.00204 PG 14 WC Microbiology SC Microbiology GA CF4KK UT WOS:000352517800001 PM 25852665 ER PT J AU Lopalco, PL DeStefano, F AF Lopalco, Pier Luigi DeStefano, Frank TI The complementary roles of Phase 3 trials and post-licensure surveillance in the evaluation of new vaccines SO VACCINE LA English DT Review DE Vaccine trials; Vaccine marketing authorisation; Vaccine safety; Vaccine effectiveness ID GUILLAIN-BARRE-SYNDROME; ROTAVIRUS VACCINATION; BORDETELLA-PERTUSSIS; INFLUENZA-A; SAFETY SURVEILLANCE; IMMUNIZATION SAFETY; ACELLULAR VACCINES; REPORTING SYSTEM; CHILDREN; INTUSSUSCEPTION AB Vaccines have led to significant reductions in morbidity and saved countless lives from many infectious diseases and are one of the most important public health successes of the modern era. Both vaccines' effectiveness and safety are keys for the success of immunisation programmes. The role of post-licensure surveillance has become increasingly recognised by regulatory authorities in the overall vaccine development process. Safety, purity, and effectiveness of vaccines are carefully assessed before licensure, but some safety and effectiveness aspects need continuing monitoring after licensure; Post-marketing activities are a necessary complement to pre-licensure activities for monitoring vaccine quality and to inform public health programmes. In the recent past, the availability of large databases together with data-mining and cross-linkage techniques have significantly improved the potentialities of post-licensure surveillance. The scope of this review is to present challenges and opportunities offered by vaccine post-licensure surveillance. While pre-licensure activities form the foundation for the development of effective and safe vaccines, post-licensure monitoring and assessment, are necessary to assure that vaccines are effective and safe when translated in real world settings. Strong partnerships and collaboration at an international level between different stakeholders is necessary for finding and optimally allocating resources and establishing robust post-licensure processes. (C) 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licensesiby-nc-nd/4.0/). C1 [Lopalco, Pier Luigi] European Ctr Dis Prevent & Control ECDC, SE-17183 Stockholm, Sweden. [DeStefano, Frank] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Lopalco, PL (reprint author), European Ctr Dis Prevent & Control ECDC, SE-17183 Stockholm, Sweden. EM pierluigi.lopalco@ecdc.europa.eu OI Lopalco, Pier Luigi/0000-0002-3181-8054 FU Intramural CDC HHS [CC999999] NR 81 TC 5 Z9 5 U1 0 U2 5 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD MAR 24 PY 2015 VL 33 IS 13 BP 1541 EP 1548 DI 10.1016/j.vaccine.2014.10.047 PG 8 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA CE7TS UT WOS:000352045300005 PM 25444788 ER PT J AU Hariri, S Bennett, NM Niccolai, LM Schafer, S Park, IU Bloch, KC Unger, ER Whitney, E Julian, P Scahill, MW Abdullan, N Levine, D Johnson, ML Steinau, M Markowitz, LE AF Hariri, Susan Bennett, Nancy M. Niccolai, Linda M. Schafer, Sean Park, Ina U. Bloch, Karen C. Unger, Elizabeth R. Whitney, Erin Julian, Pamela Scahill, Mary W. Abdullan, Nasreen Levine, Diane Johnson, Michelle L. Steinau, Martin Markowitz, Lauri E. CA HPV-IMPACT Working Grp TI Reduction in HPV 16/18-associated high grade cervical lesions following HPV vaccine introduction in the United States-2008-2012 SO VACCINE LA English DT Article DE Human papillomavirus; HPV; Vaccine; Cervical intraepithelial neoplasia; CIN; High grade cervical lesion ID HUMAN-PAPILLOMAVIRUS HPV; POTENTIAL IMPACT; STATES; WOMEN; ABNORMALITIES; PREVALENCE; PROGRAM; DISEASE; CANCER; COVERAGE AB Background: Prevention of pre-invasive cervical lesions is an important benefit of HPV vaccines, but demonstrating impact on these lesions is impeded by changes in cervical cancer screening. Monitoring vaccine-types associated with lesions can help distinguish vaccine impact from screening effects. We examined trends in prevalence of HPV 16/18 types detected in cervical intraepithelial neoplasia 2, 3, and adenocarcinoma in situ (CIN2+) among women diagnosed with CIN2+ from 2008 to 2012 by vaccination status. We estimated vaccine effectiveness against HPV 16/18-attributable CIN2+ among women who received >= 1 dose by increasing time intervals between date of first vaccination and the screening test that led to detection of CIN2+ lesion. Methods: Data are from a population-based sentinel surveillance system to monitor HPV vaccine impact on type-specific CIN2+ among adult female residents of five catchment areas in California, Connecticut, New York, Oregon, and Tennessee. Vaccination and cervical cancer screening information was retrieved. Archived diagnostic specimens were obtained from reporting laboratories for HPV DNA typing. Results: From 2008 to 2012, prevalence of HPV 16/18 in CIN2+ lesions statistically significantly decreased from 53.6% to 28.4% among women who received at least one dose (P-trend<.001) but not among unvaccinated women (57.1% vs 52.5%; P-trend=.08) or women with unknown vaccination status (55.0% vs 50.5%; P-trend=.71). Estimated vaccine effectiveness for prevention of HPV 16/18-attributable CIN2+ was 21% (95% Cl: 1-37), 49% (95% Cl: 28-64), and 72% (95% Cl: 45-86) in women who initiated vaccination 25-36 months, 37-48 months, and >48 months prior to the screening test that led to CIN2+ diagnosis. Conclusions: Population-based data from the United States indicate significant reductions in CIN2+ lesions attributable to types targeted by the vaccines and increasing HPV vaccine effectiveness with increasing interval between first vaccination and earliest detection of cervical disease. Published by Elsevier Ltd. C1 [Hariri, Susan; Johnson, Michelle L.; Markowitz, Lauri E.] Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA. [Bennett, Nancy M.; Scahill, Mary W.] Univ Rochester, Sch Med & Dent, Ctr Community Hlth, Rochester, NY 14607 USA. [Bennett, Nancy M.; Scahill, Mary W.] Univ Rochester, Sch Med & Dent, Dept Med, Rochester, NY 14607 USA. [Niccolai, Linda M.; Julian, Pamela] Yale Univ, Sch Publ Hlth, Div Epidemiol Microbial Dis, New Haven, CT 06520 USA. [Niccolai, Linda M.; Schafer, Sean] Oregon Publ Hlth Div, Ctr Publ Hlth Practice, HIV STD TB Program, Portland, OR 97232 USA. [Park, Ina U.; Whitney, Erin] Calif Dept Publ Hlth, STD Control Branch, Richmond, CA 94804 USA. [Bloch, Karen C.; Levine, Diane] Vanderbilt Univ, Med Ctr, Dept Internal Med, Nashville, TN 37232 USA. [Unger, Elizabeth R.; Steinau, Martin] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div High Consequence Pathogens & Pathol, Atlanta, GA 30333 USA. RP Hariri, S (reprint author), Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, 1600 Clifton Rd,NE MS-E02, Atlanta, GA 30333 USA. EM shariri@cdc.gov; nancy_bennett@urmc.rochester.edu; linda.niccolai@yale.edu; sean.schafer@state.or.us; ina.park@cdph.ca.gov; karen.bloch@vanderbilt.edu; eunger@cdc.gov; erin.whitney@cdph.ca.gov; pamela.julian@yale.edu; maryw_scahill@urmc.rocheter.edu; nasreen.abdullah@state.or.us; diane.levine@vanderbilt.edu; huk3@cdc.gov; msteinau@cdc.gov; lmarkowitz@cdc.gov FU U.S. Centers for Disease Control and Prevention [CIU01000307] FX This work was supported by the U.S. Centers for Disease Control and Prevention cooperative agreement CIU01000307. NR 24 TC 29 Z9 30 U1 0 U2 7 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD MAR 24 PY 2015 VL 33 IS 13 BP 1608 EP 1613 DI 10.1016/j.vaccine.2015.01.084 PG 6 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA CE7TS UT WOS:000352045300014 PM 25681664 ER PT J AU Park, YH Shi, YP Liang, B Medriano, CAD Jeon, YH Torres, E Uppal, K Slutsker, L Jones, DP AF Park, Youngja H. Shi, Ya Ping Liang, Bill Medriano, Carl Angelo D. Jeon, Young Ho Torres, Eucaris Uppal, Karan Slutsker, Laurence Jones, Dean P. TI High-resolution metabolomics to discover potential parasite-specific biomarkers in a Plasmodium falciparum erythrocytic stage culture system SO MALARIA JOURNAL LA English DT Article DE Malaria; Plasmodium falciparum; Mass spectrometry; High-resolution metabolomics (HRM); Biomarkers; Diagnostic tool ID N-ARACHIDONOYL GLYCINE; ACID; MALARIA; DIAGNOSTICS; INHIBITION; INFECTION; PATHWAYS; DATABASE; KEGG AB Background: Current available malaria diagnostic methods each have some limitations to meet the need for real-time and large-scale screening of asymptomatic and low density malaria infection at community level. It was proposed that malaria parasite-specific low molecular-weight metabolites could be used as biomarkers for the development of a malaria diagnostic tool aimed to address this diagnostic challenge. In this study, high resolution metabolomics (HRM) was employed to identify malaria parasite-specific metabolites in Plasmodium falciparum in vitro culture samples. Methods: Supernatants were collected at 12 hours interval from 3% haematocrit in vitro 48-hour time-course asynchronized culture system of P. falciparum. Liquid chromatography coupled with high resolution mass spectrometry was applied to discover potential parasite-specific metabolites in the cell culture supernatant. A metabolome-wide association study was performed to extract metabolites using Manhattan plot with false discovery rate (FDR) and hierarchical cluster analysis. The significant metabolites based on FDR cutoff were annotated using Metlin database. Standard curves were created using corresponding chemical compounds to accurately quantify potential Plasmodium-specific metabolites in culture supernatants. Results: The number of significant metabolite features was 1025 in the supernatant of the Plasmodium infected culture based on Manhattan plot with FDR q=0.05. A two way hierarchical cluster analysis showed a clear segregation of the metabolic profile of parasite infected supernatant from non-infected supernatant at four time points during the 48 hour culture. Among the 1025 annotated metabolites, the intensities of four molecules were significantly increased with culture time suggesting a positive association between the quantity of these molecules and level of parasitaemia: i) 3-methylindole, a mosquito attractant, ii) succinylacetone, a haem biosynthesis inhibitor, iii) S-methyl-L-thiocitrulline, a nitric oxide synthase inhibitor, and iv) O-arachidonoyl glycidol, a fatty acid amide hydrolase inhibitor, The highest concentrations of 3-methylindole and succinylacetone were 178 +/- 18.7 pmoles at 36 hours and 157 +/- 30.5 pmoles at 48 hours respectively in parasite infected supernatant. Conclusion: HRM with bioinformatics identified four potential parasite-specific metabolite biomarkers using in vitro culture supernatants. Further study in malaria infected human is needed to determine presence of the molecules and its relationship with parasite densities. C1 [Park, Youngja H.; Liang, Bill; Uppal, Karan; Jones, Dean P.] Emory Univ, Sch Med, Dept Med, Atlanta, GA 30322 USA. [Park, Youngja H.; Medriano, Carl Angelo D.; Jeon, Young Ho] Korea Univ, Coll Pharm, Sejong City, South Korea. [Shi, Ya Ping; Torres, Eucaris; Slutsker, Laurence] Ctr Dis Control & Prevent CDC, DPDM, Malaria Branch, Atlanta, GA USA. RP Park, YH (reprint author), Emory Univ, Sch Med, Dept Med, Atlanta, GA 30322 USA. EM yjhwang@korea.ac.kr; dpjones@emory.edu OI Park, Youngja/0000-0002-1310-148X; Medriano, Carl Angelo/0000-0002-8286-4843 FU Center for Health Discovery and Well-being of Emory University [NRF-2014R1A4A1007304]; Korea University [NRF-2014R1A1A2053787]; Malaria Branch, Division of Parasitic Diseases and Malaria (DPDM), Center for Global Health, Centers for Disease Control and Prevention (CDC); NIH [HL113451, ES009047, ES019776, AG038746]; NIAID [HHSN272201200031C] FX This research was supported in part by the Center for Health Discovery and Well-being of Emory University, grant # NRF-2014R1A4A1007304 (Y.H.J) and grant# NRF-2014R1A1A2053787 of Korea University, and by Malaria Branch, Division of Parasitic Diseases and Malaria (DPDM), Center for Global Health, Centers for Disease Control and Prevention (CDC). DPJ is supported in part by NIH grants HL113451, ES009047, ES019776 and AG038746 and NIAID Contract HHSN272201200031C. The authors acknowledged Jae Ho Cho, Korea University in making figures. We also thank Dr. S. Patrick Kachur, Malaria Branch, DPDM, CGH, CDC for his critical review of this manuscript and valuable suggestions. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 39 TC 4 Z9 4 U1 2 U2 7 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1475-2875 J9 MALARIA J JI Malar. J. PD MAR 24 PY 2015 VL 14 AR 122 DI 10.1186/s12936-015-0651-1 PG 9 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA CE8PU UT WOS:000352106700001 PM 25889340 ER PT J AU Lai, LL Davey, R Beck, A Xu, YX Suffredini, AF Palmore, T Kabbani, S Rogers, S Kobinger, G Alimonti, J Link, CJ Rubinson, L Stroher, U Wolcott, M Dorman, W Uyeki, TM Feldmann, H Lane, HC Mulligan, MJ AF Lai, Lilin Davey, Richard Beck, Allison Xu, Yongxian Suffredini, Anthony F. Palmore, Tara Kabbani, Sarah Rogers, Susan Kobinger, Gary Alimonti, Judie Link, Charles J., Jr. Rubinson, Lewis Stroeher, Ute Wolcott, Mark Dorman, William Uyeki, Timothy M. Feldmann, Heinz Lane, H. Clifford Mulligan, Mark J. TI Emergency Postexposure Vaccination With Vesicular Stomatitis Virus-Vectored Ebola Vaccine After Needlestick SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID NONHUMAN-PRIMATES; MONOCLONAL-ANTIBODIES; PROTECTION; INFECTION; FEVER AB IMPORTANCE Safe and effective vaccines and drugs are needed for the prevention and treatment of Ebola virus disease, including following a potentially high-risk exposure such as a needlestick. OBJECTIVE To assess response to postexposure vaccination in a health care worker who was exposed to the Ebola virus. DESIGN AND SETTING Case report of a physician who experienced a needlestick while working in an Ebola treatment unit in Sierra Leone on September 26, 2014. Medical evacuation to the United States was rapidly initiated. Given the concern about potentially lethal Ebola virus disease, the patient was offered, and provided his consent for, postexposure vaccination with an experimental vaccine available through an emergency Investigational New Drug application. He was vaccinated on September 28, 2014. INTERVENTIONS The vaccine used was VSV Delta G-ZEBOV, a replicating, attenuated, recombinant vesicular stomatitis virus (serotype Indiana) whose surface glycoprotein gene was replaced by the Zaire Ebola virus glycoprotein gene. This vaccine has entered a clinical trial for the prevention of Ebola in West Africa. RESULTS The vaccine was administered 43 hours after the needlestick occurred. Fever and moderate to severe symptoms developed 12 hours after vaccination and diminished over 3 to 4 days. The real-time reverse transcription polymerase chain reaction results were transiently positive for vesicular stomatitis virus nucleoprotein gene and Ebola virus glycoprotein gene (both included in the vaccine) but consistently negative for Ebola virus nucleoprotein gene (not in the vaccine). Early postvaccination cytokine secretion and T lymphocyte and plasmablast activation were detected. Subsequently, Ebola virus glycoprotein-specific antibodies and T cells became detectable, but antibodies against Ebola viral matrix protein 40 (not in the vaccine) were not detected. CONCLUSIONS AND RELEVANCE It is unknown if VSV Delta G-ZEBOV is safe or effective for postexposure vaccination in humans who have experienced a high-risk occupational exposure to the Ebola virus, such as a needlestick. In this patient, postexposure vaccination with VSV Delta G-ZEBOV induced a self-limited febrile syndrome that was associated with transient detection of the recombinant vesicular stomatitis vaccine virus in blood. Strong innate and Ebola-specific adaptive immune responses were detected after vaccination. The clinical syndrome and laboratory evidence were consistent with vaccination response, and no evidence of Ebola virus infection was detected. C1 [Lai, Lilin; Beck, Allison; Xu, Yongxian; Kabbani, Sarah; Rogers, Susan; Mulligan, Mark J.] Emory Univ, Sch Med, Dept Med, Emory Vaccine Ctr,Div Infect Dis,Hope Clin, Atlanta, GA USA. [Davey, Richard; Suffredini, Anthony F.; Palmore, Tara; Lane, H. Clifford] NIAID, Div Clin Res, Ctr Clin, NIH, Bethesda, MD 20892 USA. [Kobinger, Gary; Alimonti, Judie] Publ Hlth Agcy Canada, Natl Lab Zoonot Dis & Special Pathogens, Winnipeg, MB, Canada. [Link, Charles J., Jr.] NewLink Genet Corp, Ames, IA USA. [Rubinson, Lewis] Univ Maryland, Sch Med, Div Trauma Crit Care, R Adams Cowley Shock Trauma Ctr, Baltimore, MD 21201 USA. [Stroeher, Ute; Uyeki, Timothy M.] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Wolcott, Mark; Dorman, William] US Army, Diagnost Syst Div, Med Res Inst Infect Dis, Frederick, MD USA. [Feldmann, Heinz] NIAID, Div Intramural Res, Virol Lab, NIH, Hamilton, MT USA. RP Mulligan, MJ (reprint author), Emory Univ, Hope Clin, Emory Vaccine Ctr, 500 Irvin Ct,Ste 200, Decatur, GA 30030 USA. EM mark.mulligan@emory.edu FU Georgia Research Alliance and Emory University; National Center for Advancing Translational Sciences of the National Institutes of Health [UL1TR000454]; Emory Vaccinology Training Program under the National Institute of Allergy and Infectious Diseases, National Institutes of Health [T32AI074492]; National Institute of Allergy and Infectious Diseases Intramural Research Program at the National Institutes of Health FX This work was supported in part by the Georgia Research Alliance and Emory University (Dr Mulligan); the National Center for Advancing Translational Sciences of the National Institutes of Health (award UL1TR000454); the Emory Vaccinology Training Program under the National Institute of Allergy and Infectious Diseases, National Institutes of Health (T32AI074492 awarded to Drs Kabbani and Mulligan); and the National Institute of Allergy and Infectious Diseases Intramural Research Program at the National Institutes of Health. NR 20 TC 32 Z9 33 U1 0 U2 45 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD MAR 24 PY 2015 VL 313 IS 12 BP 1249 EP 1255 DI 10.1001/jama.2015.1995 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA CD9RJ UT WOS:000351435500024 PM 25742465 ER EF